<SEC-DOCUMENT>0001144204-17-058634.txt : 20171114
<SEC-HEADER>0001144204-17-058634.hdr.sgml : 20171114
<ACCEPTANCE-DATETIME>20171114090117
ACCESSION NUMBER:		0001144204-17-058634
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		52
CONFORMED PERIOD OF REPORT:	20170930
FILED AS OF DATE:		20171114
DATE AS OF CHANGE:		20171114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MUSTANG BIO, INC.
		CENTRAL INDEX KEY:			0001680048
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473828760
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0312

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38191
		FILM NUMBER:		171198617

	BUSINESS ADDRESS:	
		STREET 1:		2 GANSEVOORT STREET
		STREET 2:		9TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10014
		BUSINESS PHONE:		7816524507

	MAIL ADDRESS:	
		STREET 1:		2 GANSEVOORT STREET
		STREET 2:		9TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10014
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tv477598_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM&nbsp;10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B><FONT STYLE="font-family: Wingdings">&#120;</FONT></B></FONT></TD><TD><B>QUARTERLY REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: center; text-indent: -22.5pt"><B>For the
quarterly period ended September&nbsp;30, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <B>OR</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><B>&uml;</B></FONT></TD><TD><B>TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Commission File Number 000-55668</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>MUSTANG BIO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 50%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 49%; text-align: center"><FONT STYLE="font-size: 10pt"><B>47-3828760</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation or organization)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2 Gansevoort Street, 9th Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>New York, New York 10014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address including zip code of principal executive
offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(781) 652-4500</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant: (1)&nbsp;has filed
all reports required to be filed by Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such
filing requirements for the past 90 days. Yes <FONT STYLE="font-family: Wingdings">x</FONT> No <FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant has submitted electronically
and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405
of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). Yes <FONT STYLE="font-family: Wingdings">x</FONT> No <FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions
of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo; and &ldquo;emerging
growth company&rdquo; in Rule&nbsp;12b-2 of the Exchange Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><FONT STYLE="font-size: 10pt">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="width: 49%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 27%"><FONT STYLE="font-size: 10pt">Accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT><FONT STYLE="font-size: 10pt"><B>&nbsp;&nbsp;</B>(Do not check if a smaller reporting company)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Emerging growth company</FONT></TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act.&nbsp; <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a shell company
(as defined in Rule&nbsp;12b-2 of the Exchange Act). Yes&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT> No&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Class of Common Stock</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Outstanding Shares as of November 13, 2017</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 47%; text-align: center"><FONT STYLE="font-size: 10pt">Class A Common Stock, $0.0001 par value</FONT></TD>
    <TD STYLE="width: 8%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 43%; text-align: center"><FONT STYLE="font-size: 10pt">1,000,000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Common Stock, $0.0001 par value</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">25,232,139</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>MUSTANG BIO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>QUARTERLY REPORT ON FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">PART I. FINANCIAL INFORMATION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">3</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; width: 15%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 77%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 8%; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">Item 1.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">Unaudited Condensed Financial Statements</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">3</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">Condensed Balance Sheets as of September 30, 2017 (Unaudited) and December 31, 2016</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">3</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">Condensed Statements of Operations for the Three and Nine Months Ended September 30, 2017 and 2016 (Unaudited)</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">4</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">Condensed Statement of Stockholders&rsquo; Equity for the Nine Months Ended September 30, 2017 (Unaudited)</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">5</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2017 and 2016 (Unaudited)</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">6</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">Notes to the Condensed Financial Statements (Unaudited)</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">7</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">Item 2.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">22</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 27pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">Item 3.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risks</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">28</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 27pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">Item 4.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">Controls and Procedures</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">28</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">PART II. OTHER INFORMATION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">29</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">Item 1.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">Legal Proceedings</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">29</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 27pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">Item 1A</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">29</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 27pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_014"><FONT STYLE="font-size: 10pt">Item 2.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_014"><FONT STYLE="font-size: 10pt">Unregistered Sales of Equity Securities and Use of Proceeds</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_014"><FONT STYLE="font-size: 10pt">61</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 27pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_015"><FONT STYLE="font-size: 10pt">Item 3.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_015"><FONT STYLE="font-size: 10pt">Defaults Upon Senior Securities</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_015"><FONT STYLE="font-size: 10pt">61</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 27pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_016"><FONT STYLE="font-size: 10pt">Item 4.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_016"><FONT STYLE="font-size: 10pt">Mine Safety Disclosures</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_016"><FONT STYLE="font-size: 10pt">61</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 27pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_017"><FONT STYLE="font-size: 10pt">Item 5.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_017"><FONT STYLE="font-size: 10pt">Other Information</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_017"><FONT STYLE="font-size: 10pt">61</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 27pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_018"><FONT STYLE="font-size: 10pt">Item 6.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_018"><FONT STYLE="font-size: 10pt">Exhibits</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_018"><FONT STYLE="font-size: 10pt">61</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 27pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_019"><FONT STYLE="font-size: 10pt">Signatures</FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_019"><FONT STYLE="font-size: 10pt">63</FONT></A></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><A NAME="a_001"></A>PART I. FINANCIAL INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><A NAME="a_002"></A>Item 1.</TD><TD>Unaudited Condensed Financial Statements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="a_003"></A><B>MUSTANG BIO, INC.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center">Condensed
Balance Sheets</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">($ in thousands, except for share and per share
amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 27.5pt">&nbsp;<B>&nbsp;&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">(Unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; padding-left: 9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">33,209</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">27,499</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Short-term investments (certificates of deposit) - held to maturity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,088</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">414</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Interest receivables</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">35</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,746</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,499</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Property and equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">139</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">67,885</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">27,499</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS' EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,723</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">683</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Common shares issuable liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,682</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Payables and accrued expenses -&nbsp;&nbsp;related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">445</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt; padding-bottom: 1pt">Accrued interest - related party</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">413</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Current Liabilities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,792</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">3,223</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Commitments and Contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders' Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Preferred stock ($0.0001 par value), 2,000,000 shares authorized, 250,000 shares of Class A preferred stock issued and outstanding as of September 30, 2017 and December 31, 2016, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Common Stock ($0.0001 par value), 50,000,000 shares authorized</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Class A common shares, 1,000,000 shares issued and outstanding&nbsp;as of September 30, 2017 and December 31, 2016, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Common shares, 25,232,139 and 15,165,244 shares issued and outstanding&nbsp;as of September 30, 2017 and December 31, 2016, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Common stock issuable, 0 and 767,264 shares as of September 30, 2017 and December 31, 2016, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,396</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">97,897</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,998</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(32,807</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(17,120</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Stockholders&rsquo; Equity</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">65,093</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">24,276</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&rsquo; Equity</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">67,885</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">27,499</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>The accompanying notes
are an integral part of these condensed financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_004"></A><B>MUSTANG BIO, INC.</B></P>

<P STYLE="font:10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><B>Condensed
Statements of Operations</B><BR>
<FONT STYLE="text-transform: lowercase">($ in thousands, except for share and per share amounts)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: none">(Unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the three months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the nine months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left; padding-left: 9pt">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,188</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">569</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5,388</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,718</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Research and development &ndash; licenses acquired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,375</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,596</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,101</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,293</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,814</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,084</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,670</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,056</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,532</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Loss from operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,084</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,670</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(16,056</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,532</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">369</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest expense - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(46</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(220</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(156</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(156</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Change in fair value of derivative liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total other income (expense)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">144</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">369</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(374</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(6,940</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,870</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(15,687</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(3,906</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss per common share outstanding, basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.27</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.19</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.63</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.39</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding, basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">26,186,924</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,089,269</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">24,936,626</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,130,338</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>The accompanying notes are an integral part
of these condensed financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="a_005"></A><B>MUSTANG BIO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Condensed
Statement of Stockholders&rsquo; Equity</B></FONT><BR>
<FONT STYLE="font-size: 10pt">($ in thousands)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><FONT STYLE="text-transform: none">(Unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Class
    A Preferred Stock</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Class
    A Common Shares</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Common
    Shares</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Common<BR>
    Stock</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Additional
    <BR> Paid-in</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Accumulated</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Total
    <BR> Stockholders'</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Amount</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Amount</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Amount</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Issuable</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Capital</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Deficit</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Equity</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%; font-weight: bold"><FONT STYLE="font-size: 8pt">Balances at December 31, 2016</FONT></TD><TD STYLE="width: 1%; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">250,000</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">1,000,000</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">15,165,244</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">2</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">4,396</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">36,998</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(17,120</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 1%; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">24,276</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Issuance of common shares - Founders Agreement</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">982,533</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(4,396</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,630</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,234</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Issuance of common shares for license expenses</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">293,588</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,682</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,682</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Issuance of common shares and warrants for cash</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">8,610,774</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">55,969</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">55,970</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Offering cost</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(5,674</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(5,674</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Stock-based compensation expenses</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">180,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,230</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,230</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Capital contribution from Fortress</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,062</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,062</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Net loss</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(15,687</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(15,687</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">Balances at September 30, 2017</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">250,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">1,000,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">25,232,139</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">3</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">97,897</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(32,807</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">65,093</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>The accompanying notes are an integral part
of these condensed financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="a_006"></A><B>MUSTANG BIO, INC.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center">Condensed
Statements of Cash Flows<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">($ in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the nine months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(15,687</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(3,906</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Research and development-licenses acquired, expensed</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,375</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Issuance of common shares - Founders Agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,234</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">274</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Amortization of debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Change in fair value of derivative liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock-based compensation expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,230</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Capital contribution from Fortress</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,062</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(414</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Interest receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,923</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,025</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Payable and accrued expenses -&nbsp;&nbsp;related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(56</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">375</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Accrued interest - related party</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(413</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">278</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(7,781</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(1,866</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows from Investing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Purchase of short-term investment (certificates of deposit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(34,088</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Purchase of research and development licenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,375</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Purchase of fixed assets - construction-in-process</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(22</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(36,485</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows from Financing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Proceeds from Fortress Note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,963</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Payment of Fortress Note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(320</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,533</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Proceeds from NSC Note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,600</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Payment of debt issue costs associated with NSC Note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(129</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Proceeds from issuance of common stock and warrants, net of offering cost of $5,674 and $0, respectively</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">50,296</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,083</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">49,976</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,984</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net change in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,710</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,118</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash and cash equivalents, beginning of the period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,499</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents, end of the period</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">33,209</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">11,118</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash paid for interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">413</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental disclosure of noncash investing and financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Construction-in-progress included in accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">117</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issuance of common shares - Founders Agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,396</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">190</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Warrant liability associated with NSC Note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">634</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Common shares issuable for license acquired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,682</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><I>The accompanying notes are an integral part
of these condensed financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><A NAME="a_007"></A>Mustang
Bio, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center">Notes
to the Condensed Financial STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center">(UNAUDITED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Note 1 - Organization, Description of Business and Liquidity
and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mustang Bio, Inc. (the &ldquo;Company&rdquo;
or &ldquo;Mustang&rdquo;) was incorporated in Delaware on March 13, 2015 and commenced its principal operations on March 13, 2015.
Mustang was formed as a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization
of novel cancer immunotherapy products designed to utilize the power of the patient&rsquo;s own immune system to eliminate cancer
cells. The Company may acquire rights to these technologies by licensing the rights or otherwise acquiring an ownership interest
in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to
market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is a majority controlled subsidiary
of Fortress Biotech, Inc. (&ldquo;Fortress&rdquo; or &ldquo;Parent&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has incurred substantial operating
losses since its inception, and expects to continue to incur significant operating losses for the foreseeable future and may never
become profitable. As of September 30, 2017, the Company had an accumulated deficit of $32.8 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expects to continue to use the
proceeds from previous financing transactions primarily for general corporate purposes, which may include financing the Company&rsquo;s
growth, developing new or existing product candidates, and funding capital expenditures, acquisitions and investments. The Company
currently anticipates that its cash and cash equivalents balances and short-term investments held to maturity at September 30,
2017, are sufficient to fund its anticipated operating cash requirements for at least the next 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 2 - Significant Accounting Policies&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Basis of Presentation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited interim condensed
financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America
(&ldquo;GAAP&rdquo;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly,
they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of
management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments
necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures
normally included in the Company&rsquo;s annual financial statements prepared in accordance with GAAP have been condensed or omitted.
These condensed financial statement results are not necessarily indicative of results to be expected for the full fiscal year or
any future period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Therefore, these condensed financial statements
should be read in conjunction with the Company&rsquo;s audited financial statements and notes thereto for the year ended December
31, 2016, which were included in the Company&rsquo;s Form 10-K filed with the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;)
on March 31, 2017. The results of operations for any interim periods are not necessarily indicative of the results that may be
expected for the entire fiscal year or any other interim period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in
conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses
during the reporting period. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center">Mustang
Bio, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Notes
to the Condensed Financial STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">(UNAUDITED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Significant Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There have been no material changes to the
Company&rsquo;s significant accounting policies previously disclosed in the Company&rsquo;s Form 10-K filed with the SEC on March
31, 2017, with the exception of the policies listed below.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Short-term Investments &ndash; Held to Maturity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company classifies its certificates of
deposit as cash and cash equivalents or held to maturity in accordance with the Financial Accounting Standards Board (&quot;FASB&quot;)
Accounting Standards Codification (&ldquo;ASC&rdquo;) 320, <I>Investments &ndash; Debt and Equity Securities</I>. The Company considers
all investments with an original maturity in excess of three months when purchased to be short-term investments. Investments consist
of short-term FDIC insured certificates of deposit carried at amortized cost using the effective interest method. The cost of the
Company&rsquo;s certificates of deposit approximated fair value. The Company reassesses the appropriateness of the classification
of its investments at the end of each reporting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2017, the Company had approximately
$40.1 million in certificates of deposit with no more than $250,000 at any individual institution. The Company classified $6.0
million as cash and cash equivalents and classified $34.1 million of its certificates of deposits as held-to-maturity as of September
30, 2017. There were no short-term investments as of December 31, 2016. This classification was based upon management&rsquo;s determination
that it has the positive intent and ability to hold the securities until their maturity dates, as its investments mature within
one year and the underlying cash invested in these securities is not required for current operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<B><I>Stock-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expenses stock-based compensation to employees and board
members over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based awards with graded
vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion
of the award. For stock-based compensation awards to non-employees, the Company measures the fair value of the non-employee awards
at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of
these non-employee awards are recognized as compensation expense in the period of change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The assumptions used in calculating the fair
value of stock-based awards represent management&rsquo;s best estimates and involve inherent uncertainties and the application
of management&rsquo;s judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Property and equipment &ndash; construction
in process</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Leasehold improvements are amortized
over the shorter of the estimated useful lives or the term of the respective leases, upon the improvement being placed in
service. In connection with the Company&rsquo;s manufacturing facility, the Company incurred $0.1 million related to the
design of the facility which is recorded in property and equipment on the condensed balance sheet at September 30, 2017. Upon
completion of the buildout all costs associated with the buildout will be recorded as leasehold improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Recently Adopted Accounting Pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #212121">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2016, the FASB issued Accounting Standards
Update (&quot;ASU&quot;) 2016-09<I>&nbsp;Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment
Accounting</I> <FONT STYLE="color: #212121">(&ldquo;ASU 2016-09&rdquo;)</FONT>. Under ASU 2016-09, companies will no longer record
excess tax benefits and certain tax deficiencies in additional paid-in capital (&ldquo;APIC&rdquo;). Instead, they will record
all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement and the APIC pools will be
eliminated. In addition, ASU 2016-09 eliminates the requirement that excess tax benefits be realized before companies can recognize
them. ASU 2016-09 also requires companies to present excess tax benefits as an operating activity on the statement of cash flows
rather than as a financing activity. Furthermore, ASU 2016-09 will increase the amount an employer can withhold to cover income
taxes on awards and still qualify for the exception to liability classification for shares used to satisfy the employer&rsquo;s
statutory income tax withholding obligation. An employer with a statutory income tax withholding obligation will now be allowed
to withhold shares with a fair value up to the amount of taxes owed using the maximum statutory tax rate in the employee&rsquo;s
applicable jurisdiction(s). ASU 2016-09 requires a company to classify the cash paid to a tax authority when shares are withheld
to satisfy its statutory income tax withholding obligation as a financing activity on the statement of cash flows. Under current
GAAP, it was not specified how these cash flows should be classified. In addition, companies will now have to elect whether to
account for forfeitures on share-based payments by (1) recognizing forfeitures of awards as they occur or (2) estimating the number
of awards expected to be forfeited and adjusting the estimate when it is likely to change, as is currently required. The Amendments
of this ASU are effective for reporting periods beginning after December 15, 2016, with early adoption permitted but all of the
guidance must be adopted in the same period. The Company adopted ASU 2016-09 on January 1, 2017. The adoption did not have a material
impact on the Company&rsquo;s condensed financial statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Mustang
Bio, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Notes
to the Condensed Financial STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center">(UNAUDITED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2017, the FASB issued ASU 2017-01,
<I>Business Combinations (Topic 805): Clarifying the Definition of a Business </I>(&ldquo;ASU 2017-01&rdquo;). The amendments in
this update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether
transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects
many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for fiscal periods
beginning after December 15, 2017, including interim periods within those periods. The Company adopted ASU 2017-01 on January 1,
2017. The adoption did not have a material impact on the Company&rsquo;s condensed consolidated financial statements and related
disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Recently Issued Accounting Standards&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU 2016-02,
<I>Leases (Topic 842).</I> ASU 2016-02 requires an entity to recognize right-of-use assets and lease liabilities on its balance
sheet and disclose key information about leasing arrangements. Lessees and lessors are required to disclose qualitative and quantitative
information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty
of cash flows arising from leases. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning
after December&nbsp;15, 2018. Early adoption is permitted. The Company is currently evaluating the impact, if any, of adopting
this standard on its condensed consolidated financial statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2016, the FASB issued ASU 2016-15,
<I>Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments</I> (&ldquo;ASU 2016-15&rdquo;), which addresses
eight specific cash flow issues with the objective of reducing the existing diversity in practice in how certain cash receipts
and cash payments are presented and classified in the statement of cash flows. The standard is effective for fiscal years beginning
after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in
an interim period. The Company is currently in the process of evaluating the impact of this new pronouncement on its condensed
statements of cash flows and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2017, the FASB issued ASU 2017-09, Compensation&mdash;Stock
Compensation (Topic 718): <I>Scope of Modification Accounting</I> (&ldquo;ASU 2017-09&rdquo;), which clarifies when to account
for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification
accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability)
changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending December 31,
2018 and interim periods within that annual period. Early adoption is permitted. The Company is currently evaluating the impact
of adopting this standard on the condensed financial statements and disclosures, but does not expect it to have a significant impact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Mustang
Bio, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Notes
to the Condensed Financial STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">(UNAUDITED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Note 3 - License Agreements and Clinical Research Support Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>City of Hope Licenses</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February, 2017, the Company and City of
Hope National Medical Center (&ldquo;City of Hope&rdquo; or &ldquo;COH&rdquo;) amended and restated their license agreement, dated
March 17, 2015 (the &ldquo;Original&nbsp;Agreement&rdquo;), in connection with the covered patents by entering into three separate
amended and restated exclusive license agreements, one relating to CD123, one relating to IL13R&alpha;2 and one relating to the
Spacer technology, that amended the Original Agreement in certain other respects, and collectively replace the Original Agreement
in its entirety. The total potential consideration payable to COH by the Company, in equity or cash, did not, in the aggregate,
change materially from the Original Agreement. As of September 30, 2017, COH owns 1,000,000 Class A common shares and 293,588 common
shares representing approximately 5.0% of ownership, at September 30, 2017 and has the right to appoint a director to the Board
of Directors (the &ldquo;Board&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;In addition, the Company entered into
a sponsored research agreement with COH in which the Company will fund continued research in the amount of $2.0 million per year,
payable in four equal installments, until 2020. The research covered under this arrangement is for IL13R&alpha;2, CD123 and the
Spacer technology. For the three months ended September 30, 2017 and 2016, the Company recorded $0.5 million and $0.5 million,
respectively, in research and development expenses on the condensed statement of operations in connection with this agreement.
For the nine months ended September 30, 2017 and 2016, the Company recorded $1.5 million and $1.5 million, respectively, on research
and development expenses in the condensed statement of operations in connection with this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2016, the Company entered into
two consulting agreements, one with two COH scientists, whereby effective January 1, 2017, in exchange for services provided to
the Company each consultant shall be paid $60,000 per year, paid quarterly, through January 31, 2019. Further, each consultant
has agreed to serve on our Scientific Advisory Board on an as needed basis, and will receive additional compensation for those
services. In addition, for services provided during the fourth quarter of 2016, pursuant to the terms of the agreement each consultant
earned $60,000, which was paid in the first quarter of 2017. For the three and nine months ended September 30, 2017, the Company
recorded $60,000 and $90,000, respectively, on the condensed statement of operations in connection with these agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>CD123 License</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2017, the Company entered into
an Amended and Restated Exclusive License Agreement with COH to acquire intellectual property rights pertaining to patent rights
related to CD123 (the &ldquo;CD123 License&rdquo;). Pursuant to the CD123 License, the Company and COH acknowledge that an upfront
fee has already been paid under the Original Agreement. In addition, COH is eligible to receive an annual maintenance fee of $25,000
and milestone payments totaling approximately $14.5 million upon and subject to the achievement of certain milestones. Royalty
payments in the mid-single digits are due on net sales of licensed products. The Company is obligated to pay COH a percentage of
certain revenues received in connection with a sublicense in the mid-teens to mid-thirties, depending on the timing of the sublicense
in the development of any product. In addition, equity grants made under the Original Agreement were acknowledged, and the anti-dilution
provisions of the Original Agreement were carried forward.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>CD123 CRA</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2017, the Company entered into
a Clinical Research Support Agreement for CD123 (the &ldquo;CD123 CRA&rdquo;). Pursuant to the terms of the CD123 CRA the Company
made an upfront payment of $19,450 and will contribute an additional $97,490 per patient in connection with the on-going investigator
initiated study. Further, the Company agreed to fund approximately $0.2 million over three years pertaining to the clinical development
of CD123. For the three and nine months ended September 30, 2017 the Company recorded $0.6 million and $1.2, respectively, in research
and development expenses under the CD123 CRA on the condensed statement of operations. The Company recorded no expenses in 2016
related to this arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Mustang
Bio, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Notes
to the Condensed Financial STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">(UNAUDITED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>IL13R&alpha;2 License</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2017, the Company entered into
an Amended and Restated Exclusive License Agreement with COH to acquire intellectual property rights pertaining to patent rights
related to IL13R&alpha;2 (the &ldquo;IL13R&alpha;2 License&rdquo;). Pursuant to the IL13R&alpha;2 License, the Company and COH
acknowledge that an upfront fee has already been paid under the Original Agreement. In addition, COH is eligible to receive an
annual maintenance fee of $25,000 and milestone payments totaling approximately $14.5 million upon and subject to the achievement
of certain milestones. Royalty payments in the mid-single digits are due on net sales of licensed products. The Company is obligated
to pay COH a percentage of certain revenues received in connection with a sublicense in the mid-teens to mid-thirties, depending
on the timing of the sublicense in the development of any product. In addition, equity grants made under the Original Agreement
were acknowledged, and the anti-dilution provisions of the Original Agreement were carried forward.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>IL13R&alpha;2 CRA</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2017, the Company entered into
a Clinical Research Support Agreement for IL13R&alpha;2 (the &ldquo;IL13R&alpha;2 CRA&rdquo;). Pursuant to the terms of the IL13R&alpha;2
CRA the Company made an upfront payment of approximately $9,300 and will contribute an additional $0.1 million related to patient
costs in connection with the on-going investigator initiated study. Further, the Company agreed to fund approximately $0.2 million
over three years pertaining to the clinical development of IL13R&alpha;2. For the three and nine months ended September 30, 2017
the Company recorded $0.2 million and $1.2 million respectively, in research and development expenses under the IL13R&alpha;2 CRA
on the condensed statement of operations. The Company recorded no expenses in 2016 related to this arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Spacer License</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2017, the Company entered into
an Amended and Restated Exclusive License Agreement with COH to acquire intellectual property rights pertaining to patent rights
related to Spacer (the &ldquo;Spacer License&rdquo;). Pursuant to the Spacer License, the Company and COH acknowledged that an
upfront fee has already been paid under the Original Agreement. In addition, COH will receive an annual maintenance fee of $10,000.
No royalties are due if the Spacer technology is used in conjunction with a CD123 CAR or an IL13R&alpha;2 CAR, and royalty payments
in the low single digits are due on net sales of licensed products if the Spacer technology is used in conjunction with other intellectual
property. The Company is obligated to pay COH a percentage of certain revenues received in connection with a sublicense in the
mid-thirties. In addition, equity grants made under the Original Agreement were acknowledged, and the anti-dilution provisions
of the Original Agreement were carried forward.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>IV/ICV License </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2017, the Company entered into
an exclusive license agreement (the &ldquo;IV/ICV License&rdquo;) with COH to acquire intellectual property rights in patent applications
related to the intraventricular and intracerebroventricular methods of delivering T cells that express CARs. Pursuant to the IV/ICV
License, in March 2017, the Company paid COH an upfront fee of $0.1 million. COH is eligible to receive a milestone payment totaling
approximately $0.1 million, upon and subject to the achievement of a milestone, and an annual maintenance fee. Royalty payments
in the low single digits are due on net sales of licensed products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>HER2 Technology License&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 31, 2017, the Company entered into an
exclusive license agreement (the &ldquo;HER2 Agreement&rdquo;) with the COH for the use of human epidermal growth factor receptor 2 (HER2)
CAR T technology (HER2 Technology), which will initially be applied in the treatment of glioblastoma multiforme. Pursuant to the
HER2 Agreement, the Company paid an upfront fee of $0.6 million and will owe an annual maintenance fee of $50,000 (beginning in
2019). Additional payments are due for the achievement of ten development milestones totaling $14.9 million and royalty payments
in the mid-single digits are due on net sales of licensed products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Mustang
Bio, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Notes
to the Condensed Financial STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">(UNAUDITED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>CS1 Technology License&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 31, 2017, the Company entered into an
exclusive license agreement (the &ldquo;CS1 Agreement) with the COH for the use of CS1-specific CAR T technology (CS1 Technology)
to be directed against multiple myeloma. Pursuant to the CS1 Agreement, the Company paid an upfront fee of $0.6 million and will
owe an annual maintenance fee of $50,000 (beginning in 2019). Additional payments are due for the achievement of ten development
milestones totaling $14.9 million and royalty payments in the mid-single digits are due on net sales of licensed products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>PSCA Technology License&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 31, 2017, the Company entered into an
exclusive license agreement (the &ldquo;PSCA Agreement&rdquo;) with the COH for the use of prostate stem cell antigen (PSCA) CAR
T technology (PSCA Technology) to be used in the treatment of prostate cancer. Pursuant to the PSCA Agreement, the Company paid
an upfront fee of $0.3 million and will owe an annual maintenance fee of $50,000 (beginning in 2019). Additional payments are due
for the achievement of ten development milestones totaling $14.9 million and royalty payments in the mid-single digits are due
on net sales of licensed products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>University of California License</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 17, 2017, the Company entered into
an exclusive license agreement with the Regents of the University of California (the &ldquo;UCLA License&rdquo;) to acquire intellectual
property rights in patent applications related to the engineered anti-prostate stem cell antigen antibodies for cancer targeting
and detection. Pursuant to the UCLA License, the Company paid UCLA the upfront fee of $0.2 million and will owe an annual maintenance
fee of $15,000 for the first two years, $25,000 for years three and four, and $50,000 per year thereafter. Additional payments
are due for the achievement of seven development milestones, totaling $14.3 million, and royalty payments in the mid-single digits
are due on net sales of licensed products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Fred Hutchinson Cancer Research Center
License</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>CD20 Technology License</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 3, 2017, Mustang entered into an exclusive,
worldwide licensing agreement with Fred Hutchinson Cancer Research Center (&ldquo;Fred Hutch&rdquo;) for the use of a CAR T therapy
related to autologous T cells engineered to express a CD20-specific chimeric antigen receptor (&ldquo;CD20 Technology License&rdquo;).
Pursuant to the CD 20 Technology License, the Company paid Fred Hutch an upfront fee of $0.3 million and will owe an annual maintenance
fee of $50,000 on each anniversary of the license until the achievement by the Company of regulatory approval of a licensed product
using CD20 Technology. Additional payments are due for the achievement of eleven development milestones totaling $39.1 million
and royalty payments in the mid-single digits are due on net sales of licensed products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>CD20 CTA</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Also, on July 3, 2017, in conjunction
with the CD20 Technology License from Fred Hutch, Mustang entered into an investigator-initiated clinical trial agreement
(&ldquo;CD20 CTA&rdquo;) to provide partial funding for a Phase 1/2 clinical trial at Fred Hutch evaluating the safety and
efficacy of the CD20 Technology in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. In connection with the
CD20 CTA, the Company agreed to fund up to $5.3 million of costs associated with the clinical trial, which commenced during
the fourth quarter of 2017. For the three and nine months ended September 30, 2017, the Company recorded $88,000 of expense
in connection with this agreement. Further the Company made an upfront payment of $0.4 million recorded on the condensed
balance sheets as of September 30, 2017, as a prepaid expense, in connection with a startup fee related to the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Mustang
Bio, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Notes
to the Condensed Financial STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">(UNAUDITED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Research and Development Expenses &ndash;
All Licenses</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three and nine months ended September
30, 2017 and 2016, the Company recorded the following expense in research and development for licenses acquired:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Three Months Ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Nine Months Ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">($ in thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP>City of Hope</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; padding-left: 9pt">IL13R&alpha;2</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">250</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">IV/ICV</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">PSCA</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">HER2</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">CS-1</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>UCLA</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Fred Hutch CD20</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">300</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">300</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">300</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,375</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Note 4 - Related Party Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Founders Agreement and Management Services
Agreement with Fortress</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective March 13, 2015, the Company entered
into a Founders Agreement with Fortress, which was amended and restated on May 17, 2016 and again on July 26, 2016 (the &ldquo;Mustang
Founders Agreement&rdquo;). The Mustang Founders Agreement provides that, in exchange for the time and capital expended in the
formation of Mustang and the identification of specific assets the acquisition of which result in the formation of a viable emerging
growth life science company, Fortress loaned $2.0 million, representing the up-front fee required to acquire the Company&rsquo;s
license agreement with COH. The Mustang Founders Agreement has a term of 15 years, which upon expiration automatically renews for
successive one-year periods unless terminated by Fortress and the Company or a Change in Control (as defined in the Mustang Founders
Agreement) occurs. Concurrently with the second amendment on July 26, 2016 to the Mustang Founders Agreement, Fortress entered
into an Exchange Agreement whereby Fortress exchanged its 7.25 million Class B common shares for 7.0 million common shares and
250,000 Class A preferred shares. Class A Preferred Stock is identical to common shares other than as to voting rights, conversion
rights and the PIK Dividend right (as described below). Each share of Class A Preferred Stock will be entitled to vote the number
of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the shares of outstanding
Mustang common stock and (B) the whole shares of Mustang common stock into which the shares of outstanding Class A common shares
and Class A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred
Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority. Each share of Class A Preferred Stock
is convertible, at Fortress&rsquo; option, into one fully paid and nonassessable share of Mustang common stock, subject to certain
adjustments. As holders of Class A Preferred Stock, Fortress will receive on each March 13 (each a &ldquo;PIK Dividend Payment
Date&rdquo;) until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase
price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (&ldquo;PIK
Dividends&rdquo;) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two
and one-half percent (2.5%) of Mustang&rsquo;s fully-diluted outstanding capitalization on the date that is one (1) business day
prior to any PIK Dividend Payment Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As additional consideration under the Mustang
Founders Agreement, Mustang will also: (i) pay an equity fee in shares of common stock, payable within five (5) business days of
the closing of any equity or debt financing for Mustang or any of its respective subsidiaries that occurs after the effective date
of the Mustang Founders Agreement and ending on the date when Fortress no longer has majority voting control in the Company&rsquo;s
voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee
equal to four and one-half percent (4.5%) of the Company&rsquo;s annual net sales, payable on an annual basis, within ninety (90)
days of the end of each calendar year. In the event of a Change in Control, the Company will pay a one-time change in control fee
equal to five (5x) times the product of (A) net sales for the twelve (12) months immediately preceding the change in control and
(B) four and one-half percent (4.5%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 34.1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Mustang
Bio, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Notes
to the Condensed Financial STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">(UNAUDITED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 13, 2016, pursuant to the then in effect Mustang Founders
Agreement, on the anniversary date of the Founders&rsquo; Agreement, the Company issued 250,000 shares of its Class B common stock
to Fortress representing 2.5% of the fully diluted outstanding shares of the Company. Pursuant to the terms of the Mustang Founders
Agreement, as amended in July 2016, this equity fee is no longer payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective as of March 13, 2015, the Company
entered into a Management Services Agreement (the &ldquo;MSA&rdquo;) with Fortress. Pursuant to the terms of the MSA, for a period
of five years, Fortress will render advisory and consulting services to the Company. Services provided under the MSA may include,
without limitation, (i) advice and assistance concerning any and all aspects of the Company&rsquo;s operations, clinical trials,
financial planning and strategic transactions and financings and (ii) conducting relations on behalf of the Company with accountants,
attorneys, financial advisors and other professionals (collectively, the &ldquo;Services&rdquo;). The Company is obligated to utilize
clinical research services, medical education, communication and marketing services and investor relations/public relation services
of companies or individuals designated by Fortress, provided those services are offered at market prices. However, the Company
is not obligated to take or act upon any advice rendered from Fortress and Fortress shall not be liable for any of its actions
or inactions based upon their advice. Fortress and its affiliates, including the Company&rsquo;s Board of Directors, have been
contractually exempt from fiduciary duties to the Company relating to corporate opportunities. In consideration for the Services,
the Company will pay Fortress an annual consulting fee of $0.5 million (the &ldquo;Annual Consulting Fee&rdquo;), payable in advance
in equal quarterly installments on the first business day of each calendar quarter in each year, provided, however, that such Annual
Consulting Fee shall be increased to $1.0 million for each calendar year in which the Company has net assets in excess of $100
million at the beginning of the calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended September 30, 2017
and 2016, the Company recorded approximately $0.1 million and $0.1 million, respectively, as expense related to the MSA.
For the nine months ended September 30, 2017 and 2016, the Company recorded approximately $0.4 million and $0.4 million, respectively,
as expense related to the MSA. For the three and nine months ended September 30, 2017 and 2016, respectively, expenses related
to the MSA are recorded 50% in research and development expenses and 50% in general and administrative expenses on the condensed
consolidated statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Consulting Agreement with Chord Advisors,
LLC (&ldquo;Chord&rdquo;)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 8, 2016, the Company entered into
a full-service consulting agreement with Chord to provide advisory accounting services to the Company. Under the terms of the agreement,
the Company paid Chord up to $5,000 per month to perform back office accounting functions, accounting analysis and financial reporting
prior to the Company&rsquo;s filing of its Registration Statement on Form 10 on July 27, 2016, and $7,500 per month following that
date. Either party upon 30-days written notice can terminate the agreement. In addition to these services, Mr. Horin, a Managing
Partner of Chord, serves as the Company&rsquo;s Interim Chief Financial Officer. Chord also provides advisory accounting services
to Fortress under a separate agreement. For the three months ended September 30, 2017 and 2016, $22,500 and $17,500, respectively,
of expense was recognized. For the nine months ended September 30, 2017 and 2016, $67,500 and $30,300, respectively, of expense
was recognized. The expense was recorded in general and administrative expenses on the condensed statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Payable and Accrued Expenses Related Party</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company had a working capital promissory
note with Fortress, which was paid in full in 2016. In 2017, in the normal course of business Fortress pays for certain expenses
on behalf of the Company. Such expenses are recorded as Payable and accrued expenses &ndash; related party and are reimbursed to
Fortress in the normal course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>National Securities Inc.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fortress owns approximately 56.6% of National
Holdings Corporation (&ldquo;NHLD&rdquo;). National Securities Inc. (&ldquo;NSC&rdquo;) a subsidiary of NHLD acted as placement
agent for the Company&rsquo;s third-party financings (see Note 6). For the nine months ended September 30, 2017, the Company paid
NSC placement agent fees of $5.6 million and issued to NSC 861,077 warrants to purchase the Company&rsquo;s common stock. The warrants
have a five-year term and an exercise price of $8.50 per share. No fees were incurred for the three and nine months ended September
30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Mustang
Bio, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Notes
to the Condensed Financial STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">(UNAUDITED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Director Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Dr. Rosenwald</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the terms of the
Director Compensation Plan, Dr. Rosenwald will receive a cash fee of $50,000 per year paid quarterly and an annual stock
award of the greater of (i) a number of shares of common stock having a fair market value on the grant date of $50,000 or
(ii) 10,000 shares of common stock, which shares shall vest and become non-forfeitable on the third anniversary of the grant
date, subject to continued service on the Board on such date. For the three and nine months ended September 30, 2017, the
Company recognized $12,500 and $25,052, in expense in its Condensed Statements of Operations related to the director
compensation, including approximately $4,900 in expense related to an annual equity incentive grant of 10,000 restricted
shares. No expense was recorded in 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Mr. Weiss - Advisory Agreement with Caribe
BioAdvisors, LLC</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board of the Company by unanimous
written consent approved and authorized the execution of an advisory agreement dated January 1, 2017 (the &ldquo;Advisory
Agreement&rdquo;), with Caribe BioAdvisors, LLC (the &ldquo;Advisor&rdquo;), owned by Michael S. Weiss, the Chairman of the
Board, to provide the board advisory services of Mr. Weiss as Chairman of the Board. Pursuant to the Advisory Agreement, the
Advisor will be paid an annual cash fee of $60,000, paid quarterly and an annual stock award of the greater of (i) a number
of shares of common stock having a fair market value on the grant date of $50,000 or (ii) 10,000 shares of common stock,
which shares shall vest and become non-forfeitable on the third anniversary of the grant date, subject to continued service
on the Board on such date. For three and nine months ended September 30, 2017, the Company recognized $15,000 and $46,200,
respectively, in expense in its Condensed Statements of Operations related to the advisory agreement, including approximately
$4,800 and $6,000, respectively, in expense related to an annual equity incentive grant of 10,000 restricted shares. No
expense was recorded in 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Stock Awards Made to Fortress Employees</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2017, the Company made an option award
to two employees of Fortress (see Note 7).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 5 - Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Litigation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2016, Dr. Winson Tang
(&ldquo;Plaintiff&rdquo;) filed a Complaint against the Company in the Superior Court of the State of California, County of
Los Angeles. Winson Tang v. Lindsay Rosenwald et al., Case No. BC607346. As amended, the Complaint requested a declaration
that Plaintiff was a 15% owner of the Company&rsquo;s outstanding shares, and alleged two claims for breach of contract
against other Defendants. On November 3, 2017, Plaintiff and Defendants entered into a Settlement Agreement. The Settlement
Agreement did not require issuance of any new shares of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the legal settlement,
above, Fortress is required to deliver 200,000 Mustang common shares, held by Fortress, to Plaintiff in accordance with this
settlement arrangement. At September 30, 2017, the Company recorded this transaction as a capital contribution from Fortress
and a corresponding expense of approximately $2.1 million based upon the closing share price of Mustang shares as of the date
of the Settlement Agreement. In addition to the share issuance the Company paid, in November 2017, a $0.1 million cash settlement to
the plaintiff, such amount was accrued as of September 30, 2017 and recorded in general and administrative expenses on the
Condensed Consolidated Statements of Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center">Mustang
Bio, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center">Notes
to the Condensed Financial STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">(UNAUDITED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 6 - Net Loss per Share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net loss per share is computed by dividing
net loss by the weighted average number of common shares outstanding during the period less unvested restricted stock. Since dividends
are declared, paid and set aside among the holders of shares of common stock and Class A common shares pro-rata on an as-if-converted
basis, the two-class method of computing net loss per share is not required. Diluted net loss per share does not reflect the effect
of shares of common stock to be issued upon the exercise of warrants or outstanding Class A preferred shares, as their inclusion
would be anti-dilutive. The table below summarizes potentially dilutive securities that were not considered in the computation
of diluted net loss per share because they would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Potentially dilutive securities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the nine months ended September 30</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Warrants (Note 7)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">5,257,434</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">670,191</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Options (Note 7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,241,675</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Class A Preferred Shares (Note 7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Unvested restricted stock awards (Note 7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Unvested restricted stock units (Note 7)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">110,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,039,109</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">920,191</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Note 7 - Stockholders&rsquo; Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is authorized to issue 50,000,000
common shares with a par value of $0.0001 per share, of which 1,000,000 shares are designated as &ldquo;Class A common shares&rdquo;
and 2,000,000 of Preferred Stock at $0.0001 par value and 250,000 of which are designated as Class A Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Founders Agreement, on March
13, 2016 the Company issued 250,000 shares of Class B common stock to Fortress, which equaled 2.5% of the fully diluted outstanding
equity of Mustang at the time of issuance for the annual equity fee. In accordance with the amended and restated certificate of
incorporation filed on July 27, 2016, the Company issued 250,000 shares of Class A Preferred Stock, 7.0 million common shares and
cancelled 7.2 million Class B common shares. This exchange was recorded as an equity transaction and therefore no gain or loss
was recorded (see Note 4).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 31.9pt">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2017, COH executed a waiver and
acknowledgement agreement permitting issuance of the COH Anti-Dilution Shares in the form of Mustang common stock rather than Class
A common shares as originally required, and such shares were issued. Therefore, in February 2017, the Company reclassed $1.7 million
of common shares issuable liability to additional paid-in capital and issued 293,588 common shares to COH. As of September 30,
2017, COH owns 1,000,000 Class A common shares and 293,588 common shares. The shares were valued utilizing a weighted market model
at approximately $5.73 per share or approximately $1.7 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 13, 2017, the Company issued to Fortress
767,264 shares of common stock at $5.73 per share representing the stock dividend payable in connection with Fortress&rsquo; ownership
of Class A Preferred Stock. Pursuant to this issuance, the Company recorded a $4.4 million decrease in common shares issuable and
a corresponding increase in additional paid in capital to account for the issuance of the PIK Dividend (see Note 4).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 29.7pt">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The holders of common stock are entitled to
one vote per share of common stock held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Class A Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The holders of Class A common shares are entitled
to the number of votes equal to the number of whole shares of common stock into which the shares of Class A common shares held
by such holder are convertible and for a period of ten years from its issuance, the holders of the Class A common shares have the
right to appoint one member of the board of directors of Mustang; to date, the holders of Class A common shares have not yet appointed
such director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center">Mustang
Bio, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Notes
to the Condensed Financial STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">(UNAUDITED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 17, 2015, the Company entered into
the Original Agreement with COH to acquire intellectual property rights pertaining to CAR-T, (see Note 3). Pursuant to the Original
Agreement, the Company paid COH an upfront fee of $2.0 million, in April 2015 (included in research and development-licenses acquired
expenses on the Statements of Operations), and granted 1,000,000 shares of Mustang&rsquo;s Class A common shares, representing
10% ownership of Mustang, as of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Offerings and Issuances of Common Stock
and Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2016, the Company entered into
a Placement Agent Agreement with NSC relating to the Company&rsquo;s offering of shares of common stock in a private placement.
Pursuant to the Placement Agent Agreement, the Company agreed to pay NSC a cash fee of 10.0% of the gross proceeds from the offering
and granted a warrant exercisable for shares of common stock equal to 10.0% of the aggregate number of shares of common stock sold
in the offering (the &ldquo;Placement Agent Warrants&rdquo;). In addition, the Company and the investors entered into a unit purchase
agreement (the &ldquo;Unit Purchase Agreement&rdquo;). The common stock and Warrants were sold in units, with each unit consisting
of 10,000 shares of the Company&rsquo;s common stock, and Warrants exercisable for 2,500 shares of common stock at an exercise
price of $8.50 per share. The purchase price was $65,000 per unit. The warrants have a five-year term and are only exercisable
for cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 31, 2017, the Company closed the
sixth round of financing totaling gross proceeds of $55.5 million, before expenses, in a private placement of shares and warrants
for which NSC was the placement agent and received a fee of $5.5 million or approximately 10% of the gross proceeds. The Company
issued 8,536,774 unregistered shares of common stock and 2,134,193 warrants in connection with this transaction. In addition, NSC
received 853,677 warrants or approximately 10% of the shares issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 31, 2017, the Company closed the seventh
round of financing totaling gross proceeds of $0.4 million, before expenses, in a private placement of shares and warrants for
which NSC was the placement agent and received a fee of approximately $42,000 or approximately 10% of the gross proceeds. The Company
issued 64,000 unregistered shares of common stock and 16,000 warrants in connection with this transaction. In addition, NSC received
6,400 warrants or approximately 10% of the shares issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 3, 2017, the Company closed the final
round of financing totaling gross proceeds of $65,000. The Company issued 10,000 unregistered shares of common stock and 2,500
warrants in connection with this transaction. In addition, NSC received 1,000 warrants or approximately 10% of the shares issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Common Share Issuances to Fortress</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Founders Agreement, the Company
issued 215,269 shares and 47,870 shares to Fortress during the nine months ended September 30, 2017 and September 30, 2016, respectively,
representing 2.5% of the aggregate number of shares of common stock issued in the offerings noted above. For the nine months ended
September 30, 2017 and September 30, 2017, the Company recorded expense of approximately $1.2 million and $0.3 million, respectively,
related to this issuance (based upon the fair value of common shares on the date of issuance), which is included in general and
administrative expenses in the Company&rsquo;s Statements of Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Class A Preferred Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Company&rsquo;s Amended and
Restated Articles of Incorporation, 2,000,000 shares of Preferred Stock were authorized, of which 250,000 have been designated
as Class A Preferred Stock and the remainder are undesignated preferred stock. The Class A Preferred Stock is identical to undesignated
common stock other than as to voting rights, conversion rights, and the PIK Dividend right (as described below). The undesignated
Preferred Stock may be issued from time to time in one or more series. The Company&rsquo;s Board of Directors is authorized to
determine or alter the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including
sinking fund provisions, if any), the redemption price or prices, the liquidation preferences and other designations, powers, preferences
and relative, participating, optional or other special rights, if any, and the qualifications, limitations and restrictions granted
to or imposed upon any wholly unissued series of Preferred Stock, and to fix the number of shares of any series of Preferred Stock
(but not below the number of shares of any such series then outstanding).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Mustang
Bio, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Notes
to the Condensed Financial STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">(UNAUDITED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The holders of the outstanding shares of Class
A Preferred Stock shall receive on each March 13 (each a &ldquo;PIK Dividend Payment Date&rdquo;) after the original issuance date
of the Class A Preferred Stock until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed
(and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and non-assessable shares
of common stock such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to 2.5%
of the Corporation&rsquo;s fully-diluted outstanding capitalization on the date that is one business day prior to any PIK Dividend
Payment Date (&ldquo;PIK Record Date&rdquo;). In the event the Class A Preferred Stock converts into common stock, the holders
shall receive all PIK Dividends accrued through the date of such conversion. No dividend or other distribution shall be paid, or
declared and set apart for payment (other than dividends payable solely in capital stock on the capital stock of the Company) on
the shares of common stock until all PIK Dividends on the Class A Preferred Stock shall have been paid or declared and set apart
for payment. All dividends are non-cumulative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On any matter presented to the stockholders
of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders
in lieu of meeting), each holder of outstanding shares of Class A Preferred Stock shall be entitled to cast for each share of Class
A Preferred Stock held by such holder as of the record date for determining stockholders entitled to vote on such matter, the number
of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the number of shares
of outstanding common stock and (B) the whole shares of common stock in to which the shares of outstanding Class A common shares
and the Class A Preferred Stock are convertible, and the denominator of which is number of shares of outstanding Class A Preferred
Stock (the &ldquo;Class A Preferred Stock Ratio&rdquo;). Thus, the Class A Preferred Stock will at all times constitute a voting
majority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each share of Class A Preferred Stock is convertible,
at the option of the holder, into one fully paid and nonassessable share of common stock (the &ldquo;Conversion Ratio&rdquo;),
subject to certain adjustments. If the Company, at any time effects a subdivision or combination of the outstanding common stock
(by any stock split, stock dividend, recapitalization, reverse stock split or otherwise), the applicable Conversion Ratio in effect
immediately before that subdivision is proportionately decreased or increased, as applicable, so that the number of shares of common
stock issuable on conversion of each share of Class A Preferred Stock shall be increased or decreased, a applicable, in proportion
to such increase or decrease in the aggregate number of shares of common stock outstanding. Additionally, if any reorganization,
recapitalization, reclassification, consolidation or merger involving the Company occurs in which the common stock (but not the
Class A Preferred Stock) is converted into or exchanged for securities, cash or other property, then each share of Class A Preferred
Stock becomes convertible into the kind and amount of securities, cash or other property which a holder of the number of shares
of common stock of the Company issuable upon conversion of one share of the Class A Preferred Stock immediately prior to such reorganization,
recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Stock Awards</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Stock Options&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 24, 2017, the Company announced that
Manuel Litchman, M.D., had been appointed President and Chief Executive Officer. Dr. Litchman was also appointed to the Company&rsquo;s
Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The employment agreement grants Dr. Litchman
an option to purchase 1,041,675 shares of the Company&rsquo;s common stock (the &ldquo;Option&rdquo;). The Option has an exercise
price per share equal to the fair market value of a share the Company&rsquo;s common stock, $5.73 on the date of the grant of the
stock option, subject to the conditions and vesting schedule set forth in his Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center">Mustang
Bio, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center">Notes
to the Condensed Financial STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">(UNAUDITED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 7, 2017, the Company granted 200,000
options to two employees of Fortress, who provide services to the Company in connection with our research and development. These
options have an exercise price of $5.73, representing the fair market value of a share the Company&rsquo;s common stock on the
date of the grant of the stock option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Both grants have the following vesting schedule:
50% of the options vest over-time (&ldquo;Time Based Option&rdquo;) with 25% vesting over 12 months of continued service and the
remaining shares vesting in 12 equal quarterly installments thereafter, subject to continued employment. The remaining 50% (the
&ldquo;Performance Options&rdquo;) vest and become exercisable upon the occurrence of the following milestones being achieved: (i) 25%
of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of any Company product
candidate, (ii) 25% of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of
a second Company product candidate, (iii) 25% of the Performance Options vest upon the Company&rsquo;s achievement of a fully-diluted
market capitalization of $500,000,000 and (iv) 25% of the Performance Options vest upon the Company&rsquo;s achievement of a fully-diluted
market capitalization of $1,000,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The value of the stock options
granted approximated $5.5 million and was determined on the grant date using assumptions for risk free interest rate, the
expected term, expected volatility, expected dividend yield, and an exercise price of $5.73. Mustang does not expect to pay
dividends in the foreseeable future. As a result, the expected dividend yield is 0%. The fair value associated with the
market award vesting was determined utilizing a binomial valuation methodology and the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,&nbsp;2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.81% - 2.38</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 85%">Exercise Price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">5.73</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected term in years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5.5 - 10.0</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77.3</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes stock option activities for the nine
months ended September 30, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average<BR> Exercise Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average<BR> Remaining<BR> Contractual Life (in<BR> years)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Nonvested at December 31, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 55%; text-align: left">Options granted</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,241,675</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">5.73</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">9.56</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Options outstanding</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,241,675</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5.73</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9.56</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Options vested and exercisable at September 30, 2017</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2017, the Company had unrecognized
stock-based compensation expense related to options of $2.3 million with a weighted average vesting period of 1.61 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Restricted Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with the Company&rsquo;s Director
Compensation Plan, the Company granted an aggregate 180,000 restricted shares to members of its board of directors, these shares
commence vesting three years from the grant date of June 8, 2017. Annual grants to each director of 10,000 shares vest on the third
anniversary of the grant with continuous service, while the initial grant of 50,000 vests in three equal tranches commencing on
the third anniversary date of the grant and on each date thereafter so long as continuous service exists. See Note 4 for grants
made to Dr. Rosenwald and Mr. Weiss for their service as Directors to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Mustang
Bio, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">Notes
to the Condensed Financial STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">(UNAUDITED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes restricted stock award activities
for the nine months ended September 30, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average<BR> Grant&nbsp;Date Fair Value</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Nonvested at December 31, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; padding-bottom: 1pt">Granted</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">180,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">5.73</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Nonvested at September 30, 2017</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">180,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5.73</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2017, the Company had unrecognized
stock-based compensation expense related to restricted stock of $1.0 million with a weighted average vesting period of 3.53 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Restricted Stock Units</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 30, 2017, the Company granted an
aggregate of 110,000 restricted stock units to two employees. These grants vest over 4 years on the anniversary date of the
grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes restricted stock units activities
for the nine months ended September 30, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Units</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average<BR> Grant&nbsp;Date Fair Value</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Nonvested at December 31, 2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; padding-bottom: 1pt">Granted</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">110,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">5.73</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Nonvested at September 30, 2017</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">110,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5.73</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2017, the Company had unrecognized
stock-based compensation expense related to restricted stock units of approximately $0.6 million with a weighted average vesting
period of 2.25 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes stock-based
compensation expense for the three and nine months ended September 30, 2017 (in thousands).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the three months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the nine months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%">Employee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">576</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">909</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Non-employee</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">258</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">321</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">834</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,230</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Company&rsquo;s offering
of shares of common stock in a private placement, each investor received a warrant equal to 25% of the common shares purchased
in connection with the offering. Further, NSC received Placement Agent Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of warrant activities for nine months
ended September 30, 2017 is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warrants</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average<BR> Exercise Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average<BR> Remaining<BR> Contractual Life (in<BR> years)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%">Outstanding as of December 31, 2016</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">2,243,664</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">7.98</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">5.16</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Granted</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,013,770</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8.50</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.34</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Outstanding as of September 30, 2017</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,257,434</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8.28</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4.37</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center">Mustang
Bio, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center">Notes
to the Condensed Financial STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center">(UNAUDITED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon the exercise of warrants, the Company
will issue new shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note 8 &ndash; Subsequent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 27, 2017, Mustang entered
into a lease agreement with WCS - 377 Plantation Street, Inc., a Massachusetts nonprofit corporation
(&ldquo;Landlord&rdquo;). Pursuant to the terms of the lease agreement, Mustang agreed to lease 27,043 sf from the Landlord,
located at 377 Plantation Street in Worcester, MA (the &ldquo;Facility&rdquo;), through November 2026, subject to additional
extensions at Mustang&rsquo;s option. Base rent, net of abatements of $0.6 million over the lease term, totals approximately
$3.6 million, on a triple-net basis. Mustang plans to make improvements to the facility of approximately $3.5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The terms of the lease also require that
Mustang post an initial security deposit of $0.8 million, in the form of $0.5 million letter of credit and $0.3 million in
cash, which shall increase to $1.3 million ($1.0 million letter of credit, $0.3 million in cash) when the Facility is fully
occupied by Mustang. After the fifth lease year, the letter of credit obligation is subject to reduction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #1F497D">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Facility is expected to be operational for the production of
personalized CAR T therapies in 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><A NAME="a_008"></A>Item 2.</TD><TD>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>You should read the following discussion
and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and
the related notes included elsewhere in this Form 10-Q. Our consolidated financial statements have been prepared in accordance
with U.S. GAAP. The following discussion and analysis contains forward-looking statements within the meaning of Section&nbsp;27A
of the Securities Act of 1933 and Section&nbsp;21E of the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;), including,
without limitation, statements regarding our expectations, beliefs, intentions or future strategies that are signified by the words
&ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe,&rdquo; &ldquo;may,&rdquo; &ldquo;plan&rdquo;,
&ldquo;seek&rdquo; or similar language. All forward-looking statements included in this document are based on information available
to us on the date hereof, and we assume no obligation to update any such forward-looking statements. Our business and financial
performance are subject to substantial risks and uncertainties. Actual results could differ materially from those projected in
the forward-looking statements. In evaluating our business, you should carefully consider the information set forth under the heading
&ldquo;Risk Factors&rdquo; herein.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a clinical-stage biopharmaceutical company
focused on the acquisition, development and commercialization of novel cancer immunotherapy products designed to utilize the power
of the patient&rsquo;s own immune system to eliminate cancer cells. We aim to acquire rights to these technologies by licensing
or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either
out-licensing or bringing the technologies to market. <FONT STYLE="color: #333333; background-color: white">We have partnered with
the City of Hope National Medical Center (&ldquo;COH&rdquo;) and Fred Hutchinson Cancer Research Center (&ldquo;Fred Hutch&rdquo;)
in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers<FONT STYLE="font-family: Times New Roman, Times, Serif">.
</FONT>We believe that harnessing the body&rsquo;s own immune system to treat cancer is the next generation of cancer care that
may prove curative across tumor types that have proved resilient to standard pharmacological and biological treatments.&nbsp; CAR
T uses the patient&rsquo;s own T-cells to engage and destroy specific tumors.&nbsp; The process involves selecting specific T-cell
subtypes, genetically engineering them to express chimeric antigen T-cell receptors and placing them back in the patient where
they recognize and destroy cancer cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2017, we entered into an exclusive, worldwide licensing
agreement with Fred Hutch, effective July 3, 2017, for the use of a CAR T therapy related to autologous T cells engineered to express
a CD20-specific chimeric antigen receptor (&ldquo;CD20 Technology&rdquo; or &ldquo;CD 20&rdquo;). The CAR T was developed in the
laboratory of Oliver Press, M.D., Ph.D., and Brian Till, M.D., in Fred Hutch&rsquo;s Clinical Research Division. As part of the
transaction, we also entered into an investigator-initiated clinical trial agreement to provide partial funding for a Phase 1/2
clinical trial at Fred Hutch evaluating the safety and efficacy of the CD20 Technology in patients with relapsed or refractory
B-cell non-Hodgkin lymphomas. We expect to initiate this trial the fourth quarter of 2017, and will be led by principal investigator
Mazyar Shadman, M.D., Assistant Member of Fred Hutch&rsquo;s Clinical Research Division.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On August 22, 2017, we commenced trading on the Nasdaq Global Market
under the symbol MBIO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 31, 2017, we entered into exclusive,
worldwide licensing agreements with COH for the use of three novel CAR T therapies in the development of cancer treatments. The
CAR T therapies covered under the agreements include: human epidermal growth factor receptor 2 (HER2) CAR T technology (HER2 Technology),
which will initially be applied in the treatment of glioblastoma multiforme; CS1-specific CAR T technology (CS1 Technology) to
be directed against multiple myeloma; and prostate stem cell antigen (PSCA) CAR T technology (PSCA Technology) to be used in the
treatment of prostate cancer. All three technologies were developed in the laboratory of Stephen J. Forman, M.D., director of COH&rsquo;s
T cell Immunotherapy Research Laboratory, and are still in preclinical development. Currently, we have two candidates undergoing
Phase 1 studies at COH: IL13R&alpha;2 CAR T technology (IL13R&alpha;2 Technology) for glioblastoma and CD123 CAR T technology (CD123
Technology) for acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2017, we appointed Manuel Litchman,
M.D., as President and Chief Executive Officer. Dr. Litchman also joined our Board of Directors. Michael S. Weiss, who oversaw
Mustang&rsquo;s corporate operations on an interim basis, will continue to serve as Chairman of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To date, we have not received approval for
the sale of our product candidates in any market and, therefore, have not generated any product sales from our product candidates.
In addition, we have incurred substantial operating losses since our inception, and expect to continue to incur significant operating
losses for the foreseeable future and may never become profitable. As of September 30, 2017, we have an accumulated deficit of
$32.8 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Comparison of the Three Months Ended
September 30, 2017 and 2016</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the three months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left; padding-left: 9pt">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,188</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">569</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,619</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">285</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Research and development &ndash; licenses acquired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,596</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,101</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,495</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">317</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,084</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,670</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,414</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">324</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Loss from operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,084</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,670</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,414</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">324</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest expense - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(46</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-100</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(156</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-100</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Change in fair value of derivative liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">-100</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total other expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">144</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">344</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">-172</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(6,940</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,870</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(5,070</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">271</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Research and Development Expenses</I></B>
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses primarily
consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation,
payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to
third-party contract research organizations for preclinical and clinical studies, investigative sites for clinical trials, consultants,
the cost of acquiring and manufacturing clinical trial materials, costs associated with regulatory filings, laboratory costs and
other supplies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended September 30, 2017
and 2016, research and development expenses were $2.2 million and $0.6 million, respectively. The increase of $1.6 million pertains
to: $0.2 million in connection with our IL13Ra2 Clinical Research Agreement (&ldquo;CRA&rdquo;), $0.6 million in connection with
our CD123 CRA, and $88,000 related to our CRA with Fred Hutch. Additionally, we incurred $0.3 million for personnel costs, $0.1
million for other activities and $0.3 million in stock compensation for equity awards to employees and consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended September 30,
2017 and 2016, research and development expenses for licenses acquired were approximately $0.3 million and nil. The increase
of $0.3 million pertains to the acquisition of our license from Fred Hutch for CD20.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect our research and development activities
to increase as we develop our existing product candidates and potentially acquire new product candidates, reflecting increasing
costs associated with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">employee-related expenses, which include salaries and benefits, and rent expense;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">license fees and milestone payments related to in-licensed products and technology;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">expenses incurred under agreements with contract research organizations, investigative sites and
consultants that conduct our clinical trials and our preclinical activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the cost of acquiring and manufacturing clinical trial materials; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">costs associated with non-clinical activities, and obtaining regulatory approvals.&nbsp;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses consist
primarily of salaries and related expenses, including stock-based compensation, for executives and other administrative personnel,
recruitment expenses, professional fees and other corporate expenses, including investor relations, legal activities including
patent fees, and facilities-related expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended September 30,
2017 and 2016, general and administrative expenses were $4.6 million and $1.1 million, respectively. The increase of $3.5
million is attributed to $0.5 million of legal fees, $0.3 million of costs associated with our listing on the Nasdaq Global
Market, $2.2 million related to a legal settlement of which $2.1 million relates to the  value of the 200,000 Mustang
common shares contributed by Fortress and $0.1 million relates to a cash payment, $0.2 million of personnel costs and $0.1 million
of consulting fees. Additionally, stock compensation expense increased by $0.2 million primarily related to $0.5 million for
the equity award to our chief executive officer offset by a reduction of $0.3 million of expense recognized in 2016 relating
to a financing fee we paid to Fortress in connection with our capital raise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We anticipate general and administrative expenses
will increase in future periods, reflecting continued and increasing costs associated with:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">support of our expanded research and development activities, including additional product candidates
entering the clinic;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">stock compensation granted to key employees and non-employees;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">support of business development activities; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">increased professional fees and other costs associated with the regulatory requirements and increased
compliance associated with being a public reporting company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Comparison of the Nine Months Ended September
30, 2017 and 2016</I></B> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the nine months ended September 30,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left; padding-left: 9pt">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5,388</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,718</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,670</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">214</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Research and development &ndash; licenses acquired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,375</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,375</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,293</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,814</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,479</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">357</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,056</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,532</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,524</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">355</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Loss from operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(16,056</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,532</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(12,524</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">355</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">369</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">369</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest expense - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(220</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">220</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-100</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(156</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-100</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Change in fair value of derivative liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">-100</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total other expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">369</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(374</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">743</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">-199</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(15,687</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(3,906</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(11,781</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">302</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Research and Development Expenses</I></B>
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the nine months ended September 30, 2017
and 2016, research and development expenses were $5.4 million and $1.7 million, respectively. The increase of $3.7 million consists
of $1.3 million for costs under the CD123 CRA, $1.2 million for costs under the IL13Ra2 CRA, $88,000 in connection with our Fred
Hutch CRA, $0.5 million for personnel cost due to the hiring of research and development employees, $0.4 million of stock compensation
expenses in connection with grants made to employees and consultants, and $0.2 million related to outside services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the nine months ended September 30, 2017
and 2016, research and development expenses for licenses acquired were approximately $2.4 million and nil, respectively. The increase
of $2.4 million is attributed to $0.3 million related to an upfront fee for our PSCA license, $0.6 million related to an upfront
fee for our HER2 license, $0.6 million related to an upfront fee for our CS1 license, $0.1 million upfront payment related to the
acquisition of our IV-ICV license and $0.3 million in connection with the achievement of a milestone pursuant to our IL13Ra2 license.
Additionally, we incurred expenses of $0.2 million related to the acquisition of our license from UCLA and $0.3 million related
to the acquisition of our license from Fred Hutch for CD20.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect our research and development activities
to increase as we develop our existing product candidates and potentially acquire new product candidates, reflecting increasing
costs associated with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">employee-related expenses, which include salaries and benefits, and rent expense;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">license fees and milestone payments related to in-licensed products and technology;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">expenses incurred under agreements with contract research organizations, investigative sites and
consultants that conduct our clinical trials and our preclinical activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the cost of acquiring and manufacturing clinical trial materials; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">costs associated with non-clinical activities, and obtaining regulatory approvals.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses consist
primarily of salaries and related expenses, including stock-based compensation, for executives and other administrative personnel,
recruitment expenses, professional fees and other corporate expenses, including investor relations, legal activities including
patent fees, and facilities-related expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the nine months ended September 30,
2017 and 2016, general and administrative expenses were $8.3 million and $1.8 million, respectively. For the nine months
ended September 30, 2017, the increase of $6.5 million relates to $1.8 million in stock compensation expense, of which $1.0
million is related to the fee received by Fortress on third party financings pursuant to our Founders Agreement with Fortress
and $0.8 million related to expense for the equity award to our CEO, $1.2 million for legal fees, $0.9 million for outside
services of which $0.3 million relates to cost in connection with our listing on Nasdaq, $0.3 million of personnel costs
primarily related to the hiring of our chief executive officer and $2.2 million related to a legal settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We anticipate general and administrative expenses
will increase in future periods, reflecting continued and increasing costs associated with:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">support of our expanded research and development activities, including additional product candidates
entering the clinic;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">stock compensation granted to key employees and non-employees;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">support of business development activities; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">increased professional fees and other costs associated with the regulatory requirements and increased
compliance associated with being a public reporting company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have incurred substantial operating losses
since our inception and expect to continue to incur significant operating losses for the foreseeable future and may never become
profitable. As of September 30, 2017, we had an accumulated deficit of $32.8 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From September 30, 2016 through September 30,
2017, we received net proceeds of $50.3 million in eight separate private placement closings. The financing involved the sale of
units, each consisting of 10,000 shares of common stock and a warrant exercisable for 2,500 shares of common stock at an exercise
price of $8.50 per share, for a purchase price of $65,000 per unit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect to use the net proceeds from
the above financing primarily for general corporate purposes, which may include financing our growth, developing new or
existing product candidates, and funding capital expenditures, acquisitions and investments. We currently anticipate that our
cash and short-term investment balances at September 30, 2017 are sufficient to fund our anticipated operating cash
requirements for at least the next 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Cash Flows for the Nine Months Ended September 30, 2017 and
2016</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the nine months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">($ in thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">Statement of cash flows data:</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total cash (used in)/provided by:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 9pt">Operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(7,781</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(1,866</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,485</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">49,976</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,984</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net increase in cash and cash equivalents</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,710</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,118</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Operating Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in operating activities was $7.8
million for the nine months ended September 30, 2017, compared to $1.9 million for the nine months ended September 30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in operating activities for the
nine months ended September 30, 2017 was primarily due to approximately $15.7 million in net loss, partially offset by $1.0. million
in change in operating liabilities, approximately $1.2 million related to the issuance of common shares under the Founders Agreement,
$2.4 million of research and development-licenses acquired, $1.2 million of non-cash stock compensation expenses and approximately
$2.1 million of capital contribution from Fortress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in operating activities for the
nine months ended September 30, 2016, of $1.9 million was primarily due to a $3.9 million in net loss, partially offset by $1.7
million related to changes in operating assets and liabilities and $0.3 million related to the issuance of common shares under
the Founders Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Investing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in investing activities was $36.5
million for the nine months ended September 30, 2017, representing our $34.1 million investment in certificates of deposits held
to maturity and $2.4 million related to upfront payments relating to our licenses. There was no cash used or provided from investing
activities for the nine months ended September 30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Financing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash provided by financing activities was
$50.0 million during the nine months ended September 30, 2017 due to $50.3 million of net proceeds from issuance of common stock,
offset by approximately $0.3 million of proceeds used to repay the Fortress Note. Net cash provided by financing activities of
$13.0 million during the nine months ended September 30, 2016 was due to $11.1 million of net proceeds for the issuance of common
stock and $3.6 million of proceeds from our NSC Note and $1.9 million of proceeds from our Fortress Note off set by the repayment
of our Fortress Note of $3.6 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are not party to any off-balance sheet transactions.
We have no guarantees or obligations other than those which arise out of normal business operations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><A NAME="a_009"></A>Item 3.</TD><TD>Quantitative and Qualitative Disclosures About Market Risks</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Market risk represents the risk of loss that
may result from the change in value of financial instruments due to fluctuations in their market price. Market risk is inherent
in all financial instruments. Market risk may be exacerbated in times of trading illiquidity when market participants refrain from
transacting in normal quantities and/or at normal bid-offer spreads.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 44pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our assets and liabilities are denominated
in U.S. dollars. Consequently, we have not considered it necessary to use foreign currency contracts or other derivative instruments
to manage changes in currency rates. We do not now, nor do we plan to, use derivative financial instruments for speculative or
trading purposes. However, these circumstances might change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The primary quantifiable market risk associated
with our financial instruments is sensitivity to changes in interest rates. Interest rate risk represents the potential loss from
adverse changes in market interest rates. We use an interest rate sensitivity simulation to assess our interest rate risk exposure.
For purposes of presenting the possible earnings effect of a hypothetical, adverse change in interest rates over the 12-month period
from our reporting date, we assume that all interest rate sensitive financial instruments will be impacted by a hypothetical, immediate
100 basis point increase in interest rates as of the beginning of the period. The sensitivity is based upon the hypothetical assumption
that all relevant types of interest rates that affect our results would increase instantaneously, simultaneously and to the same
degree. We do not believe that our cash and equivalents have significant risk of default or illiquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The sensitivity analyses of the interest rate
sensitive financial instruments are hypothetical and should be used with caution. Changes in fair value based on a 1% or 2% variation
in an estimate generally cannot be extrapolated because the relationship of the change in the estimate to the change in fair value
may not be linear. Also, the effect of a variation in a particular estimate on the fair value of financial instruments is calculated
independent of changes in any other estimate; in practice, changes in one factor may result in changes in another factor, which
might magnify or counteract the sensitivities. In addition, the sensitivity analyses do not consider any action that we may take
to mitigate the impact of any adverse changes in the key estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 44pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on our analysis, as of September 30,
2017, the effect of a 100+/- basis point change in interest rates on the value of our financial instruments and the resultant effect
on our net loss are considered immaterial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73.7pt; text-align: justify; text-indent: -73.7pt">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><A NAME="a_010"></A>Item 4.</TD><TD>Controls and Procedures</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Evaluation of Disclosure Controls and Procedures</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 44pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the supervision and with the participation
of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the
effectiveness, as of September 30, 2017, of the design and operation of our disclosure controls and procedures, as such term is
defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e). Based on this evaluation, our principal executive officer and principal
financial officer have concluded that, as of such date, our disclosure controls and procedures are effective to ensure that information
required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods
specified in the SEC&rsquo;s rules and forms, and that such information is accumulated and communicated to our management, including
our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Changes in Internal Control over Financial
Reporting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 44pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No change in internal control over financial
reporting occurred during the most recent quarter with respect to our operations, which materially affected, or is reasonable likely
to materially affect, our internal controls over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 44pt">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><A NAME="a_011"></A>PART II. OTHER INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><A NAME="a_012"></A>Item 1.</TD><TD>Legal Proceedings</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #1F497D">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2016, Dr. Winson Tang
(&ldquo;Plaintiff&rdquo;) filed a Complaint against the Company in the Superior Court of the State of California, County of
Los Angeles.&nbsp;&nbsp;<I>Winson Tang v. Lindsay Rosenwald et al.,&nbsp;</I>Case No. BC607346.&nbsp; As amended, the
Complaint requested a declaration that Plaintiff was a 15% owner of the Company&rsquo;s outstanding shares, and alleged two
claims for breach of contract against other Defendants.&nbsp; On November 3, 2017, Plaintiff and Defendants entered into a
Settlement Agreement.&nbsp; The Settlement did not require issuance of any new shares of the Company (see Note 5).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><A NAME="a_013"></A>Item 1A</TD><TD>Risk Factors</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>The following information sets forth risk
factors that could cause our actual results to differ materially from those contained in forward-looking statements we have made
in this report and those we may make from time to time. You should carefully consider the risks described below. Our business,
financial condition or results of operations could be harmed by any of these risks. The risks and uncertainties described below
are not the only ones we face. Additional risks not presently known to us or other factors not perceived by us to present significant
risks to our business at this time also may impair our business operations.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 31.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Our Business and Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We currently have no drug products for
sale. We are heavily dependent on the success of our product candidates, and we cannot give any assurances that any of our product
candidates will receive regulatory approval or be successfully commercialized.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To date, we have invested a significant portion
of our efforts and financial resources in the acquisition and development of our product candidates. We have not demonstrated our
ability to perform the functions necessary for the successful acquisition, development or commercialization of the technologies
we are seeking to develop. As an early stage company, we have limited experience and have not yet demonstrated an ability to successfully
overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly
in the biopharmaceutical area. Our future success is substantially dependent on our ability to successfully develop, obtain regulatory
approval for, and then successfully commercialize such product candidates. Our product candidates are currently in preclinical
development or in early stage clinical trials. Our business depends entirely on the successful development and commercialization
of our product candidates, which may never occur. We currently generate no revenues from sales of any drugs, and we may never be
able to develop or commercialize a marketable drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The successful development, and any commercialization,
of our technologies and any product candidates would require us to successfully perform a variety of functions, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">developing our technology platform;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">identifying, developing, manufacturing and commercializing product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">entering into successful licensing and other arrangements with product development partners;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">participating in regulatory approval processes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">formulating and manufacturing products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">obtaining sufficient quantities of our product candidates from our third-party manufacturers as
required to meet clinical trial needs and commercial demand at launch and thereafter;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">establishing and maintaining agreements with wholesalers, distributors and group purchasing organizations
on commercially reasonable terms;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">conducting sales and marketing activities including hiring, training, deploying and supporting
our sales force and creating market demand for our product candidates through our own marketing and sales activities, and any other
arrangements to promote our product candidates that we may later establish; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">maintaining patent protection and regulatory exclusivity for our product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our operations have been limited to organizing
our company, acquiring, developing and securing our proprietary technology and identifying and obtaining preclinical data or clinical
data for various product candidates. These operations provide a limited basis for you to assess our ability to continue to develop
our technology, identify product candidates, develop and commercialize any product candidates we are able to identify and enter
into successful collaborative arrangements with other companies, as well as for you to assess the advisability of investing in
our securities. Each of these requirements will require substantial time, effort and financial resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.4pt">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each of our product candidates will require
additional preclinical or clinical development, management of preclinical, clinical and manufacturing activities, regulatory approval
in multiple jurisdictions, obtaining manufacturing supply, building of a commercial organization, and significant marketing efforts
before we generate any revenues from product sales. We are not permitted to market or promote any of our product candidates before
we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory
approval for any of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Preclinical development is highly speculative
and has a high risk of failure.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Three of our current product candidates are in
Phase 1 clinical trials and three are preclinical. Our preclinical
product candidates have never been used in humans. Preclinical development is highly speculative and carries a high risk of failure.
We can provide no assurances that preclinical toxicology and/or preclinical activity of our product candidates will support moving
any of these product candidates into clinical development. If we are unsuccessful in our preclinical development efforts for any
of these product candidates and they fail to reach clinical development, it would have a material adverse effect on our business
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Delays in clinical testing could result
in increased costs to us and delay our ability to generate revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although we are planning for certain clinical
trials relating to our product candidates, there can be no assurance that the FDA will accept our proposed trial designs. We may
experience delays in our clinical trials and we do not know whether planned clinical trials will begin on time, need to be redesigned,
enroll patients on time or be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including
delays related to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">obtaining regulatory approval to commence a trial;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">reaching agreement on acceptable terms with prospective contract research organizations, or CROs,
and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different
CROs and trial sites;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">obtaining institutional review board, or IRB, approval at each site;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">recruiting suitable patients to participate in a trial;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">clinical sites deviating from trial protocol or dropping out of a trial;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">having patients complete a trial or return for post-treatment follow-up;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">developing and validating companion diagnostics on a timely basis, if required;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">adding new clinical trial sites;&nbsp;or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">manufacturing sufficient quantities of product candidate for use in clinical trials.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patient enrollment, a significant factor in
the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity
of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials
and clinicians&rsquo; and patients&rsquo; perceptions as to the potential advantages of the drug being studied in relation to other
available therapies, including any new drugs that may be approved for the indications we are investigating. Furthermore, we intend
to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and we intend to have agreements
governing their committed activities; however, we will have limited influence over their actual performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.4pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We could encounter delays if a clinical trial
is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety
Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension
or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements
or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities
resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit
from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical
trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.4pt">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we experience delays in the completion of,
or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed,
and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing
our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our
ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and
prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of
clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.4pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may not receive regulatory approval
for our product candidates, or their approval may be further delayed, which would have a material adverse effect on our business
and financial condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our product candidates and the activities associated
with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling,
storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other
regulatory agencies in the US and by the European Medicines Agency and similar regulatory authorities outside the US. Failure to
obtain marketing approval for one or more of our product candidates or any future product candidate will prevent us from commercializing
the product candidate. We have not received approval to market any of our product candidates from regulatory authorities in any
jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and
expect to rely on third-party contract research organizations to assist us in this process. Securing marketing approval requires
the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic
indication to establish the product candidate&rsquo;s safety and efficacy. Securing marketing approval also requires the submission
of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities.
One or more of our product candidates or any future product candidate may not be effective, may be only moderately effective or
may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing
approval or prevent or limit commercial use. If any of our product candidates or any future product candidate receives marketing
approval, the accompanying label may limit the approved use of our drug in this way, which could limit sales of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The process of obtaining marketing approvals,
both in the United States and abroad, is expensive, may take many years if approval is obtained at all, and can vary substantially
based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing
approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes
in regulatory review for each submitted product application may cause delays in the approval or rejection of an application. Regulatory
authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our
data is insufficient for approval and require additional preclinical studies or clinical trials. In addition, varying interpretations
of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate.
Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render
the approved product not commercially viable.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we experience delays in obtaining approval
or if we fail to obtain approval of one or more of our product candidates or any future product candidate, the commercial prospects
for our product candidates may be harmed and our ability to generate revenue will be materially impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, even if we were to obtain approval,
regulatory authorities may approve any of our product candidates or any future product candidate for fewer or more limited indications
than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance
of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims
necessary or desirable for the successful commercialization of that product candidate. Any of these scenarios could compromise
the commercial prospects for one or more of our product candidates or any future product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Moreover, in all interactions with regulatory
authorities, we are exposed to liability risks under the Foreign Corrupt Practices Act or similar anti-bribery laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If any of our product candidates is approved
and we or our contract manufacturer(s) fail to produce the product in the volumes that we require on a timely basis, or fail to
comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the commercialization
of our product candidates or be unable to meet market demand, and may lose potential revenues.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The manufacture of pharmaceutical products
requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process
controls, and the use of specialized processing equipment. We may enter into development and supply agreements with contract manufacturers
for the completion of pre-commercialization manufacturing development activities and the manufacture of commercial supplies for
one or more of our product candidates. Any termination or disruption of our relationships with our contract manufacturers may materially
harm our business and financial condition, and frustrate any commercialization efforts for each respective product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of our contract manufacturers must comply
with strictly enforced federal, state and foreign regulations, including&nbsp;cGMP requirements enforced by the FDA through its
facilities inspection program, and we have little control over their compliance with these regulations. Any failure to comply with
applicable regulations may result in fines and civil penalties, suspension of production, suspension or delay in product approval,
product seizure or recall, or withdrawal of product approval, and would limit the availability of our product and customer confidence
in our product. Any manufacturing defect or error discovered after products have been produced and distributed could result in
even more significant consequences, including costly recall procedures, re-stocking costs, damage to our reputation and potential
for product liability claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the commercial manufacturers upon whom we
may rely to manufacture one or more of our product candidates, and any future product candidate we may in-license, fail to deliver
the required commercial quantities on a timely basis at commercially reasonable prices, we would likely be unable to meet demand
for our products and we would lose potential revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our approach to the discovery and development
of our product candidates is unproven, and we do not know whether we will be able to develop any products of commercial value.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our products candidates are emerging technologies
and, consequently, it is conceivable that such technologies may ultimately fail to identify commercially viable drugs to treat
human patients with cancer or other diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If serious adverse or unacceptable side
effects are identified during the development of one or more of our product candidates or any future product candidate, we may
need to abandon or limit our development of some of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If one or more of our product candidates or
any future product candidate are associated with undesirable side effects in clinical trials or have characteristics that are unexpected,
we may need to abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side
effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. In our industry,
many compounds that initially showed promise in early stage testing have later been found to cause serious side effects that prevented
further development of the compound. In the event that our clinical trials reveal a high or unacceptable severity and prevalence
of side effects, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order
us to cease further development or deny approval of one or more of our product candidates or any future product candidate for any
or all targeted indications. The FDA could also issue a letter requesting additional data or information prior to making a final
decision regarding whether or not to approve a product candidate. The number of requests for additional data or information issued
by the FDA in recent years has increased and has resulted in substantial delays in the approval of several new drugs. Undesirable
side effects caused by one or more of our product candidates or any future product candidate could also result in the inclusion
of unfavorable information in our product labeling, denial of regulatory approval by the FDA or other regulatory authorities for
any or all targeted indications, and in turn prevent us from commercializing and generating market acceptance and revenues from
the sale of that product candidate. Drug-related side effects could affect patient recruitment or the ability of enrolled patients
to complete the trial and could result in potential product liability claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, if one or more of our product
candidates or any future product candidate receives marketing approval and we or others later identify undesirable side effects
caused by this product, a number of potentially significant negative consequences could result, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory authorities may require the addition of unfavorable labeling statements, specific warnings
or a contraindication;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory authorities may suspend or withdraw their approval of the product, or require it to
be removed from the market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we may be required to change the way the product is administered, conduct additional clinical trials
or change the labeling of the product;&nbsp;or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our reputation may suffer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any of these events could prevent us from achieving
or maintaining market acceptance of any of our product candidates or any future product candidate or could substantially increase
our commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues from its
sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Even if one or more of our product candidates
receives regulatory approval, it and any other products we may market will remain subject to substantial regulatory scrutiny.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">One or more of our product candidates that
we may license or acquire will also be subject to ongoing requirements and review of the FDA and other regulatory authorities.
These requirements include labeling, packaging, storage, advertising, promotion, record-keeping and submission of safety and other
post-market information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality
control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples
to physicians and recordkeeping of the drug, and requirements regarding our presentations to and interactions with health care
professionals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA may also impose requirements for costly
post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product. The FDA closely regulates
the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance
with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&rsquo; communications regarding
off-label use and if we do not market our products for only their approved indications, we may be subject to enforcement action
for off-label marketing. Violations of the FDCA relating to the promotion of prescription drugs may lead to investigations alleging
violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, later discovery of previously
unknown adverse events or other problems with our products, manufacturers or manufacturing processes, or failure to comply with
regulatory requirements, may yield various results, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">restrictions on such products, operations, manufacturers or manufacturing
processes;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">restrictions on the labeling or marketing of a product;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">restrictions on product distribution or use;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">requirements to conduct post-marketing studies or clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">warning letters;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">withdrawal of the products from the market;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">refusal to approve pending applications or supplements to approved
applications that we submit;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">recall of products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">fines, restitution or disgorgement of profits;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">suspension or withdrawal of marketing or regulatory approvals;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">suspension of any ongoing clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">refusal to permit the import or export of our products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">product seizure; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">injunctions or the imposition of civil or criminal penalties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA&rsquo;s policies may change, and additional
government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are
slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able
to maintain regulatory compliance, we may lose any marketing approval that we may have obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We will need to obtain FDA approval of
any proposed product brand names, and any failure or delay associated with such approval may adversely impact our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A pharmaceutical product cannot be marketed
in the US or other countries until we have completed a rigorous and extensive regulatory review processes, including approval of
a brand name. Any brand names we intend to use for our product candidates will require approval from the FDA regardless of whether
we have secured a formal trademark registration from the US Patent and Trademark Office (PTO). The FDA typically conducts a review
of proposed product brand names, including an evaluation of potential for confusion with other product names. The FDA may also
object to a product brand name if it believes the name inappropriately implies medical claims. If the FDA objects to any of our
proposed product brand names, we may be required to adopt an alternative brand name for our product candidates. If we adopt an
alternative brand name, we would lose the benefit of our existing trademark applications for such product candidate and may be
required to expend significant additional resources in an effort to identify a suitable product brand name that would qualify under
applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to
build a successful brand identity for a new trademark in a timely manner or at all, which would limit our ability to commercialize
our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our current and future relationships
with customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable
anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and
regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative
burdens and diminished profits and future earnings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Healthcare providers, physicians and third-party
payors in the US and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which
we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable
fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and
the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which we sell,
market and distribute any product candidates for which we obtain marketing approval. In addition, we may be subject to transparency
laws and patient privacy regulation by the federal and state governments and by governments in foreign jurisdictions in which we
conduct our business. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to
operate include, but are not necessarily limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly
and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce
or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or
service, for which payment may be made under federal and state healthcare programs, such as Medicare and Medicaid;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">federal civil and criminal false claims laws and civil monetary penalty laws, including the federal
False Claims Act, which impose criminal and civil penalties, including civil whistleblower or <I>&nbsp;&nbsp;qui&nbsp;tam</I> &nbsp;&nbsp;actions,
against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the
Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease
or conceal an obligation to pay money to the federal government; the federal Health Insurance Portability and Accountability Act
of 1996, or HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program
or making false statements relating to healthcare matters;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of
2009, or HITECH, and their respective implementing regulations, which impose obligations on covered healthcare providers, health
plans, and healthcare clearinghouses, as well as their business associates that create, receive, maintain or transmit individually
identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission
of individually identifiable health information;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the federal Open Payments program, which requires manufacturers of certain approved drugs, devices,
biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&rsquo;s Health Insurance
Program, with specific exceptions, to report annually to the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, information
related to &ldquo;payments or other transfers of value&rdquo; made to physicians, which is defined to include doctors, dentists,
optometrists, podiatrists and chiropractors, and teaching hospitals and applicable manufacturers and applicable group purchasing
organizations to report annually to CMS ownership and investment interests held by the physicians and their immediate family members.
Data collection began on August&nbsp;1, 2013 with requirements for manufacturers to submit reports to CMS by March&nbsp;31, 2014
and 90&nbsp;days after the end each subsequent calendar year. Disclosure of such information was made by CMS on a publicly available
website beginning in September 2014 and is annually updated; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">analogous state and foreign laws and regulations, such as state anti-kickback and false claims
laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental
third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the
pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal
government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers
to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing
expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many
of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Efforts to ensure that our business arrangements
with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that
governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations
or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in
violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil,
criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation
in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, which
could have a material adverse effect on our business. If any of the physicians or other healthcare providers or entities with whom
we expect to do business, including our collaborators, is found not to be in compliance with applicable laws, it may be subject
to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which
could also materially affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Regulatory approval for any approved
product is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any regulatory approval is limited to those
specific diseases and indications for which a product is deemed to be safe and effective by the FDA. In addition to the FDA approval
required for new formulations, any new indication for an approved product also requires FDA approval. If we are not able to obtain
FDA approval for any desired future indications for our products, our ability to effectively market and sell our products may be
reduced and our business may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While physicians may choose to prescribe drugs
for uses that are not described in the product&rsquo;s labeling and for uses that differ from those tested in clinical studies
and approved by the regulatory authorities, our ability to promote the products is limited to those indications that are specifically
approved by the FDA. These &ldquo;off-label&rdquo; uses are common across medical specialties and may constitute an appropriate
treatment for&nbsp;some&nbsp;patients in varied circumstances. Regulatory authorities in the US generally do not regulate the behavior
of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical companies
on the subject of off-label use. If our promotional activities fail to comply with these regulations or guidelines, we may be subject
to warnings from, or enforcement action by, these authorities. In addition, our failure to follow FDA rules and guidelines relating
to promotion and advertising may cause the FDA to&nbsp;suspend or withdraw&nbsp;an approved product from the market, require a
recall or institute fines, or could result in disgorgement of money, operating restrictions, corrective advertising, injunctions
or criminal prosecution, any of which could harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are subject to new legislation, regulatory
proposals and managed care initiatives that may increase our costs of compliance and adversely affect our ability to market our
products, obtain collaborators and raise capital.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the US and some foreign jurisdictions, there
have been a number of proposed and enacted legislative and regulatory changes regarding the healthcare system that could prevent
or delay marketing approval of one or more of our product candidates, restrict or regulate post-approval activities and affect
our ability to profitably sell any of our product candidates for which we obtain marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Among policy makers and payors in the US and
elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare
costs, improving quality and expanding access. In the US, the pharmaceutical industry has been a particular focus of these efforts
and has been significantly affected by major legislative initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2010, President Obama signed into
law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act,
or collectively the ACA, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare
spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries,
impose new taxes and fees on the health industry and impose additional health policy reforms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Among the provisions of the ACA of importance
to our potential product candidates are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription
drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate
Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">expansion of healthcare fraud and abuse laws, including the federal False Claims Act and the federal
Anti-Kickback Statute, new government investigative powers and enhanced penalties for non-compliance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a new Medicare Part&nbsp;D coverage gap discount program, in which manufacturers must agree to
offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage
gap period, as a condition for a manufacturer&rsquo;s outpatient drugs to be covered under Medicare Part&nbsp;D;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">extension of a manufacturer&rsquo;s Medicaid rebate liability to covered drugs dispensed to individuals
who are enrolled in Medicaid managed care organizations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states
to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals
with income at or below 138% of the federal poverty level, thereby potentially increasing a manufacturer&rsquo;s Medicaid rebate
liability;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">expansion of the entities eligible for discounts under the 340B Drug Pricing Program;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the new requirements under the federal Open Payments program and its implementing regulations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a new requirement to annually report drug samples that manufacturers and distributors provide to
physicians; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct
comparative clinical effectiveness research, along with funding for such research.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Supreme Court upheld the ACA in the main
challenge to the constitutionality of the law in 2012. The Supreme Court also upheld federal subsidies for purchasers of insurance
through federally facilitated exchanges in a decision released in June&nbsp;2015. Any remaining legal challenges to the ACA are
viewed generally as not significantly impacting the implementation of the law if the plaintiffs prevail.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">President Trump ran for office on a platform
that supported the repeal of the ACA, and one of his first actions after his inauguration was to sign an Executive Order instructing
federal agencies to waive or delay requirements of the ACA that impose economic or regulatory burdens on states, families, the
health-care industry and others. Modifications to or repeal of all or certain provisions of the ACA have been attempted in Congress
as a result of the outcome of the recent presidential and congressional elections, consistent with statements made by the incoming
administration and members of Congress during the presidential and congressional campaigns and following the election. In January&nbsp;2017,
Congress voted to adopt a budget resolution for fiscal year 2017, or the Budget Resolution, that authorizes the implementation
of legislation that would repeal portions of the ACA. The Budget Resolution is not a law. However, it is widely viewed as the first
step toward the passage of legislation that would repeal certain aspects of the ACA. In March 2017, following the passage of the
budget resolution for fiscal year 2017, the U.S. House of Representatives passed legislation known as the American Health Care
Act of 2017, which, if enacted, would amend or repeal significant portions of the ACA. Attempts in the Senate in 2017 to pass ACA
repeal legislation, including the Better Care Reconciliation Act of 2017, so far have been unsuccessful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect that the ACA, as well as other healthcare
reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure
on the price that we receive for any approved drug. Any reduction in reimbursement from Medicare or other government healthcare
programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or
other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Legislative proposals such as expanding the
Medicaid drug rebate program to the Medicare Part&nbsp;D program, providing authority for the government to negotiate drug prices
under the Medicare Part&nbsp;D program and lowering reimbursement for drugs covered under the Medicare Part&nbsp;B program have
been raised in Congress, but have been met with opposition and have not been enacted so far.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The administration can rely on its existing
statutory authority to make policy changes that could have an impact on the drug industry.&nbsp; For example, the Medicare program
has in the past proposed to test alternative payment methodologies for drugs covered under the Part&nbsp;B program and currently
is proposing to pay hospitals less for Part B-covered drugs purchased through the 340B Drug Pricing Program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Legislative and regulatory proposals have been
made to expand post-approval requirements and restrict sales and promotional activities for drugs. We cannot be sure whether additional
legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact
of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the US
Congress of the FDA&rsquo;s approval process may significantly delay or prevent marketing approval, as well as subject us to more
stringent product labeling and post-marketing testing and other requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 13.2pt">&nbsp;&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Public concern regarding the safety of
drug products could delay or limit our ability to obtain regulatory approval,&nbsp;result in the inclusion of unfavorable information
in our labeling, or require us to undertake other activities that may entail additional costs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In light of widely publicized events concerning
the safety risk of certain drug products, the FDA,&nbsp;members of the US Congress, the Government Accountability Office, medical
professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the
withdrawal of drug products, revisions to drug labeling that further limit use of the drug products and the establishment of risk
management programs. The Food and Drug Administration Amendments Act of 2007, or FDAAA, grants significant expanded authority to
the FDA, much of which is aimed at improving the safety of drug products before and after approval. In particular, the new law
authorizes the FDA to, among other things, require post-approval studies and clinical trials, mandate changes to drug labeling
to reflect new safety information and require risk evaluation and mitigation strategies for certain drugs, including certain currently
approved drugs. It also significantly expands the federal government&rsquo;s clinical trial registry and results databank, which
we expect will result in significantly increased government oversight of clinical trials. Under the FDAAA, companies that violate
these and other provisions of the new law are subject to substantial civil monetary penalties, among other regulatory, civil and
criminal penalties. The increased attention to drug safety issues may result in a more cautious approach by the FDA in its review
of data from our clinical trials. Data from clinical trials may receive greater scrutiny, particularly with respect to safety,
which may make the FDA or other regulatory authorities more likely to require additional preclinical studies or clinical trials.
If the FDA requires us to conduct additional preclinical studies or clinical trials prior to approving any of our product candidates,
our ability to obtain approval of this product candidate will be delayed. If the FDA requires us to provide additional clinical
or preclinical data following the approval of any of our product candidates, the indications for which this product candidate is
approved may be limited or there may be specific warnings or limitations on dosing, and our efforts to commercialize our product
candidates may be otherwise adversely impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we experience delays or difficulties
in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may not be able to initiate or continue
clinical trials for one or more of our product candidates if we are unable to locate and enroll a sufficient number of eligible
patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. Some
of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates,
and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&rsquo;
product candidates. Available therapies for the indications we are pursuing can also affect enrollment in our clinical trials.
Patient enrollment is affected by other factors including, but not necessarily limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the severity of the disease under investigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the eligibility criteria for the study in question;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the perceived risks and benefits of the product candidate under study;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the efforts to facilitate timely enrollment in clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the patient referral practices of physicians;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the number of clinical trials sponsored by other companies for the same patient population;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the ability to monitor patients adequately during and after treatment; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the proximity and availability of clinical trial sites for prospective patients.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our inability to enroll a sufficient number
of patients for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials
altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidate or future
product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our product candidates are in scientific
areas of intense competition from many large pharmaceutical and biotechnology companies, many of which are significantly further
along in development or are already on the market with competing products. We expect competition for our product candidates will
intensify, and new products may emerge that provide different or better therapeutic alternatives for our targeted indications.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The biotechnology and pharmaceutical industries
are subject to rapid and intense technological change. We face, and will continue to face, competition in the development and marketing
of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical
companies. There can be no assurance that developments by others will not render one or more of our product candidates obsolete
or noncompetitive. Furthermore, new developments, including the development of other drug technologies and methods of preventing
the incidence of disease, occur in the pharmaceutical industry at a rapid pace. These developments may render one or more of our
product candidates obsolete or noncompetitive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Competitors may seek to develop alternative
formulations that do not directly infringe on our in-licensed patent rights. The commercial opportunity for one or more of our
product candidates could be significantly harmed if competitors are able to develop alternative formulations outside the scope
of our in-licensed patents. Compared to us, many of our potential competitors have substantially greater:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">capital resources;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">development resources, including personnel and technology;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">clinical trial experience;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory experience;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">expertise in prosecution of intellectual property rights;&nbsp;and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">manufacturing, distribution and sales and marketing experience.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of these factors, our competitors
may obtain regulatory approval of their products more rapidly than we are able to or may obtain patent protection or other intellectual
property rights that limit our ability to develop or commercialize one or more of our product candidates. Our competitors may also
develop drugs that are more effective, safe, useful and less costly than ours and may be more successful than us in manufacturing
and marketing their products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our commercial success depends upon us
attaining significant market acceptance of our product candidates, if approved for sale, among physicians, patients, healthcare
payors and major operators of cancer and other clinics.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Even if we obtain regulatory approval for one
or more of our product candidates, the product may not gain market acceptance among physicians, health care payors, patients and
the medical community, which are critical to commercial success. Market acceptance of any product candidate for which we receive
approval depends on a number of factors, including, but not necessarily limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the efficacy and safety as demonstrated in clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the timing of market introduction of such product candidate as well as competitive products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the clinical indications for which the drug is approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">acceptance by physicians, major operators of cancer clinics and patients of the drug as a safe
and effective treatment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the safety of such product candidate seen in a broader patient group, including its use outside
the approved indications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the availability, cost and potential advantages of alternative treatments, including less expensive
generic drugs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the availability of adequate reimbursement and pricing by third-party payors and government authorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">changes in regulatory requirements by government authorities for our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the relative convenience and ease of administration of the product candidate for clinical practices;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the product labeling or product insert required by the FDA or regulatory authority in other countries;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the approval, availability, market acceptance and reimbursement for a companion diagnostic, if
any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the prevalence and severity of adverse side effects;&nbsp;and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the effectiveness of our sales and marketing efforts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If any product candidate that we develop does
not provide a treatment regimen that is as beneficial as, or is not perceived as being as beneficial as, the current standard of
care or otherwise does not provide patient benefit, that product candidate, if approved for commercial sale by the FDA or other
regulatory authorities, likely will not achieve market acceptance. Our ability to effectively promote and sell any approved products
will also depend on pricing and cost-effectiveness, including our ability to produce a product at a competitive price and our ability
to obtain sufficient third-party coverage or reimbursement. If any product candidate is approved but does not achieve an adequate
level of acceptance by physicians, patients and third-party payors, our ability to generate revenues from that product would be
substantially reduced. In addition, our efforts to educate the medical community and third-party payors on the benefits of our
product candidates may require significant resources, may be constrained by FDA rules&nbsp;and policies on product promotion, and
may never be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If approved, our product candidates will
face competition from less expensive generic products of competitors, and, if we are unable to differentiate the benefits of our
product candidates over these less expensive alternatives, we may never generate meaningful product revenues.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Generic therapies are typically sold at lower
prices than branded therapies and are generally preferred by hospital formularies and managed care providers of health services.
We anticipate that, if approved, our product candidates will face increasing competition in the form of generic versions of branded
products of competitors that have lost or will lose their patent exclusivity. In the future, we may face additional competition
from a generic form when the patents covering it begin to expire, or earlier if the patents are successfully challenged. If we
are unable to demonstrate to physicians and payers that the key differentiating features of our product candidates translate to
overall clinical benefit or lower cost of care, we may not be able to compete with generic alternatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Reimbursement may be limited or unavailable
in certain market segments for our product candidates, which could make it difficult for us to sell our products profitably.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There is significant uncertainty related to
the third-party coverage and reimbursement of newly approved drugs. Such third-party payors include government health programs
such as Medicare, managed care providers, private health insurers and other organizations. We intend to seek approval to market
our product candidates in the US, the EU and other selected foreign jurisdictions. Market acceptance and sales of our product candidates
in both domestic and international markets will depend significantly on the availability of adequate coverage and reimbursement
from third-party payors for any of our product candidates and may be affected by existing and future health care reform measures.
Government and other third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the
level of reimbursement for new drugs and, as a result, they may not cover or provide adequate payment for our product candidates.
These payors may conclude that our product candidates are less safe, less effective or less cost-effective than existing or future
introduced products, and third-party payors may not approve our product candidates for coverage and reimbursement or may cease
providing coverage and reimbursement for these product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Obtaining coverage and reimbursement approval
for a product from a government or other third-party payor is a time consuming and costly process that could require us to provide
to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. We may not be able to provide
data sufficient to gain acceptance with respect to coverage and reimbursement. If reimbursement of our future products is unavailable
or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In some foreign countries, particularly in
the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations
with governmental authorities can take considerable time after the receipt of marketing approval for a product candidate. To obtain
reimbursement or pricing approval in some countries, we may be required to conduct additional clinical trials that compare the
cost-effectiveness of our product candidates to other available therapies. If reimbursement of our product candidates is unavailable
or limited in scope or amount in a particular country, or if pricing is set at unsatisfactory levels, we may be unable to achieve
or sustain profitability of our products in such country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are unable to establish sales,
marketing and distribution capabilities or to enter into agreements with third parties to market and sell our product candidates,
we may not be successful in commercializing our product candidates if and when they are approved.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently do not have a marketing or sales
organization for the marketing, sales and distribution of pharmaceutical products. In order to commercialize any product candidate
that receives marketing approval, we would need to build marketing, sales, distribution, managerial and other non-technical capabilities
or make arrangements with third parties to perform these services, and we may not be successful in doing so. In the event of successful
development and regulatory approval of one or more of our product candidates or any future product candidate, we expect to build
a targeted specialist sales force to market or co-promote the product. There are risks involved with establishing our own sales,
marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and
could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish
marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization
expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Factors that may inhibit our efforts to commercialize
our products on our own include, but are not necessarily limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of
physicians to prescribe any future products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the lack of complementary or other products to be offered by sales personnel, which may put us
at a competitive disadvantage from the perspective of sales efficiency relative to companies with more extensive product lines;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As an alternative to establishing our own sales
force, we may choose to partner with third parties that have well-established direct sales forces to sell, market and distribute
our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 13.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We rely, and expect to continue to rely,
on third parties to conduct our preclinical studies and clinical trials, and those third parties may not perform satisfactorily,
including failing to meet deadlines for the completion of such trials or complying with applicable regulatory requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We rely on third-party contract research organizations
and site management organizations to conduct some of our preclinical studies and all of our clinical trials for our product candidates
and for any future product candidate. We expect to continue to rely on third parties, such as contract research organizations,
site management organizations, clinical data management organizations, medical institutions and clinical investigators, to conduct
some of our preclinical studies and all of our clinical trials. The agreements with these third parties might terminate for a variety
of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, that could
delay our product development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our reliance on these third parties for research
and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example,
we will remain responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance with
the general investigational plan and protocols for the trial and for ensuring that our preclinical studies are conducted in accordance
with good laboratory practice (GLP) as appropriate. Moreover, the FDA requires us to comply with standards, commonly referred to
as good clinical practices (GCPs) for conducting, recording and reporting the results of clinical trials to assure that data and
reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected.
Regulatory authorities enforce these requirements through periodic inspections of trial sponsors, clinical investigators and trial
sites. If we or any of our clinical research organizations fail to comply with applicable GCPs, the clinical data generated in
our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform
additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory
authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition,
our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations
may require us to repeat clinical trials, which would delay the regulatory approval process. We also are required to register ongoing
clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within
specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The third parties with whom we have contracted
to help perform our preclinical studies or clinical trials may also have relationships with other entities, some of which may be
our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct
our preclinical studies or clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able
to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed
in our efforts to, successfully commercialize our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If any of our relationships with these third-party
contract research organizations or site management organizations terminates, we may not be able to enter into arrangements with
alternative contract research organizations or site management organizations or to do so on commercially reasonable terms. Switching
or adding additional contract research organizations or site management organizations involves additional cost and requires management
time and focus. In addition, there is a natural transition period when a new contract research organization or site management
organization commences work. As a result, delays could occur, which could compromise our ability to meet our desired development
timelines. Though we carefully manage our relationships with our contract research organizations or site management organizations,
there can be no assurance that we will not encounter similar challenges or delays in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We contract with third parties for the
manufacture of our product candidates for preclinical and clinical testing and may also do so for commercialization. This reliance
on third parties increases the risk that we will not have sufficient quantities of our product candidates or any future product
candidate or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not have any manufacturing facilities
or manufacturing personnel. While we have signed a lease to construct our own facility (See Note 8 to Unaudited Condensed Financial
Statements), currently we rely on third parties for the manufacture of our product candidates for preclinical and clinical testing.
This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or any
future product candidate or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development
or commercialization efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may also rely on third-party manufacturers
or third-party collaborators for the manufacture of commercial supply of one or more product candidates for which our collaborators
or we obtain marketing approval. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable
terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails
additional risks, including, but not necessarily limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">reliance on the third party for regulatory compliance and quality assurance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the possible breach of the manufacturing agreement by the third party;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">manufacturing delays if our third-party manufacturers give greater priority to the supply of other
products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreement between
us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the possible misappropriation of our proprietary information, including our trade secrets and know-how;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the possible termination or nonrenewal of the agreement by the third party at a time that is costly
or inconvenient for us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We rely on our third-party manufacturers to
produce or purchase from third-party suppliers the materials and equipment necessary to produce our product candidates for our
preclinical and clinical trials. There are a limited number of suppliers for raw materials and equipment that we use (or that are
used on our behalf) to manufacture our drugs, and there may be a need to assess alternate suppliers to prevent a possible disruption
of the manufacture of the materials and equipment necessary to produce our product candidates for our preclinical and clinical
trials, and if approved, ultimately for commercial sale. We do not have any control over the process or timing of the acquisition
of these raw materials or equipment by our third-party manufacturers. Any significant delay in the supply of a product candidate,
or the raw material components thereof, for an ongoing preclinical or clinical trial due to the need to replace a third-party manufacturer
could considerably delay completion of our preclinical or clinical trials, product testing and potential regulatory approval of
our product candidates. If our manufacturers or we are unable to purchase these raw materials or equipment after regulatory approval
has been obtained for our product candidates, the commercial launch of our product candidates would be delayed or there would be
a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The facilities used by our contract manufacturers
to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit
an NDA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturers
for compliance with cGMP regulations for manufacture of our product candidates. Third-party manufacturers may not be able to comply
with the cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party
manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines,
injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product
candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect
supplies of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">One or more of the product candidates that
we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited
number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance
failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently
have arrangements in place for redundant supply. If our current contract manufacturers cannot perform as agreed, we may be required
to replace such manufacturers. We may incur added costs and delays in identifying and qualifying any replacement manufacturers.
The DEA restricts the importation of a controlled substance finished drug product when the same substance is commercially available
in the United States, which could reduce the number of potential alternative manufacturers for one or more of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our current and anticipated future dependence
upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability
to commercialize any products that receive marketing approval on a timely and competitive basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also expect to rely on other third parties
to distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical
development or marketing approval of our product candidates or commercialization of our products, producing additional losses and
depriving us of potential product revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 13.2pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We rely on clinical data and results
obtained by third parties that could ultimately prove to be inaccurate or unreliable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of our strategy to mitigate development
risk, we seek to develop product candidates with validated mechanisms of action and we utilize biomarkers to assess potential clinical
efficacy early in the development process. This strategy necessarily relies upon clinical data and other results obtained by third
parties that may ultimately prove to be inaccurate or unreliable. Further, such clinical data and results may be based on products
or product candidates that are significantly different from our product candidates or any future product candidate. If the third-party
data and results we rely upon prove to be inaccurate, unreliable or not applicable to our product candidates or future product
candidate, we could make inaccurate assumptions and conclusions about our product candidates and our research and development efforts
could be compromised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we breach any of the agreements under
which we license rights to one or more of product candidates from others, we could lose the ability to continue to develop and
commercialize such product candidate.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because we have in-licensed the rights to all
of our product candidates from COH and Fred Hutch, and in the future will continue to in-license from additional third parties,
if there is any dispute between us and our licensor regarding our rights under our license agreement, our ability to develop and
commercialize these product candidates may be adversely affected. Any uncured, material breach under our license agreement could
result in our loss of exclusive rights to our product candidate and may lead to a complete termination of our related product development
efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may not be able to manage our business
effectively if we are unable to attract and retain key personnel.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may not be able to attract or retain qualified
management and commercial, scientific and clinical personnel in the future due to the intense competition for qualified personnel
among biotechnology, pharmaceutical and other businesses. If we are not able to attract and retain necessary personnel to accomplish
our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives,
our ability to raise additional capital and our ability to implement our business strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our employees may engage in misconduct
or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse
effect on our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are exposed to the risk of employee fraud
or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, provide accurate
information to the FDA, comply with manufacturing standards we have established, comply with federal and state health-care fraud
and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular,
sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to
prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide
range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.
Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result
in regulatory sanctions and serious harm to our reputation. The precautions we take to detect and prevent this activity may not
be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other
actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted
against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact
on our business and results of operations, including the imposition of significant fines or other sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;&nbsp;&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We face potential product liability exposure,
and if successful claims are brought against us, we may incur substantial liability for one or more of our product candidates or
a future product candidate we may license or acquire and may have to limit their commercialization.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The use of one or more of our product candidates
and any future product candidate we may license or acquire in clinical trials and the sale of any products for which we obtain
marketing approval expose us to the risk of product liability claims. For example, we may be sued if any product we develop allegedly
causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product
liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent
in the product, negligence, strict liability or a breach of warranties. Product liability claims might be brought against us by
consumers, health care providers or others using, administering or selling our products. If we cannot successfully defend ourselves
against these claims, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result
in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">withdrawal of clinical trial participants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">suspension or termination of clinical trial sites or entire trial programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">decreased demand for any product candidates or products that we may develop;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">initiation of investigations by regulators;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">impairment of our business reputation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">costs of related litigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">substantial monetary awards to patients or other claimants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">loss of revenues;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">reduced resources of our management to pursue our business strategy; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the inability to commercialize our product candidate or future product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We will obtain limited product liability insurance
coverage for any and all of our upcoming clinical trials. However, our insurance coverage may not reimburse us or may not be sufficient
to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and,
in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against
losses due to liability. When needed we intend to expand our insurance coverage to include the sale of commercial products if we
obtain marketing approval for one or more of our product candidates in development, but we may be unable to obtain commercially
reasonable product liability insurance for any products approved for marketing. On occasion, large judgments have been awarded
in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of
claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our
cash and adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our future growth depends on our ability
to identify and acquire or in-license products and if we do not successfully identify and acquire or in-license related product
candidates or integrate them into our operations, we may have limited growth opportunities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An important part of our business strategy
is to continue to develop a pipeline of product candidates by acquiring or in-licensing products, businesses or technologies that
we believe are a strategic fit with our focus on novel combinations of CAR-T cells with immuno-oncology antibodies and small molecule
kinase inhibitors. Future in-licenses or acquisitions, however, may entail numerous operational and financial risks, including,
but not necessarily limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">exposure to unknown liabilities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">disruption of our business and diversion of our management&rsquo;s time and attention to develop
acquired products or technologies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">difficulty or inability to secure financing to fund development activities for such acquired or
in-licensed technologies in the current economic environment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">higher than expected acquisition and integration costs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">increased amortization expenses;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">difficulty and cost in combining the operations and personnel of any acquired businesses with our
operations and personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">impairment of relationships with key suppliers or customers of any acquired businesses due to changes
in management and ownership; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">inability to retain key employees of any acquired businesses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have limited resources to identify and execute
the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure.
In particular, we may compete with larger pharmaceutical companies and other competitors in our efforts to establish new collaborations
and in-licensing opportunities. These competitors likely will have access to greater financial resources than us and may have greater
expertise in identifying and evaluating new opportunities. Moreover, we may devote resources to potential acquisitions or in-licensing
opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may expend our limited resources to
pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more
profitable or for which there is a greater likelihood of success.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because we have limited financial and managerial
resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may
forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater
commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable
market opportunities. Our spending on current and future research and development programs and product candidates for specific
indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target
market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing
or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization
rights to such product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we fail to comply with environmental,
health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are subject to numerous environmental, health
and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and
disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals
and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the
disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. Although
we believe that the safety procedures for handling and disposing of these materials comply with the standards prescribed by these
laws and regulations, we cannot eliminate the risk of accidental contamination or injury from these materials. In the event of
contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any
liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties
for failure to comply with such laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although we maintain workers&rsquo; compensation
insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous
materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental
liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous
or radioactive materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, we may incur substantial costs
in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and
regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also
may result in substantial fines, penalties or other sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18.7pt; text-align: justify; text-indent: -18.7pt"><B><I>Our
business and operations would suffer in the event of system failures.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18.7pt; text-align: justify; text-indent: -18.7pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Despite the implementation of security measures,
our internal computer systems are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism,
war and telecommunication and electrical failures. Any system failure, accident or security breach that causes interruptions in
our operations could result in a material disruption of our drug development programs. For example, the loss of clinical trial
data from completed clinical trials for&nbsp;one or more of our product conducts could result in delays in our regulatory approval
efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach
results in a loss or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information,
we may incur liability and the further development of one or more of our product candidates may be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are currently reliant on the
City of Hope National Medical Center and the Fred Hutchinson Cancer Research Center for a substantial portion of our
research and development efforts and the early clinical testing of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A substantial portion of our research and
development has been and will continue to be conducted by COH and Fred Hutch pursuant to a sponsored research agreement and/or
 clinical trial agreements with each of those parties. As a result, our future success is heavily dependent on the results of
research and development efforts of Dr. Stephen Forman and his laboratory team at COH and of Dr. Brian Till and his laboratory
team at Fred Hutch. We have limited control over the nature or timing of their research and limited visibility into their day-to-day
activities, and as a result can provide little assurance that their efforts will be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>CAR-T is a new approach to cancer treatment
that presents significant challenges.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have concentrated our research and development
efforts on CAR-T technology, and our future success is highly dependent on the successful development of T cell immunotherapies
in general and our CAR-T technology and product candidates in particular. Because CAR-T is a new approach to cancer immunotherapy
and cancer treatment generally, developing and commercializing our product candidates subjects us to a number of challenges, including,
but not necessarily limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">obtaining regulatory approval from the FDA and other regulatory authorities that may have very
limited experience with the commercial development of genetically modified T cell therapies for cancer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">developing and deploying consistent and reliable processes for engineering a patient&rsquo;s T
cells ex vivo and infusing the engineered T cells back into the patient;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">conditioning patients with chemotherapy in conjunction with delivering each of our products, which
may increase the risk of adverse side effects of our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">educating medical personnel regarding the potential side effect profile of each of our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">developing processes for the safe administration of these products, including long-term follow-up
for all patients who receive our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">sourcing clinical and, if approved, commercial supplies for the materials used to manufacture and
process our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">developing a manufacturing process and distribution network with a cost of goods that allows for
an attractive return on investment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">establishing sales and marketing capabilities after obtaining any regulatory approval to gain market
acceptance, and obtaining adequate coverage, reimbursement and pricing by third-party payors and government authorities; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">developing therapies for types of cancers beyond those addressed by our current product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Product candidates, even if successfully
developed and commercialized, may be effective only in combating certain specific types of cancer, and the market for drugs designed
to combat such cancer type(s) may be small and unprofitable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are many different types of cancer, and
a treatment that is effective against one type of cancer may not be effective against another. CAR-T or other technologies we pursue
may only be effective in combating specific types of cancer but not others. Even if one or more of our products proves to be an
effective treatment against a given type of cancer, the number of patients suffering from such cancer may be small, in which case
potential sales from a drug designed to combat such cancer would be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><B>&nbsp;&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are unable to obtain and maintain
patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad,
our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully
commercialize our technology and products may be impaired.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our commercial success will depend in part
on obtaining and maintaining patent protection and trade secret protection in the US and other countries with respect to&nbsp;our
product candidates or any future product candidate that we may license or acquire and the methods we use to manufacture them, as
well as successfully defending these patents and trade secrets against third-party challenges. We seek to protect our proprietary
position by filing patent applications in the United States and abroad related to our novel technologies and product candidates,
and by maintenance of our trade secrets through proper procedures. We will only be able to protect our technologies from unauthorized
use by third parties to the extent that valid and enforceable patents or trade secrets cover them in the market they are being
used or developed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The patent prosecution process is expensive
and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable
cost or in a timely manner. It is also possible that we will fail to identify any patentable aspects of our research and development
output and methodology, and, even if we do, an opportunity to obtain patent protection may have passed. Given the uncertain and
time-consuming process of filing patent applications and prosecuting them, it is possible that our product(s) or process(es) originally
covered by the scope of the patent application may have changed or been modified, leaving our product(s) or process(es) without
patent protection. If our licensors or we fail to obtain or maintain patent protection or trade secret protection for&nbsp;one
or more product candidates or any future product candidate we may license or acquire, third parties may be able to leverage our
proprietary information and products without risk of infringement, which could impair our ability to compete in the market and
adversely affect our ability to generate revenues and achieve profitability. Moreover, should we enter into other collaborations
we may be required to consult with or cede control to collaborators regarding the prosecution, maintenance and enforcement of licensed
patents. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests
of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The patent position of biotechnology and pharmaceutical
companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject
of much litigation. In addition, no consistent policy regarding the breadth of claims allowed in pharmaceutical or biotechnology
patents has emerged to date in the US. The patent situation outside the US is even more uncertain. The laws of foreign countries
may not protect our rights to the same extent as the laws of the US, and we may fail to seek or obtain patent protection in all
major markets. For example, European patent law restricts the patentability of methods of treatment of the human body more than
US law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications
in the US and other jurisdictions are typically not published until 18&nbsp;months after a first filing, or in some cases not at
all. Therefore, we cannot know with certainty whether we or our licensors were the first to make the inventions claimed in patents
or pending patent applications that we own or licensed, or that we or our licensors were the first to file for patent protection
of such inventions. In the event that a third party has also filed a US&nbsp;patent application relating to our product candidates
or a similar invention, depending upon the priority dates claimed by the competing parties, we may have to participate in interference
proceedings declared by the PTO to determine priority of invention in the US. The costs of these proceedings could be substantial
and it is possible that our efforts to establish priority of invention would be unsuccessful, resulting in a material adverse effect
on our US&nbsp;patent position. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights
are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology
or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products.
Changes in either the patent laws or interpretation of the patent laws in the US and other countries may diminish the value of
our patents or narrow the scope of our patent protection. For example, the federal courts of the US have taken an increasingly
dim view of the patent eligibility of certain subject matter, such as naturally occurring nucleic acid sequences, amino acid sequences
and certain methods of utilizing same, which include their detection in a biological sample and diagnostic conclusions arising
from their detection. Such subject matter, which had long been a staple of the biotechnology and biopharmaceutical industry to
protect their discoveries, is now considered, with few exceptions, ineligible in the first instance for protection under the patent
laws of the US. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in those
licensed from a third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Recent patent reform legislation could increase
the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued
patents. On September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith
Act includes a number of significant changes to United States patent law. These include changes to transition from a &ldquo;first-to-invent&rdquo;
system to a &ldquo;first-to-file&rdquo; system and to the way issued patents are challenged. The formation of the Patent Trial
and Appeal Board now provides a quicker and less expensive process for challenging issued patents. The PTO recently developed new
regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated
with the Leahy-Smith Act, and in particular, the first inventor-to-file provisions, only became effective on March&nbsp;16, 2013.
Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the
Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications
and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Moreover, we may be subject to a third-party
preissuance submission of prior art to the PTO, or become involved in opposition, derivation, reexamination, <I>inter partes</I>
review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of
these proceedings could be substantial and it is possible that our efforts to establish priority of invention would be unsuccessful,
resulting in a material adverse effect on our US&nbsp;patent position. An adverse determination in any such submission, patent
office trial, proceeding or litigation could reduce the scope of, render unenforceable, or invalidate, our patent rights, allow
third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our
inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or
strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating
with us to license, develop or commercialize current or future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Even if our patent applications issue as patents,
they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or
otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by
developing similar or alternative technologies or products in a non-infringing manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The issuance of a patent does not foreclose
challenges to its inventorship, scope, validity or enforceability. Therefore, our owned and licensed patents may be challenged
in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent
claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from
using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology
and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents
protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result,
our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products
similar or identical to ours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;&nbsp; <B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We depend on our licensors for the maintenance
and enforcement of intellectual property covering certain of our product candidates and have limited control, if any, over the
amount or timing of resources that our licensors devote on our behalf, or whether any financial difficulties experienced by our
licensors could result in their unwillingness or inability to secure, maintain and enforce patents protecting certain of our product
candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We depend on our licensors to protect the proprietary
rights covering&nbsp;our product candidates and we have limited, if any, control over the amount or timing of resources that they
devote on our behalf, or the priority they place on, maintaining patent rights and prosecuting patent applications to our advantage.
Moreover, we have limited, if any, control over the strategies and arguments employed in the maintenance of patent rights and the
prosecution of patent applications to our advantage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our licensors, depending on the patent or application,
are responsible for maintaining issued patents and prosecuting patent applications. We cannot be sure that they will perform as
required. Should they decide they no longer want to maintain any of the patents licensed to us, they are required to afford us
the opportunity to do so at our expense. If our licensors do not perform, and if we do not assume the maintenance of the licensed
patents in sufficient time to make required payments or filings with the appropriate governmental agencies, we risk losing the
benefit of all or some of those patent rights. Moreover, and possibly unbeknownst to us, our licensors may experience serious difficulties
related to their overall business or financial stability, and they may be unwilling or unable to continue to expend the financial
resources required to maintain and prosecute these patents and patent applications. While we intend to take actions reasonably
necessary to enforce our patent rights, we depend, in part, on our licensors to protect a substantial portion of our proprietary
rights and to inform us of the status of those protections and efforts thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our licensors may also be notified of alleged
infringement and be sued for infringement of third-party patents or other proprietary rights. We may have limited, if any, control
or involvement over the defense of these claims, and our licensors could be subject to injunctions and temporary or permanent exclusionary
orders in the US or other countries. Our licensors are not obligated to defend or assist in our defense against third-party claims
of infringement. We have limited, if any, control over the amount or timing of resources, if any, that our licensors devote on
our behalf or the priority they place on defense of such third-party claims of infringement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because of the uncertainty inherent in any
patent or other litigation involving proprietary rights, we or our licensors may not be successful in defending claims of intellectual
property infringement alleged by third parties, which could have a material adverse effect on our results of operations. Regardless
of the outcome of any litigation, defending the litigation may be expensive, time-consuming and distracting to management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Because it is difficult and costly to
protect our proprietary rights, we may not be able to ensure their protection.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The degree of future protection for our proprietary
rights is uncertain, because legal means afford only limited protection and may not adequately protect our rights or permit us
to gain or keep our competitive advantage, in addition to being costly and time consuming to undertake. For example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our licensors might not have been the first to make the inventions covered by each of our pending
patent applications and issued patents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our licensors might not have been the first to file patent applications for these inventions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">others may independently develop similar or alternative technologies or duplicate our product candidates
or any future product candidate technologies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">it is possible that none of the pending patent applications licensed to us will result in issued
patents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the scope of our issued patents may not extend to competitive products developed or produced by
others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the issued patents covering our product candidates or any future product candidate may not provide
a basis for market exclusivity for active products, may not provide us with any competitive advantages, or may be challenged by
third parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we may not develop additional proprietary technologies that are patentable;&nbsp;or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">intellectual property rights of others may have an adverse effect on our business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may become involved in lawsuits to
protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Competitors may infringe our issued patents
or other intellectual property. To counter infringement or unauthorized use, we may be required to file one or more actions for
patent infringement, which can be expensive and time consuming. Any claims we assert against accused infringers could provoke these
parties to assert counterclaims against us alleging that we infringe their patents; or provoke those parties to petition the PTO
to institute <I>inter partes</I> review against the asserted patents, which may lead to a finding that all or some of the claims
of the patent are invalid. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid
or unenforceable, in whole or in part, construe the patent&rsquo;s claims narrowly or refuse to stop the other party from using
the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation
proceeding could put one or more of our patents at risk of being invalidated, rendered unenforceable, or interpreted narrowly.
Furthermore, adverse results on US patents may affect related patents in our global portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are sued for infringing intellectual
property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in any litigation would harm
our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our ability to develop, manufacture, market
and sell one or more of our product candidates or any future product candidate that we may license or acquire depends upon our
ability to avoid infringing the proprietary rights of third parties. Numerous US and foreign issued patents and pending patent
applications, which are owned by third parties, exist in the general fields of fully human immuno-oncology targeted antibodies
and cover the use of numerous compounds and formulations in our targeted markets. Because of the uncertainty inherent in any patent
or other litigation involving proprietary rights, we and our licensors may not be successful in defending intellectual property
claims asserted by third parties, which could have a material adverse effect on our results or operations. Regardless of the outcome
of any litigation, defending the litigation may be expensive, time-consuming and distracting to management. In addition, because
patent applications can take many years to issue, there may be currently pending applications that are unknown to us, which may
later result in issued patents that one or more of our product candidates may infringe. There could also be existing patents of
which we are not aware that one or more of our product candidates may infringe, even if only inadvertently.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There is a substantial amount of litigation
involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third
party claims that we infringe their patents or misappropriated their technology, we could face a number of issues, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">infringement and other intellectual property claims which, with or without merit, can be expensive
and time consuming to litigate and can divert management&rsquo;s attention from our core business;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">substantial damages for past infringement which we may have to pay if a court decides that our
product infringes a competitor&rsquo;s patent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a court prohibiting us from selling or licensing our product unless the patent holder licenses
the patent to us, which it would not be required to do;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if a license is available from a patent holder, we may have to pay substantial royalties or grant
cross licenses to our patents;&nbsp;and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">redesigning our processes so they do not infringe, which may not be possible or could require substantial
funds, time, and may result in an inferior or less-desirable process or product.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Intellectual property litigation could
cause us to spend substantial resources and distract our personnel from their normal responsibilities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Even if resolved in our favor, litigation or
other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract
our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of
the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive
these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings
could substantially increase our operating losses and reduce the resources available for development activities or any future sales,
marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings
adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we
can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation
or other proceedings could compromise our ability to compete in the marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may need to license certain intellectual
property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A third party may hold intellectual property,
including patent rights that are important or necessary to the development and commercialization of our products. It may be necessary
for us to use the patented or proprietary technology of third parties, whom may or may not be interested in granting such a license,
to commercialize our products, in which case we would be required to obtain a license from these third parties on commercially
reasonable terms, or our business could be harmed, possibly materially.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we fail to comply with our obligations
in our intellectual property licenses and funding arrangements with third parties, we could lose rights that are important to our
business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are currently a party to license agreements
with the City of Hope and the Regents of the University of California. In the future, we may become party to licenses that are
important for product development and commercialization. If we fail to comply with our obligations under current or future license
and funding agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able
to develop, manufacture or market any product or utilize any technology that is covered by these agreements or may face other penalties
under the agreements. Such an occurrence could materially and adversely affect the value of a product candidate being developed
under any such agreement or could restrict our drug discovery activities. Termination of these agreements or reduction or elimination
of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms,
or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may be subject to claims that our
employees have wrongfully used or disclosed alleged trade secrets of their former employers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As is common in the biotechnology and pharmaceutical
industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our
competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that we
or these employees have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former
employers. Even if frivolous or unsubstantiated in nature, litigation may be necessary to defend against these claims. Even if
we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management
and the implicated employee(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are unable to protect the confidentiality
of our trade secrets, our business and competitive position would be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to seeking patent protection for
our product candidates or any future product candidate, we also rely on trade secrets, including unpatented know-how, technology
and other proprietary information, to maintain our competitive position, particularly where we do not believe patent protection
is appropriate or obtainable. However, trade secrets are difficult to protect. We limit disclosure of such trade secrets where
possible but we also seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements
with parties who do have access to them, such as our employees, our licensors, corporate collaborators, outside scientific collaborators,
contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent
assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements
and may unintentionally or willfully disclose our proprietary information, including our trade secrets, and we may not be able
to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret
is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United
States are less willing or unwilling to protect trade secrets. Moreover, if any of our trade secrets were to be lawfully obtained
or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from
using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed
by a competitor, our competitive position would be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><B>&nbsp;&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Our Finances and Capital
Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have incurred significant losses since
our inception. We expect to incur losses for the foreseeable future, and may never achieve or maintain profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are an emerging growth company with a limited
operating history. We have focused primarily on in-licensing and developing our product candidates, with the goal of supporting
regulatory approval for these product candidates. We have incurred losses since our inception in March 2015, and have an accumulated
deficit of $32.8 million as of September 30, 2017. We expect to continue to incur significant operating losses for the foreseeable
future. We also do not anticipate that we will achieve profitability for a period of time after generating material revenues, if
ever. If we are unable to generate revenues, we will not become profitable and may be unable to continue operations without continued
funding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because of the numerous risks and uncertainties
associated with developing pharmaceutical products, we are unable to predict the timing or amount of increased expenses or when
or if, we will be able to achieve profitability. Our net losses may fluctuate significantly from quarter to quarter and year to
year. We anticipate that our expenses will increase substantially if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">one or more of our product candidates are approved for commercial sale, due to our ability to establish
the necessary commercial infrastructure to launch this product candidate without substantial delays, including hiring sales and
marketing personnel and contracting with third parties for warehousing, distribution, cash collection and related commercial activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we are required by the FDA or foreign regulatory authorities, to perform studies in addition to
those currently expected;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">there are any delays in completing our clinical trials or the development of any of our product
candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we execute other collaborative, licensing or similar arrangements and the timing of payments we
may make or receive under these arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">there are variations in the level of expenses related to our future development programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">there are any product liability or intellectual property infringement lawsuits in which we may
become involved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">there are any regulatory developments affecting product candidates of our competitors;&nbsp;and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">one or more of our product candidates receives regulatory approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our ability to become profitable depends upon
our ability to generate revenue. To date, we have not generated any revenue from our development stage products, and we do not
know when, or if, we will generate any revenue. Our ability to generate revenue depends on a number of factors, including, but
not limited to, our ability to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">obtain regulatory approval for one or more of our product candidates, or any future product candidate
that we may license or acquire;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">manufacture commercial quantities of one or more of our product candidates or any future product
candidate, if approved, at acceptable cost levels;&nbsp;and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">develop a commercial organization and the supporting infrastructure required to successfully market
and sell one or more of our product candidates or any future product candidate, if approved.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Even if we do achieve profitability, we may
not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would
depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and
development efforts, diversify our product offerings or even continue our operations. A decline in the value of our company could
also cause you to lose all or part of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18.7pt; text-align: justify; text-indent: -18.7pt"><B><I>Our
short operating history makes it difficult to evaluate our business and prospects.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We were incorporated in March 2015 and
have only been conducting operations since March 2015. Our operations to date have been limited to preclinical operations and
the in-licensing of our product candidates. We have not yet demonstrated an ability to successfully complete clinical trials,
obtain regulatory approvals, manufacture a clinical scale or commercial scale product, or arrange for a third party to do so
on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently,
any predictions about our future performance may not be as accurate as they could be if we had a history of successfully
developing and commercializing pharmaceutical products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, as a young business, we may encounter
unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to expand our capabilities
to support commercial activities. We may not be successful in adding such capabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect our financial condition and operating
results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which
are beyond our control. Accordingly, you should not rely upon the results of any past quarterly period as an indication of future
operating performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We do not have any products that are
approved for commercial sale and therefore do not expect to generate any revenues from product sales in the foreseeable future,
if ever.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have not generated any product related revenues
to date, and do not expect to generate any such revenues for at least the next several years, if at all. To obtain revenues from
sales of our product candidates, we must succeed, either alone or with third parties, in developing, obtaining regulatory approval
for, manufacturing and marketing products with commercial potential. We may never succeed in these activities, and we may not generate
sufficient revenues to continue our business operations or achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We will require substantial additional
funding which may not be available to us on acceptable terms, or at all. If we fail to raise the necessary additional capital,
we may be unable to complete the development and commercialization of our product candidates, or continue our development programs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our operations have consumed substantial amounts
of cash since inception. We expect to significantly increase our spending to advance the preclinical and clinical development of
our product candidates and launch and commercialize any product candidates for which we receive regulatory approval, including
building our own commercial organizations to address certain markets. We will require additional capital for the further development
and commercialization of our product candidates, as well as to fund our other operating expenses and capital expenditures. As of
September 30, 2017, we had $67.3 million in cash and short-term investments (certificates of deposit). We cannot provide any assurance
that we will be able to raise funds to complete the development of our product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We cannot be certain that additional funding
will be available on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts or on terms
acceptable to us we may have to significantly delay, scale back or discontinue the development or commercialization of one or more
of our product candidates. We may also seek collaborators for one or more of our current or future product candidates at an earlier
stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available. Any of these events
could significantly harm our business, financial condition and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our future funding requirements will depend
on many factors, including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the timing, design and conduct of, and results from, preclinical and clinical trials for our product
candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the potential for delays in our efforts to seek regulatory approval for our product candidates,
and any costs associated with such delays;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the costs of establishing a commercial organization to sell, market and distribute our product
candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the rate of progress and costs of our efforts to prepare for the submission of an NDA for any product
candidates that we may in-license or acquire in the future, and the potential that we may need to conduct additional clinical trials
to support applications for regulatory approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual
property rights associated with our product candidates, including any such costs we may be required to expend if our licensors
are unwilling or unable to do so;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the cost and timing of securing sufficient supplies of our product candidates from our contract
manufacturers for clinical trials and in preparation for commercialization;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the effect of competing technological and market developments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the terms and timing of any collaborative, licensing, co-promotion or other arrangements that we
may establish;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if one or more of our product candidates are approved, the potential that we may be required to
file a lawsuit to defend our patent rights or regulatory exclusivities from challenges by companies seeking to market generic versions
of one or more of our product candidates; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the success of the commercialization of one or more of our product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Future capital requirements will also depend
on the extent to which we acquire or invest in additional complementary businesses, products and technologies, but we currently
have no commitments or agreements relating to any of these types of transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to carry out our business plan and
implement our strategy, we anticipate that we will need to obtain additional financing from time to time and may choose to raise
additional funds through strategic collaborations, licensing arrangements, public or private equity or debt financing, bank lines
of credit, asset sales, government grants, or other arrangements. We cannot be sure that any additional funding, if needed, will
be available on terms favorable to us or at all. Furthermore, any additional equity or equity-related financing may be dilutive
to our stockholders, and debt or equity financing, if available, may subject us to restrictive covenants and significant interest
costs. If we obtain funding through a strategic collaboration or licensing arrangement, we may be required to relinquish our rights
to certain of our product candidates or marketing territories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our inability to raise capital when needed
would harm our business, financial condition and results of operations, and could cause our stock value to decline or require that
we wind down our operations altogether.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Raising additional capital may cause
dilution to our existing stockholders, restrict our operations or require us to relinquish proprietary rights.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Until such time, if ever, as we can generate
substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, grants
and license and development agreements in connection with any collaborations. To the extent that we raise additional capital through
the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may
include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financing and preferred equity
financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions,
such as incurring additional debt, making capital expenditures or declaring dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we raise additional funds through collaborations,
strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable
rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may
not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required
to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and
market product candidates that we would otherwise prefer to develop and market ourselves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"><B><I>&nbsp;&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We will continue to incur significant
increased costs as a result of operating as a public company, and our management will be required to devote substantial time to
new compliance initiatives.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 22, 2017 we became a listed and traded
public company. As a public company, we incur significant legal, accounting and other expenses under the Sarbanes-Oxley Act of
2002, or the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC, and the rules of the Nasdaq Stock Exchange.
These rules impose various requirements on public companies, including requiring establishment and maintenance of effective disclosure
and financial controls and appropriate corporate governance practices. Our management and other personnel have devoted and will
continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase
our legal and financial compliance costs and make some activities more time-consuming and costly. For example, these rules and
regulations make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be
required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage.
As a result, it may be more difficult for us to attract and retain qualified persons to serve on our board of directors, our board
committees or as executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Sarbanes-Oxley Act requires, among other
things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. As a result,
we are required to periodically perform an evaluation of our internal controls over financial reporting to allow management to
report on the effectiveness of those controls, as required by Section&nbsp;404 of the Sarbanes-Oxley Act. Additionally, our independent
auditors are required to perform a similar evaluation and report on the effectiveness of our internal controls over financial reporting.
These efforts to comply with Section&nbsp;404 and related regulations have required, and continue to require, the commitment of
significant financial and managerial resources. While we anticipate maintaining the integrity of our internal controls over financial
reporting and all other aspects of Section&nbsp;404, we cannot be certain that a material weakness will not be identified when
we test the effectiveness of our control systems in the future. If a material weakness is identified, we could be subject to sanctions
or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources,
costly litigation or a loss of public confidence in our internal controls, which could have an adverse effect on the market price
of our stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Compliance with the Sarbanes-Oxley Act
of 2002 will require substantial financial and management resources and may increase the time and costs of completing an acquisition.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A business that we identify as a potential
acquisition target may not be in compliance with the provisions of the Sarbanes-Oxley Act regarding the adequacy of internal controls.
The development of the internal controls of any such entity to achieve compliance with the Sarbanes-Oxley Act may increase the
time and costs necessary to complete any such acquisition. Furthermore, any failure to implement required new or improved controls,
or difficulties encountered in the implementation of adequate controls over our financial processes and reporting in the future,
could harm our operating results or cause us to fail to meet our reporting obligations. Inferior internal controls could also cause
investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of
our securities.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are an &ldquo;emerging growth company&rdquo;
and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our securities
less attractive to investors.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are an &ldquo;emerging growth company,&rdquo;
as defined in the Jumpstart Our Business Startups Act (the &ldquo;JOBS Act&rdquo;). We will remain an &ldquo;emerging growth company&rdquo;
for up to five years. However, if our non-convertible debt issued within a three-year period or revenues exceeds $1 billion, or
the market value of our equity shares that are held by non-affiliates exceeds $700 million on the last day of the second fiscal
quarter of any given fiscal year, we would cease to be an emerging growth company as of the following fiscal year. As an emerging
growth company, we are not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley
Act, we have reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and
we are exempt from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of
any golden parachute payments not previously approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, Section 102(b)(1) of the JOBS Act
exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private
companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of
securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The
JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply
to non-emerging growth companies, but any such an election to opt out is irrevocable. We have elected not to opt out of such extended
transition period which means that when a standard is issued or revised and it has different application dates for public or private
companies, we, as an emerging growth company, will not adopt the new or revised standard until the time private companies are required
to adopt the new or revised standard. This may make comparison of our financial statements with another public company, which is
neither an emerging growth company nor an emerging growth company, which has opted out of using the extended transition period,
difficult or impossible because of the potential differences in accounting standards used.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our results of operations and liquidity
needs could be materially negatively affected by market fluctuations and economic downturn.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our results of operations could be materially
negatively affected by economic conditions generally, both in the US and elsewhere around the world. Continuing concerns over inflation,
energy costs, geopolitical issues, the availability and cost of credit, the US mortgage market and residential real estate market
in the US have contributed to increased volatility and diminished expectations for the economy and the markets going forward. These
factors, combined with volatile oil prices, declining business and consumer confidence and increased unemployment, have precipitated
an economic recession and fears of a possible depression. Domestic and international equity markets continue to experience heightened
volatility and turmoil. These events and the continuing market upheavals may have an adverse effect on us. In the event of a continuing
market downturn, our results of operations could be adversely affected by those factors in many ways, including making it more
difficult for us to raise funds if necessary, and our stock price may further decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our ability to use our pre-change NOLs
and other pre-change tax attributes to offset post-change taxable income or taxes may be subject to limitation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may, from time to time, carry net operating
loss carryforwards (&ldquo;NOLs&rdquo;) as deferred tax assets on our balance sheet.&nbsp; Under Sections 382 and 383 of the Internal
Revenue Code of 1986, as amended, if a corporation undergoes an &ldquo;ownership change&rdquo; (generally defined as a greater
than 50-percentage- point cumulative change (by value) in the equity ownership of certain stockholders over a rolling three-year
period), the corporation&rsquo;s ability to use its pre-change NOLs and other pre-change tax attributes to offset its post-change
taxable income or taxes may be limited. We may experience ownership changes in the future as a result of shifts in our stock ownership,
some of which changes are outside our control. As a result, our ability to use our pre-change NOLs and other pre-change tax attributes
to offset post-change taxable income or taxes may be subject to limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Relating to Securities Markets and
Investment in Our Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our stock may be subject to substantial
price and volume fluctuations due to a number of factors, many of which are beyond our control and may prevent our stockholders
from reselling our common stock at a profit.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The market prices for securities of biotechnology
and pharmaceutical companies have historically been highly volatile, and the market has from time to time experienced significant
price and volume fluctuations that are unrelated to the operating performance of particular companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The market price of our common stock is likely
to be highly volatile and may fluctuate substantially due to many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">announcements concerning the progress of our efforts to obtain regulatory approval for and commercialize our product candidates
or any future product candidate, including any requests we receive from the FDA for additional studies or data that result in delays
in obtaining regulatory approval or launching these product candidates, if approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">market conditions in the pharmaceutical and biotechnology sectors or the economy as a whole;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">price and volume fluctuations in the overall stock market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the failure of one or more of our product candidates or any future product candidate, if approved,
to achieve commercial success;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">announcements of the introduction of new products by us or our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">developments concerning product development results or intellectual property rights of others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">litigation or public concern about the safety of our potential products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">actual fluctuations in our quarterly operating results, and concerns by investors that such fluctuations
may occur in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">deviations in our operating results from the estimates of securities analysts or other analyst
comments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">additions or departures of key personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">health care reform legislation, including measures directed at controlling the pricing of pharmaceutical
products, and third-party coverage and reimbursement policies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">developments concerning current or future strategic collaborations;&nbsp;and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">discussion of us or our stock price by the financial and scientific press and in online investor
communities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Fortress controls a voting majority of
our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the terms of the Class A Preferred
Stock held by Fortress, Fortress is entitled to cast, for each share of Class A Preferred held by Fortress, the number of votes
that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the shares of outstanding common
stock and (B) the whole shares of common stock into which the shares of outstanding Class A common shares and the Class A Preferred
Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock. Accordingly,
Fortress is able to control or significantly influence all matters requiring approval by our stockholders, including the election
of directors and the approval of mergers or other business combination transactions. The interests of Fortress may not always coincide
with the interests of other stockholders, and Fortress may take actions that advance its own interests and are contrary to the
desires of our other stockholders. Moreover, this concentration of voting power may delay, prevent or deter a change in control
of us even when such a change may be in the best interests of all stockholders, could deprive our stockholders of an opportunity
to receive a premium for their common stock as part of a sale of Mustang or our assets, and might affect the prevailing market
price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Fortress has the right to receive a significant
grant of shares of our common stock annually which will result in the dilution of your holdings of common stock upon each grant,
which could reduce their value. City of Hope has anti-dilution protection that could result in the dilution of your holding.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the terms of the Second Amended and Restated
Founders Agreement, which became effective July 22, 2016, Fortress will receive a grant of shares of our common stock equal to
two and one-half percent (2.5%) of the gross amount of any equity or debt financing. Additionally, the Class A Preferred Stock,
as a class, will receive an annual dividend on March 13th, payable in shares of common stock in an amount equal to two and one-half
percent (2.5%) of our fully-diluted outstanding capital stock as of the business day immediately prior to March 13th of such year.
Fortress currently owns all outstanding shares of Class A Preferred Stock. These share issuances to Fortress and any other holder
of Class A Preferred Stock will dilute your holdings in our common stock and, if the value of Mustang has not grown proportionately
over the prior year, would result in a reduction in the value of your shares. The Second Amended and Restated Founders Agreement
has a term of 15 years and renews automatically for subsequent one-year periods unless terminated by Fortress or upon a Change
in Control (as defined in the Second Amended and Restated Founders Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Class A common shares held by the City
of Hope has anti-dilution protection that gives them the right to additional shares of stock under certain circumstances. The number
of shares received by COH will vary depending on the triggering event. If any shares are required to be issued to COH, your holdings
in our common stock will be diluted and result in a reduction in the value of your shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We might have received better terms from
unaffiliated third parties than the terms we receive in our agreements with Fortress.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The agreements we have entered into with Fortress
include a Management Services Agreement and the Founders Agreement. While we believe the terms of these agreements are reasonable,
they might not reflect terms that would have resulted from arm&rsquo;s-length negotiations between unaffiliated third parties.
The terms of the agreements relate to, among other things, payment of a royalty on product sales and the provision of employment
and transition services. We might have received better terms from third parties because, among other things, third parties might
have competed with each other to win our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>The dual roles of our officers and directors
who also serve in similar roles with Fortress could create a conflict of interest and will require careful monitoring by our independent
directors.&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We share some directors with Fortress, and
in addition, under the Management Services Agreement, we will also share some officers with Fortress.&nbsp; This could create conflicts
of interest between the two companies in the future.&nbsp; While we believe that the Founders Agreement and the Management Services
Agreement were negotiated by independent parties on both sides on arm&rsquo;s length terms, and the fiduciary duties of both parties
were thereby satisfied, in the future situations may arise under the operation of both agreements that may create a conflict of
interest.&nbsp; We will have to be diligent to ensure that any such situation is resolved by independent parties.&nbsp; In particular,
under the Management Services Agreement, Fortress and its affiliates are free to pursue opportunities which could potentially be
of interest to Mustang, and they are not required to notify Mustang prior to pursuing such opportunities. Any such conflict of
interest or pursuit by Fortress of a corporate opportunity independent of Mustang could expose us to claims by our investors and
creditors and could harm our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may become involved in securities
class action litigation that could divert management&rsquo;s attention and harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The stock markets have from time to time experienced
significant price and volume fluctuations that have affected the market prices for the common stock of biotechnology and pharmaceutical
companies. These broad market fluctuations may cause the market price of our stock to decline. In the past, securities class action
litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially
relevant for us because biotechnology and biopharmaceutical companies have experienced significant stock price volatility in recent
years. We may become involved in this type of litigation in the future. Litigation often is expensive and diverts management&rsquo;s
attention and resources, which could adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><A NAME="a_014"></A>Item 2.</TD><TD>Unregistered Sales of Equity Securities and Use of Proceeds</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><A NAME="a_015"></A>Item 3.</TD><TD>Defaults Upon Senior Securities</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73.7pt; text-align: justify; text-indent: -73.7pt"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><A NAME="a_016"></A>Item 4.</TD><TD>Mine Safety Disclosures</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73.7pt; text-align: justify; text-indent: -73.7pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><A NAME="a_017"></A>Item 5.</TD><TD>Other Information</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><A NAME="a_018"></A>Item 6.</TD><TD>Exhibits</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The exhibits listed on the Exhibit Index are either filed or furnished
with this report or incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>EXHIBIT INDEX</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 8%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>No.</B></P></TD>
    <TD NOWRAP STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 90%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv477598_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tv477598_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Lease Agreement, by and between the Company and WCS - 377 Plantation Street, Inc., dated October 27, 2017.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="tv477598_ex31-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">31.1</FONT></A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tv477598_ex31-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Certification of Chairman, President and Chief Executive Officer (Principal Executive Officer), pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="tv477598_ex31-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">31.2</FONT></A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tv477598_ex31-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Certification of Interim Chief Financial Officer (Principal Financial Officer), pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="tv477598_ex32-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">32.1</FONT></A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tv477598_ex32-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Certification of Chairman, President and Chief Executive Officer (Principal Executive Officer),&nbsp;pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="tv477598_ex32-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">32.2</FONT></A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tv477598_ex32-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Certification of Interim Chief Financial Officer (Principal Financial Officer), pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">101</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The following financial information from the Company&rsquo;s Quarterly Report on Form 10-Q for the period ended September 30, 2017, formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Balance Sheets, (ii) the Condensed Statements of Operations, (iii) the Condensed Statement of Stockholders&rsquo; Equity, (iv) the Condensed Statements of Cash Flows, and (v) Notes to the Condensed Financial Statements (filed herewith).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.9pt">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><A NAME="a_019"></A>Signatures</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 44pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">MUSTANG BIO, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">November 13, 2017</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Manuel Litchman</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Manuel Litchman, M.D., President and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Executive Officer (Principal Executive Officer)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ David J. Horin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">David J. Horin</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Interim Chief Financial Officer (Principal Financial Officer)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tv477598_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">LEASE AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-indent: 0in"><B>Landlord:</B></TD>
    <TD STYLE="width: 90%; text-indent: 0in"><B>WCS - 377 Plantation Street, Inc.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in"><B>Tenant:</B></TD>
    <TD STYLE="text-indent: 0in"><B>Mustang Bio, Inc.&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in"><B>Building:</B></TD>
    <TD STYLE="text-indent: 0in"><B>377 Plantation Street, Worcester, Massachusetts</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in"><B>Premises:</B></TD>
    <TD STYLE="text-indent: 0in"><B>27,043 Rentable Square Feet on the First Floor of the Building</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 6%"><B>1.</B></TD>
    <TD STYLE="vertical-align: top; width: 84%"><B>Lease of Premises</B></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right"><B>7</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>2.</B></TD>
    <TD STYLE="vertical-align: top"><B>Delivery; Acceptance of Premises; Commencement Date; Extension Option</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>7</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>3.</B></TD>
    <TD STYLE="vertical-align: top"><B>Rent</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>10</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>4.</B></TD>
    <TD STYLE="vertical-align: top"><B>Intentionally Omitted</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>10</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>5.</B></TD>
    <TD STYLE="vertical-align: top"><B>Operating Expense Payments</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>11</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>6.</B></TD>
    <TD STYLE="vertical-align: top"><B>Security Deposit</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>14</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>7.</B></TD>
    <TD STYLE="vertical-align: top"><B>Use</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>15</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>8.</B></TD>
    <TD STYLE="vertical-align: top"><B>Holding Over</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>18</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>9.</B></TD>
    <TD STYLE="vertical-align: top"><B>Taxes</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>19</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>10.</B></TD>
    <TD STYLE="vertical-align: top"><B>Parking</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>19</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>11.</B></TD>
    <TD STYLE="vertical-align: top"><B>Utilities, Services</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>20</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>12.</B></TD>
    <TD STYLE="vertical-align: top"><B>Alterations and Tenant&rsquo;s Property; Tenant&rsquo;s Work</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>21</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>13.</B></TD>
    <TD STYLE="vertical-align: top"><B>Landlord's Repairs</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>23</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>14.</B></TD>
    <TD STYLE="vertical-align: top"><B>Tenant's Repairs</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>24</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>15.</B></TD>
    <TD STYLE="vertical-align: top"><B>Mechanic's Liens</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>24</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>16.</B></TD>
    <TD STYLE="vertical-align: top"><B>Indemnification</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>25</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>17.</B></TD>
    <TD STYLE="vertical-align: top"><B>Insurance</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>25</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>18.</B></TD>
    <TD STYLE="vertical-align: top"><B>Restoration</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>27</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>19.</B></TD>
    <TD STYLE="vertical-align: top"><B>Condemnation</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>28</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>20.</B></TD>
    <TD STYLE="vertical-align: top"><B>Events of Default</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>28</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>21.</B></TD>
    <TD STYLE="vertical-align: top"><B>Landlord's Remedies</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>29</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>22.</B></TD>
    <TD STYLE="vertical-align: top"><B>Assignment and Subletting</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>32</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>23.</B></TD>
    <TD STYLE="vertical-align: top"><B>Estoppel Certificate</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>35</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>24.</B></TD>
    <TD STYLE="vertical-align: top"><B>Quiet Enjoyment</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>35</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 6%"><B>25.</B></TD>
    <TD STYLE="vertical-align: top; width: 84%"><B>Prorations</B></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right"><B>35</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>26.</B></TD>
    <TD STYLE="vertical-align: top"><B>Rules and Regulations</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>35</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>27.</B></TD>
    <TD STYLE="vertical-align: top"><B>Subordination</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>36</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>28.</B></TD>
    <TD STYLE="vertical-align: top"><B>Surrender</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>36</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>29.</B></TD>
    <TD STYLE="vertical-align: top"><B>Waiver of Jury Trial</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>37</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>30.</B></TD>
    <TD STYLE="vertical-align: top"><B>Environmental Requirements</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>38</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>31.</B></TD>
    <TD STYLE="vertical-align: top"><B>Tenant's Remedies/Limitation of Liability</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>41</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>32.</B></TD>
    <TD STYLE="vertical-align: top"><B>Inspection and Access</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>42</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>33.</B></TD>
    <TD STYLE="vertical-align: top"><B>Security</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>42</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>34.</B></TD>
    <TD STYLE="vertical-align: top"><B>Force Majeure</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>43</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>35.</B></TD>
    <TD STYLE="vertical-align: top"><B>Brokers</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>43</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>36.</B></TD>
    <TD STYLE="vertical-align: top"><B>Limitation on Landlord's Liability</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>43</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>37.</B></TD>
    <TD STYLE="vertical-align: top"><B>Severability</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>44</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>38.</B></TD>
    <TD STYLE="vertical-align: top"><B>Signs; Exterior Appearance</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>44</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>39.</B></TD>
    <TD STYLE="vertical-align: top"><B>Intentionally Omitted</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>44</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><B>40.</B></TD>
    <TD STYLE="vertical-align: top"><B>Miscellaneous</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>44</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.0</B></FONT></TD>
    <TD STYLE="vertical-align: top"><B>Introduction</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>F-3</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.0</B></FONT></TD>
    <TD STYLE="vertical-align: top"><B>Equipment</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>F-5</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>1.</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>Landlord&rsquo;s Work</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>H-1</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>2.</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>Tenant&rsquo;s Work</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>H-1</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>3.</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>Cost of Tenant&rsquo;s Work</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>H-2</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>4.</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>Access By Tenant; Work in Harmony</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>H-3</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>5.</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>Construction Requirements</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>H-4</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>6.</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Miscellaneous</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><B>H-5</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>LEASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">THIS LEASE AGREEMENT (this &quot;<B>Lease</B>&quot;)
is made as of the ____ day of October, 2017 between WCS - 377 Plantation Street, Inc., a Massachusetts nonprofit corporation (&quot;<B>Landlord</B>&quot;),
and Mustang Bio, Inc., a Delaware corporation (&quot;<B>Tenant</B>&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%"><B>Address:</B></TD>
    <TD STYLE="width: 75%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">377 Plantation Street, Worcester, Massachusetts</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>Premises:</B></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">That portion of the Property located on the first floor, as
        shown on <B>Exhibit A</B>, containing approximately 27,043 rentable square feet, as determined by Landlord.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>Property:</B></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The real property including the building (the &quot;<B>Building</B>&quot;)
in which the Premises are located, together with all improvements thereon and appurtenances thereto as described on <B>Exhibit
B</B>.&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; background-color: White">Base Rent</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; background-color: White">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Lease Year:</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Annual Base<BR>
 Rent:</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Payable in <BR>
following <BR>
Monthly <BR>
Installments:</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 25%; background-color: White">&nbsp;</TD><TD STYLE="width: 1%; background-color: White">&nbsp;</TD>
    <TD STYLE="width: 25%; text-align: left">1</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">419,166.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 23%; text-align: right">34,930.54</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left">2</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">432,688.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">36,057.33</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left">3</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">446,209.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">37,184.13</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left">4</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">459,731.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">38,310.92</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">473,252.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">39,437.71</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left">6</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">486,774.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">40,564.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left">7</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">500,295.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">41,691.29</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left">8</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">513,817.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">42,818.08</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left">9</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">527,338.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">43,944.88</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%">&nbsp;</TD>
    <TD STYLE="width: 75%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provided there is no Default under the Lease during the Base
        Term, (i) during the first Lease Year, Base Rent shall be fully abated and (ii) during the second Lease Year, 47.41% of Base Rent
        shall be abated.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>Rentable Area of Premises</B></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">27,043 sq. ft. consisting of two parcels: 14,222 square feet
        (&ldquo;<B>Section A</B>&rdquo;) and 12,821 square feet (&ldquo;<B>Section B</B>&rdquo;) as shown on <B>Exhibit A.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>Rentable Area of Property:</B></TD>
    <TD>91,147 sq. ft.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%"><B>Tenant's Share of Operating Expenses:</B></TD>
    <TD STYLE="width: 75%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Rentable Area of Premises from time to time divided by the
        Rentable Area of Property from time to time, initially being 29.67%, provided, however that Tenant shall not be responsible for
        Tenant&rsquo;s Share of Operating Expenses until the first day of the seventh month of the first Lease Year, at which time Tenant&rsquo;s
        Share of Operating Expenses shall be calculated solely including Section A of the Premises and thus will constitute 15.60% (14,222/91,147),
        until the Section B Occupancy Date at which time and thereafter Tenant&rsquo;s Share of Operating Expenses shall constitute the
        Rentable Area of Premises from time to time divided by the Rentable Area of Property from time to time, currently being 29.67%.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>Security Deposit:&nbsp;&nbsp;</B></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">$250,000.00 Cash Security Deposit and $500,000 Security
Deposit in the form of a Letter of Credit, which shall be increased to a $1,000,000 Letter of Credit on or before the Section
B Occupancy Date (&ldquo;<B>Letter of Credit Security Deposit</B>&rdquo;). The Letter of Credit shall be subject to reduction
as set forth in Section 6.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>Base Term:</B></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Base Term shall be for nine (9) years (plus any initial
        partial period should the Commencement Date occur other than on the first day of a month), such term beginning on the Commencement
        Date and ending at the end of the day prior to the ninth anniversary of the Commencement Date, provided that if the Commencement
        Date does not occur on the first day of the month, the Base Term shall expire on the last day of the month in which the ninth anniversary
        of the Commencement Date occurs.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lease Year:</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The first Lease Year shall be the period commencing on the Commencement
        Date and ending on the day prior to the first anniversary of the Commencement Date, provided that if the Commencement Date does
        not occur on the first day of the month, the first Lease Year shall expire on the last day of the month in which the first anniversary
        of the Commencement Date occurs and each Lease Year thereafter shall commence on the day following the expiration of the previous
        Lease Year and expire on the anniversary of the expiration of the previous Lease Year.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section B Occupancy Date: </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="text-align: justify">The earlier of (i) the date on which the Tenant commences use of any portion of Section B for the Permitted Use hereunder (as opposed to use of Section B for construction, setting up furniture, fixtures and equipment, conducting inspections and testing, and similar activities needed to prepare for occupancy) and (ii) the first day of the third Lease Year.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%"><B>Permitted Use:</B></TD>
    <TD STYLE="width: 75%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Scientific research and development laboratory, related office
        and other related uses consistent with the character of the Property and otherwise in compliance with the provisions of <U>Section
        7</U> hereof.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Address for Rent Payment:</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Landlord's Notice Address:</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">WCS &ndash; 377 Plantation Street, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">c/o University of Massachusetts Medical School</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">55 Lake Avenue North</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Worcester, MA 01655</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn: Bursar&rsquo;s Office</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">WCS &ndash; 377 Plantation Street, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">c/o University of Massachusetts Medical School</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">55 Lake Avenue North</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Worcester, MA 01655</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn: Director of Property Services</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">With a copy to:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Paul C. Bauer, Esq.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Bowditch &amp; Dewey, LLP</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">200 Crossing Boulevard, Suite 500</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Framingham, Massachusetts 01702</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tenant's Notice Address</B>:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Mustang Bio, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn: Manuel Litchman, CEO<BR>
        2 Gansevoort Street, 9th floor<BR>
        New York, NY 10014</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">With a copy to:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">the Premises</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn: Knut Niss, VP, Program Management</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">With a copy to:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Wyrick Robbins Yates &amp; Ponton LLP</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">4101 Lake Boone Trail, Suite 300</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Raleigh, NC 27607</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn: Anna P. McLamb, Esq.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following Exhibits and Addenda are
attached hereto and incorporated herein by this reference:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT A</B> - PREMISES DESCRIPTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT B</B> - DESCRIPTION OF PROPERTY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT C</B> - COMMENCEMENT DATE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT D</B> - RULES AND REGULATIONS&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT E</B>- TENANT&rsquo;S PERSONAL PROPERTY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT F - </B>FORM OF SURRENDER PLAN&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT G </B>&ndash; RESERVED PARKING</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT H &ndash; </B>WORK LETTER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT I &ndash; </B>HAZARDOUS MATERIALS LIST</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lease
of Premises</B>. Upon and subject to all of the terms and conditions hereof, Landlord hereby leases the Premises to Tenant and
Tenant hereby leases the Premises from Landlord. The portions of the Property which are for the non-exclusive use of tenants of
the Property are collectively referred to herein as the &quot;<B>Common Areas</B>.&quot; Landlord reserves the right to modify
Common Areas, provided that such modifications do not materially adversely affect Tenant's use of the Premises for the Permitted
Use, Tenant&rsquo;s access to the Premises, or Tenant&rsquo;s usage of reserved parking.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delivery;
Acceptance of Premises; Commencement Date; Extension Option</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Premises
Delivery.</B> Landlord shall deliver (&quot;<B>Delivery</B>&quot; or &quot;<B>Deliver</B>&quot;) the Premises to Tenant on or
about November 1, 2017. The &quot;<B>Commencement Date</B>&quot; shall be the date Landlord Delivers the Premises to Tenant. The
&quot;<B>Rent Commencement Date</B>&quot; shall be the Commencement Date, subject to the rent abatement set forth in the definition
of Base Rent set forth above. Upon request of Landlord, Tenant shall execute and deliver a written acknowledgment of the Commencement
Date, the Rent Commencement Date, the expiration date of the Term and the Section B Occupancy Date when such are established,
in the form of the &quot;<B>Acknowledgement of Commencement Date</B>&quot; attached to this Lease as <B>Exhibit C</B>; provided,
however, Tenant's failure to execute and deliver such acknowledgment shall not affect Landlord's rights hereunder. The &quot;Term&quot;
of this Lease shall be the Base Term, as defined above on the first page of this Lease, together with any Extension Term that
comes into effect in accordance with this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
Is Condition.</B> Except as set forth in this Lease: (i) Tenant shall accept the Premises in their &quot;as-is&quot; condition
as of the Commencement Date, subject to all applicable Legal Requirements (as defined in Section 7 hereof); (ii) Landlord shall
have no obligation for any defects in the Premises; and (iii) Tenant's taking possession of the Premises shall be conclusive evidence
that Tenant accepts the Premises and that the Premises were in good condition at the time possession was taken. Any occupancy
of the Premises by Tenant before the Commencement Date shall be subject to all of the terms and conditions of this Lease, excluding
the obligation to pay Base Rent and Operating Expenses. Tenant shall undertake Tenant&rsquo;s Work to prepare the Premises for
occupancy pursuant to and in accordance with Section 12 and <B>Exhibit H. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Complete
Agreement.</B> Tenant agrees and acknowledges that neither Landlord nor any agent of Landlord has made any representation or warranty
with respect to the condition of all or any portion of the Premises or the Property, and/or the suitability of the Premises or
the Property for the conduct of Tenant's business, and Tenant waives any implied warranty that the Premises or the Property are
suitable for the Permitted Use. This Lease constitutes the complete agreement of Landlord and Tenant with respect to the subject
matter hereof and supersedes any and all prior representations, inducements, promises, agreements, understandings and negotiations
which are not contained herein. Landlord in executing this Lease does so in reliance upon Tenant's representations, warranties,
acknowledgments and agreements contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; text-align: justify">(d)&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Extension
Option.</B> Provided Tenant is not in Default under this Lease at the time of notice or commencement of the Extension Term, has
not Defaulted more than three times during the Term or first Extension Term, as the case may be, and occupies at least 75% of
the Premises, Tenant shall have the option to extend the Lease (each, an &ldquo;<B>Extension Option</B>&rdquo;) beyond the expiration
of the Term for two (2) additional periods (each an &ldquo;<B>Extension Term</B>&rdquo;) consisting of five (5) years each by
providing written notice to Landlord not earlier than 15 months nor later than 12 months prior to the expiration of the Term or
the first Extension Term, as the case may be; provided, however, Tenant shall have no further right to extend the Lease. In the
event Tenant does not exercise an option to extend it shall have no further extension options. Any extension of the Lease for
an Extension Term shall be upon the same terms and conditions set forth in the Lease, except that commencing on the first day
of the first Extension Term, Base Rent shall be payable at the at the Market Rate (as defined below). Base Rent shall thereafter
be adjusted on the annual anniversary of the commencement of such Extension Term by a percentage as determined by Landlord and
agreed to by Tenant at the time the Market Rate is determined (the &ldquo;<B>Escalation Rate</B>&rdquo;). As used herein, &quot;<B>Market
Rate</B>&quot; shall mean the higher of (i) 95% of the then market rental rate in Worcester, Massachusetts, taking into account
all relevant factors including comparable building age, condition, type of use, level of finish and proximity to amenities, as
well as length of lease term and any concessions, allowances or other incentives provided to tenants in comparable space as determined
by Landlord and agreed to by Tenant or (ii) the Base Rent in effect in the last year of the Term (or first Extension Term with
respect to Base Rent for the second Extension Term).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Tenant, in a notice to Landlord sent no sooner than fifteen
(15) months prior to the scheduled expiration of the Term, requests that Landlord confirm the Market Rate and Escalation Rate that
would apply during the upcoming Extension Term, Landlord shall confirm Market Rate and Escalation Rate in a responsive notice to
Tenant (the &ldquo;<B>Advance Market Confirmation</B>&rdquo;) within fifteen (15) business days. Any delay of Landlord beyond fifteen
(15) business days in sending the Advance Market Confirmation to Tenant shall reduce the period prior to scheduled expiration of
the Term in which Tenant has to exercise the Extension Option (e.g., if Landlord takes 7 days beyond the fifteen business days
to deliver its Advance Market Confirmation to Tenant, then Tenant shall be able to give Landlord notice of exercise of the Extension
Option until the day that is 7 days after the end of the twelfth month before the scheduled expiration of the Term).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If, on or before the date which is 270 days prior to the expiration
of the Base Term of this Lease, Tenant has not agreed with Landlord's determination of the Market Rate and the rent escalations
during the Extension Term, if Tenant does not by such date notify Landlord of Tenant&rsquo;s rescission of its exercise of the
Extension Option, then Tenant shall be deemed to have elected arbitration as described below. If Tenant timely provides such notice
of rescission, the Extension Option shall be rescinded and of no further force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) Within 10 business days of Tenant's notice to Landlord of
its election (or deemed election) to arbitrate the Market Rate and the Escalation Rate, each party shall deliver to the other a
proposal containing the Market Rate and the Escalation Rate that the submitting party believes to be correct (&quot;<B>Extension
Proposal</B>&quot;). If either party fails to timely submit an Extension Proposal, the other party's submitted proposal shall determine
the Base Rent and escalations for the Extension Term. If both parties submit Extension Proposals, then Landlord and Tenant shall
meet within 7 days after delivery of the last Extension Proposal and make a good faith attempt to mutually appoint a single Arbitrator
(and defined below) to determine the Market Rate and escalations. If Landlord and Tenant are unable to agree upon a single Arbitrator,
then each shall, by written notice delivered to the other within 10 business days after the meeting, select an Arbitrator. If either
party fails to timely give notice of its selection for an Arbitrator, the other party's submitted Extension Proposal shall determine
the Market Rate and the Escalation Rate for the Extension Term. The 2 Arbitrators so appointed shall, within 5 business days after
their appointment, appoint a third Arbitrator. If the 2 Arbitrators so selected cannot agree on the selection of the third Arbitrator
within the time above specified, then either party, on behalf of both parties, may request such appointment of such third Arbitrator
by application to any state court of general jurisdiction in the jurisdiction in which the Premises are located, upon 10 business
days&rsquo; prior written notice to the other party of such intent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) The decision of the Arbitrator(s) on the appropriate Extension
Proposal shall be made within 30 days after the appointment of a single Arbitrator or the third Arbitrator, as applicable. If only
one Arbitrator is appointed, the decision of the single Arbitrator shall be final and binding upon the parties. The average of
the two closest Arbitrators in a three Arbitrator panel shall be final and binding upon the parties. Each party shall pay the fees
and expenses of the Arbitrator appointed by or on behalf of such party and the fees and expenses of the third Arbitrator shall
be borne equally by both parties. If the Market Rate and the Escalation Rate are not determined by the first day of the Extension
Term, then Tenant shall pay Landlord Base Rent in an amount equal to the Base Rent in effect immediately prior to the Extension
Term, increased by $0.50 per rentable square foot per annum, until such determination is made. After the determination of the Market
Rate and the Escalation Rate, the parties shall make any necessary adjustments to such payments made by Tenant. Landlord and Tenant
shall then execute an amendment recognizing the Market Rate and escalations for the Extension Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iii) An &quot;Arbitrator&quot; shall be any person appointed
by or on behalf of either party or appointed pursuant to the provisions hereof and: (i) shall be (A) a member of the American Institute
of Real Estate Appraisers with not less than 10 years of experience in the appraisal of improved office and high tech industrial
real estate in the greater Worcester metropolitan area, or (B) a licensed commercial real estate broker with not less than 15 years&rsquo;
experience representing landlords and/or tenants in the leasing of high tech or life sciences space in the greater Worcester metropolitan
area, (ii) devoting substantially all of their time to professional appraisal or brokerage work, as applicable, at the time of
appointment and (iii) be in all respects impartial and disinterested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Extension Right is personal to Tenant and is not assignable
without Landlord's consent, which may be granted or withheld in Landlord's sole discretion separate and apart from any consent
by Landlord to an assignment of Tenant's interest in the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding anything set forth above to the contrary, the
Extension Right shall not be in effect and Tenant may not exercise the Extension Right:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i) during any period of time that Tenant is in Default under
any provision of this Lease; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) if Tenant has been in Default under any provision of this
Lease 3 or more times, whether or not the Defaults are cured, during the 12 month period immediately prior to the date that Tenant
intends to exercise the Extension Right, whether or not the Defaults are cured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The period of time within which the Extension Right may be exercised
shall not be extended or enlarged by reason of Tenant's inability to exercise the Extension Right. The Extension Right shall terminate
and be of no further force or effect even after Tenant's due and timely exercise of the Extension Right, if, after such exercise,
but prior to the commencement date of the Extension Term, (i) Tenant fails to timely cure any Default by Tenant under this Lease;
or (ii) Tenant has Defaulted 3 or more times during the period from the date of the exercise of the Extension Right to the date
of the commencement of the Extension Term, whether or not such Defaults are cured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Rent.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Base
Rent</B>. The Security Deposit shall be due and payable on delivery of an executed copy of this Lease to Landlord. Tenant shall
pay to Landlord in advance, without demand, abatement, deduction or set-off, equal monthly installments of Base Rent on or before
the first day of each calendar month during the Term hereof after the Rent Commencement Date, in lawful money of the United States
of America , at the office of Landlord for payment of Rent set forth above, or to such other person or at such other place as
Landlord may from time to time designate in writing.; provided, however, that the installment of Rent that is payable on the Rent
Commencement Date shall not be overdue if paid by Tenant within five (5) business days of the Rent Commencement Date. Payments
of Base Rent for any fractional calendar month shall be prorated. The obligation of Tenant to pay Base Rent and other sums to
Landlord and the obligations of Landlord under this Lease are independent obligations. Tenant shall have no right at any time
to abate, reduce, or set-off any Rent (as defined in <B>Section 5</B>) due hereunder except for those abatement rights that are
expressly provided in this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional
Rent</B>. In addition to Base Rent, Tenant agrees to pay to Landlord as additional rent (&quot;<B>Additional Rent</B>&quot;):
(i) Tenant's Share of &quot;Operating Expenses&quot; (as defined in <U>Section 5</U>), and (ii) any and all other amounts Tenant
assumes or agrees to pay under the provisions of this Lease, including, without limitation, any and all other sums that may become
due by reason of any default of Tenant or failure to comply with the agreements, terms, covenants and conditions of this Lease
to be performed by Tenant, after any applicable notice and cure period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Intentionally
Omitted.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating
Expense Payments</B>. Landlord shall deliver to Tenant a written estimate of Operating Expenses for each calendar year during
the Term (the &quot;<B>Annual Estimate</B>&quot;), which may be revised by Landlord from time to time during such calendar year.
Commencing on the Rent Commencement Date and continuing thereafter on the first day of each month during the Term, Tenant shall
pay Landlord an amount equal to 1/12th of Tenant's Share of the Annual Estimate. Payments for any fractional calendar month shall
be prorated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term &quot;Operating Expenses&quot; means all costs and
expenses of any kind or description whatsoever incurred or accrued each calendar year by Landlord with respect to the Property
and the Generator (including, without duplication, Taxes (as defined in Section 9), reasonable reserves consistent with good business
practice for future repairs and replacements, and the costs of Landlord's third party property manager (provided that Tenant&rsquo;s
Share of such property management costs shall not exceed 5.0% of Base Rent) or, if there is no third party property manager, administration
rent in the amount of 5.0% of Base Rent), excluding only:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
original construction costs of the Property and renovation prior to the date of the Lease, costs of correcting defects in such
original construction or renovation and costs of any improvements made to the Property for purposes of compliance with Legal Requirements
to the extent such Legal Requirements exist as of the date hereof or insurance requirements because of another tenant at the Property
or such tenant&rsquo;s use of the Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;interest
and principal payments under any Mortgage (as defined in <U>Section 27</U>) or other debts of Landlord, financing costs and amortization
of funds borrowed by Landlord, whether secured or unsecured, and any rent payable under any ground lease pertaining to the Property
or under any leases of base building equipment for the Building such as HVAC or elevator;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;depreciation
of the Property (except for those capital improvements, for which the costs are not excluded from Operating Expenses as provided
below);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;advertising,
legal and space planning expenses and leasing commissions and other costs and expenses incurred in procuring and leasing space
to tenants for the Property, including any leasing office maintained in the Property, free rent, construction allowances and other
concessions for such tenants;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;legal,
accounting, administrative and other expenses incurred in the purchase, financing or refinancing of the Property or related to
the operation of Landlord or its affiliates as entities to the extent not related to the operation and maintenance of the Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;completing,
fixturing, improving, renovating, painting, redecorating or other work, which Landlord pays for or performs for other tenants within
their premises, and costs of correcting defects in such work as well as the cost of furnishing services to any tenant materially
in excess of Building standard services provided to tenants;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;costs
to the extent reimbursed by other tenants of the Property or Taxes to be paid directly by Tenant or other tenants of the Property</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;costs
(including attorneys' fees and costs of settlement, judgments and payments in lieu thereof) incurred in connection with disputes
with tenants, other occupants, or prospective tenants, and costs and expenses, including legal fees, incurred in connection with
negotiations or disputes with employees, consultants, management agents, leasing agents, purchasers or mortgagees of the Building;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;costs
incurred by Landlord (i) for the benefit of any particular tenant in the Building but not for the benefit of all tenants in the
Building, or (ii) due to the violation by Landlord, its employees, agents or contractors or any tenant of the terms and conditions
of any lease of space in the Property or any Legal Requirement (as defined in <U>Section 7</U>);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;penalties,
fines or interest incurred as a result of Landlord's failure to make payment of Taxes and/or to file any tax or informational returns
when due, or from Landlord's failure to make any payment of Taxes, or any other payment obligation of Landlord, required to be
made by Landlord hereunder before delinquency;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;net
income taxes of Landlord or the owner of any interest in the Property, franchise, capital stock, gift, estate or inheritance taxes
or any federal, state or local documentary taxes imposed against the Property or any portion thereof or interest therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
expenses otherwise includable within Operating Expenses to the extent actually reimbursed by persons other than tenants of the
Property under leases for space in the Property, including, without limitation, reimbursements from insurance proceeds, condemnation
awards, warranties and rebates; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;costs
for capital equipment and capital expenditures unless the same are (x) incurred to comply with laws or other governmental requirements
that only become applicable to the Property after the Effective Date, (y) incurred to achieve savings or reductions in other Operating
Expenses, or (z) incurred to make a replacement or capital repair with respect to any equipment or component with respect to which
Landlord reasonably determines that repairs are no longer commercially reasonable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Within 90 days after
the end of each calendar year (or such longer period as may be reasonably required), Landlord shall furnish to Tenant a statement
(an &quot;<B>Annual Statement</B>&quot;) showing in reasonable detail: (a) the total and Tenant's Share of actual Operating Expenses
for the previous calendar year, and (b) the total of Tenant's payments in respect of Operating Expenses for such year. If Tenant's
Share of actual Operating Expenses for such year exceeds Tenant's payments of Operating Expenses for such year, the excess shall
be due and payable by Tenant as Rent within 30 days after delivery of such Annual Statement to Tenant. If Tenant's payments of
Operating Expenses for such year exceed Tenant's Share of actual Operating Expenses for such year Landlord shall pay the excess
to Tenant within 30 days after delivery of such Annual Statement, except that after the expiration, or earlier termination of the
Term or if Tenant is delinquent in its obligation to pay Rent, Landlord shall pay the excess to Tenant after deducting all other
amounts due Landlord. Landlord shall reasonably attempt to deliver an Annual Statement by June 1 of the year following the year
to which such Annual Statement pertains. If Landlord shall failure to so deliver an Annual Statement to Tenant by August 1 of the
year following the year to which such Annual Statement pertains, then Landlord shall be deemed to have waived Landlord&rsquo;s
rights to payment, if any, from Tenant for such year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Annual Statement
shall be final and binding upon Tenant unless Tenant, within 60 days after Tenant's receipt thereof, shall contest any item therein
by giving written notice to Landlord, specifying each item contested and the reason therefor. Operating Expenses for the calendar
years in which Tenant's obligation to share therein begins and ends shall be prorated. Any such contest by Tenant shall be based
upon review of the Annual Statement by a certified public accountant engaged by Tenant (&ldquo;<B>Tenant&rsquo;s CPA</B>&rdquo;).
Tenant&rsquo;s CPA shall not be compensated on a contingency basis, in whole or in part, will not in any manner solicit or agree
to represent any other tenant of the Property for an audit or other review of Operating Expenses or an Annual Statement, shall
maintain in strict confidence any and all information obtained in connection with its review of the Annual Statement and Operating
Expenses, and shall not disclose that information to any person or entity other than to the ownership and management of Tenant
and Landlord. Notwithstanding anything set forth herein to the contrary, if the Property is not at least 95% occupied on average
during any year of the Term, Tenant's Share of Operating Expenses for such year shall be computed as though the Property had been
95% occupied on average during such year; provided, however, that (i) Landlord shall disclose in writing to Tenant if any such
adjustment is made, and (ii) no such adjustment shall result in Landlord receiving payments for Operating Expenses in excess of
the amounts incurred by Landlord for Operating Expenses. [</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&quot;<B>Tenant's Share</B>&quot;
shall be the percentage set forth on the first page of this Lease as Tenant's Share as reasonably adjusted by Landlord for changes
in the physical size of the Premises or the Property occurring thereafter Base Rent, Tenant's Share of Operating Expenses and all
other amounts payable by Tenant to Landlord hereunder are collectively referred to herein as &quot;<B>Rent</B>.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Security
Deposit</B>. As security for the performance of all of Tenant&rsquo;s obligations hereunder, Tenant shall deposit with Landlord,
upon delivery of an executed copy of this Lease to Landlord, (a) a security deposit (the &quot;<B>Security Deposit</B>&quot;)
in the amounts set forth in the defined terms of this Lease, which Security Deposit shall, as described in the defined terms,
be in the form of cash and an unconditional and irrevocable letter of credit (the &quot;<B>Letter of Credit</B>&quot;): (i) in
form and substance satisfactory to Landlord, (ii) naming Landlord as beneficiary, (iii) expressly allowing Landlord to draw upon
it at any time from time to time by delivering to the issuer notice that Landlord is entitled to draw thereunder, (iv) issued
by an FDIC-insured financial institution satisfactory to Landlord, and (v) redeemable by presentation of a sight draft in the
state of Landlord's choice. If Tenant does not provide Landlord with a substitute Letter of Credit complying with all of the requirements
hereof at least 10 days before the stated expiration date of any then current Letter of Credit, Landlord shall have the right
to draw the full amount of the current Letter of Credit and hold the funds drawn in cash without obligation for interest thereon
as the Security Deposit. The Security Deposit shall be held by Landlord as security for the performance of Tenant's obligations
under this Lease. The Security Deposit is not an advance rental deposit or a measure of Landlord's damages in case of Tenant's
default. Upon each occurrence of a Default (as defined in <U>Section 20</U>), Landlord may use all or any part of the Security
Deposit to pay delinquent payments due under this Lease, future rent damages provided in this Lease as they come due, and the
cost of any damage, injury, expense or liability caused by such Default, without prejudice to any other remedy provided herein
or provided by law. Landlord's right to use the Security Deposit under this <U>Section 6</U> includes the right to use the Security
Deposit to pay future rent damages following the termination of this Lease pursuant to <U>Section 21(c)</U> below. Upon any use
of all or any portion of the Security Deposit, Tenant shall pay Landlord on demand the amount that will restore the Security Deposit
to the amount set forth on Page 1 of this Lease. Tenant hereby waives the provisions of any law, now or hereafter in force which
provide that Landlord may claim from a security deposit only those sums reasonably necessary to remedy defaults in the payment
of Rent, to repair damage caused by Tenant or to clean the Premises, it being agreed that Landlord may, in addition, claim those
sums reasonably necessary to compensate Landlord for any other loss or damage, foreseeable or unforeseeable, caused by the act
or omission of Tenant or any officer, employee, agent or invitee of Tenant, as long as the same also constitutes a Default under
this Lease. Upon bankruptcy or other debtor-creditor proceedings against Tenant, the Security Deposit shall be deemed to be applied
first to the payment of Rent and other charges due Landlord for periods prior to the filing of such proceedings. Upon any such
use of all or any portion of the Security Deposit, Tenant shall, within 5 days after demand from Landlord, restore the Security
Deposit to its original amount. If Tenant shall fully perform every provision of this Lease to be performed by Tenant, the Security
Deposit, or any balance thereof (i.e., after deducting therefrom all amounts to which Landlord is entitled under the provisions
of this Lease), shall be returned to Tenant (or, at Landlord's option, to the last assignee of Tenant's interest hereunder) within
30 days after the expiration or earlier termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Landlord transfers
its interest in the Property or this Lease, Landlord shall transfer any Security Deposit then held by Landlord to a person or entity
assuming Landlord's obligations under this <U>Section 6</U>. Only upon such transfer to such transferee, shall Landlord have no
further obligation with respect to the Security Deposit, and Tenant's right to the return of the Security Deposit shall apply solely
against Landlord's transferee. The Security Deposit is not an advance rental deposit or a measure of Landlord's damages in case
of Tenant's default. Landlord's obligation respecting the Security Deposit is that of a debtor, not a trustee, and no interest
shall accrue thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Letter of Credit
Security Deposit shall be subject to adjustment as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) If, after
the expiration of the fifth Lease Year, Tenant is not then in Default under this Lease, has not been in Default more than twice
during the Term, and the Landlord has not drawn on the Letter of Credit Security Deposit, then the Letter of Credit Security Deposit
shall be reduced to $750,000.00 either by amendment or replacement of the Letter of Credit).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii) If,
after the expiration of the sixth Lease Year, Tenant is not then in Default under this Lease, has not been in Default more than
twice during the Term, and the Landlord has not drawn on the Letter of Credit Security Deposit, then the Letter of Credit Security
Deposit shall be reduced to $375,000.00 either by amendment or replacement of the Letter of Credit).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii) If,
after the expiration of the seventh Lease Year, Tenant is not then in Default under this Lease, has not been in Default more than
twice during the Term, and the Landlord has not drawn on the Letter of Credit Security Deposit, then the Letter of Credit Security
Deposit shall be released and cancelled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Permitted
Use</B>. The Premises shall be used solely for the Permitted Use set forth in the basic lease provisions on page 1 of this Lease,
and in compliance with all laws, orders, judgments, ordinances, regulations, codes, directives, permits, licenses, covenants and
restrictions now or hereafter applicable to the Premises, and to the use and occupancy thereof, including, without limitation,
the Americans With Disabilities Act, 42 U.S.C. &sect; 12101, et seq. (together with the regulations promulgated pursuant thereto,
&quot;<B>ADA</B>&quot;) (collectively, &quot;<B>Legal Requirements</B>&quot; and each, a &quot;<B>Legal Requirement</B>&quot;).
Except as provided herein, Landlord shall be responsible for compliance of those portions of the Property not then leased to Tenant
or other parties other than Landlord or Landlord&rsquo;s affiliates, including but not limited to common areas, with Legal Requirements.
Tenant shall, upon 5 days' written notice from Landlord, discontinue any use of the Premises which is declared by any Governmental
Authority (as defined in <U>Section 9</U>) having jurisdiction to be a violation of a Legal Requirement. Tenant will not use or
permit the Premises to be used for any purpose or in any manner that would void Tenant's or Landlord's insurance, increase the
insurance risk, or cause the disallowance of any sprinkler or other credits, it being acknowledged that use of the Premises for
the Permitted Use shall not be prohibited or impaired hereby. Tenant shall not permit any part of the Premises to be used as a
&quot;place of public accommodation&quot;, as defined in the ADA or any similar legal requirement. Tenant shall reimburse Landlord
promptly upon demand for any additional premium charged for any such insurance policy by reason of Tenant's failure to comply
with the provisions of this Section or otherwise caused by Tenant's use and/or occupancy of the Premises for any use or purpose
other than the Permitted Use. Tenant will use the Premises in a careful, safe and proper manner and will not commit or permit
waste, overload the floor or structure of the Premises, subject the Premises to use that would damage the Premises or obstruct
or interfere with the rights of Landlord or other tenants or occupants of the Property, including conducting or giving notice
of any auction, liquidation, or going out of business sale on the Premises, or using or allowing the Premises to be used for any
unlawful purpose. Tenant shall cause any equipment or machinery to be installed in the Premises so as to reasonably prevent or
mitigate sounds or vibrations from the Premises from extending into Common Areas, or other occupied space in the Property. Tenant
shall not transport or move any machinery or equipment weighing 500 pounds or more through the Common Areas of the Property or
in the Property elevators without the prior written consent of Landlord, not to be unreasonably withheld, conditioned or delayed.
Tenant shall not exceed Building floor load limits within the Premises or Building. Except as the same may be accommodated by
Tenant&rsquo;s Work or other approved Alterations to the Premises, Tenant shall not, without the prior written consent of Landlord,
use the Premises in any manner which will require ventilation, air exchange, heating, gas, steam, electricity or water beyond
the existing capacity of the Property as proportionately allocated to the Premises based upon Tenant's Share as usually furnished
for the Permitted Use. Subject to security protocols established by Landlord from time to time for the Building and other express
provisions of this Lease, Tenant will have access to the Building, Common Areas and the Premises 24 hours a day, 7 days a week
and 365/366 days a year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal
Requirements</B>. Tenant, at its sole expense, shall make any alterations or modifications to the interior or the exterior of
the Premises or the Property that are required by Legal Requirements (including, without limitation, compliance of the Premises
with the ADA), related to Tenant's particular use or occupancy of the Premises or required as part of any Alterations. Landlord
shall be responsible for any such alterations or modifications to the extent they arise out of use or occupancy of, or alterations
to, the Property made by or for Landlord or other tenants or prospective tenants at the Property (other than Tenant). Notwithstanding
any other provision herein to the contrary, Tenant shall be responsible for any and all demands, claims, liabilities, losses,
costs, expenses, actions, causes of action, damages or judgments, and all reasonable expenses incurred in investigating or resisting
the same (including, without limitation, reasonable attorneys' fees, charges and disbursements and costs of suit) (collectively,
&quot;<B>Claims</B>&quot;) arising out of or in connection with Legal Requirements that are related to Tenant's particular use
or occupancy of the Premises, and Tenant shall indemnify, defend, hold and save Landlord harmless from and against any and all
Claims arising out of or in connection with any failure of the Premises to comply with any such Legal Requirement except to the
extent such compliance is expressly Landlord&rsquo;s responsibility under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Emergency
Generator</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall have the right to use on a shared basis in common with other tenants and occupants of the Property the emergency standby
generator (&ldquo;<B>Generator</B>&rdquo;) at the Property in the event of a power outage. Tenant&rsquo;s use of the Generator
shall not exceed 30 kW. Without limiting the generality of the foregoing or any other term or provision of this Lease, Tenant,
in its use of the Generator, shall comply with all permits with respect to the Generator and all Environmental Laws and other Legal
Requirements. Tenant shall indemnify and hold Landlord harmless from and against any and all claims of any kind or nature to the
extent related to the use of the Generator by Tenant or any other Tenant Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord
shall have no obligation or liability to Tenant on account of, or in any way related to, the condition, use or operation of the
Generator nor shall Landlord have any obligation or liability to Tenant or any other party on account of any use or non-use of
or damage to the Generator caused by any other tenant, subtenant, licensee, invitee, agent, servant, contractor or other party
who may, from time to time, make use of the same nor shall Landlord have any obligation to Tenant on account of or in any way related
to any failure of the Generator to comply with Environmental Requirements or other Legal Requirements or, except as specifically
set forth in this Section 7(c), for any failure of the Generator to function or operate in any particular manner. While the Generator
installed at the Property as of the Effective Date may meet National Fire Protection Association (&ldquo;<B>NFPA</B>&rdquo;) Life
Safety Code requirements, Landlord makes no warranty or representation as to such compliance and shall not be responsible for maintaining
the Generator or any additional or replacement Generator in compliance with such requirements. In the event Tenant requires generator
capacity that is NFPA Life Safety Code compliant, Tenant shall be solely responsible for ensuring such compliance or obtaining
generator capacity that is so compliant, all at Tenant&rsquo;s sole cost and expense. If replacement of the Generator is appropriate
in Landlord&rsquo;s judgment, Landlord shall replace the Generator with one having capacity sufficient to allow Tenant 30 kW of
usage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall be solely responsible for all costs and expenses which Landlord may suffer or incur or pay on account of or in any way related
to the use of Generator by Tenant or any Tenant Party (including, without limitation, any damage caused to the Generator).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
costs and expenses incurred by Landlord from time to time to maintain and repair the Generator shall be included in Operating Expenses.
Notwithstanding the foregoing to the contrary, Tenant shall be responsible for one hundred (100%) percent of the Generator expenses
that are attributable to any (a) damage caused to the Generator by Tenant or any Tenant Party, (b) any failure of Tenant or any
Tenant Party to comply with Legal Requirements related to the Generator and all such costs and expenses shall be due and payable
as Additional Rent within fifteen (15) days after being billed by Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord
shall be responsible for maintenance, repair and replacement of the Generator but in no event shall Landlord be responsible for
any maintenance, repair or replacement of the Generator to the extent the need therefor is caused by any failure of Tenant or any
Tenant Party to observe, perform and comply with this Lease or by any act or omission of the Tenant or any Tenant Party or by reason
of any damage caused to the Generator by Tenant or any Tenant Party. Without limiting any other term or provision of this Lease
in no event shall Landlord have any obligation or liability to Tenant on account of, or in any way related to, any use, non-use
of, or damage to the Generator nor any failure of the Generator to operate or function caused by any other tenant, subtenant, licensee,
invitee, agent, servant, contractor or other party who may from time to time make use of the same nor on account of any failure
of any such other Tenant, subtenant, licensee, invitee, agent, servant, contractor or other party to comply with Legal Requirements
in any way related to the Generator or the use thereof. In no event shall Landlord have any liability to Tenant for lost revenues,
profits, damage to business or consequential damages on account of, or in any way related to, the failure of Landlord to maintain,
repair or replace the Generator nor for any failure of the Generator to operate or function properly, nor shall Landlord have any
obligation to Tenant on account of or in any way related to any failure of the Generator to comply with Environmental Requirements
or other Legal Requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
limiting any other term or provision of this Lease, Landlord reserves the right to curtail, suspend, interrupt and/or stop use
of the Generator without thereby incurring any liability to Tenant or any Tenant Party when necessary by reason of accident or
emergency, or for repairs, alterations, replacements or improvements in the judgment of Landlord desirable or necessary or when
required in order to comply with Legal Requirements or when use thereof is interrupted, suspended or prevented under Legal Requirements
or by strikes, lockouts, difficulty of obtaining materials, accidents or any other cause beyond Landlord's control or by laws,
orders or inability by exercise of reasonable diligence, to obtain electricity, water, gas, steam, coal, oil or other suitable
fuel or power. No diminution or abatement of rent or other compensation, nor any direct, indirect or consequential damages or claims
for lost profits, or damage to business shall, or will be, claimed by Tenant (or any Tenant Party) as a result of, nor shall this
Lease nor any of the obligations of Tenant or any Tenant Party be affected or reduced by reason of any such interruption, curtailment,
or suspension. Failure or omission on the part of Landlord to maintain, repair or replace the Generator or to comply with Legal
Requirements related to the Generator shall not be construed as an eviction of Tenant, actual or constructive, or, except as noted
in Section 11, entitle Tenant to an abatement of Base Rent, nor to render the Landlord liable in damages, nor release Tenant from
prompt fulfillment of any of its covenants under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, Tenant, at its sole cost, may install its own generator using the concrete pad located adjacent to the Generator. Installation
and wiring shall be pursuant to plans submitted for approval to Landlord, which approval shall not be unreasonably withheld, conditioned
or delayed. Tenant shall be responsible for all repair, maintenance and replacement costs associated with this Tenant-installed
generator. At the end of the term, Tenant shall remove any Tenant-installed generator and all wiring associated with the same and
restore the property on which it was located to its previous condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holding
Over</B>. If, with Landlord's express written consent, Tenant retains possession of the Premises after the termination of the
Term, (i) unless otherwise agreed in such written consent, such possession shall be subject to immediate termination by Landlord
at any time, (ii) all of the other terms and provisions of this Lease (including, without limitation, the adjustment of Base Rent
pursuant to <U>Section 4</U> hereof) shall remain in full force and effect (excluding any expansion or renewal option or other
similar right or option) during such holdover period, (iii) Tenant shall continue to pay Base Rent in the amount payable upon
the date of the expiration or earlier termination of this Lease or such other amount as Landlord may indicate, in Landlord's sole
and absolute discretion, in such written consent, and (iv) all other payments shall continue under the terms of this Lease. If
Tenant remains in possession of the Premises after the expiration or earlier termination of the Term without the express written
consent of Landlord, (A) Tenant shall become a tenant at sufferance upon the terms of this Lease except that the monthly Base
Rent payment shall be equal to 150% of Base Rent in effect during the last 30 days of the Term, and (B) Tenant shall be responsible
for all damages suffered by Landlord resulting from or occasioned by Tenant's holding over, including consequential damages. No
holding over by Tenant, whether with or without consent of Landlord, shall operate to extend this Lease except as otherwise expressly
provided, and this <U>Section 8</U> shall not be construed as consent for Tenant to retain possession of the Premises. Acceptance
by Landlord of Rent after the expiration of the Term or earlier termination of this Lease shall not result in a renewal or reinstatement
of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taxes</B>.
Tenant shall pay, as part of Operating Expenses, all taxes, levies, fees, assessments and governmental charges of any kind, existing
as of the Commencement Date or thereafter enacted (collectively referred to as &quot;<B>Taxes</B>&quot;), imposed by any federal,
state, regional, municipal, local or other governmental authority or agency, including, without limitation, quasi-public agencies
(collectively, &quot;<B>Governmental Authority</B>&quot;) during the Term, including, without limitation, all Taxes if imposed
in lieu of a tax on Landlord&rsquo;s income: (i) imposed on or measured by or based, in whole or in part, on rent payable to (or
gross receipts received by) Landlord under this Lease and/or from the rental by Landlord of the Property or any portion thereof,
or (ii) based on the square footage, assessed value or other measure or evaluation of any kind of the Premises or the Property,
or (iii) assessed or imposed by or on the operation or maintenance of any portion of the Premises or the Property, including parking,
or (iv) assessed or imposed by, or at the direction of, or resulting from Legal Requirements, or interpretations thereof, promulgated
by any Governmental Authority, or (v) imposed as a license or other fee, charge, tax, or assessment on Landlord's business or
occupation of leasing space in the Property. Landlord may contest by appropriate legal proceedings the amount, validity, or application
of any Taxes or liens securing Taxes. Taxes shall not include any net income taxes imposed on Landlord except to the extent such
net income taxes are in substitution for any Taxes payable hereunder. If any such Tax is levied or assessed directly against Tenant,
then Tenant shall be responsible for and shall pay the same at such times and in such manner as the taxing authority shall require.
Tenant shall pay, prior to delinquency, any and all Taxes levied or assessed against any personal property or trade fixtures placed
by Tenant in the Premises, whether levied or assessed against Landlord or Tenant. If any Taxes on Tenant's personal property or
trade fixtures are levied against Landlord or Landlord's property, or if the assessed valuation of the Property is increased by
a value attributable to improvements in or alterations to the Premises made after the Commencement Date, whether owned by Landlord
or Tenant and whether or not affixed to the real property so as to become a part thereof, higher than the base valuation on which
Landlord from time-to-time allocates Taxes to all tenants in the Property, Landlord shall have the right, but not the obligation,
to pay such Taxes. The amount of any such payment by Landlord shall constitute Additional Rent due from Tenant to Landlord within
30 days of demand. Notwithstanding anything set forth herein to the contrary, if any portion of the Property is exempt from real
property taxation and the Premises is not exempt from real property taxation, Tenant shall pay its share of such Taxes based on
multiplying the Taxes for Property by a fraction of which the rentable square footage of the Premises is the numerator and the
rentable square footage of the Property that is not exempt from real property taxation is the denominator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parking</B>.
Subject to all matters of record, Force Majeure, a Taking (as defined in Section 19 below) and the exercise by Landlord of its
rights hereunder, Tenant shall have the right to park in up to 28 parking spaces of which 6 will be reserved, in the location
shown on the site plan attached hereto as <B>Exhibit G</B>, until the Section B Occupancy Date and thereafter 54 parking spaces
of which 12 will be reserved, in the location shown on the site plan attached hereto as <B>Exhibit G</B>, at no additional expense
to the Tenant during the Term of the Lease, subject in each case to Landlord's rules and regulations. Landlord shall not be responsible
for enforcing Tenant's parking rights against any third parties, other than other tenants of the Property. Parking shall be for
licensed, operative motor vehicles only by officers, directors, employees, visitors and contractors of Tenant. No overnight parking
shall be permitted without Landlord&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Utilities,
Services</B>. The Building will be operated with twenty-four hour, seven day access, such access to be controlled during non-Business
Hours (as hereinafter defined). Landlord shall provide, subject to the terms and limitations of this <U>Section 11</U>, water,
electricity, heat, chilled water, hot water, electrical, fire protection, light, power, sewer, and other utilities (including
gas and fire sprinklers to the extent the Property is plumbed for such services), refuse and trash collection and janitorial services
(collectively, &quot;<B>Utilities</B>&quot;). Central heat and air conditioning shall be provided during Business Hours in season,
at such temperatures and in such amounts as are provided by Landlord as standard to other tenants of the Building or as may be
controlled by applicable laws, ordinances, rules and regulations or by voluntary conservation programs with which comparable laboratory
and office buildings in the greater Worcester metropolitan area are complying. The term &ldquo;<B>Business Hours</B>&rdquo; shall
be deemed to be Monday through Friday from 8:00&nbsp;A.M. to 6:00 P.M. and Saturday from 8:00 A.M. to 1:00 P.M., excepting Holidays.
The term &ldquo;<B>Holidays</B>&rdquo; shall mean all federally observed holidays, including New Year&rsquo;s Day, President&rsquo;s
Day, Memorial Day, Independence Day, Labor Day, Thanksgiving Day, Christmas Day, and to the extent of utilities or services provided
by union members engaged at the Property, such other holidays observed by such unions. The term &ldquo;<B>Business Day</B>&rdquo;
or &ldquo;<B>business day</B>&rdquo; shall mean all days other than Holidays, Saturdays and Sundays. Tenant may request heating,
ventilation, air conditioning provided by Landlord to Tenant (i) during hours other than Business Hours, (ii) on Saturdays (after
Business Hours), Sundays, or Holidays, said heating, ventilation and air conditioning or extra service to be furnished solely
upon the prior written request of Tenant given with such advance notice as Landlord may reasonably require and Tenant shall pay
to Landlord Landlord&rsquo;s standard charge for overtime HVAC on an hourly basis from time to time established by Landlord (the
current standard charge for after-hours heating from November to March is $15.00 per hour, for after-hours cooling from April
through October is $5.00 per hour, in either case with a four hour minimum. Landlord shall pay, as Operating Expenses or subject
to Tenant's reimbursement obligation, for all utilities used on the Premises, all maintenance charges for utilities, and any storm
sewer charges or other similar charges for utilities imposed by any Governmental Authority or utility provider, and any taxes,
penalties, surcharges or similar charges thereon. Landlord may cause, at Tenant's expense, any utilities to be separately metered
or charged directly to Tenant by the provider. Tenant shall pay directly to the utility provider, prior to delinquency, any separately
metered utilities and services which may be furnished to Tenant or the Premises during the Term. Tenant shall pay, as part of
Operating Expenses, its share of all charges for jointly metered utilities based upon consumption, as reasonably determined by
Landlord. No interruption or failure of utilities, from any cause whatsoever other than the negligence or willful misconduct of
Landlord or its officers, directors, employees, managers, agents, invitees and contractors (collectively, &quot;<B>Landlord Parties</B>&quot;),
shall result in eviction or constructive eviction of Tenant, termination of this Lease or the abatement of Rent, provided, however
that, in the event that Landlord is unable to supply any of the Utilities due to the negligence or willful misconduct of a Landlord
Party, and such inability materially impairs Tenant&rsquo;s ability to carry on the Permitted Use in the Premises for a period
of three (3) consecutive Business Days, Base Rent and Additional Rent shall be abated effective as of the first day of such material
interference with the Permitted Use. Such abatement shall continue until the applicable Utilities have been restored to such extent
that the lack of any remaining services no longer materially impairs Tenant&rsquo;s ability to carry on the Permitted Use in the
Premises. Tenant shall not be entitled to such an abatement to the extent that Landlord&rsquo;s inability to supply a Utility
to Tenant is caused by Tenant or Tenant Parties. In the event of any stoppage or interruption of a Utility to the Premises, Landlord
shall use commercially reasonable efforts to restore such Utility to the Premises as soon as possible, which as to restoration
actions in the control of an applicable Utility provider shall only require notice to such provider and reasonable follow up and
shall not require any restoration action by Landlord. Landlord shall promptly notify Tenant of any planned or actual interruption
of Utilities, and shall keep Tenant advised of the status of such restoration efforts. Tenant agrees to limit use of water and
sewer with respect to Common Areas to normal restroom use. Notwithstanding the foregoing, Tenant shall pay directly to the utility
or direct to Landlord for its own electricity usage as measured by a separate electric meter or submeter exclusively serving the
Premises (to be installed by Landlord at its expense as herein provided), including usage for any specialty HVAC equipment for
Tenant&rsquo;s lab, except during the first six (6) months of the first Lease Year, in which Landlord shall cause such amounts
to be paid. Additionally, but without any duplication of expense, Tenant shall pay Tenant&rsquo;s Share of any single-meter utilities
that are chargeable hereunder as Operating Expenses and for the equal benefit to all Building tenants. It shall be Landlord&rsquo;s
sole cost and expense to meter either by meter or submeter promptly, separately both Section A and Section B of the Premises.
Tenant shall commence payment of electricity charges for Section A commencing with the seventh (7<SUP>th</SUP>) month of the first
Lease Year and with respect to Section B commencing on the Section B Occupancy Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If required, and subject to Landlord&rsquo;s
reasonable approval, Tenant shall be allowed to place additional HVAC equipment to serve the Premises outside of the Premises in
a location to be mutually agreed upon by Landlord and Tenant. Installation of such equipment shall constitute an Alteration and
the installation and maintenance of such equipment shall be performed by Tenant&rsquo;s contractor at Tenant&rsquo;s sole expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alterations
and Tenant&rsquo;s Property; Tenant&rsquo;s Work</B>. Tenant&rsquo;s initial work to prepare the Premises for occupancy (<B>&ldquo;Tenant&rsquo;s
Work&rdquo;</B>) shall constitute Alterations and be constructed by Tenant pursuant to the terms and conditions of <B>Exhibit
H</B>. Any alterations, additions, or improvements made to the Premises by or on behalf of Tenant other than Tenant&rsquo;s Work,
including additional locks or bolts of any kind or nature upon any doors or windows in the Premises, but excluding installation,
removal or realignment of furniture systems (other than removal of furniture systems owned by Landlord) not involving any modifications
to the structure or connections (other than by ordinary plugs or jacks) to Building Systems (as defined in <U>Section 13</U>)
(&quot;<B>Alterations</B>&quot;) shall be subject to Landlord's prior written consent, which may be given or withheld in Landlord's
sole discretion if any such Alteration affects the structure or Building Systems and shall not be otherwise unreasonably withheld,
conditioned or delayed. Any request for approval of Alterations shall be in writing, delivered not less than 15 business days
in advance of any proposed construction, and accompanied by plans, specifications, bid proposals, work contracts and such other
information concerning the nature and cost of the Alterations as may be reasonably requested by Landlord, including the identities
and mailing addresses of all persons performing work or supplying materials. Landlord's right to review plans and specifications
and to monitor construction shall be solely for its own benefit, and Landlord shall have no duty to ensure that such plans and
specifications or construction comply with applicable Legal Requirements. Tenant shall cause, at its sole cost and expense, all
Alterations to comply with insurance requirements and with Legal Requirements and shall implement at its sole cost and expense
any alteration or modification required by Legal Requirements as a result of any Alterations. Except with respect to Tenant&rsquo;s
Work (the terms of which payment from Tenant to Landlord are provided in Section 3.C. of <B>Exhibit H</B>), Tenant shall pay to
Landlord, as Additional Rent, an amount equal to any third-party costs actually incurred by Landlord and reasonable allocated
costs associated with in-house evaluation for plan review, coordination, scheduling and supervision. Before Tenant begins any
Alteration, Landlord may post on and about the Premises notices of non-responsibility pursuant to applicable law. Tenant shall
reimburse Landlord for, and indemnify and hold Landlord harmless from, any expense incurred by Landlord by reason of faulty work
done by Tenant or its contractors, delays caused by such work, or inadequate cleanup, in each case, in connection with an Alteration
by Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tenant shall provide
(and cause each contractor or subcontractor to provide) certificates of insurance for workers' compensation and other coverage
in amounts and from an insurance company satisfactory to Landlord protecting Landlord against liability for personal injury or
property damage during construction. Upon completion of any Alterations, Tenant shall deliver to Landlord: (i) sworn statements
setting forth the names of all contractors and subcontractors who did the work and final lien waivers from all such contractors
and subcontractors; and (ii) &quot;as built&quot; plans for any such Alteration, unless the Alteration did not require the issuance
of a permit from a Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except for Removable
Installations (as hereinafter defined), all Installations (as hereinafter defined) shall be and shall remain the property of Landlord
during the Term and following the expiration or earlier termination of the Term, shall not be removed by Tenant at any time during
the Term, and shall remain upon and be surrendered with the Premises as a part thereof. Notwithstanding the foregoing, Landlord
may, at the time its approval of any such Installation is requested, notify Tenant that Landlord requires that Tenant remove such
Installation upon the expiration or earlier termination of the Term, in which event Tenant shall remove such Installation in accordance
with the immediately succeeding sentence. Upon the expiration or earlier termination of the Term, Tenant shall remove (i) all wires,
cables or similar equipment which Tenant has installed in the Premises or in the risers or plenums of the Building, (ii) any Installations
for which Landlord has given Tenant notice of removal in accordance with the immediately preceding sentence, and (iii) all of Tenant's
Property (as hereinafter defined), and Tenant shall restore and repair any damage caused by or occasioned as a result of such removal,
including, without limitation, capping off all such connections behind the walls of the Premises and repairing any holes. During
any restoration period beyond the expiration or earlier termination of the Term, Tenant shall pay Rent to Landlord as provided
herein as if said space were otherwise occupied by Tenant. If Landlord is requested by Tenant or any lender, lessor or other person
or entity claiming an interest in any of Tenant's Property to waive any lien Landlord may have against any of Tenant's Property,
and Landlord consents to such waiver, then Landlord shall be entitled to be paid as administrative rent a fee of $1,000 per occurrence
for its time and effort in preparing and negotiating such a waiver of lien.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this
Lease, (x) &quot;<B>Removable Installations</B>&quot; means any items listed on <B>Exhibit E</B> attached hereto and any items
agreed by Landlord in writing to be characterized as Removable Installations, (y) &quot;<B>Tenant's Property</B>'' means Removable
Installations and, other than Installations, any personal property or equipment of Tenant that may be removed without material
damage to the Premises, and (z) &quot;<B>Installations</B>&quot; means, except to the extent included in Tenant&rsquo;s Work, all
property of any kind if paid for by Landlord, all Alterations, all fixtures, and all partitions, hardware, built-in machinery,
built-in casework and cabinets and other similar additions, equipment, property and improvements built into the Premises so as
to become an integral part of the Premises, including, without limitation, fume hoods which penetrate the roof or plenum area,
built-in cold rooms, built-in warm rooms, walk-in cold rooms, walk-in warm rooms, deionized water systems, glass washing equipment,
autoclaves, chillers, built-in plumbing, electrical and mechanical equipment and systems, and any power generator and transfer
switch.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord's
Repairs</B>. Landlord, as an Operating Expense, shall maintain all of the structural, exterior, parking and other Common Areas
of the Property, including the Building foundation, roof, roof system, and exterior walls, exterior windows and doors and the
frames and casing therefor, and HVAC, plumbing, fire sprinklers and other life-safety systems, security systems for the Building,
elevators, the Generator, and all other building systems serving the Premises and other portions of the Property (&quot;<B>Building
Systems</B>&quot;) (but excluding therefrom systems solely serving the Premises as listed in Section 14(ii) below), in good repair,
reasonable wear and tear and uninsured losses and damages caused by Tenant, or by any of Tenant's agents, servants, employees,
invitees and contractors (collectively, &quot;<B>Tenant Parties</B>&quot; and each, a &quot;<B>Tenant Party</B>&quot;) excluded.
Losses and damages caused by Tenant or any Tenant Party shall be repaired by Landlord, to the extent not covered by insurance,
at Tenant's sole cost and expense. Landlord reserves the right to stop Building Systems services when necessary (i) by reason
of accident or emergency, or (ii) for planned repairs, alterations or improvements, which are, in the judgment of Landlord, desirable
or necessary to be made, until said repairs, alterations or improvements shall have been completed. Landlord shall have no responsibility
or liability for failure to supply Building Systems services during any such period of interruption; <U>provided</U>, <U>however</U>,
that Landlord shall, except in case of emergency, make a commercially reasonable effort to give Tenant 24 hours&rsquo; advance
notice of any planned stoppage of Building Systems services for routine maintenance, repairs, alterations or improvements, and,
if reasonably feasible, to conduct any routine maintenance, repairs, alterations or improvements to Building Systems that would
require a stoppage that would materially affect Tenant&rsquo;s use and enjoyment of the Premises for the Permitted Use after Business
Hours. Tenant shall promptly give Landlord written notice of any repair required by Landlord pursuant to this Section, after which
Landlord shall make a commercially reasonable effort to effect such repair.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Landlord is in default in the performance
of any of its obligations under this <U>Section 13</U>, beyond applicable notice and cure periods, then Tenant shall have the right
to remedy such default on Landlord&rsquo;s behalf (provided that Tenant uses reasonable efforts to avoid violating or rendering
void any warranties maintained by Landlord), in which event Landlord shall reimburse Tenant within forty five (45) days after invoice
for all reasonable costs and expenses incurred by Tenant in connection therewith. Tenant&rsquo;s self-help rights under this <U>Section
13</U> shall be exercised by Tenant only (i) with respect to conditions actually existing within the Premises (and not affecting
the structural components of the Building or systems serving other tenants of the Building), (ii) with respect to conditions that
materially affect Tenant&rsquo;s ability to use and enjoy the Premises, and (iii) after Tenant has provided Landlord with notice
of Tenant&rsquo;s intention to exercise such right, and Landlord has failed to commence action to remedy the condition complained
of within ten (10) days after its receipt of such notice (or if Landlord commences to do the act required within such period but
fails to proceed diligently thereafter). Tenant&rsquo;s remedies under this <U>Section 13</U> are personal to Tenant and may not
be exercised by any subtenants or assignees (other than an assignee through a Permitted Assignment) against Landlord. Tenant shall
indemnify, save harmless and defend Landlord and its members, managers, officers, mortgagees, agents, employees, independent contractors,
invitees and other persons acting under them from and against all liability, claim or cost (including reasonable attorneys&rsquo;
fees) arising in whole or in part out of any negligence or willful misconduct in connection with Tenant&rsquo;s exercise of its
remedies pursuant to this <U>Section 13</U>. Except as provided in the preceding sentence, Tenant waives its rights under any state
or local law to terminate this Lease or to make such repairs at Landlord's expense and agrees that the parties' respective rights
with respect to such matters shall be solely as set forth herein. Repairs required as the result of fire, earthquake, flood, vandalism,
war, or similar cause of damage or destruction shall be controlled by <U>Section 18</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant's
Repairs</B>. Subject to <U>Section 13</U> hereof, Tenant, at its expense, (i) shall repair, replace and maintain in good condition
all portions of the Premises, including, without limitation, entries, doors, ceilings, interior windows, interior walls, and the
interior side of demising walls, and (ii) shall bear the cost of maintenance and repair, by contractors reasonably acceptable
to the Landlord (Landlord approval of contractors for HVAC and plumbing in clean rooms as part of Tenant&rsquo;s Work shall be
deemed approved for repairs to such installations), or, in Landlord&rsquo;s discretion by Landlord or Landlord&rsquo;s contractor
on behalf of Tenant at Tenant&rsquo;s expense (except that Tenant shall not be required to pay expenses that exceed pricing available
in the Worcester, MA area for similar services from third-party vendors), of all facilities which are not expressly required to
be maintained or repaired by Landlord and which are located in the Premises, including, without limitation, lavatory, shower,
toilet, wash basin and kitchen facilities, and supplemental heating and air conditioning systems (including all plumbing connected
to said facilities or systems installed by or on behalf of Tenant or existing in the Premises at the time of Landlord&rsquo;s
delivery of the Premises to Tenant). Such repair and replacement may include capital expenditures and repairs whose benefit may
extend beyond the Term. Should Tenant fail to make any such repair or replacement or fail to maintain the Premises, Landlord shall
give Tenant notice of such failure. If Tenant fails to commence cure of such failure within 10 days of Landlord's notice, and
thereafter diligently prosecute such cure to completion, Landlord may perform such work and shall be reimbursed by Tenant within
10 days after demand therefor; provided, however, that if such failure by Tenant creates or could create an emergency, Landlord
may immediately commence cure of such failure and shall thereafter be entitled to recover the costs of such cure from Tenant.
Subject to <U>Sections 17</U> and <U>18</U>, Tenant shall bear the full uninsured cost of any repair or replacement to any part
of the Property that results from damage caused by Tenant or any Tenant Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;Mechanic's
Liens</B>. Tenant shall discharge, by bond or otherwise, any mechanic's lien filed against the Premises or against the Property
for work validly claimed to have been done for, or materials validly claimed to have been furnished to, Tenant within 30 days
after the filing thereof, at Tenant's sole cost and shall otherwise keep the Premises and the Property free from any liens arising
out of work performed, materials furnished or obligations actually incurred by Tenant. Should Tenant fail to discharge any lien
as required herein, Landlord shall have the right, but not the obligation, to pay such claim or post a bond or otherwise provide
security to eliminate the lien as a claim against title to the Property and the cost thereof shall be immediately due from Tenant
as Additional Rent. If Tenant shall lease or finance the acquisition of office equipment, furnishings, or other personal property
of a removable nature utilized by Tenant in the operation of Tenant's business, Tenant warrants that any Uniform Commercial Code
Financing Statement filed as a matter of public record by any lessor or creditor of Tenant will upon its face or by exhibit thereto
indicate that such Financing Statement is applicable only to removable personal property of Tenant located within the Premises.
In no event shall the address of the Property be furnished on the statement without qualifying language as to applicability of
the lien only to removable personal property, located in an identified suite held by Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification</B>.
Tenant hereby indemnifies and agrees to defend, save and hold Landlord harmless from and against any and all Claims for injury
or death to persons or damage to property occurring within or about the Premises, to the extent arising directly or indirectly
out of the use or occupancy of the Premises or a breach or default by Tenant in the performance of any of its obligations hereunder,
but not to the extent caused by the willful misconduct or negligence of Landlord. Landlord shall not be liable to Tenant for,
and Tenant assumes all risk of damage to, personal property (including, without limitation, loss of records kept within the Premises),
except due to the negligence of willful misconduct of Landlord or a Landlord Party. Tenant further hereby irrevocably waives any
and all Claims for injury to Tenant's business or loss of income relating to any such damage or destruction of personal property
(including, without limitation, any loss of records), unless caused by the willful misconduct or negligence of Landlord. Landlord
shall not be liable for any damages arising from any act, omission or neglect of any tenant in the Property or of any other third
party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance</B>.
Tenant, at its sole cost and expense, shall maintain during the Term: (i)&nbsp;all risk property insurance with business interruption
and extra expense coverage, covering the full replacement cost of all property and improvements installed or placed in the Premises
by Tenant at Tenant's expense, including its laboratory equipment, office furniture, trade fixtures, office equipment, inventory,
merchandise and all other items of Tenant Property, in an amount adequate to cover their replacement cost, including a vandalism
and malicious mischief endorsement, and sprinkler leakage coverage; business interruption insurance, loss of income and extra
expense insurance covering all perils covered by a standard, &ldquo;Special Form&rdquo; (as defined from time-to-time by the insurance
industry) property insurance policy; (ii)&nbsp;workers' compensation insurance with no less than the minimum limits required by
law; (iii)&nbsp;employer's liability insurance with such limits as required by law; and (iv)&nbsp;commercial general liability
insurance, with a minimum limit of not less than $3,000,000 per occurrence for bodily injury and property damage with respect
to the Premises. In addition, Tenant shall carry such other coverages, and in such amounts, as are required by Landlord from time
to time, so long as such coverages and amounts are consistent with properties comparable to the Property in the greater Worcester
metropolitan area. The commercial general liability insurance policy shall name Worcester Campus Services, and Landlord and Landlord
Parties as additional insureds; insure on an occurrence and not a claims-made basis; be issued by insurance companies which have
a rating of not less than policyholder rating of A and financial category rating of at least Class X in &quot;Best's Insurance
Guide&quot;; shall not be cancelable for nonpayment of premium unless 30 days prior written notice shall have been given to Landlord
from the insurer; contain a hostile fire endorsement and a contractual liability endorsement; and provide primary coverage to
Landlord (any policy issued to Landlord providing duplicate or similar coverage shall be deemed excess over Tenant's policies).
Certificates of insurance showing the limits of coverage required hereunder and showing Landlord and Property Agent as additional
insureds, along with reasonable evidence of the payment of premiums for the applicable period, shall be delivered to Landlord
by Tenant within three (3) days of the Commencement Date, but in any event prior to Tenant entering the Premises, and upon each
renewal of said insurance. Any of Tenant&rsquo;s policies may be a &quot;blanket policy&quot; with an aggregate per location endorsement,
which specifically provides that the amount of insurance shall not be prejudiced by other losses covered by the policy. Tenant
shall, at least 5 days prior to the expiration of such policies, furnish Landlord with renewal certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In each instance where
insurance is to name Landlord as an additional insured, Tenant shall upon written request of Landlord also designate and furnish
certificates so evidencing Landlord as additional insured to: (i) any lender of Landlord holding a security interest in the Property
or any portion thereof, (ii) the landlord under any lease wherein Landlord is tenant of the real property on which the Property
is located, if the interest of Landlord is or shall become that of a tenant under a ground or other underlying lease rather than
that of a fee owner, and/or (iii) any management company retained by Landlord to manage the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Landlord shall maintain
the following insurance during the Term either through third party insurance or Commonwealth of Massachusetts self-insurance: (i)
Property insurance for the Building and Property, including the Tenant&rsquo;s Work, in amounts equal to full replacement cost
(exclusive of the costs of excavation, foundations and footings, engineering costs or such other costs that would not be incurred
in the event of a rebuild and without reference to depreciation taken by Landlord upon its books or tax returns), provided that
such coverage shall not be less than the amount of such insurance Landlord&rsquo;s Holder, if any, requires Landlord to maintain,
providing protection against any peril generally included within the classification &ldquo;Fire and Extended Coverage,&rdquo; together
with insurance against sprinkler damage (if applicable), vandalism and malicious mischief and sprinkler leakage; (ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT>Commercial
General Liability insurance with limits of not less than Three Million Dollars ($3,000,000) per occurrence/general aggregate for
bodily injury (including death), or property damage with respect to the Property; and (iii)&nbsp;subject to availability thereof
and if Landlord deems it appropriate, coverage against flood, environmental hazard, earthquake, loss or failure of building equipment,
rental loss during the period of repairs or rebuilding, Workers&rsquo; Compensation insurance and fidelity bonds for employees
employed to perform services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Landlord shall maintain
such other liability, property and other insurance coverage as it deems prudent in its sole discretion and all such insurance shall
be included as part of the Operating Expenses. The Property may be included in a blanket policy (in which case the cost of such
insurance allocable to the Property will be determined by Landlord based upon the insurer's cost calculations). Tenant shall also
reimburse Landlord for any increased premiums or additional insurance which Landlord reasonably deems necessary as a result of
Tenant's use of the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The property insurance
obtained by Landlord and Tenant shall include a waiver of subrogation by the insurers and all rights based upon an assignment from
its insured, against Landlord or Tenant, and their respective officers, directors, employees, managers, agents, invitees and contractors
(&quot;<B>Related Parties</B>&quot;), in connection with any loss or damage thereby insured against. Neither party nor its respective
Related Parties shall be liable to the other for loss or damage caused by any risk insured against under property insurance required
to be maintained hereunder, and each party waives any claims against the other party, and its respective Related Parties, for such
loss or damage. The failure of a party to insure its property shall not void this waiver. Landlord and its respective Related Parties
shall not be liable for, and Tenant hereby waives all claims against such parties for, business interruption and losses occasioned
thereby sustained by Tenant or any person claiming through Tenant resulting from any accident or occurrence in or upon the Premises
or the Property from any cause whatsoever. If the foregoing waivers shall contravene any law with respect to exculpatory agreements,
the liability of Landlord or Tenant shall be deemed not released but shall be secondary to the other's insurer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Landlord may require
insurance policy limits to be raised to conform with requirements of Landlord's lender and/or to bring coverage limits to levels
then being generally required of new tenants within the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restoration</B>.
If, at any time during the Term, the Property or the Premises are damaged or destroyed by a fire or other insured casualty, Landlord
shall notify Tenant as soon as possible but in any event within 60 days after the earlier of notification or discovery of such
damage as to the amount of time Landlord reasonably estimates it will take to restore the Property or the Premises, as applicable
(the &quot;<B>Restoration Period</B>&quot;). If the Restoration Period is estimated to exceed 270 days from the later of receipt
of insurance proceeds and commencement of such work with all required permits therefor (the &quot;<B>Maximum Restoration Period</B>&quot;),
Landlord may, in such notice, elect to terminate this Lease as of the date of such damage or destruction. Unless Landlord so elects
to terminate this Lease, Landlord shall, subject to receipt of sufficient insurance proceeds (with any deductible to be treated
as a current Operating Expense), promptly restore the Premises (excluding the improvements installed by Tenant or by Landlord
and paid for by Tenant), subject to delays arising from the collection of insurance proceeds, from Force Majeure events or as
needed to obtain any license, clearance or other authorization of any kind required to enter into and restore the Premises issued
by any Governmental Authority having jurisdiction over the use, storage, handling, treatment, generation, release, disposal, removal
or remediation of Hazardous Materials (as defined in <U>Section 30</U>) in, on or about the Premises (collectively referred to
herein as &quot;<B>Hazardous Materials Clearances</B>&quot;); <U>provided</U>, <U>however</U>, that if repair or restoration of
the Premises is not substantially complete as of the end of the Maximum Restoration Period or, if longer, the Restoration Period,
Landlord may, in its sole and absolute discretion, by notice to Tenant elect not to proceed with such repair and restoration,
in which event Landlord shall be relieved of its obligation to make such repairs or restoration and this Lease shall terminate
as of the date that is 75 days after the earlier of: (i) discovery of such damage or destruction, or (ii) the date all required
permits, including any Hazardous Materials Clearances, are obtained, and Landlord shall return to Tenant any Rent previously paid
by Tenant for any portion of the Term after the date of such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tenant, at its expense,
shall promptly perform, subject to delays arising from the collection of insurance proceeds, from Force Majeure (as defined in
<U>Section 34</U>) events or to obtain Hazardous Material Clearances, all repairs or restoration not required to be done by Landlord
and shall promptly re-enter the Premises upon Landlord&rsquo;s completion of the restorations and repairs and issuance of any certificate
of occupancy in connection therewith and commence doing business in accordance with this Lease. Notwithstanding the foregoing,
Landlord or Tenant may terminate this Lease if the Premises are damaged during the last 12 months of the Term and Landlord reasonably
estimates that it will take more than 2 months to repair such damage, or if Landlord is denied its claim for insurance proceeds
for such restoration. Rent shall be abated from the date of the damage or destruction until the Premises are repaired and restored,
in the proportion which the area of the Premises, if any, which is not usable by Tenant bears to the total area of the Premises,
unless Landlord provides Tenant with other comparable space in the Building for the Permitted Use during the period of repair that
is suitable for the temporary conduct of the Permitted Use. The remedies provided to Tenant in this <U>Section 18</U> shall be
the sole remedies of Tenant, and except as provided in this <U>Section 18</U>, Tenant waives any right to terminate the Lease by
reason of damage or casualty loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provisions of this
Lease, including this <U>Section 18</U>, constitute an express agreement between Landlord and Tenant with respect to any and all
damage to, or destruction of, all or any part of the Premises, or any other portion of the Property, and any statute or regulation
which is now or may hereafter be in effect shall have no application to this Lease or any damage or destruction to all or any part
of the Premises or any other portion of the Property, the parties hereto expressly agreeing that this <U>Section 18</U> sets forth
their entire understanding and agreement with respect to such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Condemnation</B>.
If the whole or any material part of the Premises or the Property is taken for any public or quasi-public use under governmental
law, ordinance, or regulation, or by right of eminent domain, or by private purchase in lieu thereof (a &quot;<B>Taking</B>&quot;
or &quot;<B>Taken</B>&quot;), and the Taking would in Landlord's reasonable judgment, either prevent or materially interfere with
Tenant's use of the Premises or materially interfere with or impair Landlord's ownership or operation of the Property, then upon
written notice by Landlord this Lease shall terminate and Rent shall be apportioned as of said date. If part of the Premises shall
be Taken, and this Lease is not terminated as provided above, Landlord shall promptly restore the Premises and the Property as
nearly as is commercially reasonable under the circumstances to their condition prior to such partial Taking and the rentable
square footage of the Building, the rentable square footage of the Premises, Tenant's Share of Operating Expenses and the Rent
payable hereunder during the unexpired Term shall be reduced to such extent fair and reasonable under the circumstances. Upon
any such Taking, Landlord shall be entitled to receive the entire price or award from any such Taking without any payment to Tenant,
and Tenant hereby assigns to Landlord Tenant's interest, if any, in such award. Tenant shall have the right, to the extent that
same shall not diminish Landlord's award, to make a separate claim against the condemning authority (but not Landlord) for such
compensation as may be separately awarded or recoverable by Tenant for moving expenses and damage to Tenant's trade fixtures,
if a separate award for such items is made to Tenant. Tenant hereby waives any and all rights it might otherwise have pursuant
to any provision of state law to terminate this Lease upon a partial Taking of the Premises or the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Events
of Default</B>. Each of the following events shall be a default (&quot;<B>Default</B>&quot;) by Tenant under this Lease:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
Defaults</B>. Tenant shall fail to pay any installment of Rent or any other payment hereunder when due; <U>provided</U>, <U>however</U>,
that for the first two (2) overdue payments in any twelve (12) month period, there shall be no Default unless Tenant shall have
failed to make such overdue payment within five (5) days after receiving written notice of such failure from Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance</B>.
Any insurance required to be maintained by Tenant pursuant to this Lease shall be canceled or terminated or shall expire or shall
be reduced or materially changed, or Landlord shall receive a notice of nonrenewal of any such insurance and Tenant shall fail
to obtain replacement insurance within 20 days of notice from Landlord to renew the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abandonment</B>.
Tenant shall abandon the Premises by vacating the Premises and failing to secure and maintain the Premises as required herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Improper
Transfer</B>. Tenant shall assign, sublease or otherwise transfer or attempt to transfer all or any portion of Tenant's interest
in this Lease or the Premises except as expressly permitted herein, or Tenant's interest in this Lease shall be attached, executed
upon, or otherwise judicially seized and such action is not released within 90 days of the action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens</B>.
Tenant shall fail to discharge or otherwise obtain the release of any lien placed upon the Premises in violation of this Lease
within 30 days after Tenant receives notice that any such lien is filed against the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insolvency
Events</B>. Tenant or any guarantor or surety of Tenant's obligations hereunder shall: (A) make a general assignment for the benefit
of creditors; (B) commence any case, proceeding or other action seeking to have an order for relief entered on its behalf as a
debtor or to adjudicate it a bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, liquidation, dissolution
or composition of it or its debts or seeking appointment of a receiver, trustee, custodian or other similar official for it or
for all or of any substantial part of its property (collectively a &ldquo;<B>Proceeding for Relief&rdquo;</B>); (C) become the
subject of any Proceeding for Relief which is not dismissed within 90 days of its filing or entry; or (D) die or suffer a legal
disability (if Tenant, guarantor, or surety is an individual) or be dissolved or otherwise fail to maintain its legal existence
(if Tenant, guarantor or surety is a corporation, partnership or other entity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Estoppel
Certificate or Subordination Agreement</B>. Tenant fails to execute any document required from Tenant under <U>Sections 23</U>
or <U>27</U> within 7 days after a second notice requesting such document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
Defaults</B>. Tenant shall fail to comply with any provision of this Lease other than those specifically referred to in this <U>Section
20</U>, and, except as otherwise expressly provided herein, such failure shall continue for a period of 10 business days after
written notice thereof from Landlord to Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any notice given under <U>Section 20(h)</U>
hereof shall: (i) specify the alleged default, (ii) demand that Tenant cure such default, (iii) be in lieu of, and not in addition
to, or shall be deemed to be, any notice required under any provision of applicable law, and (iv) not be deemed a forfeiture or
a termination of this Lease unless Landlord elects otherwise in such notice; <U>provided</U> that if the nature of Tenant's default
pursuant to <U>Section 20(h)</U> is such that it cannot be cured by the payment of money and reasonably requires more than 10 business
days to cure, then Tenant shall not be deemed to be in default if Tenant commences such cure within said 10 business day period
and thereafter diligently prosecutes the same to completion; <U>provided</U>, <U>however</U>, that such cure shall be completed
no later than 60 days from the date of Landlord's notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Landlord's
Remedies.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
By Landlord; Interest</B>. Upon a Default by Tenant hereunder, Landlord may, without waiving or releasing any obligation of Tenant
hereunder, make such payment or perform such act. All sums so paid or incurred by Landlord, together with interest thereon, from
the date such sums were paid or incurred, at the annual rate equal to 12% per annum or the highest rate permitted by law (the
&quot;<B>Default Rate</B>&quot;), whichever is less, shall be payable to Landlord on demand as Additional Rent. Nothing herein
shall be construed to create or impose a duty on Landlord to mitigate any damages resulting from Tenant's Default hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Late
Payment Rent</B>. Late payment by Tenant to Landlord of Rent and other sums due will cause Landlord to incur costs not contemplated
by this Lease, the exact amount of which will be extremely difficult and impracticable to ascertain. Such costs include, but are
not limited to, processing and accounting charges and late charges which may be imposed on Landlord under any Mortgage covering
the Premises. Therefore, if any installment of Rent due from Tenant is not received by Landlord within 5 days after the date such
payment is due, Tenant shall pay to Landlord an additional sum equal to 6% of the overdue Rent as a late charge. The parties agree
that this late charge represents a fair and reasonable estimate of the costs Landlord will incur by reason of late payment by
Tenant. In addition to the late charge, Rent not paid when due shall bear interest at the Default Rate from the 5th day after
the date due until paid. Notwithstanding the preceding provisions of this Section, for the first overdue payment in any twelve
(12) month period, there shall be no late charge or interest unless Tenant shall have failed to make such overdue payment within
five (5) days after receiving written notice of such failure from Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Remedies</B>.
Upon the occurrence of a Default, Landlord, at its option, without further notice or demand to Tenant, shall have in addition
to all other rights and remedies provided in this Lease, at law or in equity, the option to pursue any one or more of the following
remedies, each and all of which shall be cumulative and nonexclusive, without any notice or demand whatsoever:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Terminate
this Lease, or at Landlord's option, Tenant's right to possession only, in which event Tenant shall immediately surrender the Premises
to Landlord, and if Tenant fails to do so, Landlord may, without prejudice to any other remedy which it may have for possession
or arrearages in rent, enter upon and take possession of the Premises and expel or remove Tenant and any other person who may be
occupying the Premises or any part thereof, without being liable for prosecution or any claim or damages therefor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
any termination of this Lease, whether pursuant to the foregoing <U>Section 21(c)(i)</U> or otherwise, Landlord may recover from
Tenant the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
worth at the time of award of any unpaid rent which has been earned at the time of such termination; plus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
worth at the time of award of the amount by which the unpaid rent which would have been earned after termination until the time
of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided (it being agreed that Tenant
shall be notified and provided a reasonable opportunity to offer such proof); plus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
worth at the time of award of the amount by which the unpaid rent for the balance of the Term after the time of award exceeds the
amount of such rental loss that Tenant proves could have been reasonably avoided; plus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(D)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
other amount necessary to compensate Landlord for all the detriment incurred by Landlord due to Tenant's failure to perform its
obligations under this Lease, specifically including, but not limited to, brokerage commissions and advertising expenses incurred,
expenses of remodeling the Premises or any portion thereof for a new tenant, whether for the same or a different use, and any special
concessions made to obtain a new tenant; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(E)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
Landlord's election, such other amounts in addition to or in lieu of the foregoing as may be permitted from time to time by applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term &quot;<B>rent</B>&quot; as used
in this <U>Section 21</U> shall be deemed to be and to mean all sums of every nature required to be paid by Tenant pursuant to
the terms of this Lease, whether to Landlord or to others. As used in <U>Sections 21(c)(ii) (A)</U> and <U>(B)</U>, above, the
&quot;<B>worth at the time of award</B>&quot; shall be computed by allowing interest at the Default Rate. As used in <U>Section
21(c)(ii)(C)</U> above, the &quot;<B>worth at the time of award</B>&quot; shall be computed by discounting such amount at the discount
rate of the Federal Reserve Bank of Boston at the time of award plus 1%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord
may continue this Lease in effect after Tenant's Default and recover rent as it becomes due (Landlord and Tenant hereby agreeing
that Tenant has the right to sublet or assign hereunder, subject only to reasonable limitations). Accordingly, if Landlord does
not elect to terminate this Lease following a Default by Tenant, Landlord may, from time to time, without terminating this Lease,
enforce all of its rights and remedies hereunder, including the right to recover all Rent as it becomes due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether
or not Landlord elects to terminate this Lease following a Default by Tenant, Landlord shall have the right to terminate any and
all subleases, licenses, concessions or other consensual arrangements for possession entered into by Tenant and affecting the Premises
or may, in Landlord's sole discretion, succeed to Tenant's interest in such subleases, licenses, concessions or arrangements. Upon
Landlord's election to succeed to Tenant's interest in any such subleases, licenses, concessions or arrangements, Tenant shall,
as of the date of notice by Landlord of such election, have no further right to or interest in the rent or other consideration
receivable thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Independent
of the exercise of any other remedy of Landlord hereunder or under applicable law, Landlord may conduct an environmental test of
the Premises as generally described in Section 30(d) hereof, at Tenant's expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect
of Exercise</B>. Exercise by Landlord of any remedies hereunder or otherwise available shall not be deemed to be an acceptance
of surrender of the Premises and/or a termination of this Lease by Landlord, it being understood that such surrender and/or termination
can be effected only by the express written agreement of Landlord and Tenant. Any law, usage, or custom to the contrary notwithstanding,
Landlord shall have the right at all times to enforce the provisions of this Lease in strict accordance with the terms hereof;
and the failure of Landlord at any time to enforce its rights under this Lease strictly in accordance with same shall not be construed
as having created a custom in any way or manner contrary to the specific terms, provisions, and covenants of this Lease or as
having modified the same and shall not be deemed a waiver of Landlord's right to enforce one or more of its rights in connection
with any subsequent default. A receipt by Landlord of Rent or other payment with knowledge of the breach of any covenant hereof
shall not be deemed a waiver of such breach, and no waiver by Landlord of any provision of this Lease shall be deemed to have
been made unless expressed in writing and signed by Landlord. To the greatest extent permitted by law, Tenant waives the service
of notice of Landlord's intention to re-enter, re-take or otherwise obtain possession of the Premises as provided in any statute,
or to institute legal proceedings to that end, and also waives all right of redemption in case Tenant shall be dispossessed by
a judgment or by warrant of any court or judge. Any reletting of the Premises or any portion thereof shall be on such terms and
conditions as Landlord in its sole discretion may determine. Landlord shall not be liable for, nor shall Tenant's obligations
hereunder be diminished because of, Landlord's failure to relet the Premises or collect rent due in respect of such reletting
or otherwise to mitigate any damages arising by reason of Tenant's Default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Assignment
and Subletting.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General
Prohibition</B>. Without Landlord's prior written consent subject to and on the conditions described in this <U>Section 22</U>,
Tenant shall not, directly or indirectly, voluntarily or by operation of law, assign this Lease or sublease the Premises or any
part thereof or mortgage, pledge, or hypothecate its leasehold interest or grant any concession or license within the Premises,
and any attempt to do any of the foregoing shall be void and of no effect. If Tenant is a corporation, partnership or limited
liability company, the shares or other ownership interests thereof which are not actively traded upon a stock exchange or in the
over-the-counter market, a transfer or series of transfers whereby 50% or more of the issued and outstanding shares or other ownership
interests of such corporation are, or voting control is, transferred (but excepting transfers upon deaths of individual owners)
from a person or persons or entity or entities which were owners thereof on the Effective Date to persons or entities who were
not owners of shares or other ownership interests of the corporation, partnership or limited liability company on the Effective
Date, shall be deemed an assignment of this Lease requiring the consent of Landlord as provided in this <U>Section 22</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Permitted
Transfers</B>. If Tenant desires to assign, sublease, hypothecate or otherwise transfer this Lease or sublet the Premises, then
at least 10 business days but not more than 45 business days, before the date Tenant desires the assignment or sublease to be
effective (the &quot;<B>Assignment Date</B>&quot;), Tenant shall give Landlord a notice (the &quot;<B>Assignment Notice</B>&quot;)
containing such information about the proposed assignee or sublessee, including the proposed use of the Premises and any Hazardous
Materials proposed to be used, stored handled, treated, generated in or released or disposed of from the Premises, the Assignment
Date, any relationship between Tenant and the proposed assignee or sublessee, and all material terms and conditions of the proposed
assignment or sublease, including a copy of any proposed assignment or sublease in its final form, and such other information
as Landlord may deem reasonably necessary or appropriate to its consideration whether to grant its consent. Landlord may, by giving
written notice to Tenant within 15 business days after receipt of the Assignment Notice: (i) grant such consent, which shall not
be unreasonably withheld, conditioned or delayed, (ii) refuse such consent, in its reasonable discretion, or (iv) terminate this
Lease with respect to the space described in the Assignment Notice as of the Assignment Date (an &quot;<B>Assignment Termination</B>&quot;).
Any proposed assignee or sublessee, with respect to any research and development laboratory use, will use the Premises for a scientific
use consistent with a Science Plan (i.e., a brief description of the scientific uses to be made of the research and development
space) approved for its proposed use of the Premises, which approval Landlord shall be in Landlord&rsquo;s reasonable discretion.
If Landlord delivers notice of its election to exercise an Assignment Termination, which must be given (if at all) within 10 business
days of Landlord&rsquo;s receipt of the Assignment Notice, Tenant shall have the right to withdraw such Assignment Notice by written
notice to Landlord of such election within 5 business days after Landlord's notice electing to exercise the Assignment Termination.
If Tenant withdraws such Assignment Notice, this Lease shall continue in full force and effect. If Tenant does not withdraw such
Assignment Notice, this Lease, and the term and estate herein granted, shall terminate as of the Assignment Date with respect
to the space described in such Assignment Notice. No failure of Landlord to exercise any such option to terminate this Lease,
or to deliver a timely notice in response to the Assignment Notice, shall be deemed to be Landlord's consent to the proposed assignment,
sublease or other transfer. Tenant shall pay to Landlord a fee equal to One Thousand Five Hundred Dollars ($1,500) in connection
with its consideration of any Assignment Notice and/or its preparation or review of any consent documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the preceding provisions of this <U>Section 22(b)</U>, Tenant shall have the right to assign the Lease or sublet the Premises,
or any part thereof, without Landlord&rsquo;s consent, but subject to Landlord&rsquo;s rights to notice and prohibition contained
herein, to any parent, subsidiary, affiliate or controlled corporation or to corporation which Tenant may be converted or with
which Tenant may merge (each a &ldquo;<B>Permitted Assignment</B>&rdquo;) provided such transferee has a net worth equal to or
greater than that of Tenant immediately prior to such transfer and such transferee agrees to be bound under the terms of this Lease.
Tenant shall in any event provide prior written notice to Landlord of Tenant&rsquo;s intent to undertake a Permitted Assignment,
the identity of the assignee or sublessee, as applicable, and financial information for the proposed transferee and the Tenant
dated within thirty (30) days of the submission that is reasonably satisfactory to Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional
Conditions</B>. As a condition to any such assignment or subletting, whether or not Landlord's consent is required, Landlord may
require:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that
any assignee or subtenant agree, in writing at the time of such assignment or subletting, that if Landlord gives such party notice
that Tenant is in default under this Lease, such party shall thereafter make all payments otherwise due Tenant directly to Landlord,
which payments will be received by Landlord without any liability except to credit such payment against those due under the Lease,
and any such third party shall agree to attorn to Landlord or its successors and assigns should this Lease be terminated for any
reason; provided, however, in no event shall Landlord or its successors or assigns be obligated to accept such attornment; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
list of Hazardous Materials, certified by the proposed assignee or sublessee to be true and correct, which the proposed assignee
or sublessee intends to use, store, handle, treat, generate in or release or dispose of from the Premises, together with copies
of all documents relating to such use, storage, handling, treatment, generation, release or disposal of Hazardous Materials by
the proposed assignee or subtenant in the Premises or on the Property, prior to the proposed assignment or subletting, including,
without limitation: permits; approvals; reports and correspondence; storage and management plans; plans relating to the installation
of any storage tanks to be installed in or under the Property (provided, said installation of tanks shall only be permitted after
Landlord has given its written consent to do so, which consent may be withheld in Landlord's sole and absolute discretion); and
all closure plans or any other documents required by any and all federal, state and local Governmental Authorities for any storage
tanks installed in, on or under the Property for the closure of any such tanks. Neither Tenant nor any such proposed assignee or
subtenant is required, however, to provide Landlord with any portion(s) of the such documents containing information of a proprietary
nature which, in and of themselves, do not contain a reference to any Hazardous Materials or hazardous activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Release of Tenant, Sharing of Excess Rents</B>. Notwithstanding any assignment or subletting, Tenant and any guarantor or surety
of Tenant's obligations under this Lease shall at all times remain full and primarily responsible and liable for the payment of
Rent and for compliance with all of Tenant's other obligations under this Lease. If the Rent due and payable by a sublessee or
assignee (or a combination of the rental payable under such sublease or assignment plus any bonus or other consideration therefore
or incident thereto in any form) less the reasonable expenses of Tenant in assigning or subletting (including broker commissions,
improvement allowances and other concessions, renovation expenses and legal fees, each as incurred by Tenant and amortized over
the remaining term of this Lease with respect to an assignment or over the term of the sublease with respect to a sublease), exceeds
the rental payable under this Lease, (excluding however, any Rent payable under this Section) (&quot;<B>Excess Rent</B>&quot;),
then Tenant shall be bound and obligated to pay Landlord as Additional Rent hereunder 50% of such Excess Rent within 10 days following
receipt thereof by Tenant. If Tenant shall sublet the Premises or any part thereof, Tenant hereby immediately and irrevocably
assigns to Landlord, as security for Tenant's obligations under this Lease, all rent from any such subletting, and Landlord as
assignee and as attorney-in-fact for Tenant, or a receiver for Tenant appointed on Landlord's application, may collect such rent
and apply it toward Tenant's obligations under this Lease; except that, until the occurrence of a Default, Tenant shall have the
right to collect such rent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Waiver</B>. The consent by Landlord to an assignment or subletting shall not relieve Tenant or any assignees of this Lease or
any sublessees of the Premises from obtaining the consent of Landlord to any further assignment or subletting nor shall it release
Tenant or any assignee or sublessee of Tenant from full and primary liability under the Lease. The acceptance of Rent hereunder,
or the acceptance of performance of any other term, covenant, or condition thereof, from any other person or entity shall not
be deemed to be a waiver of any of the provisions of this Lease or a consent to any subletting, assignment or other transfer of
the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
Conduct of Proposed Transferee</B>. Notwithstanding any other provision of this <U>Section 22</U>, if (i) the proposed assignee
or sublessee of Tenant has been required by any prior landlord, lender or Governmental Authority to take remedial action in connection
with Hazardous Materials contaminating a property, where the contamination resulted from such party's action or use of the property
in question, (ii) the proposed assignee or sublessee is subject to an enforcement order issued by any Governmental Authority in
connection with the use, storage, handling, treatment, generation, release or disposal of Hazardous Materials (including, without
limitation, any order related to the failure to make a required reporting to any Governmental Authority), or (iii) because of
the existence of a pre-existing environmental condition in the vicinity of or underlying the Property, the risk that Landlord
would be targeted as a responsible party in connection with the remediation of such pre-existing environmental condition would
be materially increased or exacerbated by the proposed use of Hazardous Materials by such proposed assignee or sublessee, Landlord
shall have the absolute right to refuse to consent to any assignment or subletting to any such party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">23.&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Estoppel
Certificate</B>. Tenant shall, within 10 business days of written notice from Landlord, execute, acknowledge and deliver a statement
in writing in any form reasonably requested by a proposed lender or purchaser, (i) certifying that this Lease is unmodified and
in full force and effect (or, if modified, stating the nature of such modification and certifying that this Lease as so modified
is in full force and effect) and the dates to which the rental and other charges are paid in advance, if any, (ii) acknowledging
that there are not any uncured defaults on the part of Landlord hereunder, or specifying such defaults if any are claimed, and
(iii) setting forth such further information with respect to the status of this Lease or the Premises as may be reasonably requested
thereon. Any such statement may be relied upon by any prospective purchaser or encumbrancer of all or any portion of the real
property of which the Premises are a part. If Tenant shall fail to deliver such statement within such time, Landlord may, at its
option, send a second notice to Tenant with the same statement, which notice also shall provide in large bold type <B>THIS IS
THE SECOND NOTICE REQUESTING AN ESTOPPEL CERTIFICATE PURSUANT TO SECTION 23 OF THE LEASE; ANY FAILURE TO RESPOND IN SEVEN DAYS
SHALL BE A DEFAULT UNDER THE LEASE,</B> and if such 7 day period shall elapse after Tenant&rsquo;s receipt of the second notice
with no executed statement from Tenant, then at the option of Landlord, such shall constitute a Default under this Lease, and,
in any event, shall be conclusive upon Tenant that this Lease is in full force and effect and without modification except as may
be represented by Landlord in any certificate prepared by Landlord and delivered to Tenant for execution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">24.&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Quiet
Enjoyment</B>. So long as Tenant is not in Default under this Lease, Tenant shall, subject to the terms of this Lease, at all
times during the Term, have peaceful and quiet enjoyment of the Premises against any person claiming by, through or under Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">25.&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prorations</B>.
All prorations required or permitted to be made hereunder shall be made on the basis of a 360 day year and 30 day months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">26.&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rules
and Regulations</B>. Tenant shall, at all times during the Term and any extension thereof, comply with all reasonable rules and
regulations at any time or from time to time established by Landlord covering use of the Premises and the Property. The current
rules and regulations are attached hereto as <B>Exhibit D</B>. If there is any conflict between said rules and regulations and
other provisions of this Lease, the terms and provisions of this Lease shall control. Landlord shall not have any liability or
obligation for the breach of any rules or regulations by other tenants in the Property. Landlord shall not enforce such rules
and regulations in a discriminatory manner among tenants in the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">27.&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subordination</B>.
This Lease and Tenant's interest and rights hereunder are hereby made and shall be subject and subordinate at all times to the
lien of any Mortgage now existing or hereafter created on or against the Property or the Premises, and all amendments, restatements,
renewals, modifications, consolidations, refinancing, assignments and extensions thereof, without the necessity of any further
instrument or act on the part of Tenant; <U>provided</U>, <U>however</U> that so long as there is no Default hereunder, Tenant's
right to possession of the Premises shall not be disturbed by the Holder of any such Mortgage. Tenant agrees, at the election
of the Holder of any such Mortgage, to attorn to any such Holder. Tenant agrees upon demand to execute, acknowledge and deliver
such instruments, confirming such subordination, and such instruments of attornment as shall be requested by any such Holder,
provided any such instruments shall contain appropriate non-disturbance provisions assuring Tenant's quiet enjoyment of the Premises
as set forth in <U>Section&nbsp;24</U> hereof and shall not vary the terms of this <U>Section 27</U>. Notwithstanding the foregoing,
any such Holder may at any time subordinate its Mortgage to this Lease, without Tenant's consent, by notice in writing to Tenant,
and thereupon this Lease shall be deemed prior to such Mortgage without regard to their respective dates of execution, delivery
or recording and in that event such Holder shall have the same rights with respect to this Lease as though this Lease had been
executed prior to the execution, delivery and recording of such Mortgage and had been assigned to such Holder. The term &quot;<B>Mortgage</B>&quot;
whenever used in this Lease shall be deemed to include deeds of trust, security assignments and any other encumbrances, and any
reference to the &quot;<B>Holder</B>&quot; of a Mortgage shall be deemed to include the beneficiary under a deed of trust.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">28.&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Surrender</B>.
Upon the expiration of the Term or earlier termination of Tenant's right of possession, Tenant shall surrender the Premises to
Landlord (i) in the same condition as received, subject to leaving in place the Tenant&rsquo;s Work (except to the extent that
Tenant requested a determination by Landlord as to such removal with Landlord&rsquo;s approval of Tenant&rsquo;s Work and Landlord
has identified in writing in its approval(s) of Tenant&rsquo;s Work any items that are not comparable to improvements for lab
space in the Worcester market, any of such items to be removed by Tenant under this Section) and any Installations for which removal
is not required pursuant to <U>Section 12</U> above, (ii) free of Hazardous Materials brought upon, kept, used, stored, handled,
treated, generated in, or released or disposed of from, the Premises by any person other than a Landlord Party (collectively,
&quot;<B>Tenant HazMat Operations</B>&quot;) and released of all Hazardous Materials Clearances, (iii) broom clean, ordinary wear
and tear and casualty loss and condemnation covered by <U>Sections 18</U> and <U>19</U> excepted. At least 3 months prior to the
surrender of the Premises, Tenant shall deliver to Landlord a narrative description of the actions proposed (or required by any
Governmental Authority) to be taken by Tenant in order to surrender the Premises (including any Installations permitted by Landlord
to remain in the Premises) at the expiration or earlier termination of the Term, free from any residual impact from the Tenant
HazMat Operations and otherwise released for unrestricted use and occupancy (the &quot;<B>Surrender Plan</B>&quot;). Such Surrender
Plan shall be in a format and with the amount of detail as reasonably required by Landlord by form provided by Landlord and attached
at <B>Exhibit F</B> and accompanied by a current listing of (i) all Hazardous Materials licenses and permits held by or on behalf
of any Tenant Party with respect to the Premises, and (ii) all Hazardous Materials used, stored, handled, treated, generated,
released or disposed of from the Premises, and shall be subject to the review and approval of Landlord's environmental consultant.
In connection with the review and approval of the Surrender Plan, upon the request of Landlord, Tenant shall deliver to Landlord
or its consultant such additional non-proprietary information concerning Tenant HazMat Operations as Landlord shall request. On
or before such surrender, Tenant shall deliver to Landlord evidence that the approved Surrender Plan shall have been satisfactorily
completed and Landlord shall have the right, subject to reimbursement at Tenant's expense as set forth below, to cause Landlord's
environmental consultant to inspect the Premises and perform such additional procedures as may be deemed reasonably necessary
to confirm that the Premises are, as of the effective date of such surrender or early termination of the Lease, free from any
residual impact from Tenant HazMat Operations. Tenant shall reimburse Landlord, as Additional Rent, for the actual out-of pocket
expense incurred by Landlord for Landlord's environmental consultant to review and approve the Surrender Plan and to visit the
Premises and verify satisfactory completion of the same, which cost shall not exceed $5,000. Landlord shall have the unrestricted
right to deliver such Surrender Plan and any report by Landlord's environmental consultant with respect to the surrender of the
Premises to third parties. Provided Tenant&rsquo;s Work is reasonably standard and comparable to improvements for lab space in
the Worcester market, Landlord shall not require Tenant to remove Tenant&rsquo;s Work performed with respect to initial occupancy
at the expiration or earlier termination of the Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Tenant shall fail
to prepare or submit a Surrender Plan approved by Landlord, or if Tenant shall fail to complete the approved Surrender Plan, or
if such Surrender Plan, whether or not approved by Landlord, shall fail to adequately address any residual effect of Tenant HazMat
Operations in, on or about the Premises, Landlord shall have the right to take such actions as Landlord may deem reasonable or
appropriate to assure that the Premises and the Property are surrendered free from any residual impact from Tenant HazMat Operations,
the cost of which actions shall be reimbursed by Tenant as Additional Rent, without regard to the limitation set forth in the first
paragraph of this <U>Section 28</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tenant shall immediately
return to Landlord all keys and/or access cards to parking, the Property, restrooms or all or any portion of the Premises furnished
to or otherwise procured by Tenant. If any such access card or key provided to Tenant by Landlord is lost, Tenant shall pay to
Landlord, at Landlord's election, either the cost of replacing such lost access card or key or the cost of reprogramming the access
security system in which such access card was used or changing the lock or locks opened by such lost key. Any Tenant's Property,
Alterations and property not so removed by Tenant as permitted or required herein shall be deemed abandoned and, to the extent
Tenant was required to remove the same from the Premises under this Lease, may be stored, removed, and disposed of by Landlord
at Tenant's expense, and Tenant waives all claims against Landlord for any damages resulting from Landlord's retention and/or disposition
of such property. All obligations of Tenant hereunder not fully performed as of the termination of the Term, including the obligations
of Tenant under <U>Section 30</U> hereof, shall survive the expiration or earlier termination of the Term, including, without limitation,
indemnity obligations, payment obligations with respect to Rent and obligations concerning the condition and repair of the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Waiver
of Jury Trial</B>. TO THE EXTENT PERMITTED BY LAW, TENANT AND LANDLORD WAIVE ANY RIGHT TO TRIAL BY JURY OR TO HAVE A JURY PARTICIPATE
IN RESOLVING ANY DISPUTE, WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE, BETWEEN LANDLORD AND TENANT ARISING OUT OF THIS LEASE
OR ANY OTHER INSTRUMENT, DOCUMENT, OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS RELATED HERETO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">30.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Environmental
Requirements.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prohibition/Compliance/Indemnity</B>.
Tenant shall not cause or permit any Hazardous Materials (as hereinafter defined) to be brought upon, kept, used, stored, handled,
treated, generated in or about, or released or disposed of from, the Premises or the Property in violation of applicable Environmental
Requirements (as hereinafter defined) by Tenant or any Tenant Party. If Tenant breaches the obligation stated in the preceding
sentence, or if the presence of Hazardous Materials in the Premises during the Term or any holding over results in contamination
of the Premises, the Property or any adjacent property or if contamination of the Premises, the Property or any adjacent property
by Hazardous Materials brought into, kept, used, stored, handled, treated, generated in or about, or released or disposed of from,
the Premises by anyone other than Landlord and Landlord's employees, agents and contractors otherwise occurs during the Term or
any holding over, Tenant hereby indemnifies and shall defend and hold Landlord, its officers, directors, employees, agents and
contractors harmless from any and all actions (including, without limitation, remedial or enforcement actions of any kind, administrative
or judicial proceedings, and orders or judgments arising out of or resulting therefrom), costs, claims, damages (including, without
limitation, punitive damages and damages based upon diminution in value of the Premises or the Property, or the loss of, or restriction
on, use of the Premises or any portion of the Property), expenses (including, without limitation, attorneys', consultants' and
experts' fees, court costs and amounts paid in settlement of any claims or actions), fines, forfeitures or other civil, administrative
or criminal penalties, injunctive or other relief (whether or not based upon personal injury, property damage, or contamination
of, or adverse effects upon, the environment, water tables or natural resources), liabilities or losses (collectively, &quot;<B>Environmental
Claims</B>&quot;) to the extent that the same are caused by a breach of the aforesaid obligation of Tenant, whether such Environmental
Claims arise during or after the Term. This indemnification of Landlord by Tenant includes, without limitation, costs incurred
in connection with any investigation of site conditions or any cleanup, treatment, remedial, removal, or restoration work required
by any federal, state or local Governmental Authority because of Hazardous Materials present in the air, soil or ground water
above, on, or under the Premises. Without limiting the foregoing, if the presence of any Hazardous Materials on the Premises,
the Property or any adjacent property caused or permitted by Tenant or any Tenant Party, results in any contamination of the Premises,
the Property or any adjacent property, Tenant shall promptly take all actions at its sole expense and in accordance with applicable
Environmental Requirements as are necessary to return the affected portion(s) of the Premises, the Property or any adjacent property
to the condition existing prior to the time of such contamination, provided that Landlord's approval of such action shall first
be obtained, which approval shall not unreasonably be withheld so long as such actions would not potentially have any material
adverse long-term or short-term effect on the Premises or the Property. Notwithstanding any provisions of this Section 30 or otherwise
in this Lease to the contrary, Tenant shall not have or incur no liability under this Section 30 because of the existence of an
environmental condition in the vicinity of or underlying the Property dating prior to Tenant being granted possession of the Premises
(a &ldquo;Prior Environmental Condition&rdquo;), or because of any risk that Landlord or Tenant would be targeted as a responsible
party in connection with the remediation of any such Prior Environmental Condition at the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Business</B>.
Landlord acknowledges that it is not the intent of this <U>Section 30</U>, nor shall this Section be interpreted or applied so
as, to prohibit, restrict or impair Tenant&rsquo;s use of the Premises for the Permitted Use. Tenant may operate its business
according to prudent industry practices so long as the use or presence of Hazardous Materials is strictly and properly monitored
according to all then applicable Environmental Requirements. As a material inducement to Landlord to allow Tenant to use Hazardous
Materials in connection with its business, Tenant has provided the list attached hereto as <B>Exhibit I</B> identifying each type
of Hazardous Materials that Tenant reasonably anticipates will be brought upon, kept, used, stored, handled, treated, generated
on, or released or disposed of from, the Premises and setting forth any and all governmental approvals or permits required in
connection with the presence, use, storage, handling, treatment, generation, release or disposal of such Hazardous Materials on
or from the Premises (&quot;<B>Hazardous Materials List</B>&quot;). Tenant shall deliver to Landlord an updated Hazardous Materials
List at least once a year and shall also deliver an updated list before any new Hazardous Material is brought onto, kept, used,
stored, handled, treated, generated on, or released or disposed of from, the Premises. Tenant shall deliver to Landlord true and
correct copies of the following documents (the &quot;<B>Haz Mat Documents</B>&quot;) relating to the use, storage, handling, treatment,
generation, release or disposal of Hazardous Materials prior to the Commencement Date, or if unavailable at that time, concurrent
with the receipt from or submission to a Governmental Authority: permits; approvals; reports, and correspondence to and from a
Governmental Authority; storage and management plans, notice of violations of any Legal Requirements; and the following only in
the event that Tenant installs any storage tanks in or under the Property (provided, said installation of tanks shall only be
permitted after Landlord has given Tenant its written consent to do so, which consent may be withheld in Landlord's sole and absolute
discretion): (x) plans relating to the installation of any such storage tanks to be installed in or under the Property; and (y)
all closure plans or any other documents, which Tenant is required to deliver to any and all federal, state and local Governmental
Authorities for any storage tanks installed in, on or under the Property for the closure of any such tanks; and a Surrender Plan
(to the extent surrender in accordance with <U>Section 28</U> cannot be accomplished in 3 months). Tenant is not, and shall not
be, required to provide Landlord with any portion(s) of the Haz Mat Documents containing information of a confidential or proprietary
nature which, in and of themselves, do not contain a reference to any Hazardous Materials or hazardous activities. It is not the
intent of this Section to obligate Tenant to provide Landlord with information which could be detrimental to Tenant's business
should such information become possessed by Tenant's competitors. On request, Landlord will execute and deliver to Tenant a confidentiality
agreement covering disclosures from Tenant to Landlord under this <U>Section 30</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
Representation and Warranty</B>. Tenant hereby represents and warrants to Landlord that (i) neither Tenant nor any of its legal
predecessors has been required by any prior landlord, lender or Governmental Authority at any time to take remedial action in
connection with Hazardous Materials contaminating a property which contamination was permitted by Tenant of such predecessor or
resulted from Tenant's or such predecessor's action or use of the property in question, and (ii) Tenant is not subject to any
enforcement order issued by any Governmental Authority in connection with the use, storage, handling, treatment, generation, release
or disposal of Hazardous Materials (including, without limitation, any order related to the failure to make a required reporting
to any Governmental Authority). If Landlord determines that this representation and warranty was not true as of the Effective
Date, Landlord shall have the right to terminate this Lease in Landlord's sole and absolute discretion by notice to Tenant. To
the best knowledge of Tenant, Mustang Therapeutics, Inc., is the only legal predecessor to Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Testing</B>.
At any time, and from time to time, prior to the expiration or earlier termination of the Term, Landlord shall have the right
to conduct appropriate tests of the Premises and the Property to determine if contamination has occurred as a result of Tenant's
use of the Premises. If needed in connection with such testing, upon the request of Landlord, Tenant shall deliver to Landlord
or its consultant such non-proprietary information concerning the use of Hazardous Materials in or about the Premises by Tenant
or any Tenant Party. If the final written report of such testing confirms that contamination has occurred for which Tenant is
liable under this <U>Section 30</U> (i.e., which is not a Prior Environmental Condition), then Tenant shall pay all costs to conduct
such tests, but in all other cases, Landlord shall pay the costs of such tests (which shall not constitute an Operating Expense).
Landlord shall provide Tenant with a copy of all third party, non-confidential reports and tests of the Premises made by or on
behalf of Landlord during the Term without representation or warranty and subject to a confidentiality agreement. Tenant shall,
at its sole cost and expense, promptly and satisfactorily remediate, in accordance with all Environmental Requirements, any environmental
conditions identified by such testing, other than, and except to the extent arising from, Prior Environmental Conditions. Landlord's
receipt of or satisfaction with any environmental assessment in no way waives any rights which Landlord may have against Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Control
Areas</B>. Tenant shall be allowed to utilize up to its &ldquo;pro rata share&rdquo; (as herein defined) of the Hazardous Materials
inventory within any control area or zone (located within the Premises), as designated by the applicable building code, for chemical
use or storage. As used in the preceding sentence, Tenant's pro rata share of any control areas or zones located within the Premises
shall be determined based on the rentable square footage that Tenant leases within the applicable control area or zone. For purposes
of example only, if a control area or zone contains 10,000 rentable square feet and 2,000 rentable square feet of a tenant's premises
are located within such control area or zone (while such premises as a whole contains 5,000 rentable square feet), the applicable
tenant's pro rata share of such control area would be 20%. The first floor of the Building will constitute one control zone. The
maximum quantity permitted in a control zone shall be determined by the standards set forth in the International Building Code
and International Fire Code and varies for each floor of a building. The currently permitted quantity for the first floor of the
Building is 480 gallons for Class 1B flammable liquids. If additional control zones are required due to excess inventory or different
types of flammables, Tenant may request Landlord approval of work necessary to the Building to permit such additional control
zones, which approval shall be granted or denied in Landlord&rsquo;s sole discretion and Tenant shall be responsible for all costs
of such necessary work associated with construction and code compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Underground
Tanks</B>. If underground or other storage tanks storing Hazardous Materials located on the Premises or the Property are used
by Tenant or are hereafter placed on the Premises or the Property by Tenant, Tenant shall install, use, monitor, operate, maintain,
upgrade and manage such storage tanks, maintain appropriate records, obtain and maintain appropriate insurance, implement reporting
procedures, properly close any underground storage tanks, and take or cause to be taken all other actions necessary or required
under applicable state and federal Legal Requirements, as such now exists or may hereafter be adopted or amended in connection
with Tenant&rsquo;s installation, use, maintenance, management, operation, upgrading and closure of such storage tanks. Notwithstanding
the preceding terms of this paragraph, and other than storage tanks installed by or on behalf of Tenant within the Premises, Tenant
shall not be responsible for assuring compliance with Legal Requirements of any storage tanks on the Property, but not the Premises
by parties other than Tenant or Tenant Related Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant's
Obligations</B>. Tenant's obligations under this <U>Section 30</U> shall survive the expiration or earlier termination of this
Lease. During any period of time after the expiration or earlier termination of this Lease required by Tenant (or Landlord after
failure of Tenant to do so) to complete the removal from the Premises of any Hazardous Materials (including, without limitation,
the release and termination of any licenses or permits restricting the use of the Premises and the completion of Tenant&rsquo;s
obligations under <U>Section 28</U>), which Tenant is obligated to remove by the terms of this Lease, Tenant shall continue to
be responsible for Rent in accordance with this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitions</B>.
As used herein, the term &quot;<B>Environmental Requirements</B>&quot; means all applicable present and future statutes, regulations,
ordinances, rules, codes, judgments, orders or other similar enactments of any Governmental Authority regulating or relating to
health, safety, or environmental conditions on, under, or about the Premises or the Property, or the environment, including without
limitation, the following: the Comprehensive Environmental Response, Compensation and Liability Act; the Resource Conservation
and Recovery Act; and all state and local counterparts thereto, and any regulations or policies promulgated or issued thereunder.
As used herein, the term &quot;<B>Hazardous Materials</B>&quot; means and includes any substance, material, waste, pollutant,
or contaminant listed or defined as hazardous or toxic, or regulated by reason of its impact or potential impact on humans, animals
and/or the environment under any Environmental Requirements, asbestos and petroleum, including crude oil or any fraction thereof,
natural gas liquids, liquefied natural gas, or synthetic gas usable for fuel (or mixtures of natural gas and such synthetic gas).
As defined in Environmental Requirements, Tenant is and shall be deemed to be the &quot;<B>operator</B>&quot; of Tenant's &quot;<B>facility</B>&quot;
and the &quot;<B>owner</B>&quot; of all Hazardous Materials brought on the Premises by Tenant or any Tenant Party, and the wastes,
by-products, or residues generated, resulting, or produced therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">31.&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant's
Remedies/Limitation of Liability</B>. Landlord shall not be in default hereunder unless Landlord fails to perform any of its obligations
hereunder within 30 days after written notice from Tenant specifying such failure (unless such performance will, due to the nature
of the obligation, require a period of time in excess of 30 days, then after such period of time as is reasonably necessary).
Upon any default by Landlord, Tenant shall give notice by registered or certified mail to any Holder of a Mortgage covering the
Premises Tenant shall offer such Holder and/or Landlord a reasonable opportunity to cure the default, including time to obtain
possession of the Property by power of sale or a judicial action if such should prove necessary to effect a cure; <U>provided
</U>Landlord shall have furnished to Tenant in writing the names and addresses of all such persons who are to receive such notices.
All obligations of Landlord hereunder shall be construed as covenants, not conditions; and, except as may be otherwise expressly
provided in this Lease, Tenant may not terminate this Lease for breach of Landlord's obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All obligations of
Landlord under this Lease will be binding upon Landlord only during the period of its ownership of the Premises and not thereafter,
except insofar as Landlord may fail to transfer the Security Deposit to any successor Landlord under this Lease. Except as provided
in the previous sentence, the term &quot;<B>Landlord</B>&quot; in this Lease shall mean only the owner for the time being of the
Premises. Upon the transfer by such owner to its proper successor under this Lease of the Security Deposit and its interest in
the Premises, such owner shall thereupon be released and discharged from all obligations of Landlord thereafter accruing, but such
obligations shall be binding during the Term upon each new owner for the duration of such owner's ownership.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">32.&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inspection
and Access</B>. Landlord and its agents, representatives, contractors and guests may enter the Premises, subject to the terms
of this Section, during Business Hours on not less than 24 hours advance written notice (except in the case of emergencies in
which case no such notice shall be required and such entry may be at any time) for the purpose of (i) inspecting the Premises,
(ii) making repairs, and (iii)&nbsp;showing the Premises to prospective purchasers or lenders and, during the last year of the
Term, to prospective tenants. Tenant shall at all times, except in the case of emergencies, have the right to appoint an employee
or other representative to escort Landlord or its agents, representatives, contractors or guests while the same are in the Premises,
provided such escort does not materially and adversely impair Landlord's access rights hereunder. Tenant may from time to time
adopt commercially reasonable systems and procedures for the security, access and safety of the Premises (whether they be for
purposes of confidentiality, guarding of trade secrets, health and safety, mitigation of contamination of scientific research
or its results, or other business purposes), its occupants, entry, use and contents, and Landlord, its agents, employees, contractors,
guests and invitees, shall comply with such systems and procedures in connection with any entry into the Premises provided that
such systems and procedures shall not materially affect Landlord&rsquo;s access and inspection rights hereunder. Landlord may
erect a suitable sign on the Premises, during the last year of the Term, stating the Premises are available to let or that the
Property is available for sale. Landlord may grant easements, make public dedications, designate Common Areas and create restrictions
on or about the Property, <U>provided</U> that no such easement, dedication, designation or restriction materially, adversely
affects Tenant's use or occupancy of the Premises for the Permitted Use. At Landlord's request, Tenant shall execute such instruments
as may be necessary for such easements, dedications or restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">33.&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Security</B>.
Tenant acknowledges and agrees that security devices and services, if any, while intended to deter crime may not in given instances
prevent theft or other criminal acts and that Landlord is not providing any security services with respect to the Premises. Tenant
agrees that Landlord shall not be liable to Tenant for, and Tenant waives any claim against Landlord with respect to, any loss
by theft or any other damage suffered or incurred by Tenant in connection with any unauthorized entry into the Premises or any
other breach of security with respect to the Premises, except to the extent arising from the negligence or misconduct of Landlord
or a Landlord Party. Tenant shall be solely responsible for the personal safety of Tenant's officers, employees, agents, contractors,
guests and invitees while any such person is in, on or about the Premises and/or the Property. Tenant may at Tenant's cost obtain
insurance coverage to the extent Tenant desires protection against such criminal acts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">34.<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Force
Majeure</B>. Landlord shall not be responsible or liable for delays in the performance of its obligations hereunder when caused
by, related to, or arising out of acts of God, sinkholes or subsidence, strikes, lockouts, or other labor disputes, embargoes,
quarantines, weather, national, regional, or local disasters, catastrophes, or catastrophes, inability to obtain labor or materials
(or reasonable substitutes therefore) at reasonable costs or failure of, or inability to obtain, utilities necessary for performance,
governmental restrictions, orders, limitations, regulations, or controls, national emergencies, delay in issuance or revocation
of permits, enemy or hostile governmental action, terrorism, insurrection, riots, civil disturbance or commotion, fire or other
casualty, and other causes or events beyond the reasonable control of Landlord (&quot;<B>Force Majeure</B>&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">35.&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Brokers</B>.
Landlord and Tenant each represents and warrants that Kelleher &amp; Sadowsky Associates, Inc. and Cranberry Hill Associates,
Inc. (collectively, the &ldquo;<B>Broker</B>&rdquo;), it has not dealt with any broker, agent or other person in connection with
this transaction and that no parties other than Broker brought about this transaction. Landlord and Tenant each hereby agree to
indemnify and hold the other harmless from and against any claims by any broker, other than the Broker, if any named in this <U>Section
35</U>, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable,
with regard to this leasing transaction. In the event that a transaction is consummated, the Landlord shall be responsible for
the payment of all brokerage fees to Broker as per a separate agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">36.&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitation
on Landlord's Liability</B>. NOTWITHSTANDING ANYTHING SET FORTH HEREIN OR IN ANY OTHER AGREEMENT BETWEEN LANDLORD AND TENANT TO
THE CONTRARY: (A) EXCEPT TO THE EXTENT OF DAMAGE FROM NEGLIGENCE OR MISCONDUCT OF LANDLORD OR A LANDLORD PARTY, LANDLORD SHALL
NOT BE LIABLE TO TENANT OR ANY OTHER PERSON FOR (AND TENANT ASSUMES ALL RISK OF) LOSS, DAMAGE OR INJURY, WHETHER ACTUAL OR CONSEQUENTIAL
TO: TENANT&rsquo;S OR ANY OTHER PARTY&rsquo;S PERSONAL PROPERTY OF EVERY KIND AND DESCRIPTION, INCLUDING, WITHOUT LIMITATION TRADE
FIXTURES, EQUIPMENT, INVENTORY, SCIENTIFIC RESEARCH, SCIENTIFIC EXPERIMENTS, LABORATORY ANIMALS, PRODUCT, SPECIMENS, SAMPLES,
AND/OR SCIENTIFIC, BUSINESS, ACCOUNTING AND OTHER RECORDS OF EVERY KIND AND DESCRIPTION KEPT AT THE PREMISES AND ANY AND ALL INCOME
DERIVED OR DERIVABLE THEREFROM; (B) THERE SHALL BE NO PERSONAL RECOURSE TO LANDLORD FOR ANY ACT OR OCCURRENCE IN, ON OR ABOUT
THE PREMISES OR ARISING IN ANY WAY UNDER THIS LEASE OR ANY OTHER AGREEMENT BETWEEN LANDLORD AND TENANT WITH RESPECT TO THE SUBJECT
MATTER HEREOF; ANY LIABILITY OF LANDLORD HEREUNDER SHALL BE STRICTLY LIMITED SOLELY TO (i) LANDLORD'S INTEREST IN THE PROPERTY
OR ANY PROCEEDS FROM SALE OR CONDEMNATION THEREOF AND (ii) ANY INSURANCE PROCEEDS PAYABLE IN RESPECT OF LANDLORD'S INTEREST IN
THE PROPERTY OR IN CONNECTION WITH ANY SUCH LOSS; AND (C) IN NO EVENT SHALL ANY PERSONAL LIABILITY BE ASSERTED AGAINST LANDLORD
IN CONNECTION WITH THIS LEASE NOR SHALL ANY RECOURSE BE HAD TO ANY OTHER PROPERTY OR ASSETS OF LANDLORD OR ANY OF LANDLORD'S OFFICERS,
DIRECTORS, EMPLOYEES, AGENTS OR CONTRACTORS. UNDER NO CIRCUMSTANCES SHALL LANDLORD OR ANY OF LANDLORD'S OFFICERS, DIRECTORS, EMPLOYEES,
AGENTS OR CONTRACTORS BE LIABLE FOR INJURY TO TENANT&rsquo;S BUSINESS OR FOR ANY LOSS OF INCOME OR PROFIT THEREFROM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">37.&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severability</B>.
If any clause or provision of this Lease is illegal, invalid or unenforceable under present or future laws, then and in that event,
it is the intention of the parties hereto that the remainder of this Lease shall not be affected thereby. It is also the intention
of the parties to this Lease that in lieu of each clause or provision of this Lease that is illegal, invalid or unenforceable,
there be added, as a part of this Lease, a clause or provision as similar in effect to such illegal, invalid or unenforceable
clause or provision as shall be legal, valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">38.&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Signs;
Exterior Appearance</B>. Tenant shall not, without the prior written consent of Landlord, which may be granted or withheld in
Landlord's sole discretion: (i) attach any awnings, exterior lights, decorations, balloons, flags, pennants, banners, painting
or other projection to any outside wall of the Property, (ii) use any curtains, blinds, shades or screens other than Landlord's
standard window coverings, (iii) coat or otherwise sunscreen the interior or exterior of any windows, (iv) place any bottles,
parcels, or other articles on the window sills, (v)&nbsp;place any equipment, furniture or other items of personal property on
any exterior balcony, or (vi)&nbsp;paint, affix or exhibit on any part of the Premises or the Property any signs, notices, window
or door lettering, placards, decorations, or advertising media of any type which can be viewed from the exterior of the Premises.
Interior signs on doors and the directory tablet shall be inscribed, painted or affixed for Tenant by Landlord at the sole cost
and expense of Tenant, and shall be of a size, color and type acceptable to Landlord. Nothing may be placed on the exterior of
corridor walls or corridor doors other than Landlord's standard lettering. The directory tablet shall be provided exclusively
for the display of the name and location of tenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">39.&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intentionally
Omitted</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">40.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Miscellaneous.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices</B>.
All notices or other communications between the parties shall be in writing and shall be deemed duly given upon delivery or refusal
to accept delivery by the addressee thereof if delivered in person, or upon actual receipt if delivered by reputable overnight
guaranty courier, addressed and sent to the parties at their addresses set forth above. Landlord and Tenant may from time to time
by written notice to the other designate another address for receipt of future notices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Joint
and Several Liability</B>. If and when included within the term &quot;<B>Tenant</B>,&quot; as used in this instrument, there is
more than one person or entity, each shall be jointly and severally liable for the obligations of Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
Information</B>. As of the Commencement Date, Tenant is subject to the public reporting requirements of the Securities Exchange
Act of 1934, and publically reports such financial information on a nonconsolidated basis with any other entity, but in the event
Tenant ceases to be subject to the public reporting requirements of the Securities Exchange Act of 1934 or publically reports
financial information on a consolidated or rolled up basis with ny entity other than a wholly owned subsidiary of Tenant, the
following terms of this <U>Section 40(c)</U> shall apply, and only in such event. Subject to the terms of the preceding sentence,
Tenant shall furnish Landlord with true and complete copies of (i) Tenant's most recent audited annual financial statements within
90 days of the end of each of Tenant's fiscal years during the Term, (ii) Tenant's most recent unaudited quarterly financial statements
within 45 days of the end of each of Tenant's first three fiscal quarters of each of Tenant's fiscal years during the Term, (iii)
at Landlord's request from time to time, updated business plans, including cash flow projections and/or pro forma balance sheets
and income statements, all of which shall be treated by Landlord as confidential information belonging to Tenant, (iv) at Landlord's
request from time to time corporate brochures and/or profiles prepared by Tenant for prospective investors, and (v) any other
financial information or summaries that Tenant typically provides to its lenders or shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recordation</B>.
This Lease shall not be recorded, but upon request of either party a memorandum of lease shall be executed by the parties and
may be recorded at Tenant&rsquo;s expense in the appropriate public registry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interpretation</B>.
The normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be
employed in the interpretation of this Lease or any exhibits or amendments hereto. Words of any gender used in this Lease shall
be held and construed to include any other gender, and words in the singular number shall be held to include the plural, unless
the context otherwise requires. The captions inserted in this Lease are for convenience only and in no way define, limit or otherwise
describe the scope or intent of this Lease, or any provision hereof, or in any way affect the interpretation of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not
Binding Until Executed</B>. The submission by Landlord to Tenant of this Lease shall have no binding force or effect, shall not
constitute an option for the leasing of the Premises, nor confer any right or impose any obligations upon either party until the
&ldquo;Effective Date&rdquo; (as defined on the signature page hereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitations
on Interest</B>. It is expressly the intent of Landlord and Tenant at all times to comply with applicable law governing the maximum
rate or amount of any interest payable on or in connection with this Lease. If applicable law is ever judicially interpreted so
as to render usurious any interest called for under this Lease, or contracted for, charged, taken, reserved, or received with
respect to this Lease, then it is Landlord's and Tenant's express intent that all excess amounts theretofore collected by Landlord
be credited on the applicable obligation (or, if the obligation has been or would thereby be paid in full, refunded to Tenant),
and the provisions of this Lease immediately shall be deemed reformed and the amounts thereafter collectible hereunder reduced,
without the necessity of the execution of any new document, so as to comply with the applicable law, but so as to permit the recovery
of the fullest amount otherwise called for hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Choice
of Law</B>. Construction and interpretation of this Lease shall be governed by the internal laws of the state in which the Premises
are located, excluding any principles of conflicts of laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Time</B>.
Time is of the essence as to the performance of each party&rsquo;s obligations under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OFAC</B>.
Tenant, for itself and for and all beneficial owners of Tenant, and Landlord, for itself and for all beneficial owners of Landlord,
each represents and warrants that they currently (a) in compliance with and shall at all times during the Term of this Lease remain
in compliance with the regulations of the Office of Foreign Assets Control (&quot;<B>OFAC</B>&quot;) of the U.S. Department of
Treasury and any statute, executive order, or regulation relating thereto (collectively, the &quot;<B>OFAC Rules</B>&quot;), (b)
not listed on, and shall not during the term of this Lease be listed on, the Specially Designated Nationals and Blocked Persons
List maintained by OFAC and/or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing
statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting
business under the OFAC Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k)&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incorporation
by Reference</B>. All exhibits and addenda attached hereto are hereby incorporated into this Lease and made a part hereof. If
there is any conflict between such exhibits or addenda and the terms of this Lease, such exhibits or addenda shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l)&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire
Agreement</B>. This Lease, including the exhibits attached hereto, constitutes the entire agreement between Landlord and Tenant
pertaining to the subject matter hereof and supersedes all prior and contemporaneous agreements, understandings, letters of intent,
negotiations and discussions, whether oral or written, of the parties, and there are no warranties, representations or other agreements,
express or implied, made to either party by the other party in connection with the subject matter hereof except as specifically
set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m)&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Accord and Satisfaction</B>. No payment by Tenant or receipt by Landlord of a lesser amount than the monthly installment of Base
Rent or any Additional Rent will be other than on account of the earliest stipulated Base Rent and Additional Rent, nor will any
endorsement or statement on any check or letter accompanying a check for payment of any Base Rent or Additional Rent be an accord
and satisfaction. Landlord may accept such check or payment without prejudice to Landlord's right to recover the balance of such
Rent or to pursue any other remedy provided in this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(n)&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medical
School Facilities</B>. Tenant, together with its employees, will have access to the following University of Massachusetts Medical
School facilities and resources: the library (including any computers available for use in the library including use of any online
databases subscribed to from time to time by the library for use on such in-library computers), fitness center, cafeteria and
certain research cores as identified by the University from time-to-time. Such access shall be subject to any rules and regulations
of the University of Massachusetts Medical School in effect from time to time, limits on hours, closure for whatever reason, and
fees for use of the fitness center and cafeteria. Any such facilities and resources may be terminated, modified, moved or limited
in the sole discretion of the University of Massachusetts Medical School. Access may be limited or prohibited at any times for
any purposes including, but not limited to repairs, reserved functions, meetings, or any other purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(o)&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hazardous
Activities</B>. Notwithstanding any other provision of this Lease, Landlord, for itself and its employees, agents and contractors,
reserves the right to refuse to perform any repairs or services in any portion of the Premises which, pursuant to Tenant's routine
safety guidelines, practices or custom or prudent industry practices, require any form of protective clothing or equipment other
than safety glasses. In any such case, Tenant shall contract with parties who are acceptable to Landlord, in Landlord's reasonable
discretion, for all such repairs and services, and Landlord shall, to the extent required, equitably adjust Tenant's Share of
Operating Expenses in respect of such repairs or services to reflect that Landlord is not providing such repairs or services to
Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(p)&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Public
Reporting Status</B><FONT STYLE="font-weight: normal">. As of the Commencement Date, Tenant is subject to the public reporting
requirements of the Securities Exchange Act of 1934. Landlord acknowledges that this Lease, or material terms of this Lease may
need to be disclosed by Tenant for purposes of compliance with applicable laws. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
Publicity<FONT STYLE="font-weight: normal">. The content of any public announcement, press release or similar statement or publicity
concerning the entering into of this Lease must be pre-approved in writing by both Landlord and Tenant, which approval shall not
be unreasonably withheld, conditioned or delayed. Each of Landlord and Tenant will advise the Broker of the requirements of this
paragraph.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Signatures on next page]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, Landlord and Tenant
have executed this Lease as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">TENANT:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">MUSTANG BIO, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 5%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 45%; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">Its:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">LANDLORD:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">WCS - 377 PLANTATION STREET, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">Its:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXHIBIT A TO LEASE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>DESCRIPTION OF PREMISES</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="tv477598_ex10-1img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT B TO LEASE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>DESCRIPTION OF PROPERTY</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The land and the building thereon in Worcester, Worcester County,
Massachusetts, on the westerly side of the easement taking of Plantation Street shown as Parcel 10A on a Plan by Cullinan Engineering
Co., Inc. entitled &quot;Plan . of Property Owned by Worcester Business Development Corporation of Parcels 10A, 10B, 10C, Plantation
Street, Worcester, Massachusetts,&quot; dated December 16, 1992, and recorded in the Worcester District Registry of Deeds (&quot;Registry&quot;)
in Plan Book 670, Plan 70, (the &quot;Plan&quot;) containing 4.2929 acres, more or less, bounded and described as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beginning at a point on the westerly side of the easement taking
of Plantation Street at the most easterly corner of Parcel 10A; said point also being the most Southerly corner of Parcel IOC as
shown on the Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; padding-left: 0.5in">THENCE</TD>
    <TD STYLE="width: 80%; text-align: justify">South 23 degrees 14' 23&quot; West by the westerly side of such easement taking of Plantation Street, a distance of three hundred and thirty-nine and thirteen hundredths (339.13) feet to a point at land now or formerly of University of Massachusetts Foundation, Inc.;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">THENCE</TD>
    <TD STYLE="text-align: justify">by land now or formerly of University of Massachusetts Foundation, Inc. the following three (3) courses: North 65 degrees 28' 00&quot; West, a distance of sixty and six hundredths (60.06) feet to a point of curvature; In a westerly direction by a curve to the left having a radius of five hundred and four and fifty hundredths (504.50) feet, an arc distance of one hundred and forty and eighty-two hundredths (140.82) feet to a point of tangency;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">THENCE</TD>
    <TD STYLE="text-align: justify">North 81 degrees 27' 35&quot; West, a distance of one hundred eighty-three and ninety-five hundredths (183.95) feet to a point;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">THENCE</TD>
    <TD STYLE="text-align: justify">North 07 degrees 38' 48&quot; West, along other land now or formerly of Worcester Business Development Corporation a distance of sixty and ninety-two hundredths (60.92) feet to a point;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">THENCE</TD>
    <TD STYLE="text-align: justify">North 07 degrees 38' 50&quot; West along land now or formerly of the Commonwealth of Massachusetts (Department of Mental Health), a distance of one hundred fifty (150.00) feet to a point;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">THENCE</TD>
    <TD STYLE="text-align: justify">North 15 degrees 38' 45&quot; West continuing along land now or formerly of Commonwealth of Massachusetts (Department of Mental Health), a distance of two hundred and seventy-seven and one hundred eighty-five thousandths (277.185) feet to a point at 10C as shown on the Plan;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; padding-left: 0.5in">THENCE</TD>
    <TD STYLE="width: 80%; text-align: justify">South 67 degrees 06' 49&quot; East along other land of Worcester Business Development Corporation, a distance of six hundred and fifty-nine and sixty-seven hundredths (659.67) feet to the point of beginning.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Together with that portion of the parcel shown on the plan as
&quot;City of Worcester - Permanent Roadway Easement Taking December 1991&quot; which adjoins Parcel 10A, (said parcel and Parcel
10A being hereinafter together referred to as the &quot;Premises&quot;) bounded and described as follows,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">BEGINNING at the Northerly line of Parcel
10A and the Southerly line of Parcel IOC as shown on the Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; padding-left: 0.5in">THENCE</TD>
    <TD STYLE="width: 80%">North 23 degrees 14' 23&quot; East forty-six and eighty-two hundredths (46.82) feet;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">THENCE</TD>
    <TD STYLE="text-align: justify">by a curve having a radius of two thousand five hundred and seventeen and sixty hundredths (2517.60) feet, a -distance of two hundred thirty-eight and ninety hundredths (238.90) feet;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">THENCE</TD>
    <TD>by said curve a distance of twenty (20.00) feet;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">THENCE</TD>
    <TD>South 71 degrees 47' 26&quot; East eighty-one and seventy-six hundredths (81.76) feet;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">THENCE</TD>
    <TD>South 19 degrees 17' 00&quot; West two hundred and fifty (250.00) feet;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">THENCE</TD>
    <TD STYLE="text-align: justify">South 30 degrees 53' 30&quot; West three hundred and twenty-two and eighty-four hundredths (322.84) feet;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">THENCE</TD>
    <TD>South 24 degrees 32' 00&quot; West eighty-three and fourteen hundredths (83.14) feet;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">THENCE</TD>
    <TD>North 65 degrees 28' 00&quot; West forty and fifty-four hundredths (40.54) feet;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">THENCE</TD>
    <TD STYLE="text-align: justify">North 23 degrees 14' 23&quot; East three hundred and thirty-nine and thirteen hundredths (339.13) feet to the point of beginning.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Excepting therefrom the premises described in a Deed to Worcester
Business Development Corporation dated February 26. 1999 recorded in Book 21120, Page 120.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT C TO LEASE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>ACKNOWLEDGMENT OF COMMENCEMENT DATE</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">This <B>ACKNOWLEDGMENT OF COMMENCEMENT DATE</B>
is made this _____ day of _____________, ____, between _________________________________, a _________________ limited liability
company (&quot;Landlord&quot;), and ______________________, a ______________ limited liability company (&quot;<B>Tenant</B>&quot;),
and is attached to and made a part of the Lease dated _______________, 2017 (the &quot;<B>Lease</B>&quot;), by and between Landlord
and Tenant. Any initially capitalized terms used but not defined herein shall have the meanings given them in the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Landlord and Tenant hereby acknowledge and
agree, for all purposes of the Lease, that the Commencement Date of the Base Term of the Lease is __________, _____, the Rent Commencement
Date is _________________, 20___, and the termination date of the Base Term of the Lease shall be midnight on _____________, 20___.
<B><I><U>{After Schedule B Occupancy Date: </U></I></B>The Schedule B Occupancy Date was: _____________.} In case of a conflict
between the terms of the Lease and the terms of this Acknowledgment of Commencement Date, this Acknowledgment of Commencement Date
shall control for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">IN WITNESS WHEREOF, Landlord and Tenant
have executed this ACKNOWLEDGMENT OF COMMENCEMENT DATE to be effective on the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">TENANT:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">_______________________________,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">a _____________ limited liability company</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Its:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">LANDLORD:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">________________________________,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">a ____________ limited liability company</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT D TO LEASE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RULES AND REGULATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
sign, placard, picture, advertisement, name or notice shall be installed or displayed in any part of the outside or inside of the
Property if visible from a public area without prior written consent of the Landlord. Landlord shall have the right to remove,
at Tenant&rsquo;s expense and without notice, and sign installed or displayed in violation of this rule. All approved signs or
lettering in public corridors shall be inscribed or affixed at the expense of the Tenant by a person or vendor chosen by Landlord
and in conformance with the Property standard signage program. In addition, Landlord reserves the right to change from time to
time the format of the signs or lettering and to require previously approved signs or lettering to be appropriately altered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall not obstruct any sidewalks, halls, passages, exits, entrances, elevators, escalators or stairways to the Property. The halls,
passages, exits, entrances, elevators, escalators and stairways are not for the general public, and Landlord shall in all cases
retain the right to control and prevent access thereto of all persons whose presence in the judgment of the Landlord would be prejudicial
to the safety, character, reputation and interest of the Property and its tenants. However, nothing herein contained shall be construed
to prevent such access to persons with whom any tenant normally deals in the ordinary course of its business, unless such persons
are engaged in illegal activities. No tenant and no employee or invitee of any tenant shall go upon the roof the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall not place any objects, including antennas, outdoor furniture, etc., in the parking areas, landscaped areas or other areas
outside of its Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="color: #010101">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Tenant
shall not install any radio or television antenna, loudspeaker or other device on the roof or exterior walls of the Property. Tenant
shall not interfere with radio or television broadcasting or reception from or in the Property elsewhere.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="color: #010101">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
directory of the Property will be provided exclusively for the display of the name and location of tenants only and Landlord reserves
the right to exclude any other names therefrom. No more than one entries on the directory located in the Property lobby designating
Tenant shall be installed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="color: #010101">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Except
as specifically set forth in the Lease, all cleaning services for the Premises shall be arranged exclusively through the Landlord.
Tenant shall not cause any unnecessary labor or service by carelessness or indifference to the good order and cleanliness of the
Premises, however occurring.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="color: #010101">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Landlord
will furnish Tenant free of charge with an appropriate number of electronic access cards and parking passes. Tenant shall pay a
Ten Dollar ($10) replacement charge for the replacement of any lost access card or parking pass. Landlord may make a reasonable
charge for any keys. Tenant shall not make or have made additional keys, and Tenant shall not alter any lock or install a new or
additional locks or bolts on any door of its Premises. Tenant upon termination of its tenancy, shall delivery to Landlord the keys
of all doors which have been furnished to Tenant, and in the event of loss of any keys so furnished, shall pay Landlord therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
for animals assisting the disabled, no animals shall be allowed in the offices, halls, or corridors in the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall not disturb the occupants of the Property or adjoining buildings by the use of any radio or musical instrument or by the
making of loud or improper noises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt"><FONT STYLE="color: #010101">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
Tenant desires telegraphic, telephonic or other electric connections in the Premises, Landlord or its agent will direct the electrician
as to where and how the wires may be introduced; and, without such direction, no boring or cutting of wires will be permitted</FONT><FONT STYLE="color: #3A3A3A">.</FONT>
<FONT STYLE="color: #010101">Any such installation or connection shall be made at Tenant's expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall not install or operate any steam or gas engine or boiler, or other mechanical apparatus in the Premises, except as specifically
approved in the Lease. The use of oil, gas or inflammable liquids for heating, lighting or any other purpose is expressly prohibited.
Explosives or other articles deemed extra hazardous shall not be brought into the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parking
any type of recreational vehicles is specifically prohibited on or about the Property. Except for the overnight parking of operative
vehicles, no vehicle of any type shall be stored in the parking areas at any time. In the event that a vehicle is disabled, it
shall be removed within 48 hours. There shall be no &quot;For Sale&quot; or other advertising signs on or about any parked vehicle.
All vehicles shall be parked in the designated parking areas in conformity with all signs and other markings. All parking will
be open parking, and no reserved parking, numbering or lettering of individual spaces will be permitted except as specified by
Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall maintain the Premises free from rodents, insects and other pests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall not use any method of heating or air conditioning such as space heaters or fans other than supplied by Landlord. Tenant shall
not waste electricity, water or air conditioning. Tenant shall keep corridor doors closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall close and lock the doors of its Premises and entirely shut all water faucets or other water apparatus before Tenant and its
employees leave the Premises. Tenant shall be responsible for any damage or injuries sustained by other tenants or occupants of
the Property or by Landlord for noncompliance with this rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord
reserves the right to exclude or expel from the Property any person who, in the judgment of Landlord, is intoxicated or under the
influence of liquor or drugs or who shall in any manner do any act in violation of the Rules and Regulations of the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall not cause any unnecessary labor by reason of Tenant's carelessness or indifference in the preservation of good order and
cleanliness. Landlord shall not be responsible to Tenant for any loss of property on the Premises, however occurring, or for any
damage done to the effects of Tenant by the janitors or any other employee or person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall give Landlord prompt notice of any defects in the water, lawn sprinkler, sewage, gas pipes, electrical lights and fixtures,
heating apparatus, or any other service equipment affecting the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall not permit storage outside the Premises, including without limitation, outside storage of trucks and other vehicles, or dumping
of waste or refuse or permit any harmful materials to be placed in any drainage system or sanitary system in or about the Premises.
The toilet rooms, toilets, urinals, wash bowls and other apparatus shall not be used for any purpose other than that for which
they were constructed. No foreign substance of any kind whatsoever shall be thrown therein, and the expense of any breakage, stoppage
or damage resulting from the violation of this rule shall be borne by Tenant who, or whose employees or invitees shall have caused
it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
moveable trash receptacles provided by the trash disposal firm for the Premises must be kept in the trash enclosure areas, if any,
provided for that purpose. Tenant shall store all its trash and garbage within its Premises. Tenant shall not place in any trash
box or receptacle any material which cannot be disposed of in the ordinary and customary manner of trash or garbage disposal. All
garbage and refuse disposal shall be made in accordance with direction issues from time to time by Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
auction, public or private, will be permitted on the Premises or the Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
awnings shall be placed over the windows in the Premises except with the prior written consent of Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall use and keep in place the Property standard window covering. Tenant shall not place anything or allow anything to be placed
against or near any doors or windows which may appear unsightly, in the opinion of the Landlord, from outside of the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Premises shall not be used for lodging, sleeping or cooking or for any immoral or illegal purposes or for any purpose other than
that specified in the Lease. No gaming devices shall be operated in the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">25.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
cooking shall be done or permitted by any Tenant in the Premises, except that use of Underwriters&rsquo; Laboratory approved equipment
for brewing coffee, tea, hot chocolate and similar beverages shall be permitted, provided that such equipment and is in accordance
with all applicable federal, state and city laws, codes, ordinances, rules and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">26.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as approved by Landlord, Tenant shall to mark, drive nails, screw or drill into partitions, woodwork or plaster or in any way deface
the Premises. Tenant shall not curt or bore holes for wires. Tenant shall not affix any floor covering to the floor of the Premises
in any manner except as approved by Landlord. Tenant shall repair any damage resulting from noncompliance with this rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">27.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall ascertain from Landlord the maximum amount of electrical current which can safely be used in the Premises, taking into account
the capacity of the electrical wiring in the Property and the Premises and the needs of other tenants, and shall not use more than
such safe capacity. Landlord's consent to the installation of electric equipment shall not relieve Tenant from the obligation not
to use more electricity than such safe capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">28.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
assumes full responsibility for protecting the Premises from theft, robbery and pilferage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">29.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall pay on demand the cost of replacement of any glass doors broken in or on the perimeter of the Premises during the continuance
of the Lease if same is broken as a result of tenant, its employees or agents negligence, unless the glass shall be broken by Landlord
its employees or agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">30.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall not install, maintain or operate upon the Premises any vending machines or video game machines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">31.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord
may waive any one or more of these Rules and Regulations for the benefit of any particular tenant or tenants, but no such waiver
by Landlord shall be construed as a waiver of such Rules and Regulations in favor of any other tenant or tenants, nor prevent Landlord
from thereafter enforcing any such Rules and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">32.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Canvasing,
soliciting and peddling in or about the Property is expressly prohibited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">33.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the benefit of all tenants, Landlord shall have the right to reasonably limit freight elevator use during peak use hours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">34.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall not install or operate on the Premises any machinery or mechanical devices of a nature not directly related to Tenant's ordinary
use of the Premises and shall keep all such machinery free of vibration, noise and air waves which may be transmitted beyond the
Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">35.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Rules and Regulations are in addition to, and shall not be construed to in any way modify or amend, in whole or in part, the terms,
covenants, agreements and conditions of any lease of any premises on the Property. Landlord shall have the right to amend these
Rules and Regulations at any time during the term hereof, with notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010101">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.7pt; color: #010101">36.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Smoking
and the use of tobacco is not permitted in the Building, at the Property, or on the grounds of Biotech Park and the University
of Massachusetts Medical School.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT E</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TENANT&rsquo;S PERSONAL PROPERTY (REMOVABLE
INSTALLATIONS)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">To-be</FONT>-installed
generator, if installed pursuant to Section 7(c)(vii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT F</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TENANT&rsquo;S SURRENDER PLAN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Tenant Surrender Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Name of Tenant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Addressed of Leased Space</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Prepared for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Owner</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Address</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Prepared by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>TENANT NAME</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>CITY, STATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Month Year</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><B>Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 82%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.0</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Introduction</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General Site Information</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemical, Biological, and Radioactive Agents</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemical Agents</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biological Agents</FONT></TD>
    <TD STYLE="text-align: right">F-4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radiological Agents</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.0</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment</FONT></TD>
    <TD STYLE="text-align: right">F-5</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment Inventory</FONT></TD>
    <TD STYLE="text-align: right">F-5</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposition of Equipment</FONT></TD>
    <TD STYLE="text-align: right">F-5</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.0</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waste Management and Wastewater Discharges</FONT></TD>
    <TD STYLE="text-align: right"></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hazardous Waste</FONT></TD>
    <TD STYLE="text-align: right"></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biological Waste</FONT></TD>
    <TD STYLE="text-align: right"></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radiological Waste</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wastewater Discharges</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.0</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decontamination Procedures</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposition of Equipment</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chemical Use Areas</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biological Agent Use Areas</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radiological Agent Use Areas</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Final Waste Shipments</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.0</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permits</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.0</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spills</FONT></TD>
    <TD STYLE="text-align: right"></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">List of Appendices</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Appendix A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-indent: -0.4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-indent: -0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-size: 12pt">Introduction</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-indent: -0.4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purpose of this Surrender Plan is to provide detailed information
regarding decommissioning procedures followed by a tenant at the conclusion of its tenancy at the leased space (&ldquo;the Premises&rdquo;).
This Surrender Plan will be used by Owner to evaluate, from a health and safety standpoint, whether the space will be suitable
for re-occupancy by a biotechnology tenant. This Surrender Plan includes information regarding the tenant&rsquo;s operations, types
of hazardous materials used, waste management practices, decontamination procedures, and permit closure/transfer documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>General
Tenant Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding: 3pt"><FONT STYLE="font-size: 10pt">Name of tenant</FONT></TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt"><FONT STYLE="font-size: 10pt">Address of leased space (include Suite numbers)</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt"><FONT STYLE="font-size: 10pt">Length of time at leased space</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD ROWSPAN="3" STYLE="width: 35%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt"><FONT STYLE="font-size: 10pt">Approximate square footage of leased space</FONT></TD>
    <TD STYLE="width: 24%; border-bottom: Black 1pt solid; padding: 3pt"><FONT STYLE="font-size: 10pt">Office space:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 41%; border-bottom: Black 1pt solid; padding: 3pt; border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding: 3pt"><FONT STYLE="font-size: 10pt">Lab space:</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding: 3pt"><FONT STYLE="font-size: 10pt">Total:</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD ROWSPAN="5" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt"><FONT STYLE="font-size: 10pt">Tenant contact (for follow-up questions regarding Surrender Plan)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 3pt"><FONT STYLE="font-size: 10pt">Name</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding: 3pt"><FONT STYLE="font-size: 10pt">Title</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding: 3pt"><FONT STYLE="font-size: 10pt">Years with company</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding: 3pt"><FONT STYLE="font-size: 10pt">Telephone number</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding: 3pt"><FONT STYLE="font-size: 10pt">E-mail address</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt"><FONT STYLE="font-size: 10pt">Lease end date</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt"><FONT STYLE="font-size: 10pt">Scheduled date for vacating leased space</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt"><FONT STYLE="font-size: 10pt">Location company is moving to</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt"><FONT STYLE="font-size: 10pt">Site plan included?</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes, see Appendix ____</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: justify"><FONT STYLE="font-size: 10pt">General description of operations (include Biosafety level(s) of laboratory spaces, the nature of the company&rsquo;s business, and types of activities conducted on-site)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Chemical,
Biological, and Radioactive Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This section provides information regarding chemical, biological
(including vivariums), radiological agents (collectively &quot;Agents&quot;) used on the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Chemical
Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Identify all chemicals used at the property, including name,
quantity(ies) used, maximum volume of storage containers, etc., OR refer to a chemical inventory to be included in an Appendix
to this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Biological
Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Identify all biological agents used at the property, including
name, quantity(ies) used, maximum volume of storage containers, etc., OR refer to a biological agent inventory to be included in
an Appendix to this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Radiological
Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Identify all radiological materials used at the property, including
name, quantity(ies) used, maximum volume of storage containers, etc., OR refer to a radiological material inventory to be included
in an Appendix to this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-indent: -0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-size: 12pt">Equipment</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-indent: -0.4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The section describes the equipment used by the tenant, and
identifies which equipment will be moved off-site and which equipment will remain on the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Equipment
Inventory</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please provide an inventory of equipment, instruments, and laboratory
apparatus (collectively &quot;Equipment&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Disposition
of Equipment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Describe Equipment to be removed from the Premises, and Equipment
to remain at the Premises. Equipment to remain at the Premises which is not the property of Owner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT G</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PLAN SHOWING RESERVED PARKING</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">G-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tv477598_ex10-1img2.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">G-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT H</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WORK LETTER WITH RESPECT TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TENANT&rsquo;S WORK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Landlord and Tenant agree as follows with
respect to the improvements to be installed in the Premises:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 125.25pt; text-align: justify; text-indent: -89.25pt"><FONT STYLE="text-transform: uppercase"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Landlord&rsquo;s
Work</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 125.25pt; text-align: justify; text-indent: -89.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;Landlord,
at Landlord&rsquo;s sole cost and expense, shall put the Premises into base building condition as set forth in Schedule 1 attached
hereto and hereby made a part hereof (&ldquo;<B>Landlord&rsquo;s Work</B>&rdquo;) on or before on or before the Commencement Date
provided that that portion of Landlord&rsquo;s Work described as the Concurrent Work on Schedule 1 (collectively, the &ldquo;<B>Concurrent
Work</B>&rdquo;) is to be performed by Landlord concurrently with the performance of the Tenant&rsquo;s Work (as such term is hereinafter
defined) in a timely manner so as not to delay completion of the Tenant&rsquo;s Work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 125.25pt; text-align: justify; text-indent: -89.25pt"><FONT STYLE="text-transform: uppercase"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tenant&rsquo;s
Work.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 125.25pt; text-align: justify; text-indent: -89.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Tenant&rsquo;s
Work</U></B>. Tenant shall provide the construction material, hardware and equipment and the labor to construct and install the
improvements to the Premises described in the Plans (as that term is hereinafter described). The material, hardware, equipment
and labor as incorporated into the Premises pursuant to the Plans are herein collectively referred to as the &ldquo;<B>Tenant&rsquo;s
Work</B>&rdquo;. Subject to the provisions of this <B>Exhibit F</B> (the &ldquo;<B>Work Letter</B>&rdquo;), Tenant shall proceed
diligently to cause the Tenant&rsquo;s Work approved by Landlord to be completed in accordance with the terms and conditions of
the Lease and this Work Letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Plans</U></B>.
Tenant agrees to cause its architect and engineer to prepare plans and specifications for Tenant&rsquo;s Work (which shall include
(i) furniture plans showing details of space occupancy; (ii) sprinkler locations; (iii) reflected ceiling plans; (iv) partition
and door location plans; (v) electrical and telephone plans noting any special requirements; (vi) fire safety systems; (vii) detail
plans; (viii) finish plans and schedules and also specifications for the Tenant&rsquo;s Work to be performed in the Premises; (ix)
mechanical and electrical, fire alarm, life safety, and plumbing drawings for the Premises and deliver said drawings to Landlord.
Landlord agrees to either approve or disapprove said architectural construction drawings in writing within ten (10) business days
of receipt thereof by Landlord. Failure to approve or disapprove within such ten (10) business day period shall result in said
drawings being deemed approved by Landlord. If Landlord disapproves of said drawings, Landlord agrees to advise Tenant in writing
generally of the required changes. Tenant shall deliver to Landlord architectural construction drawings revised pursuant to Landlord&rsquo;s
comments within ten (10) business days of receipt of Landlord&rsquo;s comments, after which Landlord shall have a period of two
(2) business days to either approve or disapprove said drawings in writing, and if Landlord fails to give written notice of its
approval or disapproval of the revisions within such two (2) business day period shall result in said revisions being deemed approved
by Landlord. The revision procedure shall be repeated until Landlord approves the architectural construction drawings for the Premises.
The plans and specifications described above are referred to as the &ldquo;<B>Plans</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>No
Representations by Landlord</U></B>. Neither review nor approval by Landlord of any of the Plans shall constitute a representation
or warranty by Landlord that such Plans either (i) are complete or suitable for their intended purpose or (ii) comply with applicable
laws, ordinances, codes and regulations, it being expressly agreed by Tenant that Landlord assumes no responsibility or liability
whatsoever to Tenant or to any other person or entity for such completeness, suitability or compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 125.25pt; text-align: justify; text-indent: -89.25pt"><FONT STYLE="text-transform: uppercase"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cost
of Tenant&rsquo;s Work.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 125.25pt; text-align: justify; text-indent: -89.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>General
Contract</U>. </B>Prior to commencement of any portion of the Tenant&rsquo;s Work, Tenant shall obtain a contract to perform the
Tenant&rsquo;s Work by bidding the Tenant&rsquo;s Work to one (1) or more of those licensed general contractors approved by Landlord,
which approval shall not be unreasonably withheld or delayed. Landlord confirms its approval of Hodess Construction Corporation
(100 John L Dietsch Sq, North Attleboro, MA 02763, Ph: 508.695.1012), or any of its wholly owned subsidiaries as Contractor. Promptly
after entering into a general contract for Tenant&rsquo;s Work with its selected general contractor (the &ldquo;<B>Contractor</B>&rdquo;)
Tenant agrees to promptly give Landlord a copy of the contract. The Contractor shall notify Landlord in advance of the identities
of all subcontractors who will be performing work in the Premises. All such subcontractors shall be licensed. Tenant shall not
be relieved of any of its obligations under this Work Letter by the fact that Landlord approved the Contractor or the fact that
Landlord may have notice of subcontractors used by the Contractor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Allowance</U></B>.
Landlord shall reimburse Tenant up to Thirty Dollars ($30.00) per square foot of Rentable Area in the Premises with respect to
Section A (14,222 RSF) (the <B>&ldquo;Phase I Allowance&rdquo;) </B>and Forty Dollars ($40.00) per square foot of Rentable Area
in the Premises with respect to Section B (12,821 RSF) (the &ldquo;<B>Phase II Allowance&rdquo;</B> and collectively with the Phase
I Allowance, the &ldquo;<B>Allowance</B>&rdquo;) for hard (and as permitted below, soft) costs of the Tenant&rsquo;s Work. Tenant
shall pay all costs of the Tenant&rsquo;s Work in excess of the Allowance. All amounts shall be paid by Tenant within thirty (30)
days after Tenant&rsquo;s receipt of invoices therefor. The Phase I Allowance shall be available to Tenant commencing on the Commencement
Date and expiring on the expiration of the first Lease Year, up to Ten Dollars ($10.00) per square foot of the Phase II Allowance
shall be available for demolition costs associated with preconstruction demolition of Section B, commencing on such demolition
work with the remaining balance of the Phase II Allowance available to Tenant commencing on the Section B Occupancy Date and expiring
one year thereafter. Tenant may use up to $3.00 per square foot of Rentable Area in the Premises of the Allowance not required
to pay hard costs for non-hard cost items, including soft costs, cabling, telephone, furniture and moving.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Coordination
Fee</U></B>. Tenant shall pay a plan review, construction coordination and management, and overhead fee to Landlord in an amount
equal to the lesser of (i) two percent (2%) of Landlord&rsquo;s total Allowance contribution, or (ii) Landlord&rsquo;s actual costs,
to cover Landlord&rsquo;s plan review, coordination, supervision and overhead and related expenses allocable to such work (the
&ldquo;<B>Coordination Fee</B>&rdquo;). The Coordination Fee shall be deducted by Landlord from the Allowance, in an amount not
to exceed two percent (2%) of the amount disbursed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Payment
of Allowance</U></B>. Landlord shall make payments of the Allowance only one time per month upon receipt of invoices, sworn statements,
mechanics lien waivers as provided herein and such other documentation as Landlord may reasonably request. Landlord shall have
no obligation to make any payment of the Allowance at any time that Tenant is in default hereunder or under the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Intentionally
deleted.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">F.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Draw
Requests</U></B>. Tenant shall make draw requests based upon costs incurred for completed work as of the date of the draw request.
Tenant shall present to Landlord a letter requesting a disbursement of funds, invoices (or paid receipts for each item paid by
Tenant and for which Tenant is seeking reimbursement), a copy of any cancelled checks pursuant to which such invoice has been paid,
and, with respect to any construction to any portion of the Premises, such lien waivers (for lienable items) required by the Landlord.
The lien waiver from the general contractor and from each subcontractor and material supplier must be delivered with each draw
request. Landlord shall have no obligation to make a payment until all waivers for the prior draw are submitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">G.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Payment
of Draw Requests</U></B>. Draw requests shall be submitted to Landlord no more often than monthly. Not later than five (5) business
days after receipt of a draw request from Tenant, Landlord will review the applicable portion of Tenant&rsquo;s Work and Tenant&rsquo;s
draw request and advise Tenant in writing of any respects in which the draw request is disapproved and the reason for such disapproval.
Such advice need not comply with the notice provisions of the Lease. Draw requests shall be paid, subject to the foregoing approval
procedure, not later than fifteen (15) business days after the draw request is received by Landlord. Landlord and Tenant agree
to cooperate in attempting to resolve disapproved portions of each draw request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">H.&nbsp;&nbsp;&nbsp;&nbsp;[Intentionally
deleted.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 125.25pt; text-align: justify; text-indent: -89.25pt"><FONT STYLE="text-transform: uppercase"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Access
By Tenant; Work in Harmony.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 125.25pt; text-align: justify; text-indent: -89.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Landlord shall permit
Tenant and Tenant&rsquo;s agents, representatives, employees, suppliers, contractors, subcontractors, mechanics and workmen (i)
to enter the Premises prior to the completion of the Landlord&rsquo;s Work, and (ii) to access base building systems, including
without limitation, chilled water, hot water, electrical and life-safety protection. Tenant agrees for itself and its agents, representatives,
employees, suppliers, contractors, subcontractors, workmen, mechanics, and suppliers, that all such parties shall work in harmony
and not unreasonably interfere with Landlord and Landlord&rsquo;s agents, representatives, employees, suppliers, contractors, subcontractors,
mechanics, and workmen in doing the Landlord&rsquo;s Work in the Premises or work for other tenants and occupants of the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 125.25pt; text-align: justify; text-indent: -89.25pt"><FONT STYLE="text-transform: uppercase"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Construction
Requirements.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 125.25pt; text-align: justify; text-indent: -89.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Conditions
of Entry</U></B>. Tenant agrees that the entry into the Premises by Tenant and its contractors shall be deemed to be under all
of the terms, covenants, conditions and provisions of the Lease except as to the covenant to pay Rent and Tenant further agrees
that in connection therewith Landlord shall not be liable in any way for any injury, loss or damage which may occur to any of Tenant&rsquo;s
employees, agents or contractors, to Tenant&rsquo;s Work or installations made in the Premises or to property placed therein prior
to the Commencement Date and thereafter, the same being at Tenant&rsquo;s sole risk. In addition, Tenant shall require all entities
performing work on behalf of Tenant to provide protection for existing improvements to an extent that is satisfactory to Landlord
and shall allow Landlord access to the Premises, for inspection purposes, at all times during the period when Tenant is undertaking
construction activities therein. Tenant agrees to protect, indemnify, defend and hold Landlord and its agents, partners, contractors
and employees harmless from and against any and all losses, damages, liabilities, claims, liens, costs and expenses, including
reasonable attorneys&rsquo; fees, of whatever nature, including those to the Premises, the Building (including the Landlord&rsquo;s
Work), any other property of Landlord, or to the person and property of Tenant, its employees, agents, invitees, licensees and
others arising out of or in connection with the activities of Tenant or any entity performing work on behalf of Tenant in or about
the Premises or the Building. Further, Tenant shall cause such damage to be repaired at Tenant&rsquo;s expense and if Tenant fails
to cause such damage to be repaired promptly upon Landlord&rsquo;s demand therefor, Landlord may in addition to any other rights
or remedies available to Landlord under this Lease or at law or equity cause such damage to be repaired, in which event Tenant
shall promptly upon Landlord&rsquo;s demand pay to Landlord the cost of such repairs;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Ingress
and Egress</U></B>. All contractors and subcontractors shall use only those service corridors and service entrances designated
by Landlord for ingress and egress of personnel, and the delivery and removal of equipment and material through or across any common
areas of the Building shall only be permitted with the written approval of Landlord and during hours determined by Landlord. Landlord
shall have the right to order Tenant or any contractor or subcontractor who repeatedly violates the above requirements to cease
work in the Building and leave the Building and remove its equipment and its employees from the Building and, at Landlord&rsquo;s
option, restore any portion of the Building on which it has done work to its original condition;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Trash
Removal</U></B>. During the performance of Tenant&rsquo;s Work and Tenant&rsquo;s fixturing, Landlord may provide trash removal
service from a location designated by Landlord. Tenant shall be responsible for breaking down boxes and placing trash in Landlord&rsquo;s
containers at such designated location. Tenant shall accumulate its trash in containers supplied by Landlord and Tenant shall not
permit trash to accumulate within the Premises or in the corridors or public areas adjacent to the Premises. Tenant shall cause
each entity employed by it to perform work on the Premises to abide by the provisions of this Work Letter as to the storage of
trash and shall require each such entity to perform its work in a way that dust or dirt is contained entirely within the Premises
and not within any other portion of the Building and shall cause Tenant&rsquo;s contractors to leave the Premises in broom-clean
condition at the end of each day. Should Landlord deem it necessary to remove Tenant&rsquo;s trash because of accumulation, Tenant
shall pay to Landlord an additional reasonable charge for such removal on a time and material basis. The cost to Tenant for Landlord
removing such trash will be based on reasonable and competitive cost which Tenant could have secured independently had Landlord
not provided such service;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D.&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Performance
of Work</U></B>. Tenant agrees that all services and work performed on the Premises by, on behalf of, or for the account of Tenant,
including installation of telephones, carpeting, materials and personal property delivered to the Premises shall be done in a first-class
workmanlike manner using only good grades of material, in compliance with Legal Requirements including the ADA, and shall be performed
only by persons covered by a collective bargaining agreement with the appropriate trade union. Tenant at Tenant&rsquo;s cost shall
secure all requisite permits and approvals for Tenant&rsquo;s Work including, but not limited to, a Building Permit and a Certificate
of Occupancy issued by the City of Worcester;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Insurance</U></B>.
Tenant shall provide, or shall cause Tenant&rsquo;s General Contractor to provide, insurance which satisfy the requirements of
Section 17 of this Lease, shall include (if permitted by the insurer) a waiver of subrogation in favor of Landlord, and shall insure
Landlord and Tenant, as their respective interests may appear, and shall also provide insurance during the course of construction
with respect to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify"><U>Comprehensive General Liability Insurance</U>. Comprehensive
general liability insurance as required by Section 17 of this Lease shall be in an aggregate amount, which may include umbrellas,
of not less than $3,000,000 (a portion of which coverage may be evidenced by an umbrella policy of liability insurance), and shall
name Landlord as additional insured;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify"><U>Worker&rsquo;s Compensation Insurance</U>. Worker&rsquo;s
compensation insurance, to the extent required by law;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify"><U>Builders Risk Insurance</U>. Special Purpose (formerly
known as &ldquo;All Risk&rdquo;) Builders Risk Insurance on 100% of the cost of the Tenant Improvements, covering damage to such
improvements; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify"><U>Automobile Liability Insurance</U>. Automobile Liability
coverage with bodily injury limits of at least $1,000,000.00 per accident and $500,000.00 per accident for property damage.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">F.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Indemnification</U></B>.
EXCEPT TO THE EXTENT SUCH COSTS, LOSSES, LIABILITIES OR ACTIONS RESULT FROM LANDLORD&rsquo;S NEGLIGENCE AND/OR WILLFUL MISCONDUCT,
OR THE NEGLIGENCE OR WILLFUL MISCONDUCT OF LANDLORD&rsquo;S EMPLOYEES, CONTRACTORS OR AGENTS, TENANT SHALL INDEMNIFY AND HOLD LANDLORD
HARMLESS FROM AND AGAINST ALL COSTS (INCLUDING REASONABLE ATTORNEY&rsquo;S FEES AND COSTS OF SUIT), LOSSES, LIABILITIES OR CAUSES
OF ACTION ARISING OUT OF OR RELATING TO TENANT&rsquo;S CONSTRUCTION OF THE TENANT&rsquo;S WORK, INCLUDING, BUT NOT LIMITED TO,
ANY MECHANIC&rsquo;S OR MATERIALMEN&rsquo;S LIENS ASSERTED IN CONNECTION THEREWITH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 125.25pt; text-align: justify; text-indent: -89.25pt"><FONT STYLE="text-transform: uppercase"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 125.25pt; text-align: justify; text-indent: -89.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;Except
as expressly set forth herein, Landlord has no other agreement with Tenant and has no other obligation to do any other work or
pay any amounts with respect to the Premises. Any other work in the Premises which may be permitted by Landlord pursuant to the
terms and conditions of the Lease shall be done at Tenant&rsquo;s sole cost and expense and in accordance with the terms and conditions
of the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Work Letter shall not be deemed applicable to any additional space added to the original Premises (i.e., both Section A and Section
B of the Premises) at any time or from time to time, whether by any options under the Lease or otherwise, or to any portion of
the original Premises or any additions thereto in the event of a renewal or extension of the initial term of the Lease, whether
by any options under the Lease or otherwise, unless expressly so provided in the Lease or any amendment or supplement thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
failure by Tenant to pay any monies due Landlord pursuant to this Work Letter within the time period herein stated shall be deemed
a Default under the terms of the Lease for which Landlord shall be entitled to exercise all remedies available to Landlord for
nonpayment of Rent, following applicable notices and cure periods. All late payments of such monies shall bear interest and shall
be subject to a late charge in the same manner as late payments of Rent pursuant to the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
indemnification and exculpatory provision set forth in Section&nbsp;16 of the Lease as well as all other terms and provisions of
the Lease, insofar as they are applicable to this Work Letter, are hereby incorporated herein by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall be solely responsible to determine at the site all dimensions of the Premises and the Building which affect any work that
may be performed by Tenant or any of Tenant&rsquo;s contractors hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
of Tenant&rsquo;s Work paid for by Landlord may be depreciated by Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>LANDLORD&rsquo;S WORK</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Landlord shall deliver the Premises with all base building systems,
including but not limited to HVAC, electrical, life safety, plumbing systems (including DI water), in good working condition as
of the Commencement Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Landlord, at Landlord&rsquo;s sole cost and expense, shall provide
Tenant with secured, keyed access to all laboratory and office space under lease by the Commencement Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is Concurrent Work: Tenant acknowledges that Landlord
needs to modify the 1st floor Building egress in accordance with the revised egress plan delivered to Tenant and dated May 24,
2017. Although this work will not be completed prior to the Commencement Date, it will be completed promptly thereafter so as not
to negatively impact Tenant&rsquo;s construction or occupancy of the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">H-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">HAZARDOUS MATERIALS LIST</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%; text-align: center; vertical-align: bottom"><B>Material</B></TD>
    <TD STYLE="width: 14%; text-align: center; vertical-align: bottom"><B>Classification</B></TD>
    <TD STYLE="width: 13%; text-align: center; vertical-align: bottom"><B>Quantity <BR>
(max)</B></TD>
    <TD STYLE="width: 12%; text-align: center; vertical-align: bottom"><B>Storage</B></TD>
    <TD STYLE="width: 33%; text-align: center; vertical-align: bottom"><B>Comment</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Human blood</TD>
    <TD STYLE="text-align: center">BL2</TD>
    <TD STYLE="text-align: center">6L</TD>
    <TD STYLE="text-align: center">RT</TD>
    <TD STYLE="text-align: center">No long-term storage</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Primary human cells</TD>
    <TD STYLE="text-align: center">BL2</TD>
    <TD STYLE="text-align: center">&lt;1L</TD>
    <TD STYLE="text-align: center">N2</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Lentivirus</TD>
    <TD STYLE="text-align: center">BL2</TD>
    <TD STYLE="text-align: center">&lt;1L</TD>
    <TD STYLE="text-align: center">-80C/N2</TD>
    <TD STYLE="text-align: center">Replication incompetent</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Adeno associated virus (AAV)</TD>
    <TD STYLE="text-align: center">BL2</TD>
    <TD STYLE="text-align: center">&lt;1L</TD>
    <TD STYLE="text-align: center">-80C/N2</TD>
    <TD STYLE="text-align: center">Replication incompetent</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Retrovirus</TD>
    <TD STYLE="text-align: center">BL2</TD>
    <TD STYLE="text-align: center">&lt;1L</TD>
    <TD STYLE="text-align: center">-80C/N2</TD>
    <TD STYLE="text-align: center">Replication incompetent</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Ethanol</TD>
    <TD STYLE="text-align: center">flammable</TD>
    <TD STYLE="text-align: center">1gal</TD>
    <TD STYLE="text-align: center">RT</TD>
    <TD STYLE="text-align: center">Stored in fire safe cabinet</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Methanol</TD>
    <TD STYLE="text-align: center">flammable</TD>
    <TD STYLE="text-align: center">1gal</TD>
    <TD STYLE="text-align: center">RT</TD>
    <TD STYLE="text-align: center">Stored in fire safe cabinet</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Propanol</TD>
    <TD STYLE="text-align: center">flammable</TD>
    <TD STYLE="text-align: center">1gal</TD>
    <TD STYLE="text-align: center">RT</TD>
    <TD STYLE="text-align: center">Stored in fire safe cabinet</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Hydrocloric acid (HCL)</TD>
    <TD STYLE="text-align: center">acid</TD>
    <TD STYLE="text-align: center">1L</TD>
    <TD STYLE="text-align: center">RT</TD>
    <TD STYLE="text-align: center">Stored in corrosion safe cabinet</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">NaOH</TD>
    <TD STYLE="text-align: center">base</TD>
    <TD STYLE="text-align: center">1L</TD>
    <TD STYLE="text-align: center">RT</TD>
    <TD STYLE="text-align: center">Stored in corrosion safe cabinet</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Options: NewSection Last; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>tv477598_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>MUSTANG BIO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF
2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Manuel Litchman, M.D., President and Chief
Executive Officer (Principal Executive Officer), certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 30.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this Quarterly Report on Form 10-Q of Mustang Bio,
Inc. (the &ldquo;Registrant&rdquo;);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement
of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and
cash flows of the Registrant as of, and for, the periods presented in this report;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Registrant&rsquo;s other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and
have:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in
which this report is being prepared;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">designed such internal control over financial reporting, or caused
such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">c.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">evaluated the effectiveness of Registrant&rsquo;s disclosure controls
and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">d.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">disclosed in this report any change in the Registrant&rsquo;s internal
control over financial reporting that occurred during the Registrant&rsquo;s most recent fiscal quarter (the Registrant&rsquo;s
fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
Registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Registrant&rsquo;s other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the Registrant&rsquo;s auditors and the audit
committee of the Registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">all significant deficiencies and material weaknesses in the design
or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&rsquo;s
ability to record, process, summarize and report financial information; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any fraud, whether or not material, that involves management or other
employees who have a significant role in the Registrant&rsquo;s internal controls over financial reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">November 13, 2017</FONT></TD>
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/ Manuel Litchman</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Manuel Litchman, M.D., President and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Executive Officer </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>tv477598_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>MUSTANG BIO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF
2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, David J. Horin, Interim Chief Financial
Officer (Principal Financial Officer), certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 30.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this Quarterly Report on Form 10-Q of Mustang Bio,
Inc. (the &ldquo;Registrant&rdquo;);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement
of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and
cash flows of the Registrant as of, and for, the periods presented in this report;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Registrant&rsquo;s other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and
have:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in
which this report is being prepared;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">designed such internal control over financial reporting, or caused
such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">c.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">evaluated the effectiveness of Registrant&rsquo;s disclosure controls
and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">d.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">disclosed in this report any change in the Registrant&rsquo;s internal
control over financial reporting that occurred during the Registrant&rsquo;s most recent fiscal quarter (the Registrant&rsquo;s
fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
Registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Registrant&rsquo;s other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the Registrant&rsquo;s auditors and the audit
committee of the Registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">all significant deficiencies and material weaknesses in the design
or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&rsquo;s
ability to record, process, summarize and report financial information; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any fraud, whether or not material, that involves management or other
employees who have a significant role in the Registrant&rsquo;s internal controls over financial reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">November 13, 2017</FONT></TD>
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/ David J. Horin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">David J. Horin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Interim Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>tv477598_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>MUSTANG BIO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&nbsp;1350
AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Quarterly Report of
Mustang Bio, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the quarterly period ended September 30, 2017, as filed with the
Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Manuel Litchman, M.D., President, and Chief
Executive Officer, hereby certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley
Act of 2002, that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 44pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Report fully complies with the requirements of Section&nbsp;13(a)
or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company, as of, and for, the periods presented in the Report.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 44pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">November 13, 2017</FONT></TD>
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/ Manuel Litchman</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Manuel Litchman, M.D., President and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Executive Officer </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>tv477598_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>MUSTANG BIO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&nbsp;1350
AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Quarterly Report of
Mustang Bio, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the quarterly period ended September 30, 2017, as filed with the
Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, David J. Horin, Interim Chief Financial Officer,
hereby certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002,
that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 44pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Report fully complies with the requirements of Section&nbsp;13(a)
or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company, as of, and for, the periods presented in the Report.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 44pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">November 13, 2017</FONT></TD>
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">/s/ David J. Horin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">David J. Horin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Interim Chief Financial Officer </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Principal Financial Officer) </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tv477598_ex10-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv477598_ex10-1img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!]@*> P$1  (1 0,1 ?_$ 1D  0 " @(# 0$
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M -G^/]U'WI?[-<__ */R_P#D:?787\]%^FO]FGX376[\8+2'[:]#_P!G^/\
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M&X>UPLH(<!%E\Q/VCP%A^#^'\/1^"QV><LL-K2]F)&0MO[D5KV6V,1O8]O\
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M6/U@%?J3C]O\[_SW+_RTG^%3RHOR5^P4^Q-,_M1K'ZP"OU)Q^W^=_P">Y?\
MEI/\*GE1?DK]@I]B:9_:C6/U@%?J3C]O\[_SW+_RTG^%3RHOR5^P4^Q-,_M1
MK'ZP"OU)Q^W^=_Y[E_Y:3_"IY47Y*_8*?8FF?VHUC]8!7ZDX_;_._P#/<O\
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M_P!GIN8ZG?P8] _\D5!_WMC^?#/WR?\ S8[D_P#?69_Z=Z[+Q_\ F,/]&O\
M)4@N>:UN4XI3BE.*5HWLMN.5U]T3LS<T*FE+_*U_75FVJH(5);D$<YF1(67Y
M<F&/+S((,0F7F:2DLQ)3L4='?=0RZI&&U>@?=5V/#]Y/WA\5V-/G0\;%R64(
MCD2;2$\+/959XU>63;Y4"-)&LDSQH70,6&KG9)P\1\D*7*+>P]/\1T'4FQL
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MTT5NKLW>E2LXRGXL=A*34:]G)M%A5&<N-./D'4%I$7"LR7E?"A3OPXSSHX
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M_P!V&^?XP>T^*5/'BE?-9Y]O,[N?QJ_><UAUGI=(LFTMJ8.S+)8=AQY$@;2
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M5*9<,J^GM*<F8RQBL/[JW=>1M$'<':KNXAVJ,G,W,<EC].@4X /F31JV2D9
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M8H$A\<*9E3N'F9^,Q7<?,XRUBD?[J_=4P4XW</:DOF+&R!,G,8OY\K18H0#
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M9-&BU.-ME+#KFNO#I<@J3$LL$MFVQI%<J#40.RY/?(PB(AQR4:(Q* B)"R-
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M]=0 #UO\2JWQ?KIO#85(#7&JJWKF+:LA)5CL\K9%ADW$^4MADOL^;9IE\=$
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M<MMH]FBE1UMX85\*WE-8M8?%I0;=5)^O+SVB[VV^EEP5=HUEHQW?A"#!L=9
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MEICO.M(?2I*5JQCURI6Q>*5 GR+EH[.AP=0L9VOTG56U=JTS66\-FVFI5:Z
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M,J$4]0&948T#D,13 <@,LH$H-*C)$J/+BM31I"&T\WEUIQOXD8PI.4^N.*5
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MA6 G6A<!LE+,%9$6%":&5YENP6Z2F*&^8CP9$QY'V_\ NU,\?W4<XD#&-_\
M6C"==LL<;!XN/RW$L:2*81+ H:49V63B<4@DSC'+E1XJ'K?,6.=%?7Y+#H3U
M=18D:V/3:OB<V6X4M6YU]1.J>(LMZ=USTAB-B.9^=?GT6ELH4TQ8&/M7**V>
MIA5M18<,]ED?8S5?9S'B2%,T>AM*EJ($<^NH@&S%QAI\I51([BS$Y,$<>/DZ
MN7;=FXF)FMNF8/W'W&WE+C8XT/6Q]OI_ 22/5\+,O3]3#K<UI4IUTJFL.T4.
MTT+JAKQT+8M.VVK$SP^JZ]U[!U[?!5OCGK27NK[C[U.UBNN4.=B,0D#11=O6
M(J4@7"5.M\UY:=39%E(J*RR8TI'02Y(G3)8FP!*39T>;D#>B-LR>YLJ,Y.4<
M;@<1%-M5UZ,/<+;?XE*C3TK"ILMY6-:OV;T[52-);TTO1= 43;(_=+=N)A4H
MIU8J5CHVT;A7"EFF""=;LSPQ\;3P(^7,+58:LLEG55?*X-VYB47=A--Y966>
M\\\@:%A(TCO,\RR+,WT\[O-C!'FCR) N)E9.,JY'-3(O!<"L'%02S&!IH!KI
M;0"UM1H>A \2AM(Q\V6[D"H6^%F+&@;K[@  T&$BLP=B[#!U 97SB+8#5%A[
MU.NA:L/KMP,J*6R4/F"(TH"%D0!("8N(DS9W7AHE;2\TSD$L[%;-*SNSA"#$
MOT\[M+CC;&8(R,/+R\4&+C8BO;_;R/G23Y%0!_P>B_74:'K<^)5;5S\V6R@"
MI]WCL'MG'9,SJX7 "'JFR>HB*5#KM.M>R,W)5S4.?M%:V:28=E7.U4C;=L,Q
MI*[(R+@O;(,PF6W'F:G%S%4\<)(C+021DB]X\5HGQ8O"J_'!ARX$#'0;\3M?
M$<G^L]P9(*NO74'WM?<?M8,?SIF_)B%5?;(OE_WU<:+2NWNI*1?J9L78=+M]
M)U7;.P.SU;#1ORU5"UUQB]"PN-74^/L01+MK.!)D6$8>A.P*^X*JR(D.)(D<
ME8]C+!CKL\HQJJI$L9C\M#D01109),<+Q*6S<7%S6:/CHR_<7<+RYKX^.J_I
M.M[^F][FQ)(U-_A9EU<VABLMS4J>\ S9M6JO8^BC;%LRYU>N=8XSEJDFS9$X
M\WFGZBO]"N5GL,"33DZ*!S:T_" #SD\"50O7ZYK5?K;,HLX5>7CB03(D$,:L
M&V*H6-YU*SNTT2K'.1+E_5RALK&QLHK/S4ZOS?.-%Q,.-CF3H22?7Z;=-#J-
M%VCPDKI&/EQ7D)-;6D]CK[J.A:J%5QEFXR6>NO3>5*KZKIKO5=IUFF4,CUDQ
ML%%T*4JTZQA$=<5V7%E,,);G -80""2DAIZTS5/-4C(FB(W"82%RQ9WRUD3)
MF*.SO'LES$SIE$;&/9E]S948Q<88O XY+CH?5:WJ6VT:==%VC77PPJ=QW2G3
M0G0TN478"M8&).:@NMJO!CLIM^%K';VINP?WRLU*Y66>4K)^N'*_DC4]DR(P
M6O,P@Y%$0,.2W+N%B2EV'&C8R3,$#.QWNPD=F=BUR[#&R)Y9L< LK>'"S,O$
M :<A>W.VT2%<C):!ZO=T^T  _I*K=/UTVMA4K=-]B.QEL["T+5]]U*BKZRV-
M2 VR!SEJK$2T6\",VHW>[A2M-":O!M) I=W#UEI#QMF39&H!#9D]I!2SK17X
MC+'+.WTQ9RS+.K2%BTB8S*^,@AD>22$-%BM@P,()Y<<-B]O8[KQ/$B?F\B6=
M7Q>[3T7T.HL#JVXZ@'Q2GYDEHP!5</G91>[E>^KVN:X)LUW 6^V4*<+J8(2W
MLIJQ7NT;3+"5'0ZDPDKVA;+T_"<@RK*1Q&A6N=$S$!1D H,3*P5L=O &3(1T
M50JIC/&V-&)8D19"T."<*%FGB@FWXW;V,[<CR1R.<R(41U]H(]]]QL3IJVXZ
M$BQE/@2T0),G>X?72A7GK[VRVQ)ZRTO55)U;UHWO"U8#L%#U&]M>QW#,F&[9
MMW'RJ(TVGT6%6S *,$C38;B%-SI"JO4XS3C3\Q'8^P8B>\>%@*I(K\EA1A5A
M9T*^:,F""/&D82R*6W9N-AY+!Y?'W#W"^N)CC#E'^KR'I9&/7V6))&@_)+#I
M^JB_&-?:5TX_@B=5_P#!PT?^YE6.?EQSW_;V=_Z[/_Z5Z[M%^J7^Y'\E?/=M
M+N-=NIGGE[IS:=U$[/\ ;U=MZ0]38DRL]9*M6+4;IF ]EOTGZ]:F+%9:TF$%
M)))X8CN-N.J4^TO&48QZ*YQ57K]^QORH_5.H;<F@[-\;/D=I5R<&NFHM>-:R
MUZW.)!&(6"+YP/[&Q7V306/ S[KDN(MZ.VC&<J7CTSZ*5J@G^5O]6S0Q@3$Z
M,=]G9-W'2X%42W1-<N9LCT]J3 C_ $##6PW%FDN2L91C,1+^<J3G&,9SCTXI
M4@/ =T_Z$;_\5'5F]WGJYU?VELQX3L*)L2P733VL;;L)L[%V]L*)%BWB:8"$
MK P5;$1HZ643EI=^32UE./;^#BE2X07_ "?6G'92(T7Q?UJR 2!$5*=@5WKZ
M*+BB4"1(&%8.94,8S*BR8TEIV.^C"\9PI*D*_,SCBE;FK6_/#@=NP^U5*_=#
M">PJQ6( 46=!YT[(M0&H"Y;N!@X?-AQ<DAP(;-G.880VI#+#CRL(^'*\XRI5
M0.Q5[YWQ<[V[T&H75?=-4T[V-WC9CA?:'8%4 MI6]7FY:UO&M]R'450M9,"-
M7?8^DVR)"Q+<R0B1YLZ(T-:CJ0E2E:BU#=]*T5PQ7/(E3^F4T_2+L>J&TNO=
M(W]K:\$K/N\33W1C_8PIC85AJ\D(4LQB5Z/R')#! 3(<;F(CH6CW$*59RYWD
M\>-I[!:?C??!ZL4FA:@B; ?LMN+[3T<7J5SAV*D"0=2@@)D,Y+L)\W%*RGU3
M$3X4?Y7,)QS+KF7&LK4J:$;R >*R$SF-#[1=.(D?.7%9CQKSK1AG*G?^VJRT
MT^AOU<_ZK/I]W^;Q4DD]:@]Y%^V/B:V/T/[:TAC=W3"TR3VAMAQ1X"#8M<S)
M\XHR E2A.!; S.26"T8E':=B+C>DAJ2A"VLI6E.<*BNF\($*\U*7::72:Y:M
M/='3/7?2.X>KFB]@K07N3$W89Z_0ME;@BR2"'+5K[7FU[+6'"]?K!*<4D_*S
MU$%J@XE-P6U*^A?BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI50?D1SZ7C8_P#DN>^>?Z4S3O%*
MLZ%L'I6J1T:K$( FSR->Q&*X5*P7"@L8>>K;;8@@2&,R83Q&!"(*;<>82\TI
MYM.486G.?BPI7RH;_P"L_9\)L71=X\IFE^P_>*GTC? ^W;1VCJ2[_?JZ9C]2
M1:G<F"#$OQ^TRI4FSU]B)89P:2ZJ;7;NZA,1QQPJXTTEM2E?53IZRZUN.J]>
M6K3>!2=4'Z>!*:Z0#K\BJ!VJ=+',. &1M8EC TNO0V1V4(1"=B1G(R<>VII&
M4Y3A2MD<4J OD!I>MM@5?KI5MF5^P7 <1[3T+(2F@#6*NBQ%X]&V<^1</VU)
MZN2:S6ZA2T%K%*?CR%29.0R(;3;BY6$Y4K3WCKO6C#5DN0_577JV:+9OFMZ9
MNS7A:Q;//[(3MG0UCLMNK='O4B"9/FU:\-3I8)Z2L,O*WDPIT9S,AU676F%*
MDSV+_P"/[H%_A&;._B9]G^*5T?CI^YU(H/[+MW?NZ[)XI4PK.$39JU8:VN?/
M%HL ,L$43%2GH10<DK D0%3QLV.XU(B3XF)'N,NMK2MMQ.%)SC.,9XI7Q^;H
MZ&=7=5#>ANK^V]/NEQ[)AO)AJBL"INXMB[\VGIW:]0VCM\G.GFJ$WL"T676)
M1[8579'?7A[Z&3&)[3[<ME>,8<<:C4:&E?3+_)_=#_Q*>IG\S_Z'34/\S\S_
M /$_^9S)YLWY;_I-_9J+#U"G\G[T._$IZF?XNFH/YF?7'_XG_G_=_H\>;-^6
M_P"DW]FEAZA4%N[5%Z"=,*_#V1<ND?1>'J<?KG=5MM]EL^D-;C)HT]0JM ,T
MD-"CC]<D&%#;6:E?)2I"U*=86XS[;+GQ*REYLWY;_I-_9I8>H55Y4N]GBYLN
MQVM3 ^N7BUV7L.G.&(EUJ-!T=7H1?:3CLFQ_3"VFE&J%+A@Q]5"B(I XP5<(
M.NL3,I86VIK.5/-F_+?])O[-+#U"I[V&E=:M.0M=??<\?O1W8<W9.O\ :FPQ
MV.NO40?;2 *)3=>T:Y@A5BJ;%1M!>"Q)E6>1&>+9?Q$DL)C.X;B*>RUB/-F_
M+?\ 2;^S2P]0J?\ I7J#TGN.M=5;28Z5=4JT;N%$HE\RT'T#JN,L.1/ A-D2
MQ"F(J;<K&!LV3CVEYS\>,MI5_HL<AGD?XV8CVDG^4U-A4\.5I6MMI;AU?I.L
MNW#;%YKM#KC:W&DD;!/;B_-OLQGICT8;$3[DXI+:A1W'E,QFG74LMK<RGX$*
MSA2OF"NOFE\70+MYVOV=M[5.S=P:\4,TCJ2I[1:ZM)V91W[!K'&SYEK;K]M+
M-OPHX@G$OHB7#SE;#DQB0EW+6$_"I2E:FWIY _ GV\35H>PNI7:"S5&PCK3K
M '1Z/TZ=K]8O1XW,$&'40ET^#$L9C8-7(U2/)'X'D$2(2XZ_5I25.)4I5278
M([X)J1:-?[>Z^]=.Q5>2  [0TR6U9?>G%E-C]X;DL#)-O-HLE^LVUZ<T*V1J
MITJ](:'B6X\N.\M"W&LHCQVFU*AOHC;?3#5.]:X/W%UFV-7ET%1W[YDR_P#4
MERTV*B!KM43PINQGM>(VH'>#3&Y+T# Z2W%@Y:7_ *:QE;WQ*<4J_2@^2_HU
ML'M#XH:Y"VKL*BZWZ[U+M_'V%NOL#KZ;UKJY,7M?6DD6*,U,P9L91IO"C2G8
MN'F)SF8CJX^<OY<7C.%*N,'V7P47"557W^Q_5R\9UE5J.U':MG84%:(,L708
MA8-K:SW%BR6>9$MI6E1"3[(PF0Q(>CXPW\2U9:9^!2H?^3ZH] MA>([MQ;^L
M&\1VUQ/7K154T(,32^QM@OM/$HKVP 5PIM+M(YBW$ EE,BY1C$F!B<F3(REI
MA*,J2PVE"E36VYXVMK]DZK(/B.Q=HT^U:2F;,!$ZDO6V-61"E2O_ %?UEI0V
MSLM^@V@-+LMM 3J(T6&/(4F&KYAYA]O.%_$E2OWZG\0DFA:VG]?[!V0V;;M)
M-;)K=YB$3Y5JW[AML$#H5W4T<!?K5>1%@K\D4&L?M%Q,6..]L>U'88;5A<=A
MU"E5F;DJ)+7GF2C5*UVF3>#NN/$3H>MV'8!F.1&R[%($[=O%5.VJQ6T4MV=0
MH-E0ZM!24+;>LA9$Q08-A$\HAUO[?_=L$K?=+SL,0<F7NCCU  A?<ZX63(BK
M!);ZJ963S8892O'P-&>0Y$M!AA&ZWS%OKXB?1 _K_* .H^$:V)'C-]B:M>LX
M[!L[&BKU<_KR%=&;8 V1*(2R8><(I :BMT+4MY&1)NSHT:<P! B*"X=&LR8$
M!;HK4 Z0Q&A+DW&8_(1ZJ-F4OE+MDQ9DZ#S,E9QER;AM5BL^;'ES(60.4RNY
MLM#D9!Q^!Q50Z.JZ]&'N%MH^Q2HZVNL*FPO*U504+2O?V/'G-W"+&K6O3#(9
MBX:DK>MK:^<%WT;1K?>JNF'7]D;Q8>-QZB6LF3)!^188K%2RW!M)^(Y.4A#E
MWE3(W.[H\3B1G8R/,'$S#'F9YH+/-'.ZKC9&1B*L_,3HO!\((>,@FE,6MH.N
MGHM:VHT.@(^(!M(Q\V2[D"KDM$B;0-U%IX->$D"5X8U_KH)8F"$3-J*3CY6-
M&M4>-+$%WU?:J5:;!%?- Z\1D9>M\UMV[W>2D+'@Q5)79$D9F*!/-=F:1(2I
MB08TS--CW2 P(1BYF9C Q\;&R=O]OH^=)D3T'H]/3T7ZFXT.IN?$JG5S\V6R
M@"J4O$,N23[$=[)[YA^TQ">W-V0)4*0<@;3C19EB[#V".@>3)BI,%ZVL;"?]
MA3%?!18+NR2+++,IY@(T1SRQ+0LJ1[HO)< GP8S1MB1DA1\46'+APM<VWXG:
M^(^X_4\_DW5UU.MQ[[[C]K!C^=,WJB%6*Z\D$9'>?L%(+B; [";UD\85:C""
M%DJAF/=9FL:>1R_LZNPX!*1DG-K$@0;^RR%HMTEE%2J&(T)N3(501E3#C8Z,
MAC:) $C2,Q^6K9,,<<622D+HI;*Q<7)+)Q\1?N#N!I,QX(%F_4GTW/6][Z$D
MCJ#\+,/C/RHK+<U WNQ/1!\I72\G)LCP^?&V-I6,:&SK^2U^WA@+7NQ@K,VQ
M$:]"F5L3+J[498J8S2D_+TN)Z5\5F029DR%0JK+%])CA61U"A55YE*Y$AGB5
M(9R),KZJ53D8F/E%9^9G1N;YIHN)QX8"Z'<>OX!T%C<C1=HT8KI&/EQWD)-3
MM\D-[I=0Z7]E0-OL@BOD"&HB]= UL@)3$*/&1T)L;4@8G7 EV4FJSZU];;3"
M'2EKKVJ!DK$LN]-N))S$>'"3$% DOFAF9B9,E77*8QN[R+MFSDS)E$9:,)D]
MS9:_2XHQN QB9&HZZ6]R_#KH.B[1KKX85\37E;3972S;6N=J]==%)UG>@]L9
M :=TS7IH^L00L(F+EB:O#FC D/7LYY(43*8-")Y &$EY< P%1I5VN$J0O$"$
MBC%55WG'S6,TC-*X-P3]/--+/B@W0V&+E9>( \S;.WNWD2-<C(9Z@.F@T'X0
M &_256T'ZV4WL*K:\<M&N!ON;WGV9$',SM:_A"]A:1-L FQVN\P"MLV#9=-'
M@==DCK65:3NLW:G*DN2''M#QOVGEQOGK#*S7X\B/C89OIM22LRL6)9E@96Q8
M_*D=WC!CQ#AQ-Y.1-"&Q^W\9EXOBUGYJ>698Z^[[?B-Q8'5MQU .LI\;VC %
M3<ORC4[OGJ/VZD3(U(YI\H7*;#>9-66H)?(D]O )H4K;:OEBT[F)[)+6%+#Z
ME-0U;'+1<":^J'6,*4["*V*2JATG1T0!5CQF5L6/S8T5)"T6$<2)C-'#)NQ^
MW,5CR/)'(YS(B1'Q>[7UM\1L=1JVXZ$C69O EH@2:X?*_&:>[L=!RC[D5EC.
MY=)1BKQR!9)R2SC>ZW@TZ0:N&K@[LNW&0L@4F 417Y@T,(RWBOUEJ2D<\_F8
MHPH"*MW;RT54B/1B<J&*&#)-K$ALO$Q<T[I+/W'W$^Q<;'(G[-3J?S221^BS
M+TTAA_&-6G>0J,O/1_N)!^2DO2V- ;;2N"[7@Y,C"EU&AS1<I#E3C/-5(,:I
M@.<B),RTXL!JH1);"C,3+<0E/I[%V.$G[OX5FV-CR<CB#_'2I(N3DK(MF!&5
MDQ94J&2)#MS.X<E&S\LP<+C11G%DZ8\GK"-Z@186_N5*C0_BQ [5O(2:OWZ=
M]@-#(ZD=7&E[NU"EQCKOI>,\C.RJ9\34B+KFN1I+#F,FO5#T>0TMM:<_HD+3
ME.?3.,XY^77/?]O9W_KL_P#Z5_5I7=(OU2_W(_DJH^JWP*6\U'EGN-!L=>M,
M<9XJ-%RQY4 3#6,3DH*E;)E-L+?CN$!;RVGDHRMIW"T^BL86G*<^F>)K)7S!
M^5&F]S>H9CJ!7;IN*YNN[$Z!:K AVJEKJ!M9.GQNOJ!L2@6VA#+0+:J\90*\
MF;R])ANQ&X:H 6<ZR^W(5$;4\I4/*#VA?LT &Q<=?=T;C?A(=NQ]@[GJ6EM
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MJ_T[ TX?)D#$*)/D)&MMY(K<;S"?NK<_+;R.YNUI&=49 K\H6?SI#'C*JGC
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MUW6:3==%F];5U^XWB>'I[?T44_DF0O$X".EL5G UYIKZ,[-(-1DQ<YF8R/\
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MZN]AXR!6&7OR8=JM-G E4V'XYK54K1*J@&T1@XG8PHLY7@PF<@V3FL@Q55M
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MO=']?1!46UU*E2/K0&JEWTP:?!EN'K'EVSSV$I[#VEQ/W3/W?QLF-W+R[_\
MM)&61N-($H9XXUD?,CSF=H\S)'TN3EXZ'(Y26->.XI5XG'D)PSR9_P!.X:&/
MX.F_IU-MI6UU7Q*IT0'>_P PBI=:*\8^J**'U9!5K[I/>[QH0IL@S7NK]'>K
M3UEW%K;:%BL-DF-[ E61L.\*NU+US81GV2@*B_1A\J(KYJ:MB8AV%^-W.?\
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M<U9M5P!+MW";1O454242'M(M.TID=NK@$P:S%DOXB';CLL:DJZ.JJJHF,RM
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M([/#>'!.+"1#)-#OQ^W<1AQ7%C(YS(GE2+7Z#33T$]3<"QU;<=0#8S-XWM$
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M<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*J \B>?\ ;OLC_);]]O\
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M2G=C9";+0# FDDFAS65%QP5@GR\<,F.[#@.!2?(:>=.J?0L=!/D'0#J#Z=P
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M# F%$+/B/]!K2Y;3$Z4F<?[R\**.'#@[0[1WQKC(%&#D@CRY'S8D6"?. 5Y
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M&5;K67+"F8HP.)2F?<"#;65OQAD*1.;K']YN%BR1LW:':,?D/!X6PY\=D.!
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MEN7L,TQ]8/2HU3'QXCT[VQ2^_='.KRL2[IC,I@4Q.SR0AHL5L.%O*GE@#8W
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M)(E2)$A6?><4KZN^*4XI45N\/\$/L1_R66?_ %'GBE:=Z.[*,2PE#T\N"-2
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M[^:!NDD9RP$DK-+)Z#;%GFER,91<'3#S<O$4O*^SMGMM%09&25O0/8-!^<
M?TE5M!K--K85'_N]O[I>=J742Y[-OVF;/HQC>>3Q%!>M$]PCXE4<I.R<RY$:
M@EOALDA@A:QSWROVBAHL6Q[-'=,'$CP,>%$5#L<9I"VY,B,%CN98&5\9#&[O
M)%>'%?#B(BR9X=V+VWC.O%\8L_-Y$DJ!K;T@_A^+4"QU;<=0#XIF\;VC %:,
MK&B]3]U;7=M::[[ ;>,Z[I39'9HHS"!=E!%3I-6[&L5ZMD]?3R$PKK@UMRU)
MCBAV*T1A-OSKD7<< 0!\>MP\O<LKMBD#;)',CI&H BQ75L>,SQJJ2%X<)L2,
MF6''EW8_;F*S<GR9R.;R(8UCXO41U]+=38ZC5MQT)&LS>!+1@FM4^4'KS4^K
MO675PP?:7':@&OA77>NQ=DD#)=S8$X$['-V>':;>-DR,;TM<,RML<;/-YBB!
M3K.*Y752WF2I#D0!&(CC4,[B)%6.,G=O)R<>.'&R3T8JV7A8><UY").YNY'\
MM,;',GUGV]3ZM"2P_19EZ:0PZW-3/&>:#IDV!@$A<3M-/@C@JC< F,ZWWD2_
M/;HQ*+KH$7$$J^(DUJIE)LN4[""21[;X?6572M@,S+L\YZ>C7$K2@WC259O"
M-JSY22KEN714#()<^/-E4O$CE,GN;,1LO,;'X'&C1YM;TVM[EMMZ^FRE1U]$
M*^%;RDFNWF>8GIL%Q,8;$=G&F 6+'A3H;J=LH2EJ/J%,<BB8"#G(!$:$P&,F
M/E:<*(9E"J>XI^SGLE;%(90V.6TH,\X#*X9BSO+.&7((QY&>6")9,A,B51C9
M63C!<GF\E5X;AUQ^*@EE+;;0?\ Z:C0FPL-5!TC'S)+N0*/>8;IRQF2.4$[,
MMH:?G YF&.J.U"41+8FOXVF:;C";#$RX6KU>F/H?'!RSJG+3:7%6JY//16HP
M[!LJ109YP4V;W+.SIL\L#&G>26"(B-X@1B9V7BC9@1E.WNW4;+>;(#:.@]WH
M/7Q  $ZW^)5;XC>67PV%0*\8?8CN87TW4-4:KU;H2U:[S<=W5FK2=IV;8C=S
ME3K"/!;9"4 M2Z?59 YR/M8S;L/LAF',$KZZ(S%EOXKHQUA.TQ.,YD<O T+
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MM=)X<5&<:2\1(Q!++LE:FXJ9"&UNX>;%^4OVBEC79_RSO7K\9CQ0?^="K_\
MT>./.B_*7[12QK96NO,3T;*.%<;8[I^.*CM,HB9".4+OA0MF.$7%Y?\ GDDF
MC=-U@D0B,E+>6U-KF9>RM6,I;^#&5/-B_*7[12QK\VP_,7TF&$![6J>YGC:N
MPIV&XX5FWSOU1M:3X1##^4M18(T+0MFL$HBXWHM3ZY49:5_H/:SC]'EYT7Y2
M_:*6-:^_EG>O7XS'B@_\Z%7_ /H\<>;%^4OVBEC7X4^>'HG23,2'NWLCT^&
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M+ /J9VXE@,&2PHC(.7"SD&X(6+^G/0(;&5N^]*RTS[Y^["S)]^'#R(75EBY
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MRW'!CD_%>QC;;$&ADA.VX2/%:(XR[@J1R%H<27$C.^-92^+VSBN<S,;(Y[)
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M6AF=YL<&/&>);8V7DXH:'AXBG!<$LO)2SS*]%NM_9>_I%@=2#U4-K(;RRV0
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MZ/4 .:6S)!0A[;K=&!OQ1Y>ZS&W[&76/K<3]-I)RH<.)^/X,(HD60R<5Q$1
MCD#Y DE3$>.!U8HO(3PB3'X;'\OB<+ZOEYV8 ENCR^BUGD/4:6&ZY'Y -C(;
MR-MC%9RQX<?&@C$66SU7H[C.?I4H:C-@N]F%2F,H=KU?=7*"%XIJZUU\U[N&
MWQC3$_:-OQ]/KK<.O09$Y=Y>3#M)$_'<$LEY@Y'#<5CR*S*))@%EQFBQ)DAV
MG9.SP]O\>?J^2:?E,B.!03H0\MM+?,<CU#HUV%_5K*_A2R FH/\ 53QB^/\
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M_&\(K,918<+Q4+[GC#N5BFQBN/(N. V-!E-Y?#X)/+<R[Y<\.-398?')Z/\
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MTM8S/HMHQ>I L>'#QGQ6F7W>K-+<CQFH$A"2]KL\F/)A@9S@E;QTY53$AF6
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M-27&$OUG6RF50##4-MX;;-UT4U$]TU=6TF)E?O$^&Z4CL2$8N&U)[+ME(XA
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M#UA"-,!+"]%*V:+9RD19H2)-+9*;()M+MUL7"K4*)%S>1V0NS,T:QM(7<R)
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M2CVXKD-F99YKV$41AFQ7L)(918"[9(E7)F.W\F7+BS9D\P*=F7W3E)YLWTO
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M)EM-E%%]3:]<RU)'V6PQSS=U$A6E?/1"+J+W=Q.Q+) S\<1Y;5DW(;BXC85
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MYUYIY"L+6I7JK*E;^XI4+.]!/;8[5U+;U3!W+*8)[:K(_9LKKZ#K![< G6N
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MXP1Q;2L./%XKQHBI%?1B<G&CB@R6T)\6;BXF:VY[/W)W&X5<;%J2?23Z_3^
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MCT6(] '34  Z+M&H!TA'C>\A %[W8KX6](V[$9;,:.VG7(J*@<_*#Q\LR;V
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M^6NQ3C\#C>*>F@N+>Y?A_B7:/S85]<IJ.U]\7>Q3EEH9<5VOW%N15-KLJL#
MG8*R27,PB,K N[0%TR.JO$H].F63."!OZ<99=56*YENQVEYO+[8UP7(W9&0!
M\+L27,@ 8C'F9Y8=K2^8]L3+R\4"3.D"]N]OK%B)/-3V#^2WM%@>EOB56T4?
M.ENQ J,^_.AW8C5>M]1:VU5V_P!WF&=U[F1I(KJX+8;3)U#/UOOZX6J]K&UB
M!F%7C==KE]F0XCD&&2C.S;3'C3;#*B0P:82'+,[02/D9-XC%N;QR) \9QU\J
M5I)8 8X)<:-E@R,C%#0<% Z\)PJR\M/+*L6N+#6_LO>^HL#J03J VLI^9):,
M 5-#IUI.]Z[[!;) [(,ZNV"/K6C 57:>UUKRFN4IS.T]E)L&!%F?J&L=?6W8
M<^VEP2V&8,)Q4S:2F(L>/B%6,.OKJ582*$#Q&&0#01XS1''C+@ ,6AP9,2)_
M,CC;?C=LXKG*R3D<[E(!/H]=Q[6O<_:P8Z$]9F\*VB6K0G!P;'S4J8/#NJ?P
M9E$ID]R/)4\U*=CU2U2R]GJD-&93,UY#0*R':^WAXH^AB@49M,=N=,Y81;@L
M,2L%\"JJI;6QR852#()L0+Y>'B9C;85W]R=PLTK8\%1?TGV^G\!N1^BS+UTA
MBTN:HVW/\Q([9Z4N%^'E;0='=XZ90J5L>NV.N:MT#I:DT)X,+-:SEO5[YF;4
MM_Q,2H\"VS8L,H*HPV/'K(=S$YUSUUV6/,@(4++#(@  $F3YHR69T"K(5FRH
MLN53)CXTA3)[CR4;E.3:#A,>**K:J?40?8MK=>FBE1H2-(5\"7D)-?5'XUX$
M.!>^U,5B%!'O#YNCAOTZ/%0)D!H3&OY[@\,JHQT?*ZS'183K:X-7<=D%1<-Q
MI99U921+^'Q']Z,A^W^SYUNRRQ<JV_1Q*QS$#2?4GQ9SE@1+G!4QYY%9<)%P
MXH;\EPOZW('J*:>KPG2WXOL7J!\1W$U)[R%?P#.Z'^"SOK]S"S\^/JY^L)\5
MW_BT^A7^"/H+]S2N\4J?'%*<4IQ2J3NV7_CM_$C_ ,C7?G]S>I<4J['BE.*4
MXI4<.X.Y3_7;JOV&WO518<U9=0Z?ONPP(FP)FK!$2U5KL\O AET#94$@L<_)
MBI2\EE]EU2,YPE:<^BL*543M'NYY3='=<]<=KM@U3HP7U9=2F@/?K]6!;NCW
M9L/O2U4T# 2T\2V;(#QB(V-;DJ<7Z26T.-YSA#J<>F5*^@7BE?&9X]<-R(/=
M>/E+))U?D=[A"/IF&)=M6O!S;<AP:'GU=:HL*>U8"@W#@NE0W$KNQ2'\[87V
M*Z$RE?Z5=L7C^[#LR5?E*.V8Y#(+XVL61F!Y5R3N(:&-]N1RA79Q6/)]-QD<
MG*YQ9>G3:YN0.OSB+=>H6PM[2-$ZN1=R$6K!<K3.P](D2&9[4IJ3,ERYA E<
M(Q!BS3D@2$XB4#MQ3%W@7,S%2-FRA:62NV##**^ 3"I\!YYSD0IQRL4:M&Z%
M5551,9D,"><B)'(6CQ7Q8F,\4>06Q^WL9FY+DC/S>2B+7KJ=?M/734C5MQT)
M&LI\"6C!-<WG<X4])DNJ81'^J$I,DH69A*1B"A%5L1DU9:>W[<+Y)"D [!80
M:,_*(RU0*$WEW,Z;RJ(++%$-S-Y:*L<9>^^^1#%%!DF[;C?+P\++/S#O[D[B
M?9]/!0^L^TZG\!)(_19EZ?J8?2:KQ\L<1F3X]NS$$A':Q'6*I@UV 7$R4/OD
M*QL:@#7X+]>IKF1@ZQ4D(21$<C-+S3M1B9+01K,RS$YKS=-HFV)&%E,@'17R
MD9,IB5VI)MFRX\R92T22E<SNC+4YF88."QD1IZ:G2WN7X?=HI4=2/# OA6\I
MJ*Q71_CUBTG7M)N^H+D!%DB6=?$JL?W??-:EJJS6=AQA[CX /8]D8!#SHPVE
MB6)K[<J4U0Z:[)L-@=(%G8PY)W;86WK)YF]V9W><2"5O(D>26';)EK/(!C9&
M3 %FYO(5>%X=8>)AGE9Z?5:WLM;4  Z+8>( Z1CYDEY"!75BNK_0/:FJQFS]
M*]<9NW57[9OWN@E7H?:[8N9C7WVBTB%",?+D]DE$AI.!%9E3*Q6"KCAAS#$J
MS6M<(<VP.Y$CRPEG=]LR^8[/(P3;Y0$$TDV1CG;$8588N7DX@*8,93M[M]6R
MY,F<!8^[0::]=0 #UO\ $JMJQ^;+X0!7+Q][4ZUZ>V!W? !\)U]1[/O2FXH-
M1D -X;E(1ZT5T;6;#*JAZPD(1LE>$EWFEIQ7H4B,]LLRRVVY(CU..ZVY(2;$
MD4R!TEB!N?DXC1MBQJ221>+ ;"B;K9\;M?$<+&,CN#+\#1AI:Q][7W'[6W'W
M-.PUM$M6:-]Q.M\A37P;-7(?*.0?CESJGMF>R\J]CUQEN3C];HT6<8BV6+!P
M-LM@$H8GVT@TU2:J@>%8?D9)YC%42)U4&-5542,@HIR(E6'(8I"T*$Y.)AY1
M:'B86;GN=:;D98HJ&WK]?K/70ZCK?X69=9#\J*R FH^&O+3T)K5FE5.?O*4F
MY0R,*&^+53=@#S<.P2DJK<84N16ZHW)#75@"E39:>'B^W1JNG%;IS"Y[\HAA
M&KY(58T#1.$555"_F"9C-$JPY'BECG<'(Q,3)82\K,K<]SKIQ\4,1'3J==?9
M:VAU'0CHS#1!\J*[DFO3&\M_0X:N'(8VS:FI#'MRQ:8&GKW6)[**L537J^Z$
MC?96<%IQN,Y*>17F6$2Q&K0&7YC>"5OF^XBLE\V(@;)8)E/XTN2LXR7V>@+-
MFQ9DRA2W@RNZ,Q B?3\!BM</"?2"/<MK?Q*5'YL"FYO*U8]XES(>QZ$W'9ZT
M]#(C[1W2[*$P,D' L;WS461>7+?6,Q5;8<5DN:'#_C+!A1CX!-.;:D6JWJ>E
MQAT?-F?SG>1VO$0[.[2%P]V^FF9\C& :568+B9F7AJ&S9 G;G;RIB1Y$Q6MI
MZ?=^$6!Z?E*K?"/G2^(@59\VTAY#7PLM3U$VX342+'&$+-&)L6F:X9$)9%6!
MZ.;O<2XEXBR08254R2V859<M=J7%K,.'&YD9V1C=FC$18LS2) T9QU$4EY(0
M8L1L:-A!E9&.&@X/'9>'X=9N5GGEJ.OMO[+WOJ-#JVXZJ#K*?F260 5 N18@
M$#L:1(V"QU5N'+WO?9,]T_?KL8BDXUGZ>4F#+FFVVT#X>RQ5T,-LQI7TY4:9
MMTHVU"%?)5^"]ES&X>("& -$8G1?"JXS1MCJ)%1%DW18DN)"QE1)2V)VQB,<
MS,.1SF0 L]=3K>_MO?3T:L&.FGBF;PK:(5D'49^&XH^^J2+>0C2'6HB\O!*Z
MNM*8^P=AJIHL7(JQA<,0I&4@S)^OXR0GX]J@T]M.?G9JI LZ08XM8(@5$MMO
M_6((XX<C0,=<O"P\LVC&_N7N1BYQ\=8]I]^OV$DC]%F7K^IATN:FS[BXCJY$
MAR1"S!?DN/NR9XRGRXDFFP4CR2YQ00W*#4210@LM,,E.%I=$:E#/IKU?3,MI
M"1(0VK,@BB"R"15 "I)DJRY+[T"1R%9<M<R53+!%D%<GN+)0\ER1@X7&BC9T
MU.EO</AZZC1=HT)&D*^!+R$FJ!NSG7+;S?4?R+TY4G3D77PN[;WOKCC^IMG!
M=DN$8L6!N"GU:MBXUX)Q!,2BTBV%6UAIV%"J8))RBAK"3I)EM%6E5P&OO$RL
MQ+.V0C"=A%))(\>V;-7*E40330A9^X,I1Q7&B#A8)7>;?@M^#IJ +Z+M&H!T
MB7QO>0@#,>OO6'=8S7/C( &+116ZC6=BTC8K,VN:C-E]N'AQ'4K^XZW0+*%M
M5EE:N@S+24"Y(0!TN"W'BHC,6ZP9CPT06\UE:WFO(["2TC,TDH%M@^FFFEGQ
MAMCV C%S,S#'RU,?;7;J&0Y.10>@#IIT'X0 #UO\2JW76:;2PJU+L>OYW25U
M7'<Q(COLU#X7(,]%ECRX-PV-7)#"(TVS(8FW@;L$Q%4^PU)PU8-R&6%DYN85
M1@1FG,S;\5UW;TF1R=?+Q'1L:,AB2NZ'"?"B;;)(F[%[8Q&&+B#(YW(=UCXA
MZQ;VM\1^UMQZ#XIF\36B J(-^GNYJ!9V03D-QGRWD0G-*([&%,?.L$J]: I(
MM-)U.#\=FAFR,= \@4C)05N)%I "OH8K\-]YS'8P2;$)693"GA"P%#%>>.*.
M.6Z8S8\9.1CP3EH.$QRW,<PTW+311+/47]&OMZZ$DCK<Z$C60_+CM&":L9 /
MJQ7PDV5+6A* D<C*G$[*S&6MT2'@5JPES-RJ$?Y9M0:.^@+8;&!;^5"1G&J)
M0VED)$V9RT:!U$4*ABVQ%5(C)I(QGACB@R3=_-(.5AXF6=^6ZOW%W$RXT<$%
M0?6?XS;IH22/5\+,NBCY,7B)-45=FM]Z@A@-':;@[#"5_9NN/)W5;9?:E@D3
MZ_OTT%7^R^Q,MD+7,Q!,,5,K6!IQEQ P4\H'K</+;=PF4;*REMPNV<7\,L,J
M:6,F4LPRI+6"G;/GQYDR=7*97=.8F]OI^W\6QGI["/<MMH^Q2H_-@7365JM
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MF7XC\F+PW-16+E,1[&18?+O#2D7L;OB9,9F7'76O2<-NN=4RL,G.(D*RW.8
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M*1W>,M%B28L3"&>>(/C=NXK+QG'#(YN>1U==!8W]FZ]]1UU8,=0#K,WC>T8
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MCN59?,=VDE2,C:!CS32SXX(C,8*XF9DXBF/ C*=O=OJ^7+D3@!>P'LM87]H
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MH^*2,$M)*3N^8[.\H7T?33RS9&/>UM,3,RL,%8AL[<[=5I6R<BI&N@]G0?G
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M<MMH_"%*CWK ITW2FN,=+<+,5F/[4.5&R!B0(4$<,#.!GAT63;*U B5^V3)
MRK3*P-<=/5L 9<?ATR$\]>KR[)/284'%I)!D!WD/F0OYK.S2/*)1(RX\SM-C
MJ),A<APN)FYF*JR<G*J=O]OI%QT61D$!;0:'3T6M;4:'06^)5;1!>66[D"N+
M'RSC,5IG,.7\\T);'#XT=RPQIC5B+/6.MQHM:M+[!>VPK04C/' @<ZZS.V 5
M9=N5U<A@8<&%F9'97=W+)Y9D+NS"%E,,8@F9I\<&/':",KB963B*T7#X[)P7
M K/R,^1. '\=K#KU-QH=3<^)0VLA^;+9 !7'WH9!#SBY@XC%FQWW)#[TTC>(
MI2'=#:83F9+S:H!W8\+9MBAX2[B-B,9W.<BIC-?3**.QEZ?'C,JJKQ2QL  %
MCQ&C;%BW#:#OBPFP(6\)??C=L8LAE?ZON'*LD:'U$'WM?<?M;<?59IF%O#$N
MOF5+9>S)>DD(V6&T6 I.FE3^);:8\UQFGVLZ:LM.1B21^T)!EH!8CX)M$^PR
M&VZ!0FF!3$\EF(D\O;'$A\PF&-5CBVFZ Y,$44&2=J>0A;,P\/+)APD9NX^X
MWDS),;%$G74]-3J?7H22O6_PLRZM^IALH+5XE$H<%YS,PI$%YB/EI\A\N?%U
M63%DU(0V%LAPN<K.71=2)4D+(0&+%0[;HG6 =Y%3J+<RS3)4QFBJ'0!5\SS%
M1%"1O.K+/(9H8HXLBTF2F3(#E08^25R.=R%;F>::#B8887?Q6OU-N@L22- 0
M/"2-(A\N.\A)'O8>;:6RS"?Q#7$?'MH^677Z7*@RJ>&66A9;CSG2%>US)UM6
M)>90^"[F2&TZ#?48)*(W:>PPU#,DJ&66TB2*YU\W*5UR9 C>) DV:N=.NR:5
M=F3W+E(,+%&+P&/)([IH-+>Y?A%_<NT=!J(5\3;I2!7K9]E7R8T?EC*GLUX?
M$A#849E;R\9E6RJ"P=2M\CY>,P.8]VQ5P%8GLM1O5[8&P'5OY'#E7>2V_*R2
M;#SG9W<FU]N/D22Y.,-S&0[<+-R\)=TG@[;[;18QE9(6_%'LZ#\( !]7Q*K=
M-9IM=JUZD.1)C"(\-8XHV6CPXS:(;)&WPST:X&W"H@9#@'I$0]L01>K)#<)P
M84]48MN XRY8+&L?3X,:.[=B\,AEF+PM"S,2S1XS1'&B$<DC/"&API,2%ACR
MRPA\?MO%9>-XM<GF\B65(ZBPL;^\WN;@:ZL&.H!L9F\;VC %1KW[H+[_ ),(
MLF-G2!E0+:NN%/DP@I F:-/F;UL>DE)%]8V53B@&YV--@M.OHH4A(#XB%=KE
MLN5\!B#5!V):,4<;QNNU7B\MX]JK&F,8VQXS+':.8O%C/APL9\:&<MB]O8[G
ME>3;)YO(2$22#[;W]-[W-CJ-6#'1B/%*1L2T8)J)6L/&12M*$[#;JCM1V!?+
M25)%KE:R9:[F6JD/KMG L3V-9V$?LLJ4J>!<>$L!;S\51MF>3)?9:JQYT[#\
MIN(E=PB1HP2T*HBQ];DY..BP9.FV^[-PL+*8&=]W<?<KK&(,4C;4D^N^OX#J
M/T69>GZF'6[5:<_/B@WUJF$XX*;!DOY6](,U^BRP$RE <1RGQ2X&)E?HQO6U
M8F(BR'8&)0+2=>E?3A6"5W(N.I +EQ@*HF@D06 27*69<F7<EE<I-EQ9LRF5
M5E\O+[HS(_JLPXO 8JH7PGU$>T+:P]FBE1II=8%.U=TK5RC.L1<Q&HCL:)*C
M+",P&![ T"\#<"#G[. C#@A^5,K]1GT\+(=, @YAV0/UT,?=N-M<FV>;$AIE
MW&2K22$R02"4LS,\RS"9Q!*SRPJLV2F5(JX^5DXRI-S4Z)PG"K!Q,$TY#30:
M$6]EK:C0Z#:-5!TC'S)+R$"O#"8WP1&HZ(;V9382..@1!GU5AY!<A)M-7APP
M%NDLD+0R8FM/GZ^!/NM2+1/0]>KVZP,9@0,6DE;<[R,R[#*SNT@C(\M%QYV:
M;&!2 QJ5P\O+PU9,"$IV]VZDF6^3D$!Z![/1?KJ-#UO\2JVK&\LME %>I3T*
M:QE;DD>78*15J;:<FD[U%-PKH?\ 90Y*RIP=8M@@]DVB'ASV,8C'=WV&-^F9
M%T0<C"K#S()-JAX'A<7(6/$:)L6+HNCPX<N# VW?X\3M7#DLOU?<.4Q$:$>@
M@^]K[C^ L&/N:=A^+$M>UZ3&>3(F39L6<B8FP$)+T\LLV@NT3D1ZI92Y,U74
M,SSPVR%6F@5A.!T-3KE*0U1J.U'!,RYSE$!C*PP*T;1^2BA(Q%Y9C!R(8TBF
M)2%X(RV7AXF26BXR,OW!W \O(20XZR==3K>_IO>^A)(Z@GPLRZN?E160$UY>
MEI0]*D2R3$9R.\7FD)Q$]"KJXCE<&(KEB)DSM1P_ K4BKBY2 )<H#;<'T4:Z
MBETIN6?F32""(I1(H8RRL(U1$B:;<)G\^&..+)L\XG=3EX^/ED3<K.K<[SS0
M\=#CXS/3<GU]3;H+$DCI8>$E=$'RHKN2:];DJ-!>8CXF,"'!TIE*5// *'.&
MS*2!<E^^I4AV=6-8$=85*;\<=G.)032E?D9E.?4KT1;0T++(ADDM*LR'3YN4
MDBY4H&T ;)\],Z=/&WR\KNC+3RE^E[>Q69W0V&EO<MMH^Q=HZ=5@77Q2M7F$
MJ.XV/ABEQ_;7FO0AS N ,')6Y$9?MM6'AZU:9;L46P A..V"M@;"ZN* CO/7
MZ]NOE),$?Q+("7R<DWTF=F>1Y-'(QYWDGQU#2&9@N'FY>$HDS'5.W.W4CPXL
MC)H!T ]GHM[0 #TM\2JVBZS2W8@5Y;7&G,MQH.8A1DC''16VH3<RWQS,6RE7
M3X(7#%V%Z*7N(*U&8SQD6)*K8([.+,N6NWNPJQ$BQ7+,6@<RSEHGB9V)8IC-
M$T,8AED:2$-'C2X\;+BSY..'@X+'9>&X1,CEIIIE=18:@_AO<W L=2"?$ =9
M3\R2T8 KFKVY#2W7<L$FR,>8\E$AR;;(YN)<#*!\EZ8[#^1,WH'LJPQ4L2WV
M,1CFZ3D9 L>D91H"G%P&,3A$O$T3*+C9CF)L6(N H;?%B2X,+%HT??B]KXKG
M+R3E=P9(577VW_#?<?M8,>O1IF&U=L0JN;R#26OM=T!>*SH4ILEW\H,U[!^W
M6=YHW+;"6&M6 Q,5J:(HK>IJY49H.8/#,,"$/,-4^FLY'1)LUS$%\0Q\9-NQ
M(454B"[+;\G'C2#)-HS&N[,P\/+8B$%^Y>Y7,_TV*)]I]O4]?Q221UO\+,O7
M2&$6NU6"VJJ5VU#"5?O5?#6 9F6J:8&6R'6APP5-HD..Q+(E9#,4G5:.:UQ!
MRQ!E$!K,H-IT0ZV"KB9]RG/2$0!'D1JB!9,:1555"R9 F7(D\R)%BEVS9D>7
M*IR(8<@IE=QY:'DN2.-PF-'&S4'70CW"UA8ZC12HT)%UA4[$O(2:PU&E]00'
MI*(VI==C9+]N=ND_$;7=&JDY%^B5W,B7:UAS@^6)I]OK%-?]^(V:<E0=:@9"
MK':'2-MGQ82,C6R TLI$JR*Y)9I,A9%R'$,FZ6(++EKF3*(<B?'"9//Y$8XG
MBQC\)C2S&.F@TM;U"UA<:'1=HU .D0/F/>0@5L*+&3G$=IB,W\.?H8Z'!'AW
MIR/<>>?N-:#BZU=G&G23WHIRR *X>=2F:][NPMAO-LX'CL9))-NYG8BWFNS/
M($T &-/(\^*"(QTP<S-Q%)B79VUVRC/]3E5 '_!Z/S@ &Z_E*K=?UTQM9:K5
MU5VSV#U.\PF]3-(TF,VA!W9UFZZT^1<+)>7-8ZXJQFS7 @_2#EJVR8K=F(6Q
MC;MCF/0X-RL3(K[4&5>^C$>++',Y\ _>CL.#[0BZ211<I$PMM:,QY42B%HU_
MJ^(85M&O'8I>+CT"8TDDF2L['E>$_6Y!]!*'WW4ZWZM?KO;5SJ !:M\^1#NK
MO/>>@]A6J?U "ZZW=H#9>T]+Z-V7J?LP"M.\0FZ/L0\U?*YKRC)U:\O:6L+=
M0URF[:/D(R!F@(<J1)=C.0&)<;Y!KGZRKQ]^,S=78OJ'U"WJCOAN+7%?*]5Z
M75'-'UH+5CVGOJ]1V0FPMCW*]9QTY<[5]Z:KS'VD$NN*(3I>5/QB$1'P,H4J
M).VM*[-T[Y9>U];K.K]*[XJM=ZCZJW-NZM6Z[W?0VEJ=2[=8]AULV(K.IZBN
MSQ=@:WAC;1-B/U0E*=Q(9ER7F6Y$E[$?*E1WW+EKK1HN5LKJGTZZSZHH/8:Q
M/]*9'8WKOO[M9K?8LN;LVJE7HM5+:[V56Z#>K'1]<CJ7'^1AV5D7#93&;:AH
M?:=6^M2KY:SJ^B:S_)YK/:J($: W*V^+M@K:+]%>FKO=D))Z]H6W.*6R?,(V
M%S#+JU+C1LRU1H/QY1'0VCTQQ2ID= NM&H[!XS]!U/-?G@7=[]1].0]IW, >
M-P=FVQ![5X%!!\CLA^;+N3CJV9;J6/69EN*V\I#"6D9^'BE:7[)>&3QOLU7>
M781SKB*D;?$U>P[@'7=JT7 :>A;4I0N'<,["&SA1N&X-N=O-TD:X<(,X2\1R
MQG*_13CN7%*A[0]E[&">+?J=Y+J?6^NE;[F;@VQJJ3<K\WI^PO5J8,[N=I*;
MJS9$9T(QLR)9B)*##M\.<R_.-2F,2ARL-L,H?PEI2K;;=M?;@CRD:(TFS<8N
M-'7CI!V*V,2H;0-EJ8[M#7.Y^O=?@VR98ER7GY,7%9V*[$C0FVF4QUX?<6M[
M+R$L*5$3\H8^'/CA,84RB2E78;K"E49ST]N0E6YZLG,=SXDK3[;^,_"KUQG'
MIG[N,_F<4K4&S?%GW"V8"T$(UQO*K]1,4+7]HJED>U@Q6K;-!2A)_?\ .UW&
MJT\WK5DC$$9B[?AN?]Z)0-4!R(]AQ$O*(F4*5W^MO&?WK?ZWTKK]MWMC53@W
M65EM%SUX:+ZXI1NR K,)HU;$:=F*=HU9U77/>UWL%!6PAR6(2RD"5\F\\N6^
MVGV%*^?@9U<I54W)WN[";'O!@Q81_=OLC:=X4F'NFY::C/Q*'8R&;K>=?3]=
MW(*0%5@)/O)'!%TD,P5.,RV %<<9(/S);'Z4=KM?[M.S%A!>>3MO%C&W^L.9
M%R\V:&'RI@N.SH5;)Q\#<,**17YGFY#!CXD+=/F_SS(OH!,Q]6FU03<:Z_"6
M^(CY<8N6-3$%>*#IF/BCW80[L!$"P$5]UC.>UN[ZJAQK7;S]JFRWWH&PIU8I
M2Q[II+EEG(^9"ZV"/,BH_P!6MTM>&<X<3K:-H9FE0"P$N4CIDREU2SLLV:F;
M,IE2-MF5W/EH<K,.-P..BM'3K<6]R]![-%VC2_PPJ=JWE)JJ>^==]/5XII]B
MJZ^[)[E"6*Q7ZM&H6A^Q.[$2#0.J;?V;82K7R>SMO0I-7*U&N5*"Z-'PW"OV
M;;F),VEQR5*CPT[4CJ4=V8/O61V>21IPZSL()9)9<<"3(7+E48^3D8P7)YJ9
M%X/A%@XF";(:H]'HZ=!;IJ  =!M&H!TC'S)+R$"LHTMUSZ6]@JW0Y.RZ;V/U
M;4+_ )OPS80[<'87:K87)39X0)L:M4[7)K&[C>NS,H7-;3]&#'2WU5Z9ARP6
M]Z'!;BP5XYYI(M\SMXPTCEI'VL#&!BY$TLV+=8S&I7"RLW$!BXZ(KVYVXDF7
M)DY*R #8>X:#U^( !NM_B56U<_.F(4 5:([XO.H1.H"J/ K6U$TIAK#M0K=;
MW_V .5\4S:F8U>JN*(-AW,66LT">L3AVOK:^0,;+/L+FM?2*8/4\]:[8[EF<
M0R0O<DB/%:)L6*UV(+0X+X$+>6 @DQ>V,639&,KN'*\$=?:#[VON/VMN.OH:
M9A<[8EK\2_%9U"COIGHA[Z6MF5]5P^YVV[)&Q:DQ0F-81$O%ZU?&Y]J&RYV<
MPR9$+'1(NUG2BMTYEH;%FE,1'NW(B%4"&((BQK$4,2G(A"P9#F*#Z:-FRL/&
MRV:+BHG?GN>:7D9L?'J3[?3?TWZZ'4:G<?"S+JY^5%9 376>/[250ZXW?N[K
MZAD;TR JN_QB(D786V4V4]4H=;T[6*^<)2K4!69E4TO[!-T?9+6J25+UQB;F
MJ53$HW+7*:Q8ZID+$+*R2QQJJK&THE\YQ/"JPY!#Y,<T@.9B8F4RR\M.'Y[N
M!X>,BQX".E_6"?3:UM#J.A \+,ND8^5$"Y)J;.U],5W:P8/4KHY9( ,)88Y(
MQ6@DD1KZ(68J=-,!B%0ML:?",BJ@-I]&M#[3@]+^ FF0$KWI+Q.[3\M\R2/'
MFH3N62"5&N27RA,N5+;4KLFS(LZ=?&RA,ONK+C$48Q>W\<DA=?81^;;:/L4J
M.G58%-SNE-1?K'C*ZHZ^'21="H=CH!DY[0BQ&JF9G [=8@9"$(-1*289O#I*
M#!B"*M684NL!"OMOU(*PNY7*>F:]&'YAY%R \CNKQ,)69F<R!PQ&/,[2X]GD
M69K8>;F8H#YC!.W>W$3%7(R"M;3TZ>SVC0]+?$JMHOZV8EK"I-T+1=*H!I@Y
M31)-LH6'+%K@,*L-O@6R#=;D]?:E$.5JR+C%-F1OK;<F=3AMB<:,WM[WK':7
M8%3AQ8:KRS(I=I)/+2,R%W,D>.R&",0RL9H=T>,^-$RXN1D8H?'X+&<<-PJY
M'+9$TP >H7O:VA/4W&AU:Y\0#:RGYDEHP!6ENF-,"UO7>W7!#Q Y#MO:3M78
M9C)FXM[8&SW[;O$W5B3;3].C"R!BHW\Q768LR# :B']KV*,H/#3"JD*;+D0C
M""001W@>'8/"(\9H6QXVD5(TD+08,F#"Q>**0R8W;.*YSLULGN#*6-'47.M[
M^MKW-M2-6#'0D6,S#:NV);U,%_#BUR9D]YV1E63D^9+)&7ENR,+0S3[*8-6.
MH1\I8CS7$M5X\<KK2EOI0U0* U[22)%4Q[%5(,=0H^4BJD0 %KY,$<4&2VK*
M-V9B8N:P"$OW)W(^\XV*(/K/MZG\!)(_19E_H8=-S57?O3HKL/<1DX;?[+77
M4RI5ZV,:FCZ74J?1H&*@3H]=H=F!6-YQDX,JAC6( '#3-.P%KKVM6%M5X9%,
MV.0[AO"&CE54AV2H\80*-V4KKDR^9$@1RLN8N7*IR(H)2F5W'E*>1Y0XW"01
M1-.HU-QK_<VL+'4:+M&A(\,*^!+R$FMJ=8.I3G6]:&WKM9[I/"0IU1&V@\LL
M!OI6+".N;2AE+NS9+$8H%>VE2FI;Y)I,48*K&K!4M5DL$=^UR(0Z/8O&ZEG9
M9?,$CDL[9*NN2XAD=GCVRY29TRB+(GB"Y7<62J\3Q2XW!P23.U'LM;V=-1UT
M7:-0#X81\Q[RD"I;LQE.9C16(?P(0V#'1(0T"N0EI#[[]NK 8%6[DZTM2',(
M<L0('87/=)/X=O\ L!UMAL>.SG>4*'FD>[$RNS/-MN0!C3RRSXP.HN,++R\-
M=L";.W.VT:1LG)$ >@#U#0?A  ;])5;K^NFTVK42N^<CXNCO;:1'ELMQ%=<=
MG.KELV@Q'@/CK<.(38N6[')BJM-B&;#.PE3DR'FVK#MXS'42G8'TT<PV[5V.
M-*KN7CG20ZDQXKQOC0E7)=-\."^%"WE,T0DQNV<1_IL097/Y+,CXAIJ"/:U]
MQ^UMQUUL9FU;;$M9UU>C8=ZN]<G7(41<%_K[K*0Q#4U<B TE#L5+J]<)3B4A
MYMN]V +>2\- <A*C);LNR)T=JG5M$.L09TU^T3"!A!$?+FC=%.Q8X#$T"&:.
M.&*8M'C/AQ,<C'@RF;'X*%WYKF6GYF>&",==3J#?UF]]"21JVXZ$KK*?EQVC
M!)QSL3U_V)NA^=*K^Z"FF6V]7;<JB;<%#@XVP!EBLB:W6K!?96PA."0&O!:F
M*"-5VQ30H]^ .C/(HM(1(F_-3N8E:,A8(%4[O)141#*/&QR,>*.#)(>8NX.;
MAX665?,EW=Q=R/'CICXPG7J?;U-NFA)(Z6^%F7X1\F$$W-8IH7J9=])V\68L
M.\K7M&'65$R,1^_52JU2_ ;8)U?0Z"9DYO(QI0ZACM=4ZH)DI0N/+BZ;@EEM
M_-$[<^Q%:KNBE3Q;)$D707;*$BY4MPHOMES$SIUW-?9E=TY:;F.+V_C^)J#Z
MB/S;;1]B[1^; OY4IJ97TM2V4BT"U>S[8D5@6T!@B6VD#H<BRB!#=<N#[HFM
M,U@4^\9! 3;CL*FPGWKS>79)Q^% Y:::&97DR)%='$K,S2M+N$K#'F=IL8"3
M(^H<+BYF7BJLO)R*G;_;Z1<?'D9- "- .EO1;IJ-#H+?$JMH@^;+=R!5-VS_
M %K);4N@:=KL-8Z5IKLSU:J83;-<I]/^=$CCEIC6S7VEE@-E, WKCF,/(R#4
M%UY#$J\J6U8K9\I%1&BYD%D=\AW9"ID9F:1(MAA08\TC38X9,>2%&7$R<G#5
MH.&@=>!X%9^4GGG5Z+#V>B][FX%CJ03X@&UD/S9;( *N5<CYDMNONQD%6BC4
MIQMMYLS<HA^);S*8ZGILQE$"R;)"[&/PL8>RRF(;W.<BXB1\#:*-^-R5E$3+
M&CF%X2H)!BQFA;&BW6127@P9<*%_"&,F+VQBR&:4Y7<.598M?7K?WM>Y^U@Q
M]S3,+#;$M<9*'5XDSR;CTA,C!PA)DDRKLK)!$Y3%1L98G8Z;%P_*@&YK30"P
M'@36)IYQMJ@T)EL:S-(.3$R*4QL0*I7RD58XPNPI?)@CC@R6LKQ*6S,/$RV,
M6(I?N/N)VRGQ\91];>WJ?P$DKZ_A9EU;]3"-H)K"]F5"==*%?JJY'AI?LE;M
MPAQ=B0/"#H,P=67:@8,EY P4? 57.OAD](DH0@0YP;60I:*A4F2-JFS)B*[X
M718HBK!E15 #3AER)#-%&L<Q63*7+D4Y4&/D%,CG\A6YGFVQN&@A@:=;W/M]
MG06)N-%VCPDC2(?+CO(2:K8A]1N^P7;,BZ1NQE<:HLNZZ8LEAU@$!TK1IGY+
M3&N9%>8UB)OD?2=HSJ1K20 D^;CE%M3%T\)+2HVJ'9GV(^<1;'E!9F2;S%D-
MV:3+5URY0KDLFR;-7.G4)+,H3*[ER4&#AC%[?QWD9J/9:WJ7X1]B[1T&JPJ=
MS;I2!5E>OZU]F:?5*?##1 F! ZO@8M>K[D\XQ%5$=F6^M!0$#8D06_):&QW'
M+(!#VA#*8BG'[]?E9=^FCL[#OMWY$[7_ %KL[R7T.W&GDER,8;B9#;"S,K"6
M\ED[;[<41C*R1%N@'L&@_"  ?5\2JW36:;7:M91[>)S+<>,RR19)L1(+3$4>
M0M\(XQ;RZS0</ '&78ECV(-O9^"LM"'DE1BNWC3"[#9%CZ:/CQWLFXX\ADE9
MHGB9G)9TQFB.-&(I9'>(-!A/B0N,>6: /C]N8KKQG%KD\YDR2(ZBPU!_#>YN
M!8ZL&.H!L9F\;VB !BQWK+QH72SM@5DFVH[3G7W;\B38G[Q ]MR/;1DL),?5
ML:9"9:GQM@V.*F 3L$9A)?9YJ,@!6V850'.2%]F[%QR>].(@\O;MY'&58QCA
M"K8Z^8@&([E(WQ(F\W'Q)G.+P.-(>1Y5\CF\I8A@R3_5Y#?\0ZW]>A\0U.XZ
M%AXI2-B6C6];"_)RR4$KT2\6@07*:(EJAI'N:<MD&"KYIZL";5V$0,J\P_[.
M%H$ILDX-,1 2_E#DOY1]325):6I/Y29?^>3_ -/)_?M7>5^$>X?R5/;R4Y]+
MWM;U_,_DE_(#G^D5TK_G\UZFK>:3_894?V, /]:HG%*R?BE.*4XI3BE.*5"7
MLS_"2\<W\[LEMW^))VDQQ2O7XZ/N]1Z!G_==N[]W79/%*F]Q2OF2_*!/#3O3
MR-R=,[5ZQFZ8QL'6BS$.YU*YD&Q"K:#=B-P:\FH%%QXT 8?@.%)SC\J9.C*;
M90U\NK#B?A5RG"\WS';G*0\WP&3-A\OCDF.:)MKH64HUC_;*S*P((*D@@@U2
M2..9#'* T9Z@]*^5]G\GY[KNLEP>P_(/U:T?8X,LA7K+IS<MQV,,M=9:C$'9
ML<00:>JY<39J]+;D-S()&'+GCB++R7VWEJ4OT]4;]XS[]W8NW=?,%RTC$^:+
MEI8Q%(U]OQ21 1N>IC&P^#2M']D<9T\B.VGH]1N/L.OOUK]S7Y/SVL8C(AL>
M63H:Q#;C/0FXC&S+^S$;AR'42)$1N,U2D,-Q7WVDK6WA.$+6G&<XSG&/21^\
M;]^X<2#NOF0ZNK B4 ADC\E&'@T*1?+0C5$)1;*2*?LCC.GD1V]WK-S]IU/M
MK=5$_)>?)9M<(_9M=>0_JI?J^N>4'235;N.T3 ]1)YF.DS#D2H]*6E4J1'4T
MF2E7JIQOX<+]4^F.0G[Q?WZQ;#'W5S"^7Y6VTJC;Y%_(V^#3R=S&*UO+))6Q
M)-#Q'&'K!'K?T>OK]OI]=8)<_P G+[S:YLLVJWWRD=+Z?;!N(TF>"/[&V4-,
MPOGQ3;,1^1&>IB7V52@CJ&T*SZ9S%5A&/T&?3E1^\3]^BH(QW5R_E@* /-6U
MDD,R"VRUEF)E Z>8?,^+6G[)XR]_(CO[O6+?R:>[2L(G?D]W:(I"<&D_*YT&
M)#7L0TNCB&QKY-@.I'-^R.2[#DTAV.XD>UG*6,93G#*<^B/3'#_O$_?I(K))
MW5R[(ZNK RJ=PDD$L@:Z:B24"20&^]P&:Y%Z#B>,'2"/T>CU"P^P:#U5(+K5
MX/O(QKZ7?8.HH?2KOS7I$K4N']B&F9TND4&51KB_<9^OM?'[_(H8THW<QLOY
M6V,BV)K;4!YIKWV)?IC%I?WC/OWFW&7NOF6+^;N)E!+>> LVZZ:^:JJLAZNH
M"M=0!0<1Q@Z01Z6]'JZ?9Z/56F#W@:[O6.V7LG?.\73WJA:B%VMTPQUYM=@V
M'2F]9(,V>9:(E9J0IBO'0LW7+&)K+X22.($(#T3#64OK>;7\,M^\;]^[-O/=
M?,[RQ8GSA?<8O(+7V]3#\J_HB^6+)I3]D<9_,1_9[;_RZ^_6OP.?D_\ VS=P
MYAWRV=%'?>^=][W=I;$<][ZDMMTE[OQTS/N?47&DJD?%Z^]E.,K^+TQPG[QO
MW[Q,K1=U\PK(8RMI0-IA0QP[;)IY4;,D5OU:L0E@30\1QAZP1^GT>O4_:>OK
MK<="_)?O)3MD1+LNMO(GU2OX1LG/&SC59N6T3,-!=<"*T2AR94>E+QB:X+?9
M0]A6?B7'4E*O5'ICE8_WBOOUB5%B[JYA4C$84"50%$+%X@ $L!$[,\8&B.2Z
MV8WH>)XP]8(];^CU]?MZ&L)N?Y.5WHUO9)53OOE'Z84VUC,0)LL"?V-LH88@
M?,#$M#)3L1ZF)>84X&>2AA7W,XC*PE/HC/IRH_>(^_,+L_UIY?:5VD>:MBOF
M>=M/@U4S?-(Z&3QF[:U/[)XS^8C^SV6_DT]VE8FCP =LVO;]KRV=%&L,Y@Y:
MPWM'8:,-Y&87@9EOX:9CX,C<.*^7]/3V/BS\'P^N>6?]XK[]90PE[JYA@ZRJ
MUY0=PF8/,#==1,X#2W_6$#?NM4#B.,'2"/T>CU=/L]'JK>_7/PB>1ZE%[ZQJ
MYSIIY!@TMC6<69?[#]5*TG7<FIWA%UE4JA6C8DBC#"<JW#\KC6B,,:GMM#92
M&W'&):F\8F3]XS[]YB6D[KYDNS2,29023,@CE))0ZR1@(YZL@",2HM0<1Q@Z
M01^CT>K4?8=1[:TY:/ WW@LUUV(5O_=CIYU&M)6\7$B6ZZV@YL&D0M;Q;+8I
M-EC5ZE#(M>.@2>M5,R6'!,H:1(0GXZ$84\I]IS"9'[QWW\!@X[LYGS P8'SA
M?<(_)5@=NC+#\I2-5C\"V72G[(XOIY$=O=[;_P NOOKJU^ 'MHY[ON>6WHJY
ME_YWW\N;2V(O+WU-+:27NY53,^Y]10TC$CU]?>PG&%_%C&.0G[Q?W[1%#%W7
MS"F,Q%+2@;3 "(-MDT\D,PBM^KW'9:YH>(XP]8(];^CU]?M]/KK<.O\ \F!\
MD^V!<FR:S\BO5*^AX9*2.EF:M=-HEXD<M].CQY<5Z3&I:O;FY$2&FEXS^BS'
M4E'^@^YRJ_O$??FJ"->Z>7$:A !YJV C<RQBVRUDE)E4=!(2X\6M/V3QG7R(
M[Z^CUBQ_BT]VE85<OR<;O1K&QO56]^43IA2;4-;%S7P)W8FR11> W\CE 62J
M(Y2T/1_@&N_#&5]S*&%>B/1.?3A_WB?OTD0QR=U<NR,K*095(*O)YSJ;IJ'E
M^8X.CN S78 T_9/&#401W]WJ%A]@T'LK$V_ !VS:]OVO+9T4:]G$/#/M[2V(
MCVL#G5OCDM_#3,>VD>^XI;&$^F&EJRI'IG.<\F3]XO[]9@XE[JYAA)YNZ\H.
M[S[>?NNFOG;5$M_U@ #7  H.(XP=((]+>CU=/L]'JK<NA/!YY(*H:OT+5!_I
M_P!_14\'2X!*ZD?J)BF:O("[Z-O+H"C6[96*8%E62VP(3L:QQ!B"&$"9V,25
M,27(^>6?]XW[^'8LW=G,[V9F)\X7+/&(6).SJT(\HGKY7R[[-*?LCBQ_B(_L
M]1O_ "Z^_6M:7'P0]YK9?MEF-B=S>G?3RTF;U<"Q/KI8R]\H@>@P+48=-QA-
M!'#0!^M%]:RH:V/I\H:1GQGFV<-O.YDLNH1"_O&??NC*Z=U\P'0H5(E (,:&
M*,BR:>7&3'':VQ"56P)N_9'&'K!';W>LW/VG4^NNF7X >VKN7%.^6WHJXIY4
MI;RG-I[%6IU<]A$6<MQ2J;G*US8K:6GLY]<NMIPA7JG&,<B/]XO[]80BP]U<
MPJQ^5M E4!1 2T(6R:")F9HP/@8EELQ)H>(XP]8(];^CU]?M]/KK;NO?R8;R
M1[8'2SVL/(SU/OHP:2Q!FE:I==HEX\$LR,;CHCOR(M+5[$UH/)2TGU]%)C+^
M#'Z#/IR!^\1]^801CNGE_+"A;>:MMHE\\+;9:WG?.MT,OS#X]:?LGC.OD1W]
MWLM_)I[M*Q"[?DX/>S5]@55=@>4'IE1[/"C")J@5@V'LH45B1&FG/H,GY1VF
M)=8:884OY3/ICVTYS[?IC.?66_>*^_5U97[JY@JPD# RJ=PF<23 W37S7 :6
M_P"L8 O>PI^R>,'2"/T>CU:#[/1ZJP]'Y/\ ]LFTH0WY:^B:$-HC--H1M'8:
M4(;A2%3(3:$XIF,);AS%Y>:3CTPV[G*T^BL^O)D_>+^_:8LTO=?,,SF4L3*"
M29U"3$G;J94 20G5T 5KJ+4'$<8.D$?H]'JZ?9Z*V=IGP8^2VO';_$TS=.H'
M?6&3IP8(5MT]TB<I&IRF=@UN]98IEHV6S4@,J]6>" ?B&HL!)#VPQ-SYKV7W
MHJN2?WC?OX+^9_K9S(E#[K^:+[O*\G=?9H1#\H$:B,[ 0NE/V1Q?3R([>[VW
M_EU]^M;'NGAL[(W78NQ#.TKGT*Z=7<U;3,LYU_([D[&ZRK%29L6(KROO;  B
M;'4I>M[#':;>CNBR4V(MS#C+RD/LNLMUC_>*^_>+88^[.94QF(I:51M,"E(2
MO@T,*DK%;]6"=EKFAXCC#>\$>M_1Z^OV^GUUU'A\\3]N\DD3M3:879LUUT;Z
M\[M+: FYIC-^W+5]KRA\.9'L=I''S^TJ$2A RT&.Q'2PE"UR8"D8=4E.?;SW
M7MC]Z?OKC.*EXKO.%>Y@)HY<67,RLB&7!>..2-#CG&VJ?+,K30B576#(MD1*
MLP5UUYN$QG</CGR="&"J"&N0=;^NUC:UQH=-*M8VA^3HV34@>OV6S>2[>!&(
M?V/JS7<=ZM:#LQF7$LVRK4%U/6S)G,?LE&P*"X798PZ?/RI"80K/M,81C/P+
MYQ?WJ<2(!8.RN'2--H1?K^2946,7@C"M(P:."<MFJC[UFSV^LRQD3*A7%^PV
M/7)D)_N4]/4].I'AN.B^%;"HS-^(6J46%9^P;_D^[(4C\$DL$V143<GK HN4
MNGT(YL#7]#/ZEKJ.QEDE'4_7:8>"!H+C R?&:C*?PPPPZF6O'_\ 5+@F,0OV
M3P\F. H*29_)R!T!\V1)2TQ:5<O)MEYY=F?/G5!E-+!&D(G]B->XR9 ?8J#V
M C33:OA6WPB^VQ-ZNL&^)#NV_$'D!?E6:'QUH"$1#4?HOJIAH5'""UQZ1!A0
ME;.=B1AM$=F.D1,/*%QHIQYPHM#I'.)6!_>H@?\ 7]F\3+N!#[^0Y,F7S#NR
MFD83!C)G62++D!$CXJ+AQM%B PE^Q".F1(/5X$TM\-M.B]5'0,=QNVM1/[@^
M-/RG:7UI4+-H+NA;NS)AG9>NPUEUG1NL&C:!8H^N1CY@[-)LF[I:;L+,BX=R
M2T:)CY4.1DZ=DI(3UOOLMN-RW[U2/<OV?Q!D;=N89W)*Q9[)+(I29?+D?'"X
M2-%L.+@@XV)].CN6?L.W_P"8DM_<IZ.@Z:B_B-_B;5KZ5JG14;R7U*MVL!MK
MH+VWW+Z6TTU2K5=2VA9!XK23Y6 0,0]CC8MGI$8O E'X\H\8@ML)EWH@N#"-
M$5B('RS_ *UQOWQ?<_SO \?S>5RN/VYW+)!*^9@PXW(NF/D033Q88PLA()U5
MCA&"'%FN8N%@^H?"QVSY_/30?C^0BE>-4,T(("L2@N" 6W"X_&N6'60VW':+
M5E7B;E#NU/D^\ET/;FC"H.K&.L>O='[4H^S9%;NZ[!:*W=)X^[B+I::X7-5>
MWW'V"#/UA0Y4:&*EJP/C1XB(3;2/"_WBN]>R.Y\/MOA>R>23DX.)QLQ))(X,
MG&@C\_(22*''@R8XVB@10P1/FR,/G9,\N1-(1R?$XV3"TTF2FPR%2 2&)L+$
MD@FY/IZ#T   5?5O7J;UNUII#;VQJ)IJCUJ]ZWZ8;5TM1;4/%8^LU?60^@V!
M^/6!4R0X^IAM3B/1Z5GUG2$9RAYY:,Y3GYDKF:^0/QL5C84SI'TWN^S/*QW_
M .OVI]QTV5!HAW4)4C/TQK";4[R.UQ=Z_LZ+.A1I^H:]7]CV6!#C6&3EZLS\
M$V%)EQU>K?%*]MOZ=:[VQVCU7O*G=T_)5V%+S[UK;7]MW$5^M4W8UYH:;168
MM;1J8?*:;>/59N#?8Q<#9247(I]<EMP:W*=RMYE2LK.>$KMCY!M]=Q"U*[S6
M\_3NL_;H[HBESNU.RMZ7#:&9>O\ 5NO+0.,GYM-75 IR4#F[-D-C)S[*IC#;
M:T(7[#F/C4KZ7>R6F2O7CPA[@T&:,CK :T[X];-K$H>$QYD846)4S2[]>EDA
ML>>X]/9@2I$%2VDOK4]AO./CSE7KQ2OC!Z =G-1=?[L,W+LIJ][_ -?V/1E7
MJ('KK;N^O7NMZMI)MT/K]"3H*N3]F1Y /%>S42# N-@</FX8-R$S\OOLX6I2
MMG=R>V&FNQ6W-7;.UJ(L76VB:]K!RNW'154\A76_[VFWB1QTDL;)O&4[:B.O
M1R./C&3FGHT_"X#2L1D-/X7E:E:9J7<.;5]-:DTW*7J2<-UA5NJ8!9:!WZZZ
MPVRYW0/8?56UK +A#)MI=&Q*;* Z]DOUJ&J-@C"MAV1)E.+C9PC*E3)ZJ^65
M&CNQU WK::%J^\KJ&L>T.MI0(9W_ .MLZ025M_8G7FP!+5%S8+9+5%.NQM*S
M)MS]'<,RK0=6]&2AK&494J.WD8\A93N2QV<"@0E3IK6^2.E449,/NKIK8-SK
M)T#9::2>A6&GT:UNRBM?"2*1G[&MBFH[T"0<)KE.J2Y\?/3/N7X7ANY/O<[;
MX'N.&+(X#+YG&BR(I&E2.2%I!O21X")E1AH[1$2A;^7XK5I\C))#@32PDB58
MR018D&VA%]+^_3UU;'2^DUFCTJI-73O#WP,7--4$N68S2^W.V2-,)V(@.@U2
M07I\)$5ZQF]?PKNQ)0"6WC)38%F=^EAFT"(<DIG[57LW[KA9).R^W]RD*P?]
MI0/>,?42!Q)RICQYY(2&GCD9HN%XX#*Y"1\Z:/%KKGU&;Z,B7_\ @(UT'1+D
M ]"-9'\* *"U9/GIDU$2N9)[E>0IJ/&5+DJ;)=V[UB"E@$RBN%$%#8$=/:?#
M K*^AZS%A+<EEZQK8J-7;)S?F9C=O]2_NNF(AB[-[?,C[5O''RN^\Q\Z,QQ3
M<JA$LL *X&/D,C+A"3FN7;%@\J!GU&:-3D2V]I3T:&Y"= ?B(OXK1Q[C<UJ,
M9XBNCT'-@GWB@WC95C,G3]@N-SV[M>S8OUBL\.9'/[&*W6S12F*[7STE<KYF
M[SW$3QFO1LM(K&2]LFX1%[%F9<.=%B8''XN'C</C846+BXN,D\^+#ARRO)#C
MP13RMDY6/E3[CCPNZ9'<L\?U&3]-P.*JR854J69V8R%BS,;!BP !)(%E*CJ>
MD(-A>5M(8>1K3HW0]KZ:"=2W_?\ JFO&]F'P5PP#V[MBOBOL[2XH[9]5JALC
M>[I9A6IZ]7YTM$Z *=B3)53$O,EK,XLC+5&CZ6]65VD=9 X9W9I'G#B=_)GD
MDE@ DG&5(!C3SXH6?F9E7A>%6#BH9IFM;U:?@MTU  .@VC4!M(Q\R2[D"M_U
MWIYKSL%L,T(I._>ZAG3- KI"A1]EU??AQD?=MGWV\(O4ZIZI"SJR(Q=8V1@A
MY329RT-FE/+L]D?APXV&<XO-GC4O.P3)'F2,SL(MGE@8\\LDN/=83$EL/)R\
M:Z8$97@.WXWS6R9UFP.@Z:#U]=0 #UN?$%;XC\V4[;"HY^1+HM'U3UA-7?2N
M^NV9VY3=EU >*"V#L&?N% .-]C=E ZQ/3.>GP:I(=K%I>:^2&FW%-&]B26I,
M]N+&KT)E][*/.QI;R-Y1C+$WV8C1OBHH!9E+PX3X&.Y4JH?$[9QI J?5=PY/
MAC1AIK?\Z^[["VX_G3$:[8A4RZEXS 8^HUMN_=I^XK^P4 UR[X3I?:Z]S:'F
MX%JD-U1:9--?9!2[/9*...Q71L,C&PLE;S"VZM74.C8TTBC'$LS[3"HC12@C
M00B)D\M#D8ZB*=S'CMCH6R\;%RB\7&1,W.\Z\O(RX\%2;#KKZ];]=#J-3<^$
MLNKGY45D!-=0]T_I^B=DQ6;/V:[GU[7!Z$"6"N5@[+DD"Z9L37(<CK<_6[Y?
M8H$H!H[+%>,C\R# MIR!72:950KKL\U(6M,>*=%BB"R1N$"HL;RB5929X53'
MG823I/*#EXV-E,)>5E1^<YUHN.BQX"Z:G0ZZWM:VAU&@('A)71!\J*[DFJPO
M'9I/4=RC=H+GM'LKO_7(ZL;FT,0C6:H]H8.LHMQ,/U*=9!LD\O(Z5.P47(=:
M<58324Q:*#;3[+<HXN-$S61AEL$4QRX\R$M^MRA.N1(JL+@QS9D6=.H4LFS*
M[HRHQ!']+V_BW8/#KJ"/<MK#\(4J/7=85-SNE:I(;SU_KC3^H=M:^LG;KLL(
MVE1?O<) #;!V>EUV#<M)6_<H.XTF[A91X)DHHX>KUJ4^Q79S\9X%\HNU6A;+
MTB"PN[2M,VYVOC,LC.[.3N+,,;)9Y\;5ED(7#R\S$4/F2*.WNW53&6;(*UNG
M73T?A&A]7Q*K:*/FS7:PJ/715E_=_7K8<8QVI[8;#[#VP[)HVJ-7@]ME%'S5
MCV96*=?"I4_ GPR\8L$DWEYY[,9J2S#+LQWB1V5%'0&LOVFDE231O*CC,C2.
MS+"4;'58I#YL%TQWQ8&^FR,G'5\?@H77BN'6?EII9: "WK)M8=>NHT.IW'4
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MPX2,R=FCR2*W29#B*K6?FRSDYY"-H\IDBAV21NJ!51#+O$C^;$J09+!YHIY
M<G$Q,IAD<Q.K=P=P/%QL,,!&ZZG0^TVM86.HZ$#PLRZ1CY45W)-2JV5XP.J^
MRRT:1M:AWB\S@_U\"6CV*YE*C@M7%&9>PI],N<>%,8JE.8K1$EDM\IA*A6H
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MQ2HZD>&!?"MY6J7'8KI!H30W2/M^ U=2K+6*J9US?[_)URC-_>I+6PAP8O?
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M1G54%ZGPFY9@"4G,0458H54BRFQ:94*ONO-4RK)+&79+R+112/MQ\?801&H
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M1C33XX7)[AR4'%\0,?A8)96>FPTM^"UA<"QT7:-0#X8AXY+R$"HP=I 0O>%
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MJ^O*B2:%^._M*;627&::UT$FYGC;0X/3D19-D5BQI>;L=HC/&IXFZ$1[Q$9
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M9#>6Y:6+;-F#)D @GG@"S\_D*O$\4(>'QYI6CV#3^+IJ-#HNT:@'2(?,>\A
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MCXLM& 53=DO'[+G!U^)\224S;W=D;&.\EWR'E$BRVBE9Y<=0\L<TB_39.3C
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MF1,F,3-$(Y(8\>+%X\%V3(@.5&<+!(ECX..;]J<KYW-9$<2:A+NZQPKOED)
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MR#?"V]V>%H6OTBQ6B;%C^(FSPX,F# _@51)B]KXTG_YON#+&V.OJ-_>U]Q_
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M'T/D^>,I[7(.R7,BSLA-;F/*[HR8P!])V_C$%\/L(_-MM'V*5'O6!3^-*U6
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M&7RH(HX<AK1R0H6S,7$RF,?'HS]Q=Q/+G/!C)-]+GVG76]_"22.H/PLRZO\
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M(R,2SICM$<>,0N[R0[H<-\.)A!-/ KP<! Z\3Q*3\SD2SK%KZ#4&WHO>YO8
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M3D1*L4Y,>*T,9.3B8F26BX>!GYWG&EY*6"*A/\=_3?KH=1JUSX69=9#\J*R
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M<&:*,7D:-@!ZR1TJ)E _*#.@D2C5%^XE-EU&^#ZX,2<K%8U^P1A5@_2 T>"
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M,?"\YRO)F0YAE$AR)H.10*YQ0%R8=Y&TBL$_ Y4TY\4:PD2ZBX-Y(D2VVUK
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M:D=PY;!LZ*=/0H0F42@51P]877K4:;BY],0I2,N?"XZM*$*<PI4XJ1MVKW:
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MDN-HRYA"D^V_<3][6#]S_<^=SG)<=+R>%G<1-A-%'D#&=?-E@E$@D,,X8*8
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3<=+21T)4,:^TV\Y,<C1GU*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tv477598_ex10-1img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv477598_ex10-1img2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@#2 *> P$1  (1 0,1 ?_$ (\   $#!0$! 0
M       &!P@! P0%"0(*"P$!                     !    8! P,"!0(#
M!@0#!@ / 0(#! 4&!P 1$B$3"#$405$B%0EA%G$R(_"!D:%"%[%2,R3!)1C1
MX6)R0PKQDC2"HK(U12894W-49#81 0                    #_V@ , P$
M A$#$0 _ /OPT!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#
M0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@-
M: T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H
M#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@-
M : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!
MH#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@
M- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T
M!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&
M@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- :
MT!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0
M&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- :
M T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#
M0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@-
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M6:2*BZ3A-JH0KEZV;")'"ITR)&_KB ")@]>G70+1%($4DB (F J210.(@)C
M0@%+OL(AT /A_'XZ"[H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- :
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MTA.6".;,F*?;:NS*/)13_MT"<0 RR@ )B^N@<]/?B(_3L"BA"@4>0 5(PI%
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M[C'2:;MJ8IR'(J"QP1F..S51PG@8A7KA7Y1_3LGT19R5Q)X^R+ '*VLE5D3
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M0LQ#)NEX:XRD8P*#<[UPF8ASG.=(A VT#S@ % "E "E  *!2AL %#H!0 -@
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M/$]58U:KEE%F[,'1G$O89N5L5DD7$@H#Z1>2L[..Y*3<K.G8BJ*9E>V03?2
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M\A()RE$IUFZY!D[B6/AHEXU.T9SA&JZ)5'@%35(Y[AB*B0P!H)G@0A1,8O\
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M_*"P9PKTY!Q%=R!D5O-91@GLK,RA+=6:K@-EC?'3MO#+M@AXB=@K0_E@<I$
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M,0Q=RF*8/00]=!Z 0$ $! 0'T$! 0'^\-!70&@- : T ;Z2&/Z@7U#04 =P
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ML3DY@8H2+/D44QV4 Q>]N' >@[^@^N@N(2<8Z365;2+!RDV !<*H/6RR;<!
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M9[QRI#YW,0S%.N-XJ0R[9(!0K%-M,.Y=8SV-QTJX CD 0;%<ORI+$,99NH'
M ?>A8UHN,(=O7Z-68V"8(%.=19 @N9*0=*B'NGTQ,O#.)::DW9B@*SETLJLH
M(!R,.P; N] : T!H#0,EY+6X*%X\9QN7)X52NXHOLBV-'D14? ]3K4B1B+0C
M@Y$3N >'3X@(]1Z;"/00R/'6EH8ZP#A6B-A(9&I8LHD$!R-U&A3GCZW'(JJ
MU6575;]Q4IAX&.82B.PCH'%M;!S*5J>C&;TT<]DH:4C63\#&(#)[(,'#-F[$
MQ! X"W<KE.&W7<-!M6#=1HQ9-%3F56:M&K=9<P[F<*HH)IJ+B81$QA4,41$1
MZB.@R] : T!H-.$VQ4D'$:U=M'CYD5 SYDV636<M".%^RF=P0BAQ;]1W$#@
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M-L;X\9W%WD)G1*>UOS]N+1]=6];AT;6\;&(FD9!U/ILRRBR1DTB%$#*B E*
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M,X.46R-8;U7)^%J]@_9N,+E:J]"V">9LI!C%R5EB(Q>(;.DVDBB=8#*;(\A
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MFQ36-Y6A5*-E;+;L>56#EI&R-H5E&K*'BZ_<%)--H_GFW=(HHJJR(V4$ABE
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MG]Q8QZCM)P9I'1\4B@JHX<*),62)'AES";N'%-L4""GUW'X[Z!JG&5#W(L]
MX89Q5TDXU16-4N#UPH;%\1*I]PCMB\GXXKH9N6AS\!<1S(#*%[A2J*);B( G
MZ%X]1T5.C?<EV.9RWD]V!E2V"UD$*S5%%."B\;CRF%-]HJD85<@'3.)5WI@
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M@;#\Q$-C&-T$?F81'_PT%= : T%. #U$H#^O'?\ \- AY=9L3(%);'.X!RM
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M1OX]TN9)CJQNV\+;<FQEVR":$*^=H6.VL:0WKLA<[&)HXQ%#EB"1D8904Q3
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M55W=VGI6XVIVQ9)M)2QV6574<2\M,O#\W3AX[7.)NJG;)OLGQ+].@6$C+QD
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MN%7[AD@L\FYIP!2O[)9Y98[^R626VY=V1F99=58XF,<2@<" /$A=@<+0&@-
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M:#3(RQ7;^3C4FKE)6+60;*NG;59%JN=Y'D>(J,5E"D(^2(9<J:G;,8 /N41
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M):/O'*,G8>]1*URS6I$V6TU&.R1?HK)5T_VI\<ZLM,U?&Z;Z48($0;SE@?\
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MK<I0()!%02@(CT'099""4R@B;<AA)VB<0 $2@0I3$ P=3 8P;]=!<T#74=L
MVC+SDGU%?7./#ZCOA,<S.GUYBH7DZ4.4A2*H[%! H(@'0 $W(= Z(!L !\NF
M@- : T!H#0&@;=*-;)97E;&K-)J.4Z'%0*%=[!2+H-C3;^37E2+]SFZ3<JB"
M8AQV2%/U^K07,?UR+HU'C(. B&[6+8.)1RWCX6(2A$04DYN2D7@I1":O;36.
MY='.<PF#OG.8X[";;0.$0W,A#\3IB8O+MJE JI?_ )B@)@#;^.@]: T!H#0&
M@- W-=9O$[-D%96;4>-G%CKZK2(%ZP72ABIL8X5N*:(F?,E) 2<A27,4#!L)
M"?5N8'&W /40#T#J.W41  #K\1$=@_70&@- : T!H#0&@:>LYUP_<LAVC$]7
MR'6IS(]+(]/9Z@P>BI+1)8Q:,;RG=(*945S13F9:).@2.H+95P0B@%,.V@@5
MY)V7R#J>6Y>N7.U$MN(LB1M9GL.8\QA6Y:LW)ROBO)E2N>6:=*6=C8CS4_<I
MK%:#E:,39&9 \1;NT2(B<!-H)->)2\\C$9;KSAY<Y>B5;+TLPQ%.WQ2?>3LC
M0).N5FQ(M"2UG )Z8C("P2[Z/;+.C*."IMNTH<QDQ'0)N'FK;BJT7_$V"L5W
MS(JLM>;/>#SET5:T3"N+I.Z(,YZ0@F%K=-%INR1#FQO'$DHUAX^262</UR"H
M3;BF&+&Y59^.]<F+9Y$Y@A)MQ%+,(-]2L(XWFU:#CA"<=2+]N/[>K;.T6M<6
M:<&Z,ZE7ZB23=NDJ=1)$IM!NL$^445GW-.:*?6Y9E"QN!G3NE7.A3L:"-O>3
MRTK[BN9,B)8CWLJ8]G85JZ;)$.W*<'C=3<_T" AS+A+<?QL\[<G9*=^3N1?+
MK]P5.3K-%\?Z"K.9?N,5!OXV&EFT=,+5UBSQYC%2)LL%P.YE'J"+]HH1P/%R
MFMS"24+"^9WF,6/L]^N/_IBPZ_DI(L30,%-H:PYQ8LVI?MJQY_/$^HG"U[[R
MW<J)N"UEBLL= PD(Z+Q4#0..'CUX0>/K-GC%I8)#&N0K]/5NRO[W%W.PO<[W
M)_$6=K[!S/Y-,C+VQ.#?6!(K-T45FK);D= VP**%,#P^6$MEFC0E5NF.,K4S
M%56C;Y24KXSG**6R2%V+9+Y58-Q#H6!Q*MF%/9N(9R[!1X+990JPIF$Y"%'<
M.+^0?&2XY7D<*XZQ\UR(]S'4O)_+.3+S=I>>R YPWEJGU*;R+>L0WA:_0TN_
M@XTDVTF&U=;.XQ\C+Q2ZCA%9$02*&@Z'8N_'K6<03[JRD\@[]4YJ<EK,112K
MR5>A+M:\7M+:.2H7'5SN+YE*V*T.L?RSQ^V5DX\6B[N(6(W7)Q2(;0//;<WR
M*_F_B#Q[L=2A9S%60_'RQ9>J#V6KK"2E6>5Z#<&9RKBI(KF<Q0,JH]251.5M
MW"/3!Q4*/+8)G)N9U=)F9..0C3J&34=$DE0>J(E]V4JK4A8]8A#*K-1,9-3D
M)""  8HZ"RTK:18Q&-F'SJQ"D[<O#.I0B *K**R:DBV*LDU30;*%CBBFBCN0
M3%(B41$3"(B"C,4AA 1*&X#R 0Z"!M_7?UZ@.W\-!78.' "E NP[!Q 0#?T'
M;T';0'R_@ ?X!MH#0&@- : T!\! 0W 0$! ?B ^N@1%4O<+;YF^0L05V*^/;
M*A4IQ=8S06IY@\'%SQT68-W2ZP>W83"'<[Q$3\C!L42["(:?->3X_"N(LD99
MDV2DHVQ]39VT%B$E#H+33V,8JK1D&BNFW=G;KS4EV6I%.TIP,L!A*(!MH+&&
MJPW@*+$R:M.B:):;VFCD7(U?@W+MXP1R3<(Z/D+FH1Z^'W+PP2A12[I@)S(D
M'TE]- ZV@- : T%# (E'8QB?RB)BB " %,4P[B;H!3 &PC\ '010QU>)?,<K
MD+,-(L<?+XYC0FL7X[1@S.E'C^1I]K<Q>2Y]=)ZW;1;I=U88 [6(43.JDJW3
M!03I@H(""[N>6Z5@K%HWW*-@EF<'Q1(BYL#-(EGEI:;%56%IX1K4A"J65P<Y
M&3=N/$5UR@3?<>H:!ZTS#E6%?QB!'GC[6'#^IN(21:/&#_)<C7D'B*]I@).*
M;H+Q%'7EV("@@NU=NW;01$VQ3;@4'NJ=-K%'B4X2K0[:)CR*K.5"H (N'KUR
MJ9=Y(R3PXF>24B^<',HLNNHHHJ<PB81Z:!2@4I?0-A_C\-Q';;TZ;Z"@B)=S
M#U* ;@4@"*G3<1Z;[=0#8/UT%0'< '80W#?8?4-_@/ZAH*&-Q !WVZ@&^PCM
MO\=@^7^&@YO96\8DVM1\=L7L92^2;"I^1MP\A;K<8)OC]H]E2+.<@6*=CK:R
MLZJ$/]ILCG(OL#*-TE'*:2!3)@"@%'01\#'E H&;9D:\)H6I4SP]R/EEDYR/
M'DM+>#DLT9P9R5S>S$956CA-Q'JLZT4\:QCTRI&[.Y>X45-!-WPZRE YEK%\
MO]&0QFXQ=,7D[7'ESQLK)%7R&E#P[!G9[9=(A]7JTQK]E?6@CHHM&J*B14@)
MNLJ?<0"2CJ*EW%ZK\HF]6+!Q5>G47;4'*I$7+^1=,"L3*-""**ZC9NB?B<^P
MD W3J8= M=M : T%! !#8?[A^("'4#!\C /IH/.W$Q1 @B780,(=3%  $0V,
M.P  CZ[C_P".@C_9_(BKM;!-8ZQNU+E_,,1"+32V/*E)MBHQ2)BF-&#>+@9-
MW7J$WF#$,1L9\?O.#%$$DE! 2@"H>8^2R*KCRV9%9R<5+UME]R>8XC+<O,4
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M$;8ZPV1[Y4W:'^SL5J)5L*U521L8@JC(1MHFK'-OD(0O-<R;YL]A(\S@PI)
M*0D #''D!= ]]5GHFUP$3881PLYBI=I[Y@NZ341779J'433,HBX317((B4>
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M08+])PX;.VR"Z[11RS7;HO&W 7+555-0GN6Y5 %/OM]RG()MPY '3;?0)!O
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M!H#0&@-]NH^@=1_@'41_N#00$JOB\K7,-9)KHW>HNVU^\M6/EJ69"'42K\7
M,_("@9H^QF;<C^Y?J05)%'WVQ"@_<=[AL3D8)ZK+)HD%0YBAP$H"!C 0O]00
M*3<P_$3= V]1$ ^.@U\T^>LX&6DHMD>1D&L._?QL<)%.;YZ@R5<LF7;3#O<W
M2Y2I\2ARW-L'700UD?.#&&/L,1^1O)\7OC1,3:QX-G1;&Y3FKY,RIX>'>JC0
MZ_6$IJ9M*Z8S0=M-DV<KHBD;ND*8ARE#F+-XXRMY&5F_U3Q[QID[Q^I7D;!0
MM,R!Y2>5LC-R><\L0<%WG2#*EX*A572KF/=Q+Y4II:3)&IA&+B<!*9/L@#_>
M/WXHZ=5:A7[CEI97*/D&\@*&G,77.DBIF!A4'U:@DX%9G5Z N^+07)(!DU21
MBEW_ -R%-, ,804*/(.@-@HT9B#&-UGXB+D\N7-I7'4[&PU_E3O_ -W3U+B'
M4K$0D1#)M4JG4UUA8F*W"/CVB8+F*8^YMSZ" ?D9G?R%_>N$+UAN6EIS&&8H
M2CWFHXV5C18QDQ0YZL*5'+E0MKB(AYV086.N2%RKDXT4'F5B!7XCR(W4V#1>
M(WA]E9O@\*GY'SY,87Z]U+&CENK!33&2O=8O6%;66;Q!D&/2<1JS)"TURORB
M$#,"L99-ZK#(FW.DON 3\QCX^T''-MM:]'H=A:Q,O99R1FS9"N$[.5-)2P2[
M6TS!\44)[-2]<@VTC92F>++%8,#^ZWXB<IOI#/\ )"GSMQQ5+LH_"]1\AI>-
MO=3GXG#^29F,BJO+1\7,L&CMP5PZ9G@D749$JNI!BC(D<H>Y(03%$Y2 4'1H
M,//3>.$T+Y2HG%MIGVCYK/5^B6,7QX9L5PLSC4VMOC&,0NL_+$(HB*J)2=DP
M\4QV* Z#!PCA:*PA26%,96FY7LT<_GGR-KR'-+6.X+!8GX2<@V>SKC_NGJ/O
M-S$YB)BEV#<=MQ!UF\3%-'[Z4:Q<:UDY0R)Y.2;L6J+^1.W;IM&YWSQ-(KAV
M=!HB1(@J&,)4R 4-@  T&',R<A'-7:T;"K3;ANR7<-H]JX1:KOG9$G)F[,%5
MR@W0*X<I)IBH8P@F"HG,7B41$(U4%YY&90NJL]D:GO\  V-8=G49&%HZ=FJL
M_<[);T4'"]J2M,]59"5CB4U!9R5J@W2-W7Q6P+'!'D"8 Z%1P?2Z?(1$JT6L
M\I)P$C;9.)>S]LG)59FZNIF SZ?!=V";IBJ2/2*D@L"B*'$1(4HCN .^4I2
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M5IB/'KF1.U[_ ')25FZO'3\Y+/4'3-JZ9O75DE7HF14%0Q1_J<_K$A0U'FE
MSEL8>-]6K\B^8.Y'RMP_)/DVYFR;![!59U*6>:0F%53)N0:),XH54B(")U71
M$B&**8GV#Y=_S2N[3DOSHPEXJQ]JL=EB\>T+%..(9W89 R\H]ME]DQ2G[-+/
M')D&\C.OF0LSJO#@43F*8FX!H.W_ )N._P ;GA7XS4RA9^P]BW)TK7J%'TO&
MF.4ZI7E,D6LT5$G8!(MI1 B4[4H9\_;*'>2ON$B)J*'X"HKL00^+C*JK^>DG
M&;ZWAM+"6+[=/R\50FM0:V=O3&JT$U;N7T#7K5//WS^?E8R/>('?+%<FY'4
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M"BUX>MI2LS-E8.)*5E_;R%@DG4M)D0=S#Y\](W%XZ$4DP.*:9/I#YZ!Q] :
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M$?D/Q3X'XU=3,RY8VO+D\T=-<;XK:OT D9:2,D(I3MD(FI[J%IT6<2F<.3%
MZW1) !.;D0/C6\A\:>8?D'AZU?D4\B9*1_:UGO4'3Z@I959!FM-M[/\ =G!
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M&PR=7G#R4#,PI22D2[78.?8JR\>S3DV0.VBQ"KMS'3,8@]?30./H#0&@- :
MT!H#0&@J'J'\0T'-GQJEIR9AO,6ZTZYTRN7C)/F)D>ITB2N#%9:IJRV/V-7H
M#9BUC@D(J0GWKAG4W29DVZHG%TBH8H&*0P:#I&7N<$P5.4ZA2$[ADB&23,H
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MO%+2TNR8\R-[!&-F;EX5D@=1+<A%R@<4MC=>H #"?CGC';#PSP9(21%0D[A
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ML_D6F+DXD'#'($_E6WSU<LT6K6II&*G"0::Z:CD'XK$'NG,B103'*(=17@K
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M?B9A2TYKO/M'$97O;-V,.YL4%5U;#+O#B5G"1\M8W32+3D79$SBDF8PG5$G
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M1HB[1*W533%0I&Z*9"CN9!!$O!,1W$Q?7KH-YH#0&@-!0Q0,4Q1 # 8H@)1
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M("?DOBUI;P\RO7(1^2#N&21HF(*O/F*N)(V2R9DFFUA(KM9N!UVT.O[K9V)
M$3);AL(CL(0Y_*1BS\AV3E_',_A%=9=&O4BPG@\CQU&LR%+DFMV;/(YLUMM@
M+)2+$DY2(-JT5(JT*JNJB*AN*2W='B"T\<W?D9/SWY!+7;WV-G-M16QC@U"U
MH)SE383%]QOA\4I.;2@EF\NZBTI.:R(V,B502 !3 4"#L.@Z/9"R?8<4T,UM
MG*6I9U6L]4:^$/4)1([Y=*R3T17@?D":0C2[1X28N5$NISIHF*01,)=P? >@
MB'R'04T!H#0&@-!@O#2!1;"Q(U,05P!X+DZQ3$;BFI]38$4E ,OW@)T.)2"7
M?J [:#3Q*%A'W9K42!77"5>+PIXA)X4K2* I CR/1>F.HI+)E%0%5$^"9P,
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M&,A&^6L19/F\27J7JK4S*LVM]$QL9.1MIBV0[HL D8N82!9!(YTTERB4-O0
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M=S$VIO%W D/9FJUBDRR+JHKSD8W/$UMPJP*E%,WC*,49O96,:R).\N)E2KK
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MVDUE'XOH=0BB$_'2+<Y").QX\03$$]A 1$'H526.=$Z:XHII&,99,"E-WRB
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M*I].@<K0&@- : T&K>2C5C(0K%<#=^8<O&[(W(@%*LU8+/5"F YRF,)T$3
M% P[_#XZ#9[!MM\-MOCZ>GKZZ!-6Q,J\'(,U&CMZA))(Q3Q!BJ=%V5E)N4X]
MTY04*)>T9HW=F5$X"!@*0>.X[:!1(HIMD4FR1031;I)HI)E$1*1-$@)IE#D(
MB(%(4 Z]=!<T%!$ $H"( )C<2@(^HB CL']P:!*S<Q)%D&D%$Q#N0.^0>>^E
MD7C)HQKI4TB'0/(*JF6>@Y>&-LW!) _4!,80 -!OF+1./9H,D3+*@W0*0#NG
M!W#E<0 ?K7=+F,==8X@/(PB(CH,1-=3W#]J=O**G(FDY,H=$I6QBO-T@9L'
MB4#BS AC&#U+S =Q$=@"IG(,XTSE0'"23$BIC*21TTU>TB E.NNHJ<$RI\/J
M*(CN.WP$=!S;Q1YKH>6&*JOFB@>)N1,J8[#(%M;0S^.MN+7\A&V+$]GEH).?
M2@E[<@9LLZ?1IUF!"JG.9-8G,2B.@]0_D53,/U0E:DO&WSAHL;=;=*2L>N_Q
MK)Y17KEOLSLEB?IMGE?L=U=0T3'R '<I=T/M9#F.F4?1,0WTE^3SPX95Z1)(
M9L6QQ.'<%KS!3+6,<ET8(N<E1*RC'TFA8ZI!-%$3.U2J@0SIL"Y2F(!T]P$
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M':@V2A+;:91U:RH2KQ6O3=EJ$\=:+IDE6:\!(U (XW:=I")C 7B :":/3H
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M<&M-"N5.%SC@VE9<^WGDK(PF'T;:)FNI5JY3T O(%**:::Q5F1%#E2,FF B
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M38H["(B;ZB 4>O\ =MH,5:.9.!$R[9NJ81W QVS<YP'^GON8Z9N0B*1>HAN
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MCV9R)CW.!@V 0]2&:/*YU?*;CIUA_%N,)._0-\<1TF]O-TRV,"^JT)[YE+3
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MX[9(:/W6/LRXZMR,;8EZJ[^QVJ%=*A/M%FR;QBBW,]1</ :^[(8ZB)#I<-Q
MP\3; ^Z*B3A)-=NHFN@J4#I+('*JBJ0P;E.FH03$.0P>@@.V@N;#\A_PT%-
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M2TBNREJN,J17R@_6*X?$^U5V.:J)NETBE157*JF(',4  1#H&V@=;0&@- :
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MF@BD0"\2HH@7B0@; 4/306E& '644!RY(1<HE.D"OT(F%/MBJV()#%3,<O\
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M!V$/30:J,KJ449 6\C)""2\D[6(JZ4,B]<R8%%91TB(B4P)*EYI[#]!C#ML
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M:ML A8X<S!PJHB5!VSDT!*U;/T#2$:L#N+%ZQ<MW!7C1M(II+F3+P,<R0!R
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MFD9(%^(D+MMH.=S;)-#Q!Y,6>*PWD3%^8(7/OE>V@[A@>TPCF)S3A;,CMBK
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M)KJ9YW*4>)7\RX(@2./)F52 HB<H* V !_E+H.D:2J2Z2:Z*A%D5DR+(JI&
MZ:J2I0.FHF<HB4Y#D, @(=! =![T'-7*RR5C_)-A:(>A.O(C&'C/>;P92KKN
M"N*M8;'>8\6\O97",BV0CX"6@:(YBS)G264?'D2) 4""*A G[1;3'7:IPEMB
M&<FQC+"S+*,D9AG["1[#@QA(H[:=Q045EBEYB CN/+<>N^@8',V7C5#R&\1L
M0FAXV0:YJLV6EW#]S)$;R,,KC#&KFT,7+"*,@H:417>.R$65*=/VI@2ZCW!*
M(2KT!H,9<@&.4?JZ)J\@ .1#)[!R*H00V5*._4NX;AH-=78Y*)AF+!%)@DFB
MF<2$C6)(QGLJJ=8#)," !6PF _U%_P";?0;K0:"U56LW6N2U7N5>AK76)EN#
M:8KMAC6DO#2C<BJ2Y$7\<^27:.DR+I$.4#D-Q.0#!U !T&@H.+\>8NB#06,Z
M34\?0BRYG:L33J]%U]BJY5,90ZZR$:W;D75$QQ'<P#ZCMH-;'254EK]+UI%D
MB%HQY'Q,R1<5C$2!M?TI!(5D$P<*J&2,G"&(<5  @GVX=?0(D9D>0EFQ]YXT
M<K%X5SCIO6[_ #$JX>./;O3H4:OY29#$BFY5,T<PB$ 4J8%!$IEBD,)0 =Q"
M<\-)(6*L1$Q%O$5D)R!CY..E"&3>(J)R,8D[9OB&(?L.TC=TAPV-P4#X[:#5
M4>H1U/B%V;%E&-7\E)R$Q9WL;"-H%O8[+(J%/+V-:+:+K()N)98G,P\SB;??
M?00M\:F<?->:'GS=TCI.7L3)>/\ B$''NU7[@&%2QR\MRA5':JIRI<I2]K<F
MY0#M' ?X:#H/H#0&@- :!@LTS%0;R>.(ZS8^DKP\7R)3V\,[0CE0;4][*N9$
M$[B,\<$FK1.!&*Y.DP6*H*)P$Q3D';0.J,HP"1@89\_C8N8EXB5F0JSE5FL^
M?M(X\668=M2I+$(LA"R,VU*Y73(=,5'*>XAW"[AMHJ,0BD'":230J[UXN_?N
M&K%NQ,^?.!*"CQV1N  N[,DF0AE3B8YP(&X] T&RT!H#004\]);:AX-J H'<
MI9'\N/'NHN(5!J#J0L,?'6\+[)1\:)R&;(.ACZ8HL9182I%004 Q@WT&JS-E
MM]0%;I%41_+PD5C/Q*LUBF,752K,K18JY:K1*5YCC8B3-E8(Y%C9V"#1\BPC
MS*=N0(=0Q%"E2[F@F%4XEG(Q<M+/E+)(IW1-%.:@[<,A]L;&CX\M<D&L35Y9
M5RC P\P#,ZZC=+D@Y%85?J[G(P6KK94\:U>)&OTYU/F-,5BHP%/JZD!$KE1D
MGS>.$T8WEY"'C 8UJ&*L^5;)'[HLV:@(IG, %$$[AG%LSC&/N"MHR+8<D6F]
MW65NL[+S @VBX]=\1M',8.HP":BS:M5V.C8]$A6J9SE%QW51$3*&T%<[9>0P
MOCN>MS6OO+W;6T<Y6IN,()\Q;W#(DN@HU3&#JS-V?NOG:8.RJ+"F13L(@)S
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M>R*&$S\N2\*NGIFS2'R FJ4Y7T6#A!G*[D432%X4IA"3.%?)S#&:$9%*CW@
ML,;[9*7QK=6SJG9'JCT[9$J<7*U*R)1\\G_6 4@7*FLW65Y"FLH&PB$DB' X
M;@42B4>)RC_I/L F+O\ 'COMOH JJ0F5*(B I'(0YCAP)NHF10NQAZ"&R@!O
M_P W306%G;=$R)5%443K+%;ID74!$5UU"<TT4NZ)3*K"4H[$(!C?W:#( >0B
M8ABF3$"\=NH@;ZA$1'_X@$.GPVT%= :!L<V-)U_AG+K&KI.G%F>8OO[2NH,
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M KDD>'104K<@I$QCPT6WX$,U/!NCMU#,4>V!13% Q"\=MNFV@S_L\*1N9O\
M:XHK15^,L=#V+,&RDH+H'II,Z?:[1Y 7P L*XAW.[]?+EUT"*B\08AA;>YO4
M-C+'<5>WQ%CNK9&U"O,[.Y*Y#@Y54EVS!.14]R!ME#\_ZFX@81WT#;Y)\9<<
M77'>1L>5!%KA,V5TVD=?;AB.&KU4NLO"'?,U)^,"::1Y5FKFQ0Z:K$SO85VZ
M;DRB0@H!3 #VU2LURAU>NTJK1[.#K-2A8NN0$0V B+>.B8IH@PCF:)1V$02;
MID+N.YC".X[B.@48==]NO$=AV]0'UV$/ATT!H#0&@U$S*PT:FDC,JHI-Y)8(
MLB+E%11%XNZ244!F8H)'14(L@FH @<.)NH#\=!"?\?L Q_\ 3>PLH)KMW>1\
M@Y2R9)KL918L$[/;LE6^:8'KZ+=<K5K&-X=^W2531332,NF8WU; .@G:4Z(B
M"*2A#G2(0#$*H"BA2B4#)B?J)OJ*.X"/J Z!O[376\_9($7;1TLS;P5D25=M
M))Q'*M7#F0JZC4A5&CE!SQ<E9J <Z>XE(0Q1Z'$!!50D4,+$QT4B]>O$HUFW
M9$<2RYG\BX!'8IUG;U7BNX<&+N43CORV ?GH-QOMUX\OF [=0_OZ".@1MO?,
M$8B>5D6$F\BXN,<GEFS5!39\V.S%<Q&HIB5PY4*0@E_H"8P''CL(B&P*AN=L
M](VD4BD5!9N55JY$A@4,U<E(J0P H4BB8+)B41*( (>FW3096W7?;J/_  ]-
M : T!H(7YPC+^_\ *;Q34I61&6/8Y!AE96XMG%=2G%LDP;5&IO"8]*X,":L4
MU7<H!(*K%71$HLR"7F8H$,#_ .)JACVCPEDA,<O$GD>XR+D"QV0Q98LNNWO-
MOLSZTVYF\5 YA9KMY68,!6P@44$>!=MMA$+>:Y/[1BS(<F5T]:J,Z;/K).&)
M1%9LJWBW2Q%#J%*<&S-0R/!=4VP)IF,.X"&^@2OC'3Y.C8-Q+6%A@TX:#Q3C
M2-B&D7'/V3M!PC3XP;$K)KNY!TF\-(3QE%T (@V%%,XD.!S[FT#_ .@- : T
M!H#0-A*/%J0S=R=ON,E*1;VVLBQXI5U59_'?N*:CX^"@$$JPV444C&;I4J)G
M#A =DSF474 I3' '0'U'^/PT%- : ]0$/T'^[IZ_W:#DS74LC//R(WE:#B@R
M%#4V&\?<5W7(DU"P)7E'%K4,OY.F9]=F@C&"$I8FDXQ@6SUBB5%L634 >1Q.
M!@EM7*FUPIE2LP,5:X1FWSQDO.^1;1$'JHM)R\6F3BVE@B>$E%H^P;?LBL1(
M-5%W0D5?)()"(F5#J$GVSMXL]E6Z\0[9LV M 92:KB/6;S15VH+N3LVS5VN_
M;!'K#V3@Y21,<X;I@8FQM!=:2#!^H\19/6CM:.<D92*+=PDLM'/5&C5^1G((
MIG,HR=F8O45@24 I^TL0^W$Q1$(G>,D@ZR1:\]YOE'L-,)S.4[#BG',C&QYF
MRS#%>(WZU?;Q*[E90SARJYOYIQXL(D3_ *BP !=@+H)>Z T#09GRD_Q; 5]S
M!4:QY%M5QN,'1JM5Z[V6G=E)HRZJTG-S[Y%6'K,#"Q3-PZ7=O!*D)DB(EY*J
MIE,%,+X0I6"ZY*052+(OY"R3\A;+K;["]/*VV\6J4,7W=@LTNJ '>O?;I)H)
M%*!$4&Z1$TR$*7;0/!H#0&@05MFKU$S->+6:<TL];5CK>[MKL9M"-F(YU%Q"
M+FIQL$P7**<JZLTL8[8XG,DDV(7N'.'0I@W%2FYFPUNO34U6'].DI:'8OI6K
M2SEB[E*Y(+H%.ZAGKJ-7<,':[!?=,543F34  ,4=AVT&":_5HEQ?4/O29K)'
M5]A9WB!(&;-')Q$G)'B69R3OL @UWBCQ,>35-P9RFF'<.0I! V@RZG<Z[=V+
MZ1K;U1ZUC9>0@GHJLWK%5"3BU>R[0,B^0;JF*4VPE.4!3.40$HB&@5 [_#;?
MX;^G]^V@2LM'6+[+V*]+)H33,CQ1HXFFY'K9ZY.@X%HD](B<ADVQ71T]SE^L
MJ91V 1T#&46F^2<]4G4=G^XXM<R\A/'6<1.+:[*!6EJ>ZJ;J+=5&;4N N'$^
MFI8W7N5E@1:E<-"]GMDW$1#46EQE93!=TC_$Z5QQ*7VC WH5%C;9#N8RHM;)
M0YB.@+77I5FV-')QL:DQ8NT&Q$0[::@IG(H*6W('=O4B[B\03$G>H5E.236K
M(.;/7*U-143&S,HDW;JR<1!S%XD8"*0CWKQ,Z:)I)RV**!N*A@$1'001\)?,
M#Q\S/,Y6QQ1L<9.Q_:8-O-6>ZT*8KCRT4QK!)23YDE*UNX5E"1I4@TL_O%$V
MS!HY,JX!J<B"9TTNX<%+^.S,*+WQ>KE>LU8MM4EL<Y*R=B%>$?4NR,7$+'UN
MU3<K2QD&*[#OQ;5SCY_&J "@F%!0PMU#=\APT$SFN:\6O)).(3M[-&36_P"F
MR?LI:,6-MV]PVD8]J4!#NEWZ]-] K:O::A=8U6<IEBKULAU'J[526K4Q'S4<
M>38* U>M57D:NX;E>QYT"D43,8#IF+L8 '0*;B.V_KOZ;=?\PW#01@\RL80&
M7?&_(=.M,H2"KR1JE<IB747>,_91N.+M7,@OQ(]CFKR29G<LZT='N-R=XH*C
MQ$HCR (F?CJFH7,5;M\_8V&/AD\?YORA=:U3$&4X;(- LU]NV3^_>[,K/^W
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M<*DFF)2MP?%F@3:B@L!E13!+C].X@.@5A44N153\CJ)I*)<AV$>!C)F-OMT
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M>1:Q>25RL)Q]9K5:B+[4(>-D)2Y7>5(WK\<W86"JNUG14S.Y9=9WL1L< $P
MY\5@BZ9:K%CC_,*7J608VV-7L:KANEL)".Q- 1"[_P!PV(Z=OEBV6\6-%!%(
M/N+HS1%$V_8:IFW4,#_5W'%%J$LK-56K0E>D'$%!UATXB(UHP4=5ZL(JMZU#
M+F02*8T=7TG"P-$@$"(]X^P== U?CWAQUAIQG!HX>JRK?(F=+CE=I)K((M1<
MIWIC"2+IFF@D[>JE0@Y BK%,RIBJ*$;@?B &#02&.@@KMWTDW E$>(K)D-Q
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MAX;U5:G7L:W.B*.Y*W1\E$R$^K*2DH\=.$6A6;UJ#$J2"""*Z0.%P%8PE(<
M7N-J5E0A<E'R#:S+1U\LLO-Q#9J]=?N*C0LG3JI!-Z_!2**A(Z)"+F(N1><V
MP'**[H%"" B8- K7U>L4W.4(ZQ))BSHUWD7+Q;[X &LD0C2)6+C962;L#-TW
M"3J;D$5#-50$2J(]P0$- NJVQE&,=[>764<.DI*;!-<S@5S'CCRKQ2)[YQZG
M4+&G2#8>I1#;0*'0&@@E^1V!8+^)&;K(BV UHB<=SD!5'IY2?C$6DA?5XVG'
M3?E@)%@,A&NON:?=2<E71#B F3.4!*(2]H%>CJI3JO7XV'B8-M&0K$BD7#-$
M&D<V=N$O>2!VB+=)%(!<R:ZJIS<2BHH<QS;F,(Z!8&ZFZ?R;  %ZA^O4 Z#_
M 'Z!N$[5&.<L/J%V3#,0>/H>Z@L5QP2-'V6PV* (W48D(!1'W%:.(*B8VX&$
M.(;;B#C!Z!T .GH'4 _0!^(!H*Z!C_(N(2L&)IR =P4A98R>EZ7#3<'%HN7$
MA(0$A>*VWGDVZ+4Q%@[40=8YU"F(*1"B;<-M ]#1LDS:MV;=/M-V::;-NERW
M[;=LF5)$I1,/(Y2I$#U'<?70>0:-".#OR-FY7BR2::[LJ*!7"R*)5.PDJY*4
M#JI)"J;B!C"!>0[;;CH,DP 8HE'T-MO_ '#OH*Z T$#?R&-'[?#U ND!6G=K
MMV.?(;!EJJT1'R#J-D'+Q6^Q<!)H,E6J9P<+.(*9=$[*HD1. _6<H!OH'^QR
M=P7+.>FCMJ9(!F<?R3)7O&4[J+^DD I#H 8R;95LHQ4(82_SCUW'H.@8?\A:
MIG6"*[6F[)%[)9 SSX^T!F0\:21>>TG,O5&0F/:%6!,K8X0T*LHH<1$G:2,
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M[,[L 5%/?B*@<O70;,1$?41]=_7_ "_AH* 4"CN!0 =@ !VV] V#TVWV ?\
M/05VZB.Y@WV$0W'8=MP]-]NN^@\\0#CL&P%VV /38"B4 V_3??\ CH Q"F$#
M"'4NP@ "( .P\@W#?KL8-P^&@]?VV^'Z]/UT%OM$X\?JX[E$ Y#](D_E OR*
M =-OETT%P-@WV  W_FVZ;_Q^&_70>0* #ON;?<!WY#O]([@7?UX"/J'H.@]!
MT 0Z]3&,.X[]3#N/]W7I\@T!H#00$_(=&N+5C7"F.FD@^;*Y%\K_ !Z@W<;&
MO08N[# P]V1N-EAQ4,DLFHS/"UI95<AR\3II"&X&$! )\$3!, (5,2$(!4T_
MK$_]-,@%)R$PB81$/F(C\^N@]Z!M$7,<3+\T@$,U)*AC6JJKV(&IRO',<K:[
M8BS@SON0D5;-'15EB)<0%,S@QA$>6@<H-M@V]-@V_A\-!70-+F!K87T33F]<
M9HNUBY0Q\[E>^1J<K>OLK W=S3I,79RE3<-V: F(8@"J _R!OZ Q%K\BWM-\
ME7N*5*1F2_M'N/*S+M$L=8MG;!5:_**34Z=92R7UV:+K,5+/8M9$ZC,7*IR-
M^T;B B',);?>F'VP) #+>W PMA+[93O>Z]Y]L]H+<4M^Y]P'L_\ ]/EL/+CN
M.@W>@ #?I\^F@UPO4BNT&IRK NJ3D'%%R9$!'N[@98I1;EZIF]1^7S#01O\
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M3\OX=0;-)I\JSR?C&RQCH6E;AT)R><)J0+:Q,A28,UP*3DJ0[M8IDVQ5CE,
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M ,(V*C'+?_RB.=V&C35;D)MR^,!.\X323,!Q,8QR#].@RJEFOS5;0X/9:P>
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MY XZN^;Y3+WD!_O32KY<CV7%-><U)G7'^)819U(<J6D]9+K%G8MLQ4:E374
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M\KL<>6"DMFTZ^D+56[54;:M,22T;*5(C2(<(3J!&C1$KL7"R3<HI'* <50V
M(T4NT8B\/WLY'5^DY$H>(93)5DHK2AU#QVGW<>WMS9-*6'(+:4JC.3ECT-Q$
M=J.;O%4 074+SW  ,8 6-B\T/&"MS3;)2EWGI 91A%4%:OQ6/,KSEL0>OII5
M2*3:TZ/K1W3!(7AE/>+G;_2!4Q,<I #<%54///P\MQF:B.?:#69APF\04J>0
M9=3'%VC56ZXE72L%*NI8.<AG6S8#$]RV3,HD('((D.&@D;6LGXYOB0_L6^TB
M[$)V$W/[6L\+8^P$@BHLT*Y)$OW(H [12,8O/B)B@(AN #H-9C^>-,IV^/;Q
MB$5%U2XR])B^+9X@1^SARM_=NDO<E!8XI/5U4>29U$3"F)B]-P -/:&-L9R%
M<C:O573VO5\(IU%A%7I&K)@LS!1JK&SD:M&OC2,.#$X"4A!.4X;@8I1 #:!W
M6R:B0 !BE ITRG./(QS@L.P]L3"(%$I.1O0 #;;096@- ?WB'ZAZZ!(V2MRL
MXJ4\?<9RLD^V2L>=.'0C!,HM(LEVK>1,L\:.50=1"RI5FX ($!1,.0"!C (4
MK=:E(.(J,:_MTU975;B4XV3F)<K,K^VN$V16HRTV5F@W; _45)WC=HA"=P1V
M+ML !E6E@B^@I-DY6%%N[:B@NL4AE#I(F6 _,$R  GW.780#KU';0*8=Q$>G
M7<>G3_QV#0>=QWV-L7Z=]Q$!#<1,  .V^VX  _WZ +N)=Q#B._4NY1V+_P V
M_+80T%!.78HEY'$_4I0  $0]-_J, >OZZ!$6K)N/*0V]W;KU3JJW%ZVC$W%D
ML\)"-S2;YX2/8L>](/4B>Y<OE"I%)U-S'80WT" D?)/ \0>-*XRY0%!F+"RI
M[ B-C8N@=V9Z[.S:PS L<+SWDHY>@*8($ 3@?<1Z .@>YD^0?((.VBZ;AFJ4
M125(80YEW$.9@/Q'T#8=P 0-\- F_OCN12=E3J4OR25=(]N12CFJ;E1H8H$4
M 5G2H>U= ?DF<2FY% 1  $- S=@:9$M1Y&.<^.^*Y)@BW.,6]NMXC7[-=P0R
M)DD74*QH,N*:?<.8=N]ZDWW 1#07J_@^M/E62UNQAA2,2;=N08H5"KK,Y!I-
MIF!8KM&9+]M$S=,PG_I@@4W(.6^P[:#99QQ!<LO5-2M57/62,'/"3L/,1]OQ
M>VJY;*S0BBCW84Y[5"V&*D(F36-S5!5L8P@ %W$H=08:/\-LJ?LJ;IEG\[_*
MFU_>USJC9%%,3P%D8-C)%2^W,9"OX[C2(M3'#D.Q.X(B(<P#0,.V_&E=V]XJ
MUZD_-O/V3IREH12$?!951KAJF=I'J2*L2N]9XJ;8VE'\K$N9!P=NX<NU]NZ<
MIP.4VV@Z+4BGW+]JJ0F9YRFY'DBRRKEFXBZ4$'#-XU!8?M*"D1+2EC,XD6K<
M"]QR*NYE1,8I2!L !IKF^R%1J<XG6!,4OE81A8WLFM/_ 'FFPH-V[9PK7$0>
M,&]B4:$!T#=)V<45 ,7D9,G+B301U\7H;R=Q[19#_=3$56>7O(.1+QD"\2D)
MG +"LB:RS:KF(0;EF*;&@,5!5\C1@S:INU 1;MB@ D$1* 3@CGCQV"H2$,YB
MSI.#HHD=N8UT+Q%,""201,R=+]M(YS"'%3@MTZEVVT%BSV1C4X9S.2+68>,V
MIT"+(P4-(S\B .%B(@J2-BF[EZH@B)^2ABD$$R )AZ (Z""GFOE7%!<2U&Q6
M)Y!F:53..*Y K*]O+/2H9O(N9=S$M7LM)LXQ1TS28(2"KI(5 [!E$"@?</I$
M']MV7J;.1$%*T'..':\9K/P+J2?75Y%2$9(UQ9T4\BQCT7$_7EX^<DXY%5)H
MZ!0Q$5!$QTE"AQT&ZBZ,W9P=C9ELF0EV4MDU/(RLW)SS=1TR;DM%;M98&NR1
MG'LT,;J,XKVBC8IN QRCD@@!C;&!\] ?W[?KZ[?KH-*C).RK']^T008B!C(/
MDUU-]^X5,B#AHNDFLDL(FVW#D41WZZ!&9>@VEMQE?:LZGR5=.9J4XV-8U70,
M$JZ?[:Y<M)YP\$PD;M(MPV!=4PF+Q2(8=P]= T5>M=<IC&:R1>[1$K4M'%>,
MH9[E-O*)+U:UOP!ZP>.X*6:N5/>E=2;TI2J%XF[JY2@(CUT$&_"_R>\5*S=O
M,J9GL\XGJ;VU^4,TQKS:YY':14N[I%$I%2HE7<)NK=)-5IA@JO"/5$3(G632
M35!,QN9=@#J77,KXQMQ$5*QDJ@61-=LR>HJP-N@)5-=G($$[)TB+*27%1N\
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M&@23',L-,S,[7YA_CV(2:T=;(4:FAD2$LL[(4UL.[BV.ZBP;(R:%33(H00=
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M>6[W* QU3[1>[4\!A7*?!2=AFG0AS.FPBFBKM<J"6_)PZ6!/@DD7<ZJIBD*
MF, :!H?&?'YJ=CL;-- NYR#F"7=Y:R1+/R%"3<V*WD2>,818P$(9./I%=]G"
ML40 I4FK$OTE.8^X2&T'DQR)\3*'(0!.1,HG,4H&44,!$TP$P@ G4.( 4/41
M'8- W&-L7P6,D;@,4[E):4OEZL.0+3/SJZ3N8E9F=63(W;KN4D4 ^VUV%:-8
MR/1VV;L&:*8;\1$0<G0&@C?Y%9(N.*O]E;)7CL!JDIG*D43)S5W'&>*_LZ_^
M_K#:18K) *T>O$6I]'KF4+T%(#%, E$=!(XX@4I@,)@Y;)\B (B G$"@;I\
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MQ+Y1R(3%TSVSD;C-WTV(_'RH4Z@R4[/0TE$R1GB]DG9'[A(HB9<B*IP*D E
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MO$I3("$155)"HLGLS(-B_NYM#V-I[6ONQ;E.I]K6EB,/O#4SDO#<12.4NY@
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MD7+<J0$]2=M-(H'#Y@.@WAOIVY" ;[[ (AN.P"([!ON(@ :#QW";@7?<1#<
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M\+.,EZB0A'1RK@)/JV#00\PFQ)CC'?F3?K?XY6%M@?R)\D\:?D"Q#)PU1F9
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MS<-W;I"0+;I%I66D:NBR(=SV9%]*I(&.&Q4RJ"8YBD Q@!6  % "@&P% "@
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MN!0 I2@)A-Q I"D H"/78 +\=]![T!H#0&@- : T!H*AU$/X_P!O7IH,=N'
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M$F0IG&#VM4-6):T!O5[^RC;CCF3AVJ<;$.J-8JA,DN%5E6C5D5$%6JQ%#@0
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MG3;06'!3]AQV2D[_ +94$!';_KB4Q4=]_3ZQVW^6@P8-DY9PD6T>J=QV@R:
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MF?@;F/>  %-(Q"%-]0[[@903;:"_H#0&@J'40#YCH(AYX\2L)YURUB+*V5Z
MWMDOAQN_=TYZYE7K1HRL#V5BEX=9[&,3(*R!XJ0:E<-3"N4J:IC<BFW#8)<&
M44(=$@[#W5.!A#?< [9C[@4>I!W#]=!;>+H),W!W/$Z)6QSN$U"E.0Z(D-W"
M'*8! Q#%W#8=P'0(R=QICJVQ\;&VBA4RQ1L4X5>1L;-UB%E8YBY6;F:*K-6+
MYDLU14.V'@(E( B4 #01FFOQ\>$-PFS66<\:L5O)XBP*_<F<(XBE47"+@5$C
MM_MSID1N=!4FY!3*7B/\NP=- QF<\588H\9*XSEO(S.M;@7T/0Z_BCQ]P1<I
M)#(U<<0K&>:OVE>B*W[VQS49=D9)IW%)9,K5HJW[@NB$4#@#18)\:/,*@4M+
M'2&6;?@CQPEH#)RT9CAPA4L\9,Q16C5J(;1<;8<J6!,DB-AFIE_(R:,?$IR*
M4>/_ &Z:Q0)N4-P[E/(3#6&)B2@/,CQ8GL1RS&@)U#,V=\?23:WN8BS,6YVZ
M,O'TEY$T:X35I=!(J(&&+,_?G6-[@RBH<R@X>*_*A1LT?VC(E@9S&<)6LV&.
MJN%ZM"Y0Q5C;*,C$/UW=41Q8.=FT6V;761KD2BBNV*KR4<JB"?,%"B(.#,92
M\O(;* W%YXR7U]C-6NKL(^KTK+>+K&]?2/9D'L<O8J9,QD$_@)=XX%)%=TVF
M739J0J9#%, J" )W(7GIDVGX^5D:[X*>6E@R@M"(O8RCR%)9MJ\I8!>()2$#
M)WR"D["S:HMD3J*%>I-7"2@<.)1W,!0;F(MV*,G93J\SY1/\GVK*E7O+)]1*
M8SPQEII@?#%L?T\8(J$*\=5<\-?.*-E,HK/3)E43R*!SH)M$D@1*"'_)+Y$>
M,+GQ2O\ 0;5E?'=]LU>E,<RQL<7.MQSR:L;2IWVMA;6$379-M$JA+N84'1EC
MMA[B*8&3(!2*#N"CS#&?C6\A/'&<J>+9#PX93U^952EX^D^S3*W,Q5UEE6IZ
M4P6D(!)C=82334BQ*3BHFJ443$.(E P"$RZ7@GQ1B B;=5H7&RLA!4E?%ZTU
M%V8DA"KU^(!J>6@9+G,.X]R,?(' ZIW!#/$E%/K.43]0A_Y ?C?P3D")\C\P
M91PY$YMM%HJ#28I5>A++<T[;3'E=J1"/(#&]U>/WR[%E99Y T@DW08)(H*N%
M" DJ!]M!)_&V.1:,:76D<D9]K,!1\?UN.JZ\S?&S@+V+V-8RSB8ER.X9-\4]
M-%<L8";H&C93<R?8_I%$ R;+XWYY7L\O9L>^;.6Z.WGG%;5EJO,T'$=_@&QJ
M^Q*P64K:$_4RO8!2?;$!1XF191!9<"J D4=^0*:QUSR#JV/YHM>SBQMV4U8R
MSQ^/D+9CVGPM;G;.Z;NGE7:SS> 2CE@"/2:B191!PV15(7F9,H@("#<X2N'G
M\?(D%">2U'\9ZU2++7RRS"4Q3.W>=LD19&21',E39QO8Y%DQ>NU&G,Q'[ AV
M:9R[ 54!Z ].07_E0P4D5,5PV!K2@1F!X]K>)B^TU_[_ -TIW$7!XB-MS5=J
M@Q%,Q3E%(5E3& 02  $P)ZI73S 6/)-[OA+"C((X[<B$I6\VS[MI.=\2%5,P
M82.,V[IA[,>7,KQ5(QQV @&#<=!LF&6,Z(7&JPEH\<UHJHSBEE4L-^B\F568
MBZ)'PCEV5@YG8_BT?O%9F/13<$(U!3AWNV/]0AP &&+^0SQPDF-AL<Q6?(6+
MKC!LC'O)BQ>.F6HZOR!!L25=9EA7BM:XRYI:8>HD;D0%0S@IR&( [[Z!_&_E
M)BV84A&L=#9.E)B<0DY2%A4<19#2E%TH) KI94Z;R!:-F"RR*PBV*X62.X$I
MBD 1 0T$.\I^0.(/(#"F1/&W)-OR]5G>7Y62PFK9_P#TQY!IYH\;8Y9IMXEV
MULL7.UQ1<\=( V7>J*I,UDC"<I$S@(B$QXJ)LE>S)1*LVJ;->N0."I*'0OJ<
MDHT12")GZ0R_;*M9;L46;=W*F:%7243<=M)!(Q0(.VV@Q;! /7=:QV2/JW[M
M2<>0,/9)'WI.*]59LKI(OCV9N*?:*!H15DF8@G*;<AQ 0WZZ"30>@==^GJ/7
M?]=!70&@0=KKU5G;%0'4Z]%*;K,Y(6*HL22_L%'LBE"/HU\<T>5<BDPW:QD@
MJ<R? Q4O^H(;@ Z!<<3=KCS^OM[<]_\ 5Q_FWX[^OZ;Z"YH#05 -]NFX;A^H
M=!_\-!QNI+JP6_PMS]D"4FI-6T^1GE39&L>[>LFDD^&"+GBOXEK4*";9--(T
M<C1Z@"28&,0K5M])!#@41!T?-:%H5Q\M/QP8]MEVEZTM'Y-R!DJJ5NOQC:7<
M6ZUXXCZ6_@H2P)'0<.HVH+Q)Y4[EWNFD4R!0,(F H '360>%8,GL@=%TX(R:
MN7AV[%NH\>KD;)'6,BS:(@*SITJ!.*:9 $QSB !U'0>VCDCQJU>)$732=MT'
M*:;INLS=)D<)E5(1RT<D2<-'!"GV.FH4IR&W P ("&@U\+.1\^V=.XT71D64
MO-0:XNV#Z.4"0@)1U#R14D7[=LJNU*^9J BX(!D'*?%1(YTS%,(;?0&@- :
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MR61SW#T=)N@W=-25^)Q;BND5>-JJ"*HE;$80ZPN#-P;ID3*FL! $P%#8)O\
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M4\]X?R75,90E[*>2J\0CD6W5>Q2,&J55N$^Z5JK<K)B5RJV%($%%1<"3B80
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MN@F1%%$.@$(D(AL'K_,707= : T!H#?05W'YC_B.@P78 <[1,X <IGK90"'
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MK,G?-W#F;JN5TFB;MP9DF<4T0.H8A""(;;B(B&T*B0A3% 1^HP&$P["83!Q
M!'<! 1 "AU$!T%W0&@- C 4F3Y$%#[@<*\G3C'^V@D0"!-KS" $>&6$HG,H1
MD@8I"[\0 YA$!';8%IL&_'X;[?W>F@MJ)]U-0@**)B*9B<DC%(<O<#B"A#B4
MPE4)MN4=M@'0-B;&+8R:A$+WD]F!UUES$0N+A/=950RAQ ZS94Y$S''^4H\
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MRU?8148A"1$I=%8"M/Y.,D)5!Z9!%JZ; NHW*L8VPJ<0 P!H'W4 YG#<"%.
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M#Q$PF,( !>73?TT'HARJ$!1,P'(;^4Y! Q#=1#<I@Z&#</4-![Z_KU_ST%-
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M(Z!9Z T!H#04$Q2AN8Q2AR @"(@&YC" %+\P,8P[  ]1T%=!7;ION'4=O[P
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M5QK@KI)/#NV$U$/0*G+5:T12JC.R52>;[@+2;K\J@JW<)^G,O,HB0Q3"#D:
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M$ >(!QW !VZ:#1&Q=C4Q%$S8^I9DUC31E4QK40)%#62)^PV$3$%H)3#.0?\
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M(.4N)%  YBEX&Z@#%>-D'6:S>/*B%IL:O&,#YW&<F.^H^7;N[?9Z;696U.F
MN0 $FJKY<H@FF8Y""([B&^P!+<?T]- :"UNKWQ+]/8]N)]^!^?> ^VW<_P"E
MQ[?^G;EOU]- WM,39JV?)KQN*ZZCJVQJ4@59(4T&[V*I]>C ]H"O(%2"DW+S
M.7IW-]M_70.1\?0?7TW#?^&_IOH*:!IK]4L<2:$G,Y#/#1;!RDTB7,^_LKVM
M BBDN*C%)-Z:28MV;PKLX<3%$ICB.VX^F@Y V7$V-LN^8/CA?',MD%],M_,+
M+2]29R&6K-+5E>A8'Q6V!.>HD&G-NJW^WFV18Y!)PX30(Z.H==J<YBE$ #<>
M5%5J2F<_'?#O^Y'E_8GD]Y)U*739JY0?M(.OS=BI-ULU/E:=8+)7I1K88S'R
M]&<.G\>+DQV:+KJ)C*$* =L4V:R,82/)(O3.$F ,R2ZOM5I$5BH=DLDIW6QV
M2SSN?U1Y(BD8_J02]-!%:$\>\U5N+"+B?,G*BB9>V=-26QAX]N^#E67-(RCD
M2Q^+8<R@R+<YT0 QA[1CBH F$ * 1GRI^,6+R_DFUY.M>87*%@LS^M.7#RIT
M?_;R6DV=:*0C=C=)G'%OJ#FY*NTB DHZ6*BX(A_2(8I-@ %BS_'O17K2DX]N
MRM?E,:XW=V&U8X1QS393"EMH5GFUXSWDA"Y$H5U0FE9&652<'D.Z '?IJAWC
M'X#R!1K?CKP0G.MK']XR5+2?MG];64R!<)++(*TBS)%96^C,S9$_<B\1"VYC
MS1>*H'3<=M4P=P"\0*"3)X;9MA'Y:?%^6F3(7Q5C*"5DEAUD]:*7UI.,&ZZ2
M=?8YT7K3N_,L7)QA@:E:(;2B:*9.#@!* :#7-?#^Z3\CBBX4LU&\<)BH8Y+C
MR,OF"KO;).15Q<U[\I2Z/9<?Y)Q@M3<EP"+UT5TZ+,I-7Q%E%NTL0RAQ$')P
MQXZQ"=ZELH369)_-F:\5.I[%4+9;I4(.L4C%ZTE%P<O9V%'Q;06]-K#%_/1L
MHS][)@=PZ<$'M=X"@8F@0<%X*9>I25MC\2^8%PP55+<_FGKC'>-<?U^3H\"[
MG9!]*3$W1VN2I*[SM'F9R3>F=.08OP:IKG/V4R<M] C8+P RMCTU-GL3Y5H=
M3R)627AC<+Y*U2=M[[/T+?7J4E/1^=FECEGRMK<.I!JFNFX0=-3,E-P;@FD!
M4P!U<6^+V3Y^UXLR=Y!W& 9-<'+R;W$?CIA.FHX\PW6)@\4^@DK//1SZ:M4K
M:;$T9NE?M12O6S*.!8QRIF44$2!XQU%WFH9X\C/*"4Q'F [3,E"P+ Q^/ _:
MDA8HEWC=KD-A(HM8I"S"S2565ED%%S@XX&*NF8!'8_$);4')LA=J@YM$EBS*
M% ?,F[I5>H72%B&UE55:) H+:.2B9V6CI!1T(\4!*X JAN@B70;* R*UG/V@
MDXJ=]K;ZXM)MXUCK)6%V;F%) ]L7"5G79+R,;!N7I%0%H15<1<AOPZ@( $<?
M+QO4LN8ZL^!'KZZ5.X6&<I;:@WACC2WVB$K>26KT+E0K(>1A8ITS+"14W6TR
M2+@R[9-%-04CK)F5*.@@;C"SYSF\VYS=XG\)I.D^3<Y#Q%1RIY&72^6%AXTK
M-)]O'B.0<8UVQ-"3-J.LXAD)!Q"M&+=R M2(.G)3>H:-^WQ]B.J*4;&%5O\
MY#X7:8'I> /(BH52LVS'F:H@]9GI5:)R#1JK:JW _O&-M,C:W*,NRCUSG9H
M5P50Y>X)P>+.K'R8\I6-(&(I;_POHN%;?"Y&QQ,Y@?U9]8,A9IIYBEQI7):M
M5.1L:=8Q1V5G1)-==TF]7!0I2$(4AN88=LS]89S'[FK'\?\ '6/L@S&0DK"]
MM,AY.88:X:B<FMO_ #-YDX\NVLB]EG(TD@"CH8W[8E(OR(%26(D4QE "8+'(
M>(/$OQ'57AKK4[C7O'?'L957"D?:($0E[?&Q+5M&P;URW>*M8F;MLVY2$B*H
M@<ON@,("7KH%QXUT5WB3#39:_P!NB9ZZVB5GLG97N2<FU&O.KS=7YIF?^V/S
M"@S0KD,*Z;!C_(0K1LGL ;[:!PF63ZO,7#(='79RC-+',;5WEEL<]&&CJ4X-
M;&CF091\9/2/:CY=PR8H$4=]H3)H"LF4QN8B4 3>3<X4/'&+K5>8NP5:7&$:
MEC8",B9B-=)2URFETXRJ5I$L8JY$CF9GW[=+8I#&(0YE!#B4P@%SQZQ; X7Q
M=7L>Q4H6;EFWO[#<IY==HM+V>\6I^O/6^SRQFVPG<RTZ_5,7D @F@":11XD+
MH'M$Q Z"<@#\A.4!_P !$!T'K8?D/^ Z!#Y!R/3<6UQY:+O-)1$:U0<*(H$1
M<2$S,+MT3+_;*Y 1Z3J:L<RN4NR+-D@NX5,( 4@Z"+C:L9N\GN,KD"1LWC]@
MMV6/?P&,ZL_-#YER%%N4%%5O]W+.D"JU"AGS=5,/L$.9&3)N<KQZ4?Z!0F)
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ML!A^#43?-E[)DEZQD$WB1HUW?[*=DT9R#=5NY9HID>)B=LX*H;Z3F.8F_00
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MH.9?W0BW>2XO5%R*+H#P4(0N^RG/02TZ>FX\?GN.^WSW]=]M!8='<)M7*C1
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M"55JU=K HD4%= [^3<P8QPW")V/)]V@*9#*S-=KZ;R:?)-P/+VR71@J\T*D
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MH%;23>SQ$;(O4A?)J%1:D0>$*BKRV#68*H5BG/"G)=RQ>JX<7;-.&83(E0R
MXQM"WF\K>2-K?7EYD1I)3\Q&S;R>_P#.F#*)!J\0(VA&X%133( ;B#8-('"U
M7\C?,;$]L<-W7C]XJXTI_DI6<0)4\UNK-*SSDR/,?)*T/4$FCMK96T,^BV3I
MC%*H.X^,>6%P<B9 ,/$%/DF+M^*O(GQ'RY5\>XJH,W*0WCC6WSW$\(E3Y>_V
M/+.1&=8S?1++$14>UC;+58G'-FBYQCS:<F+UDNJ15(I#  =_1]1_B.@IH/(I
MIG$!.&XE 0#^!PV/_B&@;G(0%:KXY=D)N1ID:#3_ )3' I9*+FX03'VZ%  D
M=@$>F^P>HAH')'^8?XC_ ,=!0/J]! =M_B'P]?\ #04W#D!/]0[B   C_*(
M.X@'$-A$/4=!7^W00'_AH#0&@UTN[!C$RCP^X)M(U^Y5. @7MD;M%EQ/R'KN
M';Z?+UT&@Q]/&M%%I]D.! -.UN'E?Z:_N2"#UBBN0P+_ /U>9#@(C\Q'0+#0
M&@::[6*%)=<-UL;\^KDO9K-8)&$@8I@:1;Y"9U>I2[^:@Y.02;.&T3%QZ*Z;
MT5CJ)=Q=!-$HF,?B(16O/FG::MY0W7 D5B)K,URGX0O>1VEU?7J+@E[9?Z=
MP=C3QRRC'+=96":.X^>0*>7=$.U*H?8H&%-0H Y"/FAB-CB>HYDN2KRG4NS8
M$?9_=R[P[=U&0<'&.:@P=5E9]S:G?6AQ)W%!NS031 '1TE #B/$!"05!O37(
M<*2QQD#88F!>HQ3ZOR4\C&-D[/#S,)&SC.:B&[*4?O46';D@0.#Q)JN#A)0
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M)R*L3][5YNGKP5KLM49)6EL9 DXC#2*D?%V:,[9N\XKED_IK-E1*4QB&';H
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M)3#L;J8  ?I'Y^G707B <0VX"4I>A!$0^H/GQ'J4/XB.@J(;>O3X_P!WSZ?
M- ;!_P Q/\>O^'KH//(/G_D/_LVT%2_5Z=/U'H _PT /3]?X"'_CMH*B'$ ,
M(&$!VZ%*)C=?T#0>.0#_ ,W_ .*8/\Q#;07 *)O3X: X#_8!'_@&@J8#B!0
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M3D38FB115.H)UD@$B20F.4NX:"U+>7V-*M*1<5?*GFR@JRK1HY1D+'A3(JT
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M0JBS<RR(J(N#(G,)!4((E.(;AT$-!D'(D8VQFZ1P*'\XIHB0HAL(E$3!N4P
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MWN)#?;;E[Q7UV]=M_G\-!C.*NFNY]R$S.MP! $0;H/Q*W Q=N*PD,0PF.4P
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MRS$X5LJ@TX%5.#@054 3 4@"!0"]9,;X[N2I'%OH-+M3A/;MN+'5X2:73V
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H&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- : T!H#0&@- :#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>ck0001680048-20170930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 2.0 on 13-Nov-2017 [06:42:58] {PM} EST - www.datatracks.com -->
<!-- Based on XBRL 2.1 -->
<xbrli:xbrl xmlns:ck0001680048="http://www.mustangbio.com/20170930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
  <link:schemaRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd" />

<!--Context Section-->
  <xbrli:context id="P01_01_2016To09_30_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_02_2017To01_31_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-02</xbrli:startDate>

      <xbrli:endDate>2017-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2017To02_28_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-02-01</xbrli:startDate>

      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_17_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-02-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2017To03_31_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_17_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To09_30_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To09_30_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

<!--Dimension Section-->
  <xbrli:context id="PAsOn09_30_2017_CommonClassAMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_CommonClassAMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_CommonStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_CommonStockIssuableMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001680048:CommonStockIssuableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_RetainedEarningsMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_CommonClassAMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_CommonStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_CommonStockIssuableMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001680048:CommonStockIssuableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_RetainedEarningsMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2017_CommonStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2017_CommonStockIssuableMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001680048:CommonStockIssuableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2017_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2017_RetainedEarningsMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:CityOfHopeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_StephenFormanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:StephenFormanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_ChristineBrownMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:ChristineBrownMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_17_2017_ArCd123LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_CityOfHopeMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:ArCd123LicenseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:CityOfHopeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-02-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2017To02_28_2017_ArCd123LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_CityOfHopeMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:ArCd123LicenseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:CityOfHopeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-02-01</xbrli:startDate>

      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To09_30_2017_ArCd123LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_CityOfHopeMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:CityOfHopeMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:ArCd123LicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_28_2017_ArCd123LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_CityOfHopeMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:CityOfHopeMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:ArCd123LicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_17_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_IlLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:IlLicenseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:CityOfHopeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-02-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2017To02_28_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_IlLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:IlLicenseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:CityOfHopeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-02-01</xbrli:startDate>

      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2017To02_28_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_Il13ra2MemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:CityOfHopeMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:Il13ra2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-02-01</xbrli:startDate>

      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_28_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_IlLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:CityOfHopeMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:IlLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2017To02_28_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_SpacerLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:SpacerLicenseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:CityOfHopeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-02-01</xbrli:startDate>

      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2017To02_17_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:CityOfHopeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-02-01</xbrli:startDate>

      <xbrli:endDate>2017-02-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_17_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:CityOfHopeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-02-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To07_03_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_Her2TechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:Her2TechnologyLicenseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:CityOfHopeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-07-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_03_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_Her2TechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:Her2TechnologyLicenseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:CityOfHopeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-07-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2017To05_31_2017_CsTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:CsTechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-05-01</xbrli:startDate>

      <xbrli:endDate>2017-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_31_2017_CsTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:CsTechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2017To05_31_2017_PscaTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:PscaTechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-05-01</xbrli:startDate>

      <xbrli:endDate>2017-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_31_2017_PscaTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:PscaTechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To09_30_2017_ArIl13LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:ArIl13LicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To09_30_2017_IvicvLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:IvicvLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To09_30_2017_UclaLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:UclaLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To09_30_2016_ArIl13LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:ArIl13LicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To09_30_2016_IvicvLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:IvicvLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To09_30_2016_UclaLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:UclaLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_ArIl13LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:ArIl13LicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_IvicvLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:IvicvLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_PscaTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:PscaTechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_Her2TechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:Her2TechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_UclaLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:UclaLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To09_30_2016_ArIl13LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:ArIl13LicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To09_30_2016_IvicvLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:IvicvLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To09_30_2016_PscaTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:PscaTechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To09_30_2016_Her2TechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:Her2TechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To09_30_2016_UclaLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:UclaLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To09_30_2017_PscaTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:PscaTechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To09_30_2017_Her2TechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:Her2TechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To09_30_2016_Her2TechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:Her2TechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To09_30_2016_PscaTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:PscaTechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To07_26_2016_CommonClassBMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-07-26</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To07_26_2016_ConvertibleCommonStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-07-26</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_17_2016_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2016To03_13_2016_CommonClassBMemberusgaapStatementClassOfStockAxis_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>

      <xbrli:endDate>2016-03-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_13_2016_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-03-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To09_30_2016_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To09_30_2017_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To09_30_2016_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2017_NationalHoldingsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:NationalHoldingsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_NationalHoldingsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:NationalHoldingsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To09_30_2017_BoardOfDirectorsChairmanMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_BoardOfDirectorsChairmanMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_AdvisorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:AdvisorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_WarrantMemberusgaapInvestmentTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_PreferredClassAMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_UnvestedRestrictedStockAwardsMemberMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ck0001680048:UnvestedRestrictedStockAwardsMemberMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To09_30_2016_WarrantMemberusgaapInvestmentTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To09_30_2016_EmployeeStockOptionMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To09_30_2016_PreferredClassAMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To09_30_2016_UnvestedRestrictedStockAwardsMemberMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ck0001680048:UnvestedRestrictedStockAwardsMemberMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To09_30_2016_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2017_PreferredClassAMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_13_2016_CommonClassBMemberusgaapStatementClassOfStockAxis_FortressBiotechIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-03-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_27_2016_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-07-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_27_2016_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-07-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To07_27_2016_CommonClassBMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-07-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2016To03_13_2016_CommonClassBMemberusgaapStatementClassOfStockAxis_FortressBiotechIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>

      <xbrli:endDate>2016-03-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2017To02_28_2017_CityOfHopeNationalMedicalCenterMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-02-01</xbrli:startDate>

      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2017_CityOfHopeNationalMedicalCenterMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2017_CityOfHopeNationalMedicalCenterMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_LicenseAgreementMemberck0001680048AgreementTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="ck0001680048:AgreementTypeAxis">ck0001680048:LicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2017To03_13_2017_FortressBiotechIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>

      <xbrli:endDate>2017-03-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_13_2017_FortressBiotechIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-03-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_30_2015_CityOfHopeNationalMedicalCenterMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_LicenseAgreementMemberck0001680048AgreementTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="ck0001680048:AgreementTypeAxis">ck0001680048:LicenseAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2015To03_17_2015_CityOfHopeNationalMedicalCenterMemberdeiLegalEntityAxis_LicenseAgreementMemberck0001680048AgreementTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="ck0001680048:AgreementTypeAxis">ck0001680048:LicenseAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:CityOfHopeNationalMedicalCenterMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>

      <xbrli:endDate>2015-03-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_01_2016To09_30_2016_NationalSecuritiesIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:NationalSecuritiesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-09-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_01_2016To09_30_2016_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-09-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2016_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_02_2017To01_31_2017_NationalHoldingsCorporationMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:NationalHoldingsCorporationMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-02</xbrli:startDate>

      <xbrli:endDate>2017-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_02_2017To01_31_2017_UnregisteredCommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ck0001680048:UnregisteredCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-02</xbrli:startDate>

      <xbrli:endDate>2017-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_02_2017To01_31_2017_NationalSecuritiesIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:NationalSecuritiesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-02</xbrli:startDate>

      <xbrli:endDate>2017-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2017To03_31_2017_NationalHoldingsCorporationMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:NationalHoldingsCorporationMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2017To03_31_2017_UnregisteredCommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ck0001680048:UnregisteredCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2017To03_31_2017_NationalSecuritiesIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:NationalSecuritiesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2017To04_07_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>

      <xbrli:endDate>2017-04-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_07_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-04-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2017To06_08_2017_DirectorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-06-01</xbrli:startDate>

      <xbrli:endDate>2017-06-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_DirectorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2017_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2017To06_30_2017_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-06-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2017_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To09_30_2017_EmployeeMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">ck0001680048:EmployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To09_30_2017_NonEmployeeMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">ck0001680048:NonEmployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To09_30_2016_EmployeeMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">ck0001680048:EmployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To09_30_2016_NonEmployeeMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">ck0001680048:NonEmployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_EmployeeMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">ck0001680048:EmployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_NonEmployeeMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">ck0001680048:NonEmployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To09_30_2016_EmployeeMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">ck0001680048:EmployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To09_30_2016_NonEmployeeMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">ck0001680048:NonEmployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_17_2016_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_17_2016_NationalHoldingsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:NationalHoldingsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_DirectorMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To07_26_2016_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-07-26</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2015To03_13_2015_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>

      <xbrli:endDate>2015-03-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_13_2015_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2016To04_08_2016_ChordAdvisorsLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:ChordAdvisorsLlcMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>

      <xbrli:endDate>2016-04-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To09_30_2017_FredHutchCd20MemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:FredHutchCd20Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To09_30_2016_FredHutchCd20MemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:FredHutchCd20Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_FredHutchCd20MemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:FredHutchCd20Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To09_30_2016_FredHutchCd20MemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:FredHutchCd20Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To09_30_2017_CsTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:CsTechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To09_30_2016_CsTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:CsTechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_CsTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:CsTechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To09_30_2016_CsTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:CsTechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_ArCd123LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_CityOfHopeMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:CityOfHopeMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:ArCd123LicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2017To08_03_2017_NationalHoldingsCorporationMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:NationalHoldingsCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-08-01</xbrli:startDate>

      <xbrli:endDate>2017-08-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2017To08_03_2017_NationalHoldingsCorporationMemberdeiLegalEntityAxis_UnregisteredCommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ck0001680048:UnregisteredCommonStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:NationalHoldingsCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-08-01</xbrli:startDate>

      <xbrli:endDate>2017-08-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2017To08_03_2017_NationalHoldingsCorporationMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:NationalHoldingsCorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-08-01</xbrli:startDate>

      <xbrli:endDate>2017-08-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2017To08_03_2017_NationalSecuritiesIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:NationalSecuritiesIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-08-01</xbrli:startDate>

      <xbrli:endDate>2017-08-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis_FortressBiotechIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2017_FortressBiotechIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To07_03_2017_Cd20TechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_FredHutchinsonCancerResearchCenterMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:Cd20TechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-07-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_03_2017_Cd20ClinicalAgreementMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_FredHutchinsonCancerResearchCenterMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:Cd20ClinicalAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-07-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To09_30_2017_Cd20ClinicalAgreementMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_FredHutchinsonCancerResearchCenterMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:Cd20ClinicalAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_Cd20ClinicalAgreementMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_FredHutchinsonCancerResearchCenterMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:Cd20ClinicalAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2017To03_17_2017_UclaLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_UniversityOfCaliforniaMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:UniversityOfCaliforniaMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:UclaLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>

      <xbrli:endDate>2017-03-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_17_2017_UclaLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_UniversityOfCaliforniaMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:UniversityOfCaliforniaMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:UclaLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-03-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_Il13ra2MemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:CityOfHopeMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:Il13ra2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_13_2017_CommonStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-11-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_13_2017_CommonClassAMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-11-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_17_2017_UniversityOfCaliforniaMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:UniversityOfCaliforniaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-03-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_03_2017_Cd20TechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_FredHutchinsonCancerResearchCenterMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:Cd20TechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-07-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To09_30_2017_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To09_30_2017_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To09_30_2016_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To09_30_2016_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To09_30_2016_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To09_30_2016_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To01_15_2016_CityOfHopeMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:CityOfHopeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-01-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To09_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis_FortressBiotechIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001680048:FortressBiotechIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2017_CashAndCashEquivalentsMemberusgaapInvestmentTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2017_HeldtomaturitySecuritiesMemberusgaapInformationByCategoryOfDebtSecurityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_27_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-10-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2017To10_27_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-10-01</xbrli:startDate>

      <xbrli:endDate>2017-10-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_27_2017_LetterOfCreditMemberusgaapShortTermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-10-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_27_2017_CashMemberusgaapInvestmentTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-10-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2017To10_27_2017_LetterOfCreditMemberusgaapShortTermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-10-01</xbrli:startDate>

      <xbrli:endDate>2017-10-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2017To10_27_2017_CashMemberusgaapInvestmentTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-10-01</xbrli:startDate>

      <xbrli:endDate>2017-10-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2017_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To09_30_2017_DirectorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To09_30_2017_BoardOfDirectorsChairmanMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_BoardOfDirectorsChairmanMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To09_30_2017_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To09_30_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_Il13ra2MemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001680048:CityOfHopeMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ck0001680048:Il13ra2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To09_30_2016_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001680048</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD_per_Share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>

      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>

  <xbrli:unit id="acre">
    <xbrli:measure>utr:acre</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>

<!--Element Section-->
  <dei:DocumentType contextRef="P01_01_2017To09_30_2017" id="Factid_1">10-Q</dei:DocumentType>

  <dei:AmendmentFlag contextRef="P01_01_2017To09_30_2017" id="Factid_2">false</dei:AmendmentFlag>

  <dei:DocumentPeriodEndDate contextRef="P01_01_2017To09_30_2017" id="Factid_3">2017-09-30</dei:DocumentPeriodEndDate>

  <dei:DocumentFiscalYearFocus contextRef="P01_01_2017To09_30_2017" id="Factid_4">2017</dei:DocumentFiscalYearFocus>

  <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2017To09_30_2017" id="Factid_5">Q3</dei:DocumentFiscalPeriodFocus>

  <dei:EntityRegistrantName contextRef="P01_01_2017To09_30_2017" id="Factid_6">MUSTANG BIO, INC.</dei:EntityRegistrantName>

  <dei:EntityCentralIndexKey contextRef="P01_01_2017To09_30_2017" id="Factid_7">0001680048</dei:EntityCentralIndexKey>

  <dei:CurrentFiscalYearEndDate contextRef="P01_01_2017To09_30_2017" id="Factid_8">--12-31</dei:CurrentFiscalYearEndDate>

  <dei:EntityFilerCategory contextRef="P01_01_2017To09_30_2017" id="Factid_9">Non-accelerated Filer</dei:EntityFilerCategory>

  <us-gaap:AssetsCurrent contextRef="PAsOn09_30_2017" id="Factid_10" unitRef="USD" decimals="-3">67746000</us-gaap:AssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn12_31_2016" id="Factid_11" unitRef="USD" decimals="-3">27499000</us-gaap:AssetsCurrent>

  <us-gaap:Assets contextRef="PAsOn09_30_2017" id="Factid_12" unitRef="USD" decimals="-3">67885000</us-gaap:Assets>

  <us-gaap:Assets contextRef="PAsOn12_31_2016" id="Factid_13" unitRef="USD" decimals="-3">27499000</us-gaap:Assets>

  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="PAsOn09_30_2017" id="Factid_14" unitRef="USD" decimals="-3">2723000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>

  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="PAsOn12_31_2016" id="Factid_15" unitRef="USD" decimals="-3">683000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>

  <ck0001680048:AccruedInterestRelatedPartyCurrent contextRef="PAsOn09_30_2017" id="Factid_16" unitRef="USD" decimals="-3">0</ck0001680048:AccruedInterestRelatedPartyCurrent>

  <ck0001680048:AccruedInterestRelatedPartyCurrent contextRef="PAsOn12_31_2016" id="Factid_17" unitRef="USD" decimals="-3">413000</ck0001680048:AccruedInterestRelatedPartyCurrent>

  <us-gaap:Liabilities contextRef="PAsOn09_30_2017" id="Factid_18" unitRef="USD" decimals="-3">2792000</us-gaap:Liabilities>

  <us-gaap:Liabilities contextRef="PAsOn12_31_2016" id="Factid_19" unitRef="USD" decimals="-3">3223000</us-gaap:Liabilities>

  <us-gaap:PreferredStockValue contextRef="PAsOn09_30_2017" id="Factid_20" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>

  <us-gaap:PreferredStockValue contextRef="PAsOn12_31_2016" id="Factid_21" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn09_30_2017" id="Factid_22" unitRef="USD" decimals="-3">3000</us-gaap:CommonStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn12_31_2016" id="Factid_23" unitRef="USD" decimals="-3">2000</us-gaap:CommonStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn09_30_2017_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_24" unitRef="USD" decimals="-3">0</us-gaap:CommonStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn12_31_2016_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_25" unitRef="USD" decimals="-3">0</us-gaap:CommonStockValue>

  <us-gaap:CommonStockSharesSubscriptions contextRef="PAsOn09_30_2017" id="Factid_26" unitRef="USD" decimals="-3">0</us-gaap:CommonStockSharesSubscriptions>

  <us-gaap:CommonStockSharesSubscriptions contextRef="PAsOn12_31_2016" id="Factid_27" unitRef="USD" decimals="-3">4396000</us-gaap:CommonStockSharesSubscriptions>

  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="PAsOn09_30_2017" id="Factid_28" unitRef="USD" decimals="-3">97897000</us-gaap:AdditionalPaidInCapitalCommonStock>

  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="PAsOn12_31_2016" id="Factid_29" unitRef="USD" decimals="-3">36998000</us-gaap:AdditionalPaidInCapitalCommonStock>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn09_30_2017" id="Factid_30" unitRef="USD" decimals="-3">-32807000</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2016" id="Factid_31" unitRef="USD" decimals="-3">-17120000</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:StockholdersEquity contextRef="PAsOn09_30_2017" id="Factid_32" unitRef="USD" decimals="-3">65093000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016" id="Factid_33" unitRef="USD" decimals="-3">24276000</us-gaap:StockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn09_30_2017" id="Factid_34" unitRef="USD" decimals="-3">67885000</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2016" id="Factid_35" unitRef="USD" decimals="-3">27499000</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:PrepaidExpenseCurrent contextRef="PAsOn09_30_2017" id="Factid_36" unitRef="USD" decimals="-3">414000</us-gaap:PrepaidExpenseCurrent>

  <us-gaap:PrepaidExpenseCurrent contextRef="PAsOn12_31_2016" id="Factid_37" unitRef="USD" decimals="-3">0</us-gaap:PrepaidExpenseCurrent>

  <us-gaap:OtherShortTermInvestments contextRef="PAsOn09_30_2017" id="Factid_38" unitRef="USD" decimals="-3">34088000</us-gaap:OtherShortTermInvestments>

  <us-gaap:OtherShortTermInvestments contextRef="PAsOn12_31_2016" id="Factid_39" unitRef="USD" decimals="-3">0</us-gaap:OtherShortTermInvestments>

  <us-gaap:CashEquivalentsAtCarryingValue contextRef="PAsOn09_30_2017" id="Factid_40" unitRef="USD" decimals="-3">33209000</us-gaap:CashEquivalentsAtCarryingValue>

  <us-gaap:CashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2016" id="Factid_41" unitRef="USD" decimals="-3">27499000</us-gaap:CashEquivalentsAtCarryingValue>

  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="P07_01_2017To09_30_2017" id="Factid_42" unitRef="USD" decimals="-3">2188000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>

  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="P01_01_2016To09_30_2016" id="Factid_43" unitRef="USD" decimals="-3">1718000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P07_01_2017To09_30_2017" id="Factid_44" unitRef="USD" decimals="-3">300000</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P01_01_2016To09_30_2016" id="Factid_45" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P07_01_2017To09_30_2017" id="Factid_46" unitRef="USD" decimals="-3">4596000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2016To09_30_2016" id="Factid_47" unitRef="USD" decimals="-3">1814000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:OperatingIncomeLoss contextRef="P07_01_2017To09_30_2017" id="Factid_48" unitRef="USD" decimals="-3">-7084000</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2016To09_30_2016" id="Factid_49" unitRef="USD" decimals="-3">-3532000</us-gaap:OperatingIncomeLoss>

  <us-gaap:NonoperatingIncomeExpense contextRef="P07_01_2017To09_30_2017" id="Factid_50" unitRef="USD" decimals="-3">144000</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2016To09_30_2016" id="Factid_51" unitRef="USD" decimals="-3">-374000</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2016To09_30_2016" id="Factid_52" unitRef="USD" decimals="-3">-3906000</us-gaap:NetIncomeLoss>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P07_01_2017To09_30_2017" id="Factid_53" unitRef="USD_per_Share" decimals="2">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2016To09_30_2016" id="Factid_54" unitRef="USD_per_Share" decimals="2">-0.39</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P07_01_2017To09_30_2017" id="Factid_55" unitRef="shares" decimals="INF">26186924</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2016To09_30_2016" id="Factid_56" unitRef="shares" decimals="INF">10130338</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="P07_01_2016To09_30_2016" id="Factid_57" unitRef="USD" decimals="-3">569000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>

  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="P01_01_2017To09_30_2017" id="Factid_58" unitRef="USD" decimals="-3">5388000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P07_01_2016To09_30_2016" id="Factid_59" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P01_01_2017To09_30_2017" id="Factid_60" unitRef="USD" decimals="-3">2375000</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P07_01_2016To09_30_2016" id="Factid_61" unitRef="USD" decimals="-3">1101000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2017To09_30_2017" id="Factid_62" unitRef="USD" decimals="-3">8293000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:OperatingExpenses contextRef="P07_01_2017To09_30_2017" id="Factid_63" unitRef="USD" decimals="-3">7084000</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P07_01_2016To09_30_2016" id="Factid_64" unitRef="USD" decimals="-3">1670000</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P01_01_2017To09_30_2017" id="Factid_65" unitRef="USD" decimals="-3">16056000</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P01_01_2016To09_30_2016" id="Factid_66" unitRef="USD" decimals="-3">3532000</us-gaap:OperatingExpenses>

  <us-gaap:OperatingIncomeLoss contextRef="P07_01_2016To09_30_2016" id="Factid_67" unitRef="USD" decimals="-3">-1670000</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2017To09_30_2017" id="Factid_68" unitRef="USD" decimals="-3">-16056000</us-gaap:OperatingIncomeLoss>

  <us-gaap:InterestIncomeOther contextRef="P07_01_2017To09_30_2017" id="Factid_69" unitRef="USD" decimals="-3">144000</us-gaap:InterestIncomeOther>

  <us-gaap:InterestIncomeOther contextRef="P07_01_2016To09_30_2016" id="Factid_70" unitRef="USD" decimals="-3">0</us-gaap:InterestIncomeOther>

  <us-gaap:InterestIncomeOther contextRef="P01_01_2017To09_30_2017" id="Factid_71" unitRef="USD" decimals="-3">369000</us-gaap:InterestIncomeOther>

  <us-gaap:InterestIncomeOther contextRef="P01_01_2016To09_30_2016" id="Factid_72" unitRef="USD" decimals="-3">0</us-gaap:InterestIncomeOther>

  <us-gaap:NonoperatingIncomeExpense contextRef="P07_01_2016To09_30_2016" id="Factid_73" unitRef="USD" decimals="-3">-200000</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2017To09_30_2017" id="Factid_74" unitRef="USD" decimals="-3">369000</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2016To09_30_2016" id="Factid_75" unitRef="USD" decimals="-3">-1870000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To09_30_2017" id="Factid_76" unitRef="USD" decimals="-3">-15687000</us-gaap:NetIncomeLoss>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P07_01_2016To09_30_2016" id="Factid_77" unitRef="USD_per_Share" decimals="2">-0.19</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2017To09_30_2017" id="Factid_78" unitRef="USD_per_Share" decimals="2">-0.63</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P07_01_2016To09_30_2016" id="Factid_79" unitRef="shares" decimals="INF">10089269</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2017To09_30_2017" id="Factid_80" unitRef="shares" decimals="INF">24936626</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2017To09_30_2017" id="Factid_81" unitRef="USD" decimals="-3">-6940000</us-gaap:NetIncomeLoss>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2016_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_82" unitRef="shares" decimals="INF">250000</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2016_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_83" unitRef="shares" decimals="INF">1000000</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2016_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_84" unitRef="shares" decimals="INF">15165244</us-gaap:SharesOutstanding>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_85" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_86" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_87" unitRef="USD" decimals="-3">2000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_CommonStockIssuableMemberusgaapStatementClassOfStockAxis" id="Factid_88" unitRef="USD" decimals="-3">4396000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_89" unitRef="USD" decimals="-3">36998000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_90" unitRef="USD" decimals="-3">-17120000</us-gaap:StockholdersEquity>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P01_01_2017To09_30_2017" id="Factid_91" unitRef="USD" decimals="-3">1234000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P01_01_2017To09_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_92" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P01_01_2017To09_30_2017_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_93" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P01_01_2017To09_30_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_94" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P01_01_2017To09_30_2017_CommonStockIssuableMemberusgaapStatementClassOfStockAxis" id="Factid_95" unitRef="USD" decimals="-3">-4396000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P01_01_2017To09_30_2017_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_96" unitRef="USD" decimals="-3">5630000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P01_01_2017To09_30_2017_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_97" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P01_01_2017To09_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_98" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P01_01_2017To09_30_2017_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_99" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P01_01_2017To09_30_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_100" unitRef="shares" decimals="INF">982533</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2017To09_30_2017" id="Factid_101" unitRef="USD" decimals="-3">55970000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2017To09_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_102" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2017To09_30_2017_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_103" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2017To09_30_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_104" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2017To09_30_2017_CommonStockIssuableMemberusgaapStatementClassOfStockAxis" id="Factid_105" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2017To09_30_2017_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_106" unitRef="USD" decimals="-3">55969000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2017To09_30_2017_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_107" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2017To09_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_108" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2017To09_30_2017_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_109" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2017To09_30_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_110" unitRef="shares" decimals="INF">8610774</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="P01_01_2017To09_30_2017" id="Factid_111" unitRef="USD" decimals="-3">5674000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="P01_01_2017To09_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_112" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="P01_01_2017To09_30_2017_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_113" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="P01_01_2017To09_30_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_114" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="P01_01_2017To09_30_2017_CommonStockIssuableMemberusgaapStatementClassOfStockAxis" id="Factid_115" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="P01_01_2017To09_30_2017_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_116" unitRef="USD" decimals="-3">5674000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="P01_01_2017To09_30_2017_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_117" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To09_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_118" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To09_30_2017_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_119" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To09_30_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_120" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To09_30_2017_CommonStockIssuableMemberusgaapStatementClassOfStockAxis" id="Factid_121" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To09_30_2017_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_122" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To09_30_2017_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_123" unitRef="USD" decimals="-3">-15687000</us-gaap:NetIncomeLoss>

  <us-gaap:StockholdersEquity contextRef="PAsOn09_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_124" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn09_30_2017_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_125" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn09_30_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_126" unitRef="USD" decimals="-3">3000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn09_30_2017_CommonStockIssuableMemberusgaapStatementClassOfStockAxis" id="Factid_127" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn09_30_2017_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_128" unitRef="USD" decimals="-3">97897000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn09_30_2017_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_129" unitRef="USD" decimals="-3">-32807000</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn09_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_130" unitRef="shares" decimals="INF">250000</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn09_30_2017_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_131" unitRef="shares" decimals="INF">1000000</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn09_30_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_132" unitRef="shares" decimals="INF">25232139</us-gaap:SharesOutstanding>

  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="P01_01_2017To09_30_2017" id="Factid_133" unitRef="USD" decimals="-3">1682000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>

  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="P01_01_2017To09_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_134" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>

  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="P01_01_2017To09_30_2017_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_135" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>

  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="P01_01_2017To09_30_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_136" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>

  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="P01_01_2017To09_30_2017_CommonStockIssuableMemberusgaapStatementClassOfStockAxis" id="Factid_137" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>

  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="P01_01_2017To09_30_2017_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_138" unitRef="USD" decimals="-3">1682000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>

  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="P01_01_2017To09_30_2017_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_139" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>

  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="P01_01_2017To09_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_140" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>

  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="P01_01_2017To09_30_2017_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_141" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>

  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="P01_01_2017To09_30_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_142" unitRef="shares" decimals="INF">293588</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>

  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="P01_01_2017To09_30_2017" id="Factid_143" unitRef="USD" decimals="-3">1230000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>

  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="P01_01_2017To09_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_144" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>

  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="P01_01_2017To09_30_2017_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_145" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>

  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="P01_01_2017To09_30_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_146" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>

  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="P01_01_2017To09_30_2017_CommonStockIssuableMemberusgaapStatementClassOfStockAxis" id="Factid_147" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>

  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="P01_01_2017To09_30_2017_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_148" unitRef="USD" decimals="-3">1230000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>

  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="P01_01_2017To09_30_2017_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_149" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>

  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="P01_01_2017To09_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_150" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>

  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="P01_01_2017To09_30_2017_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_151" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>

  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="P01_01_2017To09_30_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_152" unitRef="shares" decimals="INF">180000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>

  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="P01_01_2017To09_30_2017" id="Factid_153" unitRef="USD" decimals="-3">1923000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="P01_01_2016To09_30_2016" id="Factid_154" unitRef="USD" decimals="-3">1025000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="P01_01_2017To09_30_2017" id="Factid_155" unitRef="USD" decimals="-3">-56000</us-gaap:IncreaseDecreaseInDueToRelatedParties>

  <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="P01_01_2016To09_30_2016" id="Factid_156" unitRef="USD" decimals="-3">375000</us-gaap:IncreaseDecreaseInDueToRelatedParties>

  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="P01_01_2017To09_30_2017" id="Factid_157" unitRef="USD" decimals="-3">-413000</us-gaap:IncreaseDecreaseInInterestPayableNet>

  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="P01_01_2016To09_30_2016" id="Factid_158" unitRef="USD" decimals="-3">278000</us-gaap:IncreaseDecreaseInInterestPayableNet>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P01_01_2017To09_30_2017" id="Factid_159" unitRef="USD" decimals="-3">-7781000</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P01_01_2016To09_30_2016" id="Factid_160" unitRef="USD" decimals="-3">-1866000</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="P01_01_2017To09_30_2017" id="Factid_161" unitRef="USD" decimals="-3">2375000</us-gaap:PaymentsToAcquireIntangibleAssets>

  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="P01_01_2016To09_30_2016" id="Factid_162" unitRef="USD" decimals="-3">0</us-gaap:PaymentsToAcquireIntangibleAssets>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P01_01_2017To09_30_2017" id="Factid_163" unitRef="USD" decimals="-3">-36485000</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P01_01_2016To09_30_2016" id="Factid_164" unitRef="USD" decimals="-3">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="P01_01_2017To09_30_2017" id="Factid_165" unitRef="USD" decimals="-3">320000</us-gaap:RepaymentsOfRelatedPartyDebt>

  <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="P01_01_2016To09_30_2016" id="Factid_166" unitRef="USD" decimals="-3">3533000</us-gaap:RepaymentsOfRelatedPartyDebt>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P01_01_2017To09_30_2017" id="Factid_167" unitRef="USD" decimals="-3">49976000</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P01_01_2016To09_30_2016" id="Factid_168" unitRef="USD" decimals="-3">12984000</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:StockIssued1 contextRef="P01_01_2017To09_30_2017" id="Factid_169" unitRef="USD" decimals="-3">4396000</us-gaap:StockIssued1>

  <us-gaap:StockIssued1 contextRef="P01_01_2016To09_30_2016" id="Factid_170" unitRef="USD" decimals="-3">190000</us-gaap:StockIssued1>

  <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff contextRef="P01_01_2017To09_30_2017" id="Factid_171" unitRef="USD" decimals="-3">2375000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>

  <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff contextRef="P01_01_2016To09_30_2016" id="Factid_172" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>

  <ck0001680048:IssuanceOfCommonStockFounderAgreementExpenses contextRef="P01_01_2017To09_30_2017" id="Factid_173" unitRef="USD" decimals="-3">1234000</ck0001680048:IssuanceOfCommonStockFounderAgreementExpenses>

  <ck0001680048:IssuanceOfCommonStockFounderAgreementExpenses contextRef="P01_01_2016To09_30_2016" id="Factid_174" unitRef="USD" decimals="-3">274000</ck0001680048:IssuanceOfCommonStockFounderAgreementExpenses>

  <us-gaap:InterestPaidNet contextRef="P01_01_2017To09_30_2017" id="Factid_175" unitRef="USD" decimals="-3">413000</us-gaap:InterestPaidNet>

  <us-gaap:InterestPaidNet contextRef="P01_01_2016To09_30_2016" id="Factid_176" unitRef="USD" decimals="-3">0</us-gaap:InterestPaidNet>

  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="P01_01_2017To09_30_2017" id="Factid_177" unitRef="USD" decimals="-3">414000</us-gaap:IncreaseDecreaseInPrepaidExpense>

  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="P01_01_2016To09_30_2016" id="Factid_178" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInPrepaidExpense>

  <ck0001680048:StockIssuableForLicenseAcquired contextRef="P01_01_2017To09_30_2017" id="Factid_179" unitRef="USD" decimals="-3">1682000</ck0001680048:StockIssuableForLicenseAcquired>

  <ck0001680048:StockIssuableForLicenseAcquired contextRef="P01_01_2016To09_30_2016" id="Factid_180" unitRef="USD" decimals="-3">0</ck0001680048:StockIssuableForLicenseAcquired>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2017To09_30_2017" id="Factid_181" unitRef="USD" decimals="-3">1230000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2016To09_30_2016" id="Factid_182" unitRef="USD" decimals="-3">0</us-gaap:ShareBasedCompensation>

  <us-gaap:PaymentsToAcquireHeldToMaturitySecurities contextRef="P01_01_2017To09_30_2017" id="Factid_183" unitRef="USD" decimals="-3">34088000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>

  <us-gaap:PaymentsToAcquireHeldToMaturitySecurities contextRef="P01_01_2016To09_30_2016" id="Factid_184" unitRef="USD" decimals="-3">0</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>

  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="P01_01_2017To09_30_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis" id="Factid_185" unitRef="shares" decimals="INF">293588</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn09_30_2017_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_186" unitRef="shares" decimals="INF">1000000</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="PAsOn09_30_2017_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_187" unitRef="pure" decimals="3">0.050</us-gaap:MinorityInterestOwnershipPercentageByParent>

  <ck0001680048:AnnualConsultingFees contextRef="P01_01_2016To12_31_2016_StephenFormanMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_188" unitRef="USD" decimals="0">60000</ck0001680048:AnnualConsultingFees>

  <ck0001680048:AnnualConsultingFees contextRef="P01_01_2016To12_31_2016_ChristineBrownMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_189" unitRef="USD" decimals="0">60000</ck0001680048:AnnualConsultingFees>

  <ck0001680048:RevenueRecognitionMilestoneMethodPaymentsDue contextRef="PAsOn02_17_2017_ArCd123LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_CityOfHopeMemberusgaapRelatedPartyTransactionAxis" id="Factid_190" unitRef="USD" decimals="-5">14500000</ck0001680048:RevenueRecognitionMilestoneMethodPaymentsDue>

  <us-gaap:MaintenanceCosts contextRef="P02_01_2017To02_28_2017_ArCd123LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_CityOfHopeMemberusgaapRelatedPartyTransactionAxis" id="Factid_191" unitRef="USD" decimals="0">25000</us-gaap:MaintenanceCosts>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P07_01_2017To09_30_2017_ArCd123LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_CityOfHopeMemberusgaapRelatedPartyTransactionAxis" id="Factid_192" unitRef="USD" decimals="-5">600000</us-gaap:ResearchAndDevelopmentExpense>

  <ck0001680048:PaymentOfUpfrontFees contextRef="P02_01_2017To02_28_2017_ArCd123LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_CityOfHopeMemberusgaapRelatedPartyTransactionAxis" id="Factid_193" unitRef="USD" decimals="0">19450</ck0001680048:PaymentOfUpfrontFees>

  <ck0001680048:LicensingArrangementsAdditionalCostsIncurred contextRef="P02_01_2017To02_28_2017_ArCd123LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_CityOfHopeMemberusgaapRelatedPartyTransactionAxis" id="Factid_194" unitRef="USD" decimals="0">97490</ck0001680048:LicensingArrangementsAdditionalCostsIncurred>

  <ck0001680048:ResearchAndDevelopmentExpenseSponsoredResearchPayment contextRef="PAsOn02_28_2017_ArCd123LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_CityOfHopeMemberusgaapRelatedPartyTransactionAxis" id="Factid_195" unitRef="USD" decimals="-5">200000</ck0001680048:ResearchAndDevelopmentExpenseSponsoredResearchPayment>

  <ck0001680048:RevenueRecognitionMilestoneMethodPaymentsDue contextRef="PAsOn02_17_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_IlLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_196" unitRef="USD" decimals="-5">14500000</ck0001680048:RevenueRecognitionMilestoneMethodPaymentsDue>

  <us-gaap:MaintenanceCosts contextRef="P02_01_2017To02_28_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_IlLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_197" unitRef="USD" decimals="0">25000</us-gaap:MaintenanceCosts>

  <ck0001680048:PaymentOfUpfrontFees contextRef="P02_01_2017To02_28_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_Il13ra2MemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_198" unitRef="USD" decimals="0">9300</ck0001680048:PaymentOfUpfrontFees>

  <ck0001680048:LicensingArrangementsAdditionalCostsIncurred contextRef="P02_01_2017To02_28_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_Il13ra2MemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_199" unitRef="USD" decimals="-5">100000</ck0001680048:LicensingArrangementsAdditionalCostsIncurred>

  <ck0001680048:ResearchAndDevelopmentExpenseSponsoredResearchPayment contextRef="PAsOn02_28_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_IlLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_200" unitRef="USD" decimals="-5">200000</ck0001680048:ResearchAndDevelopmentExpenseSponsoredResearchPayment>

  <us-gaap:MaintenanceCosts contextRef="P02_01_2017To02_28_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_SpacerLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_201" unitRef="USD" decimals="0">10000</us-gaap:MaintenanceCosts>

  <us-gaap:PaymentsForFees contextRef="P02_01_2017To02_17_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis" id="Factid_202" unitRef="USD" decimals="-5">100000</us-gaap:PaymentsForFees>

  <ck0001680048:RevenueRecognitionMilestoneMethodPaymentsDue contextRef="PAsOn02_17_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis" id="Factid_203" unitRef="USD" decimals="-5">100000</ck0001680048:RevenueRecognitionMilestoneMethodPaymentsDue>

  <ck0001680048:PaymentOfUpfrontFees contextRef="P07_01_2017To07_03_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_Her2TechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_204" unitRef="USD" decimals="-5">600000</ck0001680048:PaymentOfUpfrontFees>

  <us-gaap:MaintenanceCosts contextRef="P07_01_2017To07_03_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_Her2TechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_205" unitRef="USD" decimals="0">50000</us-gaap:MaintenanceCosts>

  <ck0001680048:RevenueRecognitionMilestoneMethodPaymentsDue contextRef="PAsOn07_03_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_Her2TechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_206" unitRef="USD" decimals="-5">14900000</ck0001680048:RevenueRecognitionMilestoneMethodPaymentsDue>

  <ck0001680048:PaymentOfUpfrontFees contextRef="P05_01_2017To05_31_2017_CsTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_207" unitRef="USD" decimals="-5">600000</ck0001680048:PaymentOfUpfrontFees>

  <ck0001680048:RevenueRecognitionMilestoneMethodPaymentsDue contextRef="PAsOn05_31_2017_CsTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_208" unitRef="USD" decimals="-5">14900000</ck0001680048:RevenueRecognitionMilestoneMethodPaymentsDue>

  <us-gaap:MaintenanceCosts contextRef="P05_01_2017To05_31_2017_CsTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_209" unitRef="USD" decimals="0">50000</us-gaap:MaintenanceCosts>

  <ck0001680048:PaymentOfUpfrontFees contextRef="P05_01_2017To05_31_2017_PscaTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_210" unitRef="USD" decimals="-5">300000</ck0001680048:PaymentOfUpfrontFees>

  <us-gaap:MaintenanceCosts contextRef="P05_01_2017To05_31_2017_PscaTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_211" unitRef="USD" decimals="0">50000</us-gaap:MaintenanceCosts>

  <ck0001680048:RevenueRecognitionMilestoneMethodPaymentsDue contextRef="PAsOn05_31_2017_PscaTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_212" unitRef="USD" decimals="-5">14900000</ck0001680048:RevenueRecognitionMilestoneMethodPaymentsDue>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P07_01_2017To09_30_2017_ArIl13LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_213" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P07_01_2017To09_30_2017_IvicvLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_214" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P07_01_2017To09_30_2017_UclaLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_215" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P07_01_2016To09_30_2016_ArIl13LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_216" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P07_01_2016To09_30_2016_IvicvLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_217" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P07_01_2016To09_30_2016_UclaLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_218" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P01_01_2017To09_30_2017_ArIl13LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_219" unitRef="USD" decimals="-3">250000</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P01_01_2017To09_30_2017_IvicvLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_220" unitRef="USD" decimals="-3">125000</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P01_01_2017To09_30_2017_PscaTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_221" unitRef="USD" decimals="-3">300000</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P01_01_2017To09_30_2017_Her2TechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_222" unitRef="USD" decimals="-3">600000</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P01_01_2017To09_30_2017_UclaLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_223" unitRef="USD" decimals="-3">200000</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P01_01_2016To09_30_2016_ArIl13LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_224" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P01_01_2016To09_30_2016_IvicvLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_225" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P01_01_2016To09_30_2016_PscaTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_226" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P01_01_2016To09_30_2016_Her2TechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_227" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P01_01_2016To09_30_2016_UclaLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_228" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P07_01_2017To09_30_2017_PscaTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_229" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P07_01_2017To09_30_2017_Her2TechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_230" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P07_01_2016To09_30_2016_Her2TechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_231" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P07_01_2016To09_30_2016_PscaTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_232" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ConversionOfStockSharesConverted1 contextRef="P07_01_2016To07_26_2016_CommonClassBMemberusgaapStatementClassOfStockAxis" id="Factid_233" unitRef="shares" decimals="-4">7250000</us-gaap:ConversionOfStockSharesConverted1>

  <us-gaap:ConversionOfStockSharesIssued1 contextRef="P07_01_2016To07_26_2016_ConvertibleCommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_234" unitRef="shares" decimals="-5">7000000</us-gaap:ConversionOfStockSharesIssued1>

  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="P05_01_2016To05_17_2016_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_235" unitRef="USD" decimals="-5">2000000</us-gaap:ProceedsFromRelatedPartyDebt>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P03_01_2016To03_13_2016_CommonClassBMemberusgaapStatementClassOfStockAxis_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_236" unitRef="shares" decimals="INF">250000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="PAsOn03_13_2016_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_237" unitRef="pure" decimals="3">0.025</us-gaap:MinorityInterestOwnershipPercentageByParent>

  <ck0001680048:IncreaseInAnnualConsultingFees contextRef="P01_01_2017To09_30_2017_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_238" unitRef="USD" decimals="-5">1000000</ck0001680048:IncreaseInAnnualConsultingFees>

  <ck0001680048:AnnualFeesExpensesOnFoundersAgreement contextRef="P01_01_2017To09_30_2017_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_239" unitRef="USD" decimals="-5">400000</ck0001680048:AnnualFeesExpensesOnFoundersAgreement>

  <ck0001680048:AnnualFeesExpensesOnFoundersAgreement contextRef="P01_01_2016To09_30_2016_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_240" unitRef="USD" decimals="-5">400000</ck0001680048:AnnualFeesExpensesOnFoundersAgreement>

  <ck0001680048:AnnualFeesExpensesOnFoundersAgreement contextRef="P07_01_2017To09_30_2017_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_241" unitRef="USD" decimals="-5">100000</ck0001680048:AnnualFeesExpensesOnFoundersAgreement>

  <ck0001680048:AnnualFeesExpensesOnFoundersAgreement contextRef="P07_01_2016To09_30_2016_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_242" unitRef="USD" decimals="-5">100000</ck0001680048:AnnualFeesExpensesOnFoundersAgreement>

  <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="PAsOn09_30_2017_NationalHoldingsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_243" unitRef="pure" decimals="3">0.566</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>

  <us-gaap:PaymentsForFees contextRef="P01_01_2017To09_30_2017_NationalHoldingsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_244" unitRef="USD" decimals="-5">5600000</us-gaap:PaymentsForFees>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn09_30_2017_NationalHoldingsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_245" unitRef="shares" decimals="INF">861077</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ProfessionalFees contextRef="P07_01_2017To09_30_2017_BoardOfDirectorsChairmanMemberusgaapTitleOfIndividualAxis" id="Factid_246" unitRef="USD" decimals="0">15000</us-gaap:ProfessionalFees>

  <us-gaap:ProfessionalFees contextRef="P01_01_2017To09_30_2017_BoardOfDirectorsChairmanMemberusgaapTitleOfIndividualAxis" id="Factid_247" unitRef="USD" decimals="0">46200</us-gaap:ProfessionalFees>

  <ck0001680048:AnnualConsultingFees contextRef="P01_01_2017To09_30_2017_AdvisorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_248" unitRef="USD" decimals="0">60000</ck0001680048:AnnualConsultingFees>

  <ck0001680048:PotentiallyDilutiveSecurities contextRef="P01_01_2017To09_30_2017" id="Factid_249" unitRef="shares" decimals="INF">7039109</ck0001680048:PotentiallyDilutiveSecurities>

  <ck0001680048:PotentiallyDilutiveSecurities contextRef="P01_01_2016To09_30_2016" id="Factid_250" unitRef="shares" decimals="INF">920191</ck0001680048:PotentiallyDilutiveSecurities>

  <ck0001680048:PotentiallyDilutiveSecurities contextRef="P01_01_2017To09_30_2017_WarrantMemberusgaapInvestmentTypeAxis" id="Factid_251" unitRef="shares" decimals="INF">5257434</ck0001680048:PotentiallyDilutiveSecurities>

  <ck0001680048:PotentiallyDilutiveSecurities contextRef="P01_01_2017To09_30_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis" id="Factid_252" unitRef="shares" decimals="INF">1241675</ck0001680048:PotentiallyDilutiveSecurities>

  <ck0001680048:PotentiallyDilutiveSecurities contextRef="P01_01_2017To09_30_2017_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_253" unitRef="shares" decimals="INF">250000</ck0001680048:PotentiallyDilutiveSecurities>

  <ck0001680048:PotentiallyDilutiveSecurities contextRef="P01_01_2017To09_30_2017_UnvestedRestrictedStockAwardsMemberMemberusgaapAwardTypeAxis" id="Factid_254" unitRef="shares" decimals="INF">180000</ck0001680048:PotentiallyDilutiveSecurities>

  <ck0001680048:PotentiallyDilutiveSecurities contextRef="P01_01_2017To09_30_2017_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_255" unitRef="shares" decimals="INF">110000</ck0001680048:PotentiallyDilutiveSecurities>

  <ck0001680048:PotentiallyDilutiveSecurities contextRef="P01_01_2016To09_30_2016_WarrantMemberusgaapInvestmentTypeAxis" id="Factid_256" unitRef="shares" decimals="INF">670191</ck0001680048:PotentiallyDilutiveSecurities>

  <ck0001680048:PotentiallyDilutiveSecurities contextRef="P01_01_2016To09_30_2016_EmployeeStockOptionMemberusgaapAwardTypeAxis" id="Factid_257" unitRef="shares" decimals="INF">0</ck0001680048:PotentiallyDilutiveSecurities>

  <ck0001680048:PotentiallyDilutiveSecurities contextRef="P01_01_2016To09_30_2016_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_258" unitRef="shares" decimals="INF">250000</ck0001680048:PotentiallyDilutiveSecurities>

  <ck0001680048:PotentiallyDilutiveSecurities contextRef="P01_01_2016To09_30_2016_UnvestedRestrictedStockAwardsMemberMemberusgaapAwardTypeAxis" id="Factid_259" unitRef="shares" decimals="INF">0</ck0001680048:PotentiallyDilutiveSecurities>

  <ck0001680048:PotentiallyDilutiveSecurities contextRef="P01_01_2016To09_30_2016_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_260" unitRef="shares" decimals="INF">0</ck0001680048:PotentiallyDilutiveSecurities>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn09_30_2017" id="Factid_261" unitRef="shares" decimals="INF">50000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn09_30_2017" id="Factid_262" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn09_30_2017_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_263" unitRef="shares" decimals="INF">1000000</us-gaap:CommonStockSharesIssued>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn09_30_2017_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_264" unitRef="shares" decimals="INF">2000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn09_30_2017_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_265" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn03_13_2016_CommonClassBMemberusgaapStatementClassOfStockAxis_FortressBiotechIncMemberdeiLegalEntityAxis" id="Factid_266" unitRef="shares" decimals="INF">250000</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn07_27_2016_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_267" unitRef="shares" decimals="INF">250000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn07_27_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_268" unitRef="shares" decimals="-5">7000000</us-gaap:CommonStockSharesIssued>

  <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="P07_01_2016To07_27_2016_CommonClassBMemberusgaapStatementClassOfStockAxis" id="Factid_269" unitRef="shares" decimals="-5">7200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>

  <ck0001680048:DilutedOutstandingEquityPercentage contextRef="P03_01_2016To03_13_2016_CommonClassBMemberusgaapStatementClassOfStockAxis_FortressBiotechIncMemberdeiLegalEntityAxis" id="Factid_270" unitRef="pure" decimals="3">0.025</ck0001680048:DilutedOutstandingEquityPercentage>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P02_01_2017To02_28_2017_CityOfHopeNationalMedicalCenterMemberdeiLegalEntityAxis" id="Factid_271" unitRef="shares" decimals="INF">293588</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:SharesIssued contextRef="PAsOn09_30_2017_CityOfHopeNationalMedicalCenterMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_272" unitRef="shares" decimals="INF">1000000</us-gaap:SharesIssued>

  <us-gaap:SharesIssued contextRef="PAsOn09_30_2017_CityOfHopeNationalMedicalCenterMemberdeiLegalEntityAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_LicenseAgreementMemberck0001680048AgreementTypeAxis" id="Factid_273" unitRef="shares" decimals="INF">293588</us-gaap:SharesIssued>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P03_01_2017To03_13_2017_FortressBiotechIncMemberdeiLegalEntityAxis" id="Factid_274" unitRef="shares" decimals="INF">767264</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <us-gaap:SharesIssuedPricePerShare contextRef="PAsOn03_13_2017_FortressBiotechIncMemberdeiLegalEntityAxis" id="Factid_275" unitRef="USD_per_Share" decimals="2">5.73</us-gaap:SharesIssuedPricePerShare>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P03_01_2017To03_13_2017_FortressBiotechIncMemberdeiLegalEntityAxis" id="Factid_276" unitRef="USD" decimals="-5">4400000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="PAsOn04_30_2015_CityOfHopeNationalMedicalCenterMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_LicenseAgreementMemberck0001680048AgreementTypeAxis" id="Factid_277" unitRef="pure" decimals="1">0.1</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>

  <ck0001680048:PaymentOfUpfrontFees contextRef="P03_01_2015To03_17_2015_CityOfHopeNationalMedicalCenterMemberdeiLegalEntityAxis_LicenseAgreementMemberck0001680048AgreementTypeAxis" id="Factid_278" unitRef="USD" decimals="-5">2000000</ck0001680048:PaymentOfUpfrontFees>

  <us-gaap:SharesOutstanding contextRef="PAsOn04_30_2015_CityOfHopeNationalMedicalCenterMemberdeiLegalEntityAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_LicenseAgreementMemberck0001680048AgreementTypeAxis" id="Factid_279" unitRef="shares" decimals="INF">1000000</us-gaap:SharesOutstanding>

  <ck0001680048:PercentageOfPlacementAgentFee contextRef="P09_01_2016To09_30_2016_NationalSecuritiesIncMemberdeiLegalEntityAxis" id="Factid_280" unitRef="pure" decimals="2">0.10</ck0001680048:PercentageOfPlacementAgentFee>

  <ck0001680048:PercentageOfSharesIssuedToPlacementAgent contextRef="P09_01_2016To09_30_2016_NationalSecuritiesIncMemberdeiLegalEntityAxis" id="Factid_281" unitRef="pure" decimals="2">0.10</ck0001680048:PercentageOfSharesIssuedToPlacementAgent>

  <ck0001680048:WarrantPurchasePricePerUnit contextRef="P09_01_2016To09_30_2016_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_282" unitRef="USD" decimals="0">65000</ck0001680048:WarrantPurchasePricePerUnit>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn09_30_2016_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_283" unitRef="shares" decimals="INF">2500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn09_30_2016_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_284" unitRef="USD_per_Share" decimals="2">8.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <ck0001680048:WarrantsIssued contextRef="P01_02_2017To01_31_2017" id="Factid_285" unitRef="shares" decimals="INF">2134193</ck0001680048:WarrantsIssued>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P01_02_2017To01_31_2017_NationalHoldingsCorporationMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_286" unitRef="USD" decimals="-5">5500000</us-gaap:PaymentsOfStockIssuanceCosts>

  <ck0001680048:PercentageOfPlacementAgentFee contextRef="P01_02_2017To01_31_2017_NationalHoldingsCorporationMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_287" unitRef="pure" decimals="1">0.1</ck0001680048:PercentageOfPlacementAgentFee>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_02_2017To01_31_2017_UnregisteredCommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_288" unitRef="shares" decimals="INF">8536774</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <ck0001680048:WarrantsIssued contextRef="P01_02_2017To01_31_2017_NationalSecuritiesIncMemberdeiLegalEntityAxis" id="Factid_289" unitRef="shares" decimals="INF">853677</ck0001680048:WarrantsIssued>

  <ck0001680048:PercentageOfSharesIssuedToPlacementAgent contextRef="P01_02_2017To01_31_2017_NationalHoldingsCorporationMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_290" unitRef="pure" decimals="1">0.1</ck0001680048:PercentageOfSharesIssuedToPlacementAgent>

  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="P01_02_2017To01_31_2017_NationalHoldingsCorporationMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_291" unitRef="USD" decimals="-5">55500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>

  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="P03_01_2017To03_31_2017_NationalHoldingsCorporationMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_292" unitRef="USD" decimals="-5">400000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P03_01_2017To03_31_2017_NationalHoldingsCorporationMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_293" unitRef="USD" decimals="0">42000</us-gaap:PaymentsOfStockIssuanceCosts>

  <ck0001680048:PercentageOfPlacementAgentFee contextRef="P03_01_2017To03_31_2017_NationalHoldingsCorporationMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_294" unitRef="pure" decimals="1">0.1</ck0001680048:PercentageOfPlacementAgentFee>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P03_01_2017To03_31_2017_UnregisteredCommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_295" unitRef="shares" decimals="INF">64000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <ck0001680048:WarrantsIssued contextRef="P03_01_2017To03_31_2017" id="Factid_296" unitRef="shares" decimals="INF">16000</ck0001680048:WarrantsIssued>

  <ck0001680048:WarrantsIssued contextRef="P03_01_2017To03_31_2017_NationalSecuritiesIncMemberdeiLegalEntityAxis" id="Factid_297" unitRef="shares" decimals="INF">6400</ck0001680048:WarrantsIssued>

  <ck0001680048:PercentageOfSharesIssuedToPlacementAgent contextRef="P03_01_2017To03_31_2017_NationalHoldingsCorporationMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_298" unitRef="pure" decimals="1">0.1</ck0001680048:PercentageOfSharesIssuedToPlacementAgent>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn09_30_2017_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_299" unitRef="shares" decimals="INF">250000</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn09_30_2017" id="Factid_300" unitRef="shares" decimals="INF">2000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:CommonStockVotingRights contextRef="P01_01_2017To09_30_2017" id="Factid_301">(1.1)</us-gaap:CommonStockVotingRights>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P04_01_2017To04_07_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_302" unitRef="shares" decimals="INF">200000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <us-gaap:SharesIssuedPricePerShare contextRef="PAsOn04_07_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_303" unitRef="USD_per_Share" decimals="2">5.73</us-gaap:SharesIssuedPricePerShare>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="P01_01_2017To09_30_2017" id="Factid_304" unitRef="USD" decimals="-4">5730000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="P01_01_2017To09_30_2017" id="Factid_305" unitRef="pure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="PAsOn09_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_306" unitRef="shares" decimals="INF">1241675</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2017To09_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_307" unitRef="shares" decimals="INF">1241675</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="PAsOn12_31_2016_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_308" unitRef="shares" decimals="INF">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn09_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_309" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="P01_01_2017To09_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_310" unitRef="USD_per_Share" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2017To09_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_311" unitRef="USD_per_Share" decimals="2">5.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn09_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_312" unitRef="USD_per_Share" decimals="2">5.73</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="PAsOn09_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_313" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

  <ck0001680048:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="P01_01_2017To09_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_314">P9Y6M22D</ck0001680048:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To09_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_315">P9Y6M22D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2017To09_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_316">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2016To12_31_2016_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_317">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2017To09_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_318" unitRef="USD" decimals="-5">2300000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To09_30_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_319">P1Y7M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P06_01_2017To06_08_2017_DirectorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_320" unitRef="shares" decimals="INF">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2017To09_30_2017_DirectorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_321" unitRef="shares" decimals="INF">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="PAsOn12_31_2016_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_322" unitRef="shares" decimals="INF">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2017To09_30_2017_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_323" unitRef="shares" decimals="INF">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="PAsOn09_30_2017_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_324" unitRef="shares" decimals="INF">180000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn12_31_2016_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_325" unitRef="USD_per_Share" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2017To09_30_2017_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_326" unitRef="USD_per_Share" decimals="2">5.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn09_30_2017_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_327" unitRef="USD_per_Share" decimals="2">5.73</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2017To09_30_2017_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_328" unitRef="USD" decimals="-5">1000000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To09_30_2017_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_329">P3Y6M11D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P06_01_2017To06_30_2017_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_330" unitRef="shares" decimals="INF">110000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="PAsOn12_31_2016_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_331" unitRef="shares" decimals="INF">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2017To09_30_2017_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_332" unitRef="shares" decimals="INF">110000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="PAsOn09_30_2017_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_333" unitRef="shares" decimals="INF">110000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn12_31_2016_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_334" unitRef="USD_per_Share" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2017To09_30_2017_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_335" unitRef="USD_per_Share" decimals="2">5.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn09_30_2017_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_336" unitRef="USD_per_Share" decimals="2">5.73</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2017To09_30_2017_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_337" unitRef="USD" decimals="-5">600000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To09_30_2017_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_338">P2Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:ShareBasedCompensation contextRef="P07_01_2017To09_30_2017" id="Factid_339" unitRef="USD" decimals="-3">834000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P07_01_2016To09_30_2016" id="Factid_340" unitRef="USD" decimals="-3">0</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P07_01_2017To09_30_2017_EmployeeMemberusgaapTitleOfIndividualAxis" id="Factid_341" unitRef="USD" decimals="-3">576000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P07_01_2017To09_30_2017_NonEmployeeMemberusgaapTitleOfIndividualAxis" id="Factid_342" unitRef="USD" decimals="-3">258000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P07_01_2016To09_30_2016_EmployeeMemberusgaapTitleOfIndividualAxis" id="Factid_343" unitRef="USD" decimals="-3">0</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P07_01_2016To09_30_2016_NonEmployeeMemberusgaapTitleOfIndividualAxis" id="Factid_344" unitRef="USD" decimals="-3">0</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2017To09_30_2017_EmployeeMemberusgaapTitleOfIndividualAxis" id="Factid_345" unitRef="USD" decimals="-3">909000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2017To09_30_2017_NonEmployeeMemberusgaapTitleOfIndividualAxis" id="Factid_346" unitRef="USD" decimals="-3">321000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2016To09_30_2016_EmployeeMemberusgaapTitleOfIndividualAxis" id="Factid_347" unitRef="USD" decimals="-3">0</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2016To09_30_2016_NonEmployeeMemberusgaapTitleOfIndividualAxis" id="Factid_348" unitRef="USD" decimals="-3">0</us-gaap:ShareBasedCompensation>

  <ck0001680048:ClassOfWarrantOrRightPercentageOfWarrantIssued contextRef="P01_01_2017To09_30_2017" id="Factid_349" unitRef="pure" decimals="2">0.25</ck0001680048:ClassOfWarrantOrRightPercentageOfWarrantIssued>

  <ck0001680048:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding contextRef="PAsOn12_31_2016" id="Factid_350" unitRef="shares" decimals="INF">2243664</ck0001680048:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="P01_01_2017To09_30_2017" id="Factid_351" unitRef="shares" decimals="INF">3013770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

  <ck0001680048:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding contextRef="PAsOn09_30_2017" id="Factid_352" unitRef="shares" decimals="INF">5257434</ck0001680048:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding>

  <ck0001680048:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2016" id="Factid_353" unitRef="USD_per_Share" decimals="2">7.98</ck0001680048:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice>

  <ck0001680048:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn09_30_2017" id="Factid_354" unitRef="USD_per_Share" decimals="2">8.28</ck0001680048:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice>

  <ck0001680048:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice contextRef="PAsOn09_30_2017" id="Factid_355" unitRef="USD_per_Share" decimals="1">8.5</ck0001680048:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice>

  <ck0001680048:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms contextRef="P01_01_2017To09_30_2017" id="Factid_356">P4Y4M2D</ck0001680048:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2016To12_31_2016" id="Factid_357">P5Y1M28D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2017To09_30_2017" id="Factid_358">P4Y4M13D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>

  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2017To09_30_2017" id="Factid_359">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Note 7 - Stockholders&amp;#8217; Equity&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Common Stock&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Company is authorized to issue &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 50,000,000&lt;/font&gt; common shares with a par value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.0001&lt;/font&gt; per share, of which &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,000,000&lt;/font&gt; shares are designated as &amp;#8220;Class A common shares&amp;#8221; and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,000,000&lt;/font&gt; of Preferred Stock at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.0001&lt;/font&gt; par value and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 250,000&lt;/font&gt; of which are designated as Class A Preferred Stock.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Pursuant to the Founders Agreement, on March 13, 2016 the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 250,000&lt;/font&gt; shares of Class B common stock to Fortress, which equaled &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2.5&lt;/font&gt;% of the fully diluted outstanding equity of Mustang at the time of issuance for the annual equity fee. In accordance with the amended and restated certificate of incorporation filed on July 27, 2016, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 250,000&lt;/font&gt; shares of Class A Preferred Stock, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 7.0&lt;/font&gt; million common shares and cancelled &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 7.2&lt;/font&gt; million Class B common shares. This exchange was recorded as an equity transaction and therefore no gain or loss was recorded (see Note 4).&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In February 2017, COH executed a waiver and acknowledgement agreement permitting issuance of the COH Anti-Dilution Shares in the form of Mustang common stock rather than Class A common shares as originally required, and such shares were issued. Therefore, in February 2017, the Company reclassed $1.7 million of common shares issuable liability to additional paid-in capital and issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 293,588&lt;/font&gt; common shares to COH. As of September 30, 2017, COH owns &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,000,000&lt;/font&gt; Class A common shares and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 293,588&lt;/font&gt; common shares. The shares were valued utilizing a weighted market model at approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.73&lt;/font&gt; per share or approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.7&lt;/font&gt; million.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;On March 13, 2017, the Company issued to Fortress &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 767,264&lt;/font&gt; shares of common stock at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.73&lt;/font&gt; per share representing the stock dividend payable in connection with Fortress&amp;#8217; ownership of Class A Preferred Stock. Pursuant to this issuance, the Company recorded a $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.4&lt;/font&gt; million decrease in common shares issuable and a corresponding increase in additional paid in capital to account for the issuance of the PIK Dividend (see Note 4).&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The holders of common stock are entitled to one vote per share of common stock held.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Class A Common Stock&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The holders of Class A common shares are entitled to the number of votes equal to the number of whole shares of common stock into which the shares of Class A common shares held by such holder are convertible and for a period of ten years from its issuance, the holders of the Class A common shares have the right to appoint one member of the board of directors of Mustang; to date, the holders of Class A common shares have not yet appointed such director.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;On March 17, 2015, the Company entered into the Original Agreement with COH to acquire intellectual property rights pertaining to CAR-T, (see Note 3). Pursuant to the Original Agreement, the Company paid COH an upfront fee of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.0&lt;/font&gt; million, in April 2015 (included in research and development-licenses acquired expenses on the Statements of Operations), and granted &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,000,000&lt;/font&gt; shares of Mustang&amp;#8217;s Class A common shares, representing &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10&lt;/font&gt;% ownership of Mustang, as of such date.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Offerings and Issuances of Common Stock and Warrants&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In September 2016, the Company entered into a Placement Agent Agreement with NSC relating to the Company&amp;#8217;s offering of shares of common stock in a private placement. Pursuant to the Placement Agent Agreement, the Company agreed to pay NSC a cash fee of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10.0&lt;/font&gt;% of the gross proceeds from the offering and granted a warrant exercisable for shares of common stock equal to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10.0&lt;/font&gt;% of the aggregate number of shares of common stock sold in the offering (the &amp;#8220;Placement Agent Warrants&amp;#8221;). In addition, the Company and the investors entered into a unit purchase agreement (the &amp;#8220;Unit Purchase Agreement&amp;#8221;). The common stock and Warrants were sold in units, with each unit consisting of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10,000&lt;/font&gt; shares of the Company&amp;#8217;s common stock, and Warrants exercisable for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,500&lt;/font&gt; shares of common stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8.50&lt;/font&gt; per share. The purchase price was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;65,000&lt;/font&gt; per unit. The warrants have a five-year term and are only exercisable for cash.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;On January 31, 2017, the Company closed the sixth round of financing totaling gross proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;55.5&lt;/font&gt; million, before expenses, in a private placement of shares and warrants for which NSC was the placement agent and received a fee of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.5&lt;/font&gt; million or approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10&lt;/font&gt;% of the gross proceeds. The Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 8,536,774&lt;/font&gt; unregistered shares of common stock and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,134,193&lt;/font&gt; warrants in connection with this transaction. In addition, NSC received &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 853,677&lt;/font&gt; warrants or approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10&lt;/font&gt;% of the shares issued.&lt;/font&gt;&lt;/div&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;On March 31, 2017, the Company closed the seventh round of financing totaling gross proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.4&lt;/font&gt; million, before expenses, in a private placement of shares and warrants for which NSC was the placement agent and received a fee of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;42,000&lt;/font&gt; or approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10&lt;/font&gt;% of the gross proceeds. The Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 64,000&lt;/font&gt; unregistered shares of common stock and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 16,000&lt;/font&gt; warrants in connection with this transaction. In addition, NSC received &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 6,400&lt;/font&gt; warrants or approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10&lt;/font&gt;% of the shares issued.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;On August 3, 2017, the Company closed the final round of financing totaling gross proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;65,000&lt;/font&gt;. The Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10,000&lt;/font&gt; unregistered shares of common stock and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,500&lt;/font&gt; warrants in connection with this transaction. In addition, NSC received &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,000&lt;/font&gt; warrants or approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10&lt;/font&gt;% of the shares issued.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;u&gt;Common Share Issuances to Fortress&lt;/u&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Pursuant to the Founders Agreement, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 215,269&lt;/font&gt; shares and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 47,870&lt;/font&gt; shares to Fortress during the nine months ended September 30, 2017 and September 30, 2016, respectively, representing &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2.5&lt;/font&gt;% of the aggregate number of shares of common stock issued in the offerings noted above. For the nine months ended September 30, 2017 and September 30, 2017, the Company recorded expense of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.2&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.3&lt;/font&gt; million, respectively, related to this issuance (based upon the fair value of common shares on the date of issuance), which is included in general and administrative expenses in the Company&amp;#8217;s Statements of Operations.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Class A Preferred Shares&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Pursuant to the Company&amp;#8217;s Amended and Restated Articles of Incorporation, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,000,000&lt;/font&gt; shares of Preferred Stock were authorized, of which &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 250,000&lt;/font&gt; have been designated as Class A Preferred Stock and the remainder are undesignated preferred stock. The Class A Preferred Stock is identical to undesignated common stock other than as to voting rights, conversion rights, and the PIK Dividend right (as described below). The undesignated Preferred Stock may be issued from time to time in one or more series. The Company&amp;#8217;s Board of Directors is authorized to determine or alter the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions, if any), the redemption price or prices, the liquidation preferences and other designations, powers, preferences and relative, participating, optional or other special rights, if any, and the qualifications, limitations and restrictions granted to or imposed upon any wholly unissued series of Preferred Stock, and to fix the number of shares of any series of Preferred Stock (but not below the number of shares of any such series then outstanding).&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The holders of the outstanding shares of Class A Preferred Stock shall receive on each March 13 (each a &amp;#8220;PIK Dividend Payment Date&amp;#8221;) after the original issuance date of the Class A Preferred Stock until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and non-assessable shares of common stock such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to 2.5% of the Corporation&amp;#8217;s fully-diluted outstanding capitalization on the date that is one business day prior to any PIK Dividend Payment Date (&amp;#8220;PIK Record Date&amp;#8221;). In the event the Class A Preferred Stock converts into common stock, the holders shall receive all PIK Dividends accrued through the date of such conversion. No dividend or other distribution shall be paid, or declared and set apart for payment (other than dividends payable solely in capital stock on the capital stock of the Company) on the shares of common stock until all PIK Dividends on the Class A Preferred Stock shall have been paid or declared and set apart for payment. All dividends are non-cumulative.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Class A Preferred Stock shall be entitled to cast for each share of Class A Preferred Stock held by such holder as of the record date for determining stockholders entitled to vote on such matter, the number of votes that is equal to one and one-tenth &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; (1.1)&lt;/font&gt; times a fraction, the numerator of which is the sum of (A) the number of shares of outstanding common stock and (B) the whole shares of common stock in to which the shares of outstanding Class A common shares and the Class A Preferred Stock are convertible, and the denominator of which is number of shares of outstanding Class A Preferred Stock (the &amp;#8220;Class A Preferred Stock Ratio&amp;#8221;). Thus, the Class A Preferred Stock will at all times constitute a voting majority.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Each share of Class A Preferred Stock is convertible, at the option of the holder, into one fully paid and nonassessable share of common stock (the &amp;#8220;Conversion Ratio&amp;#8221;), subject to certain adjustments. If the Company, at any time effects a subdivision or combination of the outstanding common stock (by any stock split, stock dividend, recapitalization, reverse stock split or otherwise), the applicable Conversion Ratio in effect immediately before that subdivision is proportionately decreased or increased, as applicable, so that the number of shares of common stock issuable on conversion of each share of Class A Preferred Stock shall be increased or decreased, a applicable, in proportion to such increase or decrease in the aggregate number of shares of common stock outstanding. Additionally, if any reorganization, recapitalization, reclassification, consolidation or merger involving the Company occurs in which the common stock (but not the Class A Preferred Stock) is converted into or exchanged for securities, cash or other property, then each share of Class A Preferred Stock becomes convertible into the kind and amount of securities, cash or other property which a holder of the number of shares of common stock of the Company issuable upon conversion of one share of the Class A Preferred Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Stock Awards&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Stock Options&amp;#160;&lt;/font&gt;&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;On April 24, 2017, the Company announced that Manuel Litchman, M.D., had been appointed President and Chief Executive Officer. Dr. Litchman was also appointed to the Company&amp;#8217;s Board of Directors.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The employment agreement grants Dr. Litchman an option to purchase 1,041,675 shares of the Company&amp;#8217;s common stock (the &amp;#8220;Option&amp;#8221;). The Option has an exercise price per share equal to the fair market value of a share the Company&amp;#8217;s common stock, $5.73 on the date of the grant of the stock option, subject to the conditions and vesting schedule set forth in his Employment Agreement.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;On April 7, 2017, the Company granted &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 200,000&lt;/font&gt; options to two employees of Fortress, who provide services to the Company in connection with our research and development. These options have an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.73&lt;/font&gt;, representing the fair market value of a share the Company&amp;#8217;s common stock on the date of the grant of the stock option.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Both grants have the following vesting schedule: 50% of the options vest over-time (&amp;#8220;Time Based Option&amp;#8221;) with 25% vesting over 12 months of continued service and the remaining shares vesting in 12 equal quarterly installments thereafter, subject to continued employment. &lt;font style="FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt"&gt;The remaining 50% (the &amp;#8220;Performance Options&amp;#8221;) vest and become exercisable upon the occurrence of the following milestones being achieved: (i) 25% of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of any Company product candidate, (ii) 25% of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of a second Company product candidate, (iii) 25% of the Performance Options vest upon the Company&amp;#8217;s achievement of a fully-diluted market capitalization of $500,000,000 and (iv) 25% of the Performance Options vest upon the Company&amp;#8217;s achievement of a fully-diluted market capitalization of $1,000,000,000.&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The value of the&amp;#160;stock options granted approximated $5.5 million and&amp;#160;was determined on the grant date using assumptions for risk free interest rate, the expected term, expected volatility, expected dividend yield, and&amp;#160;an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.73&lt;/font&gt;. Mustang does not expect to pay dividends in the foreseeable future. As a result, the expected dividend yield is &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 0&lt;/font&gt;%. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The fair value associated with the market award vesting was determined utilizing a binomial valuation methodology and the following assumptions:&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"&gt; &lt;div&gt;September&amp;#160;30,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;1.81% - 2.38&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Exercise Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;5.73&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Expected term in years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;5.5 - 10.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;77.3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;The following table summarizes stock option activities for the nine months ended September 30, 2017:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Contractual&amp;#160;Life&amp;#160;(in&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Stock&amp;#160;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Nonvested at December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Options granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,241,675&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5.73&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;9.56&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Options outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,241,675&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5.73&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;9.56&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Options vested and exercisable at September 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;As of September 30, 2017, the Company had unrecognized stock-based compensation expense related to options of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.3&lt;/font&gt; million with a weighted average vesting period of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1.61&lt;/font&gt; years.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Restricted Stock&lt;/font&gt;&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In accordance with the Company&amp;#8217;s Director Compensation Plan, the Company granted an aggregate &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 180,000&lt;/font&gt; restricted shares to members of its board of directors, these shares commence vesting three years from the grant date of June 8, 2017. Annual grants to each director of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10,000&lt;/font&gt; shares vest on the third anniversary of the grant with continuous service, while the initial grant of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 50,000&lt;/font&gt; vests in three equal tranches commencing on the third anniversary date of the grant and on each date thereafter so long as continuous service exists. See Note 4 for grants made to Dr. Rosenwald and Mr. Weiss for their service as Directors to the Company.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;The following table summarizes restricted stock award activities for the nine months ended September 30, 2017:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&amp;#160;Shares&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Grant&amp;#160;Date&amp;#160;Fair&amp;#160;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;Nonvested at December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;180,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;5.73&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;Nonvested at September 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;180,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;5.73&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;As of September 30, 2017, the Company had unrecognized stock-based compensation expense related to restricted stock of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.0&lt;/font&gt; million with a weighted average vesting period of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3.53&lt;/font&gt; years.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Restricted Stock Units&lt;/font&gt;&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;On June 30, 2017, the Company granted an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 110,000&lt;/font&gt; restricted stock units to two employees. These grants vest over 4 years on the anniversary date &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;of the grant&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;The following table summarizes restricted stock units activities for the nine months ended September 30, 2017:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&amp;#160;Units&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Grant&amp;#160;Date&amp;#160;Fair&amp;#160;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;Nonvested at December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;110,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;5.73&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;Nonvested at September 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;110,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;5.73&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;As of September 30, 2017, the Company had unrecognized stock-based compensation expense related to restricted stock units of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.6&lt;/font&gt; million with a weighted average vesting period of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2.25&lt;/font&gt; years.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2017 (in thousands).&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="28%" colspan="6"&gt; &lt;div&gt; For&amp;#160;the&amp;#160;three&amp;#160;months&amp;#160;ended&amp;#160;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="28%" colspan="6"&gt; &lt;div&gt; For&amp;#160;the&amp;#160;nine&amp;#160;months&amp;#160;ended&amp;#160;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Employee&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;576&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;909&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Non-employee&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;258&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;321&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Total stock-based compensation expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;834&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,230&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; Warrants&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In connection with the Company&amp;#8217;s offering of shares of common stock in a private placement, each investor received a warrant equal to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 25&lt;/font&gt;% of the common shares purchased in connection with the offering. Further, NSC received&amp;#160;Placement Agent Warrants.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;A summary of warrant activities for nine months ended September 30, 2017 is presented below:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Contractual&amp;#160;Life&amp;#160;(in&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Outstanding as of December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2,243,664&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;7.98&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5.16&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;3,013,770&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;8.50&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;4.34&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Outstanding as of September 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5,257,434&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;8.28&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;4.37&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Upon the exercise of warrants, the Company will issue new shares of common stock.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>

  <us-gaap:InterestReceivableCurrent contextRef="PAsOn09_30_2017" id="Factid_360" unitRef="USD" decimals="-3">35000</us-gaap:InterestReceivableCurrent>

  <us-gaap:InterestReceivableCurrent contextRef="PAsOn12_31_2016" id="Factid_361" unitRef="USD" decimals="-3">0</us-gaap:InterestReceivableCurrent>

  <ck0001680048:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsTableTextBlock contextRef="P01_01_2017To09_30_2017" id="Factid_362">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The fair value associated with the market award vesting was determined utilizing a binomial valuation methodology and the following assumptions:&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"&gt; &lt;div&gt;September&amp;#160;30,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;1.81% - 2.38&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Exercise Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;5.73&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Expected term in years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;5.5 - 10.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;77.3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ck0001680048:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsTableTextBlock>

  <ck0001680048:CommonSharesIssuableLiabilityCurrent contextRef="PAsOn09_30_2017" id="Factid_363" unitRef="USD" decimals="-3">0</ck0001680048:CommonSharesIssuableLiabilityCurrent>

  <ck0001680048:CommonSharesIssuableLiabilityCurrent contextRef="PAsOn12_31_2016" id="Factid_364" unitRef="USD" decimals="-3">1682000</ck0001680048:CommonSharesIssuableLiabilityCurrent>

  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2017To09_30_2017" id="Factid_365">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The following table summarizes stock option activities for the nine months ended September 30, 2017:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Contractual&amp;#160;Life&amp;#160;(in&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Stock&amp;#160;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Nonvested at December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Options granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,241,675&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5.73&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;9.56&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Options outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,241,675&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5.73&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;9.56&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Options vested and exercisable at September 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>

  <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="P01_01_2017To09_30_2017" id="Factid_366">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2017 (in thousands).&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="28%" colspan="6"&gt; &lt;div&gt; For&amp;#160;the&amp;#160;three&amp;#160;months&amp;#160;ended&amp;#160;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="28%" colspan="6"&gt; &lt;div&gt; For&amp;#160;the&amp;#160;nine&amp;#160;months&amp;#160;ended&amp;#160;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Employee&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;576&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;909&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Non-employee&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;258&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;321&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div&gt;Total stock-based compensation expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;834&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,230&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>

  <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="P01_01_2017To09_30_2017" id="Factid_367">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;A summary of warrant activities for nine months ended September 30, 2017 is presented below:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Contractual&amp;#160;Life&amp;#160;(in&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Outstanding as of December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;2,243,664&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;7.98&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5.16&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;3,013,770&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;8.50&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;4.34&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Outstanding as of September 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5,257,434&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;8.28&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;4.37&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>

  <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="P01_01_2017To09_30_2017_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_368">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; The following table summarizes restricted stock award activities for the nine months ended September 30, 2017: &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&amp;#160;Shares&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Grant&amp;#160;Date&amp;#160;Fair&amp;#160;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;Nonvested at December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;180,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;5.73&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;Nonvested at September 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;180,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;5.73&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>

  <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="P01_01_2017To09_30_2017_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_369">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; The following table summarizes restricted stock units activities for the nine months ended September 30, 2017: &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&amp;#160;Units&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Grant&amp;#160;Date&amp;#160;Fair&amp;#160;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;Nonvested at December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;110,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;5.73&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"&gt; &lt;div&gt;Nonvested at September 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;110,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;5.73&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>

  <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2017To09_30_2017" id="Factid_370">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;6 - Net Loss per Share&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period less unvested restricted stock. Since dividends are declared, paid and set aside among the holders of shares of common stock and Class A common shares pro-rata on an as-if-converted basis, the two-class method of computing net loss per share is not required. Diluted net loss per share does not reflect the effect of shares of common stock to be issued upon the exercise of warrants or outstanding Class A preferred shares, as their inclusion would be anti-dilutive. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive.&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Potentially dilutive securities&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt; For&amp;#160;the&amp;#160;nine&amp;#160;months&amp;#160;ended&amp;#160;September&amp;#160;30&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"&gt; &lt;div&gt;Warrants (Note 7)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5,257,434&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;670,191&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"&gt; &lt;div&gt;Options (Note 7)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,241,675&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"&gt; &lt;div&gt;Class A Preferred Shares (Note 7)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;250,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;250,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"&gt; &lt;div&gt;Unvested restricted stock awards (Note 7)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;180,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"&gt; &lt;div&gt;Unvested restricted stock units (Note 7)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;110,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;7,039,109&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;920,191&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>

  <us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock contextRef="P01_01_2017To09_30_2017" id="Factid_371">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive.&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Potentially dilutive securities&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt; For&amp;#160;the&amp;#160;nine&amp;#160;months&amp;#160;ended&amp;#160;September&amp;#160;30&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"&gt; &lt;div&gt;Warrants (Note 7)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5,257,434&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;670,191&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"&gt; &lt;div&gt;Options (Note 7)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,241,675&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"&gt; &lt;div&gt;Class A Preferred Shares (Note 7)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;250,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;250,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"&gt; &lt;div&gt;Unvested restricted stock awards (Note 7)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;180,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"&gt; &lt;div&gt;Unvested restricted stock units (Note 7)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;110,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;7,039,109&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;920,191&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock>

  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2017To09_30_2017" id="Factid_372">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Note 5 - Commitments and Contingencies&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; Litigation&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On January 15, 2016, Dr. Winson Tang (&amp;#8220;Plaintiff&amp;#8221;) filed a Complaint against the Company in the Superior Court of the State of California, County of Los Angeles. Winson Tang v. Lindsay Rosenwald et al., Case No. BC607346. As amended, the Complaint requested a declaration that Plaintiff was a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 15&lt;/font&gt;% owner of the Company&amp;#8217;s outstanding shares, and alleged two claims for breach of contract against other Defendants. On November 3, 2017, Plaintiff and Defendants entered into a Settlement Agreement. The Settlement Agreement did not require issuance of any new shares of the Company.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;In connection with the legal settlement, above, Fortress is required to deliver &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 200,000&lt;/font&gt; Mustang common shares, held by Fortress, to Plaintiff in accordance with this settlement arrangement. At September 30, 2017, the Company recorded this transaction as a capital contribution from Fortress and a corresponding expense of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.1&lt;/font&gt; million based upon the closing share price of Mustang shares as of the date of the Settlement Agreement. In addition to the share issuance the Company paid, in November 2017, a $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.1&lt;/font&gt; million cash settlement to the plaintiff, such amount was accrued as of September 30, 2017 and recorded in general and administrative expenses on the Condensed Consolidated Statements of Operations.&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn09_30_2017" id="Factid_373" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn12_31_2016" id="Factid_374" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2016" id="Factid_375" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn12_31_2016" id="Factid_376" unitRef="shares" decimals="INF">2000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn09_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_377" unitRef="shares" decimals="INF">250000</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2016_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_378" unitRef="shares" decimals="INF">250000</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn12_31_2016" id="Factid_379" unitRef="shares" decimals="INF">50000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2016_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_380" unitRef="shares" decimals="INF">1000000</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2016_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_381" unitRef="shares" decimals="INF">1000000</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn09_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_382" unitRef="shares" decimals="INF">250000</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2016_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_383" unitRef="shares" decimals="INF">250000</us-gaap:PreferredStockSharesIssued>

  <us-gaap:CommonStockSharesSubscribedButUnissued contextRef="PAsOn09_30_2017" id="Factid_384" unitRef="shares" decimals="INF">0</us-gaap:CommonStockSharesSubscribedButUnissued>

  <us-gaap:CommonStockSharesSubscribedButUnissued contextRef="PAsOn12_31_2016" id="Factid_385" unitRef="shares" decimals="INF">767264</us-gaap:CommonStockSharesSubscribedButUnissued>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn09_30_2017" id="Factid_386" unitRef="shares" decimals="INF">25232139</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn09_30_2017" id="Factid_387" unitRef="shares" decimals="INF">25232139</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2016" id="Factid_388" unitRef="shares" decimals="INF">15165244</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2016" id="Factid_389" unitRef="shares" decimals="INF">15165244</us-gaap:CommonStockSharesOutstanding>

  <ck0001680048:InterestIncomeExpensesRelatedParty contextRef="P07_01_2017To09_30_2017" id="Factid_390" unitRef="USD" decimals="-3">0</ck0001680048:InterestIncomeExpensesRelatedParty>

  <ck0001680048:InterestIncomeExpensesRelatedParty contextRef="P07_01_2016To09_30_2016" id="Factid_391" unitRef="USD" decimals="-3">-46000</ck0001680048:InterestIncomeExpensesRelatedParty>

  <ck0001680048:InterestIncomeExpensesRelatedParty contextRef="P01_01_2017To09_30_2017" id="Factid_392" unitRef="USD" decimals="-3">0</ck0001680048:InterestIncomeExpensesRelatedParty>

  <ck0001680048:InterestIncomeExpensesRelatedParty contextRef="P01_01_2016To09_30_2016" id="Factid_393" unitRef="USD" decimals="-3">-220000</ck0001680048:InterestIncomeExpensesRelatedParty>

  <us-gaap:InterestExpenseDebt contextRef="P07_01_2017To09_30_2017" id="Factid_394" unitRef="USD" decimals="-3">0</us-gaap:InterestExpenseDebt>

  <us-gaap:InterestExpenseDebt contextRef="P07_01_2016To09_30_2016" id="Factid_395" unitRef="USD" decimals="-3">156000</us-gaap:InterestExpenseDebt>

  <us-gaap:InterestExpenseDebt contextRef="P01_01_2017To09_30_2017" id="Factid_396" unitRef="USD" decimals="-3">0</us-gaap:InterestExpenseDebt>

  <us-gaap:InterestExpenseDebt contextRef="P01_01_2016To09_30_2016" id="Factid_397" unitRef="USD" decimals="-3">156000</us-gaap:InterestExpenseDebt>

  <us-gaap:FairValueAdjustmentOfWarrants contextRef="P07_01_2017To09_30_2017" id="Factid_398" unitRef="USD" decimals="-3">0</us-gaap:FairValueAdjustmentOfWarrants>

  <us-gaap:FairValueAdjustmentOfWarrants contextRef="P07_01_2016To09_30_2016" id="Factid_399" unitRef="USD" decimals="-3">-2000</us-gaap:FairValueAdjustmentOfWarrants>

  <us-gaap:FairValueAdjustmentOfWarrants contextRef="P01_01_2017To09_30_2017" id="Factid_400" unitRef="USD" decimals="-3">0</us-gaap:FairValueAdjustmentOfWarrants>

  <us-gaap:FairValueAdjustmentOfWarrants contextRef="P01_01_2016To09_30_2016" id="Factid_401" unitRef="USD" decimals="-3">-2000</us-gaap:FairValueAdjustmentOfWarrants>

  <ck0001680048:FoundersAgreementTerm contextRef="P05_01_2016To05_17_2016" id="Factid_402">P15Y</ck0001680048:FoundersAgreementTerm>

  <us-gaap:PreferredStockVotingRights contextRef="P05_01_2016To05_17_2016_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_403">Each share of Class A Preferred Stock is convertible, at Fortress option, into one fully paid and nonassessable share of Mustang common stock, subject to certain adjustments. As holders of Class A Preferred Stock, Fortress will receive on each March 13 (each a PIK Dividend Payment Date) until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (PIK Dividends) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half percent (2.5%) of Mustangs fully-diluted outstanding capitalization on the date that is one (1) business day prior to any PIK Dividend Payment Date</us-gaap:PreferredStockVotingRights>

  <ck0001680048:AdditionalConsiderationUnderFoundersAgreementDescription contextRef="P05_01_2016To05_17_2016_NationalHoldingsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_404">(i) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Mustang or any of its respective subsidiaries that occurs after the effective date of the Mustang Founders Agreement and ending on the date when Fortress no longer has majority voting control in the Companys voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of the Companys annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, the Company will pay a one-time change in control fee equal to five (5x) times the product of (A) net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%).</ck0001680048:AdditionalConsiderationUnderFoundersAgreementDescription>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="P01_01_2017To09_30_2017_DirectorMemberusgaapTitleOfIndividualAxis" id="Factid_405">Dr. Rosenwald will receive a cash fee of $50,000 per year paid quarterly and an annual stock award of the greater of (i) a number of shares of common stock having a fair market value on the grant date of $50,000 or (ii) 10,000 shares of common stock, which shares shall vest and become non-forfeitable on the third anniversary of the grant date, subject to continued service on the Board on such date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>

  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="P01_01_2017To09_30_2017" id="Factid_406" unitRef="USD" decimals="-3">0</us-gaap:AmortizationOfDebtDiscountPremium>

  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="P01_01_2016To09_30_2016" id="Factid_407" unitRef="USD" decimals="-3">90000</us-gaap:AmortizationOfDebtDiscountPremium>

  <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="P01_01_2017To09_30_2017" id="Factid_408" unitRef="USD" decimals="-3">35000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>

  <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="P01_01_2016To09_30_2016" id="Factid_409" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>

  <us-gaap:PaymentsForConstructionInProcess contextRef="P01_01_2017To09_30_2017" id="Factid_410" unitRef="USD" decimals="-3">22000</us-gaap:PaymentsForConstructionInProcess>

  <us-gaap:PaymentsForConstructionInProcess contextRef="P01_01_2016To09_30_2016" id="Factid_411" unitRef="USD" decimals="-3">0</us-gaap:PaymentsForConstructionInProcess>

  <us-gaap:ConversionOfStockSharesIssued1 contextRef="P07_01_2016To07_26_2016_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_412" unitRef="shares" decimals="INF">250000</us-gaap:ConversionOfStockSharesIssued1>

  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="P01_01_2017To09_30_2017" id="Factid_413" unitRef="USD" decimals="-3">0</us-gaap:PaymentsOfDebtIssuanceCosts>

  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="P01_01_2016To09_30_2016" id="Factid_414" unitRef="USD" decimals="-3">129000</us-gaap:PaymentsOfDebtIssuanceCosts>

  <ck0001680048:AnnualConsultingFees contextRef="P03_01_2015To03_13_2015_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_415" unitRef="USD" decimals="-5">500000</ck0001680048:AnnualConsultingFees>

  <ck0001680048:ExcessInNetAssetsValue contextRef="PAsOn03_13_2015_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_416" unitRef="USD" decimals="-6">100000000</ck0001680048:ExcessInNetAssetsValue>

  <ck0001680048:ProceedsFromNotesPayableGross contextRef="P01_01_2017To09_30_2017" id="Factid_417" unitRef="USD" decimals="-3">0</ck0001680048:ProceedsFromNotesPayableGross>

  <ck0001680048:ProceedsFromNotesPayableGross contextRef="P01_01_2016To09_30_2016" id="Factid_418" unitRef="USD" decimals="-3">3600000</ck0001680048:ProceedsFromNotesPayableGross>

  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="P01_01_2017To09_30_2017" id="Factid_419" unitRef="USD" decimals="-3">50296000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>

  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="P01_01_2016To09_30_2016" id="Factid_420" unitRef="USD" decimals="-3">11083000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>

  <us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid contextRef="P01_01_2017To09_30_2017" id="Factid_421" unitRef="USD" decimals="-3">117000</us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid>

  <us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid contextRef="P01_01_2016To09_30_2016" id="Factid_422" unitRef="USD" decimals="-3">0</us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid>

  <us-gaap:LiabilitiesAssumed1 contextRef="P01_01_2017To09_30_2017" id="Factid_423" unitRef="USD" decimals="-3">0</us-gaap:LiabilitiesAssumed1>

  <us-gaap:LiabilitiesAssumed1 contextRef="P01_01_2016To09_30_2016" id="Factid_424" unitRef="USD" decimals="-3">634000</us-gaap:LiabilitiesAssumed1>

  <us-gaap:ProfessionalFees contextRef="P07_01_2016To09_30_2016" id="Factid_425" unitRef="USD" decimals="0">17500</us-gaap:ProfessionalFees>

  <us-gaap:ProfessionalFees contextRef="P01_01_2016To09_30_2016" id="Factid_426" unitRef="USD" decimals="0">30300</us-gaap:ProfessionalFees>

  <ck0001680048:BackOfficeAccountingFunctionsExpenses contextRef="P04_01_2016To04_08_2016_ChordAdvisorsLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_427" unitRef="USD" decimals="0">5000</ck0001680048:BackOfficeAccountingFunctionsExpenses>

  <ck0001680048:AccountingAnalysisAndFinancialReportingFees contextRef="P04_01_2016To04_08_2016_ChordAdvisorsLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_428" unitRef="USD" decimals="0">7500</ck0001680048:AccountingAnalysisAndFinancialReportingFees>

  <us-gaap:OfficersCompensation contextRef="P07_01_2017To09_30_2017" id="Factid_429" unitRef="USD" decimals="0">12500</us-gaap:OfficersCompensation>

  <us-gaap:OfficersCompensation contextRef="P01_01_2017To09_30_2017" id="Factid_430" unitRef="USD" decimals="0">25052</us-gaap:OfficersCompensation>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2017To09_30_2017_DirectorMemberusgaapTitleOfIndividualAxis" id="Factid_431" unitRef="USD" decimals="0">4900</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="P01_01_2017To09_30_2017" id="Factid_432" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromRelatedPartyDebt>

  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="P01_01_2016To09_30_2016" id="Factid_433" unitRef="USD" decimals="-3">1963000</us-gaap:ProceedsFromRelatedPartyDebt>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="PAsOn09_30_2017" id="Factid_434" unitRef="USD_per_Share" decimals="2">5.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2017To09_30_2017" id="Factid_435" unitRef="pure" decimals="3">0.773</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2017To09_30_2017_MinimumMemberusgaapRangeAxis" id="Factid_436">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P01_01_2017To09_30_2017" id="Factid_437" unitRef="USD" decimals="-3">5674000</us-gaap:PaymentsOfStockIssuanceCosts>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P01_01_2016To09_30_2016" id="Factid_438" unitRef="USD" decimals="-3">0</us-gaap:PaymentsOfStockIssuanceCosts>

  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2017To09_30_2017" id="Factid_439">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Note 1 - Organization, Description of Business and Liquidity and Capital Resources&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 18.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Mustang Bio, Inc. (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Mustang&amp;#8221;) was incorporated in Delaware on March 13, 2015 and commenced its principal operations on March 13, 2015. Mustang was formed as a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel cancer immunotherapy products designed to utilize the power of the patient&amp;#8217;s own immune system to eliminate cancer cells. The Company may acquire rights to these technologies by licensing the rights or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Company is a majority controlled subsidiary of Fortress Biotech, Inc. (&amp;#8220;Fortress&amp;#8221; or &amp;#8220;Parent&amp;#8221;).&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Company has incurred substantial operating losses since its inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of September 30, 2017, the Company had an accumulated deficit of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;32.8&lt;/font&gt; million.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Company expects to continue to use the proceeds from previous financing transactions primarily for general corporate purposes, which may include financing the Company&amp;#8217;s growth, developing new or existing product candidates, and funding capital expenditures, acquisitions and investments. The Company currently anticipates that its cash and cash equivalents balances and short-term investments held to maturity at September 30, 2017, are sufficient to fund its anticipated operating cash requirements for&amp;#160;at least&amp;#160;the next 12 months.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>

  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2017To09_30_2017" id="Factid_440">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Basis of Presentation&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The accompanying unaudited interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&amp;#8220;GAAP&amp;#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company&amp;#8217;s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Therefore, these condensed financial statements should be read in conjunction with the Company&amp;#8217;s audited financial statements and notes thereto for the year ended December 31, 2016, which were included in the Company&amp;#8217;s Form 10-K filed with the U.S. Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) on March 31, 2017. The results of operations for any interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>

  <us-gaap:UseOfEstimates contextRef="P01_01_2017To09_30_2017" id="Factid_441">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Use of Estimates&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UseOfEstimates>

  <ck0001680048:SignificantAccountingPoliciesPolicyTextBlock contextRef="P01_01_2017To09_30_2017" id="Factid_442">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Significant Accounting Policies&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;There have been no material changes to the Company&amp;#8217;s significant accounting policies previously disclosed in the Company&amp;#8217;s Form 10-K filed with the SEC on March 31, 2017, with the exception of the policies listed below.&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ck0001680048:SignificantAccountingPoliciesPolicyTextBlock>

  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2017To09_30_2017" id="Factid_443">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Company expenses stock-based compensation to employees and board members over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based awards with graded vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. For stock-based compensation awards to non-employees, the Company measures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 13.2pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The assumptions used in calculating the fair value of stock-based awards represent management&amp;#8217;s best estimates and involve inherent uncertainties and the application of management&amp;#8217;s judgment.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>

  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2017To09_30_2017" id="Factid_444">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/b&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;b&gt;Property and equipment &amp;#150; construction in process&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Leasehold improvements are amortized over the shorter of the estimated useful lives or the term of the respective leases, upon the improvement being placed in service. In connection with the Company&amp;#8217;s manufacturing facility, the Company incurred $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.1&lt;/font&gt; million related to the design of the facility which is recorded in property and equipment on the condensed balance sheet at September 30, 2017. Upon completion of the buildout all costs associated with the buildout will be recorded as leasehold improvements.&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>

  <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2017To09_30_2017" id="Factid_445">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in; mso-header-mso-footer-mso-paper-source: 0"&gt; &lt;div style="CLEAR:both;TEXT-ALIGN: justify; LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; mso-style-unhide: no; mso-style-qformat: yes; mso-style-parent: ; mso-pagination: widow-orphan; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Times New Roman; mso-bidi-theme-font: minor-bidi"&gt; &lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt; mso-fareast-font-family: 'Times New Roman'"&gt; Note 8 &amp;#150; Subsequent Events&lt;/font&gt;&lt;/b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;TEXT-ALIGN: justify; LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/b&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;TEXT-ALIGN: justify; LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On October 27, 2017, Mustang entered into a lease agreement with WCS - 377 Plantation Street, Inc., a Massachusetts nonprofit corporation (&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#8220;&lt;/font&gt;Landlord&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#8221;&lt;/font&gt;). Pursuant to the terms of the lease agreement, Mustang agreed to lease &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 27,043&lt;/font&gt; sf from the Landlord, located at 377 Plantation Street in Worcester, MA (the &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#8220;&lt;/font&gt;Facility&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#8221;&lt;/font&gt;), through November 2026, subject to additional extensions at Mustang&amp;#8217;s option. Base rent, net of abatements of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.6&lt;/font&gt; million over the lease term, totals approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3.6&lt;/font&gt; million, on a triple-net basis. Mustang plans to make improvements to the facility of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3.5&lt;/font&gt; million.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The terms of the lease also require that Mustang post an initial security deposit of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.8&lt;/font&gt; million, in the form of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.5&lt;/font&gt; million letter of credit and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.3&lt;/font&gt; million in cash, which shall increase to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.3&lt;/font&gt; million ($&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.0&lt;/font&gt; million letter of credit, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.3&lt;/font&gt; million in cash) when the Facility is fully occupied by Mustang. After the fifth lease year, the letter of credit obligation is subject to reduction.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; COLOR: #1f497d"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Facility is expected to be operational for the production of personalized CAR T therapies in 2018.&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>

  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock contextRef="P01_01_2017To09_30_2017" id="Factid_446">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;For the three and nine months ended September 30, 2017 and 2016, the Company recorded the following expense in research and development for licenses acquired:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; For&amp;#160;the&amp;#160;Three&amp;#160;Months&amp;#160;Ended&amp;#160;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; For&amp;#160;the&amp;#160;Nine&amp;#160;Months&amp;#160;Ended&amp;#160;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; ($&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;City of Hope&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;IL13Ra2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;IV/ICV&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;125&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;PSCA&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;300&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;HER2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;600&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;CS-1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;600&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;UCLA&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;200&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Fred Hutch CD20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;300&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;300&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;300&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2,375&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P07_01_2017To09_30_2017_FredHutchCd20MemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_447" unitRef="USD" decimals="-3">300000</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P07_01_2016To09_30_2016_FredHutchCd20MemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_448" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P01_01_2017To09_30_2017_FredHutchCd20MemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_449" unitRef="USD" decimals="-3">300000</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P01_01_2016To09_30_2016_FredHutchCd20MemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_450" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P07_01_2017To09_30_2017_CsTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_451" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P07_01_2016To09_30_2016_CsTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_452" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P01_01_2017To09_30_2017_CsTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_453" unitRef="USD" decimals="-3">600000</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:ResearchAndDevelopmentInProcess contextRef="P01_01_2016To09_30_2016_CsTechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_454" unitRef="USD" decimals="-3">0</us-gaap:ResearchAndDevelopmentInProcess>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P09_01_2016To09_30_2016_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_455" unitRef="shares" decimals="INF">10000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P07_01_2017To09_30_2017" id="Factid_456" unitRef="USD" decimals="-5">500000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P07_01_2016To09_30_2016" id="Factid_457" unitRef="USD" decimals="-5">500000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P01_01_2017To09_30_2017" id="Factid_458">The remaining 50% (&amp;#8220;The Performance Options&amp;#8221;) vest and become exercisable upon the occurrence of the following milestones being achieved: (i) 25% of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of any Company product candidate, (ii) 25% of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of a second Company product candidate, (iii) 25% of the Performance Options vest upon the Company&amp;#8217;s achievement of a fully-diluted market capitalization of $500,000,000 and (iv) 25% of the Performance Options vest upon the Company&amp;#8217;s achievement of a fully-diluted market capitalization of $1,000,000,000.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2017To09_30_2017" id="Factid_459" unitRef="USD" decimals="-5">1500000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2016To09_30_2016" id="Factid_460" unitRef="USD" decimals="-5">1500000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2017To09_30_2017_ArCd123LicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_CityOfHopeMemberusgaapRelatedPartyTransactionAxis" id="Factid_461" unitRef="USD" decimals="-5">1200000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="P08_01_2017To08_03_2017_NationalHoldingsCorporationMemberdeiLegalEntityAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_462" unitRef="USD" decimals="0">65000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P08_01_2017To08_03_2017_NationalHoldingsCorporationMemberdeiLegalEntityAxis_UnregisteredCommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_463" unitRef="shares" decimals="INF">10000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <ck0001680048:WarrantsIssued contextRef="P08_01_2017To08_03_2017_NationalHoldingsCorporationMemberdeiLegalEntityAxis" id="Factid_464" unitRef="shares" decimals="INF">2500</ck0001680048:WarrantsIssued>

  <ck0001680048:WarrantsIssued contextRef="P08_01_2017To08_03_2017_NationalSecuritiesIncMemberdeiLegalEntityAxis" id="Factid_465" unitRef="shares" decimals="INF">1000</ck0001680048:WarrantsIssued>

  <ck0001680048:PercentageOfSharesIssuedToPlacementAgent contextRef="P08_01_2017To08_03_2017_NationalSecuritiesIncMemberdeiLegalEntityAxis" id="Factid_466" unitRef="pure" decimals="1">0.1</ck0001680048:PercentageOfSharesIssuedToPlacementAgent>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2017To09_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis_FortressBiotechIncMemberdeiLegalEntityAxis" id="Factid_467" unitRef="shares" decimals="INF">215269</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <ck0001680048:SharesOfCommonStockPercentage contextRef="PAsOn09_30_2017_FortressBiotechIncMemberdeiLegalEntityAxis" id="Factid_468" unitRef="pure" decimals="3">0.025</ck0001680048:SharesOfCommonStockPercentage>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2017To09_30_2017_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_469" unitRef="USD" decimals="-5">1200000</us-gaap:AllocatedShareBasedCompensationExpense>

  <ck0001680048:PaymentOfUpfrontFees contextRef="P07_01_2017To07_03_2017_Cd20TechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_FredHutchinsonCancerResearchCenterMemberusgaapRelatedPartyTransactionAxis" id="Factid_470" unitRef="USD" decimals="-5">300000</ck0001680048:PaymentOfUpfrontFees>

  <us-gaap:MaintenanceCosts contextRef="P07_01_2017To07_03_2017_Cd20TechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_FredHutchinsonCancerResearchCenterMemberusgaapRelatedPartyTransactionAxis" id="Factid_471" unitRef="USD" decimals="0">50000</us-gaap:MaintenanceCosts>

  <ck0001680048:ResearchAndDevelopmentExpenseSponsoredResearchPayment contextRef="PAsOn07_03_2017_Cd20ClinicalAgreementMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_FredHutchinsonCancerResearchCenterMemberusgaapRelatedPartyTransactionAxis" id="Factid_472" unitRef="USD" decimals="-5">5300000</ck0001680048:ResearchAndDevelopmentExpenseSponsoredResearchPayment>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P07_01_2017To09_30_2017_Cd20ClinicalAgreementMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_FredHutchinsonCancerResearchCenterMemberusgaapRelatedPartyTransactionAxis" id="Factid_473" unitRef="USD" decimals="0">88000</us-gaap:ResearchAndDevelopmentExpense>

  <ck0001680048:PaymentOfUpfrontFees contextRef="P01_01_2017To09_30_2017_Cd20ClinicalAgreementMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_FredHutchinsonCancerResearchCenterMemberusgaapRelatedPartyTransactionAxis" id="Factid_474" unitRef="USD" decimals="-5">400000</ck0001680048:PaymentOfUpfrontFees>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2017To09_30_2017_Cd20ClinicalAgreementMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_FredHutchinsonCancerResearchCenterMemberusgaapRelatedPartyTransactionAxis" id="Factid_475" unitRef="USD" decimals="0">88000</us-gaap:ResearchAndDevelopmentExpense>

  <ck0001680048:PaymentOfUpfrontFees contextRef="P03_01_2017To03_17_2017_UclaLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_UniversityOfCaliforniaMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_476" unitRef="USD" decimals="-5">200000</ck0001680048:PaymentOfUpfrontFees>

  <us-gaap:OtherCommitmentDueInNextTwelveMonths contextRef="PAsOn03_17_2017_UclaLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_UniversityOfCaliforniaMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_477" unitRef="USD" decimals="0">15000</us-gaap:OtherCommitmentDueInNextTwelveMonths>

  <us-gaap:OtherCommitmentDueInFourthYear contextRef="PAsOn03_17_2017_UclaLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_UniversityOfCaliforniaMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_478" unitRef="USD" decimals="0">25000</us-gaap:OtherCommitmentDueInFourthYear>

  <us-gaap:OtherCommitmentDueInSecondYear contextRef="PAsOn03_17_2017_UclaLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_UniversityOfCaliforniaMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_479" unitRef="USD" decimals="0">15000</us-gaap:OtherCommitmentDueInSecondYear>

  <us-gaap:OtherCommitmentDueInThirdYear contextRef="PAsOn03_17_2017_UclaLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_UniversityOfCaliforniaMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_480" unitRef="USD" decimals="0">25000</us-gaap:OtherCommitmentDueInThirdYear>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2017To09_30_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_Il13ra2MemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_481" unitRef="USD" decimals="-5">1200000</us-gaap:ResearchAndDevelopmentExpense>

  <dei:EntityCommonStockSharesOutstanding contextRef="PAsOn11_13_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_482" unitRef="shares" decimals="INF">25232139</dei:EntityCommonStockSharesOutstanding>

  <dei:EntityCommonStockSharesOutstanding contextRef="PAsOn11_13_2017_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_483" unitRef="shares" decimals="INF">1000000</dei:EntityCommonStockSharesOutstanding>

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn09_30_2017" id="Factid_484" unitRef="USD" xsi:nil="true" />

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn12_31_2016" id="Factid_485" unitRef="USD" xsi:nil="true" />

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P01_01_2017To09_30_2017" id="Factid_486" unitRef="USD" decimals="-3">5710000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P01_01_2016To09_30_2016" id="Factid_487" unitRef="USD" decimals="-3">11118000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2016" id="Factid_488" unitRef="USD" decimals="-3">27499000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2015" id="Factid_489" unitRef="USD" decimals="-3">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn09_30_2017" id="Factid_490" unitRef="USD" decimals="-3">33209000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn09_30_2016" id="Factid_491" unitRef="USD" decimals="-3">11118000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:InvestmentPolicyTextBlock contextRef="P01_01_2017To09_30_2017" id="Factid_492">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Short-term Investments &amp;#150; Held to Maturity&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company classifies its certificates of deposit as cash and cash equivalents or held to maturity in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 320, &lt;i&gt;Investments &amp;#150; Debt and Equity Securities&lt;/i&gt;. The Company considers all investments with an original maturity in excess of three months when purchased to be short-term investments. Investments consist of short-term FDIC insured certificates of deposit carried at amortized cost using the effective interest method. The cost of the Company&amp;#8217;s certificates of deposit approximated fair value. The Company reassesses the appropriateness of the classification of its investments at the end of each reporting period.&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;At September 30, 2017, the Company had approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;40.1&lt;/font&gt; million in certificates of deposit with no more than $250,000 at any individual institution. The Company classified $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6.0&lt;/font&gt; million as cash and cash equivalents and classified $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;34.1&lt;/font&gt; million of its certificates of deposits as held-to-maturity as of September 30, 2017. There were no short-term investments as of December 31, 2016. This classification was based upon management&amp;#8217;s determination that it has the positive intent and ability to hold the securities until their maturity dates, as its investments mature within one year and the underlying cash invested in these securities is not required for current operations.&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentPolicyTextBlock>

  <ck0001680048:ResearchAndDevelopmentExpenseSponsoredResearchPayment contextRef="PAsOn02_17_2017" id="Factid_493" unitRef="USD" decimals="-5">2000000</ck0001680048:ResearchAndDevelopmentExpenseSponsoredResearchPayment>

  <ck0001680048:DevelopmentMilestonesMethodAdditionalPaymentsDue contextRef="PAsOn03_17_2017_UniversityOfCaliforniaMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_494" unitRef="USD" decimals="-5">14300000</ck0001680048:DevelopmentMilestonesMethodAdditionalPaymentsDue>

  <ck0001680048:DevelopmentMilestonesMethodAdditionalPaymentsDue contextRef="PAsOn07_03_2017_Cd20TechnologyLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_FredHutchinsonCancerResearchCenterMemberusgaapRelatedPartyTransactionAxis" id="Factid_495" unitRef="USD" decimals="-5">39100000</ck0001680048:DevelopmentMilestonesMethodAdditionalPaymentsDue>

  <ck0001680048:AnnualFeesExpensesOnFoundersAgreementPercentage contextRef="P07_01_2017To09_30_2017_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_496" unitRef="pure" decimals="1">0.5</ck0001680048:AnnualFeesExpensesOnFoundersAgreementPercentage>

  <ck0001680048:AnnualFeesExpensesOnFoundersAgreementPercentage contextRef="P07_01_2017To09_30_2017_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_497" unitRef="pure" decimals="1">0.5</ck0001680048:AnnualFeesExpensesOnFoundersAgreementPercentage>

  <ck0001680048:AnnualFeesExpensesOnFoundersAgreementPercentage contextRef="P01_01_2017To09_30_2017_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_498" unitRef="pure" decimals="1">0.5</ck0001680048:AnnualFeesExpensesOnFoundersAgreementPercentage>

  <ck0001680048:AnnualFeesExpensesOnFoundersAgreementPercentage contextRef="P01_01_2017To09_30_2017_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_499" unitRef="pure" decimals="1">0.5</ck0001680048:AnnualFeesExpensesOnFoundersAgreementPercentage>

  <ck0001680048:AnnualFeesExpensesOnFoundersAgreementPercentage contextRef="P07_01_2016To09_30_2016_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_500" unitRef="pure" decimals="1">0.5</ck0001680048:AnnualFeesExpensesOnFoundersAgreementPercentage>

  <ck0001680048:AnnualFeesExpensesOnFoundersAgreementPercentage contextRef="P07_01_2016To09_30_2016_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_501" unitRef="pure" decimals="1">0.5</ck0001680048:AnnualFeesExpensesOnFoundersAgreementPercentage>

  <ck0001680048:AnnualFeesExpensesOnFoundersAgreementPercentage contextRef="P01_01_2016To09_30_2016_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_502" unitRef="pure" decimals="1">0.5</ck0001680048:AnnualFeesExpensesOnFoundersAgreementPercentage>

  <ck0001680048:AnnualFeesExpensesOnFoundersAgreementPercentage contextRef="P01_01_2016To09_30_2016_FortressBiotechIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_503" unitRef="pure" decimals="1">0.5</ck0001680048:AnnualFeesExpensesOnFoundersAgreementPercentage>

  <ck0001680048:LicenseAgreementDisclosureTextBlock contextRef="P01_01_2017To09_30_2017" id="Factid_504">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Note 3 - License Agreements and Clinical Research Support Agreements&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;strong&gt;&lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;City of Hope Licenses&lt;/font&gt;&lt;/u&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In February, 2017, the Company and City of Hope National Medical Center (&amp;#8220;City of Hope&amp;#8221; or &amp;#8220;COH&amp;#8221;) amended and restated their license agreement, dated March 17, 2015 (the &amp;#8220;Original&amp;#160;Agreement&amp;#8221;), in connection with the covered patents by entering into three separate amended and restated exclusive license agreements, one relating to CD123, one relating to IL13R&amp;#945;2 and one relating to the Spacer technology, that amended the Original Agreement in certain other respects, and collectively replace the Original Agreement in its entirety. The total potential consideration payable to COH by the Company, in equity or cash, did not, in the aggregate, change materially from the Original Agreement. As of September 30, 2017, COH owns &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,000,000&lt;/font&gt; Class A common shares and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 293,588&lt;/font&gt; common shares representing approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5.0&lt;/font&gt;% of ownership, at September 30, 2017 and has the right to appoint a director to the Board of Directors (the &amp;#8220;Board&amp;#8221;).&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In addition, the Company entered into a sponsored research agreement with COH in which the Company will fund continued research in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.0&lt;/font&gt; million per year, payable in four equal installments, until 2020. The research covered under this arrangement is for IL13R&amp;#945;2, CD123 and the Spacer technology. For the three months ended September 30, 2017 and 2016, the Company recorded $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.5&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.5&lt;/font&gt;&amp;#160;million,&amp;#160;respectively, in research and development expenses on the condensed statement of operations in connection with this agreement. For the nine months ended September 30, 2017 and 2016, the Company recorded $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.5&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.5&lt;/font&gt; million, respectively, on research and development expenses in the condensed statement of operations in connection with this agreement.&lt;/font&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In December 2016, the Company entered into two consulting agreements, one with two COH scientists, whereby effective January 1, 2017, in exchange for services provided to the Company each consultant shall be paid $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;60,000&lt;/font&gt; per year, paid quarterly, through January 31, 2019. Further, each consultant has agreed to serve on our Scientific Advisory Board on an as needed basis, and will receive additional compensation for those services. In addition, for services provided during the fourth quarter of 2016, pursuant to the terms of the agreement each consultant earned $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;60,000&lt;/font&gt;, which was paid in the first quarter of 2017. For the three and nine months ended September 30, 2017, the Company recorded $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;60,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;90,000&lt;/font&gt;, respectively, on the condensed statement of operations in connection with these agreements.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;CD123 License&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In February 2017, the Company entered into an Amended and Restated Exclusive License Agreement with COH to acquire intellectual property rights pertaining to patent rights related to CD123 (the &amp;#8220;CD123 License&amp;#8221;). Pursuant to the CD123 License, the Company and COH acknowledge that an upfront fee has already been paid under the Original Agreement. In addition, COH is eligible to receive an annual maintenance fee of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;25,000&lt;/font&gt; and milestone payments totaling approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;14.5&lt;/font&gt; million upon and subject to the achievement of certain milestones. Royalty payments in the mid-single digits are due on net sales of licensed products. The Company is obligated to pay COH a percentage of certain revenues received in connection with a sublicense in the mid-teens to mid-thirties, depending on the timing of the sublicense in the development of any product. In addition, equity grants made under the Original Agreement were acknowledged, and the anti-dilution provisions of the Original Agreement were carried forward.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;CD123 CRA&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In February 2017, the Company entered into a Clinical Research Support Agreement for CD123 (the &amp;#8220;CD123 CRA&amp;#8221;). Pursuant to the terms of the CD123 CRA the Company made an upfront payment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;19,450&lt;/font&gt; and will contribute an additional $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;97,490&lt;/font&gt; per patient in connection with the on-going investigator initiated study. Further, the Company agreed to fund approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.2&lt;/font&gt; million over three years pertaining to the clinical development of CD123. For the three and nine months ended September 30, 2017 the Company recorded $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.6&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.2&lt;/font&gt;, respectively, in research and development expenses under the CD123 CRA on the condensed statement of operations. The Company recorded no expenses in 2016 related to this arrangement.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"&gt; &lt;i&gt;IL13R&amp;#945;2 License&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In February 2017, the Company entered into an Amended and Restated Exclusive License Agreement with COH to acquire intellectual property rights pertaining to patent rights related to IL13R&amp;#945;2 (the &amp;#8220;IL13R&amp;#945;2 License&amp;#8221;). Pursuant to the IL13R&amp;#945;2 License, the Company and COH acknowledge that an upfront fee has already been paid under the Original Agreement. In addition, COH is eligible to receive an annual maintenance fee of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;25,000&lt;/font&gt; and milestone payments totaling approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;14.5&lt;/font&gt; million upon and subject to the achievement of certain milestones. Royalty payments in the mid-single digits are due on net sales of licensed products. The Company is obligated to pay COH a percentage of certain revenues received in connection with a sublicense in the mid-teens to mid-thirties, depending on the timing of the sublicense in the development of any product. In addition, equity grants made under the Original Agreement were acknowledged, and the anti-dilution provisions of the Original Agreement were carried forward.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;&lt;i&gt;IL13R&amp;#945;2 CRA&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In February 2017, the Company entered into a Clinical Research Support Agreement for IL13R&amp;#945;2 (the &amp;#8220;IL13R&amp;#945;2 CRA&amp;#8221;). Pursuant to the terms of the IL13R&amp;#945;2 CRA the Company made an upfront payment of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9,300&lt;/font&gt; and will contribute an additional $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.1&lt;/font&gt; million related to patient costs in connection with the on-going investigator initiated study. Further, the Company agreed to fund approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.2&lt;/font&gt; million over three years pertaining to the clinical development of IL13R&amp;#945;2. For the three and nine months ended September 30, 2017 the Company recorded $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.2&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.2&lt;/font&gt; million respectively, in research and development expenses under the IL13R&amp;#945;2 CRA on the condensed statement of operations. The Company recorded no expenses in 2016 related to this arrangement.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"&gt; &lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Spacer License&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In February 2017, the Company entered into an Amended and Restated Exclusive License Agreement with COH to acquire intellectual property rights pertaining to patent rights related to Spacer (the &amp;#8220;Spacer License&amp;#8221;). Pursuant to the Spacer License, the Company and COH acknowledged that an upfront fee has already been paid under the Original Agreement. In addition, COH will receive an annual maintenance fee of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10,000&lt;/font&gt;. No royalties are due if the Spacer technology is used in conjunction with a CD123 CAR or an IL13R&amp;#945;2 CAR, and royalty payments in the low single digits are due on net sales of licensed products if the Spacer technology is used in conjunction with other intellectual property. The Company is obligated to pay COH a percentage of certain revenues received in connection with a sublicense in the mid-thirties. In addition, equity grants made under the Original Agreement were acknowledged, and the anti-dilution provisions of the Original Agreement were carried forward.&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"&gt;&lt;i&gt;IV/ICV License&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In February 2017, the Company entered into an exclusive license agreement (the &amp;#8220;IV/ICV License&amp;#8221;) with COH to acquire intellectual property rights in patent applications related to the intraventricular and intracerebroventricular methods of delivering T cells that express CARs. Pursuant to the IV/ICV License, in March 2017, the Company paid COH an upfront fee of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.1&lt;/font&gt;&amp;#160;million. COH is eligible to receive a milestone payment totaling approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.1&lt;/font&gt;&amp;#160;million, upon and subject to the achievement of a milestone, and an annual maintenance fee. Royalty payments in the low single digits are due on net sales of licensed products.&lt;/font&gt;&lt;/div&gt; &lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"&gt; &lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;HER2 Technology License&amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;On May 31, 2017, the Company entered into an exclusive license agreement (the &amp;#8220;HER2 Agreement&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#8221;&lt;/font&gt;) with the COH for the use of human epidermal growth factor receptor 2 (HER2) CAR T technology (HER2 Technology), which will initially be applied in the treatment of glioblastoma multiforme. Pursuant to the HER2 Agreement, the Company paid an upfront fee of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.6&lt;/font&gt;&amp;#160;million and will owe an annual maintenance fee of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;50,000&lt;/font&gt; (beginning in 2019). Additional payments are due for the achievement of ten development milestones totaling $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;14.9&lt;/font&gt; million and royalty payments in the mid-single digits are due on net sales of licensed products.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"&gt; &lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;CS1 Technology License&amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;On May 31, 2017, the Company entered into an exclusive license agreement (the &amp;#8220;CS1 Agreement) with the COH for the use of CS1-specific CAR T technology (CS1 Technology) to be directed against multiple myeloma. Pursuant to the CS1 Agreement, the Company paid an upfront fee of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.6&lt;/font&gt; &lt;font style="LINE-HEIGHT: 107%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; million&lt;/font&gt; and will owe an annual maintenance fee of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;50,000&lt;/font&gt; (beginning in 2019). Additional payments are due for the achievement of ten development milestones totaling $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;14.9&lt;/font&gt; million and royalty payments in the mid-single digits are due on net sales of licensed products.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"&gt; &lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;PSCA Technology License&amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;On May 31, 2017, the Company entered into an exclusive license agreement (the &amp;#8220;PSCA Agreement&amp;#8221;) with the COH for the use of prostate stem cell antigen (PSCA) CAR T technology (PSCA Technology) to be used in the treatment of prostate cancer. Pursuant to the PSCA Agreement, the Company paid an upfront fee of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.3&lt;/font&gt; &lt;font style="LINE-HEIGHT: 107%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; million&lt;/font&gt; and will owe an annual maintenance fee of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;50,000&lt;/font&gt; (beginning in 2019). Additional payments are due for the achievement of ten development milestones totaling $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;14.9&lt;/font&gt; million and royalty payments in the mid-single digits are due on net sales of licensed products.&lt;/font&gt;&lt;/div&gt; &lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;strong&gt;&lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;University of California License&lt;/font&gt;&lt;/u&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY:times new roman,times,serif"&gt;On March 17, 2017, the Company entered into an exclusive license agreement with the Regents of the University of California (the &amp;#8220;UCLA License&amp;#8221;) to acquire intellectual property rights in patent applications related to the engineered anti-prostate stem cell antigen antibodies for cancer targeting and detection. Pursuant to the UCLA License, the Company paid UCLA the upfront fee of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.2&lt;/font&gt;&amp;#160;&lt;font style="LINE-HEIGHT: 107%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; million&lt;/font&gt; and will owe an annual maintenance fee of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15,000&lt;/font&gt;&lt;/font&gt; for the first two years, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;25,000&lt;/font&gt;&lt;/font&gt; for years three and four, and&amp;#160;&lt;font style="LINE-HEIGHT: 107%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;50,000&lt;/font&gt; per year&lt;/font&gt;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt"&gt;thereafter. Additional payments are due for the achievement of seven development milestones, totaling $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;14.3&lt;/font&gt; million, and royalty payments in the mid-single digits are due on net sales of licensed products.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;strong&gt;&lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Fred Hutchinson Cancer Research Center License&lt;/font&gt;&lt;/u&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;CD20 Technology License&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;On July 3, 2017, Mustang entered into an exclusive, worldwide licensing agreement with Fred Hutchinson Cancer Research Center (&amp;#8220;Fred Hutch&amp;#8221;) for the use of a CAR T therapy related to autologous T cells engineered to express a CD20-specific chimeric antigen receptor (&amp;#8220;CD20 Technology License&amp;#8221;). Pursuant to the CD 20 Technology License, the Company paid Fred Hutch an upfront fee of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.3&lt;/font&gt; million and will owe an annual maintenance fee of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;50,000&lt;/font&gt;&amp;#160;on&amp;#160;each anniversary of the license until the achievement by the Company of regulatory approval of a licensed product using CD20 Technology. Additional payments are due for the achievement of&amp;#160;eleven development milestones totaling $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;39.1&lt;/font&gt; million and royalty payments in the mid-single digits are due on net sales of licensed products.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;CD20 CTA&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; Also,&amp;#160;on July 3, 2017, in conjunction with the CD20 Technology License from Fred Hutch, Mustang entered into an investigator-initiated clinical trial agreement (&amp;#8220;CD20 CTA&amp;#8221;) to provide partial funding for a Phase 1/2 clinical trial at Fred Hutch evaluating the safety and efficacy of the CD20 Technology in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. In connection with the CD20 CTA, the Company agreed to fund up to&amp;#160;$&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.3&lt;/font&gt; million of costs associated with the clinical trial, which &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; commenced&lt;/font&gt; during the fourth quarter of 2017. For the three and nine months ended September 30, 2017, the Company recorded $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;88,000&lt;/font&gt;&lt;/font&gt; of expense in connection with this agreement. Further the Company made an upfront payment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.4&lt;/font&gt; &lt;font style="LINE-HEIGHT: 107%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; million&lt;/font&gt; recorded on the condensed balance sheets as of September 30, 2017, as a prepaid expense, in connection with a startup fee related to the study.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;strong&gt;&lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Research and Development Expenses &amp;#150; All Licenses&lt;/font&gt;&lt;/u&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;For the three and nine months ended September 30, 2017 and 2016, the Company recorded the following expense in research and development for licenses acquired:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; For&amp;#160;the&amp;#160;Three&amp;#160;Months&amp;#160;Ended&amp;#160;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; For&amp;#160;the&amp;#160;Nine&amp;#160;Months&amp;#160;Ended&amp;#160;September&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; ($&amp;#160;in&amp;#160;thousands)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;City of Hope&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;IL13Ra2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;IV/ICV&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;125&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;PSCA&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;300&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;HER2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;600&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;CS-1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;600&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;UCLA&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;200&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Fred Hutch CD20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;300&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;300&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;300&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2,375&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ck0001680048:LicenseAgreementDisclosureTextBlock>

  <us-gaap:OtherCommitmentDueInFifthYear contextRef="PAsOn03_17_2017_UclaLicenseMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_UniversityOfCaliforniaMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_505" unitRef="USD" decimals="0">50000</us-gaap:OtherCommitmentDueInFifthYear>

  <ck0001680048:FailedContingencyDamagesAwardedPercentage contextRef="P01_01_2016To01_15_2016_CityOfHopeMemberusgaapRelatedPartyTransactionAxis" id="Factid_506" unitRef="pure" decimals="2">0.15</ck0001680048:FailedContingencyDamagesAwardedPercentage>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2017To09_30_2017_MinimumMemberusgaapRangeAxis" id="Factid_507" unitRef="pure" decimals="4">0.0181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="P01_01_2017To09_30_2017_MaximumMemberusgaapRangeAxis" id="Factid_508" unitRef="pure" decimals="4">0.0238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2017To09_30_2017_MaximumMemberusgaapRangeAxis" id="Factid_509">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2016To09_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis_FortressBiotechIncMemberdeiLegalEntityAxis" id="Factid_510" unitRef="shares" decimals="INF">47870</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn09_30_2017" id="Factid_511" unitRef="USD" decimals="-3">139000</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn12_31_2016" id="Factid_512" unitRef="USD" decimals="-3">0</us-gaap:PropertyPlantAndEquipmentNet>

  <ck0001680048:PayablesAndAccruedexpensesRelatedPartiesCurrent contextRef="PAsOn09_30_2017" id="Factid_513" unitRef="USD" decimals="-3">69000</ck0001680048:PayablesAndAccruedexpensesRelatedPartiesCurrent>

  <ck0001680048:PayablesAndAccruedexpensesRelatedPartiesCurrent contextRef="PAsOn12_31_2016" id="Factid_514" unitRef="USD" decimals="-3">445000</ck0001680048:PayablesAndAccruedexpensesRelatedPartiesCurrent>

  <ck0001680048:AdjustmentToAdditionalPaidInCapitalCapitalContribution contextRef="P01_01_2017To09_30_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_515" unitRef="USD" decimals="-3">0</ck0001680048:AdjustmentToAdditionalPaidInCapitalCapitalContribution>

  <ck0001680048:AdjustmentToAdditionalPaidInCapitalCapitalContribution contextRef="P01_01_2017To09_30_2017_CommonClassAMemberusgaapStatementClassOfStockAxis" id="Factid_516" unitRef="USD" decimals="-3">0</ck0001680048:AdjustmentToAdditionalPaidInCapitalCapitalContribution>

  <ck0001680048:AdjustmentToAdditionalPaidInCapitalCapitalContribution contextRef="P01_01_2017To09_30_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_517" unitRef="USD" decimals="-3">0</ck0001680048:AdjustmentToAdditionalPaidInCapitalCapitalContribution>

  <ck0001680048:AdjustmentToAdditionalPaidInCapitalCapitalContribution contextRef="P01_01_2017To09_30_2017_CommonStockIssuableMemberusgaapStatementClassOfStockAxis" id="Factid_518" unitRef="USD" decimals="-3">0</ck0001680048:AdjustmentToAdditionalPaidInCapitalCapitalContribution>

  <ck0001680048:AdjustmentToAdditionalPaidInCapitalCapitalContribution contextRef="P01_01_2017To09_30_2017_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_519" unitRef="USD" decimals="-3">0</ck0001680048:AdjustmentToAdditionalPaidInCapitalCapitalContribution>

  <ck0001680048:AdjustmentToAdditionalPaidInCapitalCapitalContribution contextRef="P01_01_2017To09_30_2017" id="Factid_520" unitRef="USD" decimals="-3">2062000</ck0001680048:AdjustmentToAdditionalPaidInCapitalCapitalContribution>

  <ck0001680048:AdjustmentToAdditionalPaidInCapitalCapitalContribution contextRef="P01_01_2017To09_30_2017_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_521" unitRef="USD" decimals="-3">2062000</ck0001680048:AdjustmentToAdditionalPaidInCapitalCapitalContribution>

  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="P01_01_2017To09_30_2017" id="Factid_522" unitRef="USD" decimals="-3">2062000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>

  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="P01_01_2016To09_30_2016" id="Factid_523" unitRef="USD" decimals="-3">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>

  <ck0001680048:PropertyPlantAndEquipmentDesignCostsCapitalized contextRef="PAsOn09_30_2017" id="Factid_524" unitRef="USD" decimals="-5">100000</ck0001680048:PropertyPlantAndEquipmentDesignCostsCapitalized>

  <us-gaap:TimeDepositsAtCarryingValue contextRef="PAsOn09_30_2017_CashAndCashEquivalentsMemberusgaapInvestmentTypeAxis" id="Factid_525" unitRef="USD" decimals="-5">6000000</us-gaap:TimeDepositsAtCarryingValue>

  <us-gaap:TimeDepositsAtCarryingValue contextRef="PAsOn09_30_2017_HeldtomaturitySecuritiesMemberusgaapInformationByCategoryOfDebtSecurityAxis" id="Factid_526" unitRef="USD" decimals="-5">34100000</us-gaap:TimeDepositsAtCarryingValue>

  <us-gaap:LandSubjectToGroundLeases contextRef="PAsOn10_27_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_527" unitRef="acre" decimals="0">27043</us-gaap:LandSubjectToGroundLeases>

  <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1 contextRef="P10_01_2017To10_27_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_528" unitRef="USD" decimals="-5">600000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>

  <us-gaap:OperatingLeasesRentExpenseNet contextRef="P10_01_2017To10_27_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_529" unitRef="USD" decimals="-5">3600000</us-gaap:OperatingLeasesRentExpenseNet>

  <us-gaap:LandImprovements contextRef="PAsOn10_27_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_530" unitRef="USD" decimals="-5">3500000</us-gaap:LandImprovements>

  <us-gaap:SecurityDeposit contextRef="PAsOn10_27_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_531" unitRef="USD" decimals="-5">800000</us-gaap:SecurityDeposit>

  <us-gaap:SecurityDeposit contextRef="PAsOn10_27_2017_LetterOfCreditMemberusgaapShortTermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_532" unitRef="USD" decimals="-5">500000</us-gaap:SecurityDeposit>

  <us-gaap:SecurityDeposit contextRef="PAsOn10_27_2017_CashMemberusgaapInvestmentTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_533" unitRef="USD" decimals="-5">300000</us-gaap:SecurityDeposit>

  <us-gaap:IncreaseDecreaseInSecurityDeposits contextRef="P10_01_2017To10_27_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_534" unitRef="USD" decimals="-5">1300000</us-gaap:IncreaseDecreaseInSecurityDeposits>

  <us-gaap:IncreaseDecreaseInSecurityDeposits contextRef="P10_01_2017To10_27_2017_LetterOfCreditMemberusgaapShortTermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_535" unitRef="USD" decimals="-5">1000000</us-gaap:IncreaseDecreaseInSecurityDeposits>

  <us-gaap:IncreaseDecreaseInSecurityDeposits contextRef="P10_01_2017To10_27_2017_CashMemberusgaapInvestmentTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_536" unitRef="USD" decimals="-5">300000</us-gaap:IncreaseDecreaseInSecurityDeposits>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P02_01_2017To02_28_2017" id="Factid_537" unitRef="USD" decimals="-5">1700000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="P01_01_2017To09_30_2017" id="Factid_538" unitRef="USD" decimals="-5">2100000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>

  <us-gaap:LitigationSettlementExpense contextRef="P01_01_2017To09_30_2017" id="Factid_539" unitRef="USD" decimals="-5">100000</us-gaap:LitigationSettlementExpense>

  <ck0001680048:NumberOfSharesToBeIssuedUponLegalSettlement contextRef="PAsOn09_30_2017" id="Factid_540" unitRef="shares" decimals="INF">200000</ck0001680048:NumberOfSharesToBeIssuedUponLegalSettlement>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn09_30_2017_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_541" unitRef="USD_per_Share" decimals="2">8.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="P07_01_2017To09_30_2017_DirectorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_542" unitRef="shares" decimals="INF">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="P01_01_2017To09_30_2017_DirectorMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_543" unitRef="shares" decimals="INF">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="P01_01_2017To09_30_2017_BoardOfDirectorsChairmanMemberusgaapTitleOfIndividualAxis" id="Factid_544" unitRef="USD" decimals="0">50000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2017To09_30_2017_BoardOfDirectorsChairmanMemberusgaapTitleOfIndividualAxis" id="Factid_545" unitRef="shares" decimals="INF">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="P07_01_2017To09_30_2017_BoardOfDirectorsChairmanMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_546" unitRef="shares" decimals="INF">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="P01_01_2017To09_30_2017_BoardOfDirectorsChairmanMemberusgaapTitleOfIndividualAxis_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_547" unitRef="shares" decimals="INF">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

  <ck0001680048:ClassOfWarrantOrRightExpirationPeriod contextRef="P01_01_2017To09_30_2017_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_548">P5Y</ck0001680048:ClassOfWarrantOrRightExpirationPeriod>

  <us-gaap:ProfessionalFees contextRef="P07_01_2017To09_30_2017" id="Factid_549" unitRef="USD" decimals="0">60000</us-gaap:ProfessionalFees>

  <us-gaap:ProfessionalFees contextRef="P01_01_2017To09_30_2017" id="Factid_550" unitRef="USD" decimals="0">90000</us-gaap:ProfessionalFees>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P07_01_2017To09_30_2017_CityOfHopeMemberusgaapRelatedPartyTransactionAxis_Il13ra2MemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_551" unitRef="USD" decimals="-5">200000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2016To09_30_2016_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_552" unitRef="USD" decimals="-5">300000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P07_01_2017To09_30_2017_BoardOfDirectorsChairmanMemberusgaapTitleOfIndividualAxis" id="Factid_553" unitRef="USD" decimals="0">4800</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P01_01_2017To09_30_2017_BoardOfDirectorsChairmanMemberusgaapTitleOfIndividualAxis" id="Factid_554" unitRef="USD" decimals="0">6000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2017To09_30_2017" id="Factid_555">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Note 2 - Significant Accounting Policies&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Basis of Presentation&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The accompanying unaudited interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&amp;#8220;GAAP&amp;#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company&amp;#8217;s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Therefore, these condensed financial statements should be read in conjunction with the Company&amp;#8217;s audited financial statements and notes thereto for the year ended December 31, 2016, which were included in the Company&amp;#8217;s Form 10-K filed with the U.S. Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) on March 31, 2017. The results of operations for any interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Use of Estimates&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Significant Accounting Policies&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;There have been no material changes to the Company&amp;#8217;s significant accounting policies previously disclosed in the Company&amp;#8217;s Form 10-K filed with the SEC on March 31, 2017, with the exception of the policies listed below.&amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Short-term Investments &amp;#150; Held to Maturity&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company classifies its certificates of deposit as cash and cash equivalents or held to maturity in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 320, &lt;i&gt;Investments &amp;#150; Debt and Equity Securities&lt;/i&gt;. The Company considers all investments with an original maturity in excess of three months when purchased to be short-term investments. Investments consist of short-term FDIC insured certificates of deposit carried at amortized cost using the effective interest method. The cost of the Company&amp;#8217;s certificates of deposit approximated fair value. The Company reassesses the appropriateness of the classification of its investments at the end of each reporting period.&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;At September 30, 2017, the Company had approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;40.1&lt;/font&gt; million in certificates of deposit with no more than $250,000 at any individual institution. The Company classified $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6.0&lt;/font&gt; million as cash and cash equivalents and classified $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;34.1&lt;/font&gt; million of its certificates of deposits as held-to-maturity as of September 30, 2017. There were no short-term investments as of December 31, 2016. This classification was based upon management&amp;#8217;s determination that it has the positive intent and ability to hold the securities until their maturity dates, as its investments mature within one year and the underlying cash invested in these securities is not required for current operations.&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Stock-Based Compensation&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Company expenses stock-based compensation to employees and board members over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based awards with graded vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. For stock-based compensation awards to non-employees, the Company measures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 13.2pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The assumptions used in calculating the fair value of stock-based awards represent management&amp;#8217;s best estimates and involve inherent uncertainties and the application of management&amp;#8217;s judgment.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;b&gt;Property and equipment &amp;#150; construction in process&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Leasehold improvements are amortized over the shorter of the estimated useful lives or the term of the respective leases, upon the improvement being placed in service. In connection with the Company&amp;#8217;s manufacturing facility, the Company incurred $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.1&lt;/font&gt; million related to the design of the facility which is recorded in property and equipment on the condensed balance sheet at September 30, 2017. Upon completion of the buildout all costs associated with the buildout will be recorded as leasehold improvements.&lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;b&gt;&lt;i&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;i&gt;&lt;strong&gt;Recently Adopted Accounting Pronouncements&lt;/strong&gt;&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; COLOR: #212121; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;In March 2016, the FASB issued Accounting Standards Update ("ASU") 2016-09&lt;i&gt;&amp;#160;Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting&lt;/i&gt; &lt;font style="COLOR: #212121"&gt;(&amp;#8220;ASU 2016-09&amp;#8221;)&lt;/font&gt;. Under ASU 2016-09, companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in capital (&amp;#8220;APIC&amp;#8221;). Instead, they will record all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement and the APIC pools will be eliminated. In addition, ASU 2016-09 eliminates the requirement that excess tax benefits be realized before companies can recognize them. ASU 2016-09 also requires companies to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. Furthermore, ASU 2016-09 will increase the amount an employer can withhold to cover income taxes on awards and still qualify for the exception to liability classification for shares used to satisfy the employer&amp;#8217;s statutory income tax withholding obligation. An employer with a statutory income tax withholding obligation will now be allowed to withhold shares with a fair value up to the amount of taxes owed using the maximum statutory tax rate in the employee&amp;#8217;s applicable jurisdiction(s). ASU 2016-09 requires a company to classify the cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation as a financing activity on the statement of cash flows. Under current GAAP, it was not specified how these cash flows should be classified. In addition, companies will now have to elect whether to account for forfeitures on share-based payments by (1) recognizing forfeitures of awards as they occur or (2) estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change, as is currently required. The Amendments of this ASU are effective for reporting periods beginning after December 15, 2016, with early adoption permitted but all of the guidance must be adopted in the same period. The Company adopted ASU 2016-09 on January 1, 2017. The adoption did not have a material impact on the Company&amp;#8217;s condensed financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;In January 2017, the FASB issued ASU 2017-01, &lt;i&gt;Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/i&gt; (&amp;#8220;ASU 2017-01&amp;#8221;). The amendments in this update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for fiscal periods beginning after December 15, 2017, including interim periods within those periods. The Company adopted ASU 2017-01 on January 1, 2017. The adoption did not have a material impact on the Company&amp;#8217;s condensed consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&lt;i&gt;Recently Issued Accounting Standards&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" align="center"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;i&gt; Leases (Topic 842).&lt;/i&gt; ASU 2016-02 requires an entity to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December&amp;#160;15, 2018. Early adoption is permitted. The Company is currently evaluating the impact, if any, of adopting this standard on its condensed consolidated financial statements and related disclosures.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In August 2016, the FASB issued ASU 2016-15, &lt;i&gt; Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments&lt;/i&gt; (&amp;#8220;ASU 2016-15&amp;#8221;), which addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is currently in the process of evaluating the impact of this new pronouncement on its condensed statements of cash flows and related disclosures.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In May 2017, the FASB issued ASU 2017-09, Compensation&amp;#151;Stock Compensation (Topic 718): &lt;i&gt;Scope of Modification Accounting&lt;/i&gt; (&amp;#8220;ASU 2017-09&amp;#8221;), which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the condensed financial statements and disclosures, but does not expect it to have a significant impact.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>

  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2017To09_30_2017" id="Factid_556">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/i&gt;&lt;/b&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;b&gt;&lt;i&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;i&gt;&lt;strong&gt;Recently Adopted Accounting Pronouncements&lt;/strong&gt;&lt;/i&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; COLOR: #212121; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;In March 2016, the FASB issued Accounting Standards Update ("ASU") 2016-09&lt;i&gt;&amp;#160;Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting&lt;/i&gt; &lt;font style="COLOR: #212121"&gt;(&amp;#8220;ASU 2016-09&amp;#8221;)&lt;/font&gt;. Under ASU 2016-09, companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in capital (&amp;#8220;APIC&amp;#8221;). Instead, they will record all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement and the APIC pools will be eliminated. In addition, ASU 2016-09 eliminates the requirement that excess tax benefits be realized before companies can recognize them. ASU 2016-09 also requires companies to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. Furthermore, ASU 2016-09 will increase the amount an employer can withhold to cover income taxes on awards and still qualify for the exception to liability classification for shares used to satisfy the employer&amp;#8217;s statutory income tax withholding obligation. An employer with a statutory income tax withholding obligation will now be allowed to withhold shares with a fair value up to the amount of taxes owed using the maximum statutory tax rate in the employee&amp;#8217;s applicable jurisdiction(s). ASU 2016-09 requires a company to classify the cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation as a financing activity on the statement of cash flows. Under current GAAP, it was not specified how these cash flows should be classified. In addition, companies will now have to elect whether to account for forfeitures on share-based payments by (1) recognizing forfeitures of awards as they occur or (2) estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change, as is currently required. The Amendments of this ASU are effective for reporting periods beginning after December 15, 2016, with early adoption permitted but all of the guidance must be adopted in the same period. The Company adopted ASU 2016-09 on January 1, 2017. The adoption did not have a material impact on the Company&amp;#8217;s condensed financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;In January 2017, the FASB issued ASU 2017-01, &lt;i&gt;Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/i&gt; (&amp;#8220;ASU 2017-01&amp;#8221;). The amendments in this update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for fiscal periods beginning after December 15, 2017, including interim periods within those periods. The Company adopted ASU 2017-01 on January 1, 2017. The adoption did not have a material impact on the Company&amp;#8217;s condensed consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&lt;i&gt;Recently Issued Accounting Standards&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" align="center"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;i&gt; Leases (Topic 842).&lt;/i&gt; ASU 2016-02 requires an entity to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December&amp;#160;15, 2018. Early adoption is permitted. The Company is currently evaluating the impact, if any, of adopting this standard on its condensed consolidated financial statements and related disclosures.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In August 2016, the FASB issued ASU 2016-15, &lt;i&gt; Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments&lt;/i&gt; (&amp;#8220;ASU 2016-15&amp;#8221;), which addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is currently in the process of evaluating the impact of this new pronouncement on its condensed statements of cash flows and related disclosures.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In May 2017, the FASB issued ASU 2017-09, Compensation&amp;#151;Stock Compensation (Topic 718): &lt;i&gt;Scope of Modification Accounting&lt;/i&gt; (&amp;#8220;ASU 2017-09&amp;#8221;), which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the condensed financial statements and disclosures, but does not expect it to have a significant impact.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>

  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2017To09_30_2017" id="Factid_557">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;b&gt;Note 4 - Related Party Agreements&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&lt;i&gt;Founders Agreement and Management Services Agreement with Fortress&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Effective March 13, 2015, the Company entered into a Founders Agreement with Fortress, which was amended and restated on May 17, 2016 and again on July 26, 2016 (the &amp;#8220;Mustang Founders Agreement&amp;#8221;). The Mustang Founders Agreement provides that, in exchange for the time and capital expended in the formation of Mustang and the identification of specific assets the acquisition of which result in the formation of a viable emerging growth life science company, Fortress loaned $2.0 million, representing the up-front fee required to acquire the Company&amp;#8217;s license agreement with COH. The Mustang Founders Agreement has a term of 15 years, which upon expiration automatically renews for successive one-year periods unless terminated by Fortress and the Company or a Change in Control (as defined in the Mustang Founders Agreement) occurs. Concurrently with the second amendment on July 26, 2016 to the Mustang Founders Agreement, Fortress entered into an Exchange Agreement whereby Fortress exchanged its 7.25 million Class B common shares for 7.0 million common shares and 250,000 Class A preferred shares. Class A Preferred Stock is identical to common shares other than as to voting rights, conversion rights and the PIK Dividend right (as described below). Each share of Class A Preferred Stock will be entitled to vote the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the shares of outstanding Mustang common stock and (B) the whole shares of Mustang common stock into which the shares of outstanding Class A common shares and Class A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority. Each share of Class A Preferred Stock is convertible, at Fortress&amp;#8217; option, into one fully paid and nonassessable share of Mustang common stock, subject to certain adjustments. As holders of Class A Preferred Stock, Fortress will receive on each March 13 (each a &amp;#8220;PIK Dividend Payment Date&amp;#8221;) until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (&amp;#8220;PIK Dividends&amp;#8221;) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half percent (2.5%) of Mustang&amp;#8217;s fully-diluted outstanding capitalization on the date that is one (1) business day prior to any PIK Dividend Payment Date.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;As additional consideration under the Mustang Founders Agreement, Mustang will also: (i) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Mustang or any of its respective subsidiaries that occurs after the effective date of the Mustang Founders Agreement and ending on the date when Fortress no longer has majority voting control in the Company&amp;#8217;s voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of the Company&amp;#8217;s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, the Company will pay a one-time change in control fee equal to five (5x) times the product of (A) net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%).&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;On March 13, 2016, pursuant to the then in effect Mustang Founders Agreement, on the anniversary date of the Founders&amp;#8217; Agreement, the Company issued 250,000 shares of its Class B common stock to Fortress representing 2.5% of the fully diluted outstanding shares of the Company. Pursuant to the terms of the Mustang Founders Agreement, as amended in July 2016, this equity fee is no longer payable.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Effective as of March 13, 2015, the Company entered into a Management Services Agreement (the &amp;#8220;MSA&amp;#8221;) with Fortress. Pursuant to the terms of the MSA, for a period of five years, Fortress will render advisory and consulting services to the Company. Services provided under the MSA may include, without limitation, (i) advice and assistance concerning any and all aspects of the Company&amp;#8217;s operations, clinical trials, financial planning and strategic transactions and financings and (ii) conducting relations on behalf of the Company with accountants, attorneys, financial advisors and other professionals (collectively, the &amp;#8220;Services&amp;#8221;). The Company is obligated to utilize clinical research services, medical education, communication and marketing services and investor relations/public relation services of companies or individuals designated by Fortress, provided those services are offered at market prices. However, the Company is not obligated to take or act upon any advice rendered from Fortress and Fortress shall not be liable for any of its actions or inactions based upon their advice. Fortress and its affiliates, including the Company&amp;#8217;s Board of Directors, have been contractually exempt from fiduciary duties to the Company relating to corporate opportunities. In consideration for the Services, the Company will pay Fortress an annual consulting fee of $0.5 million (the &amp;#8220;Annual Consulting Fee&amp;#8221;), payable in advance in equal quarterly installments on the first business day of each calendar quarter in each year, provided, however, that such Annual Consulting Fee shall be increased to $1.0 million for each calendar year in which the Company has net assets in excess of $100 million at the beginning of the calendar year.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;For the three months ended September 30, 2017 and 2016, the Company recorded approximately $0.1 million and $0.1 million, respectively, as expense related to the MSA. For the nine months ended September 30, 2017 and 2016, the Company recorded approximately $0.4 million and $0.4 million, respectively, as expense related to the MSA. For the three and nine months ended September 30, 2017 and 2016, respectively, expenses related to the MSA are recorded 50% in research and development expenses and 50% in general and administrative expenses on the condensed consolidated statement of operations.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&lt;i&gt;Consulting Agreement with Chord Advisors, LLC (&amp;#8220;Chord&amp;#8221;)&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;On April 8, 2016, the Company entered into a full-service consulting agreement with Chord to provide advisory accounting services to the Company. Under the terms of the agreement, the Company paid Chord up to $5,000 per month to perform back office accounting functions, accounting analysis and financial reporting prior to the Company&amp;#8217;s filing of its Registration Statement on Form 10 on July 27, 2016, and $7,500 per month following that date. Either party upon 30-days written notice can terminate the agreement. In addition to these services, Mr. Horin, a Managing Partner of Chord, serves as the Company&amp;#8217;s Interim Chief Financial Officer. Chord also provides advisory accounting services to Fortress under a separate agreement. For the three months ended September 30, 2017 and 2016, $22,500 and $17,500, respectively, of expense was recognized. For the nine months ended September 30, 2017 and 2016, $67,500 and $30,300, respectively, of expense was recognized. The expense was recorded in general and administrative expenses on the condensed statements of operations.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;b&gt;&lt;i&gt;Payable and Accrued Expenses Related Party&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Company had a working capital promissory note with Fortress, which was paid in full in 2016. In 2017, in the normal course of business Fortress pays for certain expenses on behalf of the Company. Such expenses are recorded as Payable and accrued expenses &amp;#150; related party and are reimbursed to Fortress in the normal course of business.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&lt;i&gt;National Securities Inc.&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Fortress owns approximately 56.6% of National Holdings Corporation (&amp;#8220;NHLD&amp;#8221;). National Securities Inc. (&amp;#8220;NSC&amp;#8221;) a subsidiary of NHLD acted as placement agent for the Company&amp;#8217;s third-party financings (see Note 6). For the nine months ended September 30, 2017, the Company paid NSC placement agent fees of $5.6 million and issued to NSC 861,077 warrants to purchase the Company&amp;#8217;s common stock. The warrants have a five-year term and an exercise price of $8.50 per share. No fees were incurred for the three and nine months ended September 30, 2016.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&lt;i&gt;Director Compensation&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&lt;i&gt;Dr. Rosenwald&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;Pursuant to the terms of the Director Compensation Plan, Dr. Rosenwald will receive a cash fee of $50,000 per year paid quarterly and an annual stock award of the greater of (i) a number of shares of common stock having a fair market value on the grant date of $50,000 or (ii) 10,000 shares of common stock, which shares shall vest and become non-forfeitable on the third anniversary of the grant date, subject to continued service on the Board on such date. For the three and nine months ended September 30, 2017, the Company recognized $12,500 and $25,052, in expense in its Condensed Statements of Operations related to the director compensation, including approximately $4,900 in expense related to an annual equity incentive grant of 10,000 restricted shares. No expense was recorded in 2016.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&lt;i&gt;Mr. Weiss - Advisory Agreement with Caribe BioAdvisors, LLC&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;The Board of the Company by unanimous written consent approved and authorized the execution of an advisory agreement dated January 1, 2017 (the &amp;#8220;Advisory Agreement&amp;#8221;), with Caribe BioAdvisors, LLC (the &amp;#8220;Advisor&amp;#8221;), owned by Michael S. Weiss, the Chairman of the Board, to provide the board advisory services of Mr. Weiss as Chairman of the Board. Pursuant to the Advisory Agreement, the Advisor will be paid an annual cash fee of $60,000, paid quarterly and an annual stock award of the greater of (i) a number of shares of common stock having a fair market value on the grant date of $50,000 or (ii) 10,000 shares of common stock, which shares shall vest and become non-forfeitable on the third anniversary of the grant date, subject to continued service on the Board on such date. For three and nine months ended September 30, 2017, the Company recognized $15,000 and $46,200, respectively, in expense in its Condensed Statements of Operations related to the advisory agreement, including approximately $4,800 and $6,000, respectively, in expense related to an annual equity incentive grant of 10,000 restricted shares. No expense was recorded in 2016.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;b&gt;&lt;i&gt;Stock Awards Made to Fortress Employees&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In April 2017, the Company made an option award to two employees of Fortress (see Note 7).&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>

<!--FootNote Section Ref-->

  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
  </link:footnoteLink>
</xbrli:xbrl>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>ck0001680048-20170930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 13-Nov-2017 [06:42:58] {PM} EST - www.datatracks.com -->
<schema targetNamespace="http://www.mustangbio.com/20170930" elementFormDefault="qualified" xmlns:ck0001680048="http://www.mustangbio.com/20170930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.mustangbio.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>101 - Document - Document And Entity Information</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/CondensedBalanceSheets" id="CondensedBalanceSheets">
        <link:definition>102 - Statement - CONDENSED BALANCE SHEETS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/CondensedBalanceSheetsParenthetical" id="CondensedBalanceSheetsParenthetical">
        <link:definition>103 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/CondensedStatementsOfOperations" id="CondensedStatementsOfOperations">
        <link:definition>104 - Statement - CONDENSED STATEMENTS OF OPERATIONS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/CondensedStatementOfStockholdersEquity" id="CondensedStatementOfStockholdersEquity">
        <link:definition>105 - Statement - Condensed Statement of Stockholders&#8217; Equity</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/CondensedStatementsOfCashFlows" id="CondensedStatementsOfCashFlows">
        <link:definition>106 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/CondensedStatementsOfCashFlowsParenthetical" id="CondensedStatementsOfCashFlowsParenthetical">
        <link:definition>107 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/OrganizationDescriptionOfBusinessAndLiquidityAndCapitalResources" id="OrganizationDescriptionOfBusinessAndLiquidityAndCapitalResources">
        <link:definition>108 - Disclosure - Organization, Description of Business and Liquidity and Capital Resources</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
        <link:definition>109 - Disclosure - Significant Accounting Policies</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreements" id="LicenseAgreementsAndClinicalResearchSupportAgreements">
        <link:definition>110 - Disclosure - License Agreements and Clinical Research Support Agreements</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/RelatedPartyAgreements" id="RelatedPartyAgreements">
        <link:definition>111 - Disclosure - Related Party Agreements</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>112 - Disclosure - Commitments and Contingencies</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/NetLossPerShare" id="NetLossPerShare">
        <link:definition>113 - Disclosure - Net Loss per Share</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>114 - Disclosure - Stockholders&#39; Equity</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>115 - Disclosure - Subsequent Events</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
        <link:definition>116 - Disclosure - Significant Accounting Policies (Policies)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreementsTables" id="LicenseAgreementsAndClinicalResearchSupportAgreementsTables">
        <link:definition>117 - Disclosure - License Agreements and Clinical Research Support Agreements (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
        <link:definition>118 - Disclosure - Net Loss per Share (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
        <link:definition>119 - Disclosure - Stockholders&#39; Equity (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/OrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDetailsTextual" id="OrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDetailsTextual">
        <link:definition>120 - Disclosure - Organization, Description of Business and Liquidity and Capital Resources (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/SignificantAccountingPoliciesDetailsTextual" id="SignificantAccountingPoliciesDetailsTextual">
        <link:definition>121 - Disclosure - Significant Accounting Policies (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreementsDetails" id="LicenseAgreementsAndClinicalResearchSupportAgreementsDetails">
        <link:definition>122 - Disclosure - License Agreements and Clinical Research Support Agreements (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreementsDetailsTextual" id="LicenseAgreementsAndClinicalResearchSupportAgreementsDetailsTextual">
        <link:definition>123 - Disclosure - License Agreements and Clinical Research Support Agreements (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/RelatedPartyAgreementsDetailsTextual" id="RelatedPartyAgreementsDetailsTextual">
        <link:definition>124 - Disclosure - Related Party Agreements (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/CommitmentsAndContingenciesDetailsTextual" id="CommitmentsAndContingenciesDetailsTextual">
        <link:definition>125 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/NetLossPerShareDetails" id="NetLossPerShareDetails">
        <link:definition>126 - Disclosure - Net Loss per Share (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
        <link:definition>127 - Disclosure - Stockholders&#39; Equity (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
        <link:definition>128 - Disclosure - Stockholders&#39; Equity (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
        <link:definition>129 - Disclosure - Stockholders&#39; Equity (Details 2)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/StockholdersEquityDetails3" id="StockholdersEquityDetails3">
        <link:definition>130 - Disclosure - Stockholders&#39; Equity (Details 3)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/StockholdersEquityDetails4" id="StockholdersEquityDetails4">
        <link:definition>131 - Disclosure - Stockholders&#39; Equity (Details 4)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/StockholdersEquityDetailsTextual" id="StockholdersEquityDetailsTextual">
        <link:definition>132 - Disclosure - Stockholders&#39; Equity (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.mustangbio.com/role/SubsequentEventsDetailsTextual" id="SubsequentEventsDetailsTextual">
        <link:definition>133 - Disclosure - Subsequent Events (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:linkbaseRef xlink:type="simple" xlink:href="ck0001680048-20170930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="ck0001680048-20170930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="ck0001680048-20170930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="ck0001680048-20170930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>

  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />

  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />

  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />

  <import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />

  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />

  <import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />

  <element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_DocumentAndEntityInformationAbstract" />

  <element name="CommonSharesIssuableLiabilityCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ck0001680048_CommonSharesIssuableLiabilityCurrent" />

  <element name="PayablesAndAccruedexpensesRelatedPartiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent" />

  <element name="AccruedInterestRelatedPartyCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ck0001680048_AccruedInterestRelatedPartyCurrent" />

  <element name="InterestIncomeExpensesRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ck0001680048_InterestIncomeExpensesRelatedParty" />

  <element name="IssuanceOfCommonStockFounderAgreementExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses" />

  <element name="ProceedsFromNotesPayableGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ck0001680048_ProceedsFromNotesPayableGross" />

  <element name="SignificantAccountingPoliciesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_SignificantAccountingPoliciesPolicyTextBlock" />

  <element name="LicenseAgreementDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_LicenseAgreementDisclosureAbstract" />

  <element name="LicenseAgreementDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_LicenseAgreementDisclosureTextBlock" />

  <element name="CityOfHopeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_CityOfHopeMember" />

  <element name="PaymentOfUpfrontFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ck0001680048_PaymentOfUpfrontFees" />

  <element name="RevenueRecognitionMilestoneMethodPaymentsDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue" />

  <element name="ResearchAndDevelopmentExpenseSponsoredResearchPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ck0001680048_ResearchAndDevelopmentExpenseSponsoredResearchPayment" />

  <element name="CommonStockIssuableMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_CommonStockIssuableMember" />

  <element name="FortressBiotechIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_FortressBiotechIncMember" />

  <element name="ChordAdvisorsLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_ChordAdvisorsLlcMember" />

  <element name="NationalHoldingsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_NationalHoldingsIncMember" />

  <element name="FoundersAgreementTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_FoundersAgreementTerm" />

  <element name="AdditionalConsiderationUnderFoundersAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_AdditionalConsiderationUnderFoundersAgreementDescription" />

  <element name="AnnualConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ck0001680048_AnnualConsultingFees" />

  <element name="IncreaseInAnnualConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ck0001680048_IncreaseInAnnualConsultingFees" />

  <element name="ExcessInNetAssetsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ck0001680048_ExcessInNetAssetsValue" />

  <element name="AnnualFeesExpensesOnFoundersAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ck0001680048_AnnualFeesExpensesOnFoundersAgreement" />

  <element name="BackOfficeAccountingFunctionsExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ck0001680048_BackOfficeAccountingFunctionsExpenses" />

  <element name="AccountingAnalysisAndFinancialReportingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ck0001680048_AccountingAnalysisAndFinancialReportingFees" />

  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" />

  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice" />

  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice" />

  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms" />

  <element name="PercentageOfPlacementAgentFee" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_PercentageOfPlacementAgentFee" />

  <element name="PercentageOfSharesIssuedToPlacementAgent" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_PercentageOfSharesIssuedToPlacementAgent" />

  <element name="WarrantPurchasePricePerUnit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ck0001680048_WarrantPurchasePricePerUnit" />

  <element name="WarrantsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_WarrantsIssued" />

  <element name="NationalHoldingsCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_NationalHoldingsCorporationMember" />

  <element name="SharesOfCommonStockPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_SharesOfCommonStockPercentage" />

  <element name="FailedContingencyDamagesAwardedPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_FailedContingencyDamagesAwardedPercentage" />

  <element name="UnregisteredCommonStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_UnregisteredCommonStockMember" />

  <element name="AdjustmentToAdditionalPaidInCapitalCapitalContribution" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ck0001680048_AdjustmentToAdditionalPaidInCapitalCapitalContribution" />

  <element name="AgreementTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="ck0001680048_AgreementTypeAxis" />

  <element name="DilutedOutstandingEquityPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_DilutedOutstandingEquityPercentage" />

  <element name="CityOfHopeNationalMedicalCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_CityOfHopeNationalMedicalCenterMember" />

  <element name="AgreementTypeDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_AgreementTypeDomain" />

  <element name="LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_LicenseAgreementMember" />

  <element name="NationalSecuritiesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_NationalSecuritiesIncMember" />

  <element name="StephenFormanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_StephenFormanMember" />

  <element name="ChristineBrownMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_ChristineBrownMember" />

  <element name="LicensingArrangementsAdditionalCostsIncurred" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ck0001680048_LicensingArrangementsAdditionalCostsIncurred" />

  <element name="ArCd123LicenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_ArCd123LicenseMember" />

  <element name="IlLicenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_IlLicenseMember" />

  <element name="AdvisorMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_AdvisorMember" />

  <element name="LicenseAgreementDisclosureAbstractAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_LicenseAgreementDisclosureAbstractAbstract" />

  <element name="ArIl13LicenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_ArIl13LicenseMember" />

  <element name="IvicvLicenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_IvicvLicenseMember" />

  <element name="PscaTechnologyLicenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_PscaTechnologyLicenseMember" />

  <element name="UclaLicenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_UclaLicenseMember" />

  <element name="UniversityOfCaliforniaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_UniversityOfCaliforniaMember" />

  <element name="Her2TechnologyLicenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_Her2TechnologyLicenseMember" />

  <element name="CsTechnologyLicenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_CsTechnologyLicenseMember" />

  <element name="PotentiallyDilutiveSecurities" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_PotentiallyDilutiveSecurities" />

  <element name="UnvestedRestrictedStockAwardsMemberMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_UnvestedRestrictedStockAwardsMemberMember" />

  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsTableTextBlock" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />

  <element name="EmployeeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_EmployeeMember" />

  <element name="NonEmployeeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_NonEmployeeMember" />

  <element name="SpacerLicenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_SpacerLicenseMember" />

  <element name="ClassOfWarrantOrRightPercentageOfWarrantIssued" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_ClassOfWarrantOrRightPercentageOfWarrantIssued" />

  <element name="AnnualFeesExpensesOnFoundersAgreementPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_AnnualFeesExpensesOnFoundersAgreementPercentage" />

  <element name="StockIssuableForLicenseAcquired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ck0001680048_StockIssuableForLicenseAcquired" />

  <element name="FredHutchCd20Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_FredHutchCd20Member" />

  <element name="FredHutchinsonCancerResearchCenterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_FredHutchinsonCancerResearchCenterMember" />

  <element name="Cd20TechnologyLicenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_Cd20TechnologyLicenseMember" />

  <element name="Cd20ClinicalAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_Cd20ClinicalAgreementMember" />

  <element name="DevelopmentMilestonesMethodAdditionalPaymentsDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="ck0001680048_DevelopmentMilestonesMethodAdditionalPaymentsDue" />

  <element name="PropertyPlantAndEquipmentDesignCostsCapitalized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="ck0001680048_PropertyPlantAndEquipmentDesignCostsCapitalized" />

  <element name="Il13ra2Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_Il13ra2Member" />

  <element name="ClassOfWarrantOrRightExpirationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_ClassOfWarrantOrRightExpirationPeriod" />

  <element name="NumberOfSharesToBeIssuedUponLegalSettlement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ck0001680048_NumberOfSharesToBeIssuedUponLegalSettlement" />
</schema>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>ck0001680048-20170930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 13-Nov-2017 [06:42:58] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#CondensedBalanceSheets" roleURI="http://www.mustangbio.com/role/CondensedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#CondensedStatementsOfOperations" roleURI="http://www.mustangbio.com/role/CondensedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#CondensedStatementsOfCashFlows" roleURI="http://www.mustangbio.com/role/CondensedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#StockholdersEquity" roleURI="http://www.mustangbio.com/role/StockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#NetLossPerShareDetails" roleURI="http://www.mustangbio.com/role/NetLossPerShareDetails" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#NetLossPerShare" roleURI="http://www.mustangbio.com/role/NetLossPerShare" />

  <calculationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/CondensedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CommonSharesIssuableLiabilityCurrent" xlink:label="loc_ck0001680048_CommonSharesIssuableLiabilityCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_ck0001680048_CommonSharesIssuableLiabilityCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent" xlink:label="loc_ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AccruedInterestRelatedPartyCurrent" xlink:label="loc_ck0001680048_AccruedInterestRelatedPartyCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_ck0001680048_AccruedInterestRelatedPartyCurrent" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="50" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/CondensedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestIncomeOther" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_InterestIncomeExpensesRelatedParty" xlink:label="loc_ck0001680048_InterestIncomeExpensesRelatedParty" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_ck0001680048_InterestIncomeExpensesRelatedParty" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpenseDebt" use="optional" order="30" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="40" weight="-1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/CondensedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ProceedsFromNotesPayableGross" xlink:label="loc_ck0001680048_ProceedsFromNotesPayableGross" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ck0001680048_ProceedsFromNotesPayableGross" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts" use="optional" order="40" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForConstructionInProcess" xlink:label="loc_us-gaap_PaymentsForConstructionInProcess" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsForConstructionInProcess" use="optional" order="30" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses" xlink:label="loc_ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" use="optional" order="50" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" use="optional" order="60" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="70" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="80" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="90" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" use="optional" order="100" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties" use="optional" order="110" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" use="optional" order="120" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/NetLossPerShareDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/CondensedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherShortTermInvestments" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaap_InterestReceivableCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InterestReceivableCurrent" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="20" weight="1" />
  </calculationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>ck0001680048-20170930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 13-Nov-2017 [06:42:58] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#DocumentAndEntityInformation" roleURI="http://www.mustangbio.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#CondensedBalanceSheets" roleURI="http://www.mustangbio.com/role/CondensedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#CondensedBalanceSheetsParenthetical" roleURI="http://www.mustangbio.com/role/CondensedBalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#CondensedStatementsOfOperations" roleURI="http://www.mustangbio.com/role/CondensedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#CondensedStatementsOfCashFlows" roleURI="http://www.mustangbio.com/role/CondensedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#CondensedStatementsOfCashFlowsParenthetical" roleURI="http://www.mustangbio.com/role/CondensedStatementsOfCashFlowsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#CondensedStatementOfStockholdersEquity" roleURI="http://www.mustangbio.com/role/CondensedStatementOfStockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#SignificantAccountingPoliciesDetailsTextual" roleURI="http://www.mustangbio.com/role/SignificantAccountingPoliciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#LicenseAgreementsAndClinicalResearchSupportAgreementsDetailsTextual" roleURI="http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreementsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#RelatedPartyAgreementsDetailsTextual" roleURI="http://www.mustangbio.com/role/RelatedPartyAgreementsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#StockholdersEquityTables" roleURI="http://www.mustangbio.com/role/StockholdersEquityTables" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#StockholdersEquityDetails4" roleURI="http://www.mustangbio.com/role/StockholdersEquityDetails4" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#StockholdersEquityDetailsTextual" roleURI="http://www.mustangbio.com/role/StockholdersEquityDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#SubsequentEventsDetailsTextual" roleURI="http://www.mustangbio.com/role/SubsequentEventsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.mustangbio.com/role/CommitmentsAndContingenciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#NetLossPerShareDetails" roleURI="http://www.mustangbio.com/role/NetLossPerShareDetails" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#LicenseAgreementsAndClinicalResearchSupportAgreementsDetails" roleURI="http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreementsDetails" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#StockholdersEquityDetails1" roleURI="http://www.mustangbio.com/role/StockholdersEquityDetails1" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#StockholdersEquityDetails2" roleURI="http://www.mustangbio.com/role/StockholdersEquityDetails2" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#StockholdersEquityDetails3" roleURI="http://www.mustangbio.com/role/StockholdersEquityDetails3" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#OrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDetailsTextual" roleURI="http://www.mustangbio.com/role/OrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#StockholdersEquityDetails" roleURI="http://www.mustangbio.com/role/StockholdersEquityDetails" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_1000" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_DocumentInformationTable_3" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1001" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4" xlink:to="loc_us-gaap_ClassOfStockDomain_1001" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1001_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4" xlink:to="loc_us-gaap_ClassOfStockDomain_1001_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1002" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1001" xlink:to="loc_us-gaap_CommonStockMember_1002" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1003" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1001" xlink:to="loc_us-gaap_CommonClassAMember_1003" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_DocumentType_5" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_AmendmentFlag_6" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_DocumentPeriodEndDate_7" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_DocumentFiscalYearFocus_8" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_10" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_EntityRegistrantName_10" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_11" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_EntityCentralIndexKey_11" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_12" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_CurrentFiscalYearEndDate_12" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_13" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_EntityFilerCategory_13" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1004" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1004" use="optional" order="16" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/CondensedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_18" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_StatementTable_18" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_19" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_18" xlink:to="loc_us-gaap_StatementClassOfStockAxis_19" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_20" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_19" xlink:to="loc_us-gaap_ClassOfStockDomain_20" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_20_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_19" xlink:to="loc_us-gaap_ClassOfStockDomain_20_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_41" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_20" xlink:to="loc_us-gaap_CommonClassAMember_41" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_22" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_AssetsAbstract_22" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_24" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_AssetsCurrentAbstract_24" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_984" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_984" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_797" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_OtherShortTermInvestments_797" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_732" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_732" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaap_InterestReceivableCurrent_985" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_InterestReceivableCurrent_985" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_26" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_AssetsCurrent_26" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1018" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1018" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_27" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_Assets_27" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_28" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_28" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_29" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_29" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CommonSharesIssuableLiabilityCurrent" xlink:label="loc_ck0001680048_CommonSharesIssuableLiabilityCurrent_987" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_ck0001680048_CommonSharesIssuableLiabilityCurrent_987" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent" xlink:label="loc_ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent_1019" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent_1019" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AccruedInterestRelatedPartyCurrent" xlink:label="loc_ck0001680048_AccruedInterestRelatedPartyCurrent_32" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_ck0001680048_AccruedInterestRelatedPartyCurrent_32" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_36" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23" xlink:to="loc_us-gaap_Liabilities_36" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_37" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23" xlink:to="loc_us-gaap_CommitmentsAndContingencies_37" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_38" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23" xlink:to="loc_us-gaap_StockholdersEquityAbstract_38" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_39" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38" xlink:to="loc_us-gaap_PreferredStockValue_39" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_40" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38" xlink:to="loc_us-gaap_CommonStockValue_40" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_43" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_43" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_44" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_44" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_45" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_45" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_46" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38" xlink:to="loc_us-gaap_StockholdersEquity_46" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_47" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_47" use="optional" order="30" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/CondensedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_53" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_50" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_53" xlink:to="loc_us-gaap_StatementTable_50" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_51" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_50" xlink:to="loc_us-gaap_StatementClassOfStockAxis_51" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_52" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_51" xlink:to="loc_us-gaap_ClassOfStockDomain_52" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_52_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_51" xlink:to="loc_us-gaap_ClassOfStockDomain_52_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_58" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_52" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_58" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_63" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_52" xlink:to="loc_us-gaap_CommonClassAMember_63" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_55" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_55" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_56" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_56" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_57" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53" xlink:to="loc_us-gaap_PreferredStockSharesIssued_57" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_59" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_59" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_60" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_60" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_61" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_61" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_62" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53" xlink:to="loc_us-gaap_CommonStockSharesIssued_62" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_64" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_64" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_66" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_66" use="optional" order="15" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/CondensedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_72" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_69" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_StatementTable_69" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_70" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_69" xlink:to="loc_us-gaap_StatementClassOfStockAxis_70" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_71" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_70" xlink:to="loc_us-gaap_ClassOfStockDomain_71" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_71_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_70" xlink:to="loc_us-gaap_ClassOfStockDomain_71_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_73" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_OperatingExpensesAbstract_73" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_74" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_74" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_75" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_75" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_76" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_76" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_77" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_OperatingExpenses_77" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_78" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_OperatingIncomeLoss_78" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_79" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_79" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_742" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_79" xlink:to="loc_us-gaap_InterestIncomeOther_742" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_InterestIncomeExpensesRelatedParty" xlink:label="loc_ck0001680048_InterestIncomeExpensesRelatedParty_80" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_79" xlink:to="loc_ck0001680048_InterestIncomeExpensesRelatedParty_80" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_81" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_79" xlink:to="loc_us-gaap_InterestExpenseDebt_81" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_82" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_79" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_82" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_83" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_79" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_83" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_84" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_NetIncomeLoss_84" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_85" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_85" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_86" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_86" use="optional" order="19" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/CondensedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_108" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_89" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_108" xlink:to="loc_us-gaap_StatementTable_89" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_90" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_89" xlink:to="loc_us-gaap_StatementClassOfStockAxis_90" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_91" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_90" xlink:to="loc_us-gaap_ClassOfStockDomain_91" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_91_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_90" xlink:to="loc_us-gaap_ClassOfStockDomain_91_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_92" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_89" xlink:to="loc_us-gaap_DebtInstrumentAxis_92" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_109" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_92" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_109" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_109_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_92" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_109_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_108" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_94" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" xlink:to="loc_us-gaap_NetIncomeLoss_94" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_184" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_184" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses" xlink:label="loc_ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses_185" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" xlink:to="loc_ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses_185" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_95" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_95" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_518" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_518" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_801" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" xlink:to="loc_us-gaap_ShareBasedCompensation_801" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_1021" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_1021" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_97" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_97" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_98" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_98" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_738" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_98" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_738" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_989" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_98" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_989" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_99" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_98" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_99" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_100" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_98" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_100" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_101" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_98" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_101" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_102" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_102" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_103" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_108" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_103" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_802" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_103" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_802" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_104" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_103" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_104" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForConstructionInProcess" xlink:label="loc_us-gaap_PaymentsForConstructionInProcess_991" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_103" xlink:to="loc_us-gaap_PaymentsForConstructionInProcess_991" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_105" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_103" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_105" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_106" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_108" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_106" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_933" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_106" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_933" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_112" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_106" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_112" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ProceedsFromNotesPayableGross" xlink:label="loc_ck0001680048_ProceedsFromNotesPayableGross_467" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_106" xlink:to="loc_ck0001680048_ProceedsFromNotesPayableGross_467" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_463" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_106" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_463" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_113" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_106" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_113" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_114" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_106" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_114" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1005" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_108" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1005" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1006" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_108" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1006" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_631" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_108" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_631" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_632" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_631" xlink:to="loc_us-gaap_InterestPaidNet_632" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_118" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_108" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_118" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_992" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_118" xlink:to="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_992" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_119" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_118" xlink:to="loc_us-gaap_StockIssued1_119" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_120" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_118" xlink:to="loc_us-gaap_LiabilitiesAssumed1_120" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_StockIssuableForLicenseAcquired" xlink:label="loc_ck0001680048_StockIssuableForLicenseAcquired_743" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_118" xlink:to="loc_ck0001680048_StockIssuableForLicenseAcquired_743" use="optional" order="44" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/CondensedStatementsOfCashFlowsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_543" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_124" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_543" xlink:to="loc_us-gaap_StatementTable_124" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_125" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_124" xlink:to="loc_us-gaap_StatementClassOfStockAxis_125" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_126" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_125" xlink:to="loc_us-gaap_ClassOfStockDomain_126" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_126_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_125" xlink:to="loc_us-gaap_ClassOfStockDomain_126_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_127" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_124" xlink:to="loc_us-gaap_DebtInstrumentAxis_127" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_544" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_127" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_544" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_544_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_127" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_544_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_128" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_543" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_128" use="optional" order="8" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/CondensedStatementOfStockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_191" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_188" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StatementTable_188" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_189" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_188" xlink:to="loc_us-gaap_StatementClassOfStockAxis_189" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_190" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_189" xlink:to="loc_us-gaap_ClassOfStockDomain_190" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_190_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_189" xlink:to="loc_us-gaap_ClassOfStockDomain_190_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_195" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_190" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_195" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_196" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_190" xlink:to="loc_us-gaap_CommonClassAMember_196" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_198" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_190" xlink:to="loc_us-gaap_CommonStockMember_198" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CommonStockIssuableMember" xlink:label="loc_ck0001680048_CommonStockIssuableMember_193" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_190" xlink:to="loc_ck0001680048_CommonStockIssuableMember_193" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_199" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_190" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_199" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_200" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_190" xlink:to="loc_us-gaap_RetainedEarningsMember_200" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_192" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StockholdersEquity_192" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_212" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_SharesOutstanding_212" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_201" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_201" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_202" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_202" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_744" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_744" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_745" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_745" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_203" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_203" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_204" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_204" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_205" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_205" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_798" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_798" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_800" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_800" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AdjustmentToAdditionalPaidInCapitalCapitalContribution" xlink:label="loc_ck0001680048_AdjustmentToAdditionalPaidInCapitalCapitalContribution_1020" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_ck0001680048_AdjustmentToAdditionalPaidInCapitalCapitalContribution_1020" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_208" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_NetIncomeLoss_208" use="optional" order="23" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/SignificantAccountingPoliciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1029" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_149" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1029" xlink:to="loc_us-gaap_StatementTable_149" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_150" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_149" xlink:to="loc_us-gaap_StatementClassOfStockAxis_150" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_151" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_150" xlink:to="loc_us-gaap_ClassOfStockDomain_151" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_151_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_150" xlink:to="loc_us-gaap_ClassOfStockDomain_151_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_152" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_149" xlink:to="loc_dei_LegalEntityAxis_152" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_154" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_152" xlink:to="loc_dei_EntityDomain_154" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_154_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_152" xlink:to="loc_dei_EntityDomain_154_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_153" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_149" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_153" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_452" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_153" xlink:to="loc_us-gaap_EquityComponentDomain_452" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_452_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_153" xlink:to="loc_us-gaap_EquityComponentDomain_452_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_451" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_149" xlink:to="loc_us-gaap_InvestmentTypeAxis_451" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1024" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_451" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1024" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1024_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_451" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1024_default" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_1025" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1024" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_1025" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_1023" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_149" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_1023" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_1031" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_1023" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_1031" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_1031_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_1023" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_1031_default" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldtomaturitySecuritiesMember" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_1033" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_1031" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_1033" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_807" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1029" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_807" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_923" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1029" xlink:to="loc_us-gaap_OtherShortTermInvestments_923" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TimeDepositsAtCarryingValue" xlink:label="loc_us-gaap_TimeDepositsAtCarryingValue_1022" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1029" xlink:to="loc_us-gaap_TimeDepositsAtCarryingValue_1022" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PropertyPlantAndEquipmentDesignCostsCapitalized" xlink:label="loc_ck0001680048_PropertyPlantAndEquipmentDesignCostsCapitalized_1038" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1029" xlink:to="loc_ck0001680048_PropertyPlantAndEquipmentDesignCostsCapitalized_1038" use="optional" order="22" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreementsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_765" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_163" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_StatementTable_163" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_164" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_163" xlink:to="loc_us-gaap_StatementClassOfStockAxis_164" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_165" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_164" xlink:to="loc_us-gaap_ClassOfStockDomain_165" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_165_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_164" xlink:to="loc_us-gaap_ClassOfStockDomain_165_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_717" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_165" xlink:to="loc_us-gaap_CommonClassAMember_717" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_166" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_163" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_166" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_168" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_166" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_168" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_168_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_166" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_168_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CityOfHopeMember" xlink:label="loc_ck0001680048_CityOfHopeMember_169" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_168" xlink:to="loc_ck0001680048_CityOfHopeMember_169" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_ck0001680048_FredHutchinsonCancerResearchCenterMember_996" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_168" xlink:to="loc_ck0001680048_FredHutchinsonCancerResearchCenterMember_996" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_167" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_163" xlink:to="loc_us-gaap_TypeOfArrangementAxis_167" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_182" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_167" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_182" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_182_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_167" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_182_default" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_181" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_163" xlink:to="loc_dei_LegalEntityAxis_181" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_658" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_181" xlink:to="loc_dei_EntityDomain_658" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_658_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_181" xlink:to="loc_dei_EntityDomain_658_default" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_657" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_163" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_657" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_666" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_657" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_666" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_666_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_657" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_666_default" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_665" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_163" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_665" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_670" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_665" xlink:to="loc_us-gaap_EquityComponentDomain_670" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_670_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_665" xlink:to="loc_us-gaap_EquityComponentDomain_670_default" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_669" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_163" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_669" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_714" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_669" xlink:to="loc_us-gaap_RelatedPartyDomain_714" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_714_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_669" xlink:to="loc_us-gaap_RelatedPartyDomain_714_default" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_StephenFormanMember" xlink:label="loc_ck0001680048_StephenFormanMember_715" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_714" xlink:to="loc_ck0001680048_StephenFormanMember_715" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ChristineBrownMember" xlink:label="loc_ck0001680048_ChristineBrownMember_716" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_714" xlink:to="loc_ck0001680048_ChristineBrownMember_716" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_UniversityOfCaliforniaMember" xlink:label="loc_ck0001680048_UniversityOfCaliforniaMember_788" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_714" xlink:to="loc_ck0001680048_UniversityOfCaliforniaMember_788" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_713" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_163" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_713" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_713" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_713" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766_default" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ArCd123LicenseMember" xlink:label="loc_ck0001680048_ArCd123LicenseMember_767" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_ArCd123LicenseMember_767" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_IlLicenseMember" xlink:label="loc_ck0001680048_IlLicenseMember_768" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_IlLicenseMember_768" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_UclaLicenseMember" xlink:label="loc_ck0001680048_UclaLicenseMember_787" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_UclaLicenseMember_787" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PscaTechnologyLicenseMember" xlink:label="loc_ck0001680048_PscaTechnologyLicenseMember_829" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_PscaTechnologyLicenseMember_829" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_Her2TechnologyLicenseMember" xlink:label="loc_ck0001680048_Her2TechnologyLicenseMember_831" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_Her2TechnologyLicenseMember_831" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CsTechnologyLicenseMember" xlink:label="loc_ck0001680048_CsTechnologyLicenseMember_832" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_CsTechnologyLicenseMember_832" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SpacerLicenseMember" xlink:label="loc_ck0001680048_SpacerLicenseMember_944" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_SpacerLicenseMember_944" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_Cd20TechnologyLicenseMember" xlink:label="loc_ck0001680048_Cd20TechnologyLicenseMember_997" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_Cd20TechnologyLicenseMember_997" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_Cd20ClinicalAgreementMember" xlink:label="loc_ck0001680048_Cd20ClinicalAgreementMember_998" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_Cd20ClinicalAgreementMember_998" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_Il13ra2Member" xlink:label="loc_ck0001680048_Il13ra2Member_1042" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_Il13ra2Member_1042" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PaymentOfUpfrontFees" xlink:label="loc_ck0001680048_PaymentOfUpfrontFees_170" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_ck0001680048_PaymentOfUpfrontFees_170" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue" xlink:label="loc_ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue_173" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue_173" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ResearchAndDevelopmentExpenseSponsoredResearchPayment" xlink:label="loc_ck0001680048_ResearchAndDevelopmentExpenseSponsoredResearchPayment_179" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_ck0001680048_ResearchAndDevelopmentExpenseSponsoredResearchPayment_179" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_180" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_180" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_557" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_557" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaap_PaymentsForFees_708" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_PaymentsForFees_708" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AnnualConsultingFees" xlink:label="loc_ck0001680048_AnnualConsultingFees_710" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_ck0001680048_AnnualConsultingFees_710" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_711" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_711" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_712" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_712" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_LicensingArrangementsAdditionalCostsIncurred" xlink:label="loc_ck0001680048_LicensingArrangementsAdditionalCostsIncurred_763" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_ck0001680048_LicensingArrangementsAdditionalCostsIncurred_763" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_us-gaap_MaintenanceCosts_830" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_MaintenanceCosts_830" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_959" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_959" use="optional" order="53" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInThirdYear" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear_960" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_OtherCommitmentDueInThirdYear_960" use="optional" order="54" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInSecondYear" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear_961" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_OtherCommitmentDueInSecondYear_961" use="optional" order="55" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInFifthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFifthYear_962" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_OtherCommitmentDueInFifthYear_962" use="optional" order="56" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInFourthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear_963" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_OtherCommitmentDueInFourthYear_963" use="optional" order="57" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_DevelopmentMilestonesMethodAdditionalPaymentsDue" xlink:label="loc_ck0001680048_DevelopmentMilestonesMethodAdditionalPaymentsDue_1015" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_ck0001680048_DevelopmentMilestonesMethodAdditionalPaymentsDue_1015" use="optional" order="58" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_1043" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_ProfessionalFees_1043" use="optional" order="59" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/RelatedPartyAgreementsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1053" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_217" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_StatementTable_217" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_218" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_217" xlink:to="loc_us-gaap_StatementClassOfStockAxis_218" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_219" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_218" xlink:to="loc_us-gaap_ClassOfStockDomain_219" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_219_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_218" xlink:to="loc_us-gaap_ClassOfStockDomain_219_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_224" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_219" xlink:to="loc_us-gaap_CommonClassBMember_224" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_228" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_219" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_228" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleCommonStockMember" xlink:label="loc_us-gaap_ConvertibleCommonStockMember_628" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_219" xlink:to="loc_us-gaap_ConvertibleCommonStockMember_628" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_220" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_217" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_220" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_222" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_220" xlink:to="loc_us-gaap_RelatedPartyDomain_222" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_222_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_220" xlink:to="loc_us-gaap_RelatedPartyDomain_222_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_FortressBiotechIncMember" xlink:label="loc_ck0001680048_FortressBiotechIncMember_223" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_222" xlink:to="loc_ck0001680048_FortressBiotechIncMember_223" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ChordAdvisorsLlcMember" xlink:label="loc_ck0001680048_ChordAdvisorsLlcMember_229" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_222" xlink:to="loc_ck0001680048_ChordAdvisorsLlcMember_229" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_NationalHoldingsIncMember" xlink:label="loc_ck0001680048_NationalHoldingsIncMember_230" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_222" xlink:to="loc_ck0001680048_NationalHoldingsIncMember_230" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AdvisorMember" xlink:label="loc_ck0001680048_AdvisorMember_769" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_222" xlink:to="loc_ck0001680048_AdvisorMember_769" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_221" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_217" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_221" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_226" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_221" xlink:to="loc_us-gaap_EquityComponentDomain_226" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_226_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_221" xlink:to="loc_us-gaap_EquityComponentDomain_226_default" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_225" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_217" xlink:to="loc_us-gaap_TitleOfIndividualAxis_225" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_836" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_225" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_836" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_836_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_225" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_836_default" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_837" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_836" xlink:to="loc_us-gaap_DirectorMember_837" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_us-gaap_BoardOfDirectorsChairmanMember_850" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_836" xlink:to="loc_us-gaap_BoardOfDirectorsChairmanMember_850" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_835" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_217" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_835" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_978" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_835" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_978" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_978_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_835" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_978_default" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_979" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_978" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_979" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1016" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_978" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1016" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_977" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_217" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_977" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1051" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_977" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1051" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1051_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_977" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1051_default" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1052" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1051" xlink:to="loc_us-gaap_PrivatePlacementMember_1052" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1050" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_217" xlink:to="loc_us-gaap_AwardTypeAxis_1050" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1054" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1050" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1054" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1054_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1050" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1054_default" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1055" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1054" xlink:to="loc_us-gaap_RestrictedStockMember_1055" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_231" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_231" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_FoundersAgreementTerm" xlink:label="loc_ck0001680048_FoundersAgreementTerm_232" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_FoundersAgreementTerm_232" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_233" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_233" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_234" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_234" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaap_PreferredStockVotingRights_235" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_PreferredStockVotingRights_235" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AdditionalConsiderationUnderFoundersAgreementDescription" xlink:label="loc_ck0001680048_AdditionalConsiderationUnderFoundersAgreementDescription_236" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_AdditionalConsiderationUnderFoundersAgreementDescription_236" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_237" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_237" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_238" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_238" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AnnualConsultingFees" xlink:label="loc_ck0001680048_AnnualConsultingFees_239" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_AnnualConsultingFees_239" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_IncreaseInAnnualConsultingFees" xlink:label="loc_ck0001680048_IncreaseInAnnualConsultingFees_240" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_IncreaseInAnnualConsultingFees_240" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ExcessInNetAssetsValue" xlink:label="loc_ck0001680048_ExcessInNetAssetsValue_241" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_ExcessInNetAssetsValue_241" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AnnualFeesExpensesOnFoundersAgreement" xlink:label="loc_ck0001680048_AnnualFeesExpensesOnFoundersAgreement_242" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_AnnualFeesExpensesOnFoundersAgreement_242" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_BackOfficeAccountingFunctionsExpenses" xlink:label="loc_ck0001680048_BackOfficeAccountingFunctionsExpenses_243" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_BackOfficeAccountingFunctionsExpenses_243" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AccountingAnalysisAndFinancialReportingFees" xlink:label="loc_ck0001680048_AccountingAnalysisAndFinancialReportingFees_244" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_AccountingAnalysisAndFinancialReportingFees_244" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_245" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_ProfessionalFees_245" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_246" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_246" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaap_PaymentsForFees_251" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_PaymentsForFees_251" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_252" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_252" use="optional" order="53" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_838" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_838" use="optional" order="54" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AnnualFeesExpensesOnFoundersAgreementPercentage" xlink:label="loc_ck0001680048_AnnualFeesExpensesOnFoundersAgreementPercentage_976" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_AnnualFeesExpensesOnFoundersAgreementPercentage_976" use="optional" order="55" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_980" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_980" use="optional" order="56" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_981" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_OfficersCompensation_981" use="optional" order="57" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1044" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1044" use="optional" order="58" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ClassOfWarrantOrRightExpirationPeriod" xlink:label="loc_ck0001680048_ClassOfWarrantOrRightExpirationPeriod_1045" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_ClassOfWarrantOrRightExpirationPeriod_1045" use="optional" order="59" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1047" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1047" use="optional" order="60" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1048" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1048" use="optional" order="61" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1049" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1049" use="optional" order="62" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/StockholdersEquityTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_846" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsTableTextBlock" xlink:label="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsTableTextBlock_941" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_846" xlink:to="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsTableTextBlock_941" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_839" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_846" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_839" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_841" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_846" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_841" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_842" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_846" xlink:to="loc_us-gaap_StatementTable_842" use="optional" order="4" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_843" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_842" xlink:to="loc_us-gaap_StatementClassOfStockAxis_843" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_844" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_843" xlink:to="loc_us-gaap_ClassOfStockDomain_844" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_844_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_843" xlink:to="loc_us-gaap_ClassOfStockDomain_844_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_845" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_842" xlink:to="loc_us-gaap_AwardTypeAxis_845" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_847" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_847" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_847_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_847_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_848" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_847" xlink:to="loc_us-gaap_RestrictedStockMember_848" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_849" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_847" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_849" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_932" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_846" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_932" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_345" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_846" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_345" use="optional" order="14" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/StockholdersEquityDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_351" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_348" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_351" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_348" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_349" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_348" xlink:to="loc_us-gaap_TitleOfIndividualAxis_349" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_350" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_349" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_350" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_350_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_349" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_350_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" xlink:label="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding_352" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_351" xlink:to="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding_352" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_353" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_351" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_353" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice_355" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_351" xlink:to="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice_355" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:label="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice_357" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_351" xlink:to="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice_357" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms" xlink:label="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms_360" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_351" xlink:to="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms_360" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_358" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_351" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_358" use="optional" order="10" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/StockholdersEquityDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_364" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_364" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_365" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_364" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_365" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_365_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_364" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_365_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_395" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_365" xlink:to="loc_us-gaap_PrivatePlacementMember_395" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_366" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_dei_LegalEntityAxis_366" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_367" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_366" xlink:to="loc_dei_EntityDomain_367" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_367_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_366" xlink:to="loc_dei_EntityDomain_367_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_FortressBiotechIncMember" xlink:label="loc_ck0001680048_FortressBiotechIncMember_379" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_367" xlink:to="loc_ck0001680048_FortressBiotechIncMember_379" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_NationalHoldingsCorporationMember" xlink:label="loc_ck0001680048_NationalHoldingsCorporationMember_387" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_367" xlink:to="loc_ck0001680048_NationalHoldingsCorporationMember_387" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CityOfHopeNationalMedicalCenterMember" xlink:label="loc_ck0001680048_CityOfHopeNationalMedicalCenterMember_582" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_367" xlink:to="loc_ck0001680048_CityOfHopeNationalMedicalCenterMember_582" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_NationalSecuritiesIncMember" xlink:label="loc_ck0001680048_NationalSecuritiesIncMember_615" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_367" xlink:to="loc_ck0001680048_NationalSecuritiesIncMember_615" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_368" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_StatementClassOfStockAxis_368" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_375" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_368" xlink:to="loc_us-gaap_ClassOfStockDomain_375" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_375_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_368" xlink:to="loc_us-gaap_ClassOfStockDomain_375_default" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_376" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_375" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_376" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_377" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_375" xlink:to="loc_us-gaap_CommonClassBMember_377" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_378" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_375" xlink:to="loc_us-gaap_CommonClassAMember_378" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_735" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_375" xlink:to="loc_us-gaap_PreferredClassAMember_735" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_374" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_374" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_397" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_374" xlink:to="loc_us-gaap_EquityComponentDomain_397" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_397_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_374" xlink:to="loc_us-gaap_EquityComponentDomain_397_default" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_398" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_397" xlink:to="loc_us-gaap_CommonStockMember_398" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_UnregisteredCommonStockMember" xlink:label="loc_ck0001680048_UnregisteredCommonStockMember_464" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_397" xlink:to="loc_ck0001680048_UnregisteredCommonStockMember_464" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_396" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_396" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_400" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_396" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_400" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_400_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_396" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_400_default" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_401" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_400" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_401" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_399" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_FinancialInstrumentAxis_399" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_471" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_399" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_471" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_471_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_399" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_471_default" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_470" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_470" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_565" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_470" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_565" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_565_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_470" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_565_default" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AgreementTypeAxis" xlink:label="loc_ck0001680048_AgreementTypeAxis_564" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_ck0001680048_AgreementTypeAxis_564" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AgreementTypeDomain" xlink:label="loc_ck0001680048_AgreementTypeDomain_585" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ck0001680048_AgreementTypeAxis_564" xlink:to="loc_ck0001680048_AgreementTypeDomain_585" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AgreementTypeDomain" xlink:label="loc_ck0001680048_AgreementTypeDomain_585_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ck0001680048_AgreementTypeAxis_564" xlink:to="loc_ck0001680048_AgreementTypeDomain_585_default" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_LicenseAgreementMember" xlink:label="loc_ck0001680048_LicenseAgreementMember_586" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ck0001680048_AgreementTypeDomain_585" xlink:to="loc_ck0001680048_LicenseAgreementMember_586" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_584" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_584" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_591" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_584" xlink:to="loc_us-gaap_CapitalUnitClassDomain_591" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_591_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_584" xlink:to="loc_us-gaap_CapitalUnitClassDomain_591_default" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_590" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_590" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_760" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_590" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_760" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_760_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_590" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_760_default" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_759" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_759" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_874" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_759" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_874" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_874_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_759" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_874_default" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_875" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_874" xlink:to="loc_us-gaap_EmployeeStockOptionMember_875" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_873" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_AwardTypeAxis_873" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_878" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_873" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_878" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_878_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_873" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_878_default" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_879" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_878" xlink:to="loc_us-gaap_RestrictedStockMember_879" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_883" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_878" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_883" use="optional" order="53" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_877" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_TitleOfIndividualAxis_877" use="optional" order="54" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_881" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_877" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_881" use="optional" order="55" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_881_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_877" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_881_default" use="optional" order="56" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_882" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_881" xlink:to="loc_us-gaap_DirectorMember_882" use="optional" order="57" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_369" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_PreferredStockSharesIssued_369" use="optional" order="58" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_370" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_CommonStockSharesIssued_370" use="optional" order="59" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_372" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_372" use="optional" order="60" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_373" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_373" use="optional" order="61" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_381" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_CommonStockVotingRights_381" use="optional" order="62" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PercentageOfPlacementAgentFee" xlink:label="loc_ck0001680048_PercentageOfPlacementAgentFee_382" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_ck0001680048_PercentageOfPlacementAgentFee_382" use="optional" order="63" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PercentageOfSharesIssuedToPlacementAgent" xlink:label="loc_ck0001680048_PercentageOfSharesIssuedToPlacementAgent_383" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_ck0001680048_PercentageOfSharesIssuedToPlacementAgent_383" use="optional" order="64" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_WarrantPurchasePricePerUnit" xlink:label="loc_ck0001680048_WarrantPurchasePricePerUnit_384" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_ck0001680048_WarrantPurchasePricePerUnit_384" use="optional" order="65" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_WarrantsIssued" xlink:label="loc_ck0001680048_WarrantsIssued_386" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_ck0001680048_WarrantsIssued_386" use="optional" order="66" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharesOfCommonStockPercentage" xlink:label="loc_ck0001680048_SharesOfCommonStockPercentage_388" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_ck0001680048_SharesOfCommonStockPercentage_388" use="optional" order="67" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_389" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_389" use="optional" order="68" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_390" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_390" use="optional" order="69" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_391" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_391" use="optional" order="70" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_394" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_394" use="optional" order="71" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PaymentOfUpfrontFees" xlink:label="loc_ck0001680048_PaymentOfUpfrontFees_560" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_ck0001680048_PaymentOfUpfrontFees_560" use="optional" order="72" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_561" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_561" use="optional" order="73" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_569" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_569" use="optional" order="74" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_DilutedOutstandingEquityPercentage" xlink:label="loc_ck0001680048_DilutedOutstandingEquityPercentage_577" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_ck0001680048_DilutedOutstandingEquityPercentage_577" use="optional" order="75" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_579" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_579" use="optional" order="76" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_581" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_SharesOutstanding_581" use="optional" order="77" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_588" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_588" use="optional" order="78" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_617" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_617" use="optional" order="79" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_733" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_733" use="optional" order="80" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_734" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_734" use="optional" order="81" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_756" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_756" use="optional" order="82" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_758" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_758" use="optional" order="83" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_762" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_762" use="optional" order="84" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_872" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_872" use="optional" order="85" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_884" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_884" use="optional" order="86" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_930" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_SharesIssued_930" use="optional" order="87" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_964" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_964" use="optional" order="88" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_965" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_965" use="optional" order="89" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ClassOfWarrantOrRightPercentageOfWarrantIssued" xlink:label="loc_ck0001680048_ClassOfWarrantOrRightPercentageOfWarrantIssued_966" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_ck0001680048_ClassOfWarrantOrRightPercentageOfWarrantIssued_966" use="optional" order="90" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1046" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1046" use="optional" order="91" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/SubsequentEventsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1039" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_407" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1039" xlink:to="loc_us-gaap_SubsequentEventTable_407" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_408" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_408" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_409" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_408" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_409" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_409_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_408" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_409_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_410" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_409" xlink:to="loc_us-gaap_SubsequentEventMember_410" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_411" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_dei_LegalEntityAxis_411" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_412" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_411" xlink:to="loc_dei_EntityDomain_412" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_412_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_411" xlink:to="loc_dei_EntityDomain_412_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_414" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_414" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_425" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_414" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_425" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_425_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_414" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_425_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_424" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_424" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_428" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_424" xlink:to="loc_us-gaap_EquityComponentDomain_428" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_428_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_424" xlink:to="loc_us-gaap_EquityComponentDomain_428_default" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_427" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_DebtInstrumentAxis_427" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_433" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_427" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_433" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_433_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_427" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_433_default" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_432" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_432" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_636" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_432" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_636" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_636_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_432" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_636_default" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_635" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_635" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_642" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_635" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_642" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_642_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_635" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_642_default" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_641" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_641" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_702" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_641" xlink:to="loc_us-gaap_RelatedPartyDomain_702" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_702_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_641" xlink:to="loc_us-gaap_RelatedPartyDomain_702_default" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_701" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_StatementClassOfStockAxis_701" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_706" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_701" xlink:to="loc_us-gaap_ClassOfStockDomain_706" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_706_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_701" xlink:to="loc_us-gaap_ClassOfStockDomain_706_default" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_705" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_TitleOfIndividualAxis_705" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_751" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_705" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_751" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_751_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_705" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_751_default" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_750" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_750" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_754" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_750" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_754" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_754_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_750" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_754_default" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_753" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_753" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1036" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_753" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1036" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1036_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_753" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1036_default" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_1037" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1036" xlink:to="loc_us-gaap_LetterOfCreditMember_1037" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1035" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_InvestmentTypeAxis_1035" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1040" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_1035" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1040" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1040_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_1035" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1040_default" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_1041" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1040" xlink:to="loc_us-gaap_CashMember_1041" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_1026" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1039" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_1026" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_1027" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1039" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_1027" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_1028" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1039" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_1028" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LandImprovements" xlink:label="loc_us-gaap_LandImprovements_1030" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1039" xlink:to="loc_us-gaap_LandImprovements_1030" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_1032" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1039" xlink:to="loc_us-gaap_SecurityDeposit_1032" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_1034" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1039" xlink:to="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_1034" use="optional" order="49" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/CommitmentsAndContingenciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_447" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_440" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_447" xlink:to="loc_us-gaap_LossContingenciesTable_440" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_441" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_440" xlink:to="loc_us-gaap_StatementClassOfStockAxis_441" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_442" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_441" xlink:to="loc_us-gaap_ClassOfStockDomain_442" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_442_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_441" xlink:to="loc_us-gaap_ClassOfStockDomain_442_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_443" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_440" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_443" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_448" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_443" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_448" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_448_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_443" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_448_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CityOfHopeMember" xlink:label="loc_ck0001680048_CityOfHopeMember_449" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_448" xlink:to="loc_ck0001680048_CityOfHopeMember_449" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_FailedContingencyDamagesAwardedPercentage" xlink:label="loc_ck0001680048_FailedContingencyDamagesAwardedPercentage_446" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_447" xlink:to="loc_ck0001680048_FailedContingencyDamagesAwardedPercentage_446" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_NumberOfSharesToBeIssuedUponLegalSettlement" xlink:label="loc_ck0001680048_NumberOfSharesToBeIssuedUponLegalSettlement_1056" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_447" xlink:to="loc_ck0001680048_NumberOfSharesToBeIssuedUponLegalSettlement_1056" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_1057" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_447" xlink:to="loc_us-gaap_LitigationSettlementExpense_1057" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_1058" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_447" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_1058" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/NetLossPerShareDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_823" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_502" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_823" xlink:to="loc_us-gaap_StatementTable_502" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_503" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_502" xlink:to="loc_us-gaap_StatementClassOfStockAxis_503" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_504" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_503" xlink:to="loc_us-gaap_ClassOfStockDomain_504" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_504_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_503" xlink:to="loc_us-gaap_ClassOfStockDomain_504_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_826" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_504" xlink:to="loc_us-gaap_PreferredClassAMember_826" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_505" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_502" xlink:to="loc_us-gaap_InvestmentTypeAxis_505" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_821" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_505" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_821" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_821_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_505" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_821_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_822" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_821" xlink:to="loc_us-gaap_WarrantMember_822" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_820" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_502" xlink:to="loc_us-gaap_AwardTypeAxis_820" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_824" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_824" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_824_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_824_default" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_825" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_824" xlink:to="loc_us-gaap_EmployeeStockOptionMember_825" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_UnvestedRestrictedStockAwardsMemberMember" xlink:label="loc_ck0001680048_UnvestedRestrictedStockAwardsMemberMember_827" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_824" xlink:to="loc_ck0001680048_UnvestedRestrictedStockAwardsMemberMember_827" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_828" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_824" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_828" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PotentiallyDilutiveSecurities" xlink:label="loc_ck0001680048_PotentiallyDilutiveSecurities_819" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_823" xlink:to="loc_ck0001680048_PotentiallyDilutiveSecurities_819" use="optional" order="16" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreementsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_777" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_773" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_777" xlink:to="loc_us-gaap_StatementTable_773" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_774" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_773" xlink:to="loc_us-gaap_StatementClassOfStockAxis_774" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_775" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_774" xlink:to="loc_us-gaap_ClassOfStockDomain_775" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_775_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_774" xlink:to="loc_us-gaap_ClassOfStockDomain_775_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_776" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_773" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_776" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_776" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_776" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ArIl13LicenseMember" xlink:label="loc_ck0001680048_ArIl13LicenseMember_779" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778" xlink:to="loc_ck0001680048_ArIl13LicenseMember_779" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_IvicvLicenseMember" xlink:label="loc_ck0001680048_IvicvLicenseMember_780" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778" xlink:to="loc_ck0001680048_IvicvLicenseMember_780" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PscaTechnologyLicenseMember" xlink:label="loc_ck0001680048_PscaTechnologyLicenseMember_808" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778" xlink:to="loc_ck0001680048_PscaTechnologyLicenseMember_808" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_Her2TechnologyLicenseMember" xlink:label="loc_ck0001680048_Her2TechnologyLicenseMember_809" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778" xlink:to="loc_ck0001680048_Her2TechnologyLicenseMember_809" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CsTechnologyLicenseMember" xlink:label="loc_ck0001680048_CsTechnologyLicenseMember_810" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778" xlink:to="loc_ck0001680048_CsTechnologyLicenseMember_810" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_UclaLicenseMember" xlink:label="loc_ck0001680048_UclaLicenseMember_781" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778" xlink:to="loc_ck0001680048_UclaLicenseMember_781" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_FredHutchCd20Member" xlink:label="loc_ck0001680048_FredHutchCd20Member_995" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778" xlink:to="loc_ck0001680048_FredHutchCd20Member_995" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_782" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_777" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_782" use="optional" order="15" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/StockholdersEquityDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_855" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_StatementTable_855" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_856" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_855" xlink:to="loc_us-gaap_StatementClassOfStockAxis_856" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_857" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_856" xlink:to="loc_us-gaap_ClassOfStockDomain_857" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_857_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_856" xlink:to="loc_us-gaap_ClassOfStockDomain_857_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_858" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_855" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_858" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_865" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_858" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_865" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_865_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_858" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_865_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_866" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_865" xlink:to="loc_us-gaap_EmployeeStockOptionMember_866" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_860" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_860" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_861" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_861" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_862" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_862" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_867" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_867" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_868" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_868" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_869" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_869" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_870" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_870" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_871" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_871" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_ck0001680048_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_885" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_ck0001680048_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_885" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_886" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_886" use="optional" order="18" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/StockholdersEquityDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_895" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_888" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_895" xlink:to="loc_us-gaap_StatementTable_888" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_889" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_888" xlink:to="loc_us-gaap_StatementClassOfStockAxis_889" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_890" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_889" xlink:to="loc_us-gaap_ClassOfStockDomain_890" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_890_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_889" xlink:to="loc_us-gaap_ClassOfStockDomain_890_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_891" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_888" xlink:to="loc_us-gaap_AwardTypeAxis_891" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_896" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_891" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_896" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_896_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_891" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_896_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_897" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_896" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_897" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_920" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_896" xlink:to="loc_us-gaap_RestrictedStockMember_920" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_892" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_895" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_892" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_894" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_895" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_894" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_898" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_895" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_898" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_900" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_895" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_900" use="optional" order="13" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/StockholdersEquityDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_915" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_902" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_915" xlink:to="loc_us-gaap_StatementTable_902" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_903" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_902" xlink:to="loc_us-gaap_StatementClassOfStockAxis_903" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_904" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_903" xlink:to="loc_us-gaap_ClassOfStockDomain_904" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_904_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_903" xlink:to="loc_us-gaap_ClassOfStockDomain_904_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_905" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_902" xlink:to="loc_us-gaap_AwardTypeAxis_905" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_912" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_902" xlink:to="loc_us-gaap_TitleOfIndividualAxis_912" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_916" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_912" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_916" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_916_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_912" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_916_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_EmployeeMember" xlink:label="loc_ck0001680048_EmployeeMember_917" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_916" xlink:to="loc_ck0001680048_EmployeeMember_917" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_NonEmployeeMember" xlink:label="loc_ck0001680048_NonEmployeeMember_918" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_916" xlink:to="loc_ck0001680048_NonEmployeeMember_918" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_919" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_915" xlink:to="loc_us-gaap_ShareBasedCompensation_919" use="optional" order="13" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/OrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherOwnershipInterestsLineItems" xlink:label="loc_us-gaap_OtherOwnershipInterestsLineItems_938" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:label="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable_937" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_938" xlink:to="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable_937" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_939" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable_937" xlink:to="loc_us-gaap_StatementClassOfStockAxis_939" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_940" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_939" xlink:to="loc_us-gaap_ClassOfStockDomain_940" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_940_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_939" xlink:to="loc_us-gaap_ClassOfStockDomain_940_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_942" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_938" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_942" use="optional" order="5" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_955" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_947" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_955" xlink:to="loc_us-gaap_StatementTable_947" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_948" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_947" xlink:to="loc_us-gaap_StatementClassOfStockAxis_948" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_949" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_948" xlink:to="loc_us-gaap_ClassOfStockDomain_949" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_949_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_948" xlink:to="loc_us-gaap_ClassOfStockDomain_949_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_950" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_947" xlink:to="loc_us-gaap_RangeAxis_950" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_956" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_950" xlink:to="loc_us-gaap_RangeMember_956" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_956_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_950" xlink:to="loc_us-gaap_RangeMember_956_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_957" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_956" xlink:to="loc_us-gaap_MaximumMember_957" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_958" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_956" xlink:to="loc_us-gaap_MinimumMember_958" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_951" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_951" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_993" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_993" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_954" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_955" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_954" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_953" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_953" use="optional" order="13" />
  </definitionLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>ck0001680048-20170930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 13-Nov-2017 [06:42:58] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />

  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_DocumentAndEntityInformationAbstract" xlink:label="loc_ck0001680048_DocumentAndEntityInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document And Entity Information [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_DocumentAndEntityInformationAbstract" xlink:to="lab_ck0001680048_DocumentAndEntityInformationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#39; EQUITY</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current Assets:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherShortTermInvestments" xml:lang="en-US">Other Short-term Investments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherShortTermInvestments" xml:lang="en-US">Short-term investments (certificates of deposit) - held to maturity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments" xlink:to="lab_us-gaap_OtherShortTermInvestments" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current Liabilities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CommonSharesIssuableLiabilityCurrent" xlink:label="loc_ck0001680048_CommonSharesIssuableLiabilityCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_CommonSharesIssuableLiabilityCurrent" xml:lang="en-US">Common Shares Issuable Liability Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ck0001680048_CommonSharesIssuableLiabilityCurrent" xml:lang="en-US">Common shares issuable liability</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_CommonSharesIssuableLiabilityCurrent" xml:lang="en-US">The common shares issuable liability for the current period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_CommonSharesIssuableLiabilityCurrent" xlink:to="lab_ck0001680048_CommonSharesIssuableLiabilityCurrent" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent" xlink:label="loc_ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent" xml:lang="en-US">Payables and Accrued Expenses Related Parties Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent" xml:lang="en-US">Payables and accrued expenses - related party</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent" xml:lang="en-US">Sum of the carrying values as of the balance sheet date realted to related party obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent" xlink:to="lab_ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AccruedInterestRelatedPartyCurrent" xlink:label="loc_ck0001680048_AccruedInterestRelatedPartyCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_AccruedInterestRelatedPartyCurrent" xml:lang="en-US">Accrued Interest Related Party Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001680048_AccruedInterestRelatedPartyCurrent" xml:lang="en-US">Accrued interest - related party</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_AccruedInterestRelatedPartyCurrent" xml:lang="en-US">Carrying value as of the balance sheet date of [accrued] interest payable on all forms of related party debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_AccruedInterestRelatedPartyCurrent" xlink:to="lab_ck0001680048_AccruedInterestRelatedPartyCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total Current Liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders&#39; Equity Attributable to Parent [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders&#39; Equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock ($0.0001 par value), 2,000,000 shares authorized, 250,000 shares of Class A preferred stock issued and outstanding as of September 30, 2017 and December 31, 2016, respectively</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Common Class A [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Class A Common Shares [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesSubscriptions" xml:lang="en-US">Common Stock, Value, Subscriptions</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesSubscriptions" xml:lang="en-US">Common stock issuable, 0 and 767,264 shares as of September 30, 2017 and December 31, 2016, respectively</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesSubscriptions" xlink:to="lab_us-gaap_CommonStockSharesSubscriptions" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders&#39; Equity Attributable to Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders&#39; Equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balances</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balances</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders&#39; Equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Class A Preferred Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesSubscribedButUnissued" xml:lang="en-US">Common Stock, Shares Subscribed but Unissued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="lab_us-gaap_CommonStockSharesSubscribedButUnissued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xml:lang="en-US">Research and development</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xml:lang="en-US">Research and Development in Process</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xml:lang="en-US">Research and development - licenses acquired</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xml:lang="en-US">Research and development - licenses acquired</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest Income, Other</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest income</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_InterestIncomeExpensesRelatedParty" xlink:label="loc_ck0001680048_InterestIncomeExpensesRelatedParty" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_InterestIncomeExpensesRelatedParty" xml:lang="en-US">Interest Income Expenses, Related Party</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001680048_InterestIncomeExpensesRelatedParty" xml:lang="en-US">Interest expense - related party</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_InterestIncomeExpensesRelatedParty" xml:lang="en-US">The amount of interest income (expenses) from (to) related party.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_InterestIncomeExpensesRelatedParty" xlink:to="lab_ck0001680048_InterestIncomeExpensesRelatedParty" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest Expense, Debt</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Loss</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share outstanding, basic and diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted net loss per common share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average number of common shares outstanding, basic and diluted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xml:lang="en-US">Research and development-licenses acquired, expensed</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses" xlink:label="loc_ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses" xml:lang="en-US">Issuance Of Common Stock, Founder Agreement Expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses" xml:lang="en-US">Issuance of common shares - Founders Agreement</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses" xml:lang="en-US">Expenses relates to issuance of common stock under founder agreement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses" xlink:to="lab_ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of debt discount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of debt discount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">NSC Note Payable Net, Amortization of debt discount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xml:lang="en-US">Interest receivables</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash Flows from Investing Activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xml:lang="en-US">Payments to Acquire Held-to-maturity Securities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xml:lang="en-US">Purchase of short-term investment (certificates of deposit)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Payments to Acquire Intangible Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Purchase of research and development licenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash Flows from Financing Activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Proceeds from Related Party Debt</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Proceeds from Fortress Note</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayments of Related Party Debt</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xml:lang="en-US">Payment of Fortress Note</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ProceedsFromNotesPayableGross" xlink:label="loc_ck0001680048_ProceedsFromNotesPayableGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_ProceedsFromNotesPayableGross" xml:lang="en-US">Proceeds From Notes Payable, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ck0001680048_ProceedsFromNotesPayableGross" xml:lang="en-US">Proceeds from NSC Note</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_ProceedsFromNotesPayableGross" xml:lang="en-US">The amount of gross cash inflow from a borrowing supported by a written promise to pay an obligation.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_ProceedsFromNotesPayableGross" xlink:to="lab_ck0001680048_ProceedsFromNotesPayableGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xml:lang="en-US">Construction in Progress Expenditures Incurred but Not yet Paid</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xml:lang="en-US">Construction-in-progress included in accounts payable and accrued expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Stock Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Issuance of common shares - Founders Agreement</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Proceeds from issuance of common stock and warrants, offering cost</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SignificantAccountingPoliciesPolicyTextBlock" xlink:label="loc_ck0001680048_SignificantAccountingPoliciesPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_SignificantAccountingPoliciesPolicyTextBlock" xml:lang="en-US">Significant Accounting Policies [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_SignificantAccountingPoliciesPolicyTextBlock" xml:lang="en-US">These lines are represents policy disclosure of significant accounting policies.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_SignificantAccountingPoliciesPolicyTextBlock" xlink:to="lab_ck0001680048_SignificantAccountingPoliciesPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_LicenseAgreementDisclosureAbstract" xlink:label="loc_ck0001680048_LicenseAgreementDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_LicenseAgreementDisclosureAbstract" xml:lang="en-US">License Agreement Disclosure [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_LicenseAgreementDisclosureAbstract" xlink:to="lab_ck0001680048_LicenseAgreementDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_LicenseAgreementDisclosureTextBlock" xlink:label="loc_ck0001680048_LicenseAgreementDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_LicenseAgreementDisclosureTextBlock" xml:lang="en-US">License Agreement Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_LicenseAgreementDisclosureTextBlock" xml:lang="en-US">Disclosure of accounting policy for license agreement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_LicenseAgreementDisclosureTextBlock" xlink:to="lab_ck0001680048_LicenseAgreementDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CityOfHopeMember" xlink:label="loc_ck0001680048_CityOfHopeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_CityOfHopeMember" xml:lang="en-US">City Of Hope [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ck0001680048_CityOfHopeMember" xml:lang="en-US">City Of Hope [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_CityOfHopeMember" xlink:to="lab_ck0001680048_CityOfHopeMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PaymentOfUpfrontFees" xlink:label="loc_ck0001680048_PaymentOfUpfrontFees" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_PaymentOfUpfrontFees" xml:lang="en-US">Payment Of Upfront Fees</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_PaymentOfUpfrontFees" xml:lang="en-US">Payment of Upfront Fees</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_PaymentOfUpfrontFees" xlink:to="lab_ck0001680048_PaymentOfUpfrontFees" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue" xlink:label="loc_ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue" xml:lang="en-US">Revenue Recognition Milestone Method Payments Due</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue" xml:lang="en-US">The amount of consideration eligible to receive during the period for the milestone or milestones.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue" xlink:to="lab_ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ResearchAndDevelopmentExpenseSponsoredResearchPayment" xlink:label="loc_ck0001680048_ResearchAndDevelopmentExpenseSponsoredResearchPayment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_ResearchAndDevelopmentExpenseSponsoredResearchPayment" xml:lang="en-US">Research And Development Expense, Sponsored Research Payment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_ResearchAndDevelopmentExpenseSponsoredResearchPayment" xml:lang="en-US">The amount of research and development expense payable on achieving milestone targets.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_ResearchAndDevelopmentExpenseSponsoredResearchPayment" xlink:to="lab_ck0001680048_ResearchAndDevelopmentExpenseSponsoredResearchPayment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Change in fair value of derivative liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Change in fair value of derivative liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders&#39; Equity [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Shares [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CommonStockIssuableMember" xlink:label="loc_ck0001680048_CommonStockIssuableMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_CommonStockIssuableMember" xml:lang="en-US">Common Stock Issuable [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ck0001680048_CommonStockIssuableMember" xml:lang="en-US">Common Stock Issuable [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_CommonStockIssuableMember" xlink:to="lab_ck0001680048_CommonStockIssuableMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balances (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balances (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Issuance of common shares - Founders Agreement</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Issuance of common shares - Founders Agreement (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xml:lang="en-US">Stock Issued During Period, Value, Purchase of Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xml:lang="en-US">Issuance of common shares for license expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xml:lang="en-US">Issuance of common shares for license expenses (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of common shares and warrants for cash</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of common shares and warrants for cash (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">Offering cost</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Stock-based compensation expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_FortressBiotechIncMember" xlink:label="loc_ck0001680048_FortressBiotechIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_FortressBiotechIncMember" xml:lang="en-US">Fortress Biotech, Inc [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_FortressBiotechIncMember" xlink:to="lab_ck0001680048_FortressBiotechIncMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Common Class B [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Common Shares Class B [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ChordAdvisorsLlcMember" xlink:label="loc_ck0001680048_ChordAdvisorsLlcMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_ChordAdvisorsLlcMember" xml:lang="en-US">Chord Advisors, LLC [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_ChordAdvisorsLlcMember" xlink:to="lab_ck0001680048_ChordAdvisorsLlcMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_NationalHoldingsIncMember" xlink:label="loc_ck0001680048_NationalHoldingsIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_NationalHoldingsIncMember" xml:lang="en-US">National Holdings, Inc. [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_NationalHoldingsIncMember" xlink:to="lab_ck0001680048_NationalHoldingsIncMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_FoundersAgreementTerm" xlink:label="loc_ck0001680048_FoundersAgreementTerm" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_FoundersAgreementTerm" xml:lang="en-US">Founders Agreement Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_FoundersAgreementTerm" xml:lang="en-US">This element represents the agreement term with the founders.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_FoundersAgreementTerm" xlink:to="lab_ck0001680048_FoundersAgreementTerm" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Conversion of Stock, Shares Issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaap_PreferredStockVotingRights" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockVotingRights" xml:lang="en-US">Preferred Stock, Voting Rights</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockVotingRights" xlink:to="lab_us-gaap_PreferredStockVotingRights" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AdditionalConsiderationUnderFoundersAgreementDescription" xlink:label="loc_ck0001680048_AdditionalConsiderationUnderFoundersAgreementDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_AdditionalConsiderationUnderFoundersAgreementDescription" xml:lang="en-US">Additional Consideration Under Founders Agreement Description</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_AdditionalConsiderationUnderFoundersAgreementDescription" xml:lang="en-US">This element represents the description of the additional consideration payable to the founders as per the founders agreement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_AdditionalConsiderationUnderFoundersAgreementDescription" xlink:to="lab_ck0001680048_AdditionalConsiderationUnderFoundersAgreementDescription" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AnnualConsultingFees" xlink:label="loc_ck0001680048_AnnualConsultingFees" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_AnnualConsultingFees" xml:lang="en-US">Annual Consulting Fees</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_AnnualConsultingFees" xml:lang="en-US">This element represents the amount of annual consulting fees.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_AnnualConsultingFees" xlink:to="lab_ck0001680048_AnnualConsultingFees" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_IncreaseInAnnualConsultingFees" xlink:label="loc_ck0001680048_IncreaseInAnnualConsultingFees" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_IncreaseInAnnualConsultingFees" xml:lang="en-US">Increase In Annual Consulting Fees</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_IncreaseInAnnualConsultingFees" xml:lang="en-US">This element represents the increase in the amount of annual consulting fees.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_IncreaseInAnnualConsultingFees" xlink:to="lab_ck0001680048_IncreaseInAnnualConsultingFees" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ExcessInNetAssetsValue" xlink:label="loc_ck0001680048_ExcessInNetAssetsValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_ExcessInNetAssetsValue" xml:lang="en-US">Excess In Net Assets Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_ExcessInNetAssetsValue" xml:lang="en-US">This element represents the amount of net assets in excess of liabilities.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_ExcessInNetAssetsValue" xlink:to="lab_ck0001680048_ExcessInNetAssetsValue" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AnnualFeesExpensesOnFoundersAgreement" xlink:label="loc_ck0001680048_AnnualFeesExpensesOnFoundersAgreement" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_AnnualFeesExpensesOnFoundersAgreement" xml:lang="en-US">Annual Fees Expenses On Founders Agreement</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_AnnualFeesExpensesOnFoundersAgreement" xml:lang="en-US">This element represents the amount of expenses on the founders agreement for annual fees.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_AnnualFeesExpensesOnFoundersAgreement" xlink:to="lab_ck0001680048_AnnualFeesExpensesOnFoundersAgreement" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_BackOfficeAccountingFunctionsExpenses" xlink:label="loc_ck0001680048_BackOfficeAccountingFunctionsExpenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_BackOfficeAccountingFunctionsExpenses" xml:lang="en-US">Back Office Accounting Functions Expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_BackOfficeAccountingFunctionsExpenses" xml:lang="en-US">This element represents the amount of expenses on the back office accounting functions.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_BackOfficeAccountingFunctionsExpenses" xlink:to="lab_ck0001680048_BackOfficeAccountingFunctionsExpenses" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AccountingAnalysisAndFinancialReportingFees" xlink:label="loc_ck0001680048_AccountingAnalysisAndFinancialReportingFees" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_AccountingAnalysisAndFinancialReportingFees" xml:lang="en-US">Accounting Analysis And Financial Reporting Fees</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_AccountingAnalysisAndFinancialReportingFees" xml:lang="en-US">This element represents the amount of expenses on the accounting analysis and financial reporting.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_AccountingAnalysisAndFinancialReportingFees" xlink:to="lab_ck0001680048_AccountingAnalysisAndFinancialReportingFees" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfessionalFees" xml:lang="en-US">Professional Fees</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaap_PaymentsForFees" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForFees" xml:lang="en-US">Payments for Other Fees</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForFees" xlink:to="lab_us-gaap_PaymentsForFees" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders&#39; Equity Note [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders&#39; Equity Note Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" xlink:label="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" xml:lang="en-US">Warrants, Outstanding Beginning of year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" xml:lang="en-US">Warrants, Outstanding End of year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" xml:lang="en-US">The number of outstanding equity instruments other then option.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" xlink:to="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Warrants, Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other Than Options, Outstanding, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Beginning of year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding End of year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:label="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other Than Options, Granted, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice" xml:lang="en-US">Weighted average per share amount at which grantees can acquire shares of common stock by exercise of equity instruments other than options.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:to="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms" xlink:label="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted in Period, Weighted Average Remaining Contractual Terms</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms" xml:lang="en-US">Weighted Average Remaining Contractual Life, Granted (in years)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms" xml:lang="en-US">Weighted average remaining contractual term for equity-based awards excluding options</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms" xlink:to="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Weighted Average Remaining Contractual Life, Outstanding (in years)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockVotingRights" xml:lang="en-US">Common Stock, Voting Rights</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockVotingRights" xlink:to="lab_us-gaap_CommonStockVotingRights" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PercentageOfPlacementAgentFee" xlink:label="loc_ck0001680048_PercentageOfPlacementAgentFee" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_PercentageOfPlacementAgentFee" xml:lang="en-US">Percentage Of Placement Agent Fee</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_PercentageOfPlacementAgentFee" xml:lang="en-US">It represents the percentage of placement agent fee.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_PercentageOfPlacementAgentFee" xlink:to="lab_ck0001680048_PercentageOfPlacementAgentFee" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PercentageOfSharesIssuedToPlacementAgent" xlink:label="loc_ck0001680048_PercentageOfSharesIssuedToPlacementAgent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_PercentageOfSharesIssuedToPlacementAgent" xml:lang="en-US">Percentage Of Shares Issued To Placement Agent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_PercentageOfSharesIssuedToPlacementAgent" xml:lang="en-US">The percentage of shares issued to the placement agent.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_PercentageOfSharesIssuedToPlacementAgent" xlink:to="lab_ck0001680048_PercentageOfSharesIssuedToPlacementAgent" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_WarrantPurchasePricePerUnit" xlink:label="loc_ck0001680048_WarrantPurchasePricePerUnit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_WarrantPurchasePricePerUnit" xml:lang="en-US">Warrant Purchase Price Per Unit</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_WarrantPurchasePricePerUnit" xml:lang="en-US">The amount of warrant purchase price per unit.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_WarrantPurchasePricePerUnit" xlink:to="lab_ck0001680048_WarrantPurchasePricePerUnit" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_WarrantsIssued" xlink:label="loc_ck0001680048_WarrantsIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_WarrantsIssued" xml:lang="en-US">Warrants Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_WarrantsIssued" xml:lang="en-US">Number of warrants issued during the reporting period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_WarrantsIssued" xlink:to="lab_ck0001680048_WarrantsIssued" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_NationalHoldingsCorporationMember" xlink:label="loc_ck0001680048_NationalHoldingsCorporationMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_NationalHoldingsCorporationMember" xml:lang="en-US">National Holdings Corporation [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_NationalHoldingsCorporationMember" xlink:to="lab_ck0001680048_NationalHoldingsCorporationMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharesOfCommonStockPercentage" xlink:label="loc_ck0001680048_SharesOfCommonStockPercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_SharesOfCommonStockPercentage" xml:lang="en-US">Shares Of Common Stock, Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_SharesOfCommonStockPercentage" xml:lang="en-US">It represents of the percentage rate of common stock.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_SharesOfCommonStockPercentage" xlink:to="lab_ck0001680048_SharesOfCommonStockPercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesTable" xml:lang="en-US">Loss Contingencies [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_FailedContingencyDamagesAwardedPercentage" xlink:label="loc_ck0001680048_FailedContingencyDamagesAwardedPercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_FailedContingencyDamagesAwardedPercentage" xml:lang="en-US">Failed Contingency Damages Awarded Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_FailedContingencyDamagesAwardedPercentage" xml:lang="en-US">Percentage of failed contingency damages awarded to the plaintiff in the legal matter.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_FailedContingencyDamagesAwardedPercentage" xlink:to="lab_ck0001680048_FailedContingencyDamagesAwardedPercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesLineItems" xml:lang="en-US">Loss Contingencies [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net change in cash and cash equivalents</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_UnregisteredCommonStockMember" xlink:label="loc_ck0001680048_UnregisteredCommonStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_UnregisteredCommonStockMember" xml:lang="en-US">Unregistered Common Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_UnregisteredCommonStockMember" xlink:to="lab_ck0001680048_UnregisteredCommonStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Payments of Debt Issuance Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Payment of debt issue costs associated with NSC Note</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Stock-based compensation expenses (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AdjustmentToAdditionalPaidInCapitalCapitalContribution" xlink:label="loc_ck0001680048_AdjustmentToAdditionalPaidInCapitalCapitalContribution" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_AdjustmentToAdditionalPaidInCapitalCapitalContribution" xml:lang="en-US">Adjustment To Additional Paid In Capital, Capital Contribution</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ck0001680048_AdjustmentToAdditionalPaidInCapitalCapitalContribution" xml:lang="en-US">Capital contribution from Fortress</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_AdjustmentToAdditionalPaidInCapitalCapitalContribution" xml:lang="en-US">The increase in additional paid in capital due to capital contribution from parent entity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_AdjustmentToAdditionalPaidInCapitalCapitalContribution" xlink:to="lab_ck0001680048_AdjustmentToAdditionalPaidInCapitalCapitalContribution" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US">Capital contribution from Fortress</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of offering cost of $5,674 and $0, respectively</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AgreementTypeAxis" xlink:label="loc_ck0001680048_AgreementTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_AgreementTypeAxis" xml:lang="en-US">Agreement Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_AgreementTypeAxis" xlink:to="lab_ck0001680048_AgreementTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Options granted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_DilutedOutstandingEquityPercentage" xlink:label="loc_ck0001680048_DilutedOutstandingEquityPercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_DilutedOutstandingEquityPercentage" xml:lang="en-US">Diluted Outstanding Equity, Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_DilutedOutstandingEquityPercentage" xml:lang="en-US">Represents the percentage of diluted outstanding equity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_DilutedOutstandingEquityPercentage" xlink:to="lab_ck0001680048_DilutedOutstandingEquityPercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CityOfHopeNationalMedicalCenterMember" xlink:label="loc_ck0001680048_CityOfHopeNationalMedicalCenterMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_CityOfHopeNationalMedicalCenterMember" xml:lang="en-US">City of Hope National Medical Center [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_CityOfHopeNationalMedicalCenterMember" xlink:to="lab_ck0001680048_CityOfHopeNationalMedicalCenterMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalUnitsByClassAxis" xml:lang="en-US">Capital Units by Class [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis" xlink:to="lab_us-gaap_CapitalUnitsByClassAxis" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AgreementTypeDomain" xlink:label="loc_ck0001680048_AgreementTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_AgreementTypeDomain" xml:lang="en-US">Agreement Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_AgreementTypeDomain" xlink:to="lab_ck0001680048_AgreementTypeDomain" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_LicenseAgreementMember" xlink:label="loc_ck0001680048_LicenseAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_LicenseAgreementMember" xml:lang="en-US">License Agreement [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ck0001680048_LicenseAgreementMember" xml:lang="en-US">Original Agreement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_LicenseAgreementMember" xlink:to="lab_ck0001680048_LicenseAgreementMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalUnitClassDomain" xml:lang="en-US">Capital Unit, Class [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalUnitClassDomain" xlink:to="lab_us-gaap_CapitalUnitClassDomain" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_NationalSecuritiesIncMember" xlink:label="loc_ck0001680048_NationalSecuritiesIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_NationalSecuritiesIncMember" xml:lang="en-US">National Securities, Inc [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_NationalSecuritiesIncMember" xlink:to="lab_ck0001680048_NationalSecuritiesIncMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleCommonStockMember" xlink:label="loc_us-gaap_ConvertibleCommonStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleCommonStockMember" xml:lang="en-US">Convertible Common Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleCommonStockMember" xlink:to="lab_us-gaap_ConvertibleCommonStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents, beginning of the period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents, end of the period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Cash paid for interest</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xml:lang="en-US">Liabilities Assumed</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xml:lang="en-US">Warrant liability associated with NSC Note</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_StephenFormanMember" xlink:label="loc_ck0001680048_StephenFormanMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_StephenFormanMember" xml:lang="en-US">Stephen Forman [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_StephenFormanMember" xlink:to="lab_ck0001680048_StephenFormanMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ChristineBrownMember" xlink:label="loc_ck0001680048_ChristineBrownMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_ChristineBrownMember" xml:lang="en-US">Christine Brown [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_ChristineBrownMember" xlink:to="lab_ck0001680048_ChristineBrownMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredClassAMember" xml:lang="en-US">Preferred Class A [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredClassAMember" xlink:to="lab_us-gaap_PreferredClassAMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties" xml:lang="en-US">Increase (Decrease) in Due to Related Parties</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties" xml:lang="en-US">Payable and accrued expenses - related party</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xml:lang="en-US">Accrued interest - related party</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Other income/(expense)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other income (expense)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xml:lang="en-US">Option Indexed to Issuer&#39;s Equity [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xml:lang="en-US">Option Indexed to Issuer&#39;s Equity, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_LicensingArrangementsAdditionalCostsIncurred" xlink:label="loc_ck0001680048_LicensingArrangementsAdditionalCostsIncurred" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_LicensingArrangementsAdditionalCostsIncurred" xml:lang="en-US">Licensing Arrangements Additional Costs Incurred</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_LicensingArrangementsAdditionalCostsIncurred" xml:lang="en-US">Represents the additional costs incurred under licensing arrangement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_LicensingArrangementsAdditionalCostsIncurred" xlink:to="lab_ck0001680048_LicensingArrangementsAdditionalCostsIncurred" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ArCd123LicenseMember" xlink:label="loc_ck0001680048_ArCd123LicenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_ArCd123LicenseMember" xml:lang="en-US">AR CD123 License [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_ArCd123LicenseMember" xlink:to="lab_ck0001680048_ArCd123LicenseMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_IlLicenseMember" xlink:label="loc_ck0001680048_IlLicenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_IlLicenseMember" xml:lang="en-US">IL License [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_IlLicenseMember" xlink:to="lab_ck0001680048_IlLicenseMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AdvisorMember" xlink:label="loc_ck0001680048_AdvisorMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_AdvisorMember" xml:lang="en-US">Advisor [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_AdvisorMember" xlink:to="lab_ck0001680048_AdvisorMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_LicenseAgreementDisclosureAbstractAbstract" xlink:label="loc_ck0001680048_LicenseAgreementDisclosureAbstractAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_LicenseAgreementDisclosureAbstractAbstract" xml:lang="en-US">License Agreement Disclosure Abstract [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_LicenseAgreementDisclosureAbstractAbstract" xlink:to="lab_ck0001680048_LicenseAgreementDisclosureAbstractAbstract" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ArIl13LicenseMember" xlink:label="loc_ck0001680048_ArIl13LicenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_ArIl13LicenseMember" xml:lang="en-US">AR IL-13 License [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001680048_ArIl13LicenseMember" xml:lang="en-US">IL13Ra2 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_ArIl13LicenseMember" xlink:to="lab_ck0001680048_ArIl13LicenseMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_IvicvLicenseMember" xlink:label="loc_ck0001680048_IvicvLicenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_IvicvLicenseMember" xml:lang="en-US">IVICV License [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ck0001680048_IvicvLicenseMember" xml:lang="en-US">IV/ICV [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_IvicvLicenseMember" xlink:to="lab_ck0001680048_IvicvLicenseMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PscaTechnologyLicenseMember" xlink:label="loc_ck0001680048_PscaTechnologyLicenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_PscaTechnologyLicenseMember" xml:lang="en-US">Psca Technology License [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ck0001680048_PscaTechnologyLicenseMember" xml:lang="en-US">PSCA [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_PscaTechnologyLicenseMember" xlink:to="lab_ck0001680048_PscaTechnologyLicenseMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_UclaLicenseMember" xlink:label="loc_ck0001680048_UclaLicenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_UclaLicenseMember" xml:lang="en-US">UCLA License [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ck0001680048_UclaLicenseMember" xml:lang="en-US">UCLA [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_UclaLicenseMember" xlink:to="lab_ck0001680048_UclaLicenseMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_UniversityOfCaliforniaMember" xlink:label="loc_ck0001680048_UniversityOfCaliforniaMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_UniversityOfCaliforniaMember" xml:lang="en-US">University of California [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_UniversityOfCaliforniaMember" xlink:to="lab_ck0001680048_UniversityOfCaliforniaMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForConstructionInProcess" xlink:label="loc_us-gaap_PaymentsForConstructionInProcess" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForConstructionInProcess" xml:lang="en-US">Payments for Construction in Process</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForConstructionInProcess" xml:lang="en-US">Purchase of fixed assets - construction-in-process</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForConstructionInProcess" xlink:to="lab_us-gaap_PaymentsForConstructionInProcess" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_Her2TechnologyLicenseMember" xlink:label="loc_ck0001680048_Her2TechnologyLicenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_Her2TechnologyLicenseMember" xml:lang="en-US">Her2 Technology License [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ck0001680048_Her2TechnologyLicenseMember" xml:lang="en-US">HER2 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_Her2TechnologyLicenseMember" xlink:to="lab_ck0001680048_Her2TechnologyLicenseMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CsTechnologyLicenseMember" xlink:label="loc_ck0001680048_CsTechnologyLicenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_CsTechnologyLicenseMember" xml:lang="en-US">Cs Technology License [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ck0001680048_CsTechnologyLicenseMember" xml:lang="en-US">CS1 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_CsTechnologyLicenseMember" xlink:to="lab_ck0001680048_CsTechnologyLicenseMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PotentiallyDilutiveSecurities" xlink:label="loc_ck0001680048_PotentiallyDilutiveSecurities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_PotentiallyDilutiveSecurities" xml:lang="en-US">Potentially Dilutive Securities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_PotentiallyDilutiveSecurities" xml:lang="en-US">Number of shares Classification of diluted net loss per share.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_PotentiallyDilutiveSecurities" xlink:to="lab_ck0001680048_PotentiallyDilutiveSecurities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Option [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_UnvestedRestrictedStockAwardsMemberMember" xlink:label="loc_ck0001680048_UnvestedRestrictedStockAwardsMemberMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_UnvestedRestrictedStockAwardsMemberMember" xml:lang="en-US">Unvested Restricted Stock Awards Member [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_UnvestedRestrictedStockAwardsMemberMember" xlink:to="lab_ck0001680048_UnvestedRestrictedStockAwardsMemberMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_us-gaap_MaintenanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MaintenanceCosts" xml:lang="en-US">Maintenance Costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaintenanceCosts" xlink:to="lab_us-gaap_MaintenanceCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DirectorMember" xml:lang="en-US">Director [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectorMember" xlink:to="lab_us-gaap_DirectorMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Description</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsTableTextBlock" xlink:label="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsTableTextBlock" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsTableTextBlock" xml:lang="en-US">Tabular disclosure of Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsTableTextBlock" xlink:to="lab_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_us-gaap_BoardOfDirectorsChairmanMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BoardOfDirectorsChairmanMember" xml:lang="en-US">Board of Directors Chairman [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BoardOfDirectorsChairmanMember" xlink:to="lab_us-gaap_BoardOfDirectorsChairmanMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xml:lang="en-US">Option Indexed to Issuer&#39;s Equity, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xml:lang="en-US">Number of Nonvested at December 31, 2016</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xml:lang="en-US">Number of Nonvested at September 30, 2017</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Options vested and exercisable at September 30, 2017</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Nonvested Beginning Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Options granted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Options outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value Nonvested at December 31, 2016</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value Nonvested at September 30, 2017</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Options vested and exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Life, Options outstanding (in years)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_ck0001680048_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Options Granted Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_ck0001680048_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Weighted Average Remaining Contractual Life, Options granted (in years)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Options Granted Weighted Average Remaining Contractual Term</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="lab_ck0001680048_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Life, Options vested and exercisable (in years)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_EmployeeMember" xlink:label="loc_ck0001680048_EmployeeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_EmployeeMember" xml:lang="en-US">Employee [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_EmployeeMember" xlink:to="lab_ck0001680048_EmployeeMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_NonEmployeeMember" xlink:label="loc_ck0001680048_NonEmployeeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_NonEmployeeMember" xml:lang="en-US">Non Employee [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_NonEmployeeMember" xlink:to="lab_ck0001680048_NonEmployeeMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:label="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherOwnershipInterestsTable" xml:lang="en-US">Schedule of Other Ownership Interests [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:to="lab_us-gaap_ScheduleOfOtherOwnershipInterestsTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherOwnershipInterestsLineItems" xlink:label="loc_us-gaap_OtherOwnershipInterestsLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOwnershipInterestsLineItems" xml:lang="en-US">Other Ownership Interests [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems" xlink:to="lab_us-gaap_OtherOwnershipInterestsLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SpacerLicenseMember" xlink:label="loc_ck0001680048_SpacerLicenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_SpacerLicenseMember" xml:lang="en-US">Spacer License [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_SpacerLicenseMember" xlink:to="lab_ck0001680048_SpacerLicenseMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis" xlink:to="lab_us-gaap_RangeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Exercise Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term in years</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember" xlink:to="lab_us-gaap_RangeMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember" xlink:to="lab_us-gaap_MaximumMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember" xlink:to="lab_us-gaap_MinimumMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths" xml:lang="en-US">Other Commitment, Due in Next Twelve Months</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:to="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInThirdYear" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentDueInThirdYear" xml:lang="en-US">Other Commitment, Due in Third Year</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInThirdYear" xlink:to="lab_us-gaap_OtherCommitmentDueInThirdYear" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInSecondYear" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentDueInSecondYear" xml:lang="en-US">Other Commitment, Due in Second Year</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInSecondYear" xlink:to="lab_us-gaap_OtherCommitmentDueInSecondYear" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInFifthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFifthYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentDueInFifthYear" xml:lang="en-US">Other Commitment, Due in Fifth Year</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInFifthYear" xlink:to="lab_us-gaap_OtherCommitmentDueInFifthYear" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInFourthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentDueInFourthYear" xml:lang="en-US">Other Commitment, Due in Fourth Year</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInFourthYear" xlink:to="lab_us-gaap_OtherCommitmentDueInFourthYear" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ClassOfWarrantOrRightPercentageOfWarrantIssued" xlink:label="loc_ck0001680048_ClassOfWarrantOrRightPercentageOfWarrantIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_ClassOfWarrantOrRightPercentageOfWarrantIssued" xml:lang="en-US">Class Of Warrant Or Right, Percentage Of Warrant Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_ClassOfWarrantOrRightPercentageOfWarrantIssued" xml:lang="en-US">The percentage of warrants the investors received in the offering.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_ClassOfWarrantOrRightPercentageOfWarrantIssued" xlink:to="lab_ck0001680048_ClassOfWarrantOrRightPercentageOfWarrantIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AnnualFeesExpensesOnFoundersAgreementPercentage" xlink:label="loc_ck0001680048_AnnualFeesExpensesOnFoundersAgreementPercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_AnnualFeesExpensesOnFoundersAgreementPercentage" xml:lang="en-US">Annual Fees Expenses On Founders Agreement Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_AnnualFeesExpensesOnFoundersAgreementPercentage" xml:lang="en-US">Percentage of expenses recognized under respective heads of consolidated statement of operations.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_AnnualFeesExpensesOnFoundersAgreementPercentage" xlink:to="lab_ck0001680048_AnnualFeesExpensesOnFoundersAgreementPercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficersCompensation" xml:lang="en-US">Officers&#39; Compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficersCompensation" xlink:to="lab_us-gaap_OfficersCompensation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaap_InterestReceivableCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestReceivableCurrent" xml:lang="en-US">Interest Receivable, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestReceivableCurrent" xml:lang="en-US">Interest receivables</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_StockIssuableForLicenseAcquired" xlink:label="loc_ck0001680048_StockIssuableForLicenseAcquired" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_StockIssuableForLicenseAcquired" xml:lang="en-US">Stock Issuable for License Acquired</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ck0001680048_StockIssuableForLicenseAcquired" xml:lang="en-US">Common shares issuable for license acquired</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_StockIssuableForLicenseAcquired" xml:lang="en-US">The fair value of stock issuable for license acquired in noncash investing and financing activities.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_StockIssuableForLicenseAcquired" xlink:to="lab_ck0001680048_StockIssuableForLicenseAcquired" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_FredHutchCd20Member" xlink:label="loc_ck0001680048_FredHutchCd20Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_FredHutchCd20Member" xml:lang="en-US">Fred Hutch CD20 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_FredHutchCd20Member" xlink:to="lab_ck0001680048_FredHutchCd20Member" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_ck0001680048_FredHutchinsonCancerResearchCenterMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_FredHutchinsonCancerResearchCenterMember" xml:lang="en-US">Fred Hutchinson Cancer Research Center [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_FredHutchinsonCancerResearchCenterMember" xlink:to="lab_ck0001680048_FredHutchinsonCancerResearchCenterMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_Cd20TechnologyLicenseMember" xlink:label="loc_ck0001680048_Cd20TechnologyLicenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_Cd20TechnologyLicenseMember" xml:lang="en-US">CD20 Technology License [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_Cd20TechnologyLicenseMember" xlink:to="lab_ck0001680048_Cd20TechnologyLicenseMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_Cd20ClinicalAgreementMember" xlink:label="loc_ck0001680048_Cd20ClinicalAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_Cd20ClinicalAgreementMember" xml:lang="en-US">CD20 Clinical Agreement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_Cd20ClinicalAgreementMember" xlink:to="lab_ck0001680048_Cd20ClinicalAgreementMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_DevelopmentMilestonesMethodAdditionalPaymentsDue" xlink:label="loc_ck0001680048_DevelopmentMilestonesMethodAdditionalPaymentsDue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_DevelopmentMilestonesMethodAdditionalPaymentsDue" xml:lang="en-US">Development Milestones Method Additional Payments Due</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_DevelopmentMilestonesMethodAdditionalPaymentsDue" xml:lang="en-US">The amount of additional payment to be made for the development milestone or milestones.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_DevelopmentMilestonesMethodAdditionalPaymentsDue" xlink:to="lab_ck0001680048_DevelopmentMilestonesMethodAdditionalPaymentsDue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TimeDepositsAtCarryingValue" xlink:label="loc_us-gaap_TimeDepositsAtCarryingValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TimeDepositsAtCarryingValue" xml:lang="en-US">Time Deposits, at Carrying Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimeDepositsAtCarryingValue" xlink:to="lab_us-gaap_TimeDepositsAtCarryingValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xml:lang="en-US">Debt Security Category [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xml:lang="en-US">Land Subject to Ground Leases</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xml:lang="en-US">Operating Leases, Rent Expense, Sublease Rentals</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LandImprovements" xlink:label="loc_us-gaap_LandImprovements" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LandImprovements" xml:lang="en-US">Land Improvements</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandImprovements" xlink:to="lab_us-gaap_LandImprovements" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecurityDeposit" xml:lang="en-US">Security Deposit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldtomaturitySecuritiesMember" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xml:lang="en-US">Held-to-maturity Securities [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:to="lab_us-gaap_HeldtomaturitySecuritiesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInSecurityDeposits" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInSecurityDeposits" xml:lang="en-US">Increase (Decrease) in Security Deposits</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="lab_us-gaap_IncreaseDecreaseInSecurityDeposits" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LetterOfCreditMember" xml:lang="en-US">Letter of Credit [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PropertyPlantAndEquipmentDesignCostsCapitalized" xlink:label="loc_ck0001680048_PropertyPlantAndEquipmentDesignCostsCapitalized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_PropertyPlantAndEquipmentDesignCostsCapitalized" xml:lang="en-US">Property Plant And Equipment Design Costs Capitalized</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_PropertyPlantAndEquipmentDesignCostsCapitalized" xml:lang="en-US">Represents the cost of design capitalized to property plant and equipment.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_PropertyPlantAndEquipmentDesignCostsCapitalized" xlink:to="lab_ck0001680048_PropertyPlantAndEquipmentDesignCostsCapitalized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashMember" xml:lang="en-US">Cash [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_Il13ra2Member" xlink:label="loc_ck0001680048_Il13ra2Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_Il13ra2Member" xml:lang="en-US">IL13Ra2 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ck0001680048_Il13ra2Member" xml:lang="en-US">IL13Ra2 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_Il13ra2Member" xlink:to="lab_ck0001680048_Il13ra2Member" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ClassOfWarrantOrRightExpirationPeriod" xlink:label="loc_ck0001680048_ClassOfWarrantOrRightExpirationPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_ClassOfWarrantOrRightExpirationPeriod" xml:lang="en-US">Class Of Warrant Or Right Expiration Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_ClassOfWarrantOrRightExpirationPeriod" xml:lang="en-US">The period at which the warrants are sets to expire.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_ClassOfWarrantOrRightExpirationPeriod" xlink:to="lab_ck0001680048_ClassOfWarrantOrRightExpirationPeriod" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_NumberOfSharesToBeIssuedUponLegalSettlement" xlink:label="loc_ck0001680048_NumberOfSharesToBeIssuedUponLegalSettlement" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ck0001680048_NumberOfSharesToBeIssuedUponLegalSettlement" xml:lang="en-US">Number Of Shares To Be Issued Upon Legal Settlement</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_ck0001680048_NumberOfSharesToBeIssuedUponLegalSettlement" xml:lang="en-US">The number of shares which will be issued upon legal settlement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001680048_NumberOfSharesToBeIssuedUponLegalSettlement" xlink:to="lab_ck0001680048_NumberOfSharesToBeIssuedUponLegalSettlement" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LitigationSettlementExpense" xml:lang="en-US">Litigation Settlement, Expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" />
  </labelLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>ck0001680048-20170930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 13-Nov-2017 [06:42:58] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#DocumentAndEntityInformation" roleURI="http://www.mustangbio.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#LicenseAgreementsAndClinicalResearchSupportAgreements" roleURI="http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreements" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#RelatedPartyAgreements" roleURI="http://www.mustangbio.com/role/RelatedPartyAgreements" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#CommitmentsAndContingencies" roleURI="http://www.mustangbio.com/role/CommitmentsAndContingencies" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#NetLossPerShare" roleURI="http://www.mustangbio.com/role/NetLossPerShare" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#StockholdersEquity" roleURI="http://www.mustangbio.com/role/StockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#SubsequentEvents" roleURI="http://www.mustangbio.com/role/SubsequentEvents" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://www.mustangbio.com/role/SignificantAccountingPoliciesPolicies" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#LicenseAgreementsAndClinicalResearchSupportAgreementsTables" roleURI="http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreementsTables" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#CondensedBalanceSheets" roleURI="http://www.mustangbio.com/role/CondensedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#NetLossPerShareTables" roleURI="http://www.mustangbio.com/role/NetLossPerShareTables" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#StockholdersEquityTables" roleURI="http://www.mustangbio.com/role/StockholdersEquityTables" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#OrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDetailsTextual" roleURI="http://www.mustangbio.com/role/OrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#SignificantAccountingPoliciesDetailsTextual" roleURI="http://www.mustangbio.com/role/SignificantAccountingPoliciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#LicenseAgreementsAndClinicalResearchSupportAgreementsDetails" roleURI="http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreementsDetails" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#LicenseAgreementsAndClinicalResearchSupportAgreementsDetailsTextual" roleURI="http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreementsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#RelatedPartyAgreementsDetailsTextual" roleURI="http://www.mustangbio.com/role/RelatedPartyAgreementsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#CondensedBalanceSheetsParenthetical" roleURI="http://www.mustangbio.com/role/CondensedBalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.mustangbio.com/role/CommitmentsAndContingenciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#NetLossPerShareDetails" roleURI="http://www.mustangbio.com/role/NetLossPerShareDetails" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#StockholdersEquityDetails" roleURI="http://www.mustangbio.com/role/StockholdersEquityDetails" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#StockholdersEquityDetails1" roleURI="http://www.mustangbio.com/role/StockholdersEquityDetails1" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#StockholdersEquityDetails2" roleURI="http://www.mustangbio.com/role/StockholdersEquityDetails2" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#StockholdersEquityDetails3" roleURI="http://www.mustangbio.com/role/StockholdersEquityDetails3" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#StockholdersEquityDetails4" roleURI="http://www.mustangbio.com/role/StockholdersEquityDetails4" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#StockholdersEquityDetailsTextual" roleURI="http://www.mustangbio.com/role/StockholdersEquityDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#SubsequentEventsDetailsTextual" roleURI="http://www.mustangbio.com/role/SubsequentEventsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#CondensedStatementsOfOperations" roleURI="http://www.mustangbio.com/role/CondensedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#CondensedStatementOfStockholdersEquity" roleURI="http://www.mustangbio.com/role/CondensedStatementOfStockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#CondensedStatementsOfCashFlows" roleURI="http://www.mustangbio.com/role/CondensedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#CondensedStatementsOfCashFlowsParenthetical" roleURI="http://www.mustangbio.com/role/CondensedStatementsOfCashFlowsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#OrganizationDescriptionOfBusinessAndLiquidityAndCapitalResources" roleURI="http://www.mustangbio.com/role/OrganizationDescriptionOfBusinessAndLiquidityAndCapitalResources" />

  <roleRef xlink:type="simple" xlink:href="ck0001680048-20170930.xsd#SignificantAccountingPolicies" roleURI="http://www.mustangbio.com/role/SignificantAccountingPolicies" />

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_DocumentAndEntityInformationAbstract" xlink:label="loc_ck0001680048_DocumentAndEntityInformationAbstract_2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001680048_DocumentAndEntityInformationAbstract_2" xlink:to="loc_dei_DocumentInformationTable_3" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1001" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4" xlink:to="loc_us-gaap_ClassOfStockDomain_1001" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1002" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1001" xlink:to="loc_us-gaap_CommonStockMember_1002" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1003" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1001" xlink:to="loc_us-gaap_CommonClassAMember_1003" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_1000" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_dei_DocumentInformationLineItems_1000" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_DocumentType_5" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_AmendmentFlag_6" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_DocumentPeriodEndDate_7" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_DocumentFiscalYearFocus_8" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_10" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_EntityRegistrantName_10" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_11" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_EntityCentralIndexKey_11" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_12" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_CurrentFiscalYearEndDate_12" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_13" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_EntityFilerCategory_13" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1004" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1000" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1004" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreements">
    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_LicenseAgreementDisclosureAbstract" xlink:label="loc_ck0001680048_LicenseAgreementDisclosureAbstract_159" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_LicenseAgreementDisclosureTextBlock" xlink:label="loc_ck0001680048_LicenseAgreementDisclosureTextBlock_160" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001680048_LicenseAgreementDisclosureAbstract_159" xlink:to="loc_ck0001680048_LicenseAgreementDisclosureTextBlock_160" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/RelatedPartyAgreements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_210" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_211" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_210" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_211" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/CommitmentsAndContingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_338" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_339" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_338" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_339" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/NetLossPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_969" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_970" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_969" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_970" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_341" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_342" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_341" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_342" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_403" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_404" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_403" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_404" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/SignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_136" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_137" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_136" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_137" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_138" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_136" xlink:to="loc_us-gaap_UseOfEstimates_138" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SignificantAccountingPoliciesPolicyTextBlock" xlink:label="loc_ck0001680048_SignificantAccountingPoliciesPolicyTextBlock_967" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_136" xlink:to="loc_ck0001680048_SignificantAccountingPoliciesPolicyTextBlock_967" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_806" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_136" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_806" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_553" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_136" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_553" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_994" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_136" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_994" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_146" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_136" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_146" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreementsTables">
    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_LicenseAgreementDisclosureAbstract" xlink:label="loc_ck0001680048_LicenseAgreementDisclosureAbstract_793" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_794" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001680048_LicenseAgreementDisclosureAbstract_793" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_794" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/CondensedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_18" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_17" xlink:to="loc_us-gaap_StatementTable_18" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_19" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_18" xlink:to="loc_us-gaap_StatementClassOfStockAxis_19" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_20" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_19" xlink:to="loc_us-gaap_ClassOfStockDomain_20" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_41" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_20" xlink:to="loc_us-gaap_CommonClassAMember_41" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_21" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_18" xlink:to="loc_us-gaap_StatementLineItems_21" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_22" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_AssetsAbstract_22" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_24" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_AssetsCurrentAbstract_24" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_984" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_984" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_797" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_OtherShortTermInvestments_797" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_732" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_732" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaap_InterestReceivableCurrent_985" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_InterestReceivableCurrent_985" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_26" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_AssetsCurrent_26" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1018" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1018" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_27" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22" xlink:to="loc_us-gaap_Assets_27" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_28" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_28" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_29" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_29" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CommonSharesIssuableLiabilityCurrent" xlink:label="loc_ck0001680048_CommonSharesIssuableLiabilityCurrent_987" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_ck0001680048_CommonSharesIssuableLiabilityCurrent_987" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent" xlink:label="loc_ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent_1019" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent_1019" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AccruedInterestRelatedPartyCurrent" xlink:label="loc_ck0001680048_AccruedInterestRelatedPartyCurrent_32" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_28" xlink:to="loc_ck0001680048_AccruedInterestRelatedPartyCurrent_32" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_36" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23" xlink:to="loc_us-gaap_Liabilities_36" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_37" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23" xlink:to="loc_us-gaap_CommitmentsAndContingencies_37" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_38" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_23" xlink:to="loc_us-gaap_StockholdersEquityAbstract_38" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_39" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38" xlink:to="loc_us-gaap_PreferredStockValue_39" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_40" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38" xlink:to="loc_us-gaap_CommonStockValue_40" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_43" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_43" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_44" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_44" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_45" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_45" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_46" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38" xlink:to="loc_us-gaap_StockholdersEquity_46" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_47" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_38" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_47" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/NetLossPerShareTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_972" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_974" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_972" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_974" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/StockholdersEquityTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_344" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_842" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_344" xlink:to="loc_us-gaap_StatementTable_842" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_843" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_842" xlink:to="loc_us-gaap_StatementClassOfStockAxis_843" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_844" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_843" xlink:to="loc_us-gaap_ClassOfStockDomain_844" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_845" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_842" xlink:to="loc_us-gaap_AwardTypeAxis_845" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_847" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_845" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_847" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_848" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_847" xlink:to="loc_us-gaap_RestrictedStockMember_848" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_849" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_847" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_849" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_846" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_842" xlink:to="loc_us-gaap_StatementLineItems_846" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsTableTextBlock" xlink:label="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsTableTextBlock_941" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_846" xlink:to="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsTableTextBlock_941" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_839" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_846" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_839" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_841" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_846" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_841" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_932" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_846" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_932" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_345" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_846" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_345" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/OrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_936" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOtherOwnershipInterestsTable" xlink:label="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable_937" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_936" xlink:to="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable_937" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_939" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable_937" xlink:to="loc_us-gaap_StatementClassOfStockAxis_939" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_940" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_939" xlink:to="loc_us-gaap_ClassOfStockDomain_940" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherOwnershipInterestsLineItems" xlink:label="loc_us-gaap_OtherOwnershipInterestsLineItems_938" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOtherOwnershipInterestsTable_937" xlink:to="loc_us-gaap_OtherOwnershipInterestsLineItems_938" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_942" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherOwnershipInterestsLineItems_938" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_942" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/SignificantAccountingPoliciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_148" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_149" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_148" xlink:to="loc_us-gaap_StatementTable_149" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_150" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_149" xlink:to="loc_us-gaap_StatementClassOfStockAxis_150" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_151" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_150" xlink:to="loc_us-gaap_ClassOfStockDomain_151" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_152" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_149" xlink:to="loc_dei_LegalEntityAxis_152" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_154" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_152" xlink:to="loc_dei_EntityDomain_154" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_153" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_149" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_153" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_452" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_153" xlink:to="loc_us-gaap_EquityComponentDomain_452" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_451" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_149" xlink:to="loc_us-gaap_InvestmentTypeAxis_451" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1024" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_451" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1024" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_1025" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1024" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_1025" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_1023" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_149" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_1023" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_1031" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_1023" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_1031" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HeldtomaturitySecuritiesMember" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_1033" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_1031" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_1033" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1029" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_149" xlink:to="loc_us-gaap_StatementLineItems_1029" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_807" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1029" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_807" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_923" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1029" xlink:to="loc_us-gaap_OtherShortTermInvestments_923" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TimeDepositsAtCarryingValue" xlink:label="loc_us-gaap_TimeDepositsAtCarryingValue_1022" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1029" xlink:to="loc_us-gaap_TimeDepositsAtCarryingValue_1022" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PropertyPlantAndEquipmentDesignCostsCapitalized" xlink:label="loc_ck0001680048_PropertyPlantAndEquipmentDesignCostsCapitalized_1038" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1029" xlink:to="loc_ck0001680048_PropertyPlantAndEquipmentDesignCostsCapitalized_1038" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreementsDetails">
    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_LicenseAgreementDisclosureAbstractAbstract" xlink:label="loc_ck0001680048_LicenseAgreementDisclosureAbstractAbstract_772" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_773" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001680048_LicenseAgreementDisclosureAbstractAbstract_772" xlink:to="loc_us-gaap_StatementTable_773" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_774" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_773" xlink:to="loc_us-gaap_StatementClassOfStockAxis_774" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_775" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_774" xlink:to="loc_us-gaap_ClassOfStockDomain_775" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_776" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_773" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_776" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_776" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ArIl13LicenseMember" xlink:label="loc_ck0001680048_ArIl13LicenseMember_779" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778" xlink:to="loc_ck0001680048_ArIl13LicenseMember_779" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_IvicvLicenseMember" xlink:label="loc_ck0001680048_IvicvLicenseMember_780" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778" xlink:to="loc_ck0001680048_IvicvLicenseMember_780" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PscaTechnologyLicenseMember" xlink:label="loc_ck0001680048_PscaTechnologyLicenseMember_808" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778" xlink:to="loc_ck0001680048_PscaTechnologyLicenseMember_808" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_Her2TechnologyLicenseMember" xlink:label="loc_ck0001680048_Her2TechnologyLicenseMember_809" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778" xlink:to="loc_ck0001680048_Her2TechnologyLicenseMember_809" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CsTechnologyLicenseMember" xlink:label="loc_ck0001680048_CsTechnologyLicenseMember_810" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778" xlink:to="loc_ck0001680048_CsTechnologyLicenseMember_810" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_UclaLicenseMember" xlink:label="loc_ck0001680048_UclaLicenseMember_781" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778" xlink:to="loc_ck0001680048_UclaLicenseMember_781" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_FredHutchCd20Member" xlink:label="loc_ck0001680048_FredHutchCd20Member_995" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_778" xlink:to="loc_ck0001680048_FredHutchCd20Member_995" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_777" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_773" xlink:to="loc_us-gaap_StatementLineItems_777" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_782" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_777" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_782" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreementsDetailsTextual">
    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_LicenseAgreementDisclosureAbstract" xlink:label="loc_ck0001680048_LicenseAgreementDisclosureAbstract_162" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_163" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001680048_LicenseAgreementDisclosureAbstract_162" xlink:to="loc_us-gaap_StatementTable_163" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_164" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_163" xlink:to="loc_us-gaap_StatementClassOfStockAxis_164" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_165" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_164" xlink:to="loc_us-gaap_ClassOfStockDomain_165" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_717" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_165" xlink:to="loc_us-gaap_CommonClassAMember_717" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_166" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_163" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_166" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_168" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_166" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_168" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CityOfHopeMember" xlink:label="loc_ck0001680048_CityOfHopeMember_169" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_168" xlink:to="loc_ck0001680048_CityOfHopeMember_169" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_ck0001680048_FredHutchinsonCancerResearchCenterMember_996" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_168" xlink:to="loc_ck0001680048_FredHutchinsonCancerResearchCenterMember_996" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_167" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_163" xlink:to="loc_us-gaap_TypeOfArrangementAxis_167" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_182" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_167" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_182" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_181" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_163" xlink:to="loc_dei_LegalEntityAxis_181" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_658" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_181" xlink:to="loc_dei_EntityDomain_658" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_657" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_163" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_657" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_666" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_657" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_666" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_665" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_163" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_665" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_670" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_665" xlink:to="loc_us-gaap_EquityComponentDomain_670" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_669" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_163" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_669" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_714" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_669" xlink:to="loc_us-gaap_RelatedPartyDomain_714" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_StephenFormanMember" xlink:label="loc_ck0001680048_StephenFormanMember_715" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_714" xlink:to="loc_ck0001680048_StephenFormanMember_715" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ChristineBrownMember" xlink:label="loc_ck0001680048_ChristineBrownMember_716" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_714" xlink:to="loc_ck0001680048_ChristineBrownMember_716" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_UniversityOfCaliforniaMember" xlink:label="loc_ck0001680048_UniversityOfCaliforniaMember_788" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_714" xlink:to="loc_ck0001680048_UniversityOfCaliforniaMember_788" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_713" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_163" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_713" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_713" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ArCd123LicenseMember" xlink:label="loc_ck0001680048_ArCd123LicenseMember_767" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_ArCd123LicenseMember_767" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_IlLicenseMember" xlink:label="loc_ck0001680048_IlLicenseMember_768" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_IlLicenseMember_768" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_UclaLicenseMember" xlink:label="loc_ck0001680048_UclaLicenseMember_787" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_UclaLicenseMember_787" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PscaTechnologyLicenseMember" xlink:label="loc_ck0001680048_PscaTechnologyLicenseMember_829" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_PscaTechnologyLicenseMember_829" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_Her2TechnologyLicenseMember" xlink:label="loc_ck0001680048_Her2TechnologyLicenseMember_831" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_Her2TechnologyLicenseMember_831" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CsTechnologyLicenseMember" xlink:label="loc_ck0001680048_CsTechnologyLicenseMember_832" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_CsTechnologyLicenseMember_832" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SpacerLicenseMember" xlink:label="loc_ck0001680048_SpacerLicenseMember_944" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_SpacerLicenseMember_944" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_Cd20TechnologyLicenseMember" xlink:label="loc_ck0001680048_Cd20TechnologyLicenseMember_997" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_Cd20TechnologyLicenseMember_997" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_Cd20ClinicalAgreementMember" xlink:label="loc_ck0001680048_Cd20ClinicalAgreementMember_998" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_Cd20ClinicalAgreementMember_998" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_Il13ra2Member" xlink:label="loc_ck0001680048_Il13ra2Member_1042" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_766" xlink:to="loc_ck0001680048_Il13ra2Member_1042" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_765" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_163" xlink:to="loc_us-gaap_StatementLineItems_765" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PaymentOfUpfrontFees" xlink:label="loc_ck0001680048_PaymentOfUpfrontFees_170" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_ck0001680048_PaymentOfUpfrontFees_170" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue" xlink:label="loc_ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue_173" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue_173" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ResearchAndDevelopmentExpenseSponsoredResearchPayment" xlink:label="loc_ck0001680048_ResearchAndDevelopmentExpenseSponsoredResearchPayment_179" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_ck0001680048_ResearchAndDevelopmentExpenseSponsoredResearchPayment_179" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_180" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_180" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_557" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_557" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaap_PaymentsForFees_708" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_PaymentsForFees_708" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AnnualConsultingFees" xlink:label="loc_ck0001680048_AnnualConsultingFees_710" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_ck0001680048_AnnualConsultingFees_710" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_711" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_711" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_712" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_712" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_LicensingArrangementsAdditionalCostsIncurred" xlink:label="loc_ck0001680048_LicensingArrangementsAdditionalCostsIncurred_763" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_ck0001680048_LicensingArrangementsAdditionalCostsIncurred_763" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_us-gaap_MaintenanceCosts_830" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_MaintenanceCosts_830" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_959" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_959" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInThirdYear" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear_960" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_OtherCommitmentDueInThirdYear_960" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInSecondYear" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear_961" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_OtherCommitmentDueInSecondYear_961" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInFifthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFifthYear_962" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_OtherCommitmentDueInFifthYear_962" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInFourthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear_963" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_OtherCommitmentDueInFourthYear_963" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_DevelopmentMilestonesMethodAdditionalPaymentsDue" xlink:label="loc_ck0001680048_DevelopmentMilestonesMethodAdditionalPaymentsDue_1015" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_ck0001680048_DevelopmentMilestonesMethodAdditionalPaymentsDue_1015" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_1043" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_765" xlink:to="loc_us-gaap_ProfessionalFees_1043" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/RelatedPartyAgreementsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_216" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_217" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_216" xlink:to="loc_us-gaap_StatementTable_217" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_218" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_217" xlink:to="loc_us-gaap_StatementClassOfStockAxis_218" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_219" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_218" xlink:to="loc_us-gaap_ClassOfStockDomain_219" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_224" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_219" xlink:to="loc_us-gaap_CommonClassBMember_224" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_228" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_219" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_228" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleCommonStockMember" xlink:label="loc_us-gaap_ConvertibleCommonStockMember_628" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_219" xlink:to="loc_us-gaap_ConvertibleCommonStockMember_628" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_220" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_217" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_220" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_222" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_220" xlink:to="loc_us-gaap_RelatedPartyDomain_222" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_FortressBiotechIncMember" xlink:label="loc_ck0001680048_FortressBiotechIncMember_223" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_222" xlink:to="loc_ck0001680048_FortressBiotechIncMember_223" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ChordAdvisorsLlcMember" xlink:label="loc_ck0001680048_ChordAdvisorsLlcMember_229" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_222" xlink:to="loc_ck0001680048_ChordAdvisorsLlcMember_229" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_NationalHoldingsIncMember" xlink:label="loc_ck0001680048_NationalHoldingsIncMember_230" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_222" xlink:to="loc_ck0001680048_NationalHoldingsIncMember_230" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AdvisorMember" xlink:label="loc_ck0001680048_AdvisorMember_769" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_222" xlink:to="loc_ck0001680048_AdvisorMember_769" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_221" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_217" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_221" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_226" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_221" xlink:to="loc_us-gaap_EquityComponentDomain_226" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_225" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_217" xlink:to="loc_us-gaap_TitleOfIndividualAxis_225" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_836" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_225" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_836" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_837" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_836" xlink:to="loc_us-gaap_DirectorMember_837" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_us-gaap_BoardOfDirectorsChairmanMember_850" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_836" xlink:to="loc_us-gaap_BoardOfDirectorsChairmanMember_850" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_835" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_217" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_835" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_978" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_835" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_978" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_979" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_978" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_979" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1016" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_978" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1016" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_977" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_217" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_977" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1051" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_977" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1051" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1052" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1051" xlink:to="loc_us-gaap_PrivatePlacementMember_1052" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1050" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_217" xlink:to="loc_us-gaap_AwardTypeAxis_1050" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1054" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1050" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1054" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1055" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1054" xlink:to="loc_us-gaap_RestrictedStockMember_1055" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1053" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_217" xlink:to="loc_us-gaap_StatementLineItems_1053" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_231" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_231" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_FoundersAgreementTerm" xlink:label="loc_ck0001680048_FoundersAgreementTerm_232" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_FoundersAgreementTerm_232" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_233" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_233" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_234" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_234" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaap_PreferredStockVotingRights_235" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_PreferredStockVotingRights_235" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AdditionalConsiderationUnderFoundersAgreementDescription" xlink:label="loc_ck0001680048_AdditionalConsiderationUnderFoundersAgreementDescription_236" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_AdditionalConsiderationUnderFoundersAgreementDescription_236" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_237" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_237" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_238" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_238" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AnnualConsultingFees" xlink:label="loc_ck0001680048_AnnualConsultingFees_239" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_AnnualConsultingFees_239" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_IncreaseInAnnualConsultingFees" xlink:label="loc_ck0001680048_IncreaseInAnnualConsultingFees_240" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_IncreaseInAnnualConsultingFees_240" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ExcessInNetAssetsValue" xlink:label="loc_ck0001680048_ExcessInNetAssetsValue_241" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_ExcessInNetAssetsValue_241" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AnnualFeesExpensesOnFoundersAgreement" xlink:label="loc_ck0001680048_AnnualFeesExpensesOnFoundersAgreement_242" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_AnnualFeesExpensesOnFoundersAgreement_242" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_BackOfficeAccountingFunctionsExpenses" xlink:label="loc_ck0001680048_BackOfficeAccountingFunctionsExpenses_243" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_BackOfficeAccountingFunctionsExpenses_243" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AccountingAnalysisAndFinancialReportingFees" xlink:label="loc_ck0001680048_AccountingAnalysisAndFinancialReportingFees_244" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_AccountingAnalysisAndFinancialReportingFees_244" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_245" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_ProfessionalFees_245" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_246" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_246" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaap_PaymentsForFees_251" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_PaymentsForFees_251" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_252" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_252" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_838" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_838" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AnnualFeesExpensesOnFoundersAgreementPercentage" xlink:label="loc_ck0001680048_AnnualFeesExpensesOnFoundersAgreementPercentage_976" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_AnnualFeesExpensesOnFoundersAgreementPercentage_976" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_980" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_980" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_981" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_OfficersCompensation_981" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1044" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1044" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ClassOfWarrantOrRightExpirationPeriod" xlink:label="loc_ck0001680048_ClassOfWarrantOrRightExpirationPeriod_1045" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_ck0001680048_ClassOfWarrantOrRightExpirationPeriod_1045" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1047" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1047" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1048" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_1048" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1049" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1053" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1049" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/CondensedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_50" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49" xlink:to="loc_us-gaap_StatementTable_50" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_51" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_50" xlink:to="loc_us-gaap_StatementClassOfStockAxis_51" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_52" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_51" xlink:to="loc_us-gaap_ClassOfStockDomain_52" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_58" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_52" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_58" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_63" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_52" xlink:to="loc_us-gaap_CommonClassAMember_63" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_53" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_50" xlink:to="loc_us-gaap_StatementLineItems_53" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_55" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_55" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_56" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_56" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_57" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53" xlink:to="loc_us-gaap_PreferredStockSharesIssued_57" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_59" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_59" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_60" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_60" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_61" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_61" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_62" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53" xlink:to="loc_us-gaap_CommonStockSharesIssued_62" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_64" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_64" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_66" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_66" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/CommitmentsAndContingenciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_439" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_440" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_439" xlink:to="loc_us-gaap_LossContingenciesTable_440" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_441" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_440" xlink:to="loc_us-gaap_StatementClassOfStockAxis_441" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_442" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_441" xlink:to="loc_us-gaap_ClassOfStockDomain_442" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_443" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_440" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_443" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_448" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_443" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_448" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CityOfHopeMember" xlink:label="loc_ck0001680048_CityOfHopeMember_449" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_448" xlink:to="loc_ck0001680048_CityOfHopeMember_449" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_447" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_440" xlink:to="loc_us-gaap_LossContingenciesLineItems_447" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_FailedContingencyDamagesAwardedPercentage" xlink:label="loc_ck0001680048_FailedContingencyDamagesAwardedPercentage_446" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_447" xlink:to="loc_ck0001680048_FailedContingencyDamagesAwardedPercentage_446" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_NumberOfSharesToBeIssuedUponLegalSettlement" xlink:label="loc_ck0001680048_NumberOfSharesToBeIssuedUponLegalSettlement_1056" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_447" xlink:to="loc_ck0001680048_NumberOfSharesToBeIssuedUponLegalSettlement_1056" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_1057" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_447" xlink:to="loc_us-gaap_LitigationSettlementExpense_1057" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_1058" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_447" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_1058" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/NetLossPerShareDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_501" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_502" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_501" xlink:to="loc_us-gaap_StatementTable_502" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_503" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_502" xlink:to="loc_us-gaap_StatementClassOfStockAxis_503" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_504" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_503" xlink:to="loc_us-gaap_ClassOfStockDomain_504" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_826" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_504" xlink:to="loc_us-gaap_PreferredClassAMember_826" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_505" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_502" xlink:to="loc_us-gaap_InvestmentTypeAxis_505" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_821" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_505" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_821" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_822" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_821" xlink:to="loc_us-gaap_WarrantMember_822" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_820" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_502" xlink:to="loc_us-gaap_AwardTypeAxis_820" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_824" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_820" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_824" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_825" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_824" xlink:to="loc_us-gaap_EmployeeStockOptionMember_825" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_UnvestedRestrictedStockAwardsMemberMember" xlink:label="loc_ck0001680048_UnvestedRestrictedStockAwardsMemberMember_827" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_824" xlink:to="loc_ck0001680048_UnvestedRestrictedStockAwardsMemberMember_827" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_828" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_824" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_828" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_823" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_502" xlink:to="loc_us-gaap_StatementLineItems_823" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PotentiallyDilutiveSecurities" xlink:label="loc_ck0001680048_PotentiallyDilutiveSecurities_819" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_823" xlink:to="loc_ck0001680048_PotentiallyDilutiveSecurities_819" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_946" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_947" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_946" xlink:to="loc_us-gaap_StatementTable_947" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_948" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_947" xlink:to="loc_us-gaap_StatementClassOfStockAxis_948" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_949" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_948" xlink:to="loc_us-gaap_ClassOfStockDomain_949" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_950" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_947" xlink:to="loc_us-gaap_RangeAxis_950" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_956" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_950" xlink:to="loc_us-gaap_RangeMember_956" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_957" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_956" xlink:to="loc_us-gaap_MaximumMember_957" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_958" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_956" xlink:to="loc_us-gaap_MinimumMember_958" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_955" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_947" xlink:to="loc_us-gaap_StatementLineItems_955" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_951" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_951" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_993" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_993" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_954" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_955" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_954" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_953" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_953" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/StockholdersEquityDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_854" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_855" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_854" xlink:to="loc_us-gaap_StatementTable_855" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_856" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_855" xlink:to="loc_us-gaap_StatementClassOfStockAxis_856" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_857" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_856" xlink:to="loc_us-gaap_ClassOfStockDomain_857" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_858" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_855" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_858" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_865" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_858" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_865" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_866" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_865" xlink:to="loc_us-gaap_EmployeeStockOptionMember_866" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_855" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_860" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_860" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_861" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_861" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_863" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_863" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_862" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_862" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_867" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_867" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_868" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_868" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_869" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_869" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_870" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_870" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_871" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_871" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_ck0001680048_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_885" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_ck0001680048_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_885" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_886" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_864" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_886" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/StockholdersEquityDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_887" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_888" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_887" xlink:to="loc_us-gaap_StatementTable_888" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_889" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_888" xlink:to="loc_us-gaap_StatementClassOfStockAxis_889" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_890" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_889" xlink:to="loc_us-gaap_ClassOfStockDomain_890" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_891" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_888" xlink:to="loc_us-gaap_AwardTypeAxis_891" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_896" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_891" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_896" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_897" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_896" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_897" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_920" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_896" xlink:to="loc_us-gaap_RestrictedStockMember_920" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_895" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_888" xlink:to="loc_us-gaap_StatementLineItems_895" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_892" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_895" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_892" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_894" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_895" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_894" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_893" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_895" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_893" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_898" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_895" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_898" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_900" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_895" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_900" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_899" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_895" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_899" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/StockholdersEquityDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_901" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_902" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_901" xlink:to="loc_us-gaap_StatementTable_902" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_903" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_902" xlink:to="loc_us-gaap_StatementClassOfStockAxis_903" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_904" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_903" xlink:to="loc_us-gaap_ClassOfStockDomain_904" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_905" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_902" xlink:to="loc_us-gaap_AwardTypeAxis_905" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_912" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_902" xlink:to="loc_us-gaap_TitleOfIndividualAxis_912" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_916" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_912" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_916" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_EmployeeMember" xlink:label="loc_ck0001680048_EmployeeMember_917" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_916" xlink:to="loc_ck0001680048_EmployeeMember_917" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_NonEmployeeMember" xlink:label="loc_ck0001680048_NonEmployeeMember_918" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_916" xlink:to="loc_ck0001680048_NonEmployeeMember_918" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_915" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_902" xlink:to="loc_us-gaap_StatementLineItems_915" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_919" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_915" xlink:to="loc_us-gaap_ShareBasedCompensation_919" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/StockholdersEquityDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_347" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_348" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_347" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_348" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_349" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_348" xlink:to="loc_us-gaap_TitleOfIndividualAxis_349" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_350" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_349" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_350" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_351" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_351" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" xlink:label="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding_352" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_351" xlink:to="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding_352" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_353" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_351" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_353" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" xlink:label="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding_354" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_351" xlink:to="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding_354" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice_355" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_351" xlink:to="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice_355" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:label="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice_357" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_351" xlink:to="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice_357" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice_356" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_351" xlink:to="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice_356" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms" xlink:label="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms_360" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_351" xlink:to="loc_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms_360" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_358" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_351" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_358" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/StockholdersEquityDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_362" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_362" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_364" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_364" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_365" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_364" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_365" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_395" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_365" xlink:to="loc_us-gaap_PrivatePlacementMember_395" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_366" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_dei_LegalEntityAxis_366" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_367" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_366" xlink:to="loc_dei_EntityDomain_367" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_FortressBiotechIncMember" xlink:label="loc_ck0001680048_FortressBiotechIncMember_379" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_367" xlink:to="loc_ck0001680048_FortressBiotechIncMember_379" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_NationalHoldingsCorporationMember" xlink:label="loc_ck0001680048_NationalHoldingsCorporationMember_387" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_367" xlink:to="loc_ck0001680048_NationalHoldingsCorporationMember_387" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CityOfHopeNationalMedicalCenterMember" xlink:label="loc_ck0001680048_CityOfHopeNationalMedicalCenterMember_582" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_367" xlink:to="loc_ck0001680048_CityOfHopeNationalMedicalCenterMember_582" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_NationalSecuritiesIncMember" xlink:label="loc_ck0001680048_NationalSecuritiesIncMember_615" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_367" xlink:to="loc_ck0001680048_NationalSecuritiesIncMember_615" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_368" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_StatementClassOfStockAxis_368" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_375" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_368" xlink:to="loc_us-gaap_ClassOfStockDomain_375" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_376" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_375" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_376" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_377" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_375" xlink:to="loc_us-gaap_CommonClassBMember_377" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_378" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_375" xlink:to="loc_us-gaap_CommonClassAMember_378" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_735" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_375" xlink:to="loc_us-gaap_PreferredClassAMember_735" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_374" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_374" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_397" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_374" xlink:to="loc_us-gaap_EquityComponentDomain_397" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_398" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_397" xlink:to="loc_us-gaap_CommonStockMember_398" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_UnregisteredCommonStockMember" xlink:label="loc_ck0001680048_UnregisteredCommonStockMember_464" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_397" xlink:to="loc_ck0001680048_UnregisteredCommonStockMember_464" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_396" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_396" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_400" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_396" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_400" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_401" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_400" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_401" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_399" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_FinancialInstrumentAxis_399" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_471" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_399" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_471" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_470" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_470" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_565" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_470" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_565" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AgreementTypeAxis" xlink:label="loc_ck0001680048_AgreementTypeAxis_564" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_ck0001680048_AgreementTypeAxis_564" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AgreementTypeDomain" xlink:label="loc_ck0001680048_AgreementTypeDomain_585" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001680048_AgreementTypeAxis_564" xlink:to="loc_ck0001680048_AgreementTypeDomain_585" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_LicenseAgreementMember" xlink:label="loc_ck0001680048_LicenseAgreementMember_586" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001680048_AgreementTypeDomain_585" xlink:to="loc_ck0001680048_LicenseAgreementMember_586" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_584" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_584" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_591" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_584" xlink:to="loc_us-gaap_CapitalUnitClassDomain_591" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_590" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_590" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_760" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_590" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_760" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_759" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_759" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_874" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_759" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_874" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_875" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_874" xlink:to="loc_us-gaap_EmployeeStockOptionMember_875" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_873" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_AwardTypeAxis_873" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_878" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_873" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_878" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_879" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_878" xlink:to="loc_us-gaap_RestrictedStockMember_879" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_883" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_878" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_883" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_877" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_TitleOfIndividualAxis_877" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_881" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_877" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_881" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_882" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_881" xlink:to="loc_us-gaap_DirectorMember_882" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_363" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_369" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_PreferredStockSharesIssued_369" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_370" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_CommonStockSharesIssued_370" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_372" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_372" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_373" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_373" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_381" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_CommonStockVotingRights_381" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PercentageOfPlacementAgentFee" xlink:label="loc_ck0001680048_PercentageOfPlacementAgentFee_382" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_ck0001680048_PercentageOfPlacementAgentFee_382" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PercentageOfSharesIssuedToPlacementAgent" xlink:label="loc_ck0001680048_PercentageOfSharesIssuedToPlacementAgent_383" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_ck0001680048_PercentageOfSharesIssuedToPlacementAgent_383" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_WarrantPurchasePricePerUnit" xlink:label="loc_ck0001680048_WarrantPurchasePricePerUnit_384" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_ck0001680048_WarrantPurchasePricePerUnit_384" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_WarrantsIssued" xlink:label="loc_ck0001680048_WarrantsIssued_386" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_ck0001680048_WarrantsIssued_386" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_SharesOfCommonStockPercentage" xlink:label="loc_ck0001680048_SharesOfCommonStockPercentage_388" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_ck0001680048_SharesOfCommonStockPercentage_388" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_389" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_389" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_390" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_390" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_391" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_391" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_394" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_394" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_PaymentOfUpfrontFees" xlink:label="loc_ck0001680048_PaymentOfUpfrontFees_560" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_ck0001680048_PaymentOfUpfrontFees_560" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_561" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_561" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_569" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_569" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_DilutedOutstandingEquityPercentage" xlink:label="loc_ck0001680048_DilutedOutstandingEquityPercentage_577" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_ck0001680048_DilutedOutstandingEquityPercentage_577" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_579" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_579" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_581" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_SharesOutstanding_581" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_588" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_588" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_617" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_617" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_733" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_733" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_734" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_734" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_756" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_756" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_758" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_758" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_762" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_762" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_872" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_872" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_884" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_884" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_930" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_SharesIssued_930" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_964" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_964" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_965" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_965" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ClassOfWarrantOrRightPercentageOfWarrantIssued" xlink:label="loc_ck0001680048_ClassOfWarrantOrRightPercentageOfWarrantIssued_966" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_ck0001680048_ClassOfWarrantOrRightPercentageOfWarrantIssued_966" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1046" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1046" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/SubsequentEventsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_406" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_407" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_406" xlink:to="loc_us-gaap_SubsequentEventTable_407" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_408" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_408" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_409" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_408" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_409" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_410" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_409" xlink:to="loc_us-gaap_SubsequentEventMember_410" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_411" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_dei_LegalEntityAxis_411" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_412" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_411" xlink:to="loc_dei_EntityDomain_412" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_414" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_414" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_425" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_414" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_425" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_424" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_424" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_428" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_424" xlink:to="loc_us-gaap_EquityComponentDomain_428" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_427" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_DebtInstrumentAxis_427" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_433" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_427" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_433" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_432" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_432" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_636" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_432" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_636" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_635" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_635" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_642" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_635" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_642" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_641" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_641" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_702" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_641" xlink:to="loc_us-gaap_RelatedPartyDomain_702" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_701" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_StatementClassOfStockAxis_701" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_706" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_701" xlink:to="loc_us-gaap_ClassOfStockDomain_706" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_705" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_TitleOfIndividualAxis_705" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_751" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_705" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_751" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_750" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_750" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_754" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_750" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_754" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_753" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_753" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1036" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_753" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1036" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_1037" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1036" xlink:to="loc_us-gaap_LetterOfCreditMember_1037" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1035" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_InvestmentTypeAxis_1035" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1040" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_1035" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1040" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_1041" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1040" xlink:to="loc_us-gaap_CashMember_1041" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1039" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_407" xlink:to="loc_us-gaap_SubsequentEventLineItems_1039" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_1026" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1039" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_1026" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_1027" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1039" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_1027" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_1028" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1039" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_1028" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LandImprovements" xlink:label="loc_us-gaap_LandImprovements_1030" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1039" xlink:to="loc_us-gaap_LandImprovements_1030" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_1032" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1039" xlink:to="loc_us-gaap_SecurityDeposit_1032" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_1034" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1039" xlink:to="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_1034" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/CondensedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_68" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_69" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_68" xlink:to="loc_us-gaap_StatementTable_69" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_70" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_69" xlink:to="loc_us-gaap_StatementClassOfStockAxis_70" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_71" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_70" xlink:to="loc_us-gaap_ClassOfStockDomain_71" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_72" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_69" xlink:to="loc_us-gaap_StatementLineItems_72" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_73" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_OperatingExpensesAbstract_73" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_74" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_74" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_75" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_75" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_76" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_76" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_77" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_OperatingExpenses_77" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_78" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_OperatingIncomeLoss_78" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_79" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_79" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_742" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_79" xlink:to="loc_us-gaap_InterestIncomeOther_742" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_InterestIncomeExpensesRelatedParty" xlink:label="loc_ck0001680048_InterestIncomeExpensesRelatedParty_80" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_79" xlink:to="loc_ck0001680048_InterestIncomeExpensesRelatedParty_80" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_81" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_79" xlink:to="loc_us-gaap_InterestExpenseDebt_81" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_82" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_79" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_82" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_83" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_79" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_83" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_84" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_NetIncomeLoss_84" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_85" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_85" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_86" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_86" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/CondensedStatementOfStockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_187" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_188" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_187" xlink:to="loc_us-gaap_StatementTable_188" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_189" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_188" xlink:to="loc_us-gaap_StatementClassOfStockAxis_189" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_190" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_189" xlink:to="loc_us-gaap_ClassOfStockDomain_190" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_195" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_190" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_195" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_196" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_190" xlink:to="loc_us-gaap_CommonClassAMember_196" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_198" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_190" xlink:to="loc_us-gaap_CommonStockMember_198" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_CommonStockIssuableMember" xlink:label="loc_ck0001680048_CommonStockIssuableMember_193" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_190" xlink:to="loc_ck0001680048_CommonStockIssuableMember_193" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_199" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_190" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_199" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_200" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_190" xlink:to="loc_us-gaap_RetainedEarningsMember_200" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_191" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_188" xlink:to="loc_us-gaap_StatementLineItems_191" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_192" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StockholdersEquity_192" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_212" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_SharesOutstanding_212" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_201" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_201" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_202" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_202" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_744" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_744" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_745" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_745" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_203" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_203" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_204" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_204" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_205" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_205" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_798" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_798" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_800" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_800" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_AdjustmentToAdditionalPaidInCapitalCapitalContribution" xlink:label="loc_ck0001680048_AdjustmentToAdditionalPaidInCapitalCapitalContribution_1020" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_ck0001680048_AdjustmentToAdditionalPaidInCapitalCapitalContribution_1020" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_208" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_NetIncomeLoss_208" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_214" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_StockholdersEquity_214" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_213" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_191" xlink:to="loc_us-gaap_SharesOutstanding_213" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/CondensedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_88" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_89" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_88" xlink:to="loc_us-gaap_StatementTable_89" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_90" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_89" xlink:to="loc_us-gaap_StatementClassOfStockAxis_90" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_91" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_90" xlink:to="loc_us-gaap_ClassOfStockDomain_91" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_92" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_89" xlink:to="loc_us-gaap_DebtInstrumentAxis_92" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_109" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_92" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_109" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_108" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_89" xlink:to="loc_us-gaap_StatementLineItems_108" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_108" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_94" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" xlink:to="loc_us-gaap_NetIncomeLoss_94" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_184" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_184" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses" xlink:label="loc_ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses_185" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" xlink:to="loc_ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses_185" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_95" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_95" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_518" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_518" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_801" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" xlink:to="loc_us-gaap_ShareBasedCompensation_801" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_1021" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_1021" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_97" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_97" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_98" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_97" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_98" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_738" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_98" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_738" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_989" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_98" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_989" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_99" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_98" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_99" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_100" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_98" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_100" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_101" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_98" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_101" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_102" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_102" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_103" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_108" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_103" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_802" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_103" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_802" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_104" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_103" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_104" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForConstructionInProcess" xlink:label="loc_us-gaap_PaymentsForConstructionInProcess_991" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_103" xlink:to="loc_us-gaap_PaymentsForConstructionInProcess_991" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_105" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_103" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_105" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_106" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_108" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_106" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_933" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_106" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_933" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_112" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_106" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_112" use="optional" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_ProceedsFromNotesPayableGross" xlink:label="loc_ck0001680048_ProceedsFromNotesPayableGross_467" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_106" xlink:to="loc_ck0001680048_ProceedsFromNotesPayableGross_467" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_463" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_106" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_463" use="optional" order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_113" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_106" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_113" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_114" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_106" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_114" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1005" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_108" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1005" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1006" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_108" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1006" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1007" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_108" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1007" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_631" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_108" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_631" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_632" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_631" xlink:to="loc_us-gaap_InterestPaidNet_632" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_118" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_108" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_118" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_992" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_118" xlink:to="loc_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_992" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_119" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_118" xlink:to="loc_us-gaap_StockIssued1_119" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_120" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_118" xlink:to="loc_us-gaap_LiabilitiesAssumed1_120" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="ck0001680048-20170930.xsd#ck0001680048_StockIssuableForLicenseAcquired" xlink:label="loc_ck0001680048_StockIssuableForLicenseAcquired_743" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_118" xlink:to="loc_ck0001680048_StockIssuableForLicenseAcquired_743" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/CondensedStatementsOfCashFlowsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_123" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_124" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_123" xlink:to="loc_us-gaap_StatementTable_124" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_125" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_124" xlink:to="loc_us-gaap_StatementClassOfStockAxis_125" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_126" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_125" xlink:to="loc_us-gaap_ClassOfStockDomain_126" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_127" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_124" xlink:to="loc_us-gaap_DebtInstrumentAxis_127" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_544" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_127" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_544" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_543" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_124" xlink:to="loc_us-gaap_StatementLineItems_543" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_128" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_543" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_128" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/OrganizationDescriptionOfBusinessAndLiquidityAndCapitalResources">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_130" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_131" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_130" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_131" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.mustangbio.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_133" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_134" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_133" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_134" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763995632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Nov. 13, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MUSTANG BIO, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001680048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,232,139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764318992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 33,209<span></span>
</td>
<td class="nump">$ 27,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term investments (certificates of deposit) - held to maturity</a></td>
<td class="nump">34,088<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">414<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivables</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">67,746<span></span>
</td>
<td class="nump">27,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">67,885<span></span>
</td>
<td class="nump">27,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">2,723<span></span>
</td>
<td class="nump">683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_CommonSharesIssuableLiabilityCurrent', window );">Common shares issuable liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent', window );">Payables and accrued expenses - related party</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_AccruedInterestRelatedPartyCurrent', window );">Accrued interest - related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">413<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Current Liabilities</a></td>
<td class="nump">2,792<span></span>
</td>
<td class="nump">3,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock ($0.0001 par value), 2,000,000 shares authorized, 250,000 shares of Class A preferred stock issued and outstanding as of September 30, 2017 and December 31, 2016, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Common stock issuable, 0 and 767,264 shares as of September 30, 2017 and December 31, 2016, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">97,897<span></span>
</td>
<td class="nump">36,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(32,807)<span></span>
</td>
<td class="num">(17,120)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">65,093<span></span>
</td>
<td class="nump">24,276<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">67,885<span></span>
</td>
<td class="nump">27,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_AccruedInterestRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of related party debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_AccruedInterestRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_CommonSharesIssuableLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The common shares issuable liability for the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_CommonSharesIssuableLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date realted to related party obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_PayablesAndAccruedexpensesRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763940064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">25,232,139<span></span>
</td>
<td class="nump">15,165,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">25,232,139<span></span>
</td>
<td class="nump">15,165,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common Stock, Shares Subscribed but Unissued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">767,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763990832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 2,188<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
<td class="nump">$ 5,388<span></span>
</td>
<td class="nump">$ 1,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development - licenses acquired</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,375<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,596<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
<td class="nump">8,293<span></span>
</td>
<td class="nump">1,814<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">7,084<span></span>
</td>
<td class="nump">1,670<span></span>
</td>
<td class="nump">16,056<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(7,084)<span></span>
</td>
<td class="num">(1,670)<span></span>
</td>
<td class="num">(16,056)<span></span>
</td>
<td class="num">(3,532)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_InterestIncomeExpensesRelatedParty', window );">Interest expense - related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(220)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(156)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">144<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="num">(374)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (6,940)<span></span>
</td>
<td class="num">$ (1,870)<span></span>
</td>
<td class="num">$ (15,687)<span></span>
</td>
<td class="num">$ (3,906)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share outstanding, basic and diluted</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding, basic and diluted</a></td>
<td class="nump">26,186,924<span></span>
</td>
<td class="nump">10,089,269<span></span>
</td>
<td class="nump">24,936,626<span></span>
</td>
<td class="nump">10,130,338<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_InterestIncomeExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income (expenses) from (to) related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_InterestIncomeExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763867008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statement of Stockholders&#8217; Equity - 9 months ended Sep. 30, 2017 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Class A Preferred Stock [Member]</div></th>
<th class="th"><div>Class A Common Shares [Member]</div></th>
<th class="th"><div>Common Shares [Member]</div></th>
<th class="th"><div>Common Stock Issuable [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2016</a></td>
<td class="nump">$ 24,276<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 4,396<span></span>
</td>
<td class="nump">$ 36,998<span></span>
</td>
<td class="num">$ (17,120)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">15,165,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common shares - Founders Agreement</a></td>
<td class="nump">1,234<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(4,396)<span></span>
</td>
<td class="nump">5,630<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common shares - Founders Agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">982,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Issuance of common shares for license expenses</a></td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issuance of common shares for license expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">293,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares and warrants for cash</a></td>
<td class="nump">55,970<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">55,969<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares and warrants for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,610,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering cost</a></td>
<td class="num">(5,674)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,674)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expenses</a></td>
<td class="nump">1,230<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,230<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_AdjustmentToAdditionalPaidInCapitalCapitalContribution', window );">Capital contribution from Fortress</a></td>
<td class="nump">2,062<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,062<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,687)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,687)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Sep. 30, 2017</a></td>
<td class="nump">$ 65,093<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 97,897<span></span>
</td>
<td class="num">$ (32,807)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Sep. 30, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">25,232,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_AdjustmentToAdditionalPaidInCapitalCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in additional paid in capital due to capital contribution from parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_AdjustmentToAdditionalPaidInCapitalCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ck0001680048_CommonStockIssuableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ck0001680048_CommonStockIssuableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763970256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,687)<span></span>
</td>
<td class="num">$ (3,906)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development-licenses acquired, expensed</a></td>
<td class="nump">2,375<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses', window );">Issuance of common shares - Founders Agreement</a></td>
<td class="nump">1,234<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expenses</a></td>
<td class="nump">1,230<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Capital contribution from Fortress</a></td>
<td class="nump">2,062<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(414)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest receivables</a></td>
<td class="num">(35)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,923<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Payable and accrued expenses - related party</a></td>
<td class="num">(56)<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest - related party</a></td>
<td class="num">(413)<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(7,781)<span></span>
</td>
<td class="num">(1,866)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Purchase of short-term investment (certificates of deposit)</a></td>
<td class="num">(34,088)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of research and development licenses</a></td>
<td class="num">(2,375)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForConstructionInProcess', window );">Purchase of fixed assets - construction-in-process</a></td>
<td class="num">(22)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(36,485)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from Fortress Note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payment of Fortress Note</a></td>
<td class="num">(320)<span></span>
</td>
<td class="num">(3,533)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_ProceedsFromNotesPayableGross', window );">Proceeds from NSC Note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issue costs associated with NSC Note</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of common stock and warrants, net of offering cost of $5,674 and $0, respectively</a></td>
<td class="nump">50,296<span></span>
</td>
<td class="nump">11,083<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">49,976<span></span>
</td>
<td class="nump">12,984<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">5,710<span></span>
</td>
<td class="nump">11,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">27,499<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">33,209<span></span>
</td>
<td class="nump">11,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid', window );">Construction-in-progress included in accounts payable and accrued expenses</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common shares - Founders Agreement</a></td>
<td class="nump">4,396<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Warrant liability associated with NSC Note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_StockIssuableForLicenseAcquired', window );">Common shares issuable for license acquired</a></td>
<td class="nump">$ 1,682<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses relates to issuance of common stock under founder agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_IssuanceOfCommonStockFounderAgreementExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_ProceedsFromNotesPayableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of gross cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_ProceedsFromNotesPayableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_StockIssuableForLicenseAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issuable for license acquired in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_StockIssuableForLicenseAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for construction in progress expenditures that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid, after deduction of cash paid for capitalized interest, for interest. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForConstructionInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForConstructionInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow through purchase of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760558352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Proceeds from issuance of common stock and warrants, offering cost</a></td>
<td class="nump">$ 5,674<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6913254736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Description of Business and Liquidity and Capital Resources<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Note 1 - Organization, Description of Business and Liquidity and Capital Resources</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 18.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Mustang Bio, Inc. (the &#8220;Company&#8221; or &#8220;Mustang&#8221;) was incorporated in Delaware on March 13, 2015 and commenced its principal operations on March 13, 2015. Mustang was formed as a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel cancer immunotherapy products designed to utilize the power of the patient&#8217;s own immune system to eliminate cancer cells. The Company may acquire rights to these technologies by licensing the rights or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company is a majority controlled subsidiary of Fortress Biotech, Inc. (&#8220;Fortress&#8221; or &#8220;Parent&#8221;).</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company has incurred substantial operating losses since its inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of September 30, 2017, the Company had an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">32.8</font> million.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company expects to continue to use the proceeds from previous financing transactions primarily for general corporate purposes, which may include financing the Company&#8217;s growth, developing new or existing product candidates, and funding capital expenditures, acquisitions and investments. The Company currently anticipates that its cash and cash equivalents balances and short-term investments held to maturity at September 30, 2017, are sufficient to fund its anticipated operating cash requirements for&#160;at least&#160;the next 12 months.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760617056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Note 2 - Significant Accounting Policies&#160;</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Basis of Presentation</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The accompanying unaudited interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Therefore, these condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto for the year ended December 31, 2016, which were included in the Company&#8217;s Form 10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 31, 2017. The results of operations for any interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Use of Estimates</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Significant Accounting Policies</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">There have been no material changes to the Company&#8217;s significant accounting policies previously disclosed in the Company&#8217;s Form 10-K filed with the SEC on March 31, 2017, with the exception of the policies listed below.&#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Short-term Investments &#150; Held to Maturity</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company classifies its certificates of deposit as cash and cash equivalents or held to maturity in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification (&#8220;ASC&#8221;) 320, <i>Investments &#150; Debt and Equity Securities</i>. The Company considers all investments with an original maturity in excess of three months when purchased to be short-term investments. Investments consist of short-term FDIC insured certificates of deposit carried at amortized cost using the effective interest method. The cost of the Company&#8217;s certificates of deposit approximated fair value. The Company reassesses the appropriateness of the classification of its investments at the end of each reporting period.</div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">At September 30, 2017, the Company had approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40.1</font> million in certificates of deposit with no more than $250,000 at any individual institution. The Company classified $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.0</font> million as cash and cash equivalents and classified $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">34.1</font> million of its certificates of deposits as held-to-maturity as of September 30, 2017. There were no short-term investments as of December 31, 2016. This classification was based upon management&#8217;s determination that it has the positive intent and ability to hold the securities until their maturity dates, as its investments mature within one year and the underlying cash invested in these securities is not required for current operations.</font><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Stock-Based Compensation</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company expenses stock-based compensation to employees and board members over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based awards with graded vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. For stock-based compensation awards to non-employees, the Company measures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 13.2pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The assumptions used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Property and equipment &#150; construction in process</b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Leasehold improvements are amortized over the shorter of the estimated useful lives or the term of the respective leases, upon the improvement being placed in service. In connection with the Company&#8217;s manufacturing facility, the Company incurred $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1</font> million related to the design of the facility which is recorded in property and equipment on the condensed balance sheet at September 30, 2017. Upon completion of the buildout all costs associated with the buildout will be recorded as leasehold improvements.</div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></i></b> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><i><b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font></i></b></i></b></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><i><strong>Recently Adopted Accounting Pronouncements</strong></i></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; COLOR: #212121; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">In March 2016, the FASB issued Accounting Standards Update ("ASU") 2016-09<i>&#160;Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting</i> <font style="COLOR: #212121">(&#8220;ASU 2016-09&#8221;)</font>. Under ASU 2016-09, companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in capital (&#8220;APIC&#8221;). Instead, they will record all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement and the APIC pools will be eliminated. In addition, ASU 2016-09 eliminates the requirement that excess tax benefits be realized before companies can recognize them. ASU 2016-09 also requires companies to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. Furthermore, ASU 2016-09 will increase the amount an employer can withhold to cover income taxes on awards and still qualify for the exception to liability classification for shares used to satisfy the employer&#8217;s statutory income tax withholding obligation. An employer with a statutory income tax withholding obligation will now be allowed to withhold shares with a fair value up to the amount of taxes owed using the maximum statutory tax rate in the employee&#8217;s applicable jurisdiction(s). ASU 2016-09 requires a company to classify the cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation as a financing activity on the statement of cash flows. Under current GAAP, it was not specified how these cash flows should be classified. In addition, companies will now have to elect whether to account for forfeitures on share-based payments by (1) recognizing forfeitures of awards as they occur or (2) estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change, as is currently required. The Amendments of this ASU are effective for reporting periods beginning after December 15, 2016, with early adoption permitted but all of the guidance must be adopted in the same period. The Company adopted ASU 2016-09 on January 1, 2017. The adoption did not have a material impact on the Company&#8217;s condensed financial statements and related disclosures.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">In January 2017, the FASB issued ASU 2017-01, <i>Business Combinations (Topic 805): Clarifying the Definition of a Business</i> (&#8220;ASU 2017-01&#8221;). The amendments in this update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for fiscal periods beginning after December 15, 2017, including interim periods within those periods. The Company adopted ASU 2017-01 on January 1, 2017. The adoption did not have a material impact on the Company&#8217;s condensed consolidated financial statements and related disclosures.</font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify">&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>Recently Issued Accounting Standards&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" align="center">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In February 2016, the FASB issued ASU 2016-02, <i> Leases (Topic 842).</i> ASU 2016-02 requires an entity to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December&#160;15, 2018. Early adoption is permitted. The Company is currently evaluating the impact, if any, of adopting this standard on its condensed consolidated financial statements and related disclosures.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In August 2016, the FASB issued ASU 2016-15, <i> Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments</i> (&#8220;ASU 2016-15&#8221;), which addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is currently in the process of evaluating the impact of this new pronouncement on its condensed statements of cash flows and related disclosures.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In May 2017, the FASB issued ASU 2017-09, Compensation&#151;Stock Compensation (Topic 718): <i>Scope of Modification Accounting</i> (&#8220;ASU 2017-09&#8221;), which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the condensed financial statements and disclosures, but does not expect it to have a significant impact.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6703959040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements and Clinical Research Support Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_LicenseAgreementDisclosureAbstract', window );"><strong>License Agreement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_LicenseAgreementDisclosureTextBlock', window );">License Agreement Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Note 3 - License Agreements and Clinical Research Support Agreements</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><strong><u><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">City of Hope Licenses</font></u></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In February, 2017, the Company and City of Hope National Medical Center (&#8220;City of Hope&#8221; or &#8220;COH&#8221;) amended and restated their license agreement, dated March 17, 2015 (the &#8220;Original&#160;Agreement&#8221;), in connection with the covered patents by entering into three separate amended and restated exclusive license agreements, one relating to CD123, one relating to IL13R&#945;2 and one relating to the Spacer technology, that amended the Original Agreement in certain other respects, and collectively replace the Original Agreement in its entirety. The total potential consideration payable to COH by the Company, in equity or cash, did not, in the aggregate, change materially from the Original Agreement. As of September 30, 2017, COH owns <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> Class A common shares and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 293,588</font> common shares representing approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5.0</font>% of ownership, at September 30, 2017 and has the right to appoint a director to the Board of Directors (the &#8220;Board&#8221;).</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;<font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In addition, the Company entered into a sponsored research agreement with COH in which the Company will fund continued research in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.0</font> million per year, payable in four equal installments, until 2020. The research covered under this arrangement is for IL13R&#945;2, CD123 and the Spacer technology. For the three months ended September 30, 2017 and 2016, the Company recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.5</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.5</font>&#160;million,&#160;respectively, in research and development expenses on the condensed statement of operations in connection with this agreement. For the nine months ended September 30, 2017 and 2016, the Company recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million, respectively, on research and development expenses in the condensed statement of operations in connection with this agreement.</font></font><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font></font>&#160;</div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In December 2016, the Company entered into two consulting agreements, one with two COH scientists, whereby effective January 1, 2017, in exchange for services provided to the Company each consultant shall be paid $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60,000</font> per year, paid quarterly, through January 31, 2019. Further, each consultant has agreed to serve on our Scientific Advisory Board on an as needed basis, and will receive additional compensation for those services. In addition, for services provided during the fourth quarter of 2016, pursuant to the terms of the agreement each consultant earned $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60,000</font>, which was paid in the first quarter of 2017. For the three and nine months ended September 30, 2017, the Company recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90,000</font>, respectively, on the condensed statement of operations in connection with these agreements.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">CD123 License</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In February 2017, the Company entered into an Amended and Restated Exclusive License Agreement with COH to acquire intellectual property rights pertaining to patent rights related to CD123 (the &#8220;CD123 License&#8221;). Pursuant to the CD123 License, the Company and COH acknowledge that an upfront fee has already been paid under the Original Agreement. In addition, COH is eligible to receive an annual maintenance fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> and milestone payments totaling approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14.5</font> million upon and subject to the achievement of certain milestones. Royalty payments in the mid-single digits are due on net sales of licensed products. The Company is obligated to pay COH a percentage of certain revenues received in connection with a sublicense in the mid-teens to mid-thirties, depending on the timing of the sublicense in the development of any product. In addition, equity grants made under the Original Agreement were acknowledged, and the anti-dilution provisions of the Original Agreement were carried forward.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">CD123 CRA</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In February 2017, the Company entered into a Clinical Research Support Agreement for CD123 (the &#8220;CD123 CRA&#8221;). Pursuant to the terms of the CD123 CRA the Company made an upfront payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19,450</font> and will contribute an additional $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">97,490</font> per patient in connection with the on-going investigator initiated study. Further, the Company agreed to fund approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.2</font> million over three years pertaining to the clinical development of CD123. For the three and nine months ended September 30, 2017 the Company recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.6</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.2</font>, respectively, in research and development expenses under the CD123 CRA on the condensed statement of operations. The Company recorded no expenses in 2016 related to this arrangement.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in"> <i>IL13R&#945;2 License</i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In February 2017, the Company entered into an Amended and Restated Exclusive License Agreement with COH to acquire intellectual property rights pertaining to patent rights related to IL13R&#945;2 (the &#8220;IL13R&#945;2 License&#8221;). Pursuant to the IL13R&#945;2 License, the Company and COH acknowledge that an upfront fee has already been paid under the Original Agreement. In addition, COH is eligible to receive an annual maintenance fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> and milestone payments totaling approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14.5</font> million upon and subject to the achievement of certain milestones. Royalty payments in the mid-single digits are due on net sales of licensed products. The Company is obligated to pay COH a percentage of certain revenues received in connection with a sublicense in the mid-teens to mid-thirties, depending on the timing of the sublicense in the development of any product. In addition, equity grants made under the Original Agreement were acknowledged, and the anti-dilution provisions of the Original Agreement were carried forward.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"><i>IL13R&#945;2 CRA</i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In February 2017, the Company entered into a Clinical Research Support Agreement for IL13R&#945;2 (the &#8220;IL13R&#945;2 CRA&#8221;). Pursuant to the terms of the IL13R&#945;2 CRA the Company made an upfront payment of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,300</font> and will contribute an additional $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1</font> million related to patient costs in connection with the on-going investigator initiated study. Further, the Company agreed to fund approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.2</font> million over three years pertaining to the clinical development of IL13R&#945;2. For the three and nine months ended September 30, 2017 the Company recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.2</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.2</font> million respectively, in research and development expenses under the IL13R&#945;2 CRA on the condensed statement of operations. The Company recorded no expenses in 2016 related to this arrangement.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Spacer License</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In February 2017, the Company entered into an Amended and Restated Exclusive License Agreement with COH to acquire intellectual property rights pertaining to patent rights related to Spacer (the &#8220;Spacer License&#8221;). Pursuant to the Spacer License, the Company and COH acknowledged that an upfront fee has already been paid under the Original Agreement. In addition, COH will receive an annual maintenance fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000</font>. No royalties are due if the Spacer technology is used in conjunction with a CD123 CAR or an IL13R&#945;2 CAR, and royalty payments in the low single digits are due on net sales of licensed products if the Spacer technology is used in conjunction with other intellectual property. The Company is obligated to pay COH a percentage of certain revenues received in connection with a sublicense in the mid-thirties. In addition, equity grants made under the Original Agreement were acknowledged, and the anti-dilution provisions of the Original Agreement were carried forward.&#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; size: 8.5in 11.0in" align="justify"><i>IV/ICV License</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In February 2017, the Company entered into an exclusive license agreement (the &#8220;IV/ICV License&#8221;) with COH to acquire intellectual property rights in patent applications related to the intraventricular and intracerebroventricular methods of delivering T cells that express CARs. Pursuant to the IV/ICV License, in March 2017, the Company paid COH an upfront fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1</font>&#160;million. COH is eligible to receive a milestone payment totaling approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1</font>&#160;million, upon and subject to the achievement of a milestone, and an annual maintenance fee. Royalty payments in the low single digits are due on net sales of licensed products.</font></div> <i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">HER2 Technology License&#160;</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On May 31, 2017, the Company entered into an exclusive license agreement (the &#8220;HER2 Agreement<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#8221;</font>) with the COH for the use of human epidermal growth factor receptor 2 (HER2) CAR T technology (HER2 Technology), which will initially be applied in the treatment of glioblastoma multiforme. Pursuant to the HER2 Agreement, the Company paid an upfront fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.6</font>&#160;million and will owe an annual maintenance fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> (beginning in 2019). Additional payments are due for the achievement of ten development milestones totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14.9</font> million and royalty payments in the mid-single digits are due on net sales of licensed products.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">CS1 Technology License&#160;</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On May 31, 2017, the Company entered into an exclusive license agreement (the &#8220;CS1 Agreement) with the COH for the use of CS1-specific CAR T technology (CS1 Technology) to be directed against multiple myeloma. Pursuant to the CS1 Agreement, the Company paid an upfront fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.6</font> <font style="LINE-HEIGHT: 107%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> million</font> and will owe an annual maintenance fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> (beginning in 2019). Additional payments are due for the achievement of ten development milestones totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14.9</font> million and royalty payments in the mid-single digits are due on net sales of licensed products.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">PSCA Technology License&#160;</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On May 31, 2017, the Company entered into an exclusive license agreement (the &#8220;PSCA Agreement&#8221;) with the COH for the use of prostate stem cell antigen (PSCA) CAR T technology (PSCA Technology) to be used in the treatment of prostate cancer. Pursuant to the PSCA Agreement, the Company paid an upfront fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.3</font> <font style="LINE-HEIGHT: 107%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> million</font> and will owe an annual maintenance fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> (beginning in 2019). Additional payments are due for the achievement of ten development milestones totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14.9</font> million and royalty payments in the mid-single digits are due on net sales of licensed products.</font></div> <i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><strong><u><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">University of California License</font></u></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY:times new roman,times,serif">On March 17, 2017, the Company entered into an exclusive license agreement with the Regents of the University of California (the &#8220;UCLA License&#8221;) to acquire intellectual property rights in patent applications related to the engineered anti-prostate stem cell antigen antibodies for cancer targeting and detection. Pursuant to the UCLA License, the Company paid UCLA the upfront fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.2</font>&#160;<font style="LINE-HEIGHT: 107%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> million</font> and will owe an annual maintenance fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,000</font></font> for the first two years, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font></font> for years three and four, and&#160;<font style="LINE-HEIGHT: 107%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> per year</font></font><font style="FONT-SIZE: 10pt">&#160;</font> <font style="FONT-SIZE: 10pt">thereafter. Additional payments are due for the achievement of seven development milestones, totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14.3</font> million, and royalty payments in the mid-single digits are due on net sales of licensed products.</font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><strong><u><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Fred Hutchinson Cancer Research Center License</font></u></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">CD20 Technology License</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On July 3, 2017, Mustang entered into an exclusive, worldwide licensing agreement with Fred Hutchinson Cancer Research Center (&#8220;Fred Hutch&#8221;) for the use of a CAR T therapy related to autologous T cells engineered to express a CD20-specific chimeric antigen receptor (&#8220;CD20 Technology License&#8221;). Pursuant to the CD 20 Technology License, the Company paid Fred Hutch an upfront fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.3</font> million and will owe an annual maintenance fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font>&#160;on&#160;each anniversary of the license until the achievement by the Company of regulatory approval of a licensed product using CD20 Technology. Additional payments are due for the achievement of&#160;eleven development milestones totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">39.1</font> million and royalty payments in the mid-single digits are due on net sales of licensed products.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>CD20 CTA</i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Also,&#160;on July 3, 2017, in conjunction with the CD20 Technology License from Fred Hutch, Mustang entered into an investigator-initiated clinical trial agreement (&#8220;CD20 CTA&#8221;) to provide partial funding for a Phase 1/2 clinical trial at Fred Hutch evaluating the safety and efficacy of the CD20 Technology in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. In connection with the CD20 CTA, the Company agreed to fund up to&#160;$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.3</font> million of costs associated with the clinical trial, which <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> commenced</font> during the fourth quarter of 2017. For the three and nine months ended September 30, 2017, the Company recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">88,000</font></font> of expense in connection with this agreement. Further the Company made an upfront payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.4</font> <font style="LINE-HEIGHT: 107%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> million</font> recorded on the condensed balance sheets as of September 30, 2017, as a prepaid expense, in connection with a startup fee related to the study.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><strong><u><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Research and Development Expenses &#150; All Licenses</font></u></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>For the three and nine months ended September 30, 2017 and 2016, the Company recorded the following expense in research and development for licenses acquired:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div style="CLEAR:both;CLEAR: both"> For&#160;the&#160;Three&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div style="CLEAR:both;CLEAR: both"> For&#160;the&#160;Nine&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"> <div style="CLEAR:both;CLEAR: both"> ($&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">City of Hope</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">IL13Ra2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">IV/ICV</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">PSCA</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">300</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">HER2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">CS-1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">UCLA</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Fred Hutch CD20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">300</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">300</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">300</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,375</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_LicenseAgreementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_LicenseAgreementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_LicenseAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_LicenseAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760622064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>Note 4 - Related Party Agreements</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>Founders Agreement and Management Services Agreement with Fortress</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Effective March 13, 2015, the Company entered into a Founders Agreement with Fortress, which was amended and restated on May 17, 2016 and again on July 26, 2016 (the &#8220;Mustang Founders Agreement&#8221;). The Mustang Founders Agreement provides that, in exchange for the time and capital expended in the formation of Mustang and the identification of specific assets the acquisition of which result in the formation of a viable emerging growth life science company, Fortress loaned $2.0 million, representing the up-front fee required to acquire the Company&#8217;s license agreement with COH. The Mustang Founders Agreement has a term of 15 years, which upon expiration automatically renews for successive one-year periods unless terminated by Fortress and the Company or a Change in Control (as defined in the Mustang Founders Agreement) occurs. Concurrently with the second amendment on July 26, 2016 to the Mustang Founders Agreement, Fortress entered into an Exchange Agreement whereby Fortress exchanged its 7.25 million Class B common shares for 7.0 million common shares and 250,000 Class A preferred shares. Class A Preferred Stock is identical to common shares other than as to voting rights, conversion rights and the PIK Dividend right (as described below). Each share of Class A Preferred Stock will be entitled to vote the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the shares of outstanding Mustang common stock and (B) the whole shares of Mustang common stock into which the shares of outstanding Class A common shares and Class A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority. Each share of Class A Preferred Stock is convertible, at Fortress&#8217; option, into one fully paid and nonassessable share of Mustang common stock, subject to certain adjustments. As holders of Class A Preferred Stock, Fortress will receive on each March 13 (each a &#8220;PIK Dividend Payment Date&#8221;) until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (&#8220;PIK Dividends&#8221;) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half percent (2.5%) of Mustang&#8217;s fully-diluted outstanding capitalization on the date that is one (1) business day prior to any PIK Dividend Payment Date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">As additional consideration under the Mustang Founders Agreement, Mustang will also: (i) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Mustang or any of its respective subsidiaries that occurs after the effective date of the Mustang Founders Agreement and ending on the date when Fortress no longer has majority voting control in the Company&#8217;s voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of the Company&#8217;s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, the Company will pay a one-time change in control fee equal to five (5x) times the product of (A) net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On March 13, 2016, pursuant to the then in effect Mustang Founders Agreement, on the anniversary date of the Founders&#8217; Agreement, the Company issued 250,000 shares of its Class B common stock to Fortress representing 2.5% of the fully diluted outstanding shares of the Company. Pursuant to the terms of the Mustang Founders Agreement, as amended in July 2016, this equity fee is no longer payable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Effective as of March 13, 2015, the Company entered into a Management Services Agreement (the &#8220;MSA&#8221;) with Fortress. Pursuant to the terms of the MSA, for a period of five years, Fortress will render advisory and consulting services to the Company. Services provided under the MSA may include, without limitation, (i) advice and assistance concerning any and all aspects of the Company&#8217;s operations, clinical trials, financial planning and strategic transactions and financings and (ii) conducting relations on behalf of the Company with accountants, attorneys, financial advisors and other professionals (collectively, the &#8220;Services&#8221;). The Company is obligated to utilize clinical research services, medical education, communication and marketing services and investor relations/public relation services of companies or individuals designated by Fortress, provided those services are offered at market prices. However, the Company is not obligated to take or act upon any advice rendered from Fortress and Fortress shall not be liable for any of its actions or inactions based upon their advice. Fortress and its affiliates, including the Company&#8217;s Board of Directors, have been contractually exempt from fiduciary duties to the Company relating to corporate opportunities. In consideration for the Services, the Company will pay Fortress an annual consulting fee of $0.5 million (the &#8220;Annual Consulting Fee&#8221;), payable in advance in equal quarterly installments on the first business day of each calendar quarter in each year, provided, however, that such Annual Consulting Fee shall be increased to $1.0 million for each calendar year in which the Company has net assets in excess of $100 million at the beginning of the calendar year.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">For the three months ended September 30, 2017 and 2016, the Company recorded approximately $0.1 million and $0.1 million, respectively, as expense related to the MSA. For the nine months ended September 30, 2017 and 2016, the Company recorded approximately $0.4 million and $0.4 million, respectively, as expense related to the MSA. For the three and nine months ended September 30, 2017 and 2016, respectively, expenses related to the MSA are recorded 50% in research and development expenses and 50% in general and administrative expenses on the condensed consolidated statement of operations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>Consulting Agreement with Chord Advisors, LLC (&#8220;Chord&#8221;)</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">On April 8, 2016, the Company entered into a full-service consulting agreement with Chord to provide advisory accounting services to the Company. Under the terms of the agreement, the Company paid Chord up to $5,000 per month to perform back office accounting functions, accounting analysis and financial reporting prior to the Company&#8217;s filing of its Registration Statement on Form 10 on July 27, 2016, and $7,500 per month following that date. Either party upon 30-days written notice can terminate the agreement. In addition to these services, Mr. Horin, a Managing Partner of Chord, serves as the Company&#8217;s Interim Chief Financial Officer. Chord also provides advisory accounting services to Fortress under a separate agreement. For the three months ended September 30, 2017 and 2016, $22,500 and $17,500, respectively, of expense was recognized. For the nine months ended September 30, 2017 and 2016, $67,500 and $30,300, respectively, of expense was recognized. The expense was recorded in general and administrative expenses on the condensed statements of operations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Payable and Accrued Expenses Related Party</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company had a working capital promissory note with Fortress, which was paid in full in 2016. In 2017, in the normal course of business Fortress pays for certain expenses on behalf of the Company. Such expenses are recorded as Payable and accrued expenses &#150; related party and are reimbursed to Fortress in the normal course of business.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>National Securities Inc.</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Fortress owns approximately 56.6% of National Holdings Corporation (&#8220;NHLD&#8221;). National Securities Inc. (&#8220;NSC&#8221;) a subsidiary of NHLD acted as placement agent for the Company&#8217;s third-party financings (see Note 6). For the nine months ended September 30, 2017, the Company paid NSC placement agent fees of $5.6 million and issued to NSC 861,077 warrants to purchase the Company&#8217;s common stock. The warrants have a five-year term and an exercise price of $8.50 per share. No fees were incurred for the three and nine months ended September 30, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>Director Compensation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>Dr. Rosenwald</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Pursuant to the terms of the Director Compensation Plan, Dr. Rosenwald will receive a cash fee of $50,000 per year paid quarterly and an annual stock award of the greater of (i) a number of shares of common stock having a fair market value on the grant date of $50,000 or (ii) 10,000 shares of common stock, which shares shall vest and become non-forfeitable on the third anniversary of the grant date, subject to continued service on the Board on such date. For the three and nine months ended September 30, 2017, the Company recognized $12,500 and $25,052, in expense in its Condensed Statements of Operations related to the director compensation, including approximately $4,900 in expense related to an annual equity incentive grant of 10,000 restricted shares. No expense was recorded in 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>Mr. Weiss - Advisory Agreement with Caribe BioAdvisors, LLC</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Board of the Company by unanimous written consent approved and authorized the execution of an advisory agreement dated January 1, 2017 (the &#8220;Advisory Agreement&#8221;), with Caribe BioAdvisors, LLC (the &#8220;Advisor&#8221;), owned by Michael S. Weiss, the Chairman of the Board, to provide the board advisory services of Mr. Weiss as Chairman of the Board. Pursuant to the Advisory Agreement, the Advisor will be paid an annual cash fee of $60,000, paid quarterly and an annual stock award of the greater of (i) a number of shares of common stock having a fair market value on the grant date of $50,000 or (ii) 10,000 shares of common stock, which shares shall vest and become non-forfeitable on the third anniversary of the grant date, subject to continued service on the Board on such date. For three and nine months ended September 30, 2017, the Company recognized $15,000 and $46,200, respectively, in expense in its Condensed Statements of Operations related to the advisory agreement, including approximately $4,800 and $6,000, respectively, in expense related to an annual equity incentive grant of 10,000 restricted shares. No expense was recorded in 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>Stock Awards Made to Fortress Employees</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In April 2017, the Company made an option award to two employees of Fortress (see Note 7).</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6909199552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Note 5 - Commitments and Contingencies</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Litigation</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On January 15, 2016, Dr. Winson Tang (&#8220;Plaintiff&#8221;) filed a Complaint against the Company in the Superior Court of the State of California, County of Los Angeles. Winson Tang v. Lindsay Rosenwald et al., Case No. BC607346. As amended, the Complaint requested a declaration that Plaintiff was a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15</font>% owner of the Company&#8217;s outstanding shares, and alleged two claims for breach of contract against other Defendants. On November 3, 2017, Plaintiff and Defendants entered into a Settlement Agreement. The Settlement Agreement did not require issuance of any new shares of the Company.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In connection with the legal settlement, above, Fortress is required to deliver <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 200,000</font> Mustang common shares, held by Fortress, to Plaintiff in accordance with this settlement arrangement. At September 30, 2017, the Company recorded this transaction as a capital contribution from Fortress and a corresponding expense of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.1</font> million based upon the closing share price of Mustang shares as of the date of the Settlement Agreement. In addition to the share issuance the Company paid, in November 2017, a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1</font> million cash settlement to the plaintiff, such amount was accrued as of September 30, 2017 and recorded in general and administrative expenses on the Condensed Consolidated Statements of Operations.<font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760609008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">6 - Net Loss per Share</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period less unvested restricted stock. Since dividends are declared, paid and set aside among the holders of shares of common stock and Class A common shares pro-rata on an as-if-converted basis, the two-class method of computing net loss per share is not required. Diluted net loss per share does not reflect the effect of shares of common stock to be issued upon the exercise of warrants or outstanding Class A preferred shares, as their inclusion would be anti-dilutive. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive.&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Potentially dilutive securities</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div> For&#160;the&#160;nine&#160;months&#160;ended&#160;September&#160;30</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Warrants (Note 7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>5,257,434</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>670,191</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Options (Note 7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,241,675</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Class A Preferred Shares (Note 7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Unvested restricted stock awards (Note 7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>180,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Unvested restricted stock units (Note 7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>110,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>7,039,109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>920,191</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6907881312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Note 7 - Stockholders&#8217; Equity</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Common Stock</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company is authorized to issue <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50,000,000</font> common shares with a par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0001</font> per share, of which <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> shares are designated as &#8220;Class A common shares&#8221; and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> of Preferred Stock at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0001</font> par value and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 250,000</font> of which are designated as Class A Preferred Stock.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Pursuant to the Founders Agreement, on March 13, 2016 the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 250,000</font> shares of Class B common stock to Fortress, which equaled <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.5</font>% of the fully diluted outstanding equity of Mustang at the time of issuance for the annual equity fee. In accordance with the amended and restated certificate of incorporation filed on July 27, 2016, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 250,000</font> shares of Class A Preferred Stock, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7.0</font> million common shares and cancelled <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7.2</font> million Class B common shares. This exchange was recorded as an equity transaction and therefore no gain or loss was recorded (see Note 4).</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In February 2017, COH executed a waiver and acknowledgement agreement permitting issuance of the COH Anti-Dilution Shares in the form of Mustang common stock rather than Class A common shares as originally required, and such shares were issued. Therefore, in February 2017, the Company reclassed $1.7 million of common shares issuable liability to additional paid-in capital and issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 293,588</font> common shares to COH. As of September 30, 2017, COH owns <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> Class A common shares and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 293,588</font> common shares. The shares were valued utilizing a weighted market model at approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.73</font> per share or approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.7</font> million.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On March 13, 2017, the Company issued to Fortress <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 767,264</font> shares of common stock at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.73</font> per share representing the stock dividend payable in connection with Fortress&#8217; ownership of Class A Preferred Stock. Pursuant to this issuance, the Company recorded a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.4</font> million decrease in common shares issuable and a corresponding increase in additional paid in capital to account for the issuance of the PIK Dividend (see Note 4).</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;&#160;&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The holders of common stock are entitled to one vote per share of common stock held.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Class A Common Stock</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The holders of Class A common shares are entitled to the number of votes equal to the number of whole shares of common stock into which the shares of Class A common shares held by such holder are convertible and for a period of ten years from its issuance, the holders of the Class A common shares have the right to appoint one member of the board of directors of Mustang; to date, the holders of Class A common shares have not yet appointed such director.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On March 17, 2015, the Company entered into the Original Agreement with COH to acquire intellectual property rights pertaining to CAR-T, (see Note 3). Pursuant to the Original Agreement, the Company paid COH an upfront fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.0</font> million, in April 2015 (included in research and development-licenses acquired expenses on the Statements of Operations), and granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000,000</font> shares of Mustang&#8217;s Class A common shares, representing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% ownership of Mustang, as of such date.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Offerings and Issuances of Common Stock and Warrants</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In September 2016, the Company entered into a Placement Agent Agreement with NSC relating to the Company&#8217;s offering of shares of common stock in a private placement. Pursuant to the Placement Agent Agreement, the Company agreed to pay NSC a cash fee of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10.0</font>% of the gross proceeds from the offering and granted a warrant exercisable for shares of common stock equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10.0</font>% of the aggregate number of shares of common stock sold in the offering (the &#8220;Placement Agent Warrants&#8221;). In addition, the Company and the investors entered into a unit purchase agreement (the &#8220;Unit Purchase Agreement&#8221;). The common stock and Warrants were sold in units, with each unit consisting of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000</font> shares of the Company&#8217;s common stock, and Warrants exercisable for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,500</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.50</font> per share. The purchase price was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">65,000</font> per unit. The warrants have a five-year term and are only exercisable for cash.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On January 31, 2017, the Company closed the sixth round of financing totaling gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">55.5</font> million, before expenses, in a private placement of shares and warrants for which NSC was the placement agent and received a fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.5</font> million or approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of the gross proceeds. The Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,536,774</font> unregistered shares of common stock and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,134,193</font> warrants in connection with this transaction. In addition, NSC received <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 853,677</font> warrants or approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of the shares issued.</font></div> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On March 31, 2017, the Company closed the seventh round of financing totaling gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.4</font> million, before expenses, in a private placement of shares and warrants for which NSC was the placement agent and received a fee of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">42,000</font> or approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of the gross proceeds. The Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 64,000</font> unregistered shares of common stock and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 16,000</font> warrants in connection with this transaction. In addition, NSC received <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,400</font> warrants or approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of the shares issued.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On August 3, 2017, the Company closed the final round of financing totaling gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">65,000</font>. The Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000</font> unregistered shares of common stock and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,500</font> warrants in connection with this transaction. In addition, NSC received <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,000</font> warrants or approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of the shares issued.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><u>Common Share Issuances to Fortress</u></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Pursuant to the Founders Agreement, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 215,269</font> shares and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 47,870</font> shares to Fortress during the nine months ended September 30, 2017 and September 30, 2016, respectively, representing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.5</font>% of the aggregate number of shares of common stock issued in the offerings noted above. For the nine months ended September 30, 2017 and September 30, 2017, the Company recorded expense of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.2</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.3</font> million, respectively, related to this issuance (based upon the fair value of common shares on the date of issuance), which is included in general and administrative expenses in the Company&#8217;s Statements of Operations.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Class A Preferred Shares</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Pursuant to the Company&#8217;s Amended and Restated Articles of Incorporation, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares of Preferred Stock were authorized, of which <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 250,000</font> have been designated as Class A Preferred Stock and the remainder are undesignated preferred stock. The Class A Preferred Stock is identical to undesignated common stock other than as to voting rights, conversion rights, and the PIK Dividend right (as described below). The undesignated Preferred Stock may be issued from time to time in one or more series. The Company&#8217;s Board of Directors is authorized to determine or alter the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions, if any), the redemption price or prices, the liquidation preferences and other designations, powers, preferences and relative, participating, optional or other special rights, if any, and the qualifications, limitations and restrictions granted to or imposed upon any wholly unissued series of Preferred Stock, and to fix the number of shares of any series of Preferred Stock (but not below the number of shares of any such series then outstanding).</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The holders of the outstanding shares of Class A Preferred Stock shall receive on each March 13 (each a &#8220;PIK Dividend Payment Date&#8221;) after the original issuance date of the Class A Preferred Stock until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and non-assessable shares of common stock such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to 2.5% of the Corporation&#8217;s fully-diluted outstanding capitalization on the date that is one business day prior to any PIK Dividend Payment Date (&#8220;PIK Record Date&#8221;). In the event the Class A Preferred Stock converts into common stock, the holders shall receive all PIK Dividends accrued through the date of such conversion. No dividend or other distribution shall be paid, or declared and set apart for payment (other than dividends payable solely in capital stock on the capital stock of the Company) on the shares of common stock until all PIK Dividends on the Class A Preferred Stock shall have been paid or declared and set apart for payment. All dividends are non-cumulative.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Class A Preferred Stock shall be entitled to cast for each share of Class A Preferred Stock held by such holder as of the record date for determining stockholders entitled to vote on such matter, the number of votes that is equal to one and one-tenth <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> (1.1)</font> times a fraction, the numerator of which is the sum of (A) the number of shares of outstanding common stock and (B) the whole shares of common stock in to which the shares of outstanding Class A common shares and the Class A Preferred Stock are convertible, and the denominator of which is number of shares of outstanding Class A Preferred Stock (the &#8220;Class A Preferred Stock Ratio&#8221;). Thus, the Class A Preferred Stock will at all times constitute a voting majority.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Each share of Class A Preferred Stock is convertible, at the option of the holder, into one fully paid and nonassessable share of common stock (the &#8220;Conversion Ratio&#8221;), subject to certain adjustments. If the Company, at any time effects a subdivision or combination of the outstanding common stock (by any stock split, stock dividend, recapitalization, reverse stock split or otherwise), the applicable Conversion Ratio in effect immediately before that subdivision is proportionately decreased or increased, as applicable, so that the number of shares of common stock issuable on conversion of each share of Class A Preferred Stock shall be increased or decreased, a applicable, in proportion to such increase or decrease in the aggregate number of shares of common stock outstanding. Additionally, if any reorganization, recapitalization, reclassification, consolidation or merger involving the Company occurs in which the common stock (but not the Class A Preferred Stock) is converted into or exchanged for securities, cash or other property, then each share of Class A Preferred Stock becomes convertible into the kind and amount of securities, cash or other property which a holder of the number of shares of common stock of the Company issuable upon conversion of one share of the Class A Preferred Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Stock Awards</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><u><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Stock Options&#160;</font></u></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On April 24, 2017, the Company announced that Manuel Litchman, M.D., had been appointed President and Chief Executive Officer. Dr. Litchman was also appointed to the Company&#8217;s Board of Directors.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The employment agreement grants Dr. Litchman an option to purchase 1,041,675 shares of the Company&#8217;s common stock (the &#8220;Option&#8221;). The Option has an exercise price per share equal to the fair market value of a share the Company&#8217;s common stock, $5.73 on the date of the grant of the stock option, subject to the conditions and vesting schedule set forth in his Employment Agreement.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On April 7, 2017, the Company granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 200,000</font> options to two employees of Fortress, who provide services to the Company in connection with our research and development. These options have an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.73</font>, representing the fair market value of a share the Company&#8217;s common stock on the date of the grant of the stock option.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Both grants have the following vesting schedule: 50% of the options vest over-time (&#8220;Time Based Option&#8221;) with 25% vesting over 12 months of continued service and the remaining shares vesting in 12 equal quarterly installments thereafter, subject to continued employment. <font style="FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 10pt">The remaining 50% (the &#8220;Performance Options&#8221;) vest and become exercisable upon the occurrence of the following milestones being achieved: (i) 25% of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of any Company product candidate, (ii) 25% of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of a second Company product candidate, (iii) 25% of the Performance Options vest upon the Company&#8217;s achievement of a fully-diluted market capitalization of $500,000,000 and (iv) 25% of the Performance Options vest upon the Company&#8217;s achievement of a fully-diluted market capitalization of $1,000,000,000.</font></font></font><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The value of the&#160;stock options granted approximated $5.5 million and&#160;was determined on the grant date using assumptions for risk free interest rate, the expected term, expected volatility, expected dividend yield, and&#160;an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.73</font>. Mustang does not expect to pay dividends in the foreseeable future. As a result, the expected dividend yield is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 0</font>%. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The fair value associated with the market award vesting was determined utilizing a binomial valuation methodology and the following assumptions:</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"> <div>September&#160;30,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>1.81% - 2.38</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Exercise Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>5.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Expected term in years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>5.5 - 10.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>77.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table summarizes stock option activities for the nine months ended September 30, 2017:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Contractual&#160;Life&#160;(in</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Stock&#160;Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Nonvested at December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Options granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,241,675</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>9.56</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Options outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,241,675</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>9.56</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Options vested and exercisable at September 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">As of September 30, 2017, the Company had unrecognized stock-based compensation expense related to options of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.3</font> million with a weighted average vesting period of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.61</font> years.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><u><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Restricted Stock</font></u></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In accordance with the Company&#8217;s Director Compensation Plan, the Company granted an aggregate <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 180,000</font> restricted shares to members of its board of directors, these shares commence vesting three years from the grant date of June 8, 2017. Annual grants to each director of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000</font> shares vest on the third anniversary of the grant with continuous service, while the initial grant of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50,000</font> vests in three equal tranches commencing on the third anniversary date of the grant and on each date thereafter so long as continuous service exists. See Note 4 for grants made to Dr. Rosenwald and Mr. Weiss for their service as Directors to the Company.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table summarizes restricted stock award activities for the nine months ended September 30, 2017:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Number&#160;of&#160;Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Grant&#160;Date&#160;Fair&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Nonvested at December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>180,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>5.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Nonvested at September 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>180,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>5.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">As of September 30, 2017, the Company had unrecognized stock-based compensation expense related to restricted stock of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font> million with a weighted average vesting period of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3.53</font> years.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><u><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Restricted Stock Units</font></u></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On June 30, 2017, the Company granted an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 110,000</font> restricted stock units to two employees. These grants vest over 4 years on the anniversary date <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">of the grant</font>.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table summarizes restricted stock units activities for the nine months ended September 30, 2017:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Number&#160;of&#160;Units</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Grant&#160;Date&#160;Fair&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Nonvested at December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>110,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>5.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Nonvested at September 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>110,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>5.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">As of September 30, 2017, the Company had unrecognized stock-based compensation expense related to restricted stock units of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.6</font> million with a weighted average vesting period of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.25</font> years.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2017 (in thousands).</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="28%" colspan="6"> <div> For&#160;the&#160;three&#160;months&#160;ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="28%" colspan="6"> <div> For&#160;the&#160;nine&#160;months&#160;ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Employee</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>576</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>909</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Non-employee</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>258</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>321</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Total stock-based compensation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>834</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,230</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Warrants</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In connection with the Company&#8217;s offering of shares of common stock in a private placement, each investor received a warrant equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>% of the common shares purchased in connection with the offering. Further, NSC received&#160;Placement Agent Warrants.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of warrant activities for nine months ended September 30, 2017 is presented below:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Contractual&#160;Life&#160;(in</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Outstanding as of December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2,243,664</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>7.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>5.16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,013,770</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>8.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Outstanding as of September 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>5,257,434</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>8.28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>4.37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Upon the exercise of warrants, the Company will issue new shares of common stock.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760585392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in; mso-header-mso-footer-mso-paper-source: 0"> <div style="CLEAR:both;TEXT-ALIGN: justify; LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; mso-style-unhide: no; mso-style-qformat: yes; mso-style-parent: ; mso-pagination: widow-orphan; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Times New Roman; mso-bidi-theme-font: minor-bidi"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt; mso-fareast-font-family: 'Times New Roman'"> Note 8 &#150; Subsequent Events</font></b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both;TEXT-ALIGN: justify; LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></b> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;TEXT-ALIGN: justify; LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On October 27, 2017, Mustang entered into a lease agreement with WCS - 377 Plantation Street, Inc., a Massachusetts nonprofit corporation (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#8220;</font>Landlord<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#8221;</font>). Pursuant to the terms of the lease agreement, Mustang agreed to lease <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 27,043</font> sf from the Landlord, located at 377 Plantation Street in Worcester, MA (the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#8220;</font>Facility<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#8221;</font>), through November 2026, subject to additional extensions at Mustang&#8217;s option. Base rent, net of abatements of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.6</font> million over the lease term, totals approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.6</font> million, on a triple-net basis. Mustang plans to make improvements to the facility of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.5</font> million.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The terms of the lease also require that Mustang post an initial security deposit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.8</font> million, in the form of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.5</font> million letter of credit and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.3</font> million in cash, which shall increase to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.3</font> million ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font> million letter of credit, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.3</font> million in cash) when the Facility is fully occupied by Mustang. After the fifth lease year, the letter of credit obligation is subject to reduction.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; COLOR: #1f497d"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> The Facility is expected to be operational for the production of personalized CAR T therapies in 2018.</div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6927582160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Basis of Presentation</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The accompanying unaudited interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Therefore, these condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto for the year ended December 31, 2016, which were included in the Company&#8217;s Form 10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 31, 2017. The results of operations for any interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Use of Estimates</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_SignificantAccountingPoliciesPolicyTextBlock', window );">Significant Accounting Policies [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Significant Accounting Policies</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">There have been no material changes to the Company&#8217;s significant accounting policies previously disclosed in the Company&#8217;s Form 10-K filed with the SEC on March 31, 2017, with the exception of the policies listed below.&#160;</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Short-term Investments &#150; Held to Maturity</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company classifies its certificates of deposit as cash and cash equivalents or held to maturity in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification (&#8220;ASC&#8221;) 320, <i>Investments &#150; Debt and Equity Securities</i>. The Company considers all investments with an original maturity in excess of three months when purchased to be short-term investments. Investments consist of short-term FDIC insured certificates of deposit carried at amortized cost using the effective interest method. The cost of the Company&#8217;s certificates of deposit approximated fair value. The Company reassesses the appropriateness of the classification of its investments at the end of each reporting period.</div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">At September 30, 2017, the Company had approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40.1</font> million in certificates of deposit with no more than $250,000 at any individual institution. The Company classified $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.0</font> million as cash and cash equivalents and classified $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">34.1</font> million of its certificates of deposits as held-to-maturity as of September 30, 2017. There were no short-term investments as of December 31, 2016. This classification was based upon management&#8217;s determination that it has the positive intent and ability to hold the securities until their maturity dates, as its investments mature within one year and the underlying cash invested in these securities is not required for current operations.</font><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Stock-Based Compensation</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company expenses stock-based compensation to employees and board members over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based awards with graded vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. For stock-based compensation awards to non-employees, the Company measures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 13.2pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The assumptions used in calculating the fair value of stock-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of management&#8217;s judgment.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font></b> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Property and equipment &#150; construction in process</b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Leasehold improvements are amortized over the shorter of the estimated useful lives or the term of the respective leases, upon the improvement being placed in service. In connection with the Company&#8217;s manufacturing facility, the Company incurred $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1</font> million related to the design of the facility which is recorded in property and equipment on the condensed balance sheet at September 30, 2017. Upon completion of the buildout all costs associated with the buildout will be recorded as leasehold improvements.</div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></i></b> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><i><b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font></i></b></i></b></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><i><strong>Recently Adopted Accounting Pronouncements</strong></i></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; COLOR: #212121; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">In March 2016, the FASB issued Accounting Standards Update ("ASU") 2016-09<i>&#160;Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting</i> <font style="COLOR: #212121">(&#8220;ASU 2016-09&#8221;)</font>. Under ASU 2016-09, companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in capital (&#8220;APIC&#8221;). Instead, they will record all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement and the APIC pools will be eliminated. In addition, ASU 2016-09 eliminates the requirement that excess tax benefits be realized before companies can recognize them. ASU 2016-09 also requires companies to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. Furthermore, ASU 2016-09 will increase the amount an employer can withhold to cover income taxes on awards and still qualify for the exception to liability classification for shares used to satisfy the employer&#8217;s statutory income tax withholding obligation. An employer with a statutory income tax withholding obligation will now be allowed to withhold shares with a fair value up to the amount of taxes owed using the maximum statutory tax rate in the employee&#8217;s applicable jurisdiction(s). ASU 2016-09 requires a company to classify the cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation as a financing activity on the statement of cash flows. Under current GAAP, it was not specified how these cash flows should be classified. In addition, companies will now have to elect whether to account for forfeitures on share-based payments by (1) recognizing forfeitures of awards as they occur or (2) estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change, as is currently required. The Amendments of this ASU are effective for reporting periods beginning after December 15, 2016, with early adoption permitted but all of the guidance must be adopted in the same period. The Company adopted ASU 2016-09 on January 1, 2017. The adoption did not have a material impact on the Company&#8217;s condensed financial statements and related disclosures.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">In January 2017, the FASB issued ASU 2017-01, <i>Business Combinations (Topic 805): Clarifying the Definition of a Business</i> (&#8220;ASU 2017-01&#8221;). The amendments in this update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for fiscal periods beginning after December 15, 2017, including interim periods within those periods. The Company adopted ASU 2017-01 on January 1, 2017. The adoption did not have a material impact on the Company&#8217;s condensed consolidated financial statements and related disclosures.</font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify">&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>Recently Issued Accounting Standards&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px; font-size-adjust: none; font-stretch: normal" align="center">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In February 2016, the FASB issued ASU 2016-02, <i> Leases (Topic 842).</i> ASU 2016-02 requires an entity to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December&#160;15, 2018. Early adoption is permitted. The Company is currently evaluating the impact, if any, of adopting this standard on its condensed consolidated financial statements and related disclosures.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In August 2016, the FASB issued ASU 2016-15, <i> Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments</i> (&#8220;ASU 2016-15&#8221;), which addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is currently in the process of evaluating the impact of this new pronouncement on its condensed statements of cash flows and related disclosures.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In May 2017, the FASB issued ASU 2017-09, Compensation&#151;Stock Compensation (Topic 718): <i>Scope of Modification Accounting</i> (&#8220;ASU 2017-09&#8221;), which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the condensed financial statements and disclosures, but does not expect it to have a significant impact.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_SignificantAccountingPoliciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>These lines are represents policy disclosure of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_SignificantAccountingPoliciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2,12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75025870&amp;loc=d3e40691-111596<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760568608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements and Clinical Research Support Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_LicenseAgreementDisclosureAbstract', window );"><strong>License Agreement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock', window );">Research and Development Arrangement, Contract to Perform for Others [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">For the three and nine months ended September 30, 2017 and 2016, the Company recorded the following expense in research and development for licenses acquired:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div style="CLEAR:both;CLEAR: both"> For&#160;the&#160;Three&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div style="CLEAR:both;CLEAR: both"> For&#160;the&#160;Nine&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"> <div style="CLEAR:both;CLEAR: both"> ($&#160;in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">City of Hope</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">IL13Ra2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">IV/ICV</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">PSCA</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">300</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">HER2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">CS-1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">UCLA</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Fred Hutch CD20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">300</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">300</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">300</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,375</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_LicenseAgreementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_LicenseAgreementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760599184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock', window );">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive.&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Potentially dilutive securities</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div> For&#160;the&#160;nine&#160;months&#160;ended&#160;September&#160;30</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Warrants (Note 7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>5,257,434</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>670,191</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Options (Note 7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,241,675</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Class A Preferred Shares (Note 7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Unvested restricted stock awards (Note 7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>180,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Unvested restricted stock units (Note 7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>110,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>7,039,109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>920,191</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on basic earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764584368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsTableTextBlock', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The fair value associated with the market award vesting was determined utilizing a binomial valuation methodology and the following assumptions:</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"> <div>September&#160;30,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>1.81% - 2.38</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Exercise Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>5.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Expected term in years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>5.5 - 10.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>77.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The following table summarizes stock option activities for the nine months ended September 30, 2017:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Contractual&#160;Life&#160;(in</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Stock&#160;Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Nonvested at December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Options granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,241,675</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>9.56</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Options outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1,241,675</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>9.56</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Options vested and exercisable at September 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2017 (in thousands).</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="28%" colspan="6"> <div> For&#160;the&#160;three&#160;months&#160;ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="28%" colspan="6"> <div> For&#160;the&#160;nine&#160;months&#160;ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Employee</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>576</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>909</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Non-employee</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>258</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>321</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Total stock-based compensation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>834</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,230</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">A summary of warrant activities for nine months ended September 30, 2017 is presented below:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Contractual&#160;Life&#160;(in</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Outstanding as of December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>2,243,664</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>7.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>5.16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3,013,770</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>8.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>4.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Outstanding as of September 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>5,257,434</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>8.28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>4.37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The following table summarizes restricted stock award activities for the nine months ended September 30, 2017: <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Number&#160;of&#160;Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Grant&#160;Date&#160;Fair&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Nonvested at December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>180,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>5.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Nonvested at September 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>180,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>5.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The following table summarizes restricted stock units activities for the nine months ended September 30, 2017: <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Number&#160;of&#160;Units</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Grant&#160;Date&#160;Fair&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Nonvested at December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>110,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>5.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Nonvested at September 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>110,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>5.73</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan.  Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6659754240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization, Description of Business and Liquidity and Capital Resources (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOwnershipInterestsLineItems', window );"><strong>Other Ownership Interests [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="num">$ (32,807)<span></span>
</td>
<td class="num">$ (17,120)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOwnershipInterestsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOwnershipInterestsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764105056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash Equivalents, at Carrying Value</a></td>
<td class="nump">$ 33,209<span></span>
</td>
<td class="nump">$ 27,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Other Short-term Investments</a></td>
<td class="nump">34,088<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PropertyPlantAndEquipmentDesignCostsCapitalized', window );">Property Plant And Equipment Design Costs Capitalized</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimeDepositsAtCarryingValue', window );">Time Deposits, at Carrying Value</a></td>
<td class="nump">34,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimeDepositsAtCarryingValue', window );">Time Deposits, at Carrying Value</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_PropertyPlantAndEquipmentDesignCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the cost of design capitalized to property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_PropertyPlantAndEquipmentDesignCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimeDepositsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Any certificate of deposit or savings account held by a bank or other financial institution for a short-term specified period of time. Because of their short-term, time deposits are considered highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimeDepositsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763960032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements and Clinical Research Support Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development - licenses acquired</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,375<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_ArIl13LicenseMember', window );">IL13Ra2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development - licenses acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_IvicvLicenseMember', window );">IV/ICV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development - licenses acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_PscaTechnologyLicenseMember', window );">PSCA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development - licenses acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_Her2TechnologyLicenseMember', window );">HER2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development - licenses acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_CsTechnologyLicenseMember', window );">CS1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development - licenses acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_UclaLicenseMember', window );">UCLA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development - licenses acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_FredHutchCd20Member', window );">Fred Hutch CD20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development - licenses acquired</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_ArIl13LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_ArIl13LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_IvicvLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_IvicvLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_PscaTechnologyLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_PscaTechnologyLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_Her2TechnologyLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_Her2TechnologyLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_CsTechnologyLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_CsTechnologyLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_UclaLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_UclaLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_FredHutchCd20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_FredHutchCd20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774175984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements and Clinical Research Support Agreements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2017</div></th>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Mar. 17, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Feb. 17, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_ResearchAndDevelopmentExpenseSponsoredResearchPayment', window );">Research And Development Expense, Sponsored Research Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,232,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,232,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,165,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="nump">$ 30,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_PscaTechnologyLicenseMember', window );">Psca Technology License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PaymentOfUpfrontFees', window );">Payment Of Upfront Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue', window );">Revenue Recognition Milestone Method Payments Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaintenanceCosts', window );">Maintenance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_CsTechnologyLicenseMember', window );">Cs Technology License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PaymentOfUpfrontFees', window );">Payment Of Upfront Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue', window );">Revenue Recognition Milestone Method Payments Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaintenanceCosts', window );">Maintenance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_StephenFormanMember', window );">Stephen Forman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_AnnualConsultingFees', window );">Annual Consulting Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_ChristineBrownMember', window );">Christine Brown [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_AnnualConsultingFees', window );">Annual Consulting Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_UniversityOfCaliforniaMember', window );">University of California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_DevelopmentMilestonesMethodAdditionalPaymentsDue', window );">Development Milestones Method Additional Payments Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_UniversityOfCaliforniaMember', window );">University of California [Member] | UCLA License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PaymentOfUpfrontFees', window );">Payment Of Upfront Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInNextTwelveMonths', window );">Other Commitment, Due in Next Twelve Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInThirdYear', window );">Other Commitment, Due in Third Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInSecondYear', window );">Other Commitment, Due in Second Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInFifthYear', window );">Other Commitment, Due in Fifth Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInFourthYear', window );">Other Commitment, Due in Fourth Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ck0001680048_CityOfHopeMember', window );">City Of Hope [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue', window );">Revenue Recognition Milestone Method Payments Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock Issued During Period, Shares, Purchase of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for Other Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ck0001680048_CityOfHopeMember', window );">City Of Hope [Member] | AR CD123 License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PaymentOfUpfrontFees', window );">Payment Of Upfront Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue', window );">Revenue Recognition Milestone Method Payments Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_ResearchAndDevelopmentExpenseSponsoredResearchPayment', window );">Research And Development Expense, Sponsored Research Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_LicensingArrangementsAdditionalCostsIncurred', window );">Licensing Arrangements Additional Costs Incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaintenanceCosts', window );">Maintenance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ck0001680048_CityOfHopeMember', window );">City Of Hope [Member] | IL License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue', window );">Revenue Recognition Milestone Method Payments Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_ResearchAndDevelopmentExpenseSponsoredResearchPayment', window );">Research And Development Expense, Sponsored Research Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaintenanceCosts', window );">Maintenance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ck0001680048_CityOfHopeMember', window );">City Of Hope [Member] | Her2 Technology License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PaymentOfUpfrontFees', window );">Payment Of Upfront Fees</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue', window );">Revenue Recognition Milestone Method Payments Due</a></td>
<td class="nump">14,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaintenanceCosts', window );">Maintenance Costs</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ck0001680048_CityOfHopeMember', window );">City Of Hope [Member] | Spacer License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaintenanceCosts', window );">Maintenance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ck0001680048_CityOfHopeMember', window );">City Of Hope [Member] | IL13Ra2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PaymentOfUpfrontFees', window );">Payment Of Upfront Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_LicensingArrangementsAdditionalCostsIncurred', window );">Licensing Arrangements Additional Costs Incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ck0001680048_FredHutchinsonCancerResearchCenterMember', window );">Fred Hutchinson Cancer Research Center [Member] | CD20 Technology License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PaymentOfUpfrontFees', window );">Payment Of Upfront Fees</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaintenanceCosts', window );">Maintenance Costs</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_DevelopmentMilestonesMethodAdditionalPaymentsDue', window );">Development Milestones Method Additional Payments Due</a></td>
<td class="nump">39,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ck0001680048_FredHutchinsonCancerResearchCenterMember', window );">Fred Hutchinson Cancer Research Center [Member] | CD20 Clinical Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PaymentOfUpfrontFees', window );">Payment Of Upfront Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_ResearchAndDevelopmentExpenseSponsoredResearchPayment', window );">Research And Development Expense, Sponsored Research Payment</a></td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock Issued During Period, Shares, Purchase of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling Interest, Ownership Percentage by Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_AnnualConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of annual consulting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_AnnualConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_DevelopmentMilestonesMethodAdditionalPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional payment to be made for the development milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_DevelopmentMilestonesMethodAdditionalPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_LicensingArrangementsAdditionalCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the additional costs incurred under licensing arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_LicensingArrangementsAdditionalCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_PaymentOfUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of Upfront Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_PaymentOfUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_ResearchAndDevelopmentExpenseSponsoredResearchPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of research and development expense payable on achieving milestone targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_ResearchAndDevelopmentExpenseSponsoredResearchPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration eligible to receive during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_RevenueRecognitionMilestoneMethodPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaintenanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred and are directly related to generating maintenance revenues. Also includes cost of maintenance on client contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaintenanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment maturing in the fifth fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment maturing in the fourth fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment maturing in the next fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment maturing in the second fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment maturing in the third fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_PscaTechnologyLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_PscaTechnologyLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_CsTechnologyLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_CsTechnologyLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_StephenFormanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_StephenFormanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_ChristineBrownMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_ChristineBrownMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_UniversityOfCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_UniversityOfCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_UclaLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_UclaLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ck0001680048_CityOfHopeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ck0001680048_CityOfHopeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_ArCd123LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_ArCd123LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_IlLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_IlLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_Her2TechnologyLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_Her2TechnologyLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_SpacerLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_SpacerLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_Il13ra2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_Il13ra2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ck0001680048_FredHutchinsonCancerResearchCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ck0001680048_FredHutchinsonCancerResearchCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_Cd20TechnologyLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_Cd20TechnologyLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_Cd20ClinicalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ck0001680048_Cd20ClinicalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771999952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Agreements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 08, 2017</div></th>
<th class="th"><div>Apr. 08, 2016</div></th>
<th class="th"><div>Mar. 13, 2016</div></th>
<th class="th"><div>Mar. 13, 2015</div></th>
<th class="th"><div>Jul. 26, 2016</div></th>
<th class="th"><div>May 17, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from Related Party Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,963,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_FoundersAgreementTerm', window );">Founders Agreement Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">$ 30,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Officers' Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,013,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="nump">$ 8.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_ClassOfWarrantOrRightExpirationPeriod', window );">Class Of Warrant Or Right Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-based Compensation Arrangement by Share-based Payment Award, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dr. Rosenwald will receive a cash fee of $50,000 per year paid quarterly and an annual stock award of the greater of (i) a number of shares of common stock having a fair market value on the grant date of $50,000 or (ii) 10,000 shares of common stock, which shares shall vest and become non-forfeitable on the third anniversary of the grant date, subject to continued service on the Board on such date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Director [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_FortressBiotechIncMember', window );">Fortress Biotech, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from Related Party Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling Interest, Ownership Percentage by Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_AnnualConsultingFees', window );">Annual Consulting Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_IncreaseInAnnualConsultingFees', window );">Increase In Annual Consulting Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_ExcessInNetAssetsValue', window );">Excess In Net Assets Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_AnnualFeesExpensesOnFoundersAgreement', window );">Annual Fees Expenses On Founders Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_FortressBiotechIncMember', window );">Fortress Biotech, Inc [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_AnnualFeesExpensesOnFoundersAgreementPercentage', window );">Annual Fees Expenses On Founders Agreement Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_FortressBiotechIncMember', window );">Fortress Biotech, Inc [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_AnnualFeesExpensesOnFoundersAgreementPercentage', window );">Annual Fees Expenses On Founders Agreement Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_ChordAdvisorsLlcMember', window );">Chord Advisors, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_BackOfficeAccountingFunctionsExpenses', window );">Back Office Accounting Functions Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_AccountingAnalysisAndFinancialReportingFees', window );">Accounting Analysis And Financial Reporting Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_NationalHoldingsIncMember', window );">National Holdings, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_AdditionalConsiderationUnderFoundersAgreementDescription', window );">Additional Consideration Under Founders Agreement Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Mustang or any of its respective subsidiaries that occurs after the effective date of the Mustang Founders Agreement and ending on the date when Fortress no longer has majority voting control in the Companys voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of the Companys annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, the Company will pay a one-time change in control fee equal to five (5x) times the product of (A) net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business Acquisition, Percentage of Voting Interests Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for Other Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">861,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">861,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_AdvisorMember', window );">Advisor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_AnnualConsultingFees', window );">Annual Consulting Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member] | Fortress Biotech, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred Stock, Voting Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of Class A Preferred Stock is convertible, at Fortress option, into one fully paid and nonassessable share of Mustang common stock, subject to certain adjustments. As holders of Class A Preferred Stock, Fortress will receive on each March 13 (each a PIK Dividend Payment Date) until the date all outstanding Class A Preferred Stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (PIK Dividends) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half percent (2.5%) of Mustangs fully-diluted outstanding capitalization on the date that is one (1) business day prior to any PIK Dividend Payment Date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember', window );">Convertible Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_AccountingAnalysisAndFinancialReportingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of expenses on the accounting analysis and financial reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_AccountingAnalysisAndFinancialReportingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_AdditionalConsiderationUnderFoundersAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the description of the additional consideration payable to the founders as per the founders agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_AdditionalConsiderationUnderFoundersAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_AnnualConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of annual consulting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_AnnualConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_AnnualFeesExpensesOnFoundersAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of expenses on the founders agreement for annual fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_AnnualFeesExpensesOnFoundersAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_AnnualFeesExpensesOnFoundersAgreementPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of expenses recognized under respective heads of consolidated statement of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_AnnualFeesExpensesOnFoundersAgreementPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_BackOfficeAccountingFunctionsExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of expenses on the back office accounting functions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_BackOfficeAccountingFunctionsExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_ClassOfWarrantOrRightExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period at which the warrants are sets to expire.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_ClassOfWarrantOrRightExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_ExcessInNetAssetsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of net assets in excess of liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_ExcessInNetAssetsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_FoundersAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the agreement term with the founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_FoundersAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_IncreaseInAnnualConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the increase in the amount of annual consulting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_IncreaseInAnnualConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General descriptive information regarding an arrangement under which employees and directors receive: (a) awards of equity shares, equity share options, or other equity instruments; or (b) the entity incurs liabilities to them: (1) in amounts based, at least in part, on the price of the entity's shares or other equity instruments; or (2) that require or may require settlement by issuance of the entity's shares. Such an arrangement is usually provided to employees and directors to compensate them, provide performance incentives to them, and to attract or retain their services. May also include pertinent information particular to a plan that is not elsewhere specified in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_FortressBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_FortressBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_ChordAdvisorsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_ChordAdvisorsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_NationalHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_NationalHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_AdvisorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001680048_AdvisorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6926309808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 15, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_NumberOfSharesToBeIssuedUponLegalSettlement', window );">Number Of Shares To Be Issued Upon Legal Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation Settlement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation Settlement, Amount Awarded to Other Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ck0001680048_CityOfHopeMember', window );">City Of Hope [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_FailedContingencyDamagesAwardedPercentage', window );">Failed Contingency Damages Awarded Percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_FailedContingencyDamagesAwardedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of failed contingency damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_FailedContingencyDamagesAwardedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_NumberOfSharesToBeIssuedUponLegalSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares which will be issued upon legal settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_NumberOfSharesToBeIssuedUponLegalSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ck0001680048_CityOfHopeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ck0001680048_CityOfHopeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774255616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PotentiallyDilutiveSecurities', window );">Potentially Dilutive Securities</a></td>
<td class="nump">7,039,109<span></span>
</td>
<td class="nump">920,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PotentiallyDilutiveSecurities', window );">Potentially Dilutive Securities</a></td>
<td class="nump">1,241,675<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ck0001680048_UnvestedRestrictedStockAwardsMemberMember', window );">Unvested Restricted Stock Awards Member [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PotentiallyDilutiveSecurities', window );">Potentially Dilutive Securities</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PotentiallyDilutiveSecurities', window );">Potentially Dilutive Securities</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PotentiallyDilutiveSecurities', window );">Potentially Dilutive Securities</a></td>
<td class="nump">5,257,434<span></span>
</td>
<td class="nump">670,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Preferred Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PotentiallyDilutiveSecurities', window );">Potentially Dilutive Securities</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_PotentiallyDilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares Classification of diluted net loss per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_PotentiallyDilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ck0001680048_UnvestedRestrictedStockAwardsMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ck0001680048_UnvestedRestrictedStockAwardsMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6910811648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">77.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.38%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.81%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758769504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 1) - Employee Stock Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Nonvested at December 31, 2016</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">1,241,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Nonvested at September 30, 2017</a></td>
<td class="nump">1,241,675<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options vested and exercisable at September 30, 2017</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Nonvested Beginning Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Options granted</a></td>
<td class="nump">5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Options outstanding</a></td>
<td class="nump">5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options vested and exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Options outstanding (in years)</a></td>
<td class="text">9 years 6 months 22 days<span></span>
</td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Life, Options granted (in years)</a></td>
<td class="text">9 years 6 months 22 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Options vested and exercisable (in years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement by Share based Payment Award Options Granted Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758943872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Nonvested at December 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Granted</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Nonvested at September 30, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Nonvested at December 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Nonvested at September 30, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Nonvested at December 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Nonvested at September 30, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Nonvested at December 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Nonvested at September 30, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6913196112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 3) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="nump">$ 834<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,230<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=ck0001680048_EmployeeMember', window );">Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="nump">576<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">909<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=ck0001680048_NonEmployeeMember', window );">Non Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 321<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=ck0001680048_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=ck0001680048_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=ck0001680048_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=ck0001680048_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759343168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 4)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding', window );">Warrants, Outstanding Beginning of year | shares</a></td>
<td class="nump">2,243,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Warrants, Granted | shares</a></td>
<td class="nump">3,013,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding', window );">Warrants, Outstanding End of year | shares</a></td>
<td class="nump">5,257,434<span></span>
</td>
<td class="nump">2,243,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning of year | $ / shares</a></td>
<td class="nump">$ 7.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding End of year | $ / shares</a></td>
<td class="nump">$ 8.28<span></span>
</td>
<td class="nump">$ 7.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life, Granted (in years)</a></td>
<td class="text">4 years 4 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life, Outstanding (in years)</a></td>
<td class="text">4 years 4 months 13 days<span></span>
</td>
<td class="text">5 years 1 month 28 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of equity instruments other than options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of outstanding equity instruments other then option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783245216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 03, 2017</div></th>
<th class="th"><div>Jun. 08, 2017</div></th>
<th class="th"><div>Apr. 07, 2017</div></th>
<th class="th"><div>Mar. 13, 2017</div></th>
<th class="th"><div>Mar. 13, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jul. 27, 2016</div></th>
<th class="th"><div>Mar. 17, 2015</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Apr. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,232,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,165,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common Stock, Voting Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_WarrantsIssued', window );">Warrants Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,134,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,674,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,234,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The remaining 50% (&#8220;The Performance Options&#8221;) vest and become exercisable upon the occurrence of the following milestones being achieved: (i) 25% of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of any Company product candidate, (ii) 25% of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of a second Company product candidate, (iii) 25% of the Performance Options vest upon the Company&#8217;s achievement of a fully-diluted market capitalization of $500,000,000 and (iv) 25% of the Performance Options vest upon the Company&#8217;s achievement of a fully-diluted market capitalization of $1,000,000,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,730,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_ClassOfWarrantOrRightPercentageOfWarrantIssued', window );">Class Of Warrant Or Right, Percentage Of Warrant Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months 11 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ck0001680048_UnregisteredCommonStockMember', window );">Unregistered Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,536,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Stock Repurchased and Retired During Period, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Preferred Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001680048_FortressBiotechIncMember', window );">Fortress Biotech, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_SharesOfCommonStockPercentage', window );">Shares Of Common Stock, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">767,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001680048_FortressBiotechIncMember', window );">Fortress Biotech, Inc [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,269<span></span>
</td>
<td class="nump">47,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001680048_FortressBiotechIncMember', window );">Fortress Biotech, Inc [Member] | Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_DilutedOutstandingEquityPercentage', window );">Diluted Outstanding Equity, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001680048_NationalHoldingsCorporationMember', window );">National Holdings Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_WarrantsIssued', window );">Warrants Issued</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001680048_NationalHoldingsCorporationMember', window );">National Holdings Corporation [Member] | Unregistered Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001680048_CityOfHopeNationalMedicalCenterMember', window );">City of Hope National Medical Center [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001680048_CityOfHopeNationalMedicalCenterMember', window );">City of Hope National Medical Center [Member] | Original Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PaymentOfUpfrontFees', window );">Payment Of Upfront Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001680048_CityOfHopeNationalMedicalCenterMember', window );">City of Hope National Medical Center [Member] | Common Stock [Member] | Original Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001680048_CityOfHopeNationalMedicalCenterMember', window );">City of Hope National Medical Center [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001680048_CityOfHopeNationalMedicalCenterMember', window );">City of Hope National Medical Center [Member] | Common Class A [Member] | Original Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001680048_NationalSecuritiesIncMember', window );">National Securities, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PercentageOfPlacementAgentFee', window );">Percentage Of Placement Agent Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PercentageOfSharesIssuedToPlacementAgent', window );">Percentage Of Shares Issued To Placement Agent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_WarrantsIssued', window );">Warrants Issued</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">853,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_WarrantPurchasePricePerUnit', window );">Warrant Purchase Price Per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | National Holdings Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PercentageOfPlacementAgentFee', window );">Percentage Of Placement Agent Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001680048_PercentageOfSharesIssuedToPlacementAgent', window );">Percentage Of Shares Issued To Placement Agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_ClassOfWarrantOrRightPercentageOfWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of warrants the investors received in the offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_ClassOfWarrantOrRightPercentageOfWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_DilutedOutstandingEquityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of diluted outstanding equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_DilutedOutstandingEquityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_PaymentOfUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of Upfront Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_PaymentOfUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_PercentageOfPlacementAgentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the percentage of placement agent fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_PercentageOfPlacementAgentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_PercentageOfSharesIssuedToPlacementAgent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of shares issued to the placement agent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_PercentageOfSharesIssuedToPlacementAgent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_SharesOfCommonStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents of the percentage rate of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_SharesOfCommonStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_WarrantPurchasePricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant purchase price per unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_WarrantPurchasePricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001680048_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of award terms as to how many shares or portion of an award are no longer contingent on satisfaction of either a service condition, market condition or a performance condition, thereby giving the employee the legal right to convert the award to shares, to sell the shares, and be entitled to the cash proceeds of such sale. For example, vesting may be expressed as being 25 percent of the shares under option on each anniversary of the grant date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ck0001680048_UnregisteredCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ck0001680048_UnregisteredCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001680048_FortressBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001680048_FortressBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001680048_NationalHoldingsCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001680048_NationalHoldingsCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001680048_CityOfHopeNationalMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001680048_CityOfHopeNationalMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001680048_AgreementTypeAxis=ck0001680048_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001680048_AgreementTypeAxis=ck0001680048_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001680048_NationalSecuritiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001680048_NationalSecuritiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759543904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Textual) - Subsequent Event [Member]<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 27, 2017 </div>
<div>USD ($) </div>
<div>a</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Land Subject to Ground Leases | a</a></td>
<td class="nump">27,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1', window );">Operating Leases, Rent Expense, Sublease Rentals</a></td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating Leases, Rent Expense, Net</a></td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandImprovements', window );">Land Improvements</a></td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Increase (Decrease) in Security Deposits</a></td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Increase (Decrease) in Security Deposits</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Increase (Decrease) in Security Deposits</a></td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated deprecation and depletion of additions or improvements to real estate held for productive use. Examples include, but are not limited to, walkways, driveways, fences, and parking lots.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseSubleaseRentals1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>48
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_O"["OO.NIW[Q\870=7 K[M07U!+ P04    " !(2&Y+F5R<(Q &  "<)P
M$P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03
M<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS
M[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#
MW(*+"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S
M^!7+5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4
MPL3 :F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:
MX./Q>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;
M:)P*C5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ
M$A6UY4#3( !8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&
M<IV0!0X -\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD
M,WJ=?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z
M'&="?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S
M(M>41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(
MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU
M+,76>)7 \:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/
M:;,CIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:
MK<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1
MDEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*
MY \FIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_
MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R
MS<C'5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;
M)0G+5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R
M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ
MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR
MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2
M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE
ML<%5'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_
M13.V$I<8O./FQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7G
MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5
M' 86%S+D4.Z2D 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2
M)1(4BK ,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%
MV^)4S;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODR
MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\
MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS
MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!
M4$L#!!0    ( $A(;DNZ(5.VB0(  " )   8    >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&ULC5;;CMHP$/V5*!^P\3@7P@J0@*IJI59"6W7[;,! M$F<V@:V
M?U_;R:;9>%(M#\1VSIDSX\QXO+@+^:(NG.O@M2IKM0PO6C>/4:0.%UXQ]2 :
M7ILW)R$KILU4GB/52,Z.CE25$24DBRI6U.%JX=9V<K405UT6-=_)0%VKBLD_
M&UZ*^S*$\&WAJ3A?M%V(5HN&G?D/KG\V.VEF46_E6%2\5H6H \E/RW -CUO(
M+<$AG@M^5X-Q8$/9"_%B)U^/RY!8CWC)#]J:8.9QXUM>EM:2\>-W9S3L-2UQ
M.'ZS_MD%;X+9,\6WHOQ5'/5E&>9A<.0G=BWUD[A_X5U :1ATT7_C-UX:N/7$
M:!Q$J=Q_<+@J+:K.BG&E8J_MLZC=\]Z^2:"CX03:$6A/H/2_A+@CQ#T!$A=\
MZYD+]1/3;+60XA[(]FLUS"8%/,9F,P]VT>V=>V>B56;UMB*+Z&;-=(A-BZ #
M!/2(R-CN!2@FL*$>G;X7V/J(&!>(T0AB1X\'] 2G)R@]<?1D0$]'&^ C,EP@
M1052CSX;"?B('!?(4(',H\]' CX""*XP0Q5F/A]&$BTD=9"Z_<P$9KA(CHKD
MOL@H4S8M)!M")E)ECDK,?8ED)(% 4EP""%Y0Q+>0C4N*>+L%64Y(,O'=8:)V
MP9<:YQ:&F5)!"W@-U+<P3C $0R<R#/ JAMBW,''. %[(D'ST( "\4,&O0SH^
MJSK,NSQ/:4PAGD]HX34+?DG2B50&O"9A]N%P\7H#O^#\<',_48G[C:2B0;^I
MN#R[UJR"@[C6[EXP6.W;_]HUN.@?O+T[?&?R7-0JV MMNI[K32<A-#?^D ?C
MR<5<5_I)R4_:#F=F+-N>W4ZT:+K[2-1?BE9_ 5!+ P04    " !(2&Y+ M.5
M6'T#   ]$   &    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;(V8:V^;,!2&
M_PKB^PH^-K<JB;1DFC9IDZI-VS[3Q&E0 6= DN[?SUP:I><<HWXIV'F/_1Y?
M'NPN+J9Y;@]:=]Y+5=;MTC]TW?$^"-KM05=Y>V>.NK:_[$U3Y9TM-D]!>VQT
MOAN"JC* ,(R#*B]J?[48ZAZ:U<*<NK*H]4/CM:>JRIM_:UV:R](7_FO%C^+I
MT/45P6IQS)_T3]W].CXTMA1<6]D5E:[;PM1>H_=+_Z.XWT#:!PR*WX6^M#?O
M7I_*HS'/?>'K;NF'O2-=ZFW7-Y';QUEO=%GV+5D??Z=&_6N??>#M^VOKGX?D
M;3*/>:LWIOQ3[+K#TD]];Z?W^:GL?IC+%STE%/G>E/TW?=:EE?=.;!];4[;#
M7V][:CM33:U8*U7^,CZ+>GA>IO9?P_@ F +@&B#4;("< B0*"$9G0ZJ?\BY?
M+1IS\9IQMHYYORC$O;2#N>TKA[$;?K/9MK;VO *U",Y].Y-D/4K@5O)6L6$4
MT542V/ZO)H U 4.\O(V/^7C)QLLA7MW&)RB)49(,DGJ02 EAAA*A*DA4EO%>
M%.M%42\I\C)*HELO*DR1:D-5(>\C8GU$U ?*=AV1'I1 D[^A&H>+F'41$Q<R
M1"YB.AH1,D$E#A,):R*A)@0RD9 >XB11,?)!53/+(V6]I-0+VDWKE/0B)%ZH
M5.,8D8QUD5$7$KG(F!%)4SPS5#4S(B+D$122[2^5HP4'Q 3-)\(4$XQ5D)AD
M5!6GTF&&AYD :B;&9F!F_B8G5"+B%!Q6>"X*"D:)P3AIWF2,5QNC4<I!>,%C
M45 N2LQ%,8>\R0F5*.&:'QZ,@I(1;Z^UH-B#)".?/:J2 "XW/" %):3"A.0T
M GN9U;QUPE-2)&0;*M=RX]DF*-P4QHJ8(]>4RKOA)GBZ"8HW10XUE%R$!0S<
M'*<:'FP04A\82Y-F;CP8B9*9XX $/"&!$A)_W=9 V9<E:99@.U0FXRQ+'7X<
M)SX*287)!)2 'R2D(3'$Z$0BP+%H@&<E4%8J#"A@6!F%&5XXC P4)*X9XX$)
M%)@*8PHH#;F/-".;^4H#CTU@#I0.U &/.HC?#1C@$07T)$<V-M!#&ME0<Y*W
M/GC0 0,ZLE92<I<@/N8DHX_@YA[77ZR_Y\U34;?>H^GLE7"XN.V-Z;1M+KRS
M"1WL7?Y:*/6^ZU\3^]Z,%]JQT)GC=%D/KO\Q6/T'4$L#!!0    ( $A(;DLQ
M8O9!?@(  +\)   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULC99MK]H@
M%,>_2M,/(-"6MIIJ,EV6+=D2<Y=MKU%1F]N6#M#>??L![6TLX%5?R-/_''X'
MRH&B8_Q5G"F5P5M=-6(9GJ5L%P"(_9G61,Q82QLU<F2\)E(U^0F(EE-R,$9U
M!2((4U"3L@E7A>G;\E7!+K(J&[KE@;C4->'_UK1BW3)$X7O'2WDZ2]T!5D5+
M3O0GE;_:+5<M,'HYE#5M1,F:@-/C,OR$%AN4: .C^%W23MS4 QW*CK%7W?AV
M6(90$]&*[J5V051QI1M:5=J3XO@[. W'.;7A;?W=^Q<3O IF1P3=L.I/>9#G
M99B'P8$>R:62+ZS[2H> <!@,T7^G5UHIN291<^Q9)<Q_L+\(R>K!BT*IR5M?
MEHTINWX$)X.9WR :#*+1 'UL$ \&L64 >C(3ZF<BR:K@K MXOULMT1\%6L1J
M,?>ZTZR=&5/1"M5[76%8@*OV,TC6O22ZD413Q<:CP*,$J/E'B,@+$1G[Y!8"
M61"])#>2QDC@#$)HR38/91.:V$L3NS16P.M>@F^F40='_RR<Q[H)3^+E25R>
MV.))GEN=A[()#?;28)<FL6BP$S6&WN5Y0C@A2KU$J4N$+:+4W0<<Q1&*YQ:1
M*T08I3A*$C]1YB7*7*+4(LJ>)7*%'Q/E7J+<)<HLHMR9R-XN5Y&E693> 9E[
M0>8N2.ZW1]"?L*#K86YG+.A97<_W]U@W);J30I%#E#HY%#U)]% W)?+G4^0F
MU"B^X\&? Y$G"=J'"KG9#7F/^1/"*9,_#R)/(K2/U:!Y@NFQL&<"-S>I?MK\
M(/Q4-B+8,:DN97-U'AF35#F%,^7NK%Y38Z.B1ZFKF:KS_DG1-R1KA^<2&-]L
MJ_]02P,$%     @ 2$AN2\=2\%B6 P  X@\  !@   !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6R-EV^/FS@0QK\*XGT6; .&51)IDU"U4D]:M;J[UVSB)*B
M4W V[;<_\Z=9,C,)]R: \\QC_VS#>.877?]HCDH9YU=95,W"/1IS>O:\9GM4
M9=8\Z9.J[#][79>9L8_UP6M.M<IV75!9>-SW(Z_,\LI=SKNVUWHYUV=3Y)5Z
MK9WF7)99_7NE"GU9N,S]T_ M/QQ-V^ MYZ?LH+XK\_?IM;9/WM5EEY>J:G)=
M.;7:+]P7]IPRV09TBG]R=6E&]TZ+\J;UC_;ARV[A^NV(5*&VIK7([.5=K551
MM$YV'#\'4_?:9QLXOO_C_JF#MS!O6:/6NO@WWYGCPHU=9Z?VV;DPW_3ELQJ
M0M<9Z+^J=U58>3L2V\=6%TWWZVS/C='EX&*'4F:_^FM>===+_X_D0Q@=P(<
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M0F/DYH'TOB\*2&[=-D#FL)?Z!@JSDP [Y93(23,QS+)$&4*;R2SUK"K&^&2
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MR\;^U\9X0"G)#8Y0BQ]L,134/AP_X-E.8S89WO3S#V++-R[^ %!+ P04
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MV/_&& \H97>#(]3A!UL,"8T/QSL\VVG,)L.;?OY!;/G&Y3]02P,$%     @
M2$AN2Q7QO RW 0  T0,  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M;5/;CILP$/T5RQ^P)H2T:01(FZVJ5FJE:*MNGQT8P%I?J&W"]N\[-BRE6UYL
MS_B<,Q>/\]'89]<!>/*BI'8%[;SO3XRYJ@/%W9WI0>--8ZSB'DW;,M=;X'4D
M*<G2)'G'%!>:EGGT76R9F\%+H>%BB1N4XO;W&:09"[JCKXY'T78^.%B9][R%
M[^!_]!>+%EM4:J% .V$TL= 4]'YW.F<!'P%/ D:W.I-0R=68YV!\J0N:A(1
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M/YKI$RSUW%*R%/\%KB Q/"C!'+61+JZD'ITW:F%!*8H_S[O0<9_FFRQ=8/N
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M?#<@F *"50 >R4RIGXDD><K9X/#Q8_5$_Q/>(5"'6>A%<W9F3U4KU.H]5W]
MBN_::-(<1XV_U+Q6G"R*:)9@!3!3^%8*W\2'KRB\%<6HV1E-9S1!X+O[%<E6
MY>_"_=X.$UAA @O,JN#CJ(F6,*&;)"N88 /CVD%"*TAH 0E6(.$&Q'/?2!)9
MDT26)*'=(+8:Q!:#:$496X[K3<Z=-<W.DB:V&R16@^0#G,GF@\7N!A,O[I;N
M=3\(OS:=<"Y,JFMJ+E/%F 1EZ#ZHFFO57N<)A4KJ5]4.'#XVF7$B63_U3SPW
M\?P_4$L#!!0    ( $A(;DM-C(A&W@(  +<,   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;(U789.:,!#]*PP_X"!!0!UUYA0[[4P[<W.=MI]S&I4Y
M(#2)>OWW30)R0A;PBY#E[<N^!R[+XLKXNSA1*IV//"O$TCU)6<X]3^Q.-"?B
MB96T4%<.C.=$JB4_>J+DE.Q-4IYYV/<C+R=IX:X6)O;"5PMVEEE:T!?NB'.>
M$_YO33-V7;K(O05>T^-)ZH"W6I3D2']2^:M\X6KE-2S[-*>%2%GA<'I8NL]H
MOD6Q3C"(WRF]BKMS1TMY8^Q=+[[MEZZO*Z(9W4E-0=3A0C<TRS23JN-O3>HV
M>^K$^_,;^Q<C7HEY(X)N6/8GW<O3TIVZSIX>R#F3K^SZE=:"0M>IU7^G%YHI
MN*Y$[;%CF3"_SNXL),MK%E5*3CZJ8UJ8X[7FOZ7!";A.P$V"VGLH(:@3@L^$
MR6#"I$Z8/+I#6">$G1V\2KLQ,R&2K!:<71U>/0\ET8\=FH?J=NUTT-P=<TWY
M*53TLL)^O/ NFJC&K"L,OL-$N U); AJ$)XJH*D"0U6LL97>V6!C(Z*@4\,H
MR7:0I%5F )H5F/S)?7[4\:J"Q 92&$C@^QTM-J:#2&P$#N*PHV:(IB5F HJ9
M6&*P/X4)0I @''>C@H3]2C>CB,1&X+"#V0ZQM)1$H)((L&(&$\0@03QN13QJ
MQ2@BL1$(=Y^*(9:6DBFH9&I;@7H(9B#!;-R*V:@5HXC$1EC_L^T02TL)\N'>
MZ -F]/0UU-->T;@=-6;(CW%( D BRY%!GK8>L%$_(PQ8@GLHX":*'NBB-6;0
MDE%( D  2X9XVGK@/HJ 1HIZ7BL([J3H@5:*QGOI."0!(-BVY.%VBN!^BH"&
MBB8]%'!'10^TU!HS_+(%0)8I#_!L!WDJ1=[=T)53?C03L'!V[%Q(/5+<19LI
M^QGKH:T37Z/Y!@'Q1$_E9LC[I*]&^A^$']-".&],JE'1#'0'QB15E?M/ZD:>
MU%=$L\CH0>K36)WS:I2N%I*5]6>"UWRKK/X#4$L#!!0    ( $A(;DNC,<D#
M4P4  (@?   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;)59VW+;-A#]
M%8T^("1NO'@DS31R["AN9SSIM'VF+=C2A!15DK;2OR\OL&("9R$Z#Y$HG[V
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M.X1$U4)/Q(:-,*B5AO&>2!7R$Q(C!U(;4D\1#H(MZDDW^&5N<@=>YNPL:3?
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MA1-!2JBJ5FJEZ*I>?SMD$] !IK83KF]?VW <!Z9-?@1[F9V=@7@W24?9"R\
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M"[6,Y)KULZS?"-H.<]H9_RRD?P%02P,$%     @ 2$AN2Z OA>X+ @  $P8
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M=ZVRFTC6]+\!WO ODOX!4$L#!!0    ( $A(;DOO^?S ?@(  "D)   9
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MC/=;-W#?%U[J2Z6&!:_(.W*A/ZCZV1V$GGDSRZEN:"MKWCJ"GK?N<_"T#TR
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MT?OR"+FV<G9BAO>BHD1!-/S!P ,J_R^>-0I0/4;K'BSK-*8(_B[+1NX81T#
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M3N-'U@J+:HXY%Y0ZF<8]2H)4J995NL+]XQQ4?T0YUAHL"EF*ODDPF38I4Z[
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MX,I.^H<#$U\ [&2\:M6UB*ODER_1F>!4*3O(K6(^!U9]#;9D^ABM%MU>%?\
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M13]KV2,B.-A?<$IJ=F4+#B\]\4]02P,$%     @ 2$AN2PNM6CO] @  &18
M  \   !X;"]W;W)K8F]O:RYX;6S%F%UOVC 40/^*E9<Q:5JP0^F'2J444A6)
M 6K0WDUBP&IB4SMIN_WZ.4%1;UMVM1>/)V+'.$=.[CW7OG[1YG&M]2-Y+0ME
M1\&NJO9786BSG2BY_:[W0KD[&VU*7KFFV89V;P3/[4Z(JBQ"UN\/PY)+%=Q<
M=W,M37ASW5S\E.+%OO4W3<*S2CZ+%5^/@G[@QH5@8#MI]WL@NC+_PJ0W&YF)
MB<[J4JCJ &5$P2NIE=W)O0V(XJ48!=T0$JN<)*J2U2\R58>IW-B M(^>YJ.
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MK4U=%&/7MU SS=OSSF:.[JCVY@]02P,$%     @ 2$AN2VM_$;U^ 0  V!0
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M,<M#?=;]9YU] 5!+ 0(4 Q0    ( $A(;DL?(\\#P    !,"   +
M      "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $A(;DMF\PM@@@
M +$    0              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ 2$AN2V2'JT#N    *P(  !$              ( !F0$  &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ 2$AN2YE<G",0!@  G"<  !,
M         ( !M@(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !(
M2&Y+NB%3MHD"   @"0  &               @ 'W"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ 2$AN2P+3E5A] P  /1   !@
M         ( !M@L  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( $A(;DLQ8O9!?@(  +\)   8              "  6D/  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !(2&Y+QU+P6)8#  #B#P
M&               @ $=$@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ 2$AN2R4XVQ'J P  \A,  !@              ( !Z14  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( $A(;DL%EKE-<@0
M "06   8              "  0D:  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " !(2&Y+DL@]&L\!   @!   &               @ &Q
M'@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ 2$AN2[_A
M%+RR 0  T@,  !@              ( !MB   'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( $A(;DMH@VA^MP$  -(#   8
M  "  9XB  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !(
M2&Y+H&\ITK4!  #2 P  &0              @ &+)   >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( $A(;DOT?*)%M@$  -(#   9
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M970Q-2YX;6Q02P$"% ,4    " !(2&Y+79]')P4"   T!@  &0
M    @ $7,   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M $A(;DMT_?Z/LP$  -(#   9              "  5,R  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ 2$AN2_;.6]RR 0  T@,  !D
M             ( !/30  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " !(2&Y+[Z<ER/T!   0!@  &0              @ $F-@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( $A(;DLMUL"'M $
M -8#   9              "  5HX  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ 2$AN2[9L[H[_ 0  T 4  !D              ( !
M13H  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !(2&Y+
M38R(1MX"  "W#   &0              @ %[/   >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( $A(;DNC,<D#4P4  (@?   9
M      "  9 _  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ 2$AN2]$8]PEQ!0  \!\  !D              ( !&D4  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !(2&Y+OY57Y>T!  !C!0
M&0              @ '"2@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( $A(;DO-#4O :P(  #@(   9              "  >9,  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ 2$AN2Z OA>X+
M @  $P8  !D              ( !B$\  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " !(2&Y+]8@-6VX"  "7"   &0
M@ '*40  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( $A(
M;DOO^?S ?@(  "D)   9              "  6]4  !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ 2$AN2]FSR,)- @  9 <  !D
M         ( !)%<  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M    " !(2&Y+'2<]P5T"  "E!P  &0              @ &H60  >&PO=V]R
M:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( $A(;DNXD1%G40@  /0V
M   9              "  3Q<  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
M4$L! A0#%     @ 2$AN2XITC7ML @  A @  !D              ( !Q&0
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M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !(2&Y+S!7]2),!  !O%0  $P
M            @ $[K@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     *@ J
+ %@+  #_KP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>202</ContextCount>
  <ElementCount>197</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>102 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/CondensedBalanceSheets</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>103 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>104 - Statement - CONDENSED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/CondensedStatementsOfOperations</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>105 - Statement - Condensed Statement of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/CondensedStatementOfStockholdersEquity</Role>
      <ShortName>Condensed Statement of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>106 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/CondensedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>107 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/CondensedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>108 - Disclosure - Organization, Description of Business and Liquidity and Capital Resources</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/OrganizationDescriptionOfBusinessAndLiquidityAndCapitalResources</Role>
      <ShortName>Organization, Description of Business and Liquidity and Capital Resources</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>109 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>110 - Disclosure - License Agreements and Clinical Research Support Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreements</Role>
      <ShortName>License Agreements and Clinical Research Support Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>111 - Disclosure - Related Party Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/RelatedPartyAgreements</Role>
      <ShortName>Related Party Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>112 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>113 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>114 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>115 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>116 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>117 - Disclosure - License Agreements and Clinical Research Support Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreementsTables</Role>
      <ShortName>License Agreements and Clinical Research Support Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreements</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>118 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/NetLossPerShare</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>119 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/StockholdersEquity</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>120 - Disclosure - Organization, Description of Business and Liquidity and Capital Resources (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/OrganizationDescriptionOfBusinessAndLiquidityAndCapitalResourcesDetailsTextual</Role>
      <ShortName>Organization, Description of Business and Liquidity and Capital Resources (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/OrganizationDescriptionOfBusinessAndLiquidityAndCapitalResources</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>121 - Disclosure - Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/SignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/SignificantAccountingPoliciesPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>122 - Disclosure - License Agreements and Clinical Research Support Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreementsDetails</Role>
      <ShortName>License Agreements and Clinical Research Support Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreementsTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>123 - Disclosure - License Agreements and Clinical Research Support Agreements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreementsDetailsTextual</Role>
      <ShortName>License Agreements and Clinical Research Support Agreements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/LicenseAgreementsAndClinicalResearchSupportAgreementsTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>124 - Disclosure - Related Party Agreements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/RelatedPartyAgreementsDetailsTextual</Role>
      <ShortName>Related Party Agreements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/RelatedPartyAgreements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>125 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>126 - Disclosure - Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/NetLossPerShareTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>127 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/StockholdersEquityTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>128 - Disclosure - Stockholders' Equity (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/StockholdersEquityDetails1</Role>
      <ShortName>Stockholders' Equity (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/StockholdersEquityTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>129 - Disclosure - Stockholders' Equity (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/StockholdersEquityDetails2</Role>
      <ShortName>Stockholders' Equity (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/StockholdersEquityTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>130 - Disclosure - Stockholders' Equity (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/StockholdersEquityDetails3</Role>
      <ShortName>Stockholders' Equity (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/StockholdersEquityTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>131 - Disclosure - Stockholders' Equity (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/StockholdersEquityDetails4</Role>
      <ShortName>Stockholders' Equity (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/StockholdersEquityTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>132 - Disclosure - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/StockholdersEquityDetailsTextual</Role>
      <ShortName>Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/StockholdersEquityTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ck0001680048-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>133 - Disclosure - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mustangbio.com/role/SubsequentEventsDetailsTextual</Role>
      <ShortName>Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mustangbio.com/role/SubsequentEvents</ParentRole>
      <Position>33</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ck0001680048-20170930.xml</File>
    <File>ck0001680048-20170930.xsd</File>
    <File>ck0001680048-20170930_cal.xml</File>
    <File>ck0001680048-20170930_def.xml</File>
    <File>ck0001680048-20170930_lab.xml</File>
    <File>ck0001680048-20170930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>54
<FILENAME>0001144204-17-058634-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-17-058634-xbrl.zip
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MD)LFV#S/,)[-IGN2>T<<63.(^D&V#,UXM,'GNDN7.MHKLL!9P<+2'>0XD.Y
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MN/G<SZ;2:#"H6014B;Z0%_I+^3!.[.?$<:/1;%+<D@6$U$9]5<HK]JN)W [
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MQ#TEV@+6P#IS>$<U]\,"T5+1-;K#2V%/HS\L$&@UG?F=![Y(B#8;C*;3>@5
M]<??+4E48 HW[=+SV\J'<+G]#J42%:S)1!V&K>KTNYIP[JBRV%?+JPGM&B""
MG4%039C7% GL$?+E]8YL@R2J"__RNE2VQUQ6$ KF=<8\A!B\HQ^.[S9&%8:%
MQY7(GLYC5&&(V 1![ R( N$B[25=K3"N#<4B<-$58?^]-HH<.58^<(QW)]VR
MA+/8@5.[$58K>^D=0,1X%]/M,G)I=!#VKEQR;X8.+=MML/)V[,6:=14BHTK:
MLT8B;^5NDC<0.]'N=Y?R1N\+*=^)4\SK.-KU#ZPK0T:%I&=)/?<\N^G>E,-7
M>.#!K67B<<OJQ?J;C?U%@TYQ<R#E>5?SE+<\-YE,Q7BI0$%J*N<C8QSR^HIV
MQ>EXJT?UCGS 2/E%7:S9*PRA;#QJ:+QV7"'*:S.ZU18UEX:JB,Z2>?$BF=+D
MIHP..S-E3\SG=2#M#L;#V/E%Q<FIG)&L 2@^!;,[ W=DY0W>S2)\*.@5>=C!
MU.=U-1ULG0&6_O8**,T2;GZKT\'.I*8,QT?-D UE7WCGG1 XFTT*F<($:BKG
M(VL <N<09K%.P;OS$4HHQ!TDGN-$L_H\B#N0DB&TO :JXBPUD]JB)+GU-K77
M?I=SVDWT_DDV[I\LTWU\NG!MS:!-SY</('5,O'ZW-,<AQLUB45ZP><U7"W8+
MWYWD(XDD:X"+.]VZA!$Y-MJO6K]9A*8!/D)"IQ)K_F@1$FJ2OX,QR^LG&S1.
MVIVHVMC*&L7<X]RKXFJ3>/AIAJ;NE*3EM:?=SM$B+]R-GBP1%E]ZR"4EGI-%
MSS7<05:Y![#'NVMG4U 1Q5G2++[+HRBQ$>Q&EE<^FM8G3<%K?3NT@XCS&IC[
M!29ER*B0] Q93_,W>.Q"=*38L8(E[[P&LMMK.,5FH<N0ER7%$AU)"A&VE:/^
M1G3UWOPL.RZXP/57HN!_=PK)ISE>;/L T\+$5,U%EL2+IYL[DU]#,0N\[V;Q
MF[F*K.J&$[1[2P9(*(B)[>6):9&#K:JL9MDZK_U M>&1%K-%:\.SB(TS]EDS
M3!Q\WQO?O!C$LI^T%4@'#)HC/Y*+-0Q(XEG%%?(9]LTK-]IY'5'<ZX]"'):@
M.M%[S W#Q3/A#=O5<:+E(\E2O7#/8X>LGH@!]GXI&P6@:U^LP[\D,)[AXONO
M?AGWM]UE$O'5<GGY9&DX 44N+/.E&C8S H-]V;R#-,IPR1U1S$>#EDI\UG0
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M5#TONK=YTIM-ZY+OCERV1/2IP"[>85 Z;]$GE_SO*O9",X<B;>QX**D78/#
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M@@JO=9C^ <<9(7Q/B&:9FAUX[RTWZ 6VU<ICV!LFVA>L7;"(;'O<)GI:&I#
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M8S0(X=EB*A9_XYX#U9OR8^7T\'!"_%T(6<][#?<_0-!I:0YNOL='^:5$X;M
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MK("S+.\5UK@@Z:?8JQ(2+Z8+H=TFLPR':'X.OS4=$JXFK"=[E":]$<\>6[G
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M3D0AZKP"-M2J6,EG:)70?PA(&A[!O#O\RW*(1>L=;$?6=;:Y :?%""T\BDZ
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M&&EB-FEER%+^!#;$\;3?'T[??45LT7/1+D/'HLT1E8^T&^O%>G/)K;S&K^:
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ML+_)#+TK/GWX>)_X>VB0(B\LMS4FEJ"FDN&ESUL7-'-K37P(:YAVGARMTO\
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M Y6>DPQZ/)!Y7(JH[/9ELT5K].+'M;TR3/&"J:/*/0$S*%.GD6PZY<\DDPJ
MH*A;&YU7JF!_[7FEC%X]([U4.HU-IFE#EO^ON!2G%G6\5%/3VM-5*]81DY\R
MH&O3\U-J"A?!7&%FSX5Q^6L79J"<]:6@\FW9+Y9X:LVV\#;85Y\%E*S!?6QU
M,D8,RA?#8=HE#I/DR5^QE\N>J)I-]P;7/ -?LTZV>R,S$T%%?LCU']@3\T-/
M(UHN'"_5T-=,.*D<TQ:DA5[VK(VWER#ZX\-%[X\G%\\>Q=(+(JZYD.+9<,N
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M5F#S CKP&?>00;.+UMMBUR,+"&Q]:,^\),KZ:0Z.(U;'6^,N<-: 1W*!.1\
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MC)]Z_7!T.2&=='O_^_O-U;>OIR IV^9\,%B5Y/:?%Z/VU,+9S_Z$OZ#6O)!
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ML1T]K*FNGSGN3UU7Y4_3F:(<ZU&#G>6#&: @B6?R7C07<V7 C"I!@U,$+SW
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M$0RI=A;X#R!Z5PP@+J5.+=WG-*TE \)<W_)PM]]VHZDWY:VEF]9K]!-/ZH,
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MEIGTF\_53.M-QJL46B=Z(]R-I:MP:(U=7O9R=0/Z?F8'FI?NP3&)\C7E@[H
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M8F9._#)38QMH4K/\,0?E\L#ADAL!#C$YI[L] #Y MXI#'_\D./$G]ZV/?',
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M6H?P5^=A4;S"!>OW,)W(#N'RAD&_1X8N$0N(9M/ Y,0]UIR_FVK$'Y+D1?7
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M5B6<)!6.>D<$:FL:!BGH0*(6!EM/]?M17E0/K!@O35C5)B%J$_2='EC=L*9
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MY8^#+K52?9H4"%"XJ51#+2M]NTVUJI".T1:'Y*;XC>\<Y^TVC:QV&@2(F9/
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M$,@$:^^Z=&.]0D9YRJ^[4T59/],L][%<8\]AV$!-\Z-Z)CRNSX3+,"EJ?3,
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MR#W@LYH)Y_C4I2N$SB%:4Q+47KIMFZ'EN$O$K"07NY@K#(_\\=A>DD3CP.Z
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M_E=[5Q?0+9X7[J2 9&/TEX/[,*87K6.$]WFF.EOXJ_9\Q\JJ2*)*-RN'\'N
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M6QN$SL*2>QG&W&(93F4*DV@X#6@^>UU\<QN^UG8OCFL!+HMOTS#3RHWLXN=
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M>PW1PQGG81J S)[.+(HUS![7:58\P6QSD[S O" ^CLSIE-!8UQ09_UU(T;:
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M,1Z*("9#@1WS@U$!Z7.,5I1YO. E=%W#K=99NENM\9]!24]&.-I!\!D5:Y2
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MP8]3B:[>CZ$/-C,LEB'OB^5%D*^OX_2S3K"YG,Q!UD6I%'S^Q>K) JF3@0D
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M%R<"5WJ_^2J$68&6**3W8_1,=YOFO07L;6JM,8*Y8DO#X.M01[$#@*</$?.
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MANDJ0612/J(8YD6:8/4JUFE4/1RXW(FR_Q_1EQNE,)27-Q4H.6C1@[H#P'H
M]8,9W(</:G2DS(>/L3'T<Q31LA58=A@CEM:N2,O$YA!$._I6IL!D6Y@A/"#D
M!(+\<U./%/Y!_0]O[L"'Z()0@X<KPJB:+:KW6)9)>-R2Z.D,1E6KDB.UB@_J
MU)6N#QN!WKJB\TY1UK*K&:@[ W7;LCL_]'^<<3A<"'J30)9/KNOGV.2%0[A&
M\(6L"LT24 39"A8>*?\1ZM*S"ARM*ZXK0:O+_BCH/*G1W%\9YZ!FL$"W??#\
M-69&K]BOXQHYK6.N'#-VER:MP[SV65[ON<'@GNR_CS&6E7LTT^I!X_33FY.J
M@;/,O; Y9HKM8?HZ0-DO0;R#\^CO.Q:.MEC^I7PY+D&P@LXZ7E5R=-%)V@-*
M !H*8A94-&ZS IB*PTH1DFPR2R+8"Q6,)H_/T LVLEY@NQJAV^S=+F2SN8!H
MJ51WN3#0)XLA@B3GRGF0PXB$E>&M5VBNMR/8>@CL!P7V<<X] B -SYY)2]!N
MZC@]CC;[)!E&R7[8:NI1WB@YB+AP1@T$.8B1+=..K-.8I!YBH98:3YXUZ=W%
MS"KDXN%6TM6Y=$K*W__NPP]_ F5HK0\A<8-FL#>V5G_Z;"8J)/E^*%]*?T/0
MUD%R09Y?/E\>S6'$LC2YO9\<PC9+4>;^<E()$3X9GQ0?8UZN-U^B.9R>8]U;
M]GY"1]?M$DFDN*Y:>W4!/[$P]J_D53@3W\WK@<SBD5,4T?N7(";)+V^2LLZZ
M^H!)3F?_.$DA!W=X5+>G^6#/L/-7DGBR+5@3R.K1EP[:N(,N?:C9O XH I3
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M!SUZDV+[T>9%'&"6-%]M'C9V]&RSPW'/DS#:"IQ[\A#!A//RZ::> /:?<(H
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MJ<]#FH&*25!R"2HV >7S:W.AQILNQ<#]EW*Z'(WJU^JF33"<03F<VXP^F"O
MYS4*UV!%#0V8@Q O$ $+LZ9/=,HJH>0]3_:"Z4FL,*JJ)-*'H:P9K<?&_#VP
MQ9_^ZIR^(_?=:?W!43;=4[!V2H/82TM'B[>OS,K1FP]G%D[)GBOK1NIH^CQ!
MRMU7ZIA^);OMD4-7[[08E707K1["RC?=<L-MU>FF6RO6!EC- 7E)VW_N&E3G
MKMX\??=A-["[_QIO!3[NO>*C$AA59R4=Z1X@B:[ %@>);"8!I;L@)GGZE>D
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M+>X0_QO_"_^%I%*G@_'_ %!+ P04    " !(2&Y+HF:P3)9"  "VGP0 '0
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M>2W6M; =!89MA?[?6;9;DWY%4Y!#9]=U+6Q'06%;H?\DKTD^VC#H]SJ[WFM
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M3P!FJ]Y$5/+K!*T/&XG;\FZYY&,>9B\W89F66T2%&)Q^I&U +#3LT37./PI
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MSG:3V !2AV+ KED!\F#CA<U.R[B\00"H_*-:A<51.!@%CC=]^-$;D' CU[@
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MD8"<[BPP;FVR_>.3&.M=F+-2JO\?4$L! A0#%     @ 2$AN2\T&&A4RO@
MTWX+ !D              ( !     &-K,# P,38X,# T."TR,#$W,#DS,"YX
M;6Q02P$"% ,4    " !(2&Y+@*KKOS4.  "KE@  &0              @ %I
MO@  8VLP,# Q-C@P,#0X+3(P,3<P.3,P+GAS9%!+ 0(4 Q0    ( $A(;DN<
M$OK - @  (QF   =              "  =7,  !C:S P,#$V.# P-#@M,C Q
M-S Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( $A(;DN2R:*0(D   $],!  =
M          "  435  !C:S P,#$V.# P-#@M,C Q-S Y,S!?9&5F+GAM;%!+
M 0(4 Q0    ( $A(;DN@/SKZP4P  &D=!  =              "  :$5 0!C
M:S P,#$V.# P-#@M,C Q-S Y,S!?;&%B+GAM;%!+ 0(4 Q0    ( $A(;DNB
M9K!,ED(  +:?!  =              "  9UB 0!C:S P,#$V.# P-#@M,C Q
C-S Y,S!?<')E+GAM;%!+!08     !@ & +H!  !NI0$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
